{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "code",
      "source": [
        "!pip install Bio"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "cJGtEhmRSCfD",
        "outputId": "42036a65-7f18-49e1-fcf3-e0afff97a9af"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting Bio\n",
            "  Downloading bio-1.7.0-py3-none-any.whl (279 kB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m279.2/279.2 kB\u001b[0m \u001b[31m5.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting biopython>=1.80 (from Bio)\n",
            "  Downloading biopython-1.83-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (3.1 MB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m3.1/3.1 MB\u001b[0m \u001b[31m37.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting gprofiler-official (from Bio)\n",
            "  Downloading gprofiler_official-1.0.0-py3-none-any.whl (9.3 kB)\n",
            "Collecting mygene (from Bio)\n",
            "  Downloading mygene-3.2.2-py2.py3-none-any.whl (5.4 kB)\n",
            "Requirement already satisfied: pandas in /usr/local/lib/python3.10/dist-packages (from Bio) (2.0.3)\n",
            "Requirement already satisfied: pooch in /usr/local/lib/python3.10/dist-packages (from Bio) (1.8.1)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.10/dist-packages (from Bio) (2.31.0)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from Bio) (4.66.2)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.10/dist-packages (from biopython>=1.80->Bio) (1.25.2)\n",
            "Collecting biothings-client>=0.2.6 (from mygene->Bio)\n",
            "  Downloading biothings_client-0.3.1-py2.py3-none-any.whl (29 kB)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.10/dist-packages (from pandas->Bio) (2.8.2)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.10/dist-packages (from pandas->Bio) (2023.4)\n",
            "Requirement already satisfied: tzdata>=2022.1 in /usr/local/lib/python3.10/dist-packages (from pandas->Bio) (2024.1)\n",
            "Requirement already satisfied: platformdirs>=2.5.0 in /usr/local/lib/python3.10/dist-packages (from pooch->Bio) (4.2.0)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.10/dist-packages (from pooch->Bio) (24.0)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests->Bio) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests->Bio) (3.7)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests->Bio) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests->Bio) (2024.2.2)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.8.2->pandas->Bio) (1.16.0)\n",
            "Installing collected packages: biopython, gprofiler-official, biothings-client, mygene, Bio\n",
            "Successfully installed Bio-1.7.0 biopython-1.83 biothings-client-0.3.1 gprofiler-official-1.0.0 mygene-3.2.2\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "ot480OXFNisE"
      },
      "outputs": [],
      "source": [
        "from Bio import Entrez\n",
        "Entrez.email = \"ninachestnaja@gmail.com\""
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "search_result = Entrez.esearch(db=\"pubmed\", term=\"Anti Allergic Agents\", retmax=50)\n",
        "record = Entrez.read(search_result) # This will get the PubMed IDs (PMIDs) of the first 10 search results\n",
        "id_list = record[\"IdList\"]\n",
        "print(id_list)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "kmBqXUDYSAfC",
        "outputId": "51e3749f-39c9-46ca-c451-554af616e9f5"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "['38676596', '38676539', '38674305', '38674150', '38671158', '38671063', '38664220', '38656288', '38654248', '38650404', '38638437', '38615803', '38609111', '38608060', '38601987', '38601462', '38595247', '38576144', '38573223', '38572700', '38569391', '38567842', '38564395', '38558549', '38557452', '38556414', '38555460', '38547423', '38541174', '38541113', '38540140', '38539080', '38538160', '38538153', '38536409', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38504329', '38498418']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "Anti-Allergic\n",
        "Anti Allergic\n",
        "Anti-Allergics\n",
        "Anti Allergics\n",
        "Anti-Allergy Drugs\n",
        "Anti Allergy Drugs\n",
        "Drugs, Anti-Allergy\n",
        "Antiallergic Agents\n",
        "Agents, Antiallergic\n",
        "Antiallergic Drug\n",
        "Drug, Antiallergic\n",
        "Antiallergics\n",
        "Antiallergy Agents\n",
        "Agents, Antiallergy\n",
        "Anti-Allergy Drug\n",
        "Anti Allergy Drug\n",
        "Drug, Anti-Allergy\n",
        "Antiallergic Agent\n",
        "Agent, Antiallergic\n",
        "Antiallergic\n",
        "Anti-Allergic Agent\n",
        "Agent, Anti-Allergic\n",
        "Anti Allergic Agent\n",
        "Antiallergic Drugs\n",
        "Drugs, Antiallergic"
      ],
      "metadata": {
        "id": "k6msAtHGhYi3"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "terms = [\"Anti-Allergic\", \"Anti Allergic\", \"Anti-Allergics\", \"Anti Allergics\", \"Anti Allergy Drugs\",\n",
        "         \"Anti Allergy Drugs\", \"Drugs, Anti-Allergy\", \"Antiallergic Agents\", \"Agents, Antiallergic\",\n",
        "         \"Antiallergic Drug\", \"Drug, Antiallergic\", \"Antiallergics\", \"Antiallergy Agents\",\n",
        "         \"Agents, Antiallergy\", \"Anti-Allergy Drug\", \"Anti Allergy Drug\", \"Drug, Anti-Allergy\",\n",
        "         \"Antiallergic Agent\", \"Agent, Antiallergic\", \"Antiallergic\", \"Anti-Allergic Agent\",\n",
        "         \"Agent, Anti-Allergic\", \"Anti Allergic Agent\", \"Antiallergic Drugs\", \"Drugs, Antiallergic\"]\n",
        "all_id_list = []\n",
        "for term in terms:\n",
        "    search_result = Entrez.esearch(db=\"pubmed\", term=term, retmax=50)\n",
        "    record = Entrez.read(search_result)\n",
        "    id_list = record[\"IdList\"]\n",
        "    all_id_list.extend(id_list)\n",
        "    print(\"Term:\", term)\n",
        "    print(id_list)\n",
        "    print(\"\\n\")\n",
        "print(\"IdList:\", all_id_list)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ct1idnaNssLy",
        "outputId": "6b06f167-f9dc-46a2-d754-384eb0cd1de0"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Term: Anti-Allergic\n",
            "['38676659', '38676596', '38676539', '38675778', '38674852', '38674305', '38674150', '38671158', '38671063', '38670109', '38668524', '38666929', '38666394', '38666018', '38664220', '38663361', '38660308', '38656288', '38654248', '38652443', '38650404', '38650159', '38650035', '38647571', '38646478', '38643709', '38642328', '38638866', '38638437', '38634548', '38633616', '38623449', '38618367', '38615803', '38614062', '38609111', '38608060', '38606160', '38605816', '38601987', '38601618', '38601462', '38599291', '38595247', '38595024', '38593870', '38591212', '38589778', '38589549', '38588651']\n",
            "\n",
            "\n",
            "Term: Anti Allergic\n",
            "['38676659', '38676596', '38676539', '38675778', '38674852', '38674305', '38674150', '38671158', '38671063', '38670109', '38668524', '38666929', '38666394', '38666018', '38664220', '38663361', '38660308', '38656288', '38654248', '38652443', '38650404', '38650159', '38650035', '38647571', '38646478', '38643709', '38642328', '38638866', '38638437', '38634548', '38633616', '38623449', '38618367', '38615803', '38614062', '38609111', '38608060', '38606160', '38605816', '38601987', '38601618', '38601462', '38599291', '38595247', '38595024', '38593870', '38591212', '38589778', '38589549', '38588651']\n",
            "\n",
            "\n",
            "Term: Anti-Allergics\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38615803', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304', '38470381', '38467503', '38460418']\n",
            "\n",
            "\n",
            "Term: Anti Allergics\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38615803', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304', '38470381', '38467503', '38460418']\n",
            "\n",
            "\n",
            "Term: Anti Allergy Drugs\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38666929', '38662529', '38658483', '38656288', '38651829', '38636483', '38622023', '38615803', '38609111', '38608060', '38607224', '38601462', '38595247', '38576317', '38576144', '38573223', '38569391', '38567842', '38564395', '38561285', '38558549', '38557452', '38556414', '38556047', '38553004', '38547423', '38546317', '38543146', '38541809', '38541174', '38540140', '38539080', '38538160', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38521926', '38520199', '38516711', '38511703']\n",
            "\n",
            "\n",
            "Term: Anti Allergy Drugs\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38666929', '38662529', '38658483', '38656288', '38651829', '38636483', '38622023', '38615803', '38609111', '38608060', '38607224', '38601462', '38595247', '38576317', '38576144', '38573223', '38569391', '38567842', '38564395', '38561285', '38558549', '38557452', '38556414', '38556047', '38553004', '38547423', '38546317', '38543146', '38541809', '38541174', '38540140', '38539080', '38538160', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38521926', '38520199', '38516711', '38511703']\n",
            "\n",
            "\n",
            "Term: Drugs, Anti-Allergy\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38666929', '38662529', '38658483', '38656288', '38651829', '38636483', '38622023', '38615803', '38609111', '38608060', '38607224', '38601462', '38595247', '38576317', '38576144', '38573223', '38569391', '38567842', '38564395', '38561285', '38558549', '38557452', '38556414', '38556047', '38553004', '38547423', '38546317', '38543146', '38541809', '38541174', '38540140', '38539080', '38538160', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38521926', '38520199', '38516711', '38511703']\n",
            "\n",
            "\n",
            "Term: Antiallergic Agents\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38615803', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304', '38473970', '38470381', '38467503']\n",
            "\n",
            "\n",
            "Term: Agents, Antiallergic\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38615803', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304', '38473970', '38470381', '38467503']\n",
            "\n",
            "\n",
            "Term: Antiallergic Drug\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38647571', '38643709', '38640354', '38615803', '38611719', '38609111', '38608060', '38606160', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38526450', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38490019', '38489062', '38489059', '38483045', '38482006', '38479857']\n",
            "\n",
            "\n",
            "Term: Drug, Antiallergic\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38647571', '38643709', '38640354', '38615803', '38611719', '38609111', '38608060', '38606160', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38526450', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38490019', '38489062', '38489059', '38483045', '38482006', '38479857']\n",
            "\n",
            "\n",
            "Term: Antiallergics\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38647571', '38643709', '38640354', '38638866', '38633616', '38623449', '38615803', '38614062', '38611719', '38611357', '38609111', '38608060', '38606160', '38605816', '38601462', '38595247', '38579561', '38576144', '38573223', '38569391', '38568359', '38567842', '38566968', '38564395', '38562547', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38533200', '38532238', '38531640', '38528089', '38527052', '38526588', '38526569', '38526450', '38525509', '38522490', '38520199', '38516711', '38511703']\n",
            "\n",
            "\n",
            "Term: Antiallergy Agents\n",
            "['38676596', '38676532', '38674305', '38674150', '38671158', '38671063', '38656288', '38615803', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38566376', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304', '38470381']\n",
            "\n",
            "\n",
            "Term: Agents, Antiallergy\n",
            "['38676596', '38676532', '38674305', '38674150', '38671158', '38671063', '38656288', '38615803', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38566376', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304', '38470381']\n",
            "\n",
            "\n",
            "Term: Anti-Allergy Drug\n",
            "['38676596', '38676539', '38674305', '38674150', '38671158', '38671063', '38668995', '38664220', '38663361', '38659261', '38658483', '38658181', '38656288', '38654237', '38651829', '38648957', '38646132', '38636483', '38636200', '38626739', '38615803', '38609111', '38608060', '38607224', '38601462', '38600466', '38599291', '38598612', '38597996', '38597876', '38596897', '38595247', '38593870', '38589870', '38588651', '38587079', '38576317', '38576144', '38573223', '38572700', '38570792', '38569391', '38567842', '38564395', '38563602', '38560604', '38558549', '38557452', '38556414', '38556047']\n",
            "\n",
            "\n",
            "Term: Anti Allergy Drug\n",
            "['38676596', '38676539', '38674305', '38674150', '38671158', '38671063', '38668995', '38664220', '38663361', '38659261', '38658483', '38658181', '38656288', '38654237', '38651829', '38648957', '38646132', '38636483', '38636200', '38626739', '38615803', '38609111', '38608060', '38607224', '38601462', '38600466', '38599291', '38598612', '38597996', '38597876', '38596897', '38595247', '38593870', '38589870', '38588651', '38587079', '38576317', '38576144', '38573223', '38572700', '38570792', '38569391', '38567842', '38564395', '38563602', '38560604', '38558549', '38557452', '38556414', '38556047']\n",
            "\n",
            "\n",
            "Term: Drug, Anti-Allergy\n",
            "['38676596', '38676539', '38674305', '38674150', '38671158', '38671063', '38668995', '38664220', '38663361', '38659261', '38658483', '38658181', '38656288', '38654237', '38651829', '38648957', '38646132', '38636483', '38636200', '38626739', '38615803', '38609111', '38608060', '38607224', '38601462', '38600466', '38599291', '38598612', '38597996', '38597876', '38596897', '38595247', '38593870', '38589870', '38588651', '38587079', '38576317', '38576144', '38573223', '38572700', '38570792', '38569391', '38567842', '38564395', '38563602', '38560604', '38558549', '38557452', '38556414', '38556047']\n",
            "\n",
            "\n",
            "Term: Antiallergic Agent\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38640354', '38615803', '38611357', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38566968', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304']\n",
            "\n",
            "\n",
            "Term: Agent, Antiallergic\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38640354', '38615803', '38611357', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38566968', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304']\n",
            "\n",
            "\n",
            "Term: Antiallergic\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38647571', '38643709', '38640354', '38638866', '38633616', '38623449', '38615803', '38614062', '38611719', '38611357', '38609111', '38608060', '38606160', '38605816', '38601462', '38595247', '38579561', '38576144', '38573223', '38569391', '38568359', '38567842', '38566968', '38564395', '38562547', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38533200', '38532238', '38531640', '38528089', '38527052', '38526588', '38526569', '38526450', '38525509', '38522490', '38520199', '38516711', '38511703']\n",
            "\n",
            "\n",
            "Term: Anti-Allergic Agent\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38666018', '38656288', '38618367', '38615803', '38609111', '38608060', '38601618', '38601462', '38595247', '38595024', '38584568', '38576144', '38573223', '38569391', '38567842', '38566968', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527438', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857']\n",
            "\n",
            "\n",
            "Term: Agent, Anti-Allergic\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38666018', '38656288', '38618367', '38615803', '38609111', '38608060', '38601618', '38601462', '38595247', '38595024', '38584568', '38576144', '38573223', '38569391', '38567842', '38566968', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527438', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857']\n",
            "\n",
            "\n",
            "Term: Anti Allergic Agent\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38666018', '38656288', '38618367', '38615803', '38609111', '38608060', '38601618', '38601462', '38595247', '38595024', '38584568', '38576144', '38573223', '38569391', '38567842', '38566968', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527438', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857']\n",
            "\n",
            "\n",
            "Term: Antiallergic Drugs\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38633616', '38615803', '38609111', '38608060', '38606160', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38526450', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38490019', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821']\n",
            "\n",
            "\n",
            "Term: Drugs, Antiallergic\n",
            "['38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38633616', '38615803', '38609111', '38608060', '38606160', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38526450', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38490019', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821']\n",
            "\n",
            "\n",
            "IdList: ['38676659', '38676596', '38676539', '38675778', '38674852', '38674305', '38674150', '38671158', '38671063', '38670109', '38668524', '38666929', '38666394', '38666018', '38664220', '38663361', '38660308', '38656288', '38654248', '38652443', '38650404', '38650159', '38650035', '38647571', '38646478', '38643709', '38642328', '38638866', '38638437', '38634548', '38633616', '38623449', '38618367', '38615803', '38614062', '38609111', '38608060', '38606160', '38605816', '38601987', '38601618', '38601462', '38599291', '38595247', '38595024', '38593870', '38591212', '38589778', '38589549', '38588651', '38676659', '38676596', '38676539', '38675778', '38674852', '38674305', '38674150', '38671158', '38671063', '38670109', '38668524', '38666929', '38666394', '38666018', '38664220', '38663361', '38660308', '38656288', '38654248', '38652443', '38650404', '38650159', '38650035', '38647571', '38646478', '38643709', '38642328', '38638866', '38638437', '38634548', '38633616', '38623449', '38618367', '38615803', '38614062', '38609111', '38608060', '38606160', '38605816', '38601987', '38601618', '38601462', '38599291', '38595247', '38595024', '38593870', '38591212', '38589778', '38589549', '38588651', '38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38615803', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304', '38470381', '38467503', '38460418', '38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38615803', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304', '38470381', '38467503', '38460418', '38676596', '38674305', '38674150', '38671158', '38671063', '38666929', '38662529', '38658483', '38656288', '38651829', '38636483', '38622023', '38615803', '38609111', '38608060', '38607224', '38601462', '38595247', '38576317', '38576144', '38573223', '38569391', '38567842', '38564395', '38561285', '38558549', '38557452', '38556414', '38556047', '38553004', '38547423', '38546317', '38543146', '38541809', '38541174', '38540140', '38539080', '38538160', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38521926', '38520199', '38516711', '38511703', '38676596', '38674305', '38674150', '38671158', '38671063', '38666929', '38662529', '38658483', '38656288', '38651829', '38636483', '38622023', '38615803', '38609111', '38608060', '38607224', '38601462', '38595247', '38576317', '38576144', '38573223', '38569391', '38567842', '38564395', '38561285', '38558549', '38557452', '38556414', '38556047', '38553004', '38547423', '38546317', '38543146', '38541809', '38541174', '38540140', '38539080', '38538160', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38521926', '38520199', '38516711', '38511703', '38676596', '38674305', '38674150', '38671158', '38671063', '38666929', '38662529', '38658483', '38656288', '38651829', '38636483', '38622023', '38615803', '38609111', '38608060', '38607224', '38601462', '38595247', '38576317', '38576144', '38573223', '38569391', '38567842', '38564395', '38561285', '38558549', '38557452', '38556414', '38556047', '38553004', '38547423', '38546317', '38543146', '38541809', '38541174', '38540140', '38539080', '38538160', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38521926', '38520199', '38516711', '38511703', '38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38615803', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304', '38473970', '38470381', '38467503', '38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38615803', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304', '38473970', '38470381', '38467503', '38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38647571', '38643709', '38640354', '38615803', '38611719', '38609111', '38608060', '38606160', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38526450', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38490019', '38489062', '38489059', '38483045', '38482006', '38479857', '38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38647571', '38643709', '38640354', '38615803', '38611719', '38609111', '38608060', '38606160', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38526450', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38490019', '38489062', '38489059', '38483045', '38482006', '38479857', '38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38647571', '38643709', '38640354', '38638866', '38633616', '38623449', '38615803', '38614062', '38611719', '38611357', '38609111', '38608060', '38606160', '38605816', '38601462', '38595247', '38579561', '38576144', '38573223', '38569391', '38568359', '38567842', '38566968', '38564395', '38562547', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38533200', '38532238', '38531640', '38528089', '38527052', '38526588', '38526569', '38526450', '38525509', '38522490', '38520199', '38516711', '38511703', '38676596', '38676532', '38674305', '38674150', '38671158', '38671063', '38656288', '38615803', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38566376', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304', '38470381', '38676596', '38676532', '38674305', '38674150', '38671158', '38671063', '38656288', '38615803', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38566376', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304', '38470381', '38676596', '38676539', '38674305', '38674150', '38671158', '38671063', '38668995', '38664220', '38663361', '38659261', '38658483', '38658181', '38656288', '38654237', '38651829', '38648957', '38646132', '38636483', '38636200', '38626739', '38615803', '38609111', '38608060', '38607224', '38601462', '38600466', '38599291', '38598612', '38597996', '38597876', '38596897', '38595247', '38593870', '38589870', '38588651', '38587079', '38576317', '38576144', '38573223', '38572700', '38570792', '38569391', '38567842', '38564395', '38563602', '38560604', '38558549', '38557452', '38556414', '38556047', '38676596', '38676539', '38674305', '38674150', '38671158', '38671063', '38668995', '38664220', '38663361', '38659261', '38658483', '38658181', '38656288', '38654237', '38651829', '38648957', '38646132', '38636483', '38636200', '38626739', '38615803', '38609111', '38608060', '38607224', '38601462', '38600466', '38599291', '38598612', '38597996', '38597876', '38596897', '38595247', '38593870', '38589870', '38588651', '38587079', '38576317', '38576144', '38573223', '38572700', '38570792', '38569391', '38567842', '38564395', '38563602', '38560604', '38558549', '38557452', '38556414', '38556047', '38676596', '38676539', '38674305', '38674150', '38671158', '38671063', '38668995', '38664220', '38663361', '38659261', '38658483', '38658181', '38656288', '38654237', '38651829', '38648957', '38646132', '38636483', '38636200', '38626739', '38615803', '38609111', '38608060', '38607224', '38601462', '38600466', '38599291', '38598612', '38597996', '38597876', '38596897', '38595247', '38593870', '38589870', '38588651', '38587079', '38576317', '38576144', '38573223', '38572700', '38570792', '38569391', '38567842', '38564395', '38563602', '38560604', '38558549', '38557452', '38556414', '38556047', '38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38640354', '38615803', '38611357', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38566968', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304', '38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38640354', '38615803', '38611357', '38609111', '38608060', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38566968', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38474304', '38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38647571', '38643709', '38640354', '38638866', '38633616', '38623449', '38615803', '38614062', '38611719', '38611357', '38609111', '38608060', '38606160', '38605816', '38601462', '38595247', '38579561', '38576144', '38573223', '38569391', '38568359', '38567842', '38566968', '38564395', '38562547', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38533200', '38532238', '38531640', '38528089', '38527052', '38526588', '38526569', '38526450', '38525509', '38522490', '38520199', '38516711', '38511703', '38676596', '38674305', '38674150', '38671158', '38671063', '38666018', '38656288', '38618367', '38615803', '38609111', '38608060', '38601618', '38601462', '38595247', '38595024', '38584568', '38576144', '38573223', '38569391', '38567842', '38566968', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527438', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38676596', '38674305', '38674150', '38671158', '38671063', '38666018', '38656288', '38618367', '38615803', '38609111', '38608060', '38601618', '38601462', '38595247', '38595024', '38584568', '38576144', '38573223', '38569391', '38567842', '38566968', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527438', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38676596', '38674305', '38674150', '38671158', '38671063', '38666018', '38656288', '38618367', '38615803', '38609111', '38608060', '38601618', '38601462', '38595247', '38595024', '38584568', '38576144', '38573223', '38569391', '38567842', '38566968', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527438', '38527052', '38526588', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38489062', '38489059', '38483045', '38482006', '38479857', '38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38633616', '38615803', '38609111', '38608060', '38606160', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38526450', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38490019', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821', '38676596', '38674305', '38674150', '38671158', '38671063', '38656288', '38633616', '38615803', '38609111', '38608060', '38606160', '38601462', '38595247', '38576144', '38573223', '38569391', '38567842', '38564395', '38557452', '38556414', '38547423', '38541174', '38539080', '38538153', '38532238', '38531640', '38528089', '38527052', '38526588', '38526450', '38525509', '38522490', '38520199', '38516711', '38511703', '38508226', '38506875', '38506857', '38498418', '38493177', '38492337', '38490019', '38489062', '38489059', '38483045', '38482006', '38479857', '38478581', '38477950', '38474821']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "__Y7k3Gxt0Cy"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "fetch_result = Entrez.efetch(db=\"pubmed\", id=id_list, rettype=\"abstract\", retmode=\"xml\")\n",
        "xml_data = Entrez.read(fetch_result)\n",
        "print(xml_data['PubmedArticle'])\n",
        "# Parsing XML data depends on the information you need; you can access various parts of the data like so:\n",
        "for article in xml_data['PubmedArticle']:\n",
        "  print(article['MedlineCitation']['Article'])\n",
        "\n",
        "  #print(article['MedlineCitation']['Article']['Journal']['JournalIssue'])\n",
        "\n",
        "  #print(article['MedlineCitation']['Article']['Title'])\n",
        "  #print(article['MedlineCitation']['Article']['ArticleTitle'])\n",
        "  #print(article['MedlineCitation']['Article']['Abstract']['AbstractText'])\n",
        "\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "1rPMsuIpSekd",
        "outputId": "60c07938-9617-475d-f46c-9e03d354708c"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "[{'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38676596', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '27'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '27'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.5578/tt.202401795', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2980-3187', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '72', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Mar'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Tuberkuloz ve toraks', 'ISOAbbreviation': 'Tuberk Toraks'}, 'ArticleTitle': 'Results of omalizumab treatment in chronic eosinophilic pneumonia: Real-life data.', 'Pagination': {'StartPage': '71', 'EndPage': '81', 'MedlinePgn': '71-81'}, 'Abstract': {'AbstractText': [StringElement('Recurrences occur when corticosteroid therapy is discontinued or reduced during the treatment of chronic eosinophilic pneumonia (CEP). The probability of recurrence is once in 50% of patients and twice or more in 25%. In such instances, new treatment options are deemed necessary. This study aims to assess the efficacy of omalizumab treatment as a steroid-sparing drug in patients with CEP.', attributes={'Label': 'INTRODUCTION', 'NlmCategory': 'UNASSIGNED'}), StringElement('The clinical features of patients treated with omalizumab for recurrent CEP were evaluated retrospectively before and after treatment. All data from patients and diagnoses were reviewed. The effects of treatment on recurrence rate, oral corticosteroid (OCS) use and lung functions, peripheral eosinophil values, and symptom scores were evaluated. Radiological regression was also evaluated.', attributes={'Label': 'MATERIALS AND METHODS', 'NlmCategory': 'UNASSIGNED'}), StringElement('In the final analysis, we included ten patients with a median follow-up of 22 months after initiation of omalizumab. During this follow-up period, the results were associated with a significant reduction in the number of asthma attacks per year, the number of CEP relapses, the rate of hospitalization, the amount of corticosteroids consumed daily, and the total corticosteroid dose. In addition, improvement was observed in the symptom scores and lung functions of the patients. Systemic steroids were completely discontinued in two patients receiving omalizumab treatment. In other patients, the mean steroid dose was reduced by 77.2 percent in the first year of omalizumab treatment and 82 percent in the second year, respectively. Nevertheless, there was no elevation in peripheral eosinophil count, and radiological regression was observed.', attributes={'Label': 'RESULT', 'NlmCategory': 'UNASSIGNED'}), StringElement('Omalizumab can be an effective treatment for CEP and can be used as a steroid-sparing agent.', attributes={'Label': 'CONCLUSIONS', 'NlmCategory': 'UNASSIGNED'})]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinic of Immunology and Allergy, Health Sciences University Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye.'}], 'Identifier': [], 'LastName': 'Başa Akdoğan', 'ForeName': 'Buket', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinic of Immunology and Allergy, Health Sciences University Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye.'}], 'Identifier': [], 'LastName': 'Aksu', 'ForeName': 'Kurtuluş', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinic of Immunology and Allergy, Health Sciences University Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye.'}], 'Identifier': [], 'LastName': 'Koca Kalkan', 'ForeName': 'İlkay', 'Initials': 'İ'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinic of Immunology and Allergy, Health Sciences University Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye.'}], 'Identifier': [], 'LastName': 'Köycü Buhari', 'ForeName': 'Gözde', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinic of Immunology and Allergy, Health Sciences University Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye.'}], 'Identifier': [], 'LastName': 'Özdedeoğlu', 'ForeName': 'Özlem', 'Initials': 'Ö'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinic of Immunology and Allergy, Health Sciences University Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye.'}], 'Identifier': [], 'LastName': 'Ateş', 'ForeName': 'Hale', 'Initials': 'H'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinic of Immunology and Allergy, Health Sciences University Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye.'}], 'Identifier': [], 'LastName': 'Öner Erkekol', 'ForeName': 'Ferda', 'Initials': 'F'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})], 'VernacularTitle': 'Kronik eozinofilik pnömonide omalizumab tedavisinin sonuçları: Gerçek yaşam verileri.'}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'Turkey', 'MedlineTA': 'Tuberk Toraks', 'NlmUniqueID': '0417364', 'ISSNLinking': '0494-1373'}, 'ChemicalList': [{'RegistryNumber': '2P471X1Z11', 'NameOfSubstance': StringElement('Omalizumab', attributes={'UI': 'D000069444'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Asthmatic Agents', attributes={'UI': 'D018927'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Adrenal Cortex Hormones', attributes={'UI': 'D000305'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Omalizumab', attributes={'UI': 'D000069444', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Male', attributes={'UI': 'D008297', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Female', attributes={'UI': 'D005260', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Pulmonary Eosinophilia', attributes={'UI': 'D011657', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Retrospective Studies', attributes={'UI': 'D012189', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Middle Aged', attributes={'UI': 'D008875', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Adult', attributes={'UI': 'D000328', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Treatment Outcome', attributes={'UI': 'D016896', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Chronic Disease', attributes={'UI': 'D002908', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Asthmatic Agents', attributes={'UI': 'D018927', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Recurrence', attributes={'UI': 'D012008', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Adrenal Cortex Hormones', attributes={'UI': 'D000305', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Aged', attributes={'UI': 'D000368', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2024', 'Month': '4', 'Day': '28', 'Hour': '7', 'Minute': '23'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '28', 'Hour': '7', 'Minute': '22'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '27', 'Hour': '8', 'Minute': '18'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38676596', attributes={'IdType': 'pubmed'}), StringElement('10.5578/tt.202401795', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Severe asthma', attributes={'MajorTopicYN': 'N'}), StringElement('alarmin', attributes={'MajorTopicYN': 'N'}), StringElement('biologics', attributes={'MajorTopicYN': 'N'}), StringElement('efficacy', attributes={'MajorTopicYN': 'N'}), StringElement('epithelial dysfunction', attributes={'MajorTopicYN': 'N'}), StringElement('inflammation', attributes={'MajorTopicYN': 'N'}), StringElement('safety', attributes={'MajorTopicYN': 'N'}), StringElement('tezepelumab', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38676539', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '27'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '27'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.1177/03000605241246740', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1473-2300', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '52', 'Issue': '4', 'PubDate': {'Year': '2024', 'Month': 'Apr'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The Journal of international medical research', 'ISOAbbreviation': 'J Int Med Res'}, 'ArticleTitle': 'Tezepelumab: patient selection and place in therapy in severe asthma.', 'Pagination': {'StartPage': '3000605241246740', 'MedlinePgn': '3000605241246740'}, 'Abstract': {'AbstractText': ['Asthma is a disease characterised by heterogeneous and multifaceted airway inflammation. Despite the availability of effective treatments, a substantial percentage of patients with the type 2 (T2)-high, but mainly the T2-low, phenotype complain of persistent symptoms, airflow limitation, and poor response to treatments. Currently available biologicals target T2 cytokines, but no monoclonal antibodies or other specific therapeutic options are available for non-T2 asthma. However, targeted therapy against alarmins is radically changing this perspective. The development of alarmin-targeted therapies, of which tezepelumab (TZP) is the first example, may offer broad action on inflammatory pathways as well as an enhanced therapeutic effect on epithelial dysfunction. In this regard, TZP demonstrated positive results not only in patients with severe T2 asthma but also those with non-allergic, non-eosinophilic disease. Therefore, it is necessary to identify clinical features of patients who can benefit from an upstream targeted therapy such as anti-thymic stromal lymphopoietin. The aims of this narrative review are to understand the role of alarmins in asthma pathogenesis and epithelial dysfunction, examine the rationale underlying the indication of TZP treatment in severe asthma, summarise the results of clinical studies, and recognise the specific characteristics of patients potentially eligible for TZP treatment.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}, {'Identifier': [], 'Affiliation': 'Pulmonology and Otolaryngology Multidisciplinary Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [StringElement('0000-0003-3950-5789', attributes={'Source': 'ORCID'})], 'LastName': 'Menzella', 'ForeName': 'Francesco', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology and Otolaryngology Multidisciplinary Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}, {'Identifier': [], 'Affiliation': 'Otolaryngology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [StringElement('0000-0003-1024-2997', attributes={'Source': 'ORCID'})], 'LastName': 'Munari', 'ForeName': 'Sara', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}, {'Identifier': [], 'Affiliation': 'Pulmonology and Otolaryngology Multidisciplinary Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [], 'LastName': 'Corsi', 'ForeName': 'Lorenzo', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}, {'Identifier': [], 'Affiliation': 'Pulmonology and Otolaryngology Multidisciplinary Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [], 'LastName': 'Tonin', 'ForeName': 'Silvia', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology and Otolaryngology Multidisciplinary Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}, {'Identifier': [], 'Affiliation': 'Otolaryngology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [], 'LastName': 'Cestaro', 'ForeName': 'Walter', 'Initials': 'W'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [StringElement('0000-0001-7560-9361', attributes={'Source': 'ORCID'})], 'LastName': 'Ballarin', 'ForeName': 'Andrea', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [], 'LastName': 'Floriani', 'ForeName': 'Ariel', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [], 'LastName': 'Dartora', 'ForeName': 'Cristina', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Asthma Center and Allergy Unit, University of Verona & AOUI Verona, Policlinico GB Rossi, Verona, Italy.'}], 'Identifier': [], 'LastName': 'Senna', 'ForeName': 'Gianenrico', 'Initials': 'G'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'England', 'MedlineTA': 'J Int Med Res', 'NlmUniqueID': '0346411', 'ISSNLinking': '0300-0605'}, 'ChemicalList': [{'RegistryNumber': 'RJ1IW3B4QX', 'NameOfSubstance': StringElement('tezepelumab', attributes={'UI': 'C000622721'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Antibodies, Monoclonal, Humanized', attributes={'UI': 'D061067'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Asthmatic Agents', attributes={'UI': 'D018927'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Cytokines', attributes={'UI': 'D016207'})}, {'RegistryNumber': 'GT0IL38SP4', 'NameOfSubstance': StringElement('Thymic Stromal Lymphopoietin', attributes={'UI': 'D000094632'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Asthma', attributes={'UI': 'D001249', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Antibodies, Monoclonal, Humanized', attributes={'UI': 'D061067', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Patient Selection', attributes={'UI': 'D018579', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Asthmatic Agents', attributes={'UI': 'D018927', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Severity of Illness Index', attributes={'UI': 'D012720', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'}), StringElement('antagonists & inhibitors', attributes={'UI': 'Q000037', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Cytokines', attributes={'UI': 'D016207', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Thymic Stromal Lymphopoietin', attributes={'UI': 'D000094632', 'MajorTopicYN': 'N'})}], 'CoiStatement': 'Declaration of conflicting interestsThe authors declare that there is no conflict of interest.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2024', 'Month': '4', 'Day': '28', 'Hour': '7', 'Minute': '23'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '28', 'Hour': '7', 'Minute': '22'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '27', 'Hour': '6', 'Minute': '52'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38676539', attributes={'IdType': 'pubmed'}), StringElement('10.1177/03000605241246740', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('infusion reactions', attributes={'MajorTopicYN': 'N'}), StringElement('multiple sclerosis', attributes={'MajorTopicYN': 'N'}), StringElement('ocrelizumab', attributes={'MajorTopicYN': 'N'}), StringElement('patient reported outcomes', attributes={'MajorTopicYN': 'N'}), StringElement('pre-medication', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38674305', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '27'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '27'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '19'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('659', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.3390/medicina60040659', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1648-9144', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '60', 'Issue': '4', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '19'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Medicina (Kaunas, Lithuania)', 'ISOAbbreviation': 'Medicina (Kaunas)'}, 'ArticleTitle': 'Comparing the Risk of Infusion-Related Reactions and Tolerability in Patients Given Cetirizine or Diphenhydramine Prior to Ocrelizumab Infusion (PRECEPT).', 'Abstract': {'AbstractText': ['<i>Background:</i> Ocrelizumab is an effective medication for multiple sclerosis. However, infusion-related reactions (IRRs) are a concern for patients and may lead to discontinuation of ocrelizumab. To minimize IRRs, pre-medications are administered. However, from our experience, these medications, especially diphenhydramine, can cause marked drowsiness. The primary objective of this study was to evaluate whether cetirizine is non-inferior to diphenhydramine in limiting the proportion and severity of reactions from ocrelizumab infusions. <i>Methods:</i> Twenty participants were serially randomized in a 1:1 ratio to receive 10 mg of cetirizine or 25 mg of diphenhydramine orally prior to their first three ocrelizumab infusions. <i>Results:</i> The rate of IRRs in this study was similar across both treatment groups with no increase in the risk of severity, and no grade 3 IRRs. Further, patients receiving cetirizine experienced a reduction in fatigue. While there was not a significant difference in global satisfaction, this score increased over time in the cetirizine arm while it remained unchanged in the diphenhydramine arm. <i>Conclusions:</i> Overall, our results suggest that cetirizine does not increase the risk of infusion-related reactions compared to diphenhydramine.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Providence Brain and Spine Institute, Portland, OR 97225, USA.'}], 'Identifier': [], 'LastName': 'Smoot', 'ForeName': 'Kyle', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Providence Brain and Spine Institute, Portland, OR 97225, USA.'}], 'Identifier': [], 'LastName': 'Marginean', 'ForeName': 'Horia', 'Initials': 'H'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Providence Brain and Spine Institute, Portland, OR 97225, USA.'}], 'Identifier': [], 'LastName': 'Gervasi-Follmar', 'ForeName': 'Tiffany', 'Initials': 'T'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Providence Brain and Spine Institute, Portland, OR 97225, USA.'}], 'Identifier': [], 'LastName': 'Chen', 'ForeName': 'Chiayi', 'Initials': 'C'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': 'NA', 'Agency': 'Genentech', 'Country': ''}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Randomized Controlled Trial', attributes={'UI': 'D016449'}), StringElement('Comparative Study', attributes={'UI': 'D003160'})]}, attributes={'PubModel': 'Electronic'}), 'MedlineJournalInfo': {'Country': 'Switzerland', 'MedlineTA': 'Medicina (Kaunas)', 'NlmUniqueID': '9425208', 'ISSNLinking': '1010-660X'}, 'ChemicalList': [{'RegistryNumber': '8GTS82S83M', 'NameOfSubstance': StringElement('Diphenhydramine', attributes={'UI': 'D004155'})}, {'RegistryNumber': 'YO7261ME24', 'NameOfSubstance': StringElement('Cetirizine', attributes={'UI': 'D017332'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Antibodies, Monoclonal, Humanized', attributes={'UI': 'D061067'})}, {'RegistryNumber': 'A10SJL62JY', 'NameOfSubstance': StringElement('ocrelizumab', attributes={'UI': 'C533411'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('administration & dosage', attributes={'UI': 'Q000008', 'MajorTopicYN': 'N'}), StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Diphenhydramine', attributes={'UI': 'D004155', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'}), StringElement('administration & dosage', attributes={'UI': 'Q000008', 'MajorTopicYN': 'N'}), StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Cetirizine', attributes={'UI': 'D017332', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Female', attributes={'UI': 'D005260', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Male', attributes={'UI': 'D008297', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Adult', attributes={'UI': 'D000328', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Middle Aged', attributes={'UI': 'D008875', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'}), StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'}), StringElement('administration & dosage', attributes={'UI': 'Q000008', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Antibodies, Monoclonal, Humanized', attributes={'UI': 'D061067', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Infusions, Intravenous', attributes={'UI': 'D007262', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Multiple Sclerosis', attributes={'UI': 'D009103', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2024', 'Month': '3', 'Day': '22'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '15'}, attributes={'PubStatus': 'revised'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '17'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '27', 'Hour': '9', 'Minute': '54'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '27', 'Hour': '9', 'Minute': '53'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '27', 'Hour': '1', 'Minute': '16'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38674305', attributes={'IdType': 'pubmed'}), StringElement('10.3390/medicina60040659', attributes={'IdType': 'doi'}), StringElement('medicina60040659', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Alzheimer’s disease', attributes={'MajorTopicYN': 'N'}), StringElement('cancer', attributes={'MajorTopicYN': 'N'}), StringElement('clinical trials', attributes={'MajorTopicYN': 'N'}), StringElement('drug repurposing', attributes={'MajorTopicYN': 'N'}), StringElement('pre-clinical trials', attributes={'MajorTopicYN': 'N'}), StringElement('saracatinib', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38674150', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '27'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '27'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '22'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('4565', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.3390/ijms25084565', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1422-0067', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '25', 'Issue': '8', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '22'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'International journal of molecular sciences', 'ISOAbbreviation': 'Int J Mol Sci'}, 'ArticleTitle': 'Dual Drug Repurposing: The Example of Saracatinib.', 'Abstract': {'AbstractText': [\"Saracatinib (AZD0530) is a dual Src/Abl inhibitor initially developed by AstraZeneca for cancer treatment; however, data from 2006 to 2024 reveal that this drug has been tested not only for cancer treatment, but also for the treatment of other diseases. Despite the promising pre-clinical results and the tolerability shown in phase I trials, where a maximum tolerated dose of 175 mg was defined, phase II clinical data demonstrated a low therapeutic action against several cancers and an elevated rate of adverse effects. Recently, pre-clinical research aimed at reducing the toxic effects and enhancing the therapeutic performance of saracatinib using nanoparticles and different pharmacological combinations has shown promising results. Concomitantly, saracatinib was repurposed to treat Alzheimer's disease, targeting Fyn. It showed great clinical results and required a lower daily dose than that defined for cancer treatment, 125 mg and 175 mg, respectively. In addition to Alzheimer's disease, this Src inhibitor has also been studied in relation to other health conditions such as pulmonary and liver fibrosis and even for analgesic and anti-allergic functions. Although saracatinib is still not approved by the Food and Drug Administration (FDA), the large number of alternative uses for saracatinib and the elevated number of pre-clinical and clinical trials performed suggest the huge potential of this drug for the treatment of different kinds of diseases.\"]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.'}, {'Identifier': [], 'Affiliation': 'CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.'}], 'Identifier': [StringElement('0009-0007-5324-8826', attributes={'Source': 'ORCID'})], 'LastName': 'Ramos', 'ForeName': 'Raquel', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.'}, {'Identifier': [], 'Affiliation': 'CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.'}, {'Identifier': [], 'Affiliation': 'Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.'}], 'Identifier': [StringElement('0000-0002-1283-1042', attributes={'Source': 'ORCID'})], 'LastName': 'Vale', 'ForeName': 'Nuno', 'Initials': 'N'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Electronic'}), 'MedlineJournalInfo': {'Country': 'Switzerland', 'MedlineTA': 'Int J Mol Sci', 'NlmUniqueID': '101092791', 'ISSNLinking': '1422-0067'}, 'ChemicalList': [{'RegistryNumber': '9KD24QGH76', 'NameOfSubstance': StringElement('saracatinib', attributes={'UI': 'C515233'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Quinazolines', attributes={'UI': 'D011799'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Benzodioxoles', attributes={'UI': 'D052117'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Protein Kinase Inhibitors', attributes={'UI': 'D047428'})}, {'RegistryNumber': 'EC 2.7.10.2', 'NameOfSubstance': StringElement('src-Family Kinases', attributes={'UI': 'D019061'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Antineoplastic Agents', attributes={'UI': 'D000970'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('methods', attributes={'UI': 'Q000379', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Drug Repositioning', attributes={'UI': 'D058492', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'}), StringElement('chemistry', attributes={'UI': 'Q000737', 'MajorTopicYN': 'N'}), StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Quinazolines', attributes={'UI': 'D011799', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'}), StringElement('chemistry', attributes={'UI': 'Q000737', 'MajorTopicYN': 'N'}), StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Benzodioxoles', attributes={'UI': 'D052117', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Animals', attributes={'UI': 'D000818', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'}), StringElement('chemistry', attributes={'UI': 'Q000737', 'MajorTopicYN': 'N'}), StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'}), StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Protein Kinase Inhibitors', attributes={'UI': 'D047428', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Alzheimer Disease', attributes={'UI': 'D000544', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('antagonists & inhibitors', attributes={'UI': 'Q000037', 'MajorTopicYN': 'N'}), StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('src-Family Kinases', attributes={'UI': 'D019061', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Neoplasms', attributes={'UI': 'D009369', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'}), StringElement('chemistry', attributes={'UI': 'Q000737', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Antineoplastic Agents', attributes={'UI': 'D000970', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2024', 'Month': '3', 'Day': '5'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '11'}, attributes={'PubStatus': 'revised'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '20'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '27', 'Hour': '9', 'Minute': '52'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '27', 'Hour': '9', 'Minute': '51'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '27', 'Hour': '1', 'Minute': '15'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38674150', attributes={'IdType': 'pubmed'}), StringElement('10.3390/ijms25084565', attributes={'IdType': 'doi'}), StringElement('ijms25084565', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Advair Diskus', attributes={'MajorTopicYN': 'N'}), StringElement('batch-to-batch variability', attributes={'MajorTopicYN': 'N'}), StringElement('fluticasone', attributes={'MajorTopicYN': 'N'}), StringElement('population PK', attributes={'MajorTopicYN': 'N'}), StringElement('salmeterol', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38671158', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '26'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '26'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '26'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1208/s12248-024-00913-x', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1550-7416', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '26', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '26'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The AAPS journal', 'ISOAbbreviation': 'AAPS J'}, 'ArticleTitle': 'Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability.', 'Pagination': {'StartPage': '56', 'MedlinePgn': '56'}, 'Abstract': {'AbstractText': ['Advair Diskus is an essential treatment for asthma and chronic obstructive pulmonary disease. It is a dry powder inhaler with a combination of fluticasone propionate (FP) and salmeterol xinafoate (SX). However, the pharmacokinetics (PK) batch-to-batch variability of the reference-listed drug (RLD) hindered its generic product development. This work developed the PK models for inhaled FP and SX that could represent potential batch variability. Two batches each of the reference and the test product (R<sub>1</sub>, R<sub>2</sub>, T<sub>1</sub>, T<sub>2</sub>) of Advair Diskus (100\\xa0μg FP/50\\xa0μg SX inhalation) were administered to 60 healthy subjects in a 4-period, 4-sequence crossover study. The failure of the bioequivalence (BE) between R<sub>1</sub> and R<sub>2</sub> confirmed the high between-batch variability of the RLD. Non-linear mixed effect modeling was used to estimate the population mean PK parameters for each batch. For FP, a 2-compartment model with a sequential dual zero-order absorption best described the PK profile. For SX, a 2-compartment model with a first-order absorption model best fit the data. Both models were able to capture the plasma concentration, the maximum concentration, and the total exposure (AUC<sub>inf</sub>) adequately for each batch, which could be used to simulate the BE study in the future. In vitro properties were also measured for each batch, and the batch with a higher fraction of the fine particle (diameter\\u2009<\\u20091\\xa0µm,\\u2009<\\u20092\\xa0µm) had a higher AUC<sub>inf</sub>. This positive correlation for both FP and SX could potentially assist the batch selection for the PK BE study.'], 'CopyrightInformation': '© 2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Center for Translational Medicine, School of Pharmacy, University of Maryland, 20 North Pine Street, Baltimore, Maryland, 21201, USA.'}], 'Identifier': [], 'LastName': 'Li', 'ForeName': 'Shuhui', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Feng', 'ForeName': 'Kairui', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Lee', 'ForeName': 'Jieon', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Gong', 'ForeName': 'Yuqing', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Wu', 'ForeName': 'Fang', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Newman', 'ForeName': 'Bryan', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Yoon', 'ForeName': 'Miyoung', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Fang', 'ForeName': 'Lanyan', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Zhao', 'ForeName': 'Liang', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Center for Translational Medicine, School of Pharmacy, University of Maryland, 20 North Pine Street, Baltimore, Maryland, 21201, USA. jgobburu@rx.umaryland.edu.'}], 'Identifier': [], 'LastName': 'Gobburu', 'ForeName': 'Jogarao V S', 'Initials': 'JVS'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Randomized Controlled Trial', attributes={'UI': 'D016449'}), StringElement(\"Research Support, Non-U.S. Gov't\", attributes={'UI': 'D013485'})]}, attributes={'PubModel': 'Electronic'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'AAPS J', 'NlmUniqueID': '101223209', 'ISSNLinking': '1550-7416'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Fluticasone-Salmeterol Drug Combination', attributes={'UI': 'D000068297'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Bronchodilator Agents', attributes={'UI': 'D001993'})}, {'RegistryNumber': 'CUT2W21N7U', 'NameOfSubstance': StringElement('Fluticasone', attributes={'UI': 'D000068298'})}, {'RegistryNumber': '6EW8Q962A5', 'NameOfSubstance': StringElement('Salmeterol Xinafoate', attributes={'UI': 'D000068299'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Administration, Inhalation', attributes={'UI': 'D000280', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Cross-Over Studies', attributes={'UI': 'D018592', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Male', attributes={'UI': 'D008297', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Adult', attributes={'UI': 'D000328', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pharmacokinetics', attributes={'UI': 'Q000493', 'MajorTopicYN': 'N'}), StringElement('administration & dosage', attributes={'UI': 'Q000008', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Fluticasone-Salmeterol Drug Combination', attributes={'UI': 'D000068297', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Models, Biological', attributes={'UI': 'D008954', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Therapeutic Equivalency', attributes={'UI': 'D013810', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Young Adult', attributes={'UI': 'D055815', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Dry Powder Inhalers', attributes={'UI': 'D058995', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('pharmacokinetics', attributes={'UI': 'Q000493', 'MajorTopicYN': 'N'}), StringElement('administration & dosage', attributes={'UI': 'Q000008', 'MajorTopicYN': 'N'}), StringElement('blood', attributes={'UI': 'Q000097', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Bronchodilator Agents', attributes={'UI': 'D001993', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Female', attributes={'UI': 'D005260', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Middle Aged', attributes={'UI': 'D008875', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pharmacokinetics', attributes={'UI': 'Q000493', 'MajorTopicYN': 'N'}), StringElement('administration & dosage', attributes={'UI': 'Q000008', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Fluticasone', attributes={'UI': 'D000068298', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pharmacokinetics', attributes={'UI': 'Q000493', 'MajorTopicYN': 'N'}), StringElement('administration & dosage', attributes={'UI': 'Q000008', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Salmeterol Xinafoate', attributes={'UI': 'D000068299', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Healthy Volunteers', attributes={'UI': 'D064368', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Garantziotis S, Schwartz DA. Ecogenomics of respiratory diseases of public health significance. 2010;31:37–51. https://doi.org/10.1146/ANNUREV.PUBLHEALTH.012809.103633 .', 'ArticleIdList': [StringElement('10.1146/ANNUREV.PUBLHEALTH.012809.103633', attributes={'IdType': 'doi'})]}, {'Citation': 'AsthmaStats - Asthma severity among adults with current asthma | CDC. https://www.cdc.gov/asthma/asthma_stats/severity_adult.htm .\\xa0Accessed 26 Jan 2022.'}, {'Citation': 'Aalbers R, Vogelmeier C, Kuna P. Achieving asthma control with ICS/LABA: a review of strategies for asthma management and prevention. Respir Med. 2016;111:1–7. https://doi.org/10.1016/J.RMED.2015.11.002 .', 'ArticleIdList': [StringElement('10.1016/J.RMED.2015.11.002', attributes={'IdType': 'doi'}), StringElement('26614594', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Page C, O’Shaughnessy B, Barnes P. Pathogenesis of COPD and asthma. Handb Exp Pharmacol. 2017;237:1–21. https://doi.org/10.1007/164_2016_61 .', 'ArticleIdList': [StringElement('10.1007/164_2016_61', attributes={'IdType': 'doi'}), StringElement('27888348', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Reynolds NA, Lyseng-Williamson KA, Wiseman LR. Inhaled salmeterol/fluticasone propionate: a review of its use in asthma. Drugs. 2005;65(12):1715–34. https://doi.org/10.2165/00003495-200565120-00012 .', 'ArticleIdList': [StringElement('10.2165/00003495-200565120-00012', attributes={'IdType': 'doi'}), StringElement('16060707', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Esmailpour N, Högger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J. 1997;10(7):1496–9. https://doi.org/10.1183/09031936.97.10071496 .', 'ArticleIdList': [StringElement('10.1183/09031936.97.10071496', attributes={'IdType': 'doi'}), StringElement('9230236', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Derom EY, Pauwels RA, van der Straeten MEF. The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours. J Allergy Clin Immunol. 1992;89(4):811–5. https://doi.org/10.1016/0091-6749(92)90435-5 .', 'ArticleIdList': [StringElement('10.1016/0091-6749(92)90435-5', attributes={'IdType': 'doi'}), StringElement('1560164', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Murray J, Rosenthal R, Somerville L, et al. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. Ann Allergy Asthma Immunol. 2004;93(4):351–9. https://doi.org/10.1016/S1081-1206(10)61394-4 .', 'ArticleIdList': [StringElement('10.1016/S1081-1206(10)61394-4', attributes={'IdType': 'doi'}), StringElement('15521371', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pearlman DS, Stricker W, Weinstein S, et al. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol. 1999;82(3):257–65. https://doi.org/10.1016/S1081-1206(10)62606-3 .', 'ArticleIdList': [StringElement('10.1016/S1081-1206(10)62606-3', attributes={'IdType': 'doi'}), StringElement('10094216', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Goyal N, Hochhaus G. Demonstrating bioequivalence using pharmacokinetics: theoretical considerations across drug classes. Respiratory Drug Delivery. 2010;1:261–72.'}, {'Citation': 'United States Food and Drug Administration. Guidance on fluticasone propionate; salmeterol xinafoate. US Food and Drug Administration. 2013;2–8. https://www.accessdata.fda.gov/drugsatfda_docs/psg/FluticasoneProprionate_SalmeterolXinafoate_21077_RC09–13.pdf .'}, {'Citation': 'Burmeister Getz E, Carroll KJ, Jones B, Benet LZ. Batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: a dry powder inhaler randomized clinical trial. Clin Pharmacol Ther. 2016;100(3):223–31. https://doi.org/10.1002/cpt.373 .', 'ArticleIdList': [StringElement('10.1002/cpt.373', attributes={'IdType': 'doi'}), StringElement('27037630', attributes={'IdType': 'pubmed'}), StringElement('5102576', attributes={'IdType': 'pmc'})]}, {'Citation': 'Benet LZ, Jayachandran P, Carroll KJ, Burmeister GE. Batch-to-batch and within-subject variability: what do we know and how do these variabilities affect clinical pharmacology and bioequivalence? Clin Pharmacol Ther. 2019;105(2):326–8. https://doi.org/10.1002/cpt.1294 .', 'ArticleIdList': [StringElement('10.1002/cpt.1294', attributes={'IdType': 'doi'}), StringElement('30652313', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Can Respir J. 2018;2018:2732017. https://doi.org/10.1155/2018/2732017 .', 'ArticleIdList': [StringElement('10.1155/2018/2732017', attributes={'IdType': 'doi'}), StringElement('30018677', attributes={'IdType': 'pubmed'}), StringElement('6029458', attributes={'IdType': 'pmc'})]}, {'Citation': 'Rackauckas C, Ma Y, Noack A, et al. Accelerated predictive healthcare analytics with Pumas, a high performance pharmaceutical modeling and simulation platform. bioRxiv. 2022;2020.11.28.402297. https://doi.org/10.1101/2020.11.28.402297.'}, {'Citation': 'U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER). Statistical approaches to establishing bioequivalence. 2001.'}, {'Citation': 'R: a language and environment for statistical computing. R Foundation for Statistical Computing. 2009. Available from: http://www.R-project.org .'}, {'Citation': 'Carter AA, Rosenbaum SE, Dudley MN. Review of methods in population pharmacokinetics. Clin Res Regul Aff. 1995;12(1):1–21. https://doi.org/10.3109/10601339509079574 .', 'ArticleIdList': [StringElement('10.3109/10601339509079574', attributes={'IdType': 'doi'})]}, {'Citation': 'Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev. 1984;15(1–2):153–71. https://doi.org/10.3109/03602538409015063 .', 'ArticleIdList': [StringElement('10.3109/03602538409015063', attributes={'IdType': 'doi'}), StringElement('6745080', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Marple VA, Hochrainer D, Roberts DL, et al. Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part I: Design J Aerosol Med. 2003;16(3):283–99. https://doi.org/10.1089/089426803769017659 .', 'ArticleIdList': [StringElement('10.1089/089426803769017659', attributes={'IdType': 'doi'}), StringElement('14572326', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Labes D. Power and sample size based on two one-sided t-tests (TOST) for (bio)equivalence studies. 2013. http://cran.r-project.org/web/packages/PowerTOST/PowerTOST.pdf . Accessed 28 Sep 2022.'}, {'Citation': 'Reisner C. In-vitro /in-vivo comparisons of formoterol MDI to formoterol DPI: lessons learned.\\xa0Orlando Inhalation Conference. 2014. https://custom.cvent.com/7BA2EE65E8B64AEBB1E77F19E7FD30BC/files/event/8a749091c2c741228907ca5c70b619eb/228b0d5a93e34653ab9b033dfc7e54a7.pdf . Accessed 28 Sep 2022.'}, {'Citation': 'Advair Diskus <sup>TM</sup> package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021077s029lbl.pdf . Accessed 28 Sep 2022.'}, {'Citation': 'Falcoz C, Oliver R, McDowall JE, Ventresca P, Bye A, Daley-Yates PT. Bioavailability of orally administered micronised fluticasone propionate. Clin Pharmacokinet. 2000;39(SUPPL. 1):9–15. https://doi.org/10.2165/00003088-200039001-00002 .', 'ArticleIdList': [StringElement('10.2165/00003088-200039001-00002', attributes={'IdType': 'doi'}), StringElement('11140434', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Weber B, Hochhaus G. A pharmacokinetic simulation tool for inhaled corticosteroids. AAPS J. 2013;15(1):159–71. https://doi.org/10.1208/s12248-012-9420-z .', 'ArticleIdList': [StringElement('10.1208/s12248-012-9420-z', attributes={'IdType': 'doi'}), StringElement('23139018', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Goyal N, Hochhaus G. Demonstrating bioequivalence using pharmacokinetics: theoretical considerations across drug classes. Respiratory Drug Delivery. 2010;1:261–72.'}, {'Citation': 'Drescher SK, Jiao Y, Chen MJ, et al. Central and peripheral lung deposition of fluticasone propionate dry powder inhaler formulations in humans characterized by population pharmacokinetics. Pharm Res. 2023;40(5):1177–91. https://doi.org/10.1007/S11095-023-03472-6/TABLES/4 .', 'ArticleIdList': [StringElement('10.1007/S11095-023-03472-6/TABLES/4', attributes={'IdType': 'doi'}), StringElement('37081302', attributes={'IdType': 'pubmed'}), StringElement('10686290', attributes={'IdType': 'pmc'})]}, {'Citation': 'Soulele K, Macheras P, Silvestro L, Rizea Savu S, Karalis V. Population pharmacokinetics of fluticasone propionate/salmeterol using two different dry powder inhalers. Eur J Pharm Sci. 2015;80:33–42. https://doi.org/10.1016/J.EJPS.2015.08.009 .', 'ArticleIdList': [StringElement('10.1016/J.EJPS.2015.08.009', attributes={'IdType': 'doi'}), StringElement('26296862', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chen X, Zheng X, Jiang J, et al. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2015;35(6):586–99. https://doi.org/10.1002/PHAR.1598 .', 'ArticleIdList': [StringElement('10.1002/PHAR.1598', attributes={'IdType': 'doi'})]}, {'Citation': 'Soulele K, Macheras P, Karalis V. Pharmacokinetic analysis of inhaled salmeterol in asthma patients: evidence from two dry powder inhalers. Biopharm Drug Dispos. 2017;38(7):407–19. https://doi.org/10.1002/BDD.2077 .', 'ArticleIdList': [StringElement('10.1002/BDD.2077', attributes={'IdType': 'doi'}), StringElement('28374512', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bennett JA, Harrison TW, Tattersfield AE. The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects. Eur Respir J. 1999;13(2):445–8. https://doi.org/10.1183/09031936.99.13244599 .', 'ArticleIdList': [StringElement('10.1183/09031936.99.13244599', attributes={'IdType': 'doi'}), StringElement('10065696', attributes={'IdType': 'pubmed'})]}, {'Citation': 'U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER). Generic Drug User Fee Amendments (GDUFA) Science and Research Priority Initiatives for Fiscal Year (FY). 2021. https://www.fda.gov/media/156481/download#page=39 . Accessed 12 Jul 2023.\\xa0'}, {'Citation': 'U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER). Generic Drug User Fee Amendments (GDUFA) Science and Research Priority Initiatives for Fiscal Year (FY). 2022.\\xa0 https://www.fda.gov/media/156481/download#page=39 . Accessed 12 Jul 2023.'}, {'Citation': 'Hendrickx R, Bergström EL, Janzén DLI, et al. Translational model to predict pulmonary pharmacokinetics and efficacy in man for inhaled bronchodilators. CPT Pharmacometrics Syst Pharmacol. 2018;7(3):147–57. https://doi.org/10.1002/PSP4.12270 .', 'ArticleIdList': [StringElement('10.1002/PSP4.12270', attributes={'IdType': 'doi'}), StringElement('29280349', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev. 1984;15(1–2):153–71. https://doi.org/10.3109/03602538409015063 .', 'ArticleIdList': [StringElement('10.3109/03602538409015063', attributes={'IdType': 'doi'}), StringElement('6745080', attributes={'IdType': 'pubmed'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2023', 'Month': '5', 'Day': '23'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '20'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '27', 'Hour': '9', 'Minute': '49'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '27', 'Hour': '9', 'Minute': '48'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '26', 'Hour': '23', 'Minute': '27'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38671158', attributes={'IdType': 'pubmed'}), StringElement('10.1208/s12248-024-00913-x', attributes={'IdType': 'doi'}), StringElement('10.1208/s12248-024-00913-x', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38671063', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '26'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '26'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '26'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1038/s41598-024-59190-5', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2045-2322', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '14', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '26'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Scientific reports', 'ISOAbbreviation': 'Sci Rep'}, 'ArticleTitle': 'The new preservative-free ophthalmic formulation of bilastine 0.6% preserves the ocular surface epithelial integrity in a comparative in vitro study.', 'Pagination': {'StartPage': '9598', 'MedlinePgn': '9598'}, 'Abstract': {'AbstractText': ['Allergic conjunctivitis (AC) is the most common form of allergic eye disease and an increasingly prevalent condition. Topical eye drop treatments are the usual approach for managing AC, although their impact on the ocular surface is not frequently investigated. The aim of this study was to perform a comparative physicochemical characterization, and in vitro biological evaluations in primary conjunctival and corneal epithelial cells of the new multidose preservative-free bilastine 0.6% and main commercially available eye drops. MTT assay was used to measure cell viability; oxidative stress was analyzed with a ROS-sensitive probe; and apoptosis was evaluated monitoring caspase 3/7 activation. Differences in pH value, osmolarity, viscosity and phosphate levels were identified. Among all formulations, bilastine exhibited pH, osmolarity and viscosity values closer to tear film (7.4, 300\\xa0mOsm/l and ~\\xa01.5-10\\xa0mPa·s, respectively), and was the only phosphates-free solution. Single-dose ketotifen did not induce ROS production, and single-dose azelastine and bilastine only induced a mild increase. Bilastine and single-dose ketotifen and azelastine showed high survival rates attributable to the absence of preservative in its formulation, not inducing caspase-3/7-mediated apoptosis after 24\\xa0h. Our findings support the use of the new bilastine 0.6% for treating patients with AC to preserve and maintain the integrity of the ocular surface.'], 'CopyrightInformation': '© 2024. The Author(s).'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Research, Development and Innovation Department (R&D+I Department), Faes Farma, Av. Autonomía 10, 48940, Leioa, Bizkaia, Spain.'}, {'Identifier': [], 'Affiliation': 'Department of Cell Biology and Histology, School of Medicine and Nursing, University of the Basque Country, Leioa, Spain.'}], 'Identifier': [], 'LastName': 'Arana', 'ForeName': 'Eider', 'Initials': 'E'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Research, Development and Innovation Department (R&D+I Department), Faes Farma, Av. Autonomía 10, 48940, Leioa, Bizkaia, Spain.'}], 'Identifier': [], 'LastName': 'Gonzalo', 'ForeName': 'Ana', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Cell Biology and Histology, School of Medicine and Nursing, University of the Basque Country, Leioa, Spain.'}, {'Identifier': [], 'Affiliation': 'Biobizkaia Health Research Institute, Barakaldo, Spain.'}], 'Identifier': [], 'LastName': 'Andollo', 'ForeName': 'Noelia', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Biotechnology Area, GAIKER Technology Centre, Basque Research and Technology Alliance, Zamudio, Spain.'}], 'Identifier': [], 'LastName': 'Goñi-de-Cerio', 'ForeName': 'Felipe', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Biotechnology Area, GAIKER Technology Centre, Basque Research and Technology Alliance, Zamudio, Spain.'}], 'Identifier': [], 'LastName': 'Gómez-Fernández', 'ForeName': 'Paloma', 'Initials': 'P'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Innoprot SL, Bizkaia Technology Park, Derio, Bizkaia, Spain.'}], 'Identifier': [], 'LastName': 'Salado', 'ForeName': 'Clarisa', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Research, Development and Innovation Department (R&D+I Department), Faes Farma, Av. Autonomía 10, 48940, Leioa, Bizkaia, Spain.'}], 'Identifier': [], 'LastName': 'Hernández', 'ForeName': 'Gonzalo', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Research, Development and Innovation Department (R&D+I Department), Faes Farma, Av. Autonomía 10, 48940, Leioa, Bizkaia, Spain. tsuarez@faes.es.'}], 'Identifier': [], 'LastName': 'Suárez-Cortés', 'ForeName': 'Tatiana', 'Initials': 'T'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': 'BIKAINTEK Program (48-AF-W2-2018-00008)', 'Agency': 'Basque Government, Spain', 'Country': ''}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement(\"Research Support, Non-U.S. Gov't\", attributes={'UI': 'D013485'}), StringElement('Comparative Study', attributes={'UI': 'D003160'})]}, attributes={'PubModel': 'Electronic'}), 'MedlineJournalInfo': {'Country': 'England', 'MedlineTA': 'Sci Rep', 'NlmUniqueID': '101563288', 'ISSNLinking': '2045-2322'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Ophthalmic Solutions', attributes={'UI': 'D009883'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Preservatives, Pharmaceutical', attributes={'UI': 'D011310'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Benzimidazoles', attributes={'UI': 'D001562'})}, {'RegistryNumber': 'EC 3.4.22.-', 'NameOfSubstance': StringElement('Caspase 3', attributes={'UI': 'D053148'})}, {'RegistryNumber': 'PA1123N395', 'NameOfSubstance': StringElement('bilastine', attributes={'UI': 'C445659'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Piperidines', attributes={'UI': 'D010880'})}, {'RegistryNumber': 'EC 3.4.22.-', 'NameOfSubstance': StringElement('Caspase 7', attributes={'UI': 'D053179'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Reactive Oxygen Species', attributes={'UI': 'D017382'})}, {'RegistryNumber': 'ZQI909440X', 'NameOfSubstance': StringElement('azelastine', attributes={'UI': 'C020976'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Phthalazines', attributes={'UI': 'D010793'})}, {'RegistryNumber': 'EC 3.4.22.-', 'NameOfSubstance': StringElement('CASP3 protein, human', attributes={'UI': 'C505407'})}], 'MeshHeadingList': [{'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Ophthalmic Solutions', attributes={'UI': 'D009883', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Preservatives, Pharmaceutical', attributes={'UI': 'D011310', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('drug effects', attributes={'UI': 'Q000187', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Cell Survival', attributes={'UI': 'D002470', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'}), StringElement('chemistry', attributes={'UI': 'Q000737', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Benzimidazoles', attributes={'UI': 'D001562', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Caspase 3', attributes={'UI': 'D053148', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('drug effects', attributes={'UI': 'Q000187', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Apoptosis', attributes={'UI': 'D017209', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Piperidines', attributes={'UI': 'D010880', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug effects', attributes={'UI': 'Q000187', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Oxidative Stress', attributes={'UI': 'D018384', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug effects', attributes={'UI': 'Q000187', 'MajorTopicYN': 'N'}), StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Epithelial Cells', attributes={'UI': 'D004847', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug effects', attributes={'UI': 'Q000187', 'MajorTopicYN': 'N'}), StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'}), StringElement('pathology', attributes={'UI': 'Q000473', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Conjunctiva', attributes={'UI': 'D003228', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Caspase 7', attributes={'UI': 'D053179', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Reactive Oxygen Species', attributes={'UI': 'D017382', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'}), StringElement('pathology', attributes={'UI': 'Q000473', 'MajorTopicYN': 'N'}), StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Conjunctivitis, Allergic', attributes={'UI': 'D003233', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Phthalazines', attributes={'UI': 'D010793', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Osmolar Concentration', attributes={'UI': 'D009994', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug effects', attributes={'UI': 'Q000187', 'MajorTopicYN': 'N'}), StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Epithelium, Corneal', attributes={'UI': 'D019573', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Cells, Cultured', attributes={'UI': 'D002478', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Viscosity', attributes={'UI': 'D014783', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Leonardi, A. et al. Ocular allergy: Recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy 67(11), 1327–1337. https://doi.org/10.1111/all.12009 (2012).', 'ArticleIdList': [StringElement('10.1111/all.12009', attributes={'IdType': 'doi'}), StringElement('22947083', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Craig, J. P. et al. TFOS DEWS II definition and classification report. Ocul. Surf. 15(3), 276–283. https://doi.org/10.1016/j.jtos.2017.05.008 (2017).', 'ArticleIdList': [StringElement('10.1016/j.jtos.2017.05.008', attributes={'IdType': 'doi'}), StringElement('28736335', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chigbu, D. I. The pathophysiology of ocular allergy: A review. Cont. Lens Anterior Eye 32(1), 3–44. https://doi.org/10.1016/j.clae.2008.07.003 (2009).', 'ArticleIdList': [StringElement('10.1016/j.clae.2008.07.003', attributes={'IdType': 'doi'}), StringElement('18805042', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Azari, A. A. & Arabi, A. Conjunctivitis: A systematic review. J. Ophthal. Vis. Res. 15(3), 372–395. https://doi.org/10.18502/jovr.v15i3.7456 (2020).', 'ArticleIdList': [StringElement('10.18502/jovr.v15i3.7456', attributes={'IdType': 'doi'})]}, {'Citation': 'Sánchez-Hernández, M. C. et al. Consensus document on allergic conjunctivitis (DECA). J. Investig. Allergol. Clin. Immunol. 25(2), 94–106 (2015).', 'ArticleIdList': [StringElement('25997302', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Villegas, B. V. & Benitez-Del-Castillo, J. M. Current knowledge in allergic conjunctivitis. Turk. J. Ophthalmol. 51(1), 45–54. https://doi.org/10.4274/tjo.galenos.2020.11456 (2021).', 'ArticleIdList': [StringElement('10.4274/tjo.galenos.2020.11456', attributes={'IdType': 'doi'}), StringElement('33631915', attributes={'IdType': 'pubmed'}), StringElement('7931656', attributes={'IdType': 'pmc'})]}, {'Citation': 'Friedlaender, M. H. Ocular allergy. Curr. Opin. Allergy Clin. Immunol. 11(5), 477–482. https://doi.org/10.1097/ACI.0b013e32834a9652 (2011).', 'ArticleIdList': [StringElement('10.1097/ACI.0b013e32834a9652', attributes={'IdType': 'doi'}), StringElement('21822130', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bielory, L. et al. ICON: Diagnosis and management of allergic conjunctivitis. Ann. Allergy Asthma Immunol. 124(2), 118–134. https://doi.org/10.1016/j.anai.2019.11.014 (2020).', 'ArticleIdList': [StringElement('10.1016/j.anai.2019.11.014', attributes={'IdType': 'doi'}), StringElement('31759180', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Miyazaki, D. et al. Epidemiological aspects of allergic conjunctivitis. Allergol. Int. 69(4), 487–495. https://doi.org/10.1016/j.alit.2020.06.004 (2020).', 'ArticleIdList': [StringElement('10.1016/j.alit.2020.06.004', attributes={'IdType': 'doi'}), StringElement('32654975', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Palmares, J., Delgado, L., Cidade, M., Quadrado, M. J. & Filipe, H. P. Allergic conjunctivitis: A national cross-sectional study of clinical characteristics and quality of life. Eur. J. Ophthalmol. 20(2), 257–264. https://doi.org/10.1177/112067211002000201 (2010).', 'ArticleIdList': [StringElement('10.1177/112067211002000201', attributes={'IdType': 'doi'}), StringElement('20037906', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Dupuis, P., Prokopich, C. L., Hynes, A. & Kim, H. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin. Immunol. 16, 5. https://doi.org/10.1186/s13223-020-0403-9 (2020).', 'ArticleIdList': [StringElement('10.1186/s13223-020-0403-9', attributes={'IdType': 'doi'}), StringElement('31993069', attributes={'IdType': 'pubmed'}), StringElement('6975089', attributes={'IdType': 'pmc'})]}, {'Citation': 'La Rosa, M. et al. Allergic conjunctivitis: A comprehensive review of the literature. Ital. J. Pediatr. 39, 18. https://doi.org/10.1186/1824-7288-39-18 (2013).', 'ArticleIdList': [StringElement('10.1186/1824-7288-39-18', attributes={'IdType': 'doi'}), StringElement('23497516', attributes={'IdType': 'pubmed'}), StringElement('3640929', attributes={'IdType': 'pmc'})]}, {'Citation': 'Leonardi, A. et al. Management of ocular allergy. Allergy 74(9), 1611–1630. https://doi.org/10.1111/all.13786 (2019).', 'ArticleIdList': [StringElement('10.1111/all.13786', attributes={'IdType': 'doi'}), StringElement('30887530', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Jumelle, C., Gholizadeh, S., Annabi, N. & Dana, R. Advances and limitations of drug delivery systems formulated as eye drops. J. Control Rel. 321, 1–22. https://doi.org/10.1016/j.jconrel.2020.01.057 (2020).', 'ArticleIdList': [StringElement('10.1016/j.jconrel.2020.01.057', attributes={'IdType': 'doi'})]}, {'Citation': 'Patel, A., Cholkar, K., Agrahari, V. & Mitra, A. K. Ocular drug delivery systems: An overview. World J. Pharmacol. 2(2), 47–64. https://doi.org/10.5497/wjp.v2.i2.47 (2013).', 'ArticleIdList': [StringElement('10.5497/wjp.v2.i2.47', attributes={'IdType': 'doi'}), StringElement('25590022', attributes={'IdType': 'pubmed'}), StringElement('4289909', attributes={'IdType': 'pmc'})]}, {'Citation': 'Ben Saidane, L. P. How to deliver preservative-free eye drops in a multidose system with a safer alternative to filters? ARVO Annual Meeting Abstract. Invest. Ophthalmol. Vis. Sci. 58(8), 4460 (2017).'}, {'Citation': 'Goldstein, M. H., Silva, F. Q., Blender, N., Tran, T. & Vantipalli, S. Ocular benzalkonium chloride exposure: Problems and solutions. Eye (Lond.) 36(2), 361–368. https://doi.org/10.1038/s41433-021-01668-x (2022).', 'ArticleIdList': [StringElement('10.1038/s41433-021-01668-x', attributes={'IdType': 'doi'}), StringElement('34262161', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Baudouin, C., Labbé, A., Liang, H., Pauly, A. & Brignole-Baudouin, F. Preservatives in eyedrops: The good, the bad and the ugly. Prog. Retin. Eye Res. 29(4), 312–334. https://doi.org/10.1016/j.preteyeres.2010.03.001 (2010).', 'ArticleIdList': [StringElement('10.1016/j.preteyeres.2010.03.001', attributes={'IdType': 'doi'}), StringElement('20302969', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Coroi, M. C., Bungau, S. & Tit, M. Preservatives from the eye drops and the ocular surface. Rom. J. Ophthalmol. 59(1), 2–5 (2015).', 'ArticleIdList': [StringElement('27373107', attributes={'IdType': 'pubmed'}), StringElement('5729814', attributes={'IdType': 'pmc'})]}, {'Citation': 'Gomes, P. J., Ciolino, J. B., Arranz, P., Hernández, G. & Fernández, N. Bilastine 0.6% preservative-free eye drops, a once-daily treatment for allergic conjunctivitis. J. Investig. Allergol. Clin. Immunol. 21, 10. https://doi.org/10.18176/jiaci.0894 (2023).', 'ArticleIdList': [StringElement('10.18176/jiaci.0894', attributes={'IdType': 'doi'})]}, {'Citation': 'Church, M. K., Tiongco-Recto, M., Ridolo, E. & Novák, Z. Bilastine: A lifetime companion for the treatment of allergies. Curr. Med. Res. Opin. 36(3), 445–454. https://doi.org/10.1080/03007995.2019.1681134 (2020).', 'ArticleIdList': [StringElement('10.1080/03007995.2019.1681134', attributes={'IdType': 'doi'}), StringElement('31612732', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Carter, N. J. Bilastine: In allergic rhinitis and urticaria. Drugs 72(9), 1257–1269. https://doi.org/10.2165/11209310-000000000-00000 (2012).', 'ArticleIdList': [StringElement('10.2165/11209310-000000000-00000', attributes={'IdType': 'doi'}), StringElement('22686617', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gomes, P. J., Ciolino, J. B., Arranz, P., Hernández, G. & Fernández, N. Efficacy of once-daily ophthalmic bilastine for the treatment of allergic conjunctivitis: A dose-finding study. J. Investig. Allergol. Clin. Immunol. 1, 0. https://doi.org/10.18176/jiaci.0800 (2022).', 'ArticleIdList': [StringElement('10.18176/jiaci.0800', attributes={'IdType': 'doi'})]}, {'Citation': 'Kuna, P. et al. Safety and tolerability of bilastine 0.6% ophthalmic solution: An 8-weeks phase III study. Clin. Ophthalmol. 4(17), 735–746. https://doi.org/10.2147/OPTH.S398168 (2023).', 'ArticleIdList': [StringElement('10.2147/OPTH.S398168', attributes={'IdType': 'doi'})]}, {'Citation': 'Ridolo, E. et al. Bilastine: New insight into antihistamine treatment. Clin. Mol. Allergy 13(1), 1. https://doi.org/10.1186/s12948-015-0008-x (2015).', 'ArticleIdList': [StringElement('10.1186/s12948-015-0008-x', attributes={'IdType': 'doi'}), StringElement('25878559', attributes={'IdType': 'pubmed'}), StringElement('4397738', attributes={'IdType': 'pmc'})]}, {'Citation': 'Ochoa, D. et al. Pharmacokinetics and safety of a bilastine once-daily, preservative-free, ophthalmic formulation. Adv. Ther. 38(7), 4070–4081. https://doi.org/10.1007/s12325-021-01801-y (2021).', 'ArticleIdList': [StringElement('10.1007/s12325-021-01801-y', attributes={'IdType': 'doi'}), StringElement('34125400', attributes={'IdType': 'pubmed'}), StringElement('8280016', attributes={'IdType': 'pmc'})]}, {'Citation': 'Mantelli, F., Tranchina, L., Lambiase, A. & Bonini, S. Ocular surface damage by ophthalmic compounds. Curr. Opin. Allergy Clin. Immunol. 11(5), 464–470. https://doi.org/10.1097/ACI.0b013e32834a95c9 (2011).', 'ArticleIdList': [StringElement('10.1097/ACI.0b013e32834a95c9', attributes={'IdType': 'doi'}), StringElement('21822131', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kumar, P., Nagarajan, A. & Uchil, P. D. Analysis of cell viability by the MTT assay. Cold Spring Harb. Protoc. 6, 2018. https://doi.org/10.1101/pdb.prot095505 (2018).', 'ArticleIdList': [StringElement('10.1101/pdb.prot095505', attributes={'IdType': 'doi'})]}, {'Citation': 'Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65(1–2), 55–63. https://doi.org/10.1016/0022-1759(83)90303-4 (1983).', 'ArticleIdList': [StringElement('10.1016/0022-1759(83)90303-4', attributes={'IdType': 'doi'}), StringElement('6606682', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pauly, A. et al. Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: Responses to histamine and IFNγ and toxicological profiles. Graefe’s Arch. Clin. Exp. Ophthalmol. 245(4), 534–546. https://doi.org/10.1007/s00417-006-0353-z (2007).', 'ArticleIdList': [StringElement('10.1007/s00417-006-0353-z', attributes={'IdType': 'doi'})]}, {'Citation': 'Schuerer, N. et al. Implications for ophthalmic formulations: Ocular buffers show varied cytotoxic impact on human corneal-limbal and human conjunctival epithelial cells. Cornea 36(6), 712–718. https://doi.org/10.1097/ICO.0000000000001199 (2017).', 'ArticleIdList': [StringElement('10.1097/ICO.0000000000001199', attributes={'IdType': 'doi'}), StringElement('28399036', attributes={'IdType': 'pubmed'}), StringElement('5421463', attributes={'IdType': 'pmc'})]}, {'Citation': 'Yamada, M., Mochizuki, H., Kawai, M., Yoshino, M. & Mashima, Y. Fluorophotometric measurement of pH of human tears in vivo. Curr. Eye Res. 16(5), 482–486. https://doi.org/10.1076/ceyr.16.5.482.7050 (1997).', 'ArticleIdList': [StringElement('10.1076/ceyr.16.5.482.7050', attributes={'IdType': 'doi'}), StringElement('9154387', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Dutescu, R. M., Panfil, C. & Schrage, N. Osmolarity of prevalent eye drops, side effects, and therapeutic approaches. Cornea 34(5), 560–566. https://doi.org/10.1097/ICO.0000000000000368 (2015).', 'ArticleIdList': [StringElement('10.1097/ICO.0000000000000368', attributes={'IdType': 'doi'}), StringElement('25789693', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tomlinson, A., Khanal, S., Ramaesh, K., Diaper, C. & McFadyen, A. Tear film osmolarity: Determination of a referent for dry eye diagnosis. Invest. Ophthalmol. Vis. Sci. 47(10), 4309–4315. https://doi.org/10.1167/iovs.05-1504 (2006).', 'ArticleIdList': [StringElement('10.1167/iovs.05-1504', attributes={'IdType': 'doi'}), StringElement('17003420', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lemp, M. A. et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am. J. Ophthalmol. 151(5), 792-798.e1. https://doi.org/10.1016/j.ajo.2010.10.032 (2011).', 'ArticleIdList': [StringElement('10.1016/j.ajo.2010.10.032', attributes={'IdType': 'doi'}), StringElement('21310379', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Benelli, U., Nardi, M., Posarelli, C. & Albert, T. G. Tear osmolarity measurement using the TearLab osmolarity system in the assessment of dry eye treatment effectiveness. Cont. Lens Anterior Eye 33(2), 61–67. https://doi.org/10.1016/j.clae.2010.01.003 (2010).', 'ArticleIdList': [StringElement('10.1016/j.clae.2010.01.003', attributes={'IdType': 'doi'}), StringElement('20153684', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Zhu, H. & Chauhan, A. Effect of viscosity on tear drainage and ocular residence time. Optom. Vis. Sci. 85(8), 715–725. https://doi.org/10.1097/OPX.0b013e3181824dc4 (2008).', 'ArticleIdList': [StringElement('10.1097/OPX.0b013e3181824dc4', attributes={'IdType': 'doi'}), StringElement('18677227', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tiffany, J. M. The viscosity of human tears. Int. Ophthalmol. 15(6), 371–376. https://doi.org/10.1007/BF00137947 (1991).', 'ArticleIdList': [StringElement('10.1007/BF00137947', attributes={'IdType': 'doi'}), StringElement('1778667', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Garcia-Valldecabres, M., López-Alemany, A. & Refojo, M. F. pH stability of ophthalmic solutions. Optometry 75(3), 161–168. https://doi.org/10.1016/s1529-1839(04)70035-4 (2004).', 'ArticleIdList': [StringElement('10.1016/s1529-1839(04)70035-4', attributes={'IdType': 'doi'}), StringElement('15058697', attributes={'IdType': 'pubmed'})]}, {'Citation': 'López-Alemany, A., Montés-Micó, R. & García-Valldecabres, M. Ocular physiology and artificial tears. J. Am. Optom. Assoc. 70(7), 455–460 (1999).', 'ArticleIdList': [StringElement('10485176', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cowman, M. K., Schmidt, T. A., Raghavan, P. & Stecco, A. Viscoelastic properties of hyaluronan in physiological conditions. F1000Res. 4, 622. https://doi.org/10.12688/f1000research.6885.1 (2015).', 'ArticleIdList': [StringElement('10.12688/f1000research.6885.1', attributes={'IdType': 'doi'}), StringElement('26594344', attributes={'IdType': 'pubmed'}), StringElement('4648226', attributes={'IdType': 'pmc'})]}, {'Citation': 'Che Arif, F. A., Hilmi, M. R., Mohd Kamal, K. & Ithnin, M. H. Evaluation of 18 artificial tears based on viscosity and pH. Malays. J. Ophthalmol. 2, 96–111 (2020).', 'ArticleIdList': [StringElement('10.35119/myjo.v2i2.109', attributes={'IdType': 'doi'})]}, {'Citation': 'Baudouin, C. et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: Proceedings of the OCEAN group meeting. Ocul. Surf. 11(4), 246–258. https://doi.org/10.1016/j.jtos.2013.07.003 (2013).', 'ArticleIdList': [StringElement('10.1016/j.jtos.2013.07.003', attributes={'IdType': 'doi'}), StringElement('24112228', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Aragona, P., Simmons, P. A., Wang, H. & Wang, T. Physicochemical properties of hyaluronic acid-based lubricant eye drops. Transl. Vis. Sci. Technol. 6, 2. https://doi.org/10.1167/tvst.8.6.2 (2019).', 'ArticleIdList': [StringElement('10.1167/tvst.8.6.2', attributes={'IdType': 'doi'})]}, {'Citation': 'Lievens, C. et al. Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study. Cont. Lens. Anterior Eye 42(4), 443–449. https://doi.org/10.1016/j.clae.2018.12.003 (2019).', 'ArticleIdList': [StringElement('10.1016/j.clae.2018.12.003', attributes={'IdType': 'doi'}), StringElement('30573298', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Arshinoff, S., Hofmann, I. & Nae, H. Rheological behavior of commercial artificial tear solutions. J. Cataract. Refract. Surg. 47(5), 649–654. https://doi.org/10.1097/j.jcrs.0000000000000507 (2021).', 'ArticleIdList': [StringElement('10.1097/j.jcrs.0000000000000507', attributes={'IdType': 'doi'}), StringElement('33278230', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ali, Y. & Lehmussaari, K. Industrial perspective in ocular drug delivery. Adv. Drug. Deliv. Rev. 58(11), 1258–1268. https://doi.org/10.1016/j.addr.2006.07.022 (2006).', 'ArticleIdList': [StringElement('10.1016/j.addr.2006.07.022', attributes={'IdType': 'doi'}), StringElement('17079049', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Alvarez-Lorenzo, C., Hiratani, H. & Concheiro, A. Contact lenses for drug delivery achieving sustained release with novel systems. Am. J. Drug Deliv. 4(3), 131–151 (2006).', 'ArticleIdList': [StringElement('10.2165/00137696-200604030-00002', attributes={'IdType': 'doi'})]}, {'Citation': 'Salzillo, R. et al. Optimization of hyaluronan-based eye drop formulations [published correction appears in Carbohydr Polym. 181:1235–1236 (2018)].\\xa0Carbohydr Polym. 153:275–283; https://doi.org/10.1016/j.carbpol.2016.07.106 (2016).'}, {'Citation': 'Kathuria, A., Shamloo, K., Jhanji, V. & Sharma, A. Categorization of marketed artificial tear formulations based on their ingredients: A rational approach for their use. J. Clin. Med. 10(6), 1289. https://doi.org/10.3390/jcm10061289 (2021).', 'ArticleIdList': [StringElement('10.3390/jcm10061289', attributes={'IdType': 'doi'}), StringElement('33800965', attributes={'IdType': 'pubmed'}), StringElement('8003881', attributes={'IdType': 'pmc'})]}, {'Citation': 'Schrage, N. F., Kompa, S., Ballmann, B., Reim, M. & Langefeld, S. Relationship of eye burns with calcifications of the cornea?. Graefes Arch. Clin. Exp. Ophthalmol. 243(8), 780–784. https://doi.org/10.1007/s00417-004-1089-2 (2005).', 'ArticleIdList': [StringElement('10.1007/s00417-004-1089-2', attributes={'IdType': 'doi'}), StringElement('15756579', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bernauer, W., Thiel, M. A., Langenauer, U. M. & Rentsch, K. M. Phosphate concentration in artificial tears. Graefes Arch. Clin. Exp. Ophthalmol. 244(8), 1010–1014. https://doi.org/10.1007/s00417-005-0219-9.PMID:16418839 (2006).', 'ArticleIdList': [StringElement('10.1007/s00417-005-0219-9.PMID:16418839', attributes={'IdType': 'doi'}), StringElement('16418839', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Özalp, O., Atalay, E., Alataş, İÖ., Küskü Kiraz, Z. & Yıldırım, N. Assessment of phosphate and osmolarity levels in chronically administered eye drops. Turk. J. Ophthalmol. 49(3), 123–129. https://doi.org/10.4274/tjo.galenos.2018.43827 (2019).', 'ArticleIdList': [StringElement('10.4274/tjo.galenos.2018.43827', attributes={'IdType': 'doi'}), StringElement('31245971', attributes={'IdType': 'pubmed'}), StringElement('6624467', attributes={'IdType': 'pmc'})]}, {'Citation': 'Martínez-Soroa, I. et al. Determination of phosphate concentration in glaucoma eye drops commercially available in Spain. Arch. Soc. Esp. Oftalmol. 91(8), 363–371. https://doi.org/10.1016/j.oftal.2016.02.010 (2016).', 'ArticleIdList': [StringElement('10.1016/j.oftal.2016.02.010', attributes={'IdType': 'doi'}), StringElement('27017538', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lee, J. S., Lee, J. E., Kim, N. & Oum, B. S. Comparison of the conjunctival toxicity of topical ocular antiallergic agents. J. Ocul. Pharmacol. Ther. 24(6), 557–562. https://doi.org/10.1089/jop.2008.0071 (2008).', 'ArticleIdList': [StringElement('10.1089/jop.2008.0071', attributes={'IdType': 'doi'}), StringElement('19049267', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ayaki, M., Iwasawa, A., Yaguchi, S. & Koide, R. Preserved and unpreserved 12 anti-allergic ophthalmic solutions and ocular surface toxicity: In vitro assessment in four cultured corneal and conjunctival epithelial cell lines. Biocontrol Sci. 15(4), 143–148. https://doi.org/10.4265/bio.15.143 (2010).', 'ArticleIdList': [StringElement('10.4265/bio.15.143', attributes={'IdType': 'doi'}), StringElement('21212507', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ayaki, M., Iwasawa, A., Yaguchi, S. & Koide, R. In vitro assessment of the cytotoxicity of anti-allergic eye drops using 5 cultured corneal and conjunctival cell lines. J. Oleo Sci. 60(3), 139–144. https://doi.org/10.5650/jos.60.139 (2011).', 'ArticleIdList': [StringElement('10.5650/jos.60.139', attributes={'IdType': 'doi'}), StringElement('21343662', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pauly, A., Brasnu, E., Rianch, O. L., Brignole-Baudouin, F. & Baudouin, C. Multiple endpoint analysis of BAC-preserved and unpreserved antiallergic eye drops on a 3D-reconstituted corneal epithelial model. Mol. Vis. 17, 745–755 (2011).', 'ArticleIdList': [StringElement('21437201', attributes={'IdType': 'pubmed'}), StringElement('3062522', attributes={'IdType': 'pmc'})]}, {'Citation': 'Boboridis, K. G., Kozeis, N. & Konstas, A. G. Revisiting ocular allergy: Evaluating symptoms, benzalkonium chloride and efficacy of topical ketotifen 0.025. Ocul. Immunol. Inflamm. 28(2), 188–190. https://doi.org/10.1080/09273948.2018.1560478 (2020).', 'ArticleIdList': [StringElement('10.1080/09273948.2018.1560478', attributes={'IdType': 'doi'}), StringElement('30806132', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Guzman-Aranguez, A., Calvo, P., Ropero, I. & Pintor, J. In vitro effects of preserved and unpreserved anti-allergic drugs on human corneal epithelial cells. J. Ocul. Pharmacol. Ther. 30(9), 790–798. https://doi.org/10.1089/jop.2014.0030 (2014).', 'ArticleIdList': [StringElement('10.1089/jop.2014.0030', attributes={'IdType': 'doi'}), StringElement('25100331', attributes={'IdType': 'pubmed'}), StringElement('4220706', attributes={'IdType': 'pmc'})]}, {'Citation': 'Brasnu, E. et al. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr. Eye Res. 33(4), 303–312. https://doi.org/10.1080/02713680801971857 (2008).', 'ArticleIdList': [StringElement('10.1080/02713680801971857', attributes={'IdType': 'doi'}), StringElement('18398704', attributes={'IdType': 'pubmed'})]}, {'Citation': 'De SaintJean, M. et al. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr. Eye Res. 20(2), 85–94. https://doi.org/10.1076/0271-3683(200002)20:2;1-d;ft085 (2000).', 'ArticleIdList': [StringElement('10.1076/0271-3683(200002)20:2;1-d;ft085', attributes={'IdType': 'doi'})]}, {'Citation': 'Meloni, M., Balzaretti, S. & Ceriotti, L. Medical devices biocompatibility assessment on HCE: Evidences of delayed cytotoxicity of preserved compared to preservative free eye drops. Regul. Toxicol. Pharmacol. 106, 81–89. https://doi.org/10.1016/j.yrtph.2019.04.022 (2019).', 'ArticleIdList': [StringElement('10.1016/j.yrtph.2019.04.022', attributes={'IdType': 'doi'}), StringElement('31039384', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Abdelkader, H. & Alany, R. G. Controlled and continuous release ocular drug delivery systems: Pros and cons. Curr. Drug Deliv. 9(4), 421–430. https://doi.org/10.2174/156720112801323125 (2012).', 'ArticleIdList': [StringElement('10.2174/156720112801323125', attributes={'IdType': 'doi'}), StringElement('22640036', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Akhter, M. H. et al. Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system. Gels 8(2), 82. https://doi.org/10.3390/gels8020082 (2022).', 'ArticleIdList': [StringElement('10.3390/gels8020082', attributes={'IdType': 'doi'}), StringElement('35200463', attributes={'IdType': 'pubmed'}), StringElement('8871777', attributes={'IdType': 'pmc'})]}, {'Citation': 'Davies, N. M. Biopharmaceutical considerations in topical ocular drug delivery. Clin. Exp. Pharmacol. Physiol. 27(7), 558–562. https://doi.org/10.1046/j.1440-1681.2000.03288.x (2000).', 'ArticleIdList': [StringElement('10.1046/j.1440-1681.2000.03288.x', attributes={'IdType': 'doi'}), StringElement('10874518', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Shoham, A., Hadziahmetovic, M., Dunaief, J. L., Mydlarski, M. B. & Schipper, H. M. Oxidative stress in diseases of the human cornea. Free Radic. Biol. Med. 45(8), 1047–1055. https://doi.org/10.1016/j.freeradbiomed.2008.07.021 (2008).', 'ArticleIdList': [StringElement('10.1016/j.freeradbiomed.2008.07.021', attributes={'IdType': 'doi'}), StringElement('18718524', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Shu, D. Y. et al. Role of oxidative stress in ocular diseases: A balancing act. Metabolites 13(2), 187. https://doi.org/10.3390/metabo13020187 (2023).', 'ArticleIdList': [StringElement('10.3390/metabo13020187', attributes={'IdType': 'doi'}), StringElement('36837806', attributes={'IdType': 'pubmed'}), StringElement('9960073', attributes={'IdType': 'pmc'})]}, {'Citation': 'Nita, M. & Grzybowski, A. The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. Oxid. Med. Cell Longev. 2016, 3164734. https://doi.org/10.1155/2016/3164734 (2016).', 'ArticleIdList': [StringElement('10.1155/2016/3164734', attributes={'IdType': 'doi'}), StringElement('26881021', attributes={'IdType': 'pubmed'}), StringElement('4736974', attributes={'IdType': 'pmc'})]}, {'Citation': 'Rogov, A. G. et al. Mitochondrial dysfunctions may be one of the major causative factors underlying detrimental effects of benzalkonium chloride. Oxid, Med, Cell Longev. 10, 8956504. https://doi.org/10.1155/2020/8956504 (2020).', 'ArticleIdList': [StringElement('10.1155/2020/8956504', attributes={'IdType': 'doi'})]}, {'Citation': 'Debbasch, C. et al. Evaluation of the toxicity of benzalkonium chloride on the ocular surface. Cutan Ocul. Toxicol. 19(2), 105–115. https://doi.org/10.3109/15569520009051506 (2000).', 'ArticleIdList': [StringElement('10.3109/15569520009051506', attributes={'IdType': 'doi'})]}, {'Citation': 'Wu, H. et al. Genoprotective effect of hyaluronic acid against benzalkonium chloride-induced DNA damage in human corneal epithelial cells. Mol. Vis. 17, 3364–3370 (2011).', 'ArticleIdList': [StringElement('22219631', attributes={'IdType': 'pubmed'}), StringElement('3247171', attributes={'IdType': 'pmc'})]}, {'Citation': 'Cha, S. H., Lee, J. S., Oum, B. S. & Kim, C. D. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin. Exp. Ophthalmol. 32(2), 180–184. https://doi.org/10.1111/j.1442-9071.2004.00782.x (2004).', 'ArticleIdList': [StringElement('10.1111/j.1442-9071.2004.00782.x', attributes={'IdType': 'doi'}), StringElement('15068436', attributes={'IdType': 'pubmed'})]}, {'Citation': 'De Saint, J. M. et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 40(3), 619–630 (1999).'}, {'Citation': 'Ye, J. et al. Role of benzalkonium chloride in DNA strand breaks in human corneal epithelial cells. Graefes Arch. Clin. Exp. Ophthalmol. 249(11), 1681–1687. https://doi.org/10.1007/s00417-011-1755-0 (2011).', 'ArticleIdList': [StringElement('10.1007/s00417-011-1755-0', attributes={'IdType': 'doi'}), StringElement('21842132', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Baudouin, C. Allergic reaction to topical eyedrops. Curr. Opin. Allergy Clin. Immunol. 5(5), 459–463. https://doi.org/10.1097/01.all.0000183112.86181.9e (2005).', 'ArticleIdList': [StringElement('10.1097/01.all.0000183112.86181.9e', attributes={'IdType': 'doi'}), StringElement('16131924', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Nagai, N. et al. Decrease in corneal damage due to benzalkonium chloride by the addition of mannitol into timolol maleate eye drops. J. Oleo Sci. 64(7), 743–750. https://doi.org/10.5650/jos.ess14275 (2015).', 'ArticleIdList': [StringElement('10.5650/jos.ess14275', attributes={'IdType': 'doi'}), StringElement('26136174', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Baudouin, C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 86(7), 716–726. https://doi.org/10.1111/j.1755-3768.2008.01250.x (2008).', 'ArticleIdList': [StringElement('10.1111/j.1755-3768.2008.01250.x', attributes={'IdType': 'doi'}), StringElement('18537937', attributes={'IdType': 'pubmed'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2024', 'Month': '1', 'Day': '10'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '8'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '27', 'Hour': '9', 'Minute': '50'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '27', 'Hour': '9', 'Minute': '49'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '26', 'Hour': '23', 'Minute': '23'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38671063', attributes={'IdType': 'pubmed'}), StringElement('10.1038/s41598-024-59190-5', attributes={'IdType': 'doi'}), StringElement('10.1038/s41598-024-59190-5', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Chinese medicine', attributes={'MajorTopicYN': 'N'}), StringElement('allergy', attributes={'MajorTopicYN': 'N'}), StringElement('herbal medicine', attributes={'MajorTopicYN': 'N'}), StringElement('inflammation', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38664220', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '25'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '28'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [StringElement('e13742', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1111/crj.13742', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1752-699X', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '18', 'Issue': '4', 'PubDate': {'Year': '2024', 'Month': 'Apr'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The clinical respiratory journal', 'ISOAbbreviation': 'Clin Respir J'}, 'ArticleTitle': 'Studying of anti-inflammatory and antioxidant effects of tectorigenin in ovalbumin-induced asthma mice models.', 'Pagination': {'StartPage': 'e13742', 'MedlinePgn': 'e13742'}, 'Abstract': {'AbstractText': [StringElement('Allergic asthma is an important respiratory system problem characterized by airway inflammation, breathlessness, and bronchoconstriction. Allergic asthma and its outcomes are triggered by type 2 allergic immune responses. Tectorigenin is a methoxy-isoflavone with anti-inflammatory effects. In this study, we investigated the effects of tectorigenin on the pathophysiology of allergic asthma in an animal model.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement('Asthmatic mice were treated with tectorigenin. Then airway hyperresponsiveness (AHR), eosinophil percentage, levels of interleukin (IL)-33, IL-25, IL-13, IL-5, IL-4, total and ovalbumin (OVA)-specific immunoglobulin (Ig)E, and lung histopathology were evaluated.', attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('Tectorigenin significantly (P 〈 0.05) reduced eosinophil infiltration (41\\u2009±\\u20097%) in the broncho-alveolar lavage fluid (BALF), serum IL-5 level (41\\u2009±\\u20095, pg/mL), and bronchial and vascular inflammation (scores of 1.3\\u2009±\\u20090.2 and 1.1\\u2009±\\u20090.3, respectively) but had no significant effects on AHR, serum levels of IL-33, -25, -13, and -4 (403\\u2009±\\u200924, 56\\u2009±\\u20097, 154\\u2009±\\u200911, and 89\\u2009±\\u20096 pg/mL, respectively), total and OVA-specific IgE (2684\\u2009±\\u2009265 and 264\\u2009±\\u200919\\u2009ng/mL, respectively), goblet cell hyperplasia, and mucus production.', attributes={'Label': 'RESULT', 'NlmCategory': 'RESULTS'}), StringElement('Tectorigenin could control inflammation and the secretion of inflammatory mediators of asthma, so it can be regarded as a potential antiasthma treatment with the ability to control eosinophilia-related problems.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': '© 2024 The Authors. The Clinical Respiratory Journal published by John Wiley & Sons Ltd.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Department of Integrated Traditional Medicine and Western Medicine, Xi'an Children's Hospital, Xi'an, China.\"}], 'Identifier': [], 'LastName': 'Guo', 'ForeName': 'Jingning', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Department of Integrated Traditional Medicine and Western Medicine, Xi'an Children's Hospital, Xi'an, China.\"}], 'Identifier': [], 'LastName': 'Shi', 'ForeName': 'Yanping', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Department of Integrated Traditional Medicine and Western Medicine, Xi'an Children's Hospital, Xi'an, China.\"}], 'Identifier': [], 'LastName': 'Wang', 'ForeName': 'Yujun', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.'}], 'Identifier': [], 'LastName': 'Athari', 'ForeName': 'Seyyed Shamsadin', 'Initials': 'SS'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Department of Integrated Traditional Medicine and Western Medicine, Xi'an Children's Hospital, Xi'an, China.\"}], 'Identifier': [StringElement('0000-0002-5658-5525', attributes={'Source': 'ORCID'})], 'LastName': 'Chen', 'ForeName': 'Tao', 'Initials': 'T'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'England', 'MedlineTA': 'Clin Respir J', 'NlmUniqueID': '101315570', 'ISSNLinking': '1752-6981'}, 'ChemicalList': [{'RegistryNumber': '9006-59-1', 'NameOfSubstance': StringElement('Ovalbumin', attributes={'UI': 'D010047'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Isoflavones', attributes={'UI': 'D007529'})}, {'RegistryNumber': '855130H9CO', 'NameOfSubstance': StringElement('tectorigenin', attributes={'UI': 'C120039'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Antioxidants', attributes={'UI': 'D000975'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Inflammatory Agents', attributes={'UI': 'D000893'})}, {'RegistryNumber': '37341-29-0', 'NameOfSubstance': StringElement('Immunoglobulin E', attributes={'UI': 'D007073'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Cytokines', attributes={'UI': 'D016207'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Animals', attributes={'UI': 'D000818', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'}), StringElement('chemically induced', attributes={'UI': 'Q000139', 'MajorTopicYN': 'N'}), StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'}), StringElement('immunology', attributes={'UI': 'Q000276', 'MajorTopicYN': 'N'}), StringElement('pathology', attributes={'UI': 'Q000473', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Asthma', attributes={'UI': 'D001249', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Mice', attributes={'UI': 'D051379', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('toxicity', attributes={'UI': 'Q000633', 'MajorTopicYN': 'N'}), StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Ovalbumin', attributes={'UI': 'D010047', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'}), StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Isoflavones', attributes={'UI': 'D007529', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Disease Models, Animal', attributes={'UI': 'D004195', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Antioxidants', attributes={'UI': 'D000975', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'}), StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Inflammatory Agents', attributes={'UI': 'D000893', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Mice, Inbred BALB C', attributes={'UI': 'D008807', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('blood', attributes={'UI': 'Q000097', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Immunoglobulin E', attributes={'UI': 'D007073', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('cytology', attributes={'UI': 'Q000166', 'MajorTopicYN': 'N'}), StringElement('immunology', attributes={'UI': 'Q000276', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Bronchoalveolar Lavage Fluid', attributes={'UI': 'D001992', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Female', attributes={'UI': 'D005260', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pathology', attributes={'UI': 'Q000473', 'MajorTopicYN': 'N'}), StringElement('drug effects', attributes={'UI': 'Q000187', 'MajorTopicYN': 'N'}), StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'}), StringElement('immunology', attributes={'UI': 'Q000276', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Lung', attributes={'UI': 'D008168', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Cytokines', attributes={'UI': 'D016207', 'MajorTopicYN': 'N'})}], 'CoiStatement': 'There is no conflict of interest.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Qian L, Mehrabi Nasab E, Athari SM, Athari SS. Mitochondria signaling pathways in allergic asthma. J Invest Med. 2022;70(4):863‐882. doi:10.1136/jim-2021-002098', 'ArticleIdList': [StringElement('10.1136/jim-2021-002098', attributes={'IdType': 'doi'}), StringElement('PMC9016245', attributes={'IdType': 'pmc'}), StringElement('35168999', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Esmaeilzadeh A, Tahmasebi S, Athari SS. Chimeric antigen receptor ‐T cell therapy: applications and challenges in treatment of allergy and asthma. Biomed Pharmacother. 2020;123:109685. doi:10.1016/j.biopha.2019.109685', 'ArticleIdList': [StringElement('10.1016/j.biopha.2019.109685', attributes={'IdType': 'doi'}), StringElement('31862474', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Athari SS, Athari SM. The importance of eosinophil, platelet and dendritic cell in asthma. Asian Pacific J Tropic Dis. 2014;4(S1):S41‐S47. doi:10.1016/S2222-1808(14)60413-8', 'ArticleIdList': [StringElement('10.1016/S2222-1808(14)60413-8', attributes={'IdType': 'doi'})]}, {'Citation': 'Bagheri Lankarani K, Honarvar B, Athari SS. The mechanisms underlying Helicobacter Pylori‐mediated protection against allergic asthma. Tanaffos. 2017;16(4):251‐259.', 'ArticleIdList': [StringElement('PMC5971755', attributes={'IdType': 'pmc'}), StringElement('29849681', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Jiang J, Nasab EM, Athari SM, Athari SS. Effects of vitamin E and selenium on allergic rhinitis and asthma pathophysiology. Respir Physiol Neurobiol. 2021;286:103614. doi:10.1016/j.resp.2020.103614', 'ArticleIdList': [StringElement('10.1016/j.resp.2020.103614', attributes={'IdType': 'doi'}), StringElement('33422684', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Zhiwei W, Nasab EM, Arora P, Athari SS. Study effect of probiotics and prebiotics on treatment of OVA‐LPS‐induced of allergic asthma inflammation and pneumonia by regulating the TLR4/NF‐kB signaling pathway. J Transl Med. 2022;20(1):130. doi:10.1186/s12967-022-03337-3', 'ArticleIdList': [StringElement('10.1186/s12967-022-03337-3', attributes={'IdType': 'doi'}), StringElement('PMC8925173', attributes={'IdType': 'pmc'}), StringElement('35296330', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kim YP, Yamada M, Lim SS, et al. Inhibition by tectorigenin and tectoridin of prostaglandin E2 production and cyclooxygenase‐2 induction in rat peritoneal macrophages. Biochim Biophys Acta. 1999;1438(3):399‐407. doi:10.1016/S1388-1981(99)00067-0', 'ArticleIdList': [StringElement('10.1016/S1388-1981(99)00067-0', attributes={'IdType': 'doi'}), StringElement('10366782', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pan C‐H, Kim ES, Jung SH, Nho CW, Lee JK. Tectorigenin inhibits IFN‐γ/LPS‐induced inflammatory responses in murine macrophage RAW 264.7 cells. Arch Pharm Res. 2008;31(11):1447‐1456. doi:10.1007/s12272-001-2129-7', 'ArticleIdList': [StringElement('10.1007/s12272-001-2129-7', attributes={'IdType': 'doi'}), StringElement('19023541', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chun‐Hua MA, Ji‐Ping LIU, Rong QU, Shi‐Ping MA. Tectorigenin inhibits the inflammation of LPS‐induced acute lung injury in mice. Chin J Nat Med. 2014;12(11):0841‐0846.', 'ArticleIdList': [StringElement('25480515', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Wang Y, Jing W, Wanying Q, et al. Tectorigenin inhibits inflammation and pulmonary fibrosis in allergic asthma model of ovalbumin‐sensitized guinea pigs. J Pharm Pharmacol. 2020;72(7):956‐968. doi:10.1111/jphp.13271', 'ArticleIdList': [StringElement('10.1111/jphp.13271', attributes={'IdType': 'doi'}), StringElement('32314371', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Wang D, Nasab EM, Athari SS. Study effect of Baicalein encapsulated/loaded chitosan‐nanoparticle on allergic asthma pathology in mouse model. Saudi J Biol Sci. 2021;28(8):4311‐4317. doi:10.1016/j.sjbs.2021.04.009', 'ArticleIdList': [StringElement('10.1016/j.sjbs.2021.04.009', attributes={'IdType': 'doi'}), StringElement('PMC8324934', attributes={'IdType': 'pmc'}), StringElement('34354413', attributes={'IdType': 'pubmed'})]}, {'Citation': \"Mehrabi Nasaba E, Athari SM, Motlagh B, Athari SS. Effects of oral administration of Ocimum basilicum on goblet cell hyperplasia and upstream cytokine gene expression in allergic asthma. Revue Francaise d'Allergologie. 2020;60(2):64‐68. doi:10.1016/j.reval.2019.02.226\", 'ArticleIdList': [StringElement('10.1016/j.reval.2019.02.226', attributes={'IdType': 'doi'})]}, {'Citation': \"Masoume Athari S, Mehrabi Nasab E, Shamsadin Athari S. Study effect of Ocimum basilicum seeds on mucus production and cytokine gene expression in allergic asthma mice model. Revue Francaise d'Allergologie. 2018;58(7):489‐493. doi:10.1016/j.reval.2018.08.003\", 'ArticleIdList': [StringElement('10.1016/j.reval.2018.08.003', attributes={'IdType': 'doi'})]}, {'Citation': 'Ankermann T, Brehler R. Allergic asthma: an indication for allergen immunotherapy. Allergologie Sel. 2023;7(1):33‐38. doi:10.5414/ALX02332E', 'ArticleIdList': [StringElement('10.5414/ALX02332E', attributes={'IdType': 'doi'}), StringElement('PMC10012881', attributes={'IdType': 'pmc'}), StringElement('36925993', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Agache I, Lau S, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: house dust mite‐driven allergic asthma. Allergy. 2019;74(5):855‐873. doi:10.1111/all.13749', 'ArticleIdList': [StringElement('10.1111/all.13749', attributes={'IdType': 'doi'}), StringElement('31095767', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;8:CD001186. doi:10.1002/14651858.CD001186.pub2', 'ArticleIdList': [StringElement('10.1002/14651858.CD001186.pub2', attributes={'IdType': 'doi'}), StringElement('20687065', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Giannetti A, Ricci G, Procaccianti M, Santoro A, Caffarelli C. Safety, efficacy, and preventive role of subcutaneous and sublingual allergen immunotherapy for the treatment of pediatric asthma. J Asthma Allergy. 2020;13:575‐587. doi:10.2147/JAA.S234280', 'ArticleIdList': [StringElement('10.2147/JAA.S234280', attributes={'IdType': 'doi'}), StringElement('PMC7667503', attributes={'IdType': 'pmc'}), StringElement('33204114', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tosca MA, Licari A, Olcese R, Marseglia G, Sacco O, Ciprandi G. Immunotherapy and asthma in children. Front Pediatr. 2018;6:231. doi:10.3389/fped.2018.00231', 'ArticleIdList': [StringElement('10.3389/fped.2018.00231', attributes={'IdType': 'doi'}), StringElement('PMC6110847', attributes={'IdType': 'pmc'}), StringElement('30186823', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Schatz M, Rosenwasser L. The allergic asthma phenotype. J Allergy Clin Immunol Pract. 2014;2(6):645‐648. doi:10.1016/j.jaip.2014.09.004', 'ArticleIdList': [StringElement('10.1016/j.jaip.2014.09.004', attributes={'IdType': 'doi'}), StringElement('25439351', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Diamant Z, van Maaren M, Muraro A, Jesenak M, Striz I. Allergen immunotherapy for allergic asthma: the future seems bright. Respir Med. 2023;210:107125. doi:10.1016/j.rmed.2023.107125', 'ArticleIdList': [StringElement('10.1016/j.rmed.2023.107125', attributes={'IdType': 'doi'}), StringElement('36702170', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kaufman PB, Duke JA, Brielmann H, Boik J, Hoyt JE. A comparative survey of leguminous plants as sources of the isoflavones, genistein and daidzein: implications for human nutrition and health. J Altern Complement Med. 1997;3(1):7‐12. doi:10.1089/acm.1997.3.7', 'ArticleIdList': [StringElement('10.1089/acm.1997.3.7', attributes={'IdType': 'doi'}), StringElement('9395689', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ignarro LJ. Regulation of cytosolic guanylyl cyclase by porphyrins and metalloporphyrins. Adv Pharmacol. 1994;26:35‐65. doi:10.1016/S1054-3589(08)60050-2', 'ArticleIdList': [StringElement('10.1016/S1054-3589(08)60050-2', attributes={'IdType': 'doi'}), StringElement('7913618', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Narumi S, Finke JH, Hamilton TA. Interferon gamma and interleukin 2 synergize to induce selective monokine expression in murine peritoneal macrophages. J Biol Chem. 1990;265(12):7036‐7041. doi:10.1016/S0021-9258(19)39255-5', 'ArticleIdList': [StringElement('10.1016/S0021-9258(19)39255-5', attributes={'IdType': 'doi'}), StringElement('2108965', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Dinarello CA. Biologic basis for interleukin‐1 in disease. Blood. 1996;87(6):2095‐2147. doi:10.1182/blood.V87.6.2095.bloodjournal8762095', 'ArticleIdList': [StringElement('10.1182/blood.V87.6.2095.bloodjournal8762095', attributes={'IdType': 'doi'}), StringElement('8630372', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Makarov SS. NF‐κB as a therapeutic target in chronic inflammation: recent advances. Mol Med Today. 2000;6(11):441‐448. doi:10.1016/S1357-4310(00)01814-1', 'ArticleIdList': [StringElement('10.1016/S1357-4310(00)01814-1', attributes={'IdType': 'doi'}), StringElement('11074370', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS‐398, a new anti‐inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX‐2) activity in vitro. Prostaglandins. 1994;47(1):55‐59. doi:10.1016/0090-6980(94)90074-4', 'ArticleIdList': [StringElement('10.1016/0090-6980(94)90074-4', attributes={'IdType': 'doi'}), StringElement('8140262', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chun‐Hua MA, Ji‐Ping LI, Rong QU, Shi‐Ping MA. Tectorigenin inhibits the inflammation of LPS‐induced acute lung injury in mice. Chin J Nat Med. 2014;11:841‐846.', 'ArticleIdList': [StringElement('25480515', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Murad HA, Hasanin AH. The anti‐inflammatory effects of 1,1 dimethyl‐4‐phenylpiperazinium (DMPP) compared to dexamethasone in a guinea pig model of ovalbumin induced asthma. Eur Rev Med Pharmacol Sci. 2014;15:2228‐2236.', 'ArticleIdList': [StringElement('25070830', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ha LM, Que DTN, Huyen DTT, Long PQ, Dat NT. Toxicity, analgesic and anti‐inflammatory activities of tectorigenin. Immunopharmacol Immunotoxicol. 2013;35(3):336‐340. doi:10.3109/08923973.2013.770521', 'ArticleIdList': [StringElement('10.3109/08923973.2013.770521', attributes={'IdType': 'doi'}), StringElement('23461431', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lee KT, Sohn IC, Kim DH, et al. Hypoglycemic and hypolipidemic effects of tectorigenin and kaikasaponin III in the streptozotocin induced diabetic rat and their antioxidant activity in vitro. Arch Pharm Res. 2000;23(5):461‐466. doi:10.1007/BF02976573', 'ArticleIdList': [StringElement('10.1007/BF02976573', attributes={'IdType': 'doi'}), StringElement('11059824', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Han T, Cheng G, Liu Y, Yang H, Hu YT, Huang W. In vitro evaluation of tectoridin, tectorigenin and tectorigenin sodium sulfonate on antioxidant properties. Food Chem Toxicol. 2012;50(2):409‐414. doi:10.1016/j.fct.2011.10.066', 'ArticleIdList': [StringElement('10.1016/j.fct.2011.10.066', attributes={'IdType': 'doi'}), StringElement('22079309', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Koppert W, Wehrfritz A, Korber N, et al. The cyclooxygenase isozyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. Pain. 2004;108(1):148‐153. doi:10.1016/j.pain.2003.12.017', 'ArticleIdList': [StringElement('10.1016/j.pain.2003.12.017', attributes={'IdType': 'doi'}), StringElement('15109518', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hernandez‐Perez M, Rabanal RM. Evaluation of the antinflammatory and analgesic activity of Sideritis canariensis var. pannosa in mice. J Ethnopharmacol. 2002;81(1):43‐47. doi:10.1016/S0378-8741(02)00033-8', 'ArticleIdList': [StringElement('10.1016/S0378-8741(02)00033-8', attributes={'IdType': 'doi'}), StringElement('12020926', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Doherty NS, Robinson BV. The inflammatory response to carrageenan. J Pharm Pharmacol. 1975;27(9):701‐703.', 'ArticleIdList': [StringElement('241817', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Alrumaihi F, Almatroudi A, Allemailem KS, Rahmani AH, Khan A, Khan MA. Therapeutic effect of Bilsaan, Sambucus nigra stem exudate, on the OVA‐induced allergic asthma in mice. Oxid Med Cell Longev. 2020;2020:3620192. doi:10.1155/2020/3620192', 'ArticleIdList': [StringElement('10.1155/2020/3620192', attributes={'IdType': 'doi'}), StringElement('PMC7313152', attributes={'IdType': 'pmc'}), StringElement('32617136', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mousa AM, Almatroudi A, Alwashmi AS, et al. Thyme oil alleviates Ova‐induced bronchial asthma through modulating Th2 cytokines, IgE, TSLP and ROS. Biomed Pharmacother. 2021;140:111726. doi:10.1016/j.biopha.2021.111726', 'ArticleIdList': [StringElement('10.1016/j.biopha.2021.111726', attributes={'IdType': 'doi'}), StringElement('34111725', attributes={'IdType': 'pubmed'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2024', 'Month': '2', 'Day': '1'}, attributes={'PubStatus': 'revised'}), DictElement({'Year': '2023', 'Month': '9', 'Day': '29'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '2', 'Day': '23'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '26', 'Hour': '0', 'Minute': '52'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '26', 'Hour': '0', 'Minute': '51'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '25', 'Hour': '22', 'Minute': '42'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '25'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38664220', attributes={'IdType': 'pubmed'}), StringElement('PMC11045443', attributes={'IdType': 'pmc'}), StringElement('10.1111/crj.13742', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38656288', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '24'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '24'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '25'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1097/ACI.0000000000000985', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1473-6322', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '24', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Jun', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Current opinion in allergy and clinical immunology', 'ISOAbbreviation': 'Curr Opin Allergy Clin Immunol'}, 'ArticleTitle': 'Omalizumab is the Columbus egg for food allergies.', 'Pagination': {'StartPage': '144', 'EndPage': '146', 'MedlinePgn': '144-146'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pediatric Hospital Bambino Gesù IRCCS, Rome, Italy.'}], 'Identifier': [], 'LastName': 'Fiocchi', 'ForeName': 'Alessandro', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'NHO Sagamihara National Hospital, Tokyo, Japan.'}], 'Identifier': [], 'LastName': 'Ebisawa', 'ForeName': 'Motohiro', 'Initials': 'M'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Editorial', attributes={'UI': 'D016421'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'Curr Opin Allergy Clin Immunol', 'NlmUniqueID': '100936359', 'ISSNLinking': '1473-6322'}, 'ChemicalList': [{'RegistryNumber': '2P471X1Z11', 'NameOfSubstance': StringElement('Omalizumab', attributes={'UI': 'D000069444'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Allergic Agents', attributes={'UI': 'D018926'})}, {'RegistryNumber': '37341-29-0', 'NameOfSubstance': StringElement('Immunoglobulin E', attributes={'UI': 'D007073'})}], 'MeshHeadingList': [{'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Omalizumab', attributes={'UI': 'D000069444', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('immunology', attributes={'UI': 'Q000276', 'MajorTopicYN': 'N'}), StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Food Hypersensitivity', attributes={'UI': 'D005512', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Allergic Agents', attributes={'UI': 'D018926', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('immunology', attributes={'UI': 'Q000276', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Immunoglobulin E', attributes={'UI': 'D007073', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the treatment of multiple food allergies. N Engl J Med 2024; 390:889–899.'}, {'Citation': 'Fiocchi A, Ebisawa M. Food allergy: new therapeutic options open deeper questions. Curr Opin Allergy Clin Immunol 2023; 23:216–217.'}, {'Citation': 'Jones SM, Kim EH, Nadeau KC, et al. Immune Tolerance Network. Efficacy and safety of oral immunotherapy in children aged 1-3\\u200ayears with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Lancet 2022; 399:359–371.'}, {'Citation': 'Du Toit G, Roberts G, Sayre PH, et al. LEAP Study Team. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 2015; 372:803–813.'}, {'Citation': 'Baan EJ, de Smet VA, Hoeve CE, et al. Exploratory study of signals for asthma drugs in children, using the EudraVigilance Database of spontaneous reports. Drug Saf 2020; 43:7–16.'}, {'Citation': 'Magen E, Schlesinger M, David M, et al. Selective IgE deficiency, immune dysregulation, and autoimmunity. Allergy Asthma Proc 2014; 35:e27–e33.'}, {'Citation': 'Ferastraoaru D, Rosenstreich D. IgE deficiency is associated with high rates of new malignancies: results of a longitudinal cohort study. J Allergy Clin Immunol Pract 2020; 8:413–415.'}, {'Citation': 'Matricardi PM. The very low IgE producer: allergology, genetics, immunodeficiencies, and oncology. Biomedicines 2023; 11:1378.'}, {'Citation': 'Ishibashi S, Yanagida N, Sato S, Ebisawa M. Management of food allergy based on oral food challenge. Curr Opin Allergy Cin Immunol 2024; 24:153–159.'}, {'Citation': 'Loh W, Tang MLK. The epidemiology of food allergy in the global context. Int J Environ Res Public Health 2018; 15:2043.'}, {'Citation': 'Azzano P, Paquin M, Langlois A, et al. Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients. J Allergy Clin Immunol 2020; 147:233–243.'}, {'Citation': 'Fiocchi A, Artesani MC, Riccardi C, et al. Impact of omalizumab on food allergy in patients treated for asthma: a real-life study. J Allergy Clin Immunol Pract 2019; 7:1901.e1–1909.e1.'}, {'Citation': 'Zuberbier T, Wood RA, Bindslev-Jensen C, et al. Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2022; S2213-2198.'}, {'Citation': \"Eckl-Dorna J. Omalizumab's impact on total and allergen-specific IgE levels: a polyclonal story. Int Arch Allergy Immunol 2016; 169:69–70.\"}, {'Citation': 'Dantzer JA, Wood RA. Update on omalizumab in allergen immunotherapy. Curr Opin Allergy Clin Immunol 2021; 21:559–568.'}, {'Citation': 'Arasi S, Mennini M, Cafarotti A, Fiocchi A. Omalizumab as monotherapy for food allergy. Curr Opin Allergy Clin Immunol 2021; 21:286–291.'}, {'Citation': 'Arasi S, Nurmatov U, Dunn-Galvin A, et al. WAO consensus on DEfinition of Food Allergy SEverity (DEFASE). World Allergy Organ J 2023; 16:100753.'}, {'Citation': \"Bognanni A, Chu DK, Firmino RT, et al. WAO DRACMA Guideline Group. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guideline update - XIII - Oral immunotherapy for CMA - Systematic review. World Allergy Organ J 2022; 15:100682.\"}, {'Citation': 'Dinardo G, Cafarotti A, Galletta F, et al. Omalizumab in severe asthma and food allergies with IgE levels >1500\\u200akU/L: two-year evaluation. Pediatr Allergy Immunol 2023; 34:e14057.'}, {'Citation': 'Muraro A, de Silva D, Halken S, et al. GA2LEN Food Allergy Guideline Group; GALEN Food Allergy Guideline Group. Managing food allergy: GA2LEN guideline 2022. World Allergy Organ J 2022; 15:100687.'}, {'Citation': 'Mutarelli A, Giavina-Bianchi B, Arasi S, et al. Biologicals in IgE-mediated food allergy. Curr Opin Allergy Clin Immunol 2023; 23:205–209.'}, {'Citation': 'Fiocchi A, Vickery BP, Wood RA. The use of biologics in food allergy. Clin Exp Allergy 2021; 51:1006–1018.'}, {'Citation': 'Schuetz JP, Anderson B, Sindher SB. New biologics for food allergy. Curr Opin Allergy Cin Immunol 2024; 24:147–152.'}, {'Citation': 'Wong GWK. Options for multiple food allergies - food avoidance or pharmacologic treatment? N Engl J Med 2024; 390:946–948.'}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2024', 'Month': '4', 'Day': '24', 'Hour': '19', 'Minute': '6'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '24', 'Hour': '14', 'Minute': '20'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '24', 'Hour': '11', 'Minute': '45'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38656288', attributes={'IdType': 'pubmed'}), StringElement('10.1097/ACI.0000000000000985', attributes={'IdType': 'doi'}), StringElement('00130832-202406000-00007', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Phosphoinositide 3-kinase P110γδ asthma AZD8154', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38654248', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '24'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '26'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '23'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('175', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1186/s12931-024-02814-1', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1465-993X', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '25', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '23'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Respiratory research', 'ISOAbbreviation': 'Respir Res'}, 'ArticleTitle': 'PI3Kγδ inhibition suppresses key disease features in a rat model of asthma.', 'Pagination': {'StartPage': '175', 'MedlinePgn': '175'}, 'Abstract': {'AbstractText': [StringElement('Two isoforms of Phosphoinositide 3-kinase (PI3K), p110γ and p110δ, are predominantly expressed in leukocytes and represent attractive therapeutic targets for the treatment of allergic asthma. The study aim was to assess the impact of administration of an inhaled PI3Kγδ inhibitor (AZD8154) in a rat model of asthma.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement('Firstly, we checked that the tool compound, AZD8154, inhibited rat PI3K γ & δ kinases using rat cell-based assays. Subsequently, a time-course study was conducted in a rat model of asthma to assess PI3K activity in the lung and how it is temporally associated with other key transcription pathways and asthma like features of the model. Finally, the impact on lung dosed AZD8154 on target engagement, pathway specificity, airway inflammation and lung function changes was assessed.', attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('Data showed that AZD8154 could inhibit rat PI3K γ & δ isoforms and, in a rat model of allergic asthma the PI3K pathway was activated in the lung. Intratracheal administration of AZD8154 caused a dose related suppression PI3K pathway activation (reduction in pAkt) and unlike after budesonide treatment, STAT and NF-κB pathways were not affected by AZD8154. The suppression of the PI3K pathway led to a marked inhibition of airway inflammation and reduction in changes in lung function.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('These data show that a dual PI3Kγδ inhibitor suppress key features of disease in a rat model of asthma to a similar degree as budesonide and indicate that dual PI3Kγδ inhibition may be an effective treatment for people suffering from allergic asthma.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': '© 2024. The Author(s).'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}, {'Identifier': [], 'Affiliation': 'Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK.'}], 'Identifier': [], 'LastName': 'Pinkerton', 'ForeName': 'James W', 'Initials': 'JW'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}], 'Identifier': [], 'LastName': 'Preite', 'ForeName': 'Silvia', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}], 'Identifier': [], 'LastName': 'Piras', 'ForeName': 'Antonio', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}, {'Identifier': [], 'Affiliation': 'Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK.'}], 'Identifier': [], 'LastName': 'Zervas', 'ForeName': 'Dimitrios', 'Initials': 'D'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}, {'Identifier': [], 'Affiliation': 'Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK.'}], 'Identifier': [], 'LastName': 'Markou', 'ForeName': 'Thomais', 'Initials': 'T'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}, {'Identifier': [], 'Affiliation': 'Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK.'}], 'Identifier': [], 'LastName': 'Freeman', 'ForeName': 'Mark S', 'Initials': 'MS'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}], 'Identifier': [], 'LastName': 'Hofving', 'ForeName': 'Tobias', 'Initials': 'T'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}], 'Identifier': [], 'LastName': 'Ivarsson', 'ForeName': 'Emil', 'Initials': 'E'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}, {'Identifier': [], 'Affiliation': 'Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK.'}], 'Identifier': [], 'LastName': 'Bonvini', 'ForeName': 'Sara J', 'Initials': 'SJ'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}], 'Identifier': [], 'LastName': 'Brailsford', 'ForeName': 'Wayne', 'Initials': 'W'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}], 'Identifier': [], 'LastName': 'Yrlid', 'ForeName': 'Linda', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}, {'Identifier': [], 'Affiliation': 'Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK.'}], 'Identifier': [], 'LastName': 'Belvisi', 'ForeName': 'Maria G', 'Initials': 'MG'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden. mark.birrell@astrazeneca.com.'}, {'Identifier': [], 'Affiliation': 'Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK. mark.birrell@astrazeneca.com.'}], 'Identifier': [], 'LastName': 'Birrell', 'ForeName': 'Mark A', 'Initials': 'MA'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic'}), 'MedlineJournalInfo': {'Country': 'England', 'MedlineTA': 'Respir Res', 'NlmUniqueID': '101090633', 'ISSNLinking': '1465-9921'}, 'ChemicalList': [{'RegistryNumber': 'EC 2.7.1.137', 'NameOfSubstance': StringElement('Class Ib Phosphatidylinositol 3-Kinase', attributes={'UI': 'D058544'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Phosphoinositide-3 Kinase Inhibitors', attributes={'UI': 'D000081082'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Protein Kinase Inhibitors', attributes={'UI': 'D047428'})}, {'RegistryNumber': 'EC 2.7.1.137', 'NameOfSubstance': StringElement('Class I Phosphatidylinositol 3-Kinases', attributes={'UI': 'D058534'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Asthmatic Agents', attributes={'UI': 'D018927'})}, {'RegistryNumber': '9006-59-1', 'NameOfSubstance': StringElement('Ovalbumin', attributes={'UI': 'D010047'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Animals', attributes={'UI': 'D000818', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'}), StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Asthma', attributes={'UI': 'D001249', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Disease Models, Animal', attributes={'UI': 'D004195', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Rats', attributes={'UI': 'D051381', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Male', attributes={'UI': 'D008297', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Class Ib Phosphatidylinositol 3-Kinase', attributes={'UI': 'D058544', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Rats, Sprague-Dawley', attributes={'UI': 'D017207', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'}), StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Phosphoinositide-3 Kinase Inhibitors', attributes={'UI': 'D000081082', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug effects', attributes={'UI': 'Q000187', 'MajorTopicYN': 'N'}), StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'}), StringElement('pathology', attributes={'UI': 'Q000473', 'MajorTopicYN': 'N'}), StringElement('enzymology', attributes={'UI': 'Q000201', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Lung', attributes={'UI': 'D008168', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Dose-Response Relationship, Drug', attributes={'UI': 'D004305', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Protein Kinase Inhibitors', attributes={'UI': 'D047428', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('antagonists & inhibitors', attributes={'UI': 'Q000037', 'MajorTopicYN': 'N'}), StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Class I Phosphatidylinositol 3-Kinases', attributes={'UI': 'D058534', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Asthmatic Agents', attributes={'UI': 'D018927', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('toxicity', attributes={'UI': 'Q000633', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Ovalbumin', attributes={'UI': 'D010047', 'MajorTopicYN': 'N'})}], 'CoiStatement': 'All authors listed in the publication are employees of AstraZeneca.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396: 1204–1222.', 'ArticleIdList': [StringElement('PMC7567026', attributes={'IdType': 'pmc'}), StringElement('33069326', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hogan AD, Bernstein JA. GINA updated 2019: landmark changes recommended for asthma management. Ann Allergy Asthma Immunol. 2020;124:311–313. doi: 10.1016/j.anai.2019.11.005.', 'ArticleIdList': [StringElement('10.1016/j.anai.2019.11.005', attributes={'IdType': 'doi'}), StringElement('31734328', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hansbro PM, Scott GV, Essilfie AT, Kim RY, Starkey MR, Nguyen DH, et al. Th2 cytokine antagonists: potential treatments for severe asthma. Expert Opin Investig Drugs. 2013;22:49–69. doi: 10.1517/13543784.2013.732997.', 'ArticleIdList': [StringElement('10.1517/13543784.2013.732997', attributes={'IdType': 'doi'}), StringElement('23126660', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Wang W, Li JJ, Foster PS, Hansbro PM, Yang M. Potential therapeutic targets for steroid-resistant asthma. Curr Drug Targets. 2010;11:957–970. doi: 10.2174/138945010791591412.', 'ArticleIdList': [StringElement('10.2174/138945010791591412', attributes={'IdType': 'doi'}), StringElement('20412045', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chung KF, Godard P, Adelroth E, Ayres J, Barnes N, Barnes P, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS task force on difficult/therapy-resistant asthma. European Respiratory Society. Eur Respir J. 1999;13:1198–1208.', 'ArticleIdList': [StringElement('10414427', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis. 1993;148:S1–S26. doi: 10.1164/ajrccm/148.4_Pt_2.S1.', 'ArticleIdList': [StringElement('10.1164/ajrccm/148.4_Pt_2.S1', attributes={'IdType': 'doi'}), StringElement('8214958', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Yoo EJ, Ojiaku CA, Sunder K, Panettieri RA., Jr Phosphoinositide 3-kinase in asthma: novel roles and therapeutic approaches. Am J Respir Cell Mol Biol. 2017;56:700–707. doi: 10.1165/rcmb.2016-0308TR.', 'ArticleIdList': [StringElement('10.1165/rcmb.2016-0308TR', attributes={'IdType': 'doi'}), StringElement('PMC5516292', attributes={'IdType': 'pmc'}), StringElement('27977296', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Moradi S, Jarrahi E, Ahmadi A, Salimian J, Karimi M, Zarei A, et al. PI3K signalling in chronic obstructive pulmonary disease and opportunities for therapy. J Pathol. 2021;254(5):505–18.', 'ArticleIdList': [StringElement('33959951', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Jeong JS, Kim JS, Kim SR, Lee YC. Defining Bronchial Asthma with Phosphoinositide 3-Kinase Delta Activation: Towards Endotype-Driven Management. Int J Mol Sci. 2019;20(14):3525.', 'ArticleIdList': [StringElement('PMC6679152', attributes={'IdType': 'pmc'}), StringElement('31323822', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Whitman M, Downes CP, Keeler M, Keller T, Cantley L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature. 1988;332:644–646. doi: 10.1038/332644a0.', 'ArticleIdList': [StringElement('10.1038/332644a0', attributes={'IdType': 'doi'}), StringElement('2833705', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C, Gray PW, et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem. 1997;272:19236–19241. doi: 10.1074/jbc.272.31.19236.', 'ArticleIdList': [StringElement('10.1074/jbc.272.31.19236', attributes={'IdType': 'doi'}), StringElement('9235916', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kuo CC, Lin WT, Liang CM, Liang SM. Class I and III phosphatidylinositol 3′-kinase play distinct roles in TLR signaling pathway. J Immunol. 2006;176:5943–5949. doi: 10.4049/jimmunol.176.10.5943.', 'ArticleIdList': [StringElement('10.4049/jimmunol.176.10.5943', attributes={'IdType': 'doi'}), StringElement('16670302', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B, et al. Function of PI3Kγ in Thymocyte development, T cell activation, and neutrophil migration. Science. 2000;287:1040–1046. doi: 10.1126/science.287.5455.1040.', 'ArticleIdList': [StringElement('10.1126/science.287.5455.1040', attributes={'IdType': 'doi'}), StringElement('10669416', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Al-Alwan MM, Okkenhaug K, Vanhaesebroeck B, Hayflick JS, Marshall AJ. Requirement for phosphoinositide 3-kinase p110delta signaling in B cell antigen receptor-mediated antigen presentation. J Immunol. 2007;178:2328–2335. doi: 10.4049/jimmunol.178.4.2328.', 'ArticleIdList': [StringElement('10.4049/jimmunol.178.4.2328', attributes={'IdType': 'doi'}), StringElement('17277138', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ge Q, Moir LM, Trian T, Niimi K, Poniris M, Shepherd PR, et al. The phosphoinositide 3′-kinase p110delta modulates contractile protein production and IL-6 release in human airway smooth muscle. J Cell Physiol. 2012;227:3044–3052. doi: 10.1002/jcp.23046.', 'ArticleIdList': [StringElement('10.1002/jcp.23046', attributes={'IdType': 'doi'}), StringElement('22015454', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Jiang H, Abel PW, Toews ML, Deng C, Casale TB, Xie Y, et al. Phosphoinositide 3-kinase gamma regulates airway smooth muscle contraction by modulating calcium oscillations. J Pharmacol Exp Ther. 2010;334:703–709. doi: 10.1124/jpet.110.168518.', 'ArticleIdList': [StringElement('10.1124/jpet.110.168518', attributes={'IdType': 'doi'}), StringElement('PMC2939661', attributes={'IdType': 'pmc'}), StringElement('20501633', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Domin J, Pages F, Volinia S, Rittenhouse SE, Zvelebil MJ, Stein RC, et al. Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem J. 1997;326(Pt 1):139–147. doi: 10.1042/bj3260139.', 'ArticleIdList': [StringElement('10.1042/bj3260139', attributes={'IdType': 'doi'}), StringElement('PMC1218647', attributes={'IdType': 'pmc'}), StringElement('9337861', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Atherton HC, Jones G, Danahay H. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol. 2003;285:L730–L739. doi: 10.1152/ajplung.00089.2003.', 'ArticleIdList': [StringElement('10.1152/ajplung.00089.2003', attributes={'IdType': 'doi'}), StringElement('12794003', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Xu H, Gu LN, Yang QY, Zhao DY, Liu F. MiR-221 promotes IgE-mediated activation of mast cells degranulation by PI3K/Akt/PLCgamma/ca(2+) pathway. J Bioenerg Biomembr. 2016;48:293–299. doi: 10.1007/s10863-016-9659-7.', 'ArticleIdList': [StringElement('10.1007/s10863-016-9659-7', attributes={'IdType': 'doi'}), StringElement('27113449', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kampe M, Lampinen M, Stolt I, Janson C, Stalenheim G, Carlson M. PI3-kinase regulates eosinophil and neutrophil degranulation in patients with allergic rhinitis and allergic asthma irrespective of allergen challenge model. Inflamm. 2012;35:230–239. doi: 10.1007/s10753-011-9309-5.', 'ArticleIdList': [StringElement('10.1007/s10753-011-9309-5', attributes={'IdType': 'doi'}), StringElement('21384093', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kang BN, Ha SG, Ge XN, Hosseinkhani MR, Bahaie NS, Greenberg Y, et al. The p110δ subunit of PI3K regulates bone marrow-derived eosinophil trafficking and airway eosinophilia in allergen-challenged mice. Am J Physiol Lung Cell Mol Physiol. 2012;302:L1179–L1191. doi: 10.1152/ajplung.00005.2012.', 'ArticleIdList': [StringElement('10.1152/ajplung.00005.2012', attributes={'IdType': 'doi'}), StringElement('PMC3379039', attributes={'IdType': 'pmc'}), StringElement('22427531', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Nashed BF, Zhang T, Al-Alwan M, Srinivasan G, Halayko AJ, Okkenhaug K, et al. Role of the phosphoinositide 3-kinase p110delta in generation of type 2 cytokine responses and allergic airway inflammation. Eur J Immunol. 2007;37:416–424. doi: 10.1002/eji.200636401.', 'ArticleIdList': [StringElement('10.1002/eji.200636401', attributes={'IdType': 'doi'}), StringElement('17236236', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lim DH, Cho JY, Song DJ, Lee SY, Miller M, Broide DH. PI3K gamma-deficient mice have reduced levels of allergen-induced eosinophilic inflammation and airway remodeling. Am J Physiol Lung Cell Mol Physiol. 2009;296:L210–L219. doi: 10.1152/ajplung.90275.2008.', 'ArticleIdList': [StringElement('10.1152/ajplung.90275.2008', attributes={'IdType': 'doi'}), StringElement('PMC2643991', attributes={'IdType': 'pmc'}), StringElement('19028980', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kim RY, Horvat JC, Pinkerton JW, Starkey MR, Essilfie AT, Mayall JR, et al. MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2. J Allergy Clin Immunol. 2017;139:519–532. doi: 10.1016/j.jaci.2016.04.038.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2016.04.038', attributes={'IdType': 'doi'}), StringElement('27448447', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Barnes PJ. Kinases as novel therapeutic targets in asthma and chronic obstructive pulmonary disease. Pharmacol Rev. 2016;68:788–815. doi: 10.1124/pr.116.012518.', 'ArticleIdList': [StringElement('10.1124/pr.116.012518', attributes={'IdType': 'doi'}), StringElement('27363440', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Perry MWD, Björhall K, Bold P, Brűlls M, Börjesson U, Carlsson J, Chang HA, et al. Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma. J Med Chem. 2021;64(12):8053–75.', 'ArticleIdList': [StringElement('34080862', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Schmalbach T, Fuhr R, Albayaty M, Allen K, Douglas M, Dunbar J, et al. Duvelisib, a PI3K-δ,γ inhibitor, in subjects with mild asthma. Eur Respir J. 2015;46:PA2122. 10.1183/13993003.congress-2015.PA2122.'}, {'Citation': 'Khindri S, Cahn A, Begg M, Montembault M, Leemereise C, Cui Y, et al. A multicentre, randomized, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, tolerability, and pharmacokinetics of repeat doses of inhaled Nemiralisib in adults with persistent Uncontrolled Asthma. J Pharmacol Exp Ther. 2018;367:405–413. doi: 10.1124/jpet.118.249516.', 'ArticleIdList': [StringElement('10.1124/jpet.118.249516', attributes={'IdType': 'doi'}), StringElement('30217958', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Barnett-Vanes A, Sharrock A, Birrell MA, Rankin S. A single 9-colour flow cytometric method to characterise major leukocyte populations in the rat: validation in a model of LPS-induced pulmonary inflammation. PLoS One. 2016;11:e0142520. doi: 10.1371/journal.pone.0142520.', 'ArticleIdList': [StringElement('10.1371/journal.pone.0142520', attributes={'IdType': 'doi'}), StringElement('PMC4713146', attributes={'IdType': 'pmc'}), StringElement('26764486', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Shin J, Spatz M, Brandish P, Gervais F, Zhang-Hoover J, Leccese E, et al. Development and pharmacological validation of novel methods of B cell activation in rat whole blood. J Pharmacol Toxicol Methods. 2015;71:61–67. doi: 10.1016/j.vascn.2014.12.006.', 'ArticleIdList': [StringElement('10.1016/j.vascn.2014.12.006', attributes={'IdType': 'doi'}), StringElement('25545336', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Birrell MA, Hardaker E, Wong S, McCluskie K, Catley M, De Alba J, et al. Iκ-B Kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. Am J Respir Crit Care Med. 2005;172:962–971. doi: 10.1164/rccm.200412-1647OC.', 'ArticleIdList': [StringElement('10.1164/rccm.200412-1647OC', attributes={'IdType': 'doi'}), StringElement('16002568', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Raemdonck K, de Alba J, Birrell MA, Grace M, Maher SA, Irvin CG, et al. A role for sensory nerves in the late asthmatic response. Thorax. 2012;67:19–25. doi: 10.1136/thoraxjnl-2011-200365.', 'ArticleIdList': [StringElement('10.1136/thoraxjnl-2011-200365', attributes={'IdType': 'doi'}), StringElement('21841185', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem. 1999;274:10963–10968. doi: 10.1074/jbc.274.16.10963.', 'ArticleIdList': [StringElement('10.1074/jbc.274.16.10963', attributes={'IdType': 'doi'}), StringElement('10196176', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bi L, Okabe I, Bernard DJ, Nussbaum RL. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome. 2002;13:169–172.', 'ArticleIdList': [StringElement('11919689', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cuneo A, Barosi G, Danesi R, Fagiuoli S, Ghia P, Marzano A, et al. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper. Hematol Oncol. 2019;37:3–14. doi: 10.1002/hon.2540.', 'ArticleIdList': [StringElement('10.1002/hon.2540', attributes={'IdType': 'doi'}), StringElement('PMC6585802', attributes={'IdType': 'pmc'}), StringElement('30187496', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Birrell M, Bonvini SJ, Baker KE, Dekkak B, Miralpeix M, Tarrason G, et al. The TRPV4 ion channel plays a key role in allergic asthma. Eur Respir J. 2016;48:OA1792.'}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2024', 'Month': '1', 'Day': '5'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '15'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '24', 'Hour': '14', 'Minute': '21'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '24', 'Hour': '1', 'Minute': '43'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '23', 'Hour': '23', 'Minute': '47'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '23'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38654248', attributes={'IdType': 'pubmed'}), StringElement('PMC11040934', attributes={'IdType': 'pmc'}), StringElement('10.1186/s12931-024-02814-1', attributes={'IdType': 'doi'}), StringElement('10.1186/s12931-024-02814-1', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('antibacterial prophylaxis', attributes={'MajorTopicYN': 'N'}), StringElement('bacteriuria', attributes={'MajorTopicYN': 'N'}), StringElement('prostate cancer', attributes={'MajorTopicYN': 'N'}), StringElement('radical prostatectomy', attributes={'MajorTopicYN': 'N'}), StringElement('urethral catheter', attributes={'MajorTopicYN': 'N'}), StringElement('urinary tract infection', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38650404', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '24'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '25'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [], 'Language': ['rus'], 'Journal': {'ISSN': StringElement('1728-2985', attributes={'IssnType': 'Print'}), 'JournalIssue': DictElement({'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Mar'}}, attributes={'CitedMedium': 'Print'}), 'Title': 'Urologiia (Moscow, Russia : 1999)', 'ISOAbbreviation': 'Urologiia'}, 'ArticleTitle': '[Antibacterial prophylaxis with fosfomycin at the time of the urethral catheter removal after radical prostatectomy (prospective randomized trial)].', 'Pagination': {'StartPage': '35', 'EndPage': '40', 'MedlinePgn': '35-40'}, 'Abstract': {'AbstractText': [StringElement('To evaluate the effect of antibacterial prophylaxis using oral fosfomycin during the removal of a urethral catheter after radical prostatectomy on the development of urinary tract infection, severity of leukocyturia and bacteriuria, as well as the severity of lower urinary tract symptoms.', attributes={'Label': 'AIM', 'NlmCategory': 'OBJECTIVE'}), StringElement('A single-center, non-blind, prospective, randomized controlled trial was carried out. The main group included 40 patients, and the control group included 37 patients. In the group 1, patients received two doses of oral fosfomycin, 3 g, namely in the evening on the day of catheter removal (the first dose) and 48 hours after catheter removal (the second dose). In the group 2, patients did not receive any antibacterial prophylaxis after urethral catheter removal. The endpoints of the study were confirmed episodes of urinary tract infection within 1 month after removal of the urethral catheter, leukocyturia and bacteriuria in urinalysis/urine culture) and severity of the lower urinary tract symptoms assessed by IPSS questionnaire.', attributes={'Label': 'MATERIALS AND METHODS', 'NlmCategory': 'METHODS'}), StringElement('In the group 2, urinary tract infection was noted in 17.1%, while in the group 2 only in 2.6% of patients (p=0.032). Leukocyturia and bacteriuria were significantly less common in the group receiving antibacterial prophylaxis with fosfomycin (18.4% vs. 48.6%, respectively; p=0.006). Positive urine culture was observed in 7.9% vs. 25.7%, respectively (p=0.035). Four weeks after removal of the urethral catheter, the average IPSS score was significantly higher in the group 2 (13.2 vs. 9.5 points; p=0.002). There were no cases of allergic reaction and pseudomembranous colitis associated with C. difficile in both groups. Diarrhea cured with sorbents was noted in 2 patients (5.2%) in fosfomycin group.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('Antibacterial prophylaxis using two oral doses of fosfomycin 3 g on the day of urethral catheter removal and 48 hours after catheter removal after radical prostatectomy appears to be an effective scheme that reduces the incidence of urinary tract infection and the severity of lower urinary tract symptoms, and is characterized by a minimal risk of adverse events. It is necessary to carried out further research and develop clear recommendations for antibacterial prevention in urological interventions requiring prolonged urethral catheterization.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'CONCLUSIONS'})]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Russian Medical Academy of Continuous Professional Education, Department of Urology and Surgical Andrology, Moscow, Russia.'}, {'Identifier': [], 'Affiliation': 'S.P. Botkins State Clinical Hospital, Moscow, Russia.'}], 'Identifier': [], 'LastName': 'Veliev E', 'ForeName': 'I', 'Initials': 'I'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Russian Medical Academy of Continuous Professional Education, Department of Urology and Surgical Andrology, Moscow, Russia.'}, {'Identifier': [], 'Affiliation': 'S.P. Botkins State Clinical Hospital, Moscow, Russia.'}], 'Identifier': [], 'LastName': 'Sokolov E', 'ForeName': 'A', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Russian Medical Academy of Continuous Professional Education, Department of Urology and Surgical Andrology, Moscow, Russia.'}, {'Identifier': [], 'Affiliation': 'S.P. Botkins State Clinical Hospital, Moscow, Russia.'}], 'Identifier': [], 'LastName': 'Metelev A', 'ForeName': 'Yu', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Russian Medical Academy of Continuous Professional Education, Department of Urology and Surgical Andrology, Moscow, Russia.'}, {'Identifier': [], 'Affiliation': 'S.P. Botkins State Clinical Hospital, Moscow, Russia.'}], 'Identifier': [], 'LastName': 'Aliev E', 'ForeName': 'N', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Russian Medical Academy of Continuous Professional Education, Department of Urology and Surgical Andrology, Moscow, Russia.'}, {'Identifier': [], 'Affiliation': 'S.P. Botkins State Clinical Hospital, Moscow, Russia.'}], 'Identifier': [], 'LastName': 'Polyakova A', 'ForeName': 'S', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Russian Medical Academy of Continuous Professional Education, Department of Urology and Surgical Andrology, Moscow, Russia.'}, {'Identifier': [], 'Affiliation': 'S.P. Botkins State Clinical Hospital, Moscow, Russia.'}], 'Identifier': [], 'LastName': 'Ivkin E', 'ForeName': 'V', 'Initials': 'V'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Randomized Controlled Trial', attributes={'UI': 'D016449'}), StringElement('English Abstract', attributes={'UI': 'D004740'})]}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'Russia (Federation)', 'MedlineTA': 'Urologiia', 'NlmUniqueID': '100900900', 'ISSNLinking': '1728-2985'}, 'ChemicalList': [{'RegistryNumber': '2N81MY12TE', 'NameOfSubstance': StringElement('Fosfomycin', attributes={'UI': 'D005578'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Bacterial Agents', attributes={'UI': 'D000900'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('administration & dosage', attributes={'UI': 'Q000008', 'MajorTopicYN': 'N'}), StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Fosfomycin', attributes={'UI': 'D005578', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Male', attributes={'UI': 'D008297', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'}), StringElement('methods', attributes={'UI': 'Q000379', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Prostatectomy', attributes={'UI': 'D011468', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Middle Aged', attributes={'UI': 'D008875', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('prevention & control', attributes={'UI': 'Q000517', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Urinary Tract Infections', attributes={'UI': 'D014552', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Aged', attributes={'UI': 'D000368', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Prospective Studies', attributes={'UI': 'D011446', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('administration & dosage', attributes={'UI': 'Q000008', 'MajorTopicYN': 'N'}), StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Bacterial Agents', attributes={'UI': 'D000900', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Urinary Catheters', attributes={'UI': 'D062885', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('methods', attributes={'UI': 'Q000379', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Antibiotic Prophylaxis', attributes={'UI': 'D019072', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Urinary Catheterization', attributes={'UI': 'D014546', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Device Removal', attributes={'UI': 'D020878', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2024', 'Month': '4', 'Day': '25', 'Hour': '0', 'Minute': '54'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '23', 'Hour': '15', 'Minute': '4'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '23', 'Hour': '2', 'Minute': '13'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38650404', attributes={'IdType': 'pubmed'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('bacterial infections', attributes={'MajorTopicYN': 'N'}), StringElement('degranulation', attributes={'MajorTopicYN': 'N'}), StringElement('immunomodulation', attributes={'MajorTopicYN': 'N'}), StringElement('innate immunity', attributes={'MajorTopicYN': 'N'}), StringElement('mast cell', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38638437', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '22'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '25'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '04'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('1360296', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.3389/fimmu.2024.1360296', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1664-3224', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '15', 'PubDate': {'Year': '2024'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Frontiers in immunology', 'ISOAbbreviation': 'Front Immunol'}, 'ArticleTitle': 'MASTer cell: chief immune modulator and inductor of antimicrobial immune response.', 'Pagination': {'StartPage': '1360296', 'MedlinePgn': '1360296'}, 'Abstract': {'AbstractText': ['Mast cells have long been recognized for their involvement in allergic pathology through the immunoglobulin E (IgE)-mediated degranulation mechanism. However, there is growing evidence of other \"non-canonical\" degranulation mechanisms activated by certain pathogen recognition receptors. Mast cells release several mediators, including histamine, cytokines, chemokines, prostaglandins, and leukotrienes, to initiate and enhance inflammation. The chemical nature of activating stimuli influences receptors, triggering mechanisms for the secretion of formed and new synthesized mediators. Mast cells have more than 30 known surface receptors that activate different pathways for direct and indirect activation by microbes. Different bacterial strains stimulate mast cells through various ligands, initiating the innate immune response, which aids in clearing the bacterial burden. Mast cell interactions with adaptative immune cells also play a crucial role in infections. Recent publications revealed another \"non-canonical\" degranulation mechanism present in tryptase and chymase mast cells in humans and connective tissue mast cells in mice, occurring through the activation of the Mas-related G protein-coupled receptor (MRGPRX2/b2). This receptor represents a new therapeutic target alongside antibiotic therapy. There is an urgent need to reconsider and redefine the biological role of these MASTer cells of innate immunity, extending beyond their involvement in allergic pathology.'], 'CopyrightInformation': 'Copyright © 2024 Suárez Vázquez, López López and Salinas Carmona.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Immunology, School of Medicine and Dr. Jose Eleuterio Gonzalez University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Mexico.'}], 'Identifier': [], 'LastName': 'Suárez Vázquez', 'ForeName': 'Tomás Alejandro', 'Initials': 'TA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Immunology, School of Medicine and Dr. Jose Eleuterio Gonzalez University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Mexico.'}], 'Identifier': [], 'LastName': 'López López', 'ForeName': 'Nallely', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Immunology, School of Medicine and Dr. Jose Eleuterio Gonzalez University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Mexico.'}], 'Identifier': [], 'LastName': 'Salinas Carmona', 'ForeName': 'Mario César', 'Initials': 'MC'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Electronic-eCollection'}), 'MedlineJournalInfo': {'Country': 'Switzerland', 'MedlineTA': 'Front Immunol', 'NlmUniqueID': '101560960', 'ISSNLinking': '1664-3224'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Infective Agents', attributes={'UI': 'D000890'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Cytokines', attributes={'UI': 'D016207'})}, {'RegistryNumber': '37341-29-0', 'NameOfSubstance': StringElement('Immunoglobulin E', attributes={'UI': 'D007073'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('MRGPRX2 protein, human', attributes={'UI': 'C480039'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Nerve Tissue Proteins', attributes={'UI': 'D009419'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Receptors, Neuropeptide', attributes={'UI': 'D018013'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Receptors, G-Protein-Coupled', attributes={'UI': 'D043562'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Animals', attributes={'UI': 'D000818', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Mice', attributes={'UI': 'D051379', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Hypersensitivity', attributes={'UI': 'D006967', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Infective Agents', attributes={'UI': 'D000890', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Cytokines', attributes={'UI': 'D016207', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Immunoglobulin E', attributes={'UI': 'D007073', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Immunity, Innate', attributes={'UI': 'D007113', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Mast Cells', attributes={'UI': 'D008407', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Nerve Tissue Proteins', attributes={'UI': 'D009419', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Receptors, Neuropeptide', attributes={'UI': 'D018013', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Receptors, G-Protein-Coupled', attributes={'UI': 'D043562', 'MajorTopicYN': 'N'})}], 'CoiStatement': 'The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Siebenhaar F, Syska W, Weller K, Magerl M, Zuberbier T, Metz M, et al. . Control of pseudomonas aeruginosa skin infections in mice is mast cell-dependent. Am J Pathol. (2007) 170:1910–6. doi:\\xa010.2353/ajpath.2007.060770', 'ArticleIdList': [StringElement('10.2353/ajpath.2007.060770', attributes={'IdType': 'doi'}), StringElement('PMC1899453', attributes={'IdType': 'pmc'}), StringElement('17525259', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Swindle EJ, Brown JM, Rådinger M, DeLeo FR, Metcalfe DD. Interferon-γ enhances both the anti-bacterial and the pro-inflammatory response of human mast cells to Staphylococcus aureus. Immunology. (2015) 146:470–85. doi:\\xa010.1111/imm.12524', 'ArticleIdList': [StringElement('10.1111/imm.12524', attributes={'IdType': 'doi'}), StringElement('PMC4610635', attributes={'IdType': 'pmc'}), StringElement('26288256', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Naqvi N, Srivastava R, Naskar P, Puri N. Mast cells modulate early responses to Mycobacterium bovis Bacillus Calmette-Guerin by phagocytosis and formation of extracellular traps. Cell Immunol. (2021) 365:104380. doi:\\xa010.1016/j.cellimm.2021.104380', 'ArticleIdList': [StringElement('10.1016/j.cellimm.2021.104380', attributes={'IdType': 'doi'}), StringElement('34049012', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Carlos D, De Souza Júnior DA, De Paula L, Jamur MC, Oliver C, Ramos SG, et al. . Mast cells modulate pulmonary acute inflammation and host defense in a murine model of tuberculosis. J Infect Dis. (2007) 196:1361–8. doi:\\xa010.1086/521830', 'ArticleIdList': [StringElement('10.1086/521830', attributes={'IdType': 'doi'}), StringElement('17922401', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Jobbings CE, Sandig H, Whittingham-Dowd JK, Roberts IS, Bulfone-Paus S. Listeria monocytogenes alters mast cell phenotype, mediator and osteopontin secretion in a listeriolysin-dependent manner. Bayry J Editor PloS One. (2013) 8:e57102. doi:\\xa010.1371/journal.pone.0057102', 'ArticleIdList': [StringElement('10.1371/journal.pone.0057102', attributes={'IdType': 'doi'}), StringElement('PMC3584118', attributes={'IdType': 'pmc'}), StringElement('23460827', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Krämer S, Sellge G, Lorentz A, Krueger D, Schemann M, Feilhauer K, et al. . Selective activation of human intestinal mast cells by escherichia coli hemolysin. J Immunol. (2008) 181:1438–45. doi:\\xa010.4049/jimmunol.181.2.1438', 'ArticleIdList': [StringElement('10.4049/jimmunol.181.2.1438', attributes={'IdType': 'doi'}), StringElement('18606698', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gendrin C, Shubin NJ, Boldenow E, Merillat S, Clauson M, Power D, et al. . Mast cell chymase decreases the severity of group B Streptococcus infections. J Allergy Clin Immunol. (2018) 142:120–9. doi:\\xa010.1016/j.jaci.2017.07.042', 'ArticleIdList': [StringElement('10.1016/j.jaci.2017.07.042', attributes={'IdType': 'doi'}), StringElement('PMC5847414', attributes={'IdType': 'pmc'}), StringElement('28916188', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Sandig H, Bulfone-Paus S. TLR signaling in mast cells: common and unique features. Front Immunol. (2012) 3. doi:\\xa010.3389/fimmu.2012.00185', 'ArticleIdList': [StringElement('10.3389/fimmu.2012.00185', attributes={'IdType': 'doi'}), StringElement('PMC3389341', attributes={'IdType': 'pmc'}), StringElement('22783258', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Agier J, Pastwińska J, Brzezińska-Błaszczyk E. An overview of mast cell pattern recognition receptors. Inflammation Res. (2018) 67:737–46. doi:\\xa010.1007/s00011-018-1164-5', 'ArticleIdList': [StringElement('10.1007/s00011-018-1164-5', attributes={'IdType': 'doi'}), StringElement('PMC6096630', attributes={'IdType': 'pmc'}), StringElement('29909493', attributes={'IdType': 'pubmed'})]}, {'Citation': \"Vukman KV, Ravidà A, Aldridge AM, O'Neill SM. Mannose receptor and macrophage galactose-type lectin are involved in Bordetella pertussis mast cell interaction. J Leukoc Biol. (2013) 94:439–48. doi:\\xa010.1189/jlb.0313130\", 'ArticleIdList': [StringElement('10.1189/jlb.0313130', attributes={'IdType': 'doi'}), StringElement('23794711', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Riquelme-Neira R, Walker-Vergara R, Fernández-Blanco JA, Vergara P. IL-10 modulates the expression and activation of pattern recognition receptors in mast cells. Int J Mol Sci. (2023) 24:9875. doi:\\xa010.3390/ijms24129875', 'ArticleIdList': [StringElement('10.3390/ijms24129875', attributes={'IdType': 'doi'}), StringElement('PMC10298310', attributes={'IdType': 'pmc'}), StringElement('37373041', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Malaviya R, Ross EA, MacGregor JI, Ikeda T, Little JR, Jakschik BA, et al. . Mast cell phagocytosis of FimH-expressing enterobacteria. J Immunol. (1994) 152:1907–14. doi:\\xa010.4049/jimmunol.152.4.1907', 'ArticleIdList': [StringElement('10.4049/jimmunol.152.4.1907', attributes={'IdType': 'doi'}), StringElement('8120397', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Muñoz S, Hernández-Pando R, Abraham SN, Enciso JA. Mast cell activation by mycobacterium tuberculosis: mediator release and role of CD48. J Immunol. (2003) 170:5590–6. doi:\\xa010.4049/jimmunol.170.11.5590', 'ArticleIdList': [StringElement('10.4049/jimmunol.170.11.5590', attributes={'IdType': 'doi'}), StringElement('12759438', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Campillo-Navarro M, Leyva-Paredes K, Donis-Maturano L, González-Jiménez M, Paredes-Vivas Y, Cerbulo-Vázquez A, et al. . Listeria monocytogenes induces mast cell extracellular traps. Immunobiology. (2017) 222:432–9. doi:\\xa010.1016/j.imbio.2016.08.006', 'ArticleIdList': [StringElement('10.1016/j.imbio.2016.08.006', attributes={'IdType': 'doi'}), StringElement('27520114', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Di Nardo A, Yamasaki K, Dorschner RA, Lai Y, Gallo RL. Mast cell cathelicidin antimicrobial peptide prevents invasive group A streptococcus infection of the skin. J Immunol. (2008) 180:7565–73. doi:\\xa010.4049/jimmunol.180.11.7565', 'ArticleIdList': [StringElement('10.4049/jimmunol.180.11.7565', attributes={'IdType': 'doi'}), StringElement('PMC2664112', attributes={'IdType': 'pmc'}), StringElement('18490758', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. (2010) 10:440–52. doi:\\xa010.1038/nri2782', 'ArticleIdList': [StringElement('10.1038/nri2782', attributes={'IdType': 'doi'}), StringElement('PMC4469150', attributes={'IdType': 'pmc'}), StringElement('20498670', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gilfillan AM, Metcalfe DD. Mast cell biology: contemporary and emerging topics. In: Advances in experimental medicine and biology. Austin, Tex: Springer Science Business Media; Landes Bioscience, New York: (2011). p. 294.'}, {'Citation': 'Beaven MA. Our perception of the mast cell from Paul Ehrlich to now. Eur J Immunol. (2009) 39:11–25. doi:\\xa010.1002/eji.200838899', 'ArticleIdList': [StringElement('10.1002/eji.200838899', attributes={'IdType': 'doi'}), StringElement('PMC2950100', attributes={'IdType': 'pmc'}), StringElement('19130582', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Baccari GC, Pinelli C, Santillo A, Minucci S, Rastogi RK. Mast cells in nonmammalian vertebrates. In: International Review of Cell and Molecular Biology. Elsevier; (2011). p. 1–53. doi:\\xa010.1016/B978-0-12-386037-8.00006-5', 'ArticleIdList': [StringElement('10.1016/B978-0-12-386037-8.00006-5', attributes={'IdType': 'doi'}), StringElement('21875561', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ribatti D, Crivellato E. Mast cell ontogeny: An historical overview. Immunol Lett. (2014) 159:11–4. doi:\\xa010.1016/j.imlet.2014.02.003', 'ArticleIdList': [StringElement('10.1016/j.imlet.2014.02.003', attributes={'IdType': 'doi'}), StringElement('24534641', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kitamura Y, Shimada M, Hatanaka K, Miyano Y. Development of mast cells from grafted bone marrow cells in irradiated mice. Nature. (1977) 268:442–3. doi:\\xa010.1038/268442a0', 'ArticleIdList': [StringElement('10.1038/268442a0', attributes={'IdType': 'doi'}), StringElement('331117', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Delassus S, Titley I, Enver T. Functional and molecular analysis of hematopoietic progenitors derived from the aorta-gonad-mesonephros region of the mouse embryo. Blood. (1999) 94:1495–503. doi:\\xa010.1182/blood.V94.5.1495.417a08_1495_1503', 'ArticleIdList': [StringElement('10.1182/blood.V94.5.1495.417a08_1495_1503', attributes={'IdType': 'doi'}), StringElement('10477673', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Grootens J, Ungerstedt JS, Nilsson G, Dahlin JS. Deciphering the differentiation trajectory from hematopoietic stem cells to mast cells. Blood Adv. (2018) 2:2273–81. doi:\\xa010.1182/bloodadvances.2018019539', 'ArticleIdList': [StringElement('10.1182/bloodadvances.2018019539', attributes={'IdType': 'doi'}), StringElement('PMC6134220', attributes={'IdType': 'pmc'}), StringElement('30206100', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Li Z, Liu S, Xu J, Zhang X, Han D, Liu J, et al. . Adult connective tissue-resident mast cells originate from late erythro-myeloid progenitors. Immunity. (2018) 49:640–653.e5. doi:\\xa010.1016/j.immuni.2018.09.023', 'ArticleIdList': [StringElement('10.1016/j.immuni.2018.09.023', attributes={'IdType': 'doi'}), StringElement('30332630', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gentek R, Ghigo C, Hoeffel G, Bulle MJ, Msallam R, Gautier G, et al. . Hemogenic endothelial fate mapping reveals dual developmental origin of mast cells. Immunity. (2018) 48:1160-1171.e5. doi:\\xa010.1016/j.immuni.2018.04.025', 'ArticleIdList': [StringElement('10.1016/j.immuni.2018.04.025', attributes={'IdType': 'doi'}), StringElement('29858009', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Weitzmann A, Naumann R, Dudeck A, Zerjatke T, Gerbaulet A, Roers A. Mast cells occupy stable clonal territories in adult steady-state skin. J Invest Dermatol. (2020) 140:2433-2441.e5. doi:\\xa010.1016/j.jid.2020.03.963', 'ArticleIdList': [StringElement('10.1016/j.jid.2020.03.963', attributes={'IdType': 'doi'}), StringElement('32311397', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Leeanansaksiri W. The mast cells. BioMed J Sci Tech Res. (2023) 51:42548–52. doi:\\xa010.26717/BJSTR', 'ArticleIdList': [StringElement('10.26717/BJSTR', attributes={'IdType': 'doi'})]}, {'Citation': 'Ribatti D. The saga of mast cells. In: Milestones in Immunology. Elsevier; (2017). p. 103–27. doi:\\xa010.1016/B978-0-12-811313-4.00009-7', 'ArticleIdList': [StringElement('10.1016/B978-0-12-811313-4.00009-7', attributes={'IdType': 'doi'})]}, {'Citation': 'Irani AM, Bradford TR, Kepley CL, Schechter NM, Schwartz LB. Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem. (1989) 37:1509–15. doi:\\xa010.1177/37.10.2674273', 'ArticleIdList': [StringElement('10.1177/37.10.2674273', attributes={'IdType': 'doi'}), StringElement('2674273', attributes={'IdType': 'pubmed'})]}, {'Citation': '\\nPejler G, Åbrink M, Ringvall M, Wernersson S. Mast cell proteases. In: Advances in Immunology. Elsevier;  (2007). p. 167–255. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0065277607950063. doi:\\xa010.1016/S0065-2776(07)95006-3\\n', 'ArticleIdList': [StringElement('10.1016/S0065-2776(07)95006-3', attributes={'IdType': 'doi'}), StringElement('17869614', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Xiang Z, Block M, Löfman C, Nilsson G. IgE-mediated mast cell degranulation and recovery monitored by time-lapse photography☆. J Allergy Clin Immunol. (2001) 108:116–21. doi:\\xa010.1067/mai.2001.116124', 'ArticleIdList': [StringElement('10.1067/mai.2001.116124', attributes={'IdType': 'doi'}), StringElement('11447391', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Galli SJ, Starkl P, Marichal T, Tsai M. Mast cells and IgE in defense against venoms: Possible \"good side\" of allergy? Allergol Int. (2016) 65:3–15. doi:\\xa010.1016/j.alit.2015.09.002', 'ArticleIdList': [StringElement('10.1016/j.alit.2015.09.002', attributes={'IdType': 'doi'}), StringElement('26666482', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gurish MF, Bryce PJ, Tao H, Kisselgof AB, Thornton EM, Miller HR, et al. . IgE enhances parasite clearance and regulates mast cell responses in mice infected with trichinella spiralis. J Immunol. (2004) 172:1139–45. doi:\\xa010.4049/jimmunol.172.2.1139', 'ArticleIdList': [StringElement('10.4049/jimmunol.172.2.1139', attributes={'IdType': 'doi'}), StringElement('14707089', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Soria-Castro R, Alfaro-Doblado ÁR, Rodríguez-López G, Campillo-Navarro M, Meneses-Preza YG, Galán-Salinas A, et al. . TLR2 regulates mast cell IL-6 and IL-13 production during listeria monocytogenes infection. Front Immunol. (2021) 12. doi:\\xa010.3389/fimmu.2021.650779', 'ArticleIdList': [StringElement('10.3389/fimmu.2021.650779', attributes={'IdType': 'doi'}), StringElement('PMC8238461', attributes={'IdType': 'pmc'}), StringElement('34194428', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Starkl P, Watzenboeck ML, Popov LM, Zahalka S, Hladik A, Lakovits K, et al. . IgE Effector Mechanisms, in Concert with Mast Cells, Contribute to Acquired Host Defense against Staphylococcus aureus. Immunity. (2020) 53:793–804.e9. doi:\\xa010.1016/j.immuni.2020.08.002', 'ArticleIdList': [StringElement('10.1016/j.immuni.2020.08.002', attributes={'IdType': 'doi'}), StringElement('PMC7572876', attributes={'IdType': 'pmc'}), StringElement('32910906', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pundir P, Liu R, Vasavda C, Serhan N, Limjunyawong N, Yee R, et al. . A connective tissue mast-cell-specific receptor detects bacterial quorum-sensing molecules and mediates antibacterial immunity. Cell Host Microbe. (2019) 26:114–122.e8. doi:\\xa010.1016/j.chom.2019.06.003', 'ArticleIdList': [StringElement('10.1016/j.chom.2019.06.003', attributes={'IdType': 'doi'}), StringElement('PMC6649664', attributes={'IdType': 'pmc'}), StringElement('31278040', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Goldmann O, Sauerwein T, Molinari G, Rohde M, Förstner KU, Medina E. Cytosolic sensing of intracellular staphylococcus aureus by mast cells elicits a type I IFN response that enhances cell-autonomous immunity. J Immunol. (2022) 208:1675–85. doi:\\xa010.4049/jimmunol.2100622', 'ArticleIdList': [StringElement('10.4049/jimmunol.2100622', attributes={'IdType': 'doi'}), StringElement('35321877', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Garcia-Rodriguez KM, Goenka A, Thomson DD, Bahri R, Tontini C, Salcman B, et al. . Bacillus calmette–guérin-induced human mast cell activation relies on IL-33 priming. Int J Mol Sci. (2022) 23:7549. doi:\\xa010.3390/ijms23147549', 'ArticleIdList': [StringElement('10.3390/ijms23147549', attributes={'IdType': 'doi'}), StringElement('PMC9320129', attributes={'IdType': 'pmc'}), StringElement('35886897', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mayavannan A, Shantz E, Haidl ID, Wang J, Marshall JS. Mast cells selectively produce inflammatory mediators and impact the early response to Chlamydia reproductive tract infection. Front Immunol. (2023) 14:1166068. doi:\\xa010.3389/fimmu.2023.1166068', 'ArticleIdList': [StringElement('10.3389/fimmu.2023.1166068', attributes={'IdType': 'doi'}), StringElement('PMC10150091', attributes={'IdType': 'pmc'}), StringElement('37138882', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Yu Y, Blokhuis BR, Garssen J, Redegeld FA. Non-IgE mediated mast cell activation. Eur J Pharmacol. (2016) 778:33–43. doi:\\xa010.1016/j.ejphar.2015.07.017', 'ArticleIdList': [StringElement('10.1016/j.ejphar.2015.07.017', attributes={'IdType': 'doi'}), StringElement('26164792', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chompunud Na Ayudhya C, Roy S, Thapaliya M, Ali H. Roles of a mast cell–specific receptor MRGPRX2 in host defense and inflammation. J Dent Res. (2020) 99:882–90. doi:\\xa010.1177/0022034520919107', 'ArticleIdList': [StringElement('10.1177/0022034520919107', attributes={'IdType': 'doi'}), StringElement('PMC7346743', attributes={'IdType': 'pmc'}), StringElement('32392433', attributes={'IdType': 'pubmed'})]}, {'Citation': 'McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, et al. . Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. (2015) 519:237–41. doi:\\xa010.1038/nature14022', 'ArticleIdList': [StringElement('10.1038/nature14022', attributes={'IdType': 'doi'}), StringElement('PMC4359082', attributes={'IdType': 'pmc'}), StringElement('25517090', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Arifuzzaman M, Mobley YR, Choi HW, Bist P, Salinas CA, Brown ZD, et al. . MRGPR-mediated activation of local mast cells clears cutaneous bacterial infection and protects against reinfection. Sci Adv. (2019) 5:eaav0216. doi:\\xa010.1126/sciadv.aav0216', 'ArticleIdList': [StringElement('10.1126/sciadv.aav0216', attributes={'IdType': 'doi'}), StringElement('PMC6314830', attributes={'IdType': 'pmc'}), StringElement('30613778', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Daëron M. Innate myeloid cells under the control of adaptive immunity: the example of mast cells and basophils. Curr Opin Immunol. (2016) 38:101–8. doi:\\xa010.1016/j.coi.2015.12.004', 'ArticleIdList': [StringElement('10.1016/j.coi.2015.12.004', attributes={'IdType': 'doi'}), StringElement('26745401', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hartmann K, Henz BM, Krüger-Krasagakes S, Köhl J, Burger R, Guhl S, et al. . C3a and C5a stimulate chemotaxis of human mast cells. Blood. (1997) 89:2863–70. doi:\\xa010.1182/blood.V89.8.2863', 'ArticleIdList': [StringElement('10.1182/blood.V89.8.2863', attributes={'IdType': 'doi'}), StringElement('9108406', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lubbers R, van Essen MF, van Kooten C, Trouw LA. Production of complement components by cells of the immune system. Clin Exp Immunol. (2017) 188:183–94. doi:\\xa010.1111/cei.12952', 'ArticleIdList': [StringElement('10.1111/cei.12952', attributes={'IdType': 'doi'}), StringElement('PMC5383442', attributes={'IdType': 'pmc'}), StringElement('28249350', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Elieh Ali Komi D, Shafaghat F, Kovanen PT, Meri S. Mast cells and complement system: Ancient interactions between components of innate immunity. Allergy. (2020) 75:2818–28. doi:\\xa010.1111/all.14413', 'ArticleIdList': [StringElement('10.1111/all.14413', attributes={'IdType': 'doi'}), StringElement('32446274', attributes={'IdType': 'pubmed'})]}, {'Citation': 'McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Cutting edge: distinct toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol. (2003) 170:1625–9. doi:\\xa010.4049/jimmunol.170.4.1625', 'ArticleIdList': [StringElement('10.4049/jimmunol.170.4.1625', attributes={'IdType': 'doi'}), StringElement('12574323', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Supajatura V, Ushio H, Nakao A, Akira S, Okumura K, Ra C, et al. . Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest. (2002) 109:1351–9. doi:\\xa010.1172/JCI14704', 'ArticleIdList': [StringElement('10.1172/JCI14704', attributes={'IdType': 'doi'}), StringElement('PMC150977', attributes={'IdType': 'pmc'}), StringElement('12021251', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Applequist SE. Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int Immunol. (2002) 14:1065–74. doi:\\xa010.1093/intimm/dxf069', 'ArticleIdList': [StringElement('10.1093/intimm/dxf069', attributes={'IdType': 'doi'}), StringElement('12202403', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Varadaradjalou S, Féger F, Thieblemont N, Hamouda NB, Pleau J, Dy M, et al. . Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol. (2003) 33:899–906. doi:\\xa010.1002/eji.200323830', 'ArticleIdList': [StringElement('10.1002/eji.200323830', attributes={'IdType': 'doi'}), StringElement('12672055', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Onoguchi K, Yoneyama M, Fujita T. Retinoic acid-inducible gene-I-like receptors. J Interferon Cytokine Res. (2011) 31:27–31. doi:\\xa010.1089/jir.2010.0057', 'ArticleIdList': [StringElement('10.1089/jir.2010.0057', attributes={'IdType': 'doi'}), StringElement('20950133', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, et al. . The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc Natl Acad Sci U S A. (2000) 97:13766–71. doi:\\xa010.1073/pnas.250476497', 'ArticleIdList': [StringElement('10.1073/pnas.250476497', attributes={'IdType': 'doi'}), StringElement('PMC17650', attributes={'IdType': 'pmc'}), StringElement('11095740', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ohto U, Shibata T, Tanji H, Ishida H, Krayukhina E, Uchiyama S, et al. . Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature. (2015) 520:702–5. doi:\\xa010.1038/nature14138', 'ArticleIdList': [StringElement('10.1038/nature14138', attributes={'IdType': 'doi'}), StringElement('25686612', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kimura Y, Chihara K, Honjoh C, Takeuchi K, Yamauchi S, Yoshiki H, et al. . Dectin-1-mediated signaling leads to characteristic gene expressions and cytokine secretion via spleen tyrosine kinase (Syk) in rat mast cells. J Biol Chem. (2014) 289:31565–75. doi:\\xa010.1074/jbc.M114.581322', 'ArticleIdList': [StringElement('10.1074/jbc.M114.581322', attributes={'IdType': 'doi'}), StringElement('PMC4223353', attributes={'IdType': 'pmc'}), StringElement('25246527', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Saijo S, Ikeda S, Yamabe K, Kakuta S, Ishigame H, Akitsu A, et al. . Dectin-2 Recognition of α-Mannans and Induction of Th17 Cell Differentiation Is Essential for Host Defense against Candida albicans. Immunity. (2010) 32:681–91. doi:\\xa010.1016/j.immuni.2010.05.001', 'ArticleIdList': [StringElement('10.1016/j.immuni.2010.05.001', attributes={'IdType': 'doi'}), StringElement('20493731', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Fukuda M, Ushio H, Kawasaki J, Niyonsaba F, Takeuchi M, Baba T, et al. . Expression and functional characterization of retinoic acid-inducible gene-I-like receptors of mast cells in response to viral infection. J Innate Immun. (2013) 5:163–73. doi:\\xa010.1159/000343895', 'ArticleIdList': [StringElement('10.1159/000343895', attributes={'IdType': 'doi'}), StringElement('PMC6784038', attributes={'IdType': 'pmc'}), StringElement('23171655', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Wu L, Feng B, He S, Zheng P, Croitoru K, Yang P. Bacterial peptidoglycan breaks down intestinal tolerance via mast cell activation: The role of TLR2 and NOD2. Immunol Cell Biol. (2007) 85:538–45. doi:\\xa010.1038/sj.icb.7100079', 'ArticleIdList': [StringElement('10.1038/sj.icb.7100079', attributes={'IdType': 'doi'}), StringElement('17563761', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Feng BS, He SH, Zheng PY, Wu L, Yang PC. Mast cells play a crucial role in staphylococcus aureus peptidoglycan-induced diarrhea. Am J Pathol. (2007) 171:537–47. doi:\\xa010.2353/ajpath.2007.061274', 'ArticleIdList': [StringElement('10.2353/ajpath.2007.061274', attributes={'IdType': 'doi'}), StringElement('PMC1934528', attributes={'IdType': 'pmc'}), StringElement('17600127', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Luo K, Li N, Ye W, Gao H, Luo X, Cheng B. Activation of stimulation of interferon genes (STING) signal and cancer immunotherapy. Molecules. (2022) 27:4638. doi:\\xa010.3390/molecules27144638', 'ArticleIdList': [StringElement('10.3390/molecules27144638', attributes={'IdType': 'doi'}), StringElement('PMC9325158', attributes={'IdType': 'pmc'}), StringElement('35889509', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Li F, Wang N, Zheng Y, Luo Y, Zhang Y. cGAS- stimulator of interferon genes signaling in central nervous system disorders. Aging Dis. (2021) 12:1658–74. doi:\\xa010.14336/AD.2021.0304', 'ArticleIdList': [StringElement('10.14336/AD.2021.0304', attributes={'IdType': 'doi'}), StringElement('PMC8460300', attributes={'IdType': 'pmc'}), StringElement('34631213', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Matsuda K, Piliponsky A, Iikura M, Nakae S, Wang E, Dutta S, et al. . Monomeric IgE enhances human mast cell chemokine production: IL-4 augments and dexamethasone suppresses the response. J Allergy Clin Immunol. (2005) 116:1357–63. doi:\\xa010.1016/j.jaci.2005.08.042', 'ArticleIdList': [StringElement('10.1016/j.jaci.2005.08.042', attributes={'IdType': 'doi'}), StringElement('16337471', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gombert M, Dieu-Nosjean MC, Winterberg F, Bünemann E, Kubitza RC, Da Cunha L, et al. . CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol. (2005) 174:5082–91. doi:\\xa010.4049/jimmunol.174.8.5082', 'ArticleIdList': [StringElement('10.4049/jimmunol.174.8.5082', attributes={'IdType': 'doi'}), StringElement('15814739', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kashiwakura J, Yokoi H, Saito H, Okayama Y. T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. J Immunol. (2004) 173:5247–57. doi:\\xa010.4049/jimmunol.173.8.5247', 'ArticleIdList': [StringElement('10.4049/jimmunol.173.8.5247', attributes={'IdType': 'doi'}), StringElement('15470070', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Garcia-Rodriguez KM, Bahri R, Sattentau C, Roberts IS, Goenka A, Bulfone-Paus S. Human mast cells exhibit an individualized pattern of antimicrobial responses. Immun Inflammation Dis. (2020) 8:198–210. doi:\\xa010.1002/iid3.295', 'ArticleIdList': [StringElement('10.1002/iid3.295', attributes={'IdType': 'doi'}), StringElement('PMC7212193', attributes={'IdType': 'pmc'}), StringElement('32222064', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lee KS, Kim SR, Park SJ, Min KH, Lee KY, Choe YH, et al. . Mast cells can mediate vascular permeability through regulation of the PI3K–HIF-1α–VEGF axis. Am J Respir Crit Care Med. (2008) 178:787–97. doi:\\xa010.1164/rccm.200801-008OC', 'ArticleIdList': [StringElement('10.1164/rccm.200801-008OC', attributes={'IdType': 'doi'}), StringElement('18669818', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gao S, Liu K, Ku W, Wang D, Wake H, Qiao H, et al. . Histamine-induced high mobility group box-1 release from vascular endothelial cells through H1 receptor. Front Immunol. (2022) 13:930683. doi:\\xa010.3389/fimmu.2022.930683', 'ArticleIdList': [StringElement('10.3389/fimmu.2022.930683', attributes={'IdType': 'doi'}), StringElement('PMC9583674', attributes={'IdType': 'pmc'}), StringElement('36275732', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kunder CA, St John AL, Abraham SN. Mast cell modulation of the vascular and lymphatic endothelium. Blood. (2011) 118:5383–93. doi:\\xa010.1182/blood-2011-07-358432', 'ArticleIdList': [StringElement('10.1182/blood-2011-07-358432', attributes={'IdType': 'doi'}), StringElement('PMC3217344', attributes={'IdType': 'pmc'}), StringElement('21908429', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Van Haaster CMCJ, Derhaag JG, Engels W, Lemmens PJMR, Gijsen AP, Hornstra G, et al. . Mast cell-mediated induction of ICAM-1, VCAM-1 and E-selectin in endothelial cells in vitro: constitutive release of inducing mediators but no effect of degranulation. Pflügers Arch Eur J Physiol. (1997) 435:137–44. doi:\\xa010.1007/s004240050493', 'ArticleIdList': [StringElement('10.1007/s004240050493', attributes={'IdType': 'doi'}), StringElement('9359913', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chai OH, Han EH, Lee HK, Song CH. Mast cells play a key role in Th2 cytokine-dependent asthma model through production of adhesion molecules by liberation of TNF-α. Exp Mol Med. (2011) 43:35. doi:\\xa010.3858/emm.2011.43.1.004', 'ArticleIdList': [StringElement('10.3858/emm.2011.43.1.004', attributes={'IdType': 'doi'}), StringElement('PMC3041936', attributes={'IdType': 'pmc'}), StringElement('21169725', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Zhang J, Alcaide P, Liu L, Sun J, He A, Luscinskas FW, et al. . Regulation of endothelial cell adhesion molecule expression by mast cells, macrophages, and neutrophils. Zernecke A, editor. PloS One. (2011) 6:e14525. doi:\\xa010.1371/journal.pone.0014525', 'ArticleIdList': [StringElement('10.1371/journal.pone.0014525', attributes={'IdType': 'doi'}), StringElement('PMC3021513', attributes={'IdType': 'pmc'}), StringElement('21264293', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Suto H, Nakae S, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cell-associated TNF promotes dendritic cell migration. J Immunol. (2006) 176:4102–12. doi:\\xa010.4049/jimmunol.176.7.4102', 'ArticleIdList': [StringElement('10.4049/jimmunol.176.7.4102', attributes={'IdType': 'doi'}), StringElement('16547246', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Dudeck J, Kotrba J, Immler R, Hoffmann A, Voss M, Alexaki VI, et al. . Directional mast cell degranulation of tumor necrosis factor into blood vessels primes neutrophil extravasation. Immunity. (2021) 54:468-483.e5. doi:\\xa010.1016/j.immuni.2020.12.017', 'ArticleIdList': [StringElement('10.1016/j.immuni.2020.12.017', attributes={'IdType': 'doi'}), StringElement('33484643', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Krause P, Bruckner M, Uermösi C, Singer E, Groettrup M, Legler DF. Prostaglandin E2 enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood. (2009) 113:2451–60. doi:\\xa010.1182/blood-2008-05-157123', 'ArticleIdList': [StringElement('10.1182/blood-2008-05-157123', attributes={'IdType': 'doi'}), StringElement('19029446', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Amorim NRT, Souza-Almeida G, Luna-Gomes T, Bozza PT, Canetti C, Diaz BL, et al. . Leptin elicits in vivo eosinophil migration and activation: key role of mast cell-derived PGD2. Front Endocrinol. (2020) 11:572113. doi:\\xa010.3389/fendo.2020.572113', 'ArticleIdList': [StringElement('10.3389/fendo.2020.572113', attributes={'IdType': 'doi'}), StringElement('PMC7551309', attributes={'IdType': 'pmc'}), StringElement('33117286', attributes={'IdType': 'pubmed'})]}, {'Citation': 'De Filippo K, Dudeck A, Hasenberg M, Nye E, Van Rooijen N, Hartmann K, et al. . Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood. (2013) 121:4930–7. doi:\\xa010.1182/blood-2013-02-486217', 'ArticleIdList': [StringElement('10.1182/blood-2013-02-486217', attributes={'IdType': 'doi'}), StringElement('23645836', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. (2013) 13:159–75. doi:\\xa010.1038/nri3399', 'ArticleIdList': [StringElement('10.1038/nri3399', attributes={'IdType': 'doi'}), StringElement('23435331', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Montecucco F, Steffens S, Burger F, Da Costa A, Bianchi G, Bertolotto M, et al. . Tumor necrosis factor-alpha (TNF-α) induces integrin CD11b/CD18 (Mac-1) up-regulation and migration to the CC chemokine CCL3 (MIP-1α) on human neutrophils through defined signalling pathways. Cell Signal. (2008) 20:557–68. doi:\\xa010.1016/j.cellsig.2007.11.008', 'ArticleIdList': [StringElement('10.1016/j.cellsig.2007.11.008', attributes={'IdType': 'doi'}), StringElement('18164590', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pejler G, Alanazi S, Grujic M, Adler J, Olsson AK, Sommerhoff CP, et al. . Mast cell tryptase potentiates neutrophil extracellular trap formation. J Innate Immun. (2022) 14:433–46. doi:\\xa010.1159/000520972', 'ArticleIdList': [StringElement('10.1159/000520972', attributes={'IdType': 'doi'}), StringElement('PMC9485958', attributes={'IdType': 'pmc'}), StringElement('34937018', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chu Y, Wan S, Anderson R, Lin Y. Mast cell–macrophage dynamics in modulation of dengue virus infection in skin. Immunology. (2015) 146:163–72. doi:\\xa010.1111/imm.12492', 'ArticleIdList': [StringElement('10.1111/imm.12492', attributes={'IdType': 'doi'}), StringElement('PMC4552511', attributes={'IdType': 'pmc'}), StringElement('26059780', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tam IYS, Ng CW, Lau HYA, Tam SY. Degradation of monocyte chemoattractant protein-1 by tryptase co-released in immunoglobulin E-dependent activation of primary human cultured mast cells. Int Arch Allergy Immunol. (2018) 177:199–206. doi:\\xa010.1159/000490533', 'ArticleIdList': [StringElement('10.1159/000490533', attributes={'IdType': 'doi'}), StringElement('30021208', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lopes JP, Stylianou M, Backman E, Holmberg S, Ekoff M, Nilsson G, et al. . Cryptococcus neoformans induces MCP-1 release and delays the death of human mast cells. Front Cell Infect Microbiol. (2019) 9:289. doi:\\xa010.3389/fcimb.2019.00289', 'ArticleIdList': [StringElement('10.3389/fcimb.2019.00289', attributes={'IdType': 'doi'}), StringElement('PMC6700240', attributes={'IdType': 'pmc'}), StringElement('31456952', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Katoh N, Soga F, Nara T, Masuda K, Kishimoto S. Histamine Induces the Generation of Monocyte-Derived Dendritic Cells that Express CD14 but not CD1a. J Invest Dermatol. (2005) 125:753–60. doi:\\xa010.1111/j.0022-202X.2005.23891.x', 'ArticleIdList': [StringElement('10.1111/j.0022-202X.2005.23891.x', attributes={'IdType': 'doi'}), StringElement('16185276', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Dudeck J, Froebel J, Kotrba J, Lehmann CHK, Dudziak D, Speier S, et al. . Engulfment of mast cell secretory granules on skin inflammation boosts dendritic cell migration and priming efficiency. J Allergy Clin Immunol. (2019) 143:1849–1864.e4. doi:\\xa010.1016/j.jaci.2018.08.052', 'ArticleIdList': [StringElement('10.1016/j.jaci.2018.08.052', attributes={'IdType': 'doi'}), StringElement('30339853', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Godfrey WR, Fagnoni FF, Harara MA, Buck D, Engleman EG. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med. (1994) 180:757–62. doi:\\xa010.1084/jem.180.2.757', 'ArticleIdList': [StringElement('10.1084/jem.180.2.757', attributes={'IdType': 'doi'}), StringElement('PMC2191595', attributes={'IdType': 'pmc'}), StringElement('7913952', attributes={'IdType': 'pubmed'})]}, {'Citation': \"Frossi B, Gri G, Tripodo C, Pucillo C. Exploring a regulatory role for mast cells: 'MCregs'? Trends Immunol. (2010) 31:97–102. doi:\\xa010.1016/j.it.2009.12.007\", 'ArticleIdList': [StringElement('10.1016/j.it.2009.12.007', attributes={'IdType': 'doi'}), StringElement('20149743', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gao Y, Xu B, Zhang P, He Y, Liang X, Liu J, et al. . TNF-α Regulates mast cell functions by inhibiting cell degranulation. Cell Physiol Biochem. (2017) 44:751–62. doi:\\xa010.1159/000485288', 'ArticleIdList': [StringElement('10.1159/000485288', attributes={'IdType': 'doi'}), StringElement('29169157', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ott VL, Cambier JC, Kappler J, Marrack P, Swanson BJ. Mast cell–dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol. (2003) 4:974–81. doi:\\xa010.1038/ni971', 'ArticleIdList': [StringElement('10.1038/ni971', attributes={'IdType': 'doi'}), StringElement('12949532', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Stelekati E, Bahri R, D’Orlando O, Orinska Z, Mittrücker HW, Langenhaun R, et al. . Mast cell-mediated antigen presentation regulates CD8+ T cell effector functions. Immunity. (2009) 31:665–76. doi:\\xa010.1016/j.immuni.2009.08.022', 'ArticleIdList': [StringElement('10.1016/j.immuni.2009.08.022', attributes={'IdType': 'doi'}), StringElement('19818652', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hong GU, Park BS, Park JW, Kim SY, Ro JY. IgE production in CD40/CD40L cross-talk of B and mast cells and mediator release via TGase 2 in mouse allergic asthma. Cell Signal. (2013) 25:1514–25. doi:\\xa010.1016/j.cellsig.2013.03.010', 'ArticleIdList': [StringElement('10.1016/j.cellsig.2013.03.010', attributes={'IdType': 'doi'}), StringElement('23524335', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hong GU, Lim JY, Kim NG, Shin JH, Ro JY. IgE and IgA produced by OX40–OX40L or CD40–CD40L interaction in B cells–mast cells re-activate FcϵRI or FcαRI on mast cells in mouse allergic asthma. Eur J Pharmacol. (2015) 754:199–210. doi:\\xa010.1016/j.ejphar.2015.02.023', 'ArticleIdList': [StringElement('10.1016/j.ejphar.2015.02.023', attributes={'IdType': 'doi'}), StringElement('25704619', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Sutherland RE, Olsen JS, McKinstry A, Villalta SA, Wolters PJ. Mast cell IL-6 improves survival from klebsiella pneumonia and sepsis by enhancing neutrophil killing. J Immunol. (2008) 181:5598–605. doi:\\xa010.4049/jimmunol.181.8.5598', 'ArticleIdList': [StringElement('10.4049/jimmunol.181.8.5598', attributes={'IdType': 'doi'}), StringElement('PMC2610024', attributes={'IdType': 'pmc'}), StringElement('18832718', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Xu X, Zhang D, Lyubynska N, Wolters PJ, Killeen NP, Baluk P, et al. . Mast cells protect mice from mycoplasma pneumonia. Am J Respir Crit Care Med. (2006) 173:219–25. doi:\\xa010.1164/rccm.200507-1034OC', 'ArticleIdList': [StringElement('10.1164/rccm.200507-1034OC', attributes={'IdType': 'doi'}), StringElement('PMC2662990', attributes={'IdType': 'pmc'}), StringElement('16210667', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gendrin C, Vornhagen J, Ngo L, Whidbey C, Boldenow E, Santana-Ufret V, et al. . Mast cell degranulation by a hemolytic lipid toxin decreases GBS colonization and infection. Sci Adv. (2015) 1:e1400225. doi:\\xa010.1126/sciadv.1400225', 'ArticleIdList': [StringElement('10.1126/sciadv.1400225', attributes={'IdType': 'doi'}), StringElement('PMC4584422', attributes={'IdType': 'pmc'}), StringElement('26425734', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Malaviya R, Gao Z, Thankavel K, van der Merwe PA, Abraham SN. The mast cell tumor necrosis factor α response to FimH-expressing Escherichia coli is mediated by the glycosylphosphatidylinositol-anchored molecule CD48. Proc Natl Acad Sci. (1999) 96:8110–5. doi:\\xa010.1073/pnas.96.14.8110', 'ArticleIdList': [StringElement('10.1073/pnas.96.14.8110', attributes={'IdType': 'doi'}), StringElement('PMC22196', attributes={'IdType': 'pmc'}), StringElement('10393956', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Dominguez-Flores A, Rodríguez López GM, Soria-Castro R, López-Santiago R, Rodríguez-Cortés O, Pérez-Tapia SM, et al. . Brucella abortus induces mast cell activation through TLR-2 and TLR-4. Microb Pathog. (2023) 176:106005. doi:\\xa010.1016/j.micpath.2023.106005', 'ArticleIdList': [StringElement('10.1016/j.micpath.2023.106005', attributes={'IdType': 'doi'}), StringElement('36717005', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Rönnberg E, Guss B, Pejler G. Infection of mast cells with live streptococci causes a toll-like receptor 2- and cell-cell contact-dependent cytokine and chemokine response. Infect Immun. (2010) 78:854–64. doi:\\xa010.1128/IAI.01004-09', 'ArticleIdList': [StringElement('10.1128/IAI.01004-09', attributes={'IdType': 'doi'}), StringElement('PMC2812202', attributes={'IdType': 'pmc'}), StringElement('19933827', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Al Hamwi G, Riedel YK, Clemens S, Namasivayam V, Thimm D, Müller CE. MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs. Pharmacol Ther. (2022) 238:108259. doi:\\xa010.1016/j.pharmthera.2022.108259', 'ArticleIdList': [StringElement('10.1016/j.pharmthera.2022.108259', attributes={'IdType': 'doi'}), StringElement('35934214', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Corbière A, Loste A, Gaudenzio N. MRGPRX2 sensing of cationic compounds—A bridge between nociception and skin diseases? Exp Dermatol. (2021) 30:193–200. doi:\\xa010.1111/exd.14222', 'ArticleIdList': [StringElement('10.1111/exd.14222', attributes={'IdType': 'doi'}), StringElement('33107136', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Subramanian H, Gupta K, Ali H. Roles of MAS-related G protein coupled receptor-X2 (MRGPRX2) on mast cell-mediated host defense, pseudoallergic drug reactions and chronic inflammatory diseases. J Allergy Clin Immunol. (2016) 138:700–10. doi:\\xa010.1016/j.jaci.2016.04.051', 'ArticleIdList': [StringElement('10.1016/j.jaci.2016.04.051', attributes={'IdType': 'doi'}), StringElement('PMC5014572', attributes={'IdType': 'pmc'}), StringElement('27448446', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gupta K, Idahosa C, Roy S, Lee D, Subramanian H, Dhingra A, et al. . Differential regulation of mas-related G protein-coupled receptor X2-mediated mast cell degranulation by antimicrobial host defense peptides and porphyromonas gingivalis lipopolysaccharide. McCormick B Editor Infect Immun. (2017) 85:e00246–17. doi:\\xa010.1128/IAI.00246-17', 'ArticleIdList': [StringElement('10.1128/IAI.00246-17', attributes={'IdType': 'doi'}), StringElement('PMC5607414', attributes={'IdType': 'pmc'}), StringElement('28694291', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Subramanian H, Gupta K, Guo Q, Price R, Ali H. Mas-related gene X2 (MrgX2) is a novel G protein-coupled receptor for the antimicrobial peptide LL-37 in human mast cells. J Biol Chem. (2011) 286:44739–49. doi:\\xa010.1074/jbc.M111.277152', 'ArticleIdList': [StringElement('10.1074/jbc.M111.277152', attributes={'IdType': 'doi'}), StringElement('PMC3247983', attributes={'IdType': 'pmc'}), StringElement('22069323', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Subramanian H, Gupta K, Lee D, Bayir AK, Ahn H, Ali H. β-defensins activate human mast cells via mas-related gene X2. J Immunol. (2013) 191:345–52. doi:\\xa010.4049/jimmunol.1300023', 'ArticleIdList': [StringElement('10.4049/jimmunol.1300023', attributes={'IdType': 'doi'}), StringElement('PMC3691353', attributes={'IdType': 'pmc'}), StringElement('23698749', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Choi S, Isaacs A, Clements D, Liu D, Kim H, Scott RW, et al. . De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers. Proc Natl Acad Sci. (2009) 106:6968–73. doi:\\xa010.1073/pnas.0811818106', 'ArticleIdList': [StringElement('10.1073/pnas.0811818106', attributes={'IdType': 'doi'}), StringElement('PMC2667368', attributes={'IdType': 'pmc'}), StringElement('19359494', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Svenson J, Molchanova N, Schroeder CI. Antimicrobial peptide mimics for clinical use: does size matter? Front Immunol. (2022) 13:915368. doi:\\xa010.3389/fimmu.2022.915368', 'ArticleIdList': [StringElement('10.3389/fimmu.2022.915368', attributes={'IdType': 'doi'}), StringElement('PMC9204644', attributes={'IdType': 'pmc'}), StringElement('35720375', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Amponnawarat A, Chompunud Na Ayudhya C, Ali H. Murepavadin, a small molecule host defense peptide mimetic, activates mast cells via MRGPRX2 and mrgprb2. Front Immunol. (2021) 12:689410. doi:\\xa010.3389/fimmu.2021.689410', 'ArticleIdList': [StringElement('10.3389/fimmu.2021.689410', attributes={'IdType': 'doi'}), StringElement('PMC8261236', attributes={'IdType': 'pmc'}), StringElement('34248979', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Breivogel CS, Lambert JM, Gerfin S, Huffman JW, Razdan RK. Sensitivity to Δ9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2-/- mice. Behav Pharmacol. (2008) 19:298–307. doi:\\xa010.1097/FBP.0b013e328308f1e6', 'ArticleIdList': [StringElement('10.1097/FBP.0b013e328308f1e6', attributes={'IdType': 'doi'}), StringElement('PMC2751575', attributes={'IdType': 'pmc'}), StringElement('18622177', attributes={'IdType': 'pubmed'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2023', 'Month': '12', 'Day': '22'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '2', 'Day': '26'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '22', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '19', 'Hour': '6', 'Minute': '43'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '19', 'Hour': '3', 'Minute': '40'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '1', 'Day': '1'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38638437', attributes={'IdType': 'pubmed'}), StringElement('PMC11024470', attributes={'IdType': 'pmc'}), StringElement('10.3389/fimmu.2024.1360296', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('AFM', attributes={'MajorTopicYN': 'N'}), StringElement('AFM-IR', attributes={'MajorTopicYN': 'N'}), StringElement('Dry powder inhaler', attributes={'MajorTopicYN': 'N'}), StringElement('Infrared spectroscopy', attributes={'MajorTopicYN': 'N'}), StringElement('Nanothermal analysis', attributes={'MajorTopicYN': 'N'}), StringElement('Pharmaceutical aerosols', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38615803', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '27'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '27'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '12'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1016/j.ijpharm.2024.124116', attributes={'EIdType': 'doi', 'ValidYN': 'Y'}), StringElement('S0378-5173(24)00350-8', attributes={'EIdType': 'pii', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1873-3476', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '656', 'PubDate': {'Year': '2024', 'Month': 'May', 'Day': '10'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'International journal of pharmaceutics', 'ISOAbbreviation': 'Int J Pharm'}, 'ArticleTitle': 'Nanoscale colocalized thermal and chemical mapping of pharmaceutical powder aerosols.', 'Pagination': {'StartPage': '124116', 'MedlinePgn': '124116'}, 'Abstract': {'AbstractText': ['Inhalation of pharmaceutical aerosol formulations is widely used to treat respiratory diseases. Spatially resolved thermal characterization offers promise for better understanding drug release rates from particles; however, this has been an analytical challenge due to the small particle size (from a few micrometers down to nanometers) and the complex composition of the formulations. Here, we employ nano-thermal analysis (nanoTA) to probe the nanothermal domain of a pharmaceutical aerosol formulation containing a mixture of fluticasone propionate (FP), salmeterol xinafoate (SX), and excipient lactose, which is widely used to treat asthma and chronic obstructive pulmonary disease (COPD). Furthermore, atomic force microscopy-infrared spectroscopy (AFM-IR) and AFM force measurements are performed to provide nanochemical and nanomechanical information to complement the nanothermal data. The colocalized thermal and chemical mapping clearly reveals the surface heterogeneity of the drugs in the aerosol particles and demonstrates the contribution of the surface chemical composition to the variation in the thermal properties of the particles. We present a powerful analytical approach for in-depth characterization of thermal/chemical/morphological properties of dry powder inhaler particles at micro- and nanometer scales. This approach can be used to facilitate the comparison between generics and reference inhalation products and further the development of high-performance pharmaceutical formulations.'], 'CopyrightInformation': 'Copyright © 2024 Elsevier B.V. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Chemical & Biological Engineering, Monash University, Clayton, VIC 3800, Australia; Future Industries Institute, University of South Australia, Mawson Lakes, SA 5095, Australia.'}], 'Identifier': [], 'LastName': 'Zhang', 'ForeName': 'Jing', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Advanced Drug Delivery Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia; Department of Mechanical and Materials Engineering, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.'}], 'Identifier': [], 'LastName': 'Khanal', 'ForeName': 'Dipesh', 'Initials': 'D'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Advanced Drug Delivery Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia. Electronic address: kim.chan@sydney.edu.au.'}], 'Identifier': [], 'LastName': 'Chan', 'ForeName': 'Hak-Kim', 'Initials': 'HK'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Chemical & Biological Engineering, Monash University, Clayton, VIC 3800, Australia; Department of Mechanical and Materials Engineering, University of Alabama at Birmingham, Birmingham, AL, 35294, USA; Division of Pulmonology, Allergy, and Critical Care Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address: mmbanasz@uab.edu.'}], 'Identifier': [], 'LastName': 'Banaszak Holl', 'ForeName': 'Mark M', 'Initials': 'MM'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'}), 'MedlineJournalInfo': {'Country': 'Netherlands', 'MedlineTA': 'Int J Pharm', 'NlmUniqueID': '7804127', 'ISSNLinking': '0378-5173'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Aerosols', attributes={'UI': 'D000336'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Powders', attributes={'UI': 'D011208'})}, {'RegistryNumber': 'CUT2W21N7U', 'NameOfSubstance': StringElement('Fluticasone', attributes={'UI': 'D000068298'})}, {'RegistryNumber': '6EW8Q962A5', 'NameOfSubstance': StringElement('Salmeterol Xinafoate', attributes={'UI': 'D000068299'})}, {'RegistryNumber': 'J2B2A4N98G', 'NameOfSubstance': StringElement('Lactose', attributes={'UI': 'D007785'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Excipients', attributes={'UI': 'D005079'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Bronchodilator Agents', attributes={'UI': 'D001993'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Aerosols', attributes={'UI': 'D000336', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Powders', attributes={'UI': 'D011208', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('chemistry', attributes={'UI': 'Q000737', 'MajorTopicYN': 'N'}), StringElement('administration & dosage', attributes={'UI': 'Q000008', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Fluticasone', attributes={'UI': 'D000068298', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('chemistry', attributes={'UI': 'Q000737', 'MajorTopicYN': 'N'}), StringElement('administration & dosage', attributes={'UI': 'Q000008', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Salmeterol Xinafoate', attributes={'UI': 'D000068299', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Particle Size', attributes={'UI': 'D010316', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('chemistry', attributes={'UI': 'Q000737', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Lactose', attributes={'UI': 'D007785', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Dry Powder Inhalers', attributes={'UI': 'D058995', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('methods', attributes={'UI': 'Q000379', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Microscopy, Atomic Force', attributes={'UI': 'D018625', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('chemistry', attributes={'UI': 'Q000737', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Excipients', attributes={'UI': 'D005079', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Administration, Inhalation', attributes={'UI': 'D000280', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('administration & dosage', attributes={'UI': 'Q000008', 'MajorTopicYN': 'N'}), StringElement('chemistry', attributes={'UI': 'Q000737', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Bronchodilator Agents', attributes={'UI': 'D001993', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('methods', attributes={'UI': 'Q000379', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Spectrophotometry, Infrared', attributes={'UI': 'D013055', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('methods', attributes={'UI': 'Q000379', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Chemistry, Pharmaceutical', attributes={'UI': 'D002626', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Surface Properties', attributes={'UI': 'D013499', 'MajorTopicYN': 'N'})}], 'CoiStatement': 'Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2023', 'Month': '11', 'Day': '6'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '8'}, attributes={'PubStatus': 'revised'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '11'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '28', 'Hour': '7', 'Minute': '24'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '15', 'Hour': '0', 'Minute': '42'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '14', 'Hour': '19', 'Minute': '24'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38615803', attributes={'IdType': 'pubmed'}), StringElement('10.1016/j.ijpharm.2024.124116', attributes={'IdType': 'doi'}), StringElement('S0378-5173(24)00350-8', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38609111', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '15'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '15'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1512-0112', attributes={'IssnType': 'Print'}), 'JournalIssue': DictElement({'Issue': '347', 'PubDate': {'Year': '2024', 'Month': 'Feb'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Georgian medical news', 'ISOAbbreviation': 'Georgian Med News'}, 'ArticleTitle': 'HISTOLOGICAL AND BIOCHEMICAL STUDY OF THE EFFECT OF FEXOFENADINE ON SALIVARY GLAND IN RATS.', 'Pagination': {'StartPage': '38', 'EndPage': '40', 'MedlinePgn': '38-40'}, 'Abstract': {'AbstractText': ['Fexofenadine is a newly introduced oral non-sedating agent used for allergic diseases. We sought to investigate the effects of the use of fexofenadine on the salivary gland of adult male albino rats. 30 adult male albino rats were classified randomly into 3 groups, as follows: Group A (control group) which consisted of 10 healthy rats. Group B (treated group) which consisted of 10 rats received FEX 5mg/kg/day, and Group C (treated group) which consisted of 10 rats received FEX 10mg/kg/day. Blood samples were obtained to assess serum levels of Thioredoxin reductase (TRX) and malondialdehyde (MDA). Salivary glands were removed and prepared for histological examination. This study showed that significantly (p<0.05) higher TRX and MDA levels were observed in group B and group C, compared to group A. The histological examination for salivary tissues revealed degenerative changes in serous cells of acini were present with deep pyknotic nuclei. Vacuolar cytoplasmic degeneration is also seen in other certain cells. Blood congestion was present in the intralobular blood vessels, particularly around the striated ducts. The glandular secretion duct contained mucus and serous secretion and the wall of the duct was surrounded by many WBCs with macrophage. Fexofenadine hydrochloride use induces remarkable histopathological changes with dose-dependent response and remarkably linked to elevation of oxidative stress markers.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': '1College of Medicine, Tikrit University, Iraq.'}], 'Identifier': [], 'LastName': 'Mahmood', 'ForeName': 'E', 'Initials': 'E'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': '1College of Medicine, Tikrit University, Iraq.'}], 'Identifier': [], 'LastName': 'Sarhat', 'ForeName': 'E', 'Initials': 'E'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': '1College of Medicine, Tikrit University, Iraq.'}], 'Identifier': [], 'LastName': 'Tawfeq', 'ForeName': 'M', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': '2College of Veterinary Medicine, Tikrit University, Iraq.'}], 'Identifier': [], 'LastName': 'Wadee', 'ForeName': 'S', 'Initials': 'S'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'Georgia (Republic)', 'MedlineTA': 'Georgian Med News', 'NlmUniqueID': '101218222', 'ISSNLinking': '1512-0112'}, 'ChemicalList': [{'RegistryNumber': 'E6582LOH6V', 'NameOfSubstance': StringElement('fexofenadine', attributes={'UI': 'C093230'})}, {'RegistryNumber': '7BA5G9Y06Q', 'NameOfSubstance': StringElement('Terfenadine', attributes={'UI': 'D016593'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Rats', attributes={'UI': 'D051381', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Animals', attributes={'UI': 'D000818', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Male', attributes={'UI': 'D008297', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Salivary Glands', attributes={'UI': 'D012469', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'}), StringElement('analogs & derivatives', attributes={'UI': 'Q000031', 'MajorTopicYN': 'Y'})], 'DescriptorName': StringElement('Terfenadine', attributes={'UI': 'D016593', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Cell Nucleus', attributes={'UI': 'D002467', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Epithelial Cells', attributes={'UI': 'D004847', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2024', 'Month': '4', 'Day': '15', 'Hour': '6', 'Minute': '42'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '13', 'Hour': '10', 'Minute': '42'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '12', 'Hour': '20', 'Minute': '43'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38609111', attributes={'IdType': 'pubmed'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38608060', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '15'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '17'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [StringElement('e37852', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1097/MD.0000000000037852', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1536-5964', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '103', 'Issue': '15', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '12'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Medicine', 'ISOAbbreviation': 'Medicine (Baltimore)'}, 'ArticleTitle': 'Serotonin syndrome treated with cyproheptadine using NPi from a digital pupillometer as a therapeutic indicator: A case report.', 'Pagination': {'StartPage': 'e37852', 'MedlinePgn': 'e37852'}, 'Abstract': {'AbstractText': [StringElement('Serotonin syndrome is a potentially life-threatening condition resulting from the use of antidepressants, their interactions with other serotonergic medications, or poisoning. It presents with a triad of psychiatric, dysautonomic, and neurological symptoms and is sometimes fatal. While cyproheptadine is a specific treatment option, the optimal duration of its administration remains unclear. The purpose of this report is to quantitatively assess the endpoints of serotonin syndrome treatment. Based on the hypothesis that neurological pupil index (NPi) on a digital pupil recorder would correlate with the severity of the serotonin syndrome, we administered cyproheptadine using NPi as an indicator.', attributes={'Label': 'RATIONALE', 'NlmCategory': 'BACKGROUND'}), StringElement('A patient with a history of depression was brought to our hospital after he overdosed on 251 tablets of serotonin and noradrenaline reuptake inhibitors.', attributes={'Label': 'PATIENT CONCERNS', 'NlmCategory': 'METHODS'}), StringElement('On day 3, the patient was diagnosed with serotonin syndrome.', attributes={'Label': 'DIAGNOSES', 'NlmCategory': 'METHODS'}), StringElement('Cyproheptadine syrup was administered at 4\\u2009mg every 4 hours. The NPi of the automated pupillometer was simultaneously measured. On day 5, the NPi exceeded 3.0 cyproheptadine was discontinued.', attributes={'Label': 'INTERVENTIONS', 'NlmCategory': 'METHODS'}), StringElement('The patient was discharged on day 7.', attributes={'Label': 'OUTCOMES', 'NlmCategory': 'RESULTS'}), StringElement('The lack of considerable improvement during the treatment period suggests that the patient may have improved on his own. In this case, the relationship between NPi and the severity of serotonin syndrome could not be determined.', attributes={'Label': 'LESSONS', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': 'Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Emergency Medicine, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.'}], 'Identifier': [StringElement('0000-0002-4465-5688', attributes={'Source': 'ORCID'})], 'LastName': 'Sugaya', 'ForeName': 'Kazuki', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Emergency Medicine, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.'}], 'Identifier': [], 'LastName': 'Misawa', 'ForeName': 'Tomotaka', 'Initials': 'T'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Regional Emergency Medicine, Fukushima Medical University, Fukushima City, Fukushima, Japan.'}], 'Identifier': [], 'LastName': 'Onodera', 'ForeName': 'Makoto', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Emergency Medicine, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.'}], 'Identifier': [], 'LastName': 'Iseki', 'ForeName': 'Ken', 'Initials': 'K'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Case Reports', attributes={'UI': 'D002363'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'Medicine (Baltimore)', 'NlmUniqueID': '2985248R', 'ISSNLinking': '0025-7974'}, 'ChemicalList': [{'RegistryNumber': '333DO1RDJY', 'NameOfSubstance': StringElement('Serotonin', attributes={'UI': 'D012701'})}, {'RegistryNumber': '2YHB6175DO', 'NameOfSubstance': StringElement('Cyproheptadine', attributes={'UI': 'D003533'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Male', attributes={'UI': 'D008297', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('diagnosis', attributes={'UI': 'Q000175', 'MajorTopicYN': 'N'}), StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Serotonin Syndrome', attributes={'UI': 'D020230', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Pupil', attributes={'UI': 'D011680', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Serotonin', attributes={'UI': 'D012701', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Autonomic Nervous System Diseases', attributes={'UI': 'D001342', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Cyproheptadine', attributes={'UI': 'D003533', 'MajorTopicYN': 'N'})}], 'CoiStatement': 'The authors have no funding and conflicts of interest to disclose.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112–20.', 'ArticleIdList': [StringElement('15784664', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Dunkley EJ, Isbister GK, Sibbritt D, et al. . The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635.', 'ArticleIdList': [StringElement('12925718', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Birmes P, Coppin D, Schmitt L, et al. . Serotonin syndrome: a brief review. CMAJ. 2003;168:1439–42.', 'ArticleIdList': [StringElement('PMC155963', attributes={'IdType': 'pmc'}), StringElement('12771076', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998;16:615–9.', 'ArticleIdList': [StringElement('9696181', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Peter JM, Victor AM, Thomas JB. Serotonin syndrome presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000;79:201–9.', 'ArticleIdList': [StringElement('10941349', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin. 1997;13:763–83.', 'ArticleIdList': [StringElement('9330840', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mirtazapine 30mg Tablets. electronic medicines compendium 2021.\\nAvailable at: https://www.medicines.org.uk/emc/product/535/smpc [Access date November 10, 2023].'}, {'Citation': 'Efexor XL 75\\u2009mg hard prolonged release capsules. electronic medicines compendium 2023.\\nAvailable at: https://www.medicines.org.uk/emc/product/5474/smpc [Access date November 10, 2023].'}, {'Citation': 'Latuda 18.5mg film-coated tablets. electronic medicines compendium 2022.\\nAvailable at: https://www.medicines.org.uk/emc/product/3299/smpc [Access date November 10, 2023].'}, {'Citation': 'Frye JR, Poggemiller AM, McGonagill PW, et al. . Use of cyproheptadine for the treatment of serotonin syndrome: a case series. J Clin Psychopharmacol. 2020;40:95–9.', 'ArticleIdList': [StringElement('31860612', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cornejo AQ, Vilarinho CS, Crippa IA, et al. . The use of automated pupillometry to assess cerebral autoregulation: a retrospective study. J Intensive Care. 2020;8:57.', 'ArticleIdList': [StringElement('PMC7395368', attributes={'IdType': 'pmc'}), StringElement('32765886', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bower MW, Sweidan AJ, Xu JC, et al. . Quantitative Pupillometry in the intensive care unit. J Intensive Care Med. 2021;36:383–91.', 'ArticleIdList': [StringElement('31601157', attributes={'IdType': 'pubmed'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2024', 'Month': '4', 'Day': '15', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '12', 'Hour': '18', 'Minute': '42'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '12', 'Hour': '14', 'Minute': '13'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '12'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38608060', attributes={'IdType': 'pubmed'}), StringElement('PMC11018211', attributes={'IdType': 'pmc'}), StringElement('10.1097/MD.0000000000037852', attributes={'IdType': 'doi'}), StringElement('00005792-202404120-00015', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Helicobacter pylori', attributes={'MajorTopicYN': 'N'}), StringElement('cefuroxime', attributes={'MajorTopicYN': 'N'}), StringElement('eradication rate', attributes={'MajorTopicYN': 'N'}), StringElement('eradication therapy', attributes={'MajorTopicYN': 'N'}), StringElement('resistance rate', attributes={'MajorTopicYN': 'N'}), StringElement('safety', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38601987', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '12'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '12'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.1111/hel.13073', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1523-5378', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '29', 'Issue': '2', 'PubDate': {'Year': '2024', 'Season': 'Mar-Apr'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Helicobacter', 'ISOAbbreviation': 'Helicobacter'}, 'ArticleTitle': 'Application of cefuroxime in the eradication therapy of Helicobacter pylori infection: A review article.', 'Pagination': {'StartPage': 'e13073', 'MedlinePgn': 'e13073'}, 'Abstract': {'AbstractText': [StringElement('Helicobacter pylori infection and its associated diseases represent a significant global health concern. Patients who cannot use amoxicillin pose a therapeutic challenge and necessitate alternative medications. Preliminary research indicates that cefuroxime demonstrates promising potential for eradicating H. pylori infection, and there is a lack of comprehensive review articles on the use of cefuroxime.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement('This study conducts a thorough systematic literature review and synthesis. A comprehensive systematic search was conducted in PubMed, Web of Science, EMBASE, China National Knowledge Infrastructure, China Biology Medicine disc, and Wanfang Data up to January 13, 2024. The search strategy utilized the following keywords: (Cefuroxime) AND (Helicobacter pylori OR Helicobacter nemestrinae OR Campylobacter pylori OR Campylobacter pylori subsp. pylori OR Campylobacter pyloridis OR H. pylori OR Hp) for both English and Chinese language publications. Sixteen studies from five different countries or regions were included in final literature review.', attributes={'Label': 'MATERIALS AND METHODS', 'NlmCategory': 'METHODS'}), StringElement('Analysis results indicate that H. pylori is sensitive to cefuroxime, with resistance rates similar to amoxicillin being relatively low. Regimens containing cefuroxime have shown favorable eradication rates, which were comparable to those of the regimens containing amoxicillin. Regarding safety, the incidence of adverse reactions in cefuroxime-containing eradication regimens was comparable to that of amoxicillin-containing regimens or other bismuth quadruple regimens, with no significant increase in allergic reactions in penicillin-allergic patients. Regarding compliance, studies consistently report high compliance rates for regimens containing cefuroxime.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('Cefuroxime can serve as an alternative to amoxicillin for the patients allergic to penicillin with satisfactory efficacies, safety, and compliance.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': '© 2024 John Wiley & Sons Ltd.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Gastroenterology, Peking University Third Hospital, Beijing, China.'}], 'Identifier': [StringElement('0000-0001-7844-1357', attributes={'Source': 'ORCID'})], 'LastName': 'Mi', 'ForeName': 'Changmin', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Gastroenterology, Peking University Third Hospital, Beijing, China.'}], 'Identifier': [], 'LastName': 'Suo', 'ForeName': 'Baojun', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Gastroenterology, Peking University Third Hospital, Beijing, China.'}], 'Identifier': [], 'LastName': 'Tian', 'ForeName': 'Xueli', 'Initials': 'X'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Gastroenterology, Peking University Third Hospital, Beijing, China.'}], 'Identifier': [], 'LastName': 'Wang', 'ForeName': 'Yuxin', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Gastroenterology, Peking University Third Hospital, Beijing, China.'}], 'Identifier': [], 'LastName': 'Ma', 'ForeName': 'Lingling', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Gastroenterology, Peking University Third Hospital, Beijing, China.'}], 'Identifier': [StringElement('0000-0003-0976-419X', attributes={'Source': 'ORCID'})], 'LastName': 'Song', 'ForeName': 'Zhiqiang', 'Initials': 'Z'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': '82170562', 'Agency': 'The National Natural Science Foundation of China', 'Country': ''}, {'GrantID': '7232199', 'Agency': 'Beijing Natural Science Foundation', 'Country': ''}, {'GrantID': '2022-2-4093', 'Agency': \"Capital's Funds for Health Improvement and Research\", 'Country': ''}, {'GrantID': 'BYSYFY2021003', 'Agency': 'Youth Incubation Fund of Peking University Third Hospital', 'Country': ''}, {'GrantID': 'BYSYZD2023008', 'Agency': 'Key Clinical Projects of Peking University Third Hospital', 'Country': ''}, {'GrantID': 'BZ0371', 'Agency': 'Key Laboratory for Helicobacter pylori Infection and Upper Gastrointestinal Diseases in Beijing', 'Country': ''}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Systematic Review', attributes={'UI': 'D000078182'}), StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'England', 'MedlineTA': 'Helicobacter', 'NlmUniqueID': '9605411', 'ISSNLinking': '1083-4389'}, 'ChemicalList': [{'RegistryNumber': 'O1R9FJ93ED', 'NameOfSubstance': StringElement('Cefuroxime', attributes={'UI': 'D002444'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Bacterial Agents', attributes={'UI': 'D000900'})}, {'RegistryNumber': '804826J2HU', 'NameOfSubstance': StringElement('Amoxicillin', attributes={'UI': 'D000658'})}, {'RegistryNumber': 'U015TT5I8H', 'NameOfSubstance': StringElement('Bismuth', attributes={'UI': 'D001729'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Penicillins', attributes={'UI': 'D010406'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Proton Pump Inhibitors', attributes={'UI': 'D054328'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Helicobacter Infections', attributes={'UI': 'D016481', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Helicobacter pylori', attributes={'UI': 'D016480', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Cefuroxime', attributes={'UI': 'D002444', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Bacterial Agents', attributes={'UI': 'D000900', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Drug Therapy, Combination', attributes={'UI': 'D004359', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Amoxicillin', attributes={'UI': 'D000658', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Bismuth', attributes={'UI': 'D001729', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Penicillins', attributes={'UI': 'D010406', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Treatment Outcome', attributes={'UI': 'D016896', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Proton Pump Inhibitors', attributes={'UI': 'D054328', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta‐analysis. Lancet Gastroenterol Hepatol. 2023;8(6):553‐564.'}, {'Citation': 'Malfertheiner P, Camargo MC, El‐Omar E, et\\xa0al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023;9(1):19.'}, {'Citation': 'Foulkes WD, Polak P, Karlić R. Helicobacter pylori, homologous‐recombination genes, and gastric cancer. N Engl J Med. 2023;389(4):379‐380.'}, {'Citation': 'Helicobacter Pylori Study Group CSoG, Chinese Medical Association. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin J Gastroenterol. 2022;27(3):150‐162.'}, {'Citation': 'Malfertheiner P, Megraud F, Rokkas T, et\\xa0al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71:1724‐1762.'}, {'Citation': 'Katelaris P, Hunt R, Bazzoli F, et\\xa0al. Helicobacter pylori world gastroenterology organization global guideline. J Clin Gastroenterol. 2023;57(2):111‐126.'}, {'Citation': 'Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212‐239.'}, {'Citation': 'Song Z, Zhang J, He L, et\\xa0al. Prospective multi‐region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients. Dig Liver Dis. 2014;46(12):1077‐1081.'}, {'Citation': 'Megraud F, Coenen S, Versporten A, et\\xa0al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34‐42.'}, {'Citation': 'Ren X, Shi Y, Suo B, et\\xa0al. Individualized diagnosis and eradication therapy for Helicobacter pylori infection based on gene detection of clarithromycin resistance in stool specimens: a systematic review and meta‐analysis. Helicobacter. 2023;28(3):e12958.'}, {'Citation': 'Ding SZ, Du YQ, Lu H, et\\xa0al. Chinese consensus report on family‐based Helicobacter pylori infection control and management (2021 edition). Gut. 2022;71(2):238‐253.'}, {'Citation': 'Kato M, Ota H, Okuda M, et\\xa0al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 revised edition. Helicobacter. 2019;24(4):e12597.'}, {'Citation': \"Malfertheiner P, Megraud F, O'Morain CA, et\\xa0al. Management of Helicobacter pylori infection‐the Maastricht V/Florence consensus report. Gut. 2017;66(1):6‐30.\"}, {'Citation': 'Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393(10167):183‐198.'}, {'Citation': 'Castells M, Khan DA, Phillips EJ. Penicillin allergy. N Engl J Med. 2019;381(24):2338‐2351.'}, {'Citation': 'Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy: a review. JAMA. 2019;321(2):188‐199.'}, {'Citation': 'Zhang Y, Suo B, Tian X, et\\xa0al. New regimens as first‐line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: a randomized controlled trial. Helicobacter. 2023;28(2):e12956.'}, {'Citation': 'Song Z, Fu W, Zhou L. Cefuroxime, levofloxacin, esomeprazole, and bismuth as first‐line therapy for eradicating Helicobacter pylori in patients allergic to penicillin. BMC Gastroenterol. 2019;19(1):132.'}, {'Citation': 'Macy E. Penicillin and beta‐lactam allergy: epidemiology and diagnosis. Curr Allergy Asthma Rep. 2014;14(11):476.'}, {'Citation': 'Yocum RR, Rasmussen JR, Strominger JL. The mechanism of action of penicillin. Penicillin acylates the active site of Bacillus stearothermophilus d‐alanine carboxypeptidase. J Biol Chem. 1980;255(9):3977‐3986.'}, {'Citation': 'Lima LM, Silva B, Barbosa G, Barreiro EJ. Beta‐lactam antibiotics: an overview from a medicinal chemistry perspective. Eur J Med Chem. 2020;208:112829.'}, {'Citation': 'Tshibangu‐Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance – from biology to clinical implications. Nat Rev Gastroenterol Hepatol. 2021;18(9):613‐629.'}, {'Citation': 'Kim BJ, Kim JG. Substitutions in penicillin‐binding protein 1 in amoxicillin‐resistant Helicobacter pylori strains isolated from Korean patients. Gut Liver. 2013;7(6):655‐660.'}, {'Citation': 'Miranda A, Blanca M, Vega JM, et\\xa0al. Cross‐reactivity between a penicillin and a cephalosporin with the same side chain. J Allergy Clin Immunol. 1996;98(3):671‐677.'}, {'Citation': 'Pichichero ME, Zagursky R. Penicillin and cephalosporin allergy. Ann Allergy Asthma Immunol. 2014;112(5):404‐412.'}, {'Citation': 'Pichichero ME. Use of selected cephalosporins in penicillin‐allergic patients: a paradigm shift. Diagn Microbiol Infect Dis. 2007;57(3 Suppl):13S‐18S.'}, {'Citation': 'Campagna JD, Bond MC, Schabelman E, Hayes BD. The use of cephalosporins in penicillin‐allergic patients: a literature review. J Emerg Med. 2012;42(5):612‐620.'}, {'Citation': 'Li C, Shi Y, Suo B, Tian X, Zhou L, Song Z. PPI‐amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: a systematic review and meta‐analysis. Helicobacter. 2021;26(4):e12816.'}, {'Citation': 'Song Z, Suo B, Tian X, et\\xa0al. Tailored triple plus bismuth therapy based on previous antibiotic medication history for first‐line Helicobacter pylori eradication: a randomized trial. Dig Liver Dis. 2023;55(5):601‐607.'}, {'Citation': 'Suo B, Tian X, Zhang H, et\\xa0al. Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first‐line regimen for Helicobacter pylori eradication: a randomized controlled trial. Chin Med J. 2023;136(8):933‐940.'}, {'Citation': 'Scott LJ, Ormrod D, Goa KL. Cefuroxime axetil: an updated review of its use in the management of bacterial infections. Drugs. 2001;61(10):1455‐1500.'}, {'Citation': 'Garcia‐Rodriguez JA, Garcia Sanchez JE, Garcia Garcia MI, Garcia Sanchez E, Munoz Bellido JL. In vitro activities of new oral beta‐lactams and macrolides against Campylobacter pylori. Antimicrob Agents Chemother. 1989;33(9):1650‐1651.'}, {'Citation': 'Hassan IJ, Stark RM, Greenman J, Millar MR. Activities of beta‐lactams and macrolides against Helicobacter pylori. Antimicrob Agents Chemother. 1999;43(6):1387‐1392.'}, {'Citation': 'Czinn SJ, Carr H, Hupertz V. Susceptibility of Campylobacter pylori to the newer cephalosporin antibiotics. Chemotherapy. 1989;35(3):164‐167.'}, {'Citation': 'Bai P, Zhou LY, Xiao XM, Luo Y, Ding Y. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients. J Dig Dis. 2015;16(8):464‐470.'}, {'Citation': 'Fu W, Song Z, Zhou L, et\\xa0al. Randomized clinical trial: esomeprazole, bismuth, levofloxacin, and amoxicillin or cefuroxime as first‐line eradication regimens for Helicobacter pylori infection. Dig Dis Sci. 2017;62(6):1580‐1589.'}, {'Citation': 'Song Z, Zhou L, Xue Y, Suo B, Tian X, Niu Z. A comparative study of 14‐day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first‐line Helicobacter pylori infection eradication: a randomized trial. Helicobacter. 2020;25(6):e12762.'}, {'Citation': 'Chen GY, Chen XM, Shen HL, Xu JP, Zhou AQ. A study of cephalosporin antibiotics on the drug sensitivity profile of Helicobacter pylori in eradication failures. Guide China Med. 2011;9(26):221‐222.'}, {'Citation': 'Wang Y, Zhou HQ, Tang W. Helicobacter pylori resistant to antibiotic isolated in Suzhou area. Chin J Public Health. 2010;26(1):122‐123.'}, {'Citation': 'Zhang XM. An analysis of the prevalence of Helicobacter pylori infection in patients with gastric cancer and an analysis of the drug resistance of H. pylori. J Pathogen Biol. 2016;11(4):362‐365.'}, {'Citation': 'Bello AK, Borodo MM, Yakasai AM, Tukur AD. Helicobacter pylori antibiotic sensitivity pattern in dyspeptic patients in Kano, Nigeria. S Afr J Infect Dis. 2019;34(1):125.'}, {'Citation': 'Shao Y, Lu R, Yang Y, Xu Q, Wang B, Ye G. Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients. J Clin Lab Anal. 2018;32(4):e22339.'}, {'Citation': 'Wyeth JW, Pounder RE, Duggan AE, et\\xa0al. The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1996;10(4):623‐630.'}, {'Citation': 'Hu JF, Zeng J, Meng J, Liu DL, Wang AY, Liu H. A comparative study of the efficacy of cefuroxime tetralogy versus amoxicillin tetralogy for eradication of Helicobacter pylori. Paper presented at: The Fourth Symposium on Combined Traditional Chinese and Western Medicine and Digestive Diseases in Jiangxi Province 2011; Jiujiang, Jiangxi, China (Conference Article). 2011.'}, {'Citation': 'Liu MZ, Li YZ, Wei TL, Cai HY, Qin M. Comparison of efficacy of cefuroxime and amoxicillin in the eradication treatment of Helicobacter pylori. China Med Herald. 2021;18(28):113‐116.'}, {'Citation': 'Ni Y. Preliminary study on efficacy and safety of β‐lactam antibiotics combined with probiotics in Helicobacter pylori eradication therapy (Master thesis). Soochow University; 2022.'}], 'ReferenceList': [], 'Title': 'REFERENCES'}], 'History': [DictElement({'Year': '2024', 'Month': '3', 'Day': '7'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '28'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '12', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '11', 'Hour': '6', 'Minute': '42'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '11', 'Hour': '4', 'Minute': '24'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38601987', attributes={'IdType': 'pubmed'}), StringElement('10.1111/hel.13073', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Chinese inpatients', attributes={'MajorTopicYN': 'N'}), StringElement('allergic reactions', attributes={'MajorTopicYN': 'N'}), StringElement('iodixanol', attributes={'MajorTopicYN': 'N'}), StringElement('multi-center study', attributes={'MajorTopicYN': 'N'}), StringElement('prescription sequence symmetry analysis', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': [], 'GeneralNote': [], 'PMID': StringElement('38601462', attributes={'Version': '1'}), 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '25'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '27'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('1298021', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.3389/fphar.2024.1298021', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1663-9812', attributes={'IssnType': 'Print'}), 'JournalIssue': DictElement({'Volume': '15', 'PubDate': {'Year': '2024'}}, attributes={'CitedMedium': 'Print'}), 'Title': 'Frontiers in pharmacology', 'ISOAbbreviation': 'Front Pharmacol'}, 'ArticleTitle': 'Detection of iodixanol-induced allergic reaction signals in Chinese inpatients: a multi-center retrospective database study using prescription sequence symmetry analysis.', 'Pagination': {'StartPage': '1298021', 'MedlinePgn': '1298021'}, 'Abstract': {'AbstractText': [StringElement('This study aimed to explore the signal detection method for allergic reactions induced by inpatient iodixanol injection.', attributes={'Label': 'OBJECTIVE', 'NlmCategory': 'UNASSIGNED'}), StringElement('A database of 3,719,217 hospitalized patients from 20 large Chinese general hospitals was processed and analyzed using the prescription sequence symmetry analysis (PSSA) method.', attributes={'Label': 'METHODS', 'NlmCategory': 'UNASSIGNED'}), StringElement('126,680 inpatients who used iodixanol and were concurrently treated with anti-allergic drugs were analyzed. In the medical records of these patients, only 32 had documented iodixanol allergies. Statistical analysis identified 22 drugs in 4 categories-calcium preparations, adrenergic/dopaminergic agents, glucocorticoids, and antihistamines-as marker drugs. With time intervals of 3, 7, and 28\\xa0days, the adjusted sequence ratios (aSRs) for all anti-allergics and the 4 categories were greater than 1. The 7-day aSRs were 2.12 (95% CI: 2.08-2.15), 1.70 (95% CI: 1.68-1.73), 3.85 (95% confidence interval [CI]: 3.75-2.30), 2.30 (95% CI: 2.26-2.35), and 1.95 (95% CI: 1.89-2.02), respectively. The proportions of adverse drug events indicated by each signal were as follows: all anti-allergics (2.92%-3%), calcium gluconate (0.19%-0.52%), adrenergic/dopaminergic agents (2.20%-3.37%), glucocorticoids (3.13%-3.76%), and antihistamines (1.05%-1.32%).', attributes={'Label': 'RESULTS', 'NlmCategory': 'UNASSIGNED'}), StringElement('This first multi-center Chinese inpatient database study detected iodixanol-induced allergy signals, revealing that reactions may be much higher than those in collected spontaneous reports. Iodixanol risk exposure was closer to actual pharmaceutical care findings. PSSA application with ≤7-day intervals appears better suited for monitoring late allergic reaction signals with these drugs.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'UNASSIGNED'})], 'CopyrightInformation': 'Copyright © 2024 Zhang, Yang, Yang, Sun, Chen and Xu.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmacy, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.'}], 'Identifier': [], 'LastName': 'Zhang', 'ForeName': 'Dandan', 'Initials': 'D'}, attributes={'ValidYN': 'Y', 'EqualContrib': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Electric Engineering and Automation, East China University of Science and Technology, Shanghai, China.'}], 'Identifier': [], 'LastName': 'Yang', 'ForeName': 'Xinchen', 'Initials': 'X'}, attributes={'ValidYN': 'Y', 'EqualContrib': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Medical Department, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.\"}], 'Identifier': [], 'LastName': 'Yang', 'ForeName': 'Zhangwei', 'Initials': 'Z'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Medical Department, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.\"}], 'Identifier': [], 'LastName': 'Sun', 'ForeName': 'Wei', 'Initials': 'W'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Medical Department, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.\"}], 'Identifier': [], 'LastName': 'Chen', 'ForeName': 'Shunjie', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Health Statistics Teaching and Research Section, Tongji University, Shanghai, China.'}], 'Identifier': [], 'LastName': 'Xu', 'ForeName': 'Lingxiao', 'Initials': 'L'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic-eCollection'}), 'MedlineJournalInfo': {'Country': 'Switzerland', 'MedlineTA': 'Front Pharmacol', 'NlmUniqueID': '101548923', 'ISSNLinking': '1663-9812'}, 'CoiStatement': 'The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.'}, attributes={'Status': 'PubMed-not-MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Cha M. J., Kang D. Y., Lee W., Yoon S. H., Choi Y. H., Byun J. S., et al. (2019). Hypersensitivity reactions to iodinated contrast media: a multicenter study of 196 081 patients. Radiology 293 (1), 117–124. 10.1148/radiol.2019190485', 'ArticleIdList': [StringElement('10.1148/radiol.2019190485', attributes={'IdType': 'doi'}), StringElement('31478801', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chen Y., Huang S. T., Hsu T. C., Peng L. N., Hsiao F. Y., Chen L. K. (2022). Detecting suspected prescribing cascades by prescription sequence symmetry analysis of nationwide real-world data. J. Am. Med. Dir. Assoc. 23 (3), 468–474.e6. 10.1016/j.jamda.2021.06.035', 'ArticleIdList': [StringElement('10.1016/j.jamda.2021.06.035', attributes={'IdType': 'doi'}), StringElement('34324873', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chen Y. D., Chen J. Y., Fu G. S., Du Z. M., Fang Q., Cui L. Q., et al. (2014). Chinese expert consensus on adverse reactions associated with iodine contrast angiography applications. Chin. J. Interventional Cardiol. 22 (6), 341–348.'}, {'Citation': '\\nChina Industrial Research Network (2022). Contrast agents industry status, contrast agents market analysis\\n. https://www.chinairn.com/hyzx/20220316/16340077.shtml (Accessed March 16, 2023).'}, {'Citation': 'Häussler M. D. (2010). Safety and patient comfort with iodixanol: a postmarketing surveillance study in 9515 patients undergoing diagnostic CT examinations. Acta radiol. 51 (8), 924–933. 10.3109/02841851.2010.504739', 'ArticleIdList': [StringElement('10.3109/02841851.2010.504739', attributes={'IdType': 'doi'}), StringElement('20828300', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hazell L., Shakir S. A. (2006). Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 29 (5), 385–396. 10.2165/00002018-200629050-00003', 'ArticleIdList': [StringElement('10.2165/00002018-200629050-00003', attributes={'IdType': 'doi'}), StringElement('16689555', attributes={'IdType': 'pubmed'})]}, {'Citation': 'He B. J., Zhang M. X., Zhan S. Y. (2021). Prescription sequence symmetry analysis in pharmacoepidemiology: a systematic review. Chin. J. Epidemiol. 42 (9), 1641–1649. 10.3760/cma.j.cn112338-20201208-01386', 'ArticleIdList': [StringElement('10.3760/cma.j.cn112338-20201208-01386', attributes={'IdType': 'doi'}), StringElement('34814596', attributes={'IdType': 'pubmed'})]}, {'Citation': 'He X. L. (2017). Prevention and treatment principles of different types of iodine contrast agents. Chin. J. Prim. Med. Pharm. 24 (11), 1685–1688. 10.3760/cma.j.issn.1008-6706.2017.11.023', 'ArticleIdList': [StringElement('10.3760/cma.j.issn.1008-6706.2017.11.023', attributes={'IdType': 'doi'})]}, {'Citation': 'Hu P., Liu H. R., Cao L., Mao J., Liao Z. D., Zhou K., et al. (2022). Analysis of 141 cases of adverse drug reactions induced by iodixanol. Chin. Pharm. Aff. 36 (2), 209–216. 10.16153/j.1002-7777.2022.02.014', 'ArticleIdList': [StringElement('10.16153/j.1002-7777.2022.02.014', attributes={'IdType': 'doi'})]}, {'Citation': 'Huang Z., Hu F., Liu H., Wang M. (2022). A retrospective study to compare the effects of methylprednisolone and dexamethasone in 35 patients with anaphylactic shock due to iodinated contrast media during cardiac catheterization. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 28, e934703. 10.12659/MSM.934703', 'ArticleIdList': [StringElement('10.12659/MSM.934703', attributes={'IdType': 'doi'}), StringElement('PMC8941823', attributes={'IdType': 'pmc'}), StringElement('35304433', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kuna P., Jurkiewicz D., Czarnecka-Operacz M. M., Pawliczak R., Woroń J., Moniuszko M., et al. (2016). The role and choice criteria of antihistamines in allergy management - expert opinion. Postepy Dermatol. i Alergol. 33 (6), 397–410. 10.5114/pdia.2016.63942', 'ArticleIdList': [StringElement('10.5114/pdia.2016.63942', attributes={'IdType': 'doi'}), StringElement('PMC5183790', attributes={'IdType': 'pmc'}), StringElement('28035215', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Liu P. (2004). Application condition computing binomial proportion 95% confidence intervals using normal approximate method. Chin. J. Health Statistics 2, 85–89.'}, {'Citation': 'Lyu J., Wang L. X., Xie Y. M. (2021). Pharmacovigilance of traditional Chinese medicine: an exploration based on prescription sequence analysis and prescription sequence symmetry analysis. China J. Chin. materia medica 46 (21), 5468–5474. 10.19540/j.cnki.cjcmm.20210705.501', 'ArticleIdList': [StringElement('10.19540/j.cnki.cjcmm.20210705.501', attributes={'IdType': 'doi'}), StringElement('34951198', attributes={'IdType': 'pubmed'})]}, {'Citation': \"\\nMinistry of Health of China (2018). Statistical Bulletin on the Development of China's health undertakings in 2018\\n. https://www.chinairn.com/hyzx/20220316/16340077.shtml (Accessed November 28, 2023).\"}, {'Citation': 'Morris E. J., Hollmann J., Hofer A. K., Bhagwandass H., Oueini R., Adkins L. E., et al. (2022). Evaluating the use of prescription sequence symmetry analysis as a pharmacovigilance tool: a scoping review. Res. Soc. Adm. Pharm. RSAP 18 (7), 3079–3093. 10.1016/j.sapharm.2021.08.003', 'ArticleIdList': [StringElement('10.1016/j.sapharm.2021.08.003', attributes={'IdType': 'doi'}), StringElement('34376366', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Nie X. M., Li Y. S., Yang Z. W., Wang H., Jin S. Y., Jiao Y., et al. (2018). Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals. Clin. Microbiol. Infect. 24 (6), 658.e1–658. 10.1016/j.cmi.2017.09.014', 'ArticleIdList': [StringElement('10.1016/j.cmi.2017.09.014', attributes={'IdType': 'doi'}), StringElement('28970157', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Suh Y. J., Yoon S. H., Hong H., Hahn S., Kang D. Y., Kang H. R., et al. (2019). Acute adverse reactions to nonionic iodinated contrast media: a meta-analysis. Investig. Radiol. 54 (9), 589–599. 10.1097/RLI.0000000000000568', 'ArticleIdList': [StringElement('10.1097/RLI.0000000000000568', attributes={'IdType': 'doi'}), StringElement('30998567', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tao Q. M., Zhan S. Y. (2012). Application of prescription sequence analysis and prescription sequence symmetry analysis in pharmacoepidemiology. Chin. J. Pharmacoepidemiol. 21 (10), 517–519.'}, {'Citation': 'Tasker F., Fleming H., McNeill G., Creamer D., Walsh S. (2019). Contrast media and cutaneous reactions. Part 2: delayed hypersensitivity reactions to iodinated contrast media. Clin. Exp. dermatology 44 (8), 844–860. 10.1111/ced.13991', 'ArticleIdList': [StringElement('10.1111/ced.13991', attributes={'IdType': 'doi'}), StringElement('31162717', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Torres M. J., Trautmann A., Böhm I., Scherer K., Barbaud A., Bavbek S., et al. (2021). Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity. Allergy 76 (5), 1325–1339. 10.1111/all.14656', 'ArticleIdList': [StringElement('10.1111/all.14656', attributes={'IdType': 'doi'}), StringElement('33170954', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Xu Y. J., Zhang J., Wang R., Cai W. W., Zhao P. Z., Guo D. H. (2020). Analysis of adverse reactions of iodine contrast agent. Chin. J. Med. Imaging 28 (3), 232–235. 10.3969/j.issn.1005-5185.2020.03.020', 'ArticleIdList': [StringElement('10.3969/j.issn.1005-5185.2020.03.020', attributes={'IdType': 'doi'})]}, {'Citation': 'Zhang B. C., Hou L., Lv B., Xu Y. W. (2014). Post-marketing surveillance study with iodixanol in 20 185 Chinese patients from routine clinical practices. Br. J. radiology 87 (1034), 20130325. 10.1259/bjr.20130325', 'ArticleIdList': [StringElement('10.1259/bjr.20130325', attributes={'IdType': 'doi'}), StringElement('PMC4064546', attributes={'IdType': 'pmc'}), StringElement('24357597', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Zhang D., Li L., Xu H. W., Zhu Y. N., Zhang P., Zhou N. (2022). Observation of 110 cases of adverse drug reactions induced by iodixanol. Chin. J. Pharmacovigil. 19 (1), 83–86. 10.19803/j.1672-8629.2022.01.18', 'ArticleIdList': [StringElement('10.19803/j.1672-8629.2022.01.18', attributes={'IdType': 'doi'})]}, {'Citation': 'Zhou Y. F., Cheng Y. C., Gao S. Q., Lv L., Fang R. F., Zhan S. Y. (2019). Performance of prescription sequence symmetry analysis in detecting allergic signals of xiyanping injection: a case study. Chin. J. Pharmacoepidemiol. 28 (6), 376–379. 10.19960/j.cnki.issn1005-0698.2019.06.006', 'ArticleIdList': [StringElement('10.19960/j.cnki.issn1005-0698.2019.06.006', attributes={'IdType': 'doi'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2023', 'Month': '9', 'Day': '21'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '14'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '11', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '11', 'Hour': '6', 'Minute': '43'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '11', 'Hour': '4', 'Minute': '15'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '27'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38601462', attributes={'IdType': 'pubmed'}), StringElement('PMC11004274', attributes={'IdType': 'pmc'}), StringElement('10.3389/fphar.2024.1298021', attributes={'IdType': 'doi'}), StringElement('1298021', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Analgesia', attributes={'MajorTopicYN': 'N'}), StringElement('Analgesics, opioid', attributes={'MajorTopicYN': 'N'}), StringElement('Anterior cruciate ligament reconstruction', attributes={'MajorTopicYN': 'N'}), StringElement('Meniscus injuries', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [DictElement({'AbstractText': [StringElement('比较去痛片(复方氨基比林、非那西丁片，商品名去痛片)、盐酸曲马多缓释片(商品名：奇曼丁)及盐酸哌替啶(商品名：杜冷丁)在膝关节前交叉韧带自体肌腱单束重建术后早期的止疼效果及安全性。', attributes={'Label': '目的'}), StringElement('回顾性分析2018年11月至2019年2月，北京大学第三医院连续收治的45例由同一组医师施行膝关节镜下前交叉韧带自体肌腱单束重建术患者，术后疼痛情况和使用药物镇痛情况的临床资料。采用随机区组设计，根据前交叉韧带断裂是否合并半月板损伤将患者分为两组，A组为单纯膝关节前交叉韧带重建的患者24例，B组为前交叉韧带断裂合并半月板损伤的患者21例。两组又根据患者实际使用的术后镇痛药物各分为3组，其中，A组口服去痛片4例、口服奇曼丁11例、肌肉注射(简称肌注)杜冷丁联合盐酸异丙嗪(商品名：非那根)9例；B组口服去痛片3例、口服奇曼丁10例、肌注杜冷丁联合非那根8例。术后早期，患者诉疼痛并主动要求镇痛时随机给予去痛片、奇曼丁或杜冷丁联合非那根这三种不同的止痛药物缓解疼痛，采用疼痛视觉模拟评分(visual analogue scale，VAS)评估疼痛缓解情况，并观察不良反应发生情况。', attributes={'Label': '方法'}), StringElement('患者在性别、年龄、体重指数、住院时间等基本情况上差异无统计学意义(<i>P</i>＞0.05)。应用三种止痛药物缓解疼痛的两组患者，在用药前及用药1 h后通过VAS评分判断结果表明，患者疼痛情况明显缓解，用药前后疼痛差异有统计学意义(<i>P</i>＜0.05)。对两组患者应用的三种药物进行两两比较显示，杜冷丁联合非那根组对于疼痛缓解的程度显著高于其余两种药物(<i>P</i>＜0.05)，用药1 h后，两组差异无统计学意义(<i>P</i>＞0.05)。应用杜冷丁患者易出现恶心、呕吐等副反应，但应用杜冷丁的同时使用非那根可减少副反应。在不良反应方面，仅单纯前交叉韧带重建组中应用奇曼丁组的患者出现恶心1例，其余各组患者均未出现严重的并发症及过敏反应。', attributes={'Label': '结果'}), StringElement('无论是单纯交叉韧带重建，还是合并半月板成型或缝合的交叉韧带重建，患者应用去痛片、奇曼丁、杜冷丁联合非那根这三种药物均能有效缓解疼痛，其中杜冷丁对疼痛的缓解幅度最大。应用杜冷丁的同时，合用非那根可有效减轻患者的呕吐、恶心等不良反应，增加用药安全性。', attributes={'Label': '结论'})]}, attributes={'Type': 'Publisher', 'Language': 'chi'})], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38595247', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '11'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '25'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [], 'Language': ['chi'], 'Journal': {'ISSN': StringElement('1671-167X', attributes={'IssnType': 'Print'}), 'JournalIssue': DictElement({'Volume': '56', 'Issue': '2', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '18'}}, attributes={'CitedMedium': 'Print'}), 'Title': 'Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences', 'ISOAbbreviation': 'Beijing Da Xue Xue Bao Yi Xue Ban'}, 'ArticleTitle': '[Comparison of the early analgesic efficacy of three different drugs after anterior cruciate ligament reconstruction].', 'Pagination': {'StartPage': '293', 'EndPage': '298', 'MedlinePgn': '293-298'}, 'Abstract': {'AbstractText': [StringElement('The pain-relieving effect and safety of compound aminopyrine phenacetin tablets, tramcontin (tramadol hydrochloride sustained-release tablets) and dolantin in the early stage of autologous tendon reconstruction of the anterior cruciate ligament (ACL) of the knee joint were compared.', attributes={'Label': 'OBJECTIVE', 'NlmCategory': 'OBJECTIVE'}), StringElement('Retrospective analysis of postoperative pain and drug analgesia in 45 patients performed by the same group from November 2018 to February 2019. The random area group design was divided into two groups according to whether ACL rupture was combined with meniscal injury, group A was 24 patients with ACL reconstruction of knee joint and group B was 21 patients with ACL fracture combined with meniscus injury. The two groups were divided into three subgroups respectively according to the actual treatment of postoperative analgesic drugs received by the patients, including 4 cases of compound aminopyrine phenacetin tablets, 11 cases of oral tramcontin, 9 cases of intramuscular dolantin combined with phenergan in group A; 3 cases of compound aminopyrine phenacetin tablets, 10 cases of oral tramcontin, and 8 cases of intramuscular dolantin combined with phenergan in group B. When the early postoperative patients complain about pain and actively ask for analgesia. When the patients complained about pain after the operation and actively asked for analgesia, they were randomly given painkillers, tramcontin or dolantin combined with phenergan to relieve pain. Pain visual analogue scale (VAS) was used to evaluate pain relief and observe the occurrence of adverse reactions.', attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('There were no significant dif-ferences in gender, age, body mass index, and time of hospital stay between the two groups of patients (<i>P</i> > 0.05). In the patients who used tramcontin and dolantin combined with phenergan to relieve pain judging by VAS score before and 1 h after taking the drug, it was found that the pain situation of the patient was significantly relieved, and the difference before and after taking the drug had statistical significance (<i>P</i> < 0.05). Pairwise comparisons of the three drugs applied in the two groups showed significantly greater pain relief in the dolantin combined with phenergan group than in the remaining two drugs. There was no significant difference (<i>P</i> > 0.05). Dolantin was prone to nausea and vomiting, but the application of phenergan was also used to reduce side effects. In terms of adverse reactions, only 1 case of nausea occurred in the tramcontin group for simple ACL reconstruction, and none of the patients in the other groups showed serious complications and allergic reactions.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('Whether in cruciate ligament reconstruction alone or combined with meniscus molding or suture, compound aminopyrine phenacetin tablets, tramcontin, dolantin combined with phenergan can effectively relieve pain. Among the three drugs, dolantin caused the largest pain relief. At the same time, the combination of phenergan effectively reduced the adverse reactions, such as vomiting and nausea, and increased the drug safety.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'CONCLUSIONS'})]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine in Hebei Province, Cangzhou 061001, Hebei, China.'}, {'Identifier': [], 'Affiliation': 'Hebei Key Laboratory of Integrated Traditional and Western Medicine in Osteoarthrosis Research (Pre-paring), Cangzhou 061001, Hebei, China.'}], 'Identifier': [], 'LastName': 'Wang', 'ForeName': 'Jiangjing', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Sports Medicine, Peking University Third Hospital, Beijing 100191, China.'}], 'Identifier': [], 'LastName': 'Wei', 'ForeName': 'Shunyi', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Sports Medicine, Peking University Third Hospital, Beijing 100191, China.'}], 'Identifier': [], 'LastName': 'Ao', 'ForeName': 'Yingfang', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Sports Medicine, Peking University Third Hospital, Beijing 100191, China.'}], 'Identifier': [], 'LastName': 'Yang', 'ForeName': 'Yuping', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Comparative Study', attributes={'UI': 'D003160'}), StringElement('English Abstract', attributes={'UI': 'D004740'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'China', 'MedlineTA': 'Beijing Da Xue Xue Bao Yi Xue Ban', 'NlmUniqueID': '101125284', 'ISSNLinking': '1671-167X'}, 'ChemicalList': [{'RegistryNumber': '01704YP3MO', 'NameOfSubstance': StringElement('Aminopyrine', attributes={'UI': 'D000632'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Analgesics', attributes={'UI': 'D000700'})}, {'RegistryNumber': '9E338QE28F', 'NameOfSubstance': StringElement('Meperidine', attributes={'UI': 'D008614'})}, {'RegistryNumber': 'ER0CTH01H9', 'NameOfSubstance': StringElement('Phenacetin', attributes={'UI': 'D010615'})}, {'RegistryNumber': 'FF28EJQ494', 'NameOfSubstance': StringElement('Promethazine', attributes={'UI': 'D011398'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Aminopyrine', attributes={'UI': 'D000632', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Analgesics', attributes={'UI': 'D000700', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('surgery', attributes={'UI': 'Q000601', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anterior Cruciate Ligament Injuries', attributes={'UI': 'D000070598', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Anterior Cruciate Ligament Reconstruction', attributes={'UI': 'D059549', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('surgery', attributes={'UI': 'Q000601', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Knee Joint', attributes={'UI': 'D007719', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Meperidine', attributes={'UI': 'D008614', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('surgery', attributes={'UI': 'Q000601', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Nausea', attributes={'UI': 'D009325', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Pain, Postoperative', attributes={'UI': 'D010149', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Phenacetin', attributes={'UI': 'D010615', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Promethazine', attributes={'UI': 'D011398', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Retrospective Studies', attributes={'UI': 'D012189', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Treatment Outcome', attributes={'UI': 'D016896', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('surgery', attributes={'UI': 'Q000601', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Vomiting', attributes={'UI': 'D014839', 'MajorTopicYN': 'N'})}], 'CoiStatement': '<b>利益冲突</b>\\xa0\\xa0所有作者均声明不存在利益冲突。'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Curated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Smigielski R, Zdanowicz U, Drwiega M, et al. The anatomy of the anterior cruciate ligament and its relevance to the technique of reconstruction. Bone Joint J. 2016;98(8):1020–1026.', 'ArticleIdList': [StringElement('27482012', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Fujimaki Y, Thorhauer E, Sasaki Y, et al. Quantitative in situ analysis of the anterior cruciate ligament: Length, midsubstance cross-sectional area, and insertion site areas. Am J Sports Med. 2016;44(1):118–125. doi: 10.1177/0363546515611641.', 'ArticleIdList': [StringElement('10.1177/0363546515611641', attributes={'IdType': 'doi'}), StringElement('26564792', attributes={'IdType': 'pubmed'})]}, {'Citation': '顾 杨林, 王 予彬, 王 慧芳, et al. 关节镜下自体半腱肌前交叉韧带重建术及术后康复效果. 中国康复医学杂志. 2014;29(12):1170–1171. doi: 10.3969/j.issn.1001-1242.2014.12.017.', 'ArticleIdList': [StringElement('10.3969/j.issn.1001-1242.2014.12.017', attributes={'IdType': 'doi'})]}, {'Citation': 'Feucht MJ, Bigdon S, Bode G, et al. Associated tears of the lateral meniscus in anterior cruciate ligament injuries: Risk factors for different tear patterns. J Orthop Surg Res. 2015;10:34. doi: 10.1186/s13018-015-0184-x.', 'ArticleIdList': [StringElement('10.1186/s13018-015-0184-x', attributes={'IdType': 'doi'}), StringElement('PMC4389969', attributes={'IdType': 'pmc'}), StringElement('25889148', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ro KH, Kim HJ, Lee DH. The transportal technique shows better clinical results than the transtibial techniques for single-bundle anterior cruciate ligament reconstruction. Knee Surg Sports Traumatol Arthrosc. 2018;26(8):2371–2380. doi: 10.1007/s00167-017-4786-1.', 'ArticleIdList': [StringElement('10.1007/s00167-017-4786-1', attributes={'IdType': 'doi'}), StringElement('29189882', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Koh IJ, Chang CB, Seo ES, et al. Pain management by periarti-cular multimodal drug injection after anterior cruciate ligament reconstruction: A randomized, controlled study. Arthroscopy. 2012;28(5):649–657. doi: 10.1016/j.arthro.2011.10.015.', 'ArticleIdList': [StringElement('10.1016/j.arthro.2011.10.015', attributes={'IdType': 'doi'}), StringElement('22281194', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Apostolos K, Georgios K, Omiros C, et al. Comparison between ropivacaine 1.5 mg·ml-1 plus fentanyl 2 mg·ml-1 and ropivacaine 1.5 mg·ml-1 plus clonidine 1 mg·ml-1 as analgesic solution after anterior cruciate ligament reconstruction: A randomized clinical trial. Middle East J Anaesthesiol. 2011;21(3):341–345.', 'ArticleIdList': [StringElement('22428487', attributes={'IdType': 'pubmed'})]}, {'Citation': '邓 莹, 蔡 海河, 翟 文雯, et al. 右美托咪定联合罗哌卡因行股神经阻滞的效果: 前瞻性随机双盲对照研究. 中国微创外科杂志. 2018;18(10):865–867.'}, {'Citation': 'Buvanendran A, Kroin JS. Multimodal analgesia for controlling acute postoperative pain. Curr Opin Anaesthesiol. 2009;22(5):588–593. doi: 10.1097/ACO.0b013e328330373a.', 'ArticleIdList': [StringElement('10.1097/ACO.0b013e328330373a', attributes={'IdType': 'doi'}), StringElement('19606021', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Fu PL, Xiao J, Zhu YL, et al. Efficacy of a multimodal analgesia protocol in total knee arthroplasty: A randomized, controlled trial. Int Med Res. 2010;38(4):1404–1412. doi: 10.1177/147323001003800422.', 'ArticleIdList': [StringElement('10.1177/147323001003800422', attributes={'IdType': 'doi'}), StringElement('20926013', attributes={'IdType': 'pubmed'})]}, {'Citation': '赵 宏, 黄 志峰, 邱 贵兴, et al. 全膝关节置换后不同镇痛方法效果的比较. 中国临床康复. 2005;9(18):12–13.'}, {'Citation': '雷 昌斌, 王 东, 陈 占昆, et al. 利多卡因对关节软骨培养模型中软骨细胞活性的影响. 中国骨与关节杂志. 2013;6(3):167–170.'}, {'Citation': '侯 蕾娜, 宋 凤香, 朱 晗月, et al. 连续股神经阻滞超前镇痛对老年患者全膝关节置换术置换后早期认知功能的影响. 国际麻醉学与复苏杂志. 2015;36(6):488–492.'}, {'Citation': 'Kawahara K, Hohjoh H, Inazumi T, et al. Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. Biochim Biophys Acta. 2015;1851(4):414–421. doi: 10.1016/j.bbalip.2014.07.008.', 'ArticleIdList': [StringElement('10.1016/j.bbalip.2014.07.008', attributes={'IdType': 'doi'}), StringElement('25038274', attributes={'IdType': 'pubmed'})]}, {'Citation': '杨 炯兰, 杨 露, 覃 菊莲. 杜冷丁与非那根配伍应用于人工流产术的临床观察. 右江民族医学院学报. 2008;30(4):593–594.'}, {'Citation': '李 文东, 徐 燕, 吴 海山. 全膝关节置换术后多模式围手术期疼痛控制方案在镇痛中的作用评价. 中国组织工程研究与临床康复. 2007;11(36):7223–7226.'}, {'Citation': '龚 明富, 徐 方志, 郭 影影, et al. 不同途径硫酸镁注射联合脊髓麻醉在膝关节镜手术中的应用. 中国内镜杂志. 2019;25(5):10–14.'}, {'Citation': '晏 咏梅. 杜冷丁合并异丙嗪镇痛效果临床观察. 临床药物实践. 2010;6(19):764–765.'}, {'Citation': '袁 如威, 王 建良. 磁共振对膝板股韧带附着区半月板撕裂的诊断效果研究. 医学影像学杂志. 2018;28(3):477–480.'}, {'Citation': '傅 利锋, 胡 劲涛, 王 政, et al. 半月板成形对前交叉韧带重建术后膝关节功能恢复影响的病例对照研究. 中国骨伤. 2017;25(8):50–51.'}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2024', 'Month': '4', 'Day': '11', 'Hour': '6', 'Minute': '42'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '10', 'Hour': '6', 'Minute': '43'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '10', 'Hour': '3', 'Minute': '43'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '18'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38595247', attributes={'IdType': 'pubmed'}), StringElement('PMC11004950', attributes={'IdType': 'pmc'}), StringElement('10.19723/j.issn.1671-167X.2024.02.014', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('EpiPen', attributes={'MajorTopicYN': 'N'}), StringElement('Palforzia', attributes={'MajorTopicYN': 'N'}), StringElement('Xolair', attributes={'MajorTopicYN': 'N'}), StringElement('adverse effects', attributes={'MajorTopicYN': 'N'}), StringElement('dosage', attributes={'MajorTopicYN': 'N'}), StringElement('efficacy', attributes={'MajorTopicYN': 'N'}), StringElement('epinephrine', attributes={'MajorTopicYN': 'N'}), StringElement('food allergy', attributes={'MajorTopicYN': 'N'}), StringElement('omalizumab', attributes={'MajorTopicYN': 'N'}), StringElement('safety', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38576144', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '08'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '08'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.58347/tml.2024.1699b', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1523-2859', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '66', 'Issue': '1699', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The Medical letter on drugs and therapeutics', 'ISOAbbreviation': 'Med Lett Drugs Ther'}, 'ArticleTitle': 'Omalizumab (Xolair) for food allergy.', 'Pagination': {'StartPage': '54', 'EndPage': '56', 'MedlinePgn': '54-56'}, 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'Med Lett Drugs Ther', 'NlmUniqueID': '2985240R', 'ISSNLinking': '0025-732X'}, 'ChemicalList': [{'RegistryNumber': '2P471X1Z11', 'NameOfSubstance': StringElement('Omalizumab', attributes={'UI': 'D000069444'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Antibodies, Monoclonal', attributes={'UI': 'D000911'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Omalizumab', attributes={'UI': 'D000069444', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Asthma', attributes={'UI': 'D001249', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Antibodies, Monoclonal', attributes={'UI': 'D000911', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('diagnosis', attributes={'UI': 'Q000175', 'MajorTopicYN': 'N'}), StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Food Hypersensitivity', attributes={'UI': 'D005512', 'MajorTopicYN': 'Y'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2024', 'Month': '4', 'Day': '8', 'Hour': '6', 'Minute': '43'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '5', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '5', 'Hour': '1', 'Minute': '23'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38576144', attributes={'IdType': 'pubmed'}), StringElement('10.58347/tml.2024.1699b', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('BCL-2', attributes={'MajorTopicYN': 'N'}), StringElement('T-acute lymphoblastic leukemia', attributes={'MajorTopicYN': 'N'}), StringElement('cell apoptosis', attributes={'MajorTopicYN': 'N'}), StringElement('cell autophagy', attributes={'MajorTopicYN': 'N'}), StringElement('child', attributes={'MajorTopicYN': 'N'}), StringElement('dexamethasone-resistance', attributes={'MajorTopicYN': 'N'}), StringElement('gene c-Myc', attributes={'MajorTopicYN': 'N'}), StringElement('honokiol', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38573223', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '05'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '05'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '04'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1080/16078454.2024.2337307', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1607-8454', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '29', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Dec'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Hematology (Amsterdam, Netherlands)', 'ISOAbbreviation': 'Hematology'}, 'ArticleTitle': 'Honokiol induces apoptosis and autophagy in dexamethasone-resistant T-acute lymphoblastic leukemia CEM-C1 cells.', 'Pagination': {'StartPage': '2337307', 'MedlinePgn': '2337307'}, 'Abstract': {'AbstractText': ['<b>Objective:</b> To study whether and, if so, how honokiol overcome dexamethasone resistance in DEX-resistant CEM-C1 cells. <b>Methods:</b> We investigated the effect of honokiol (0-20 µM) on cell proliferation, cell cycle, cell apoptosis and autophagy in DEX-resistant CEM-C1 cells and DEX-sensitive CEM-C7 cells. We also determined the role of c-Myc protein and mRNA in the occurrence of T-ALL associated dexamethasone resistance western blot and reverse transcription-qPCR (RT-qPCR) analysis. <b>Results:</b> Cell Counting Kit (CCK)-8 assay shows that DEX-resistant CEM-C1 cell lines were highly resistant to dexamethasone with IC50 of 364.1\\u2009±\\u200929.5 µM for 48 h treatment. However, upon treatment with dexamethasone in combination with 1.5 µM of honokiol for 48 h, the IC50 of CEM-C1 cells significantly decreased to 126.2\\u2009±\\u200912.3 µM, and the reversal fold was 2.88. Conversely, the IC50 of CEM-C7 cells was not changed combination of dexamethasone and honokiol as compared to that of CEM-C7 cells treated with dexamethasone alone. It has been shown that honokiol induced T-ALL cell growth inhibition by apoptosis and autophagy via downregulating cell cycle-regulated proteins (Cyclin E, CDK4, and Cyclin D1) and anti-apoptotic proteins BCL-2 and upregulating pro-apoptotic proteins Bax and led to PARP cleavage. Honokiol may overcome dexamethasone resistance in DEX-resistant CEM-C1 cell lines via the suppression of c-Myc mRNA expression. <b>Conclusion:</b> The combination of honokiol and DEX were better than DEX alone in DEX-resistant CEM-C1 cell lines. Honokiol may regulate T-ALL-related dexamethasone resistance by affecting c-Myc.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Pediatric Department, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Hubei, People's Republic of China.\"}], 'Identifier': [], 'LastName': 'Liu', 'ForeName': 'Yang', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Pediatric Department, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Hubei, People's Republic of China.\"}], 'Identifier': [], 'LastName': 'Zhang', 'ForeName': 'Suqian', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Pediatric Department, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Hubei, People's Republic of China.\"}], 'Identifier': [StringElement('0000-0002-9422-2741', attributes={'Source': 'ORCID'})], 'LastName': 'Tan', 'ForeName': 'Yajuan', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'}), 'MedlineJournalInfo': {'Country': 'England', 'MedlineTA': 'Hematology', 'NlmUniqueID': '9708388', 'ISSNLinking': '1024-5332'}, 'ChemicalList': [{'RegistryNumber': '11513CCO0N', 'NameOfSubstance': StringElement('honokiol', attributes={'UI': 'C005499'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Cell Cycle Proteins', attributes={'UI': 'D018797'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('RNA, Messenger', attributes={'UI': 'D012333'})}, {'RegistryNumber': '7S5I7G3JQL', 'NameOfSubstance': StringElement('Dexamethasone', attributes={'UI': 'D003907'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Allyl Compounds', attributes={'UI': 'D000498'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Biphenyl Compounds', attributes={'UI': 'D001713'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Phenols', attributes={'UI': 'D010636'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', attributes={'UI': 'D054218', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Apoptosis', attributes={'UI': 'D017209', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Autophagy', attributes={'UI': 'D001343', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Cell Cycle Proteins', attributes={'UI': 'D018797', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('RNA, Messenger', attributes={'UI': 'D012333', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Dexamethasone', attributes={'UI': 'D003907', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Allyl Compounds', attributes={'UI': 'D000498', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Biphenyl Compounds', attributes={'UI': 'D001713', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Phenols', attributes={'UI': 'D010636', 'MajorTopicYN': 'Y'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2024', 'Month': '4', 'Day': '5', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '4', 'Hour': '12', 'Minute': '47'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '4', 'Hour': '10', 'Minute': '33'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38573223', attributes={'IdType': 'pubmed'}), StringElement('10.1080/16078454.2024.2337307', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Direct drug provocation testing', attributes={'MajorTopicYN': 'N'}), StringElement('Drug allergy', attributes={'MajorTopicYN': 'N'}), StringElement('Penicillin', attributes={'MajorTopicYN': 'N'}), StringElement('Skin testing', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38572700', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '05'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '05'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2023', 'Month': '10', 'Day': '30'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1016/j.jaip.2023.10.035', attributes={'EIdType': 'doi', 'ValidYN': 'Y'}), StringElement('S2213-2198(23)01189-3', attributes={'EIdType': 'pii', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2213-2201', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '12', 'Issue': '2', 'PubDate': {'Year': '2024', 'Month': 'Feb'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The journal of allergy and clinical immunology. In practice', 'ISOAbbreviation': 'J Allergy Clin Immunol Pract'}, 'ArticleTitle': 'Safety of Direct Drug Provocation for the Evaluation of Penicillin Allergy in Low-Risk Adults.', 'Pagination': {'StartPage': '451', 'EndPage': '457.e2', 'MedlinePgn': '451-457.e2'}, 'Abstract': {'AbstractText': [StringElement('About 10% of patients have a penicillin allergy label, but less than 5% of them are actually allergic. Unnecessary penicillin avoidance is associated with serious medical consequences. Given the growing number of these labels, it is imperative that our diagnostic strategy for penicillin allergy be as efficient as possible. The validity of traditionally used skin tests (STs) has been questioned, whereas drug provocation testing (DPT), the criterion standard, without previous ST appears very safe in most cases.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement('To evaluate the safety of direct DPT without consideration for ST results and the validity of ST in the diagnosis of penicillin allergy.', attributes={'Label': 'OBJECTIVE', 'NlmCategory': 'OBJECTIVE'}), StringElement('In this prospective cohort study without a control group, we recruited patients consulting an allergist for penicillin allergy. Patients underwent ST followed by DPT regardless of ST results. Patients with anaphylaxis to penicillin within the past 5 years or a severe delayed reaction were excluded, as were those with significant cardiorespiratory comorbidity.', attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('None of the 1002 recruited patients had a serious reaction to DPT. Ten (1.0%) had a mild immediate reaction, of whom only 1 (0.1%) was considered likely IgE-mediated. The positive and negative predictive values of ST for an immediate reaction were 3.6% and 99.1%, respectively.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('In a low-risk adult population reporting penicillin allergy, ST has very poor positive predictive value. Direct DPT without ST is safe and appears to be an ideal diagnostic strategy to remove penicillin allergy labels that could be implemented in first-line practice.', attributes={'Label': 'CONCLUSIONS', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': 'Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Brillant-Marquis', 'ForeName': 'Frédéric', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Proulx', 'ForeName': 'Émilie', 'Initials': 'É'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Ratnarajah', 'ForeName': 'Kayadri', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Lavoie', 'ForeName': 'Aubert', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Gauthier', 'ForeName': 'Amélie', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Gagnon', 'ForeName': 'Rémi', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Boursiquot', 'ForeName': 'Jean-Nicolas', 'Initials': 'JN'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Verreault', 'ForeName': 'Nina', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Marois', 'ForeName': 'Louis', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Bédard', 'ForeName': 'Marc-Antoine', 'Initials': 'MA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Boivin', 'ForeName': 'Martine', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Bédard', 'ForeName': 'Pierre-Michel', 'Initials': 'PM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Institut National de Santé Publique du Québec, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Ouakki', 'ForeName': 'Manale', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Institut National de Santé Publique du Québec, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'De Serres', 'ForeName': 'Gaston', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada. Electronic address: jean-philippe.drolet.med@ssss.gouv.qc.ca.'}], 'Identifier': [], 'LastName': 'Drolet', 'ForeName': 'Jean-Philippe', 'Initials': 'JP'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'J Allergy Clin Immunol Pract', 'NlmUniqueID': '101597220'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Penicillins', attributes={'UI': 'D010406'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Bacterial Agents', attributes={'UI': 'D000900'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Adult', attributes={'UI': 'D000328', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Prospective Studies', attributes={'UI': 'D011446', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Penicillins', attributes={'UI': 'D010406', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('diagnosis', attributes={'UI': 'Q000175', 'MajorTopicYN': 'N'}), StringElement('epidemiology', attributes={'UI': 'Q000453', 'MajorTopicYN': 'N'}), StringElement('complications', attributes={'UI': 'Q000150', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Drug Hypersensitivity', attributes={'UI': 'D004342', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Predictive Value of Tests', attributes={'UI': 'D011237', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('chemically induced', attributes={'UI': 'Q000139', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anaphylaxis', attributes={'UI': 'D000707', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('methods', attributes={'UI': 'Q000379', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Skin Tests', attributes={'UI': 'D012882', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Bacterial Agents', attributes={'UI': 'D000900', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2023', 'Month': '7', 'Day': '10'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2023', 'Month': '10', 'Day': '8'}, attributes={'PubStatus': 'revised'}), DictElement({'Year': '2023', 'Month': '10', 'Day': '17'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '5', 'Hour': '6', 'Minute': '45'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '4', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '4', 'Hour': '5', 'Minute': '53'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38572700', attributes={'IdType': 'pubmed'}), StringElement('10.1016/j.jaip.2023.10.035', attributes={'IdType': 'doi'}), StringElement('S2213-2198(23)01189-3', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Aqueous humor', attributes={'MajorTopicYN': 'N'}), StringElement('Carbon dots', attributes={'MajorTopicYN': 'N'}), StringElement('Colorimetric sensor', attributes={'MajorTopicYN': 'N'}), StringElement('Eye drops', attributes={'MajorTopicYN': 'N'}), StringElement('Ketotifen', attributes={'MajorTopicYN': 'N'}), StringElement('Silver nanoparticles', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38569391', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '22'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '22'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '27'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1016/j.saa.2024.124204', attributes={'EIdType': 'doi', 'ValidYN': 'Y'}), StringElement('S1386-1425(24)00370-6', attributes={'EIdType': 'pii', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1873-3557', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '314', 'PubDate': {'Year': '2024', 'Month': 'Jun', 'Day': '05'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy', 'ISOAbbreviation': 'Spectrochim Acta A Mol Biomol Spectrosc'}, 'ArticleTitle': 'Carbon dots-adorned silver nanoparticles as a straightforward sustainable colorimetric sensor for the rapid detection of ketotifen in eye drops and aqueous humor.', 'Pagination': {'StartPage': '124204', 'MedlinePgn': '124204'}, 'Abstract': {'AbstractText': [\"The rapid and accurate detection of drug molecules in pharmaceutical formulations and biological samples is of paramount importance. In this research article, we present a novel colorimetric sensor based on carbon dots decorated silver nanoparticles (CDs/AgNPs) for the rapid detection of ketotifen (KTF), a widely used antihistamine drug. The CDs were synthesized via a facile one-step microwave-assisted method and subsequently conjugated onto AgNPs through a simple adsorption process, forming a stable CDs/AgNPs composite. The resulting composite exhibited unique optical properties, including a strong absorption peak at 410\\xa0nm with remarkable intensity reduction and color changes upon the addition of KTF. The developed colorimetric sensor exhibited a wide linear range of 3.0-40.0\\xa0µg\\xa0mL<sup>-1</sup> (R<sup>2</sup>\\xa0=\\xa00.9996), with a %RSD of 2.41, and a low limit of detection (LOD) of 0.981\\xa0µg\\xa0mL<sup>-1</sup>. Furthermore, the sensor's practical applicability was evaluated by successfully detecting KTF in eye drops and artificial aqueous humor, demonstrating a remarkable percentage recovery exceeding 96.0\\xa0%. Finally, a comprehensive evaluation of the greenness and blueness of the method was performed using analytical eco-scale, GAPI, AGREEprep, and BAGI tools. The results of these assessments indicate its exceptional sustainability. Overall, the proposed method holds significant potential for applications in pharmaceutical quality control and therapeutic monitoring, contributing to improved patient care and drug safety in the field of ophthalmology.\"], 'CopyrightInformation': 'Copyright © 2024 Elsevier B.V. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.'}], 'Identifier': [], 'LastName': 'Saad', 'ForeName': 'Aya Magdy', 'Initials': 'AM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt. Electronic address: asmaakamal91@mans.edu.eg.'}], 'Identifier': [], 'LastName': 'El-Deen', 'ForeName': 'Asmaa Kamal', 'Initials': 'AK'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt; Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura National University, Gamasa 7731168, Egypt.'}], 'Identifier': [], 'LastName': 'Nasr', 'ForeName': 'Jenny Jeehan Mohamed', 'Initials': 'JJM'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'}), 'MedlineJournalInfo': {'Country': 'England', 'MedlineTA': 'Spectrochim Acta A Mol Biomol Spectrosc', 'NlmUniqueID': '9602533', 'ISSNLinking': '1386-1425'}, 'ChemicalList': [{'RegistryNumber': '3M4G523W1G', 'NameOfSubstance': StringElement('Silver', attributes={'UI': 'D012834'})}, {'RegistryNumber': 'X49220T18G', 'NameOfSubstance': StringElement('Ketotifen', attributes={'UI': 'D007665'})}, {'RegistryNumber': '7440-44-0', 'NameOfSubstance': StringElement('Carbon', attributes={'UI': 'D002244'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Ophthalmic Solutions', attributes={'UI': 'D009883'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Metal Nanoparticles', attributes={'UI': 'D053768', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Silver', attributes={'UI': 'D012834', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Ketotifen', attributes={'UI': 'D007665', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('methods', attributes={'UI': 'Q000379', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Colorimetry', attributes={'UI': 'D003124', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Carbon', attributes={'UI': 'D002244', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Ophthalmic Solutions', attributes={'UI': 'D009883', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Aqueous Humor', attributes={'UI': 'D001082', 'MajorTopicYN': 'N'})}], 'CoiStatement': 'Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2023', 'Month': '12', 'Day': '23'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '8'}, attributes={'PubStatus': 'revised'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '26'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '22', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '4', 'Hour': '0', 'Minute': '43'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '3', 'Hour': '18', 'Minute': '9'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38569391', attributes={'IdType': 'pubmed'}), StringElement('10.1016/j.saa.2024.124204', attributes={'IdType': 'doi'}), StringElement('S1386-1425(24)00370-6', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38567842', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '24'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '25'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '01'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1097/ACI.0000000000000987', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1473-6322', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '24', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Jun', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Current opinion in allergy and clinical immunology', 'ISOAbbreviation': 'Curr Opin Allergy Clin Immunol'}, 'ArticleTitle': 'Biological treatments in childhood asthma.', 'Pagination': {'StartPage': '114', 'EndPage': '121', 'MedlinePgn': '114-121'}, 'Abstract': {'AbstractText': [StringElement('The aim is to update the information currently available for the use of biologics in severe asthma in children, in order to facilitate their prescription as far as possible.', attributes={'Label': 'PURPOSE OF REVIEW', 'NlmCategory': 'OBJECTIVE'}), StringElement('The appearance of biologics for the treatment of severe asthma has meant a revolutionary change in the therapeutic approach to this disease. Currently, five biologics have been approved for severe asthma in children and/or adolescents by the regulatory agencies: omalizumab, mepolizumab, benralizumab, dupilumab and tezepelumab. But despite their positive results in terms of efficacy, there are still relevant points of debate that should induce caution when selecting the most appropriate biologic in a child with severe asthma. Indeed, safety is essential and, for several of the existing treatments, the availability of medium-term to long-term data in this regard is scarce.', attributes={'Label': 'RECENT FINDINGS', 'NlmCategory': 'RESULTS'}), StringElement('The use of biologics can facilitate the therapeutic paradigm shift from pleiotropic treatments to personalized medicine. However, the choice of the most appropriate biologics remains a pending issue. On the other hand, to the extent that several of the biologics have been available for a relatively short time, the most robust evidence in terms of efficacy and safety in children is that of omalizumab.', attributes={'Label': 'SUMMARY', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': 'Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Health Research Institute La Fe, Valencia.'}], 'Identifier': [], 'LastName': 'Nieto-García', 'ForeName': 'Antonio', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Allergy Service, Hospital de la Plana, Villarreal, Castellón.'}], 'Identifier': [], 'LastName': 'Nieto-Cid', 'ForeName': 'María', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pediatric Pulmonology & Allergy Unit, Hospital la Fe, Valencia, Spain.'}], 'Identifier': [], 'LastName': 'Mazón-Ramos', 'ForeName': 'Ángel', 'Initials': 'Á'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Print-Electronic'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'Curr Opin Allergy Clin Immunol', 'NlmUniqueID': '100936359', 'ISSNLinking': '1473-6322'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Asthmatic Agents', attributes={'UI': 'D018927'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Biological Products', attributes={'UI': 'D001688'})}, {'RegistryNumber': '2P471X1Z11', 'NameOfSubstance': StringElement('Omalizumab', attributes={'UI': 'D000069444'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Antibodies, Monoclonal, Humanized', attributes={'UI': 'D061067'})}, {'RegistryNumber': '71492GE1FX', 'NameOfSubstance': StringElement('benralizumab', attributes={'UI': 'C571386'})}, {'RegistryNumber': '90Z2UF0E52', 'NameOfSubstance': StringElement('mepolizumab', attributes={'UI': 'C434107'})}, {'RegistryNumber': '420K487FSG', 'NameOfSubstance': StringElement('dupilumab', attributes={'UI': 'C582203'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Asthma', attributes={'UI': 'D001249', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Child', attributes={'UI': 'D002648', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Asthmatic Agents', attributes={'UI': 'D018927', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Biological Products', attributes={'UI': 'D001688', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Adolescent', attributes={'UI': 'D000293', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Omalizumab', attributes={'UI': 'D000069444', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Antibodies, Monoclonal, Humanized', attributes={'UI': 'D061067', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('methods', attributes={'UI': 'Q000379', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Precision Medicine', attributes={'UI': 'D057285', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Palomares Ó, Sánchez-Ramón S, Dávila I, et al. dIvergEnt: how IgE axis contributes to the continuum of allergic asthma and anti-IgE therapies. Int J Mol Sci 2017; 18:E1328.'}, {'Citation': 'Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med 2022; 386:157–171.'}, {'Citation': 'Striz I, Golebski K, Strizova Z, et al. New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis. Clin Sci 2023; 137:727–753.'}, {'Citation': 'Papadopoulos NG, Čustović A, Cabana MD, et al. Pediatric asthma: an unmet need for more effective, focused treatments. Pediatr allergy Immunol 2019; 30:7–16.'}, {'Citation': 'Saxena S, Rosas-Salazar C, Fitzpatrick A, Bacharier LB. Biologics and severe asthma in children. Curr Opin Allergy Clin Immunol 2023; 23:111–118.'}, {'Citation': 'Russo D, Di Filippo P, Attanasi M, et al. Biologic therapy and severe asthma in children. Biomedicines 2021; 9:760.'}, {'Citation': 'Perikleous EP, Steiropoulos P, Nena E, Paraskakis E. Biologic therapies in pediatric asthma. J Pers Med 2022; 12:999.'}, {'Citation': 'Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with antiimmunoglobulin E antibody (omalizumab). Pediatrics 2001; 108:E36.'}, {'Citation': 'Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124:1210–1216.'}, {'Citation': 'Busse W, Morgan W, Gergen P, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364:1005–1015.'}, {'Citation': 'Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 2015; 136:1476–1485.'}, {'Citation': 'Gill MA, Liu AH, Calatroni A, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol 2018; 141:1735.e9–1743.e9.'}, {'Citation': 'Jartti T, Gern JE. Role of viral infections in the development and exacerbation of asthma in children. J Allergy Clin Immunol 2017; 140:895–906.'}, {'Citation': 'Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J 2013; 42:1224–1233.'}, {'Citation': 'Deschildre A, Marguet C, Langlois C, et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J 2015; 46:856–859.'}, {'Citation': 'Brodlie M, Spencer DA, McKean MC, et al. The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe asthma. Arch Dis Child 2012; 97:604–609.'}, {'Citation': 'Licari A, Castagnoli R, Denicolò C, et al. Omalizumab in children with severe allergic asthma: the Italian real- life experience. Curr Respir Med Rev 2017; 13:36–42.'}, {'Citation': 'Odajima H, Ebisawa M, Nagakura T, et al. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. Allergol Int 2015; 64:364–370.'}, {'Citation': 'Nieto García A, Garriga-Baraut T, Plaza Martín AM, et al. Omalizumab outcomes for up to 6\\u200ayears in pediatric patients with severe persistent allergic asthma. Pediatr Allergy Immunol 2021; 32:980–991.'}, {'Citation': 'Cheng L, Yang T, Ma X, et al. Effectiveness and safety studies of omalizumab in children and adolescents with moderate-to-severe asthma. J Pharm Pract 2023; 36:370–382.'}, {'Citation': 'Fu Z, Xu Y, Cai C. Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis. J Asthma 2020; 0903:1350–1358.'}, {'Citation': 'Fenu G, La Tessa A, Calogero C, Lombardi E. Severe pediatric asthma therapy: omalizumab—a systematic review and meta-analysis of efficacy and safety profile. Front Pediatr 2022; 10 (March):1–7.'}, {'Citation': 'Cusack RP, Sahadevan A, Lane SJ. Qualitative effects of omalizumab on concomitant IgE-mediated disease in a severe asthmatic population: a real life observational study. QJM 2016; 109:601–604.'}, {'Citation': 'Fiocchi A, Artesani MC, Riccardi C, et al. Impact of omalizumab on food allergy in patients treated for asthma: a real-life study. J allergy Clin Immunol Pract 2019; 7:1901.e5–1909.e5.'}, {'Citation': 'Gupta A, Steinfeld J, Price R, et al. Mepolizumab for severe eosinophilic asthma: a comparison of efficacy in children, adolescents, and adults. Eur Respir J 2018; 52: (Suppl 62): A5447.'}, {'Citation': 'Assesment Report - Nucala. 2018. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/nucala . [Accessed December 2023]'}, {'Citation': \"Jackson DJ, Bacharier LB, Gergen PJ, et al. US National Institute of Allergy and Infectious Disease's Inner City Asthma Consortium. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet 2022; 400:502–511.\"}, {'Citation': 'Hossny E, Caraballo L, Casale T, et al. Severe asthma and quality of life. World Allergy Organ J 2017; 10:28.'}, {'Citation': 'Votto M, De Filippo M, Licari A, et al. Biological therapies in children and adolescents with severe uncontrolled asthma: a practical review. Biologics 2021; 15:133–142.'}, {'Citation': 'Saco T, Ugalde IC, Cardet JC, Casale TB. Strategies for choosing a biologic for your patient with allergy or asthma. Ann Allergy Asthma Immunol 2021; 127:627–637.'}, {'Citation': 'FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an antiinterleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388:2128–2141.'}, {'Citation': 'Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388:2115–2127.'}, {'Citation': 'Ohta K, Adachi M, Tohda Y, et al. Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma. Allergol Int 2018; 67:266–272.'}, {'Citation': 'Busse WW, Bleecker ER, FitzGerald JM, et al. BORA study investigators. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med 2019; 7:46–59.'}, {'Citation': 'Ferrante G, Tenero L, Piazza M, Piacentini G. Severe pediatric asthma therapy: dupilumab. Front Pediatr 2022; 10:4–10.'}, {'Citation': 'Bacharier LB, Maspero JF, Katelaris CH, et al. Liberty Asthma VOYAGE Investigators. Dupilumab in children with uncontrolled moderate-to-severe asthma. N Engl J Med 2021; 385:2230–2240.'}, {'Citation': 'Fiocchi AG, Phipatanakul W, Zeiger RS, et al. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study. Eur Respir J 2023; 62:2300558.'}, {'Citation': 'Papadopoulos NG, Szefler SJ, Bacharier LB, et al. Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma. Allergy 2023; 78:2157–2167.'}, {'Citation': 'Bacharier LB, Maspero JF, Katelaris CH, et al. Liberty Asthma EXCURSION Investigators. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study. Lancet Respir Med 2024; 12:45–54.'}, {'Citation': 'Busse WW, Viswanathan R. What has been learned by cytokine targeting of asthma? J Allergy Clin Immunol 2022; 150:235–249.'}, {'Citation': 'van Dijk YE, Rutjes NW, Golebski K, et al. Developments in the management of severe asthma in children and adolescents: focus on dupilumab and tezepelumab. Pediatr Drugs 2023; 25:677–693.'}, {'Citation': 'Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med 2021; 384:1800–1809.'}, {'Citation': 'Estrada RA, Maselli DJ. In severe, uncontrolled asthma, tezepelumab reduced exacerbations over 1 y regardless of type 2 inflammation level. Ann Intern Med 2023; 176:JC128.'}, {'Citation': 'Niessen NM, Fricker M, McDonald VM, Gibson PG. T2-low: what do we know?: past, present, and future of biologic therapies in noneosinophilic asthma. Ann Allergy, Asthma Immunol 2022; 129:150–159.'}, {'Citation': 'Ramírez-Jiménez F, Pavón-Romero GF, Velásquez-Rodríguez JM, et al. Biologic therapies for asthma and allergic disease: past, present, and future. Pharmaceuticals 2023; 16:270.'}, {'Citation': 'Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol 2014; 134:560.e4–567.e4.'}, {'Citation': 'Galletta F, Caminiti L, Lugarà C, et al. Long-term safety of omalizumab in children with asthma and/or chronic spontaneous urticaria: a 4-year prospective study in real life. J Pers Med 2023; 13:1068.'}, {'Citation': 'Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 2012; 129:983.e6–989.e6.'}, {'Citation': 'Corren J, Kavati A, Ortiz B, et al. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: a systematic literature review. Allergy asthma Proc 2017; 38:250–263.'}, {'Citation': 'Lang D, Liu Z, Li D. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma: a systematic review and meta-analysis. Discov Med 2023; 35:233–241.'}, {'Citation': 'Bacharier LB, Jackson DJ. Biologics in the treatment of asthma in children and adolescents. J Allergy Clin Immunol 2023; 151:581–589.'}, {'Citation': 'Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol 2015; 26:551–556.'}, {'Citation': 'Xepapadaki P, Adachi Y, Pozo Beltrán CF, et al. Utility of biomarkers in the diagnosis and monitoring of asthmatic children. World Allergy Organ J 2023; 16:100727.'}, {'Citation': 'Nieto A, El-sayed ZA, Gómez RM, et al. Unanswered questions on the use of biologics in pediatric asthma. World Allergy Organ J 2023; 16:100837.'}, {'Citation': 'Bush A. How to choose the correct drug in severe pediatric asthma. Front Pediatr 2022; 10:902168.'}, {'Citation': 'Morjaria JB, Proiti M, Polosa R. Stratified medicine in selecting biologics for the treatment of severe asthma. Curr Opin Allergy Clin Immunol 2011; 11:58–63.'}, {'Citation': 'Wangberg H, Woessner K. Choice of biologics in asthma endotypes. Curr Opin Allergy Clin Immunol 2021; 21:79–85.'}, {'Citation': 'Saglani S, Bush A, Carroll W, et al. Biologics for paediatric severe asthma: trick or TREAT? Lancet Respir Med 2019; 7:294–296.'}, {'Citation': 'Sesé L, Schneider M, Bourgoin M, et al. Asthma with multiple allergic comorbidities is associated with complete response to omalizumab. Clin Exp Allergy 2019; 49:733–735.'}, {'Citation': 'Just J, Deschildre A, Lejeune S, Amat F. New perspectives of childhood asthma treatment with biologics. Pediatr Allergy Immunol 2019; 30:159–171.'}, {'Citation': 'Zhou H, Lu Y, Wu B, Che D. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children. J Asthma 2020; 57:87–94.'}, {'Citation': 'Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Cost-utility of omalizumab for the treatment of uncontrolled moderate-to-severe persistent pediatric allergic asthma in a middle-income country. Pediatr Pulmonol 2021; 56:2987–2996.'}, {'Citation': 'Nieto-Cid M, Garriga-Baraut T, Plaza-Martín AM, et al. Cost-effectiveness of omalizumab for the treatment of severe pediatric allergic asthma-Results of a real-life study in Spain. Pediatr Allergy Immunol 2023; 34:e13942.'}, {'Citation': 'Phipatanakul W, Mauger DT, Guilbert TW, et al. PARK Study Team. Preventing asthma in high risk kids (PARK) with omalizumab: design, rationale, methods, lessons learned and adaptation. Contemp Clin Trials 2021; 100:106228.'}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2024', 'Month': '4', 'Day': '24', 'Hour': '19', 'Minute': '5'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '3', 'Hour': '12', 'Minute': '45'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '3', 'Hour': '8', 'Minute': '12'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38567842', attributes={'IdType': 'pubmed'}), StringElement('10.1097/ACI.0000000000000987', attributes={'IdType': 'doi'}), StringElement('00130832-990000000-00118', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38564395', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '04'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '04'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.36849/JDD.7919', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1545-9616', attributes={'IssnType': 'Print'}), 'JournalIssue': DictElement({'Volume': '23', 'Issue': '4', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Journal of drugs in dermatology : JDD', 'ISOAbbreviation': 'J Drugs Dermatol'}, 'ArticleTitle': 'Clinical Impacts of Omalizumab on the Psychiatric Comorbidities of Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis.', 'Pagination': {'StartPage': 'e116', 'EndPage': 'e117', 'MedlinePgn': 'e116-e117'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Tan', 'ForeName': 'Marcus G', 'Initials': 'MG'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Bailey', 'ForeName': 'Adrian M J', 'Initials': 'AMJ'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Dorus', 'ForeName': 'Brian', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Kirchhof', 'ForeName': 'Mark G', 'Initials': 'MG'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Meta-Analysis', attributes={'UI': 'D017418'}), StringElement('Systematic Review', attributes={'UI': 'D000078182'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'J Drugs Dermatol', 'NlmUniqueID': '101160020', 'ISSNLinking': '1545-9616'}, 'ChemicalList': [{'RegistryNumber': '2P471X1Z11', 'NameOfSubstance': StringElement('Omalizumab', attributes={'UI': 'D000069444'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Allergic Agents', attributes={'UI': 'D018926'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Omalizumab', attributes={'UI': 'D000069444', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Chronic Urticaria', attributes={'UI': 'D000080223', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Allergic Agents', attributes={'UI': 'D018926', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Chronic Disease', attributes={'UI': 'D002908', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'}), StringElement('epidemiology', attributes={'UI': 'Q000453', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Urticaria', attributes={'UI': 'D014581', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Treatment Outcome', attributes={'UI': 'D016896', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2024', 'Month': '4', 'Day': '4', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '2', 'Hour': '18', 'Minute': '44'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '2', 'Hour': '13', 'Minute': '11'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38564395', attributes={'IdType': 'pubmed'}), StringElement('10.36849/JDD.7919', attributes={'IdType': 'doi'}), StringElement('S1545961624Pe116X', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Food', attributes={'MajorTopicYN': 'N'}), StringElement('Morocco', attributes={'MajorTopicYN': 'N'}), StringElement('allergies', attributes={'MajorTopicYN': 'N'}), StringElement('drug', attributes={'MajorTopicYN': 'N'}), StringElement('epidemiology', attributes={'MajorTopicYN': 'N'}), StringElement('management', attributes={'MajorTopicYN': 'N'}), StringElement('survey', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38558549', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '03'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '15'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '01', 'Day': '22'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('24', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.11604/pamj.2024.47.24.41038', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1937-8688', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '47', 'PubDate': {'Year': '2024'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The Pan African medical journal', 'ISOAbbreviation': 'Pan Afr Med J'}, 'ArticleTitle': 'An overview of a preliminary multicenter retrospective study on food and drug allergies in Moroccan pediatric population.', 'Pagination': {'StartPage': '24', 'MedlinePgn': '24'}, 'Abstract': {'AbstractText': [StringElement('this study aimed to investigate the prevalence and management of food allergies (FA) and drug allergies (DA) in Morocco. Sparse and conflicting epidemiological data exist on the exact prevalence of allergies in the country. The rise in allergies can be attributed to various factors.', attributes={'Label': 'INTRODUCTION', 'NlmCategory': 'UNASSIGNED'}), StringElement('the study analyzed data from patients with suspected FA and DA who sought medical attention. Statistical tests were used to analyze the data, percentages were computed for qualitative variables, and for quantitative variables, medians or means accompanied by standard deviations (SD) were calculated. The Chi-square test was employed to assess categorical variables. A p-value < 0.05 was considered statistically significant.', attributes={'Label': 'METHODS', 'NlmCategory': 'UNASSIGNED'}), StringElement(\"Cow's milk was the most reported food allergen (58.2%), followed by egg and nuts (23.4% and 12.1%, respectively). The most affected age group was children under 5 years. Antibiotics were the leading cause of reported drug allergies (44.8%), particularly Beta-lactams. Immediate reactions were commonly associated with antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs). Symptoms of FA included acute urticaria, vomiting, anaphylactic shock, and facial edema. Urticaria was the most frequent symptom of DA. Antihistamines and corticosteroids were the main treatments used for both FA and DA.\", attributes={'Label': 'RESULTS', 'NlmCategory': 'UNASSIGNED'}), StringElement('the prevalence of FA and DA in Morocco remains uncertain due to limited data. There is a need for centralized data collection and awareness among clinicians and the general population regarding allergies. The study highlights the importance of proper diagnosis and management of allergies to ensure patient safety. The findings emphasize the necessity of establishing a mandatory center for allergy care in Morocco to improve the understanding and management of allergic conditions.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'UNASSIGNED'})], 'CopyrightInformation': 'Copyright: Zakaria Zidane et al.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Biology and Health, Research Center of Biotechnologies and Health, University Hassan II of Casablanca, Faculty of Sciences Ben M´sik, Avenue Cdt Driss El Harti, B.P 7955, Sidi Othmane, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Zidane', 'ForeName': 'Zakaria', 'Initials': 'Z'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Biology and Health, Research Center of Biotechnologies and Health, University Hassan II of Casablanca, Faculty of Sciences Ben M´sik, Avenue Cdt Driss El Harti, B.P 7955, Sidi Othmane, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Chahine', 'ForeName': 'Chaimaa', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Biology and Health, Research Center of Biotechnologies and Health, University Hassan II of Casablanca, Faculty of Sciences Ben M´sik, Avenue Cdt Driss El Harti, B.P 7955, Sidi Othmane, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Mohtadi', 'ForeName': 'Karima', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Biology and Health, Research Center of Biotechnologies and Health, University Hassan II of Casablanca, Faculty of Sciences Ben M´sik, Avenue Cdt Driss El Harti, B.P 7955, Sidi Othmane, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Chakroun', 'ForeName': 'Azeddine', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Biology and Health, Research Center of Biotechnologies and Health, University Hassan II of Casablanca, Faculty of Sciences Ben M´sik, Avenue Cdt Driss El Harti, B.P 7955, Sidi Othmane, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Saïle', 'ForeName': 'Rachid', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Clinical Immunology, Inflammation and Allergies, University Hassan II of Casablanca, Faculty of Medicine, 19 Rue Tarik Ibnou Ziad, BP 9154, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Bousfiha', 'ForeName': 'Ahmed Aziz', 'Initials': 'AA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pediatric Service, University Hospital Mohammed VI, Oujda, Morocco.'}], 'Identifier': [], 'LastName': 'Rkain', 'ForeName': 'Maria', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Liberal Sector Allergologists, Casablanca, Rabat and Oujda, Morocco.'}], 'Identifier': [], 'LastName': 'Chaer', 'ForeName': 'Sanae Elimlahi', 'Initials': 'SE'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Liberal Sector Allergologists, Casablanca, Rabat and Oujda, Morocco.'}], 'Identifier': [], 'LastName': 'Gueddari', 'ForeName': 'Youness El', 'Initials': 'YE'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pediatric Service, University Hospital Hassan II, Fès, Morocco.'}], 'Identifier': [], 'LastName': 'Hbibi', 'ForeName': 'Mohammed', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Liberal Sector Allergologists, Casablanca, Rabat and Oujda, Morocco.'}], 'Identifier': [], 'LastName': 'Daoudi', 'ForeName': 'Laila Tazi', 'Initials': 'LT'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Clinical Immunology, Inflammation and Allergies, University Hassan II of Casablanca, Faculty of Medicine, 19 Rue Tarik Ibnou Ziad, BP 9154, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Benhsaien', 'ForeName': 'Ibtihal', 'Initials': 'I'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Medical Biotechnology, University of Mohammed V de Rabat, Faculty of Medicine of Rabat, Impasse Souissi, Rabat 10100, Morocco.'}], 'Identifier': [], 'LastName': 'Elhafidi', 'ForeName': 'Naima', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Biology and Health, Research Center of Biotechnologies and Health, University Hassan II of Casablanca, Faculty of Sciences Ben M´sik, Avenue Cdt Driss El Harti, B.P 7955, Sidi Othmane, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Alj', 'ForeName': 'Hanane Salih', 'Initials': 'HS'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Electronic-eCollection'}), 'MedlineJournalInfo': {'Country': 'Uganda', 'MedlineTA': 'Pan Afr Med J', 'NlmUniqueID': '101517926'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Allergens', attributes={'UI': 'D000485'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Bacterial Agents', attributes={'UI': 'D000900'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Animals', attributes={'UI': 'D000818', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Cattle', attributes={'UI': 'D002417', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Child', attributes={'UI': 'D002648', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Child, Preschool', attributes={'UI': 'D002675', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Female', attributes={'UI': 'D005260', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Allergens', attributes={'UI': 'D000485', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Anti-Bacterial Agents', attributes={'UI': 'D000900', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Drug Hypersensitivity', attributes={'UI': 'D004342', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('epidemiology', attributes={'UI': 'Q000453', 'MajorTopicYN': 'N'}), StringElement('diagnosis', attributes={'UI': 'Q000175', 'MajorTopicYN': 'N'}), StringElement('etiology', attributes={'UI': 'Q000209', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Food Hypersensitivity', attributes={'UI': 'D005512', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Multicenter Studies as Topic', attributes={'UI': 'D015337', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Retrospective Studies', attributes={'UI': 'D012189', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Urticaria', attributes={'UI': 'D014581', 'MajorTopicYN': 'Y'})}], 'CoiStatement': 'The authors declare no competing interests.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Curated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Plard C, Fanello S, Paré F, Racineux JL, Drouet M. Épidémiologie de la plainte allergique en médecine générale. Rev Fr d´Allergologie d´Immunologie Clin. 2008;48:476–486.'}, {'Citation': 'Pawankar R. Allergic diseases: a global public health issue. Asian Pacific Journal of Allergy and Immunology. 2012;30'}, {'Citation': 'Lakhbab F. Progression des maladies allergiques: impact du mode de vie et de l´environnement. Prise en charge et rôle du pharmacien. 2017;1:173.'}, {'Citation': 'Chalabianloo FA, Berstad J, Schjøtt B, Riedel A, Irgens E, Florvaag Clinical characteristics of patients with drug hypersensitivity in Norway: a single-centre study. Pharmacoepidemiol Drug Saf. 2011;20:506–513.', 'ArticleIdList': [StringElement('21523851', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Dierick BJH, Molen TVD, Bertine MJF, Muraro A, Maarten JP, Janwillem WHK, et al. Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy. Expert Rev Pharmacoecon Outcomes Res. 2020 Oct;20(5):437–453.', 'ArticleIdList': [StringElement('32902346', attributes={'IdType': 'pubmed'})]}, {'Citation': 'World Allergy Organization World Allergy Organization. 2020;1:5.'}, {'Citation': 'Lelièvre JD. Immunologie fondamentale et immunopathologie. Paris: Elsevier Masson. 2018;344'}, {'Citation': 'Sampath V, Elissa MA, Bahman A, Cezmi A, Mübeccel A, Helen AB, et al. Food allergy across the globe. Clinical reviews in allergy and immunology. 2021 Dec;148(6):1347–1364.', 'ArticleIdList': [StringElement('34872649', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Vyles D, Chiu A, Simpson P, Nimmer M, Adams J, Brousseau DC. Parent-reported Penicillin Allergy Symptoms in the pediatric emergency department. Acad Pediatr. 2017 Apr;17(3):251–255.', 'ArticleIdList': [StringElement('28274586', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gomes ER, Brockow K, Kuyucu S, Saretta F, Mori F, Blanca-Lopez N, et al. Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group. Allergy. 2016 Feb;71(2):149–61.', 'ArticleIdList': [StringElement('26416157', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Medecine DDE Doctorat TDE and Sciences . Etude du recrutement de l´Ouest algérien. 2018. L´allergie aux protéines du lait de vache chez le nourrisson : epidémiologie clinique et prise en charge, etude du recrutement de l´ouest algérien.'}, {'Citation': 'Molkhou P. Epidemiology of food allergy. Rev Infirm. 2005 May;111:24–7.', 'ArticleIdList': [StringElement('15991640', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Payot F. Primary prevention of IgE-mediated allergy to cow´s milk protein. Rev Fr Allergol. 2020;60:566–570.'}, {'Citation': \"Tamazouzt S, Adel-Patient K, Deschildre A, Charles MA, De Lauzon-Guillain B, Divaret-Chauveau A. Prévalence des allergies alimentaires en France: données de la cohorte ELFE. Revue Française d 'Allergologie. 2021;61:4.\"}, {'Citation': \"Schoemaker AA, Sprikkelman AB, Grimshaw KE, Roberts G, Grabenhenrich L, Rosenfeld L, et al. Incidence and natural history of challenge-proven cow's milk allergy in European children: EuroPrevall birth cohort. Allergy. 2015 Aug;70(8):963–72.\", 'ArticleIdList': [StringElement('25864712', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Samady W, Warren C, Wang J, Das R, Gupta RS. Egg Allergy in US Children. J Allergy Clin Immunol Pract. 2020;8(9):3066–3073.e6.', 'ArticleIdList': [StringElement('PMC7895443', attributes={'IdType': 'pmc'}), StringElement('32376485', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Rancé F, Dutau G. Allergie alimentaire à l´œuf de poule chez l´enfant. Rev Fr Allergol. 2010;50:S41–S45.'}, {'Citation': 'Linus BG, Sabine D, Moneret-Vautrin A, Köhli A, Lange L, Spindler T, et al. Anaphylaxis in children and adolescents. The European Anaphylaxis Registry. 2015;1:11.', 'ArticleIdList': [StringElement('26806049', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Sabouraud-Leclerc D, Bradatan E. Severe food allergies in children. Rev Fr Allergol. 2019;59:350–358.'}, {'Citation': 'Boissieu D. Allergie à I´arachide. J Pediatr Puériculture. 2002;17:20.'}, {'Citation': 'Hossny E, Motohiro E, Yehia E, Stefania A, Lamia D, Rasha E, et al. Challenges of managing food allergy in the developing world. World Allergy Organ J. 2019;12(11):100089.', 'ArticleIdList': [StringElement('PMC6909084', attributes={'IdType': 'pmc'}), StringElement('31871534', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Li J, Ludmila MO, Padukudru AM, Maggie HW, Olga SF, Ting F, et al. Comparative Study of Food Allergies in Children from China, India, and Russia: the EuroPrevall-INCO Surveys. J Allergy Clin Immunol Pract. 2020;8(4):1349–1358.e16.', 'ArticleIdList': [StringElement('31857266', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tham EH, Agnes SLY, Punchama P, Sooyoung L, Motohiro E, et al. Anaphylaxis: lessons learnt when East meets West. Pediatr Allergy Immunol. 2019;30(7):681–688.', 'ArticleIdList': [StringElement('31220363', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lee TH, Ting FL, Gary W, Marco H, Duque JM, Philip HL, et al. The unmet provision of allergy services in Hong Kong impairs capability for allergy prevention: implications for the Asia Pacific region. Asian Pacific J Allergy Immunol. 2019;37(1):1–8.', 'ArticleIdList': [StringElement('29223147', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mayte SF, Maria S, Paul K, Robert G, Galina G, Clive H, et al. Accurate and reproducible diagnosis of peanut allergy using epitope mapping. Allergy Eur J Allergy Clin Immunol. 2021;76(12):3789–3797.', 'ArticleIdList': [StringElement('PMC8607840', attributes={'IdType': 'pmc'}), StringElement('33991353', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Reinhardt M, Eigenmann P. Allergies alimentaires. Rev Med Suisse Romande. 2000;120(3):195–201.', 'ArticleIdList': [StringElement('10815448', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bush T. Adverse drug reactions in hospitalized patients. JAMA. 1998 Nov 25;280(20):1742. author reply 1743-4.', 'ArticleIdList': [StringElement('9842942', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Demoly P, Dominique HB, Nadia RP, Philippe G, Michel FB, Bousquet J. Identifier et comprendre les allergies médicamenteuses. Médecine/Sciences. 2003;19(3):327–336.', 'ArticleIdList': [StringElement('12836415', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Piccorossi A, Liccioli G, Barni S, Sarti L, Giovannini M, Verrotti A, et al. Epidemiology and drug allergy results in children investigated in allergy unit of a tertiary-care paediatric hospital setting. Ital J Pediatr. 2020;46(5):1–13.', 'ArticleIdList': [StringElement('PMC6954623', attributes={'IdType': 'pmc'}), StringElement('31924232', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Rubio M, Bousquet PJ, Gomes E, Romano A, Demoly P. Results of drug hypersensitivity evaluations in a large group of children and adults. Clin Exp Allergy. 2012;42(1):123–130.', 'ArticleIdList': [StringElement('22092779', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Katsogiannou M, Carsin A, Mazenq J, Dubus J C, Gervoise-Boyer MJ. Drug hypersensitivity in children: a retrospective analysis of 101 pharmacovigilance reports. Eur J Pediatr. 2021;180(2):495–503.', 'ArticleIdList': [StringElement('33155108', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pruszkowski A. Atopie, famille et societe. Rev Fr d´Allergologie d´Immunologie Clin. 2000;40:105–109.'}, {'Citation': 'Gomes E, Cardoso MF, Praça F, Gomes L, Mariño E, Demoly P. Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy. 2004;34(10):1597–1601.', 'ArticleIdList': [StringElement('15479276', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Fiszenson-Albala F, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol. 2003;149:1018–1022.', 'ArticleIdList': [StringElement('14632808', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Erkoçoğlu M, Aysenur K, Ersoy C, Celal O, Banu C, Aysegül A, et al. Prevalence of confirmed immediate type drug hypersensitivity reactions among school children. Pediatr Allergy Immunol. 2013;24(2):160–167.', 'ArticleIdList': [StringElement('23373964', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Blanca M, Romano A, Torres MJ, Férnandez J, Mayorga C, Rodriguez J, et al. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy Eur J Allergy Clin Immunol. 2009;64(2):183–193.', 'ArticleIdList': [StringElement('19133923', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Sharma HP, Wood RA, Bravo AR, Matsui EC. A comparison of skin prick tests, intradermal skin tests, and specific IgE in the diagnosis of mouse allergy. J Allergy Clin Immunol. 2008;121(4):933–939.', 'ArticleIdList': [StringElement('18325579', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P, et al. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy Eur J Allergy Clin Immunol. 2002;57(1):45–51.', 'ArticleIdList': [StringElement('11991289', attributes={'IdType': 'pubmed'})]}, {'Citation': \"Mill C, Primeau MN, Medoff E, Lejtenyi C, O'Keefe A, Netchiporouk E, et al. Assessing the diagnostic properties of a graded oral provocation challenge for the diagnosis of immediate and nonimmediate reactions to amoxicillin in children. JAMA Pediatr. 2016;170(6):1–8.\", 'ArticleIdList': [StringElement('27043788', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Esposito S, Castellazzi L, Tagliabue C, Principi N. Allergy to antibiotics in children: an overestimated problem. Int J Antimicrob Agents. 2016;48(4):361–366.', 'ArticleIdList': [StringElement('27554439', attributes={'IdType': 'pubmed'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2023', 'Month': '7', 'Day': '11'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '1', 'Day': '8'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '3', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '1', 'Hour': '18', 'Minute': '42'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '1', 'Hour': '17', 'Minute': '1'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '1', 'Day': '22'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38558549', attributes={'IdType': 'pubmed'}), StringElement('PMC10979813', attributes={'IdType': 'pmc'}), StringElement('10.11604/pamj.2024.47.24.41038', attributes={'IdType': 'doi'}), StringElement('PAMJ-47-24', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('biomarkers', attributes={'MajorTopicYN': 'N'}), StringElement('chronic spontaneous urticaria (csu)', attributes={'MajorTopicYN': 'N'}), StringElement('predict', attributes={'MajorTopicYN': 'N'}), StringElement('therapeutic response', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38557452', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '03'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '03'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.1684/ejd.2024.4600', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1952-4013', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '34', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Feb', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'European journal of dermatology : EJD', 'ISOAbbreviation': 'Eur J Dermatol'}, 'ArticleTitle': 'Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review.', 'Pagination': {'StartPage': '3', 'EndPage': '12', 'MedlinePgn': '3-12'}, 'Abstract': {'AbstractText': [\"Chronic spontaneous urticaria (CSU) is a relatively common dermatological disorder characterized by sudden and unpredictable onset of pruritic wheals and/or angioedema, for more than six weeks. It is a mast cell-mediated histaminergic disorder, considerably worsening patients' quality of life. Current treatment options include anti-histamines, omalizumab and cyclosporine, in a step-wise algorithmic approach, aimed at complete symptom control. Patients do not respond uniformly to these therapeutic options due to phenotypic and endotypic heterogeneity, and often remain uncontrolled/poorly controlled. Recent research is focused on identifying certain biomarkers to predict therapeutic response and facilitate patient-targeted personalized treatment, for maximum benefit. The current article summarizes various biomarkers explored to date, and also elaborates their role in predicting therapeutic response to anti-histamines, omalizumab and cyclosporine, in CSU patients. High disease activity, elevated CRP/ESR and elevated D-dimer are the most important predictors of non/poor-response to antihistamines. Low and very low baseline IgE, elevated CRP/ESR, ASST+, BAT/BHRA+, basopenia, eosinopenia, and elevated D-dimer are predictors of poor and good response to omalizumab and cyclosporine, respectively. Additionally, normal or slightly elevated baseline IgE and FceR1 overexpression are predictors of a faster response with omalizumab. However, none of these predictors have so far been completely validated and are not yet recommended for routine use. Thus, large-scale prospective studies are needed to confirm these predictive biomarkers and identify new ones to achieve the goal of personalized medicine for CSU.\"]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, Hospital del Mar. IMIM, Universitat Pompeu Fabra, Barcelona, Spain.'}], 'Identifier': [], 'LastName': 'Gimenez-Arnau', 'ForeName': 'Ana Maria', 'Initials': 'AM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, Acıbadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Turkey.'}], 'Identifier': [], 'LastName': 'Salman', 'ForeName': 'Andaç', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, College of Medicine and Sagore Dutta Hospital, Kolkata, India.'}], 'Identifier': [], 'LastName': 'Podder', 'ForeName': 'Indrashis', 'Initials': 'I'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Review', attributes={'UI': 'D016454'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'France', 'MedlineTA': 'Eur J Dermatol', 'NlmUniqueID': '9206420', 'ISSNLinking': '1167-1122'}, 'ChemicalList': [{'RegistryNumber': '2P471X1Z11', 'NameOfSubstance': StringElement('Omalizumab', attributes={'UI': 'D000069444'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Histamine Antagonists', attributes={'UI': 'D006633'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Biomarkers', attributes={'UI': 'D015415'})}, {'RegistryNumber': '83HN0GTJ6D', 'NameOfSubstance': StringElement('Cyclosporine', attributes={'UI': 'D016572'})}, {'RegistryNumber': '37341-29-0', 'NameOfSubstance': StringElement('Immunoglobulin E', attributes={'UI': 'D007073'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Allergic Agents', attributes={'UI': 'D018926'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Omalizumab', attributes={'UI': 'D000069444', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Quality of Life', attributes={'UI': 'D011788', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Chronic Disease', attributes={'UI': 'D002908', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Chronic Urticaria', attributes={'UI': 'D000080223', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'}), StringElement('diagnosis', attributes={'UI': 'Q000175', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Urticaria', attributes={'UI': 'D014581', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Histamine Antagonists', attributes={'UI': 'D006633', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Biomarkers', attributes={'UI': 'D015415', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Cyclosporine', attributes={'UI': 'D016572', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Immunoglobulin E', attributes={'UI': 'D007073', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Allergic Agents', attributes={'UI': 'D018926', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Treatment Outcome', attributes={'UI': 'D016896', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2024', 'Month': '4', 'Day': '3', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '1', 'Hour': '18', 'Minute': '42'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '1', 'Hour': '15', 'Minute': '52'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38557452', attributes={'IdType': 'pubmed'}), StringElement('10.1684/ejd.2024.4600', attributes={'IdType': 'doi'}), StringElement('ejd.2024.4600', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Olanzapine/samidorphan', attributes={'MajorTopicYN': 'N'}), StringElement('Precipitated opioid withdrawal', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38556414', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '16'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '16'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '26'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1016/j.ajem.2024.03.027', attributes={'EIdType': 'doi', 'ValidYN': 'Y'}), StringElement('S0735-6757(24)00139-6', attributes={'EIdType': 'pii', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1532-8171', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '79', 'PubDate': {'Year': '2024', 'Month': 'May'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The American journal of emergency medicine', 'ISOAbbreviation': 'Am J Emerg Med'}, 'ArticleTitle': 'Precipitated opioid withdrawal in a patient started on olanzapine/samidorphan.', 'Pagination': {'StartPage': '230.e1', 'EndPage': '230.e2', 'MedlinePgn': '230.e1-230.e2'}, 'Abstract': {'AbstractText': [StringElement('Olanzapine/Samidorphan (Lybalvi®) is a novel oral agent for the treatment of schizophrenia and bipolar I disorder. It was designed to reduce weight gain associated with olanzapine. Samidorphan is an analog of naltrexone, initially intended to treat substance use disorders by antagonizing mu, delta, and kappa opioid receptors.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement('We present the case of a 36-year-old who took their first dose of olanzapine/samidorphan shortly before calling for emergency services. The patient took diphenhydramine and an epinephrine autoinjector for what they thought was an allergic reaction but continued to have symptoms. EMS reported involuntary muscle movements thought to be due to dystonia from olanzapine. In the ED, they experienced generalized muscle spasms lasting for several seconds and diaphoresis. Initially, the staff treated for a presumed dystonic reaction to olanzapine and administered diphenhydramine 25\\xa0mg IV, diazepam 2\\xa0mg IV, midazolam 5\\xa0mg IV, and benztropine 1\\xa0mg IV without improvement. It was later determined that the patient took 16\\xa0mg of buprenorphine SL daily. With this information, precipitated opioid withdrawal was felt to be the likely cause of symptoms. The patient received 16\\xa0mg of buprenorphine for an initial Clinical Opiate Withdrawal Scale (COWS) score of 11 with repeat COWS of 6. Why should an emergency physician be aware of this? Initiating olanzapine/samidorphan in the setting of chronic opioid therapy may result in precipitated opioid withdrawal. Additional SL buprenorphine may be a reasonable treatment modality.', attributes={'Label': 'CASE REPORT', 'NlmCategory': 'METHODS'})], 'CopyrightInformation': 'Copyright © 2024 Elsevier Inc. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Virginia Poison Center, Division of Clinical Toxicology, United States of America; Department of Emergency Medicine, Virginia Commonwealth University Health System, Richmond, VA, United States of America.'}], 'Identifier': [], 'LastName': 'Chambers', 'ForeName': 'Andrew', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Emergency Medicine, Virginia Commonwealth University Health System, Richmond, VA, United States of America. Electronic address: Jessica.patton@vcuhealth.org.'}], 'Identifier': [], 'LastName': 'Patton', 'ForeName': 'Jessica', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Virginia Poison Center, Division of Clinical Toxicology, United States of America; Department of Emergency Medicine, Virginia Commonwealth University Health System, Richmond, VA, United States of America.'}], 'Identifier': [], 'LastName': 'Wills', 'ForeName': 'Brandon K', 'Initials': 'BK'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Case Reports', attributes={'UI': 'D002363'})]}, attributes={'PubModel': 'Print-Electronic'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'Am J Emerg Med', 'NlmUniqueID': '8309942', 'ISSNLinking': '0735-6757'}, 'ChemicalList': [{'RegistryNumber': 'N7U69T4SZR', 'NameOfSubstance': StringElement('Olanzapine', attributes={'UI': 'D000077152'})}, {'RegistryNumber': '7W2581Z5L8', 'NameOfSubstance': StringElement('3-carboxamido-4-hydroxynaltrexone', attributes={'UI': 'C000606131'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Narcotic Antagonists', attributes={'UI': 'D009292'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Analgesics, Opioid', attributes={'UI': 'D000701'})}, {'RegistryNumber': '5S6W795CQM', 'NameOfSubstance': StringElement('Naltrexone', attributes={'UI': 'D009271'})}, {'RegistryNumber': '40D3SCR4GZ', 'NameOfSubstance': StringElement('Buprenorphine', attributes={'UI': 'D002047'})}, {'RegistryNumber': '8GTS82S83M', 'NameOfSubstance': StringElement('Diphenhydramine', attributes={'UI': 'D004155'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Female', attributes={'UI': 'D005260', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Animals', attributes={'UI': 'D000818', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Cattle', attributes={'UI': 'D002417', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Adult', attributes={'UI': 'D000328', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Olanzapine', attributes={'UI': 'D000077152', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Narcotic Antagonists', attributes={'UI': 'D009292', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Analgesics, Opioid', attributes={'UI': 'D000701', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('analogs & derivatives', attributes={'UI': 'Q000031', 'MajorTopicYN': 'Y'})], 'DescriptorName': StringElement('Naltrexone', attributes={'UI': 'D009271', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Buprenorphine', attributes={'UI': 'D002047', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'}), StringElement('etiology', attributes={'UI': 'Q000209', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Substance Withdrawal Syndrome', attributes={'UI': 'D013375', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Diphenhydramine', attributes={'UI': 'D004155', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Opioid-Related Disorders', attributes={'UI': 'D009293', 'MajorTopicYN': 'Y'})}], 'CoiStatement': 'Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2024', 'Month': '1', 'Day': '13'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '13'}, attributes={'PubStatus': 'revised'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '20'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '16', 'Hour': '12', 'Minute': '44'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '1', 'Hour': '0', 'Minute': '42'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '31', 'Hour': '21', 'Minute': '56'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38556414', attributes={'IdType': 'pubmed'}), StringElement('10.1016/j.ajem.2024.03.027', attributes={'IdType': 'doi'}), StringElement('S0735-6757(24)00139-6', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Airway hyperreactivity', attributes={'MajorTopicYN': 'N'}), StringElement('Asthma', attributes={'MajorTopicYN': 'N'}), StringElement('COPD', attributes={'MajorTopicYN': 'N'}), StringElement('Lipopolysaccharide', attributes={'MajorTopicYN': 'N'}), StringElement('Mitochondria', attributes={'MajorTopicYN': 'N'}), StringElement('Ovalbumin', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38555460', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '01'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '02'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '30'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('146', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1186/s12931-024-02780-8', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1465-993X', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '25', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Mar', 'Day': '30'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Respiratory research', 'ISOAbbreviation': 'Respir Res'}, 'ArticleTitle': 'A novel quinoline with airway relaxant effects and anti-inflammatory properties.', 'Pagination': {'StartPage': '146', 'MedlinePgn': '146'}, 'Abstract': {'AbstractText': [StringElement('In chronic pulmonary diseases characterized by inflammation and airway obstruction, such as asthma and COPD, there are unmet needs for improved treatment. Quinolines is a group of small heterocyclic compounds that have a broad range of pharmacological properties. Here, we investigated the airway relaxant and anti-inflammatory properties of a novel quinoline (RCD405).', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement('The airway relaxant effect of RCD405 was examined in isolated airways from humans, dogs, rats and mice. Murine models of ovalbumin (OVA)-induced allergic asthma and LPS-induced airway inflammation were used to study the effects in vivo. RCD405 (10\\xa0mg/kg) or, for comparisons in selected studies, budesonide (3\\xa0mg/kg), were administered intratracheally 1\\xa0h prior to each challenge. Airway responsiveness was determined using methacholine provocation. Immune cell recruitment to bronchi was measured using flow cytometry and histological analyses were applied to investigate cell influx and goblet cell hyperplasia of the airways. Furthermore, production of cytokines and chemokines was measured using a multiplex immunoassay. The expression levels of asthma-related genes in murine lung tissue were determined by PCR. The involvement of NF-κB and metabolic activity was measured in the human monocytic cell line THP-1.', attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('RCD405 demonstrated a relaxant effect on carbachol precontracted airways in all four species investigated (potency ranking: human\\u2009=\\u2009rat\\u2009>\\u2009dog\\u2009=\\u2009mouse). The OVA-specific IgE and airway hyperresponsiveness (AHR) were significantly reduced by intratracheal treatment with RCD405, while no significant changes were observed for budesonide. In addition, administration of RCD405 to mice significantly decreased the expression of proinflammatory cytokines and chemokines as well as recruitment of immune cells to the lungs in both OVA- and LPS-induced airway inflammation, with a similar effect as for budesonide (in the OVA-model). However, the effect on gene expression of Il-4, IL-5 and Il-13 was more pronounced for RCD405 as compared to budesonide. Finally, in vitro, RCD405 reduced the LPS-induced NF-κB activation and by itself reduced cellular metabolism.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('RCD405 has airway relaxant effects, and it reduces AHR as well as airway inflammation in the models used, suggesting that it could be a clinically relevant compound to treat inflammatory airway diseases. Possible targets of this compound are complexes of mitochondrial oxidative phosphorylation, resulting in decreased metabolic activity of targeted cells as well as through pathways associated to NF-κB. However, further studies are needed to elucidate the mode of action.', attributes={'Label': 'CONCLUSIONS', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': '© 2024. The Author(s).'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Clinical Sciences Lund, Respiratory Medicine, Allergology, & Palliative Medicine, Lund University and Skåne University Hospital, Lund, Sweden.'}], 'Identifier': [], 'LastName': 'Bergwik', 'ForeName': 'Jesper', 'Initials': 'J'}, attributes={'ValidYN': 'Y', 'EqualContrib': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Experimental Asthma and Allergy Research Unit, Institute of Environmental Medicine (IMM), Karolinska Institutet, Biomedicum, Solnavägen 9, 171 65, Stockholm, Sweden.'}], 'Identifier': [], 'LastName': 'Liu', 'ForeName': 'Jielu', 'Initials': 'J'}, attributes={'ValidYN': 'Y', 'EqualContrib': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Clinical Sciences Lund, Respiratory Medicine, Allergology, & Palliative Medicine, Lund University and Skåne University Hospital, Lund, Sweden.'}], 'Identifier': [], 'LastName': 'Padra', 'ForeName': 'Médea', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Clinical Sciences Lund, Respiratory Medicine, Allergology, & Palliative Medicine, Lund University and Skåne University Hospital, Lund, Sweden.'}], 'Identifier': [], 'LastName': 'Bhongir', 'ForeName': 'Ravi K V', 'Initials': 'RKV'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Clinical Sciences Lund, Respiratory Medicine, Allergology, & Palliative Medicine, Lund University and Skåne University Hospital, Lund, Sweden.'}], 'Identifier': [], 'LastName': 'Tanner', 'ForeName': 'Lloyd', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Experimental Asthma and Allergy Research Unit, Institute of Environmental Medicine (IMM), Karolinska Institutet, Biomedicum, Solnavägen 9, 171 65, Stockholm, Sweden.'}], 'Identifier': [], 'LastName': 'Xiang', 'ForeName': 'Yujiao', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Arcede Pharma AB, Medicon Village, Lund, Sweden.'}], 'Identifier': [], 'LastName': 'Lundblad', 'ForeName': 'Mia', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Clinical Sciences Lund, Respiratory Medicine, Allergology, & Palliative Medicine, Lund University and Skåne University Hospital, Lund, Sweden.'}], 'Identifier': [], 'LastName': 'Egesten', 'ForeName': 'Arne', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Experimental Asthma and Allergy Research Unit, Institute of Environmental Medicine (IMM), Karolinska Institutet, Biomedicum, Solnavägen 9, 171 65, Stockholm, Sweden. Mikael.Adner@ki.se.'}], 'Identifier': [], 'LastName': 'Adner', 'ForeName': 'Mikael', 'Initials': 'M'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': '2020-011166', 'Agency': 'Vetenskapsrådet', 'Country': ''}, {'GrantID': '2019-01630', 'Agency': 'Vetenskapsrådet', 'Country': ''}, {'GrantID': '46402', 'Agency': 'The Swedish Government Funds for Clinical Research The Swedish Government Funds for Clinical Research', 'Country': ''}, {'GrantID': '20190160', 'Agency': 'Hjärt-Lungfonden', 'Country': ''}, {'GrantID': '20210297', 'Agency': 'Hjärt-Lungfonden', 'Country': ''}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic'}), 'MedlineJournalInfo': {'Country': 'England', 'MedlineTA': 'Respir Res', 'NlmUniqueID': '101090633', 'ISSNLinking': '1465-9921'}, 'ChemicalList': [{'RegistryNumber': 'E66400VT9R', 'NameOfSubstance': StringElement('quinoline', attributes={'UI': 'C037219'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('NF-kappa B', attributes={'UI': 'D016328'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Lipopolysaccharides', attributes={'UI': 'D008070'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Cytokines', attributes={'UI': 'D016207'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Quinolines', attributes={'UI': 'D011804'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Chemokines', attributes={'UI': 'D018925'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Inflammatory Agents', attributes={'UI': 'D000893'})}, {'RegistryNumber': '51333-22-3', 'NameOfSubstance': StringElement('Budesonide', attributes={'UI': 'D019819'})}, {'RegistryNumber': '9006-59-1', 'NameOfSubstance': StringElement('Ovalbumin', attributes={'UI': 'D010047'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Rats', attributes={'UI': 'D051381', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Mice', attributes={'UI': 'D051379', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Animals', attributes={'UI': 'D000818', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Dogs', attributes={'UI': 'D004285', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('chemically induced', attributes={'UI': 'Q000139', 'MajorTopicYN': 'N'}), StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Bronchial Hyperreactivity', attributes={'UI': 'D016535', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('NF-kappa B', attributes={'UI': 'D016328', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Lipopolysaccharides', attributes={'UI': 'D008070', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Bronchoalveolar Lavage Fluid', attributes={'UI': 'D001992', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Asthma', attributes={'UI': 'D001249', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Lung', attributes={'UI': 'D008168', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Cytokines', attributes={'UI': 'D016207', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Quinolines', attributes={'UI': 'D011804', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Chemokines', attributes={'UI': 'D018925', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Inflammatory Agents', attributes={'UI': 'D000893', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pathology', attributes={'UI': 'Q000473', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Inflammation', attributes={'UI': 'D007249', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Budesonide', attributes={'UI': 'D019819', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('toxicity', attributes={'UI': 'Q000633', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Ovalbumin', attributes={'UI': 'D010047', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Mice, Inbred BALB C', attributes={'UI': 'D008807', 'MajorTopicYN': 'N'})}], 'CoiStatement': 'A joint grant from VINNOVA was provided to Arcede Pharma AB and AE as mentioned above. AE has received a honorar as an advisor from Arcede Pharma AB that holds a patent for RCD405. MA has received funding from Arcede Pharma AB to conduct experiments for the study. ML is employed by Arcede Pharma AB.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Busse WW. The relationship of airway hyperresponsiveness and airway inflammation: airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest. 2010;138(2):4S–10S. doi: 10.1378/chest.10-0100.', 'ArticleIdList': [StringElement('10.1378/chest.10-0100', attributes={'IdType': 'doi'}), StringElement('PMC2914527', attributes={'IdType': 'pmc'}), StringElement('20668012', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Papi A, Brightling C, Pedersen SE, Reddel HK. Pathogenesis of asthma. Lancet. 2018;391:783–800. doi: 10.1016/S0140-6736(17)33311-1.', 'ArticleIdList': [StringElement('10.1016/S0140-6736(17)33311-1', attributes={'IdType': 'doi'}), StringElement('29273246', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Peters MC, Wenzel SE. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. Lancet. 2020;395(10221):371–383. doi: 10.1016/S0140-6736(19)33005-3.', 'ArticleIdList': [StringElement('10.1016/S0140-6736(19)33005-3', attributes={'IdType': 'doi'}), StringElement('PMC8522504', attributes={'IdType': 'pmc'}), StringElement('32007172', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Papi A, Blasi F, Canonica GW, Morandi L, Richeldi L, Rossi A. Treatment strategies for asthma: reshaping the concept of asthma management. Allergy Asthma Clin Immunol. 2020;16(1):1–11. doi: 10.1186/s13223-020-00472-8.', 'ArticleIdList': [StringElement('10.1186/s13223-020-00472-8', attributes={'IdType': 'doi'}), StringElement('PMC7491342', attributes={'IdType': 'pmc'}), StringElement('32944030', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hudey SN, Ledford DK, Cardet JC. Mechanisms of non-type 2 asthma. Curr Opin Immunol. 2020;66:123–128. doi: 10.1016/j.coi.2020.10.002.', 'ArticleIdList': [StringElement('10.1016/j.coi.2020.10.002', attributes={'IdType': 'doi'}), StringElement('PMC7852882', attributes={'IdType': 'pmc'}), StringElement('33160187', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946. doi: 10.1183/09031936.04.00014304.', 'ArticleIdList': [StringElement('10.1183/09031936.04.00014304', attributes={'IdType': 'doi'}), StringElement('15219010', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931–1940. doi: 10.1016/S0140-6736(17)31222-9.', 'ArticleIdList': [StringElement('10.1016/S0140-6736(17)31222-9', attributes={'IdType': 'doi'}), StringElement('28513453', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Barnes PJ. Inflammatory endotypes in COPD. Allergy. 2019;74(7):1249–1256. doi: 10.1111/all.13760.', 'ArticleIdList': [StringElement('10.1111/all.13760', attributes={'IdType': 'doi'}), StringElement('30834543', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kume H, Hojo M, Hashimoto N. Eosinophil Inflammation and Hyperresponsiveness in the Airways as Phenotypes of COPD, and Usefulness of Inhaled Glucocorticosteroids. Front Pharmacol. 2019;10. Available from: 10.3389/fphar.2019.00765.', 'ArticleIdList': [StringElement('10.3389/fphar.2019.00765', attributes={'IdType': 'doi'}), StringElement('PMC6676333', attributes={'IdType': 'pmc'}), StringElement('31404293', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Soler-Cataluña J, Martínez-García MÁ, Sánchez PR, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi: 10.1136/thx.2005.040527.', 'ArticleIdList': [StringElement('10.1136/thx.2005.040527', attributes={'IdType': 'doi'}), StringElement('PMC1747235', attributes={'IdType': 'pmc'}), StringElement('16055622', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mukherjee S, Pal M. Quinolines: a new hope against inflammation. Drug Discov Today. 2013;18(7):389–398. doi: 10.1016/j.drudis.2012.11.003.', 'ArticleIdList': [StringElement('10.1016/j.drudis.2012.11.003', attributes={'IdType': 'doi'}), StringElement('23159484', attributes={'IdType': 'pubmed'})]}, {'Citation': 'da Silva EBS, da Silva MAJ, de Sousa NRT, da Rocha PI, da Rocha PGM. New trends in biological activities and clinical studies of quinolinic analogues: a review. Curr Drug Targets. 2022;23(5):441–457. doi: 10.2174/1389450122666210415100151.', 'ArticleIdList': [StringElement('10.2174/1389450122666210415100151', attributes={'IdType': 'doi'}), StringElement('33858312', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tanner L, Single AB. Animal models reflecting chronic obstructive pulmonary disease and related respiratory disorders: translating pre-clinical data into clinical relevance. J Innate Immun. 2019;12(3):203–225. doi: 10.1159/000502489.', 'ArticleIdList': [StringElement('10.1159/000502489', attributes={'IdType': 'doi'}), StringElement('PMC7265725', attributes={'IdType': 'pmc'}), StringElement('31527372', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lee SY, Cho JH, Cho SS, Bae CS, Kim GY, Park DH. Establishment of a chronic obstructive pulmonary disease mouse model based on the elapsed time after LPS intranasal instillation. LAR. 2018;34(1):1–10. doi: 10.5625/lar.2018.34.1.1.', 'ArticleIdList': [StringElement('10.5625/lar.2018.34.1.1', attributes={'IdType': 'doi'}), StringElement('PMC5876158', attributes={'IdType': 'pmc'}), StringElement('29628971', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-κB: a blossoming of relevance to human pathobiology. Cell. 2017;168(1):37–57. doi: 10.1016/j.cell.2016.12.012.', 'ArticleIdList': [StringElement('10.1016/j.cell.2016.12.012', attributes={'IdType': 'doi'}), StringElement('PMC5268070', attributes={'IdType': 'pmc'}), StringElement('28086098', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Naline E, Zhang Y, Qian Y, Mairon N, Anderson GP, Grandordy B, et al. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J. 1994;7(5):914. doi: 10.1183/09031936.94.07050914.', 'ArticleIdList': [StringElement('10.1183/09031936.94.07050914', attributes={'IdType': 'doi'}), StringElement('7914176', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Adner M, Larsson B, Säfholm J, Naya I, Miller-Larsson A. Budesonide prevents cytokine-induced decrease of the relaxant responses to formoterol and terbutaline, but not to salmeterol, in mouse trachea. J Pharmacol Exp Ther. 2010;333(1):273. doi: 10.1124/jpet.109.156224.', 'ArticleIdList': [StringElement('10.1124/jpet.109.156224', attributes={'IdType': 'doi'}), StringElement('20061444', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Skogvall S, Dalence-Guzmán MF, Berglund M, Svensson K, Mesic A, Jönsson P, et al. Discovery of a potent and long-acting bronchorelaxing capsazepinoid, RESPIR 4–95. Pulm Pharmacol Ther. 2008;21(1):125–133. doi: 10.1016/j.pupt.2007.01.004.', 'ArticleIdList': [StringElement('10.1016/j.pupt.2007.01.004', attributes={'IdType': 'doi'}), StringElement('17374498', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Larsson OJ, Manson ML, Starkhammar M, Fuchs B, Adner M, KumlienGeorén S, et al. The TLR7 agonist imiquimod induces bronchodilation via a nonneuronal TLR7-independent mechanism: a possible role for quinoline in airway dilation. Am J Physiol Lung Cell Mol Physiol. 2016;310(11):L1121–L1129. doi: 10.1152/ajplung.00288.2015.', 'ArticleIdList': [StringElement('10.1152/ajplung.00288.2015', attributes={'IdType': 'doi'}), StringElement('27084847', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Deshpande DA, Wang WCH, McIlmoyle EL, Robinett KS, Schillinger RM, An SS, et al. Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction. Nat Med. 2010;16(11):1299–1304. doi: 10.1038/nm.2237.', 'ArticleIdList': [StringElement('10.1038/nm.2237', attributes={'IdType': 'doi'}), StringElement('PMC3066567', attributes={'IdType': 'pmc'}), StringElement('20972434', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tanner L, Bergwik J, Bhongir RK V, Pan L, Dong C, Wallner O, et al. Pharmacological OGG1 inhibition decreases murine allergic airway inflammation. Front Pharmacol. 2022;13. Available from: 10.3389/fphar.2022.999180.', 'ArticleIdList': [StringElement('10.3389/fphar.2022.999180', attributes={'IdType': 'doi'}), StringElement('PMC9619105', attributes={'IdType': 'pmc'}), StringElement('36324676', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Sharma P, Yi R, Nayak AP, Wang N, Tang F, Knight MJ, et al. Bitter taste receptor agonists mitigate features of allergic asthma in mice. Sci Rep. 2017;7(1):46166. doi: 10.1038/srep46166.', 'ArticleIdList': [StringElement('10.1038/srep46166', attributes={'IdType': 'doi'}), StringElement('PMC5387415', attributes={'IdType': 'pmc'}), StringElement('28397820', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Nials AT, Uddin S. Mouse models of allergic asthma: acute and chronic allergen challenge. Dis Model Mech. 2008;1(4–5):213–220. doi: 10.1242/dmm.000323.', 'ArticleIdList': [StringElement('10.1242/dmm.000323', attributes={'IdType': 'doi'}), StringElement('PMC2590830', attributes={'IdType': 'pmc'}), StringElement('19093027', attributes={'IdType': 'pubmed'})]}, {'Citation': 'McKenzie GJ, Bancroft A, Grencis RK, McKenzie ANJ. A distinct role for interleukin-13 in Th2-cell-mediated immune responses. Curr Biol. 1998;8(6):339–342. doi: 10.1016/S0960-9822(98)70134-4.', 'ArticleIdList': [StringElement('10.1016/S0960-9822(98)70134-4', attributes={'IdType': 'doi'}), StringElement('9512421', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Nakanishi A, Morita S, Iwashita H, Sagiya Y, Ashida Y, Shirafuji H, et al. Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma. Proc Natl Acad Sci U S A. 2001;98(9):5175–5180. doi: 10.1073/pnas.081510898.', 'ArticleIdList': [StringElement('10.1073/pnas.081510898', attributes={'IdType': 'doi'}), StringElement('PMC33183', attributes={'IdType': 'pmc'}), StringElement('11296262', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Xu W, Ghosh S, Comhair SAA, Asosingh K, Janocha AJ, Mavrakis DA, et al. Increased mitochondrial arginine metabolism supports bioenergetics in asthma. J Clin Invest. 2016;126(7):2465–2481. doi: 10.1172/JCI82925.', 'ArticleIdList': [StringElement('10.1172/JCI82925', attributes={'IdType': 'doi'}), StringElement('PMC4922712', attributes={'IdType': 'pmc'}), StringElement('27214549', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Asosingh K, Lauruschkat CD, Alemagno M, Frimel M, Wanner N, Weiss K, et al. Arginine metabolic control of airway inflammation. JCI Insight. 2020;5(2):e127801. doi: 10.1172/jci.insight.127801.', 'ArticleIdList': [StringElement('10.1172/jci.insight.127801', attributes={'IdType': 'doi'}), StringElement('PMC7098726', attributes={'IdType': 'pmc'}), StringElement('31996482', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Niese KA, Collier AR, Hajek AR, Cederbaum SD, O’Brien WE, Wills-Karp M, et al. Bone marrow cell derived arginase I is the major source of allergen-induced lung arginase but is not required for airway hyperresponsiveness, remodeling and lung inflammatory responses in mice. BMC Immunol. 2009;10(1):1–11. doi: 10.1186/1471-2172-10-33.', 'ArticleIdList': [StringElement('10.1186/1471-2172-10-33', attributes={'IdType': 'doi'}), StringElement('PMC2697973', attributes={'IdType': 'pmc'}), StringElement('19486531', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Barron L, Smith AM, El Kasmi KC, Qualls JE, Huang X, Cheever A, et al. Role of arginase 1 from myeloid cells in th2-dominated lung inflammation. PLoS ONE. 2013;8(4):e61961. doi: 10.1371/journal.pone.0061961.', 'ArticleIdList': [StringElement('10.1371/journal.pone.0061961', attributes={'IdType': 'doi'}), StringElement('PMC3634833', attributes={'IdType': 'pmc'}), StringElement('23637937', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cloots RHE, Sankaranarayanan S, Poynter ME, Terwindt E, van Dijk P, Lamers WH, et al. Arginase 1 deletion in myeloid cells affects the inflammatory response in allergic asthma, but not lung mechanics, in female mice. BMC Pulm Med. 2017;17(1):1–15. doi: 10.1186/s12890-017-0490-7.', 'ArticleIdList': [StringElement('10.1186/s12890-017-0490-7', attributes={'IdType': 'doi'}), StringElement('PMC5706166', attributes={'IdType': 'pmc'}), StringElement('29183288', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Boonpiyathad T, Satitsuksanoa P, Akdis M, Akdis CA. Il-10 producing T and B cells in allergy. Semin Immunol. 2019;44:101326.', 'ArticleIdList': [StringElement('31711770', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Nassef MZ, Hanke JE, Hiller K. Mitochondrial metabolism in macrophages. Am J Physiol Cell Physiol. 2021;321(6):C1070–C1081. doi: 10.1152/ajpcell.00126.2021.', 'ArticleIdList': [StringElement('10.1152/ajpcell.00126.2021', attributes={'IdType': 'doi'}), StringElement('PMC8959580', attributes={'IdType': 'pmc'}), StringElement('34705584', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pan S, Conaway S, Jr, Deshpande DA. Mitochondrial regulation of airway smooth muscle functions in health and pulmonary diseases. Arch Biochem Biophys. 2019;663:109–119. doi: 10.1016/j.abb.2019.01.002.', 'ArticleIdList': [StringElement('10.1016/j.abb.2019.01.002', attributes={'IdType': 'doi'}), StringElement('PMC6377851', attributes={'IdType': 'pmc'}), StringElement('30629957', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Shang XF, Morris-Natschke SL, Liu YQ, Li XH, Zhang JY, Lee KH. Biology of quinoline and quinazoline alkaloids. Alkaloids Chem Biol. 2022;88:1–47. doi: 10.1016/bs.alkal.2021.08.002.', 'ArticleIdList': [StringElement('10.1016/bs.alkal.2021.08.002', attributes={'IdType': 'doi'}), StringElement('35305754', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Jin HZ, Lee JH, Lee D, Lee HS, Hong YS, Kim YH, et al. Quinolone alkaloids with inhibitory activity against nuclear factor of activated T cells from the fruits of Evodia rutaecarpa. Biol Pharm Bull. 2004;27(6):926–928. doi: 10.1248/bpb.27.926.', 'ArticleIdList': [StringElement('10.1248/bpb.27.926', attributes={'IdType': 'doi'}), StringElement('15187449', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Yoon JS, Jeong EJ, Yang H, Kim SH, Sung SH, Kim YC. Inhibitory alkaloids from Dictamnus dasycarpus root barks on lipopolysaccharide-induced nitric oxide production in BV2 cells. J Enzyme Inhib Med Chem. 2012;27(4):490–494. doi: 10.3109/14756366.2011.598151.', 'ArticleIdList': [StringElement('10.3109/14756366.2011.598151', attributes={'IdType': 'doi'}), StringElement('21827366', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ratheesh M, Sindhu G, Helen A. Anti-inflammatory effect of quinoline alkaloid skimmianine isolated from Ruta graveolens L. Inflamm Res. 2013;62:367–376. doi: 10.1007/s00011-013-0588-1.', 'ArticleIdList': [StringElement('10.1007/s00011-013-0588-1', attributes={'IdType': 'doi'}), StringElement('23344232', attributes={'IdType': 'pubmed'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2023', 'Month': '10', 'Day': '23'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '17'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '1', 'Hour': '7', 'Minute': '18'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '31', 'Hour': '0', 'Minute': '42'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '30', 'Hour': '23', 'Minute': '25'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '30'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38555460', attributes={'IdType': 'pubmed'}), StringElement('PMC10981829', attributes={'IdType': 'pmc'}), StringElement('10.1186/s12931-024-02780-8', attributes={'IdType': 'doi'}), StringElement('10.1186/s12931-024-02780-8', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38547423', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '24'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '25'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '28'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1097/ACI.0000000000000981', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1473-6322', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '24', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Jun', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Current opinion in allergy and clinical immunology', 'ISOAbbreviation': 'Curr Opin Allergy Clin Immunol'}, 'ArticleTitle': 'New biologics for food allergy.', 'Pagination': {'StartPage': '147', 'EndPage': '152', 'MedlinePgn': '147-152'}, 'Abstract': {'AbstractText': [StringElement('This review aims to explore role of emerging biologics, including ligelizumab, UB-221, dupilumab, and antialarmins, in food allergy management. With a focus on recent developments, we evaluate their promise in mitigating adverse events during oral immunotherapy (OIT), reducing allergic reactions, and addressing the limitations of current therapeutic options.', attributes={'Label': 'PURPOSE OF REVIEW', 'NlmCategory': 'OBJECTIVE'}), StringElement('Antiimmunoglobulin E mAbs, exemplified by omalizumab, demonstrate efficacy in desensitization and safety improvement during multiallergen OIT. Next-generation antibodies like ligelizumab and UB-221 exhibit enhanced potency and unique mechanisms, holding promise for food allergy treatment. Dupilumab, targeting IL-4 receptor alpha, presents potential benefits in decreasing allergen-specific IgE and modifying the atopic march. Exploration of antialarmins, specifically anti-IL-33 (etokimab) and anti-TSLP (tezepelumab), reveals encouraging results, with etokimab showing early success in peanut allergy trials.', attributes={'Label': 'RECENT FINDINGS', 'NlmCategory': 'RESULTS'}), StringElement('Biologics hold promising potential for food allergy treatment. Tailoring therapeutic approaches based on shared decision-making becomes pivotal. While omalizumab remains a significant option, next-generation anti-IgE antibodies and agents targeting alarmins exhibit unique strengths. Dupilumab, despite limited success as monotherapy, shows promise as an adjunct for OIT. Careful consideration of treatment goals, patient preferences, and the evolving landscape of biologics will shape future clinical practice, offering allergists an expanded toolbox for personalized food allergy management.', attributes={'Label': 'SUMMARY', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': 'Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pathology, Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.'}], 'Identifier': [], 'LastName': 'Schuetz', 'ForeName': 'Jackson P', 'Initials': 'JP'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Anderson', 'ForeName': 'Brent', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Sindher', 'ForeName': 'Sayantani B', 'Initials': 'SB'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Print-Electronic'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'Curr Opin Allergy Clin Immunol', 'NlmUniqueID': '100936359', 'ISSNLinking': '1473-6322'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Biological Products', attributes={'UI': 'D001688'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Allergic Agents', attributes={'UI': 'D018926'})}, {'RegistryNumber': '37341-29-0', 'NameOfSubstance': StringElement('Immunoglobulin E', attributes={'UI': 'D007073'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Antibodies, Monoclonal, Humanized', attributes={'UI': 'D061067'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Antibodies, Monoclonal', attributes={'UI': 'D000911'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Allergens', attributes={'UI': 'D000485'})}, {'RegistryNumber': '2P471X1Z11', 'NameOfSubstance': StringElement('Omalizumab', attributes={'UI': 'D000069444'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('immunology', attributes={'UI': 'Q000276', 'MajorTopicYN': 'N'}), StringElement('therapy', attributes={'UI': 'Q000628', 'MajorTopicYN': 'N'}), StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Food Hypersensitivity', attributes={'UI': 'D005512', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'}), StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Biological Products', attributes={'UI': 'D001688', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('methods', attributes={'UI': 'Q000379', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Desensitization, Immunologic', attributes={'UI': 'D003888', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Animals', attributes={'UI': 'D000818', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Allergic Agents', attributes={'UI': 'D018926', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('immunology', attributes={'UI': 'Q000276', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Immunoglobulin E', attributes={'UI': 'D007073', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'}), StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Antibodies, Monoclonal, Humanized', attributes={'UI': 'D061067', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Antibodies, Monoclonal', attributes={'UI': 'D000911', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('immunology', attributes={'UI': 'Q000276', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Allergens', attributes={'UI': 'D000485', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Omalizumab', attributes={'UI': 'D000069444', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Sindher SB, Long A, Chin AR, et al. Food allergy, mechanisms, diagnosis and treatment: innovation through a multitargeted approach. Allergy 2022; 77:2937–2948.'}, {'Citation': 'Sindher SB, Fiocchi A, Zuberbier T, et al. The role of biologics in the treatment of food allergy. J Allergy Clin Immunol Pract 2023; 12:562–568.'}, {'Citation': 'Zuberbier T, Wood RA, Bindslev-Jensen C, et al. Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2022; 11:1134–1146.'}, {'Citation': 'Sindher SB, Barshow S, Tirumalasetty J, et al. The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders. J Allergy Clin Immunol 2023; 151:595–606.'}, {'Citation': 'MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol 2017; 139:873–881. e8.'}, {'Citation': 'Brandstrom J, Vetander M, Sundqvist AC, et al. Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents. Clin Exp Allergy 2019; 49:1328–1341.'}, {'Citation': \"Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. J Allergy Clin Immunol 2016; 137:1103–1110. e11.\"}, {'Citation': 'Wood R, Togias A, Sicherer S, et al. Omalizumab for the treatment of multiple food allergy (OUtMATCH). J Allergy Clin Immunol 2024; 153:AB378.'}, {'Citation': 'Wood RA, Chinthrajah RS, Eggel A, et al. The rationale for development of ligelizumab in food allergy. World Allergy Organ J 2022; 15:100690.'}, {'Citation': 'Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun 2020; 11:165.'}, {'Citation': 'Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 2014; 44:1371–1385.'}, {'Citation': 'Wedi B. Ligelizumab for the treatment of chronic spontaneous urticaria. Expert Opin Biol Ther 2020; 20:853–861.'}, {'Citation': 'Maurer M, Gimenez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med 2019; 381:1321–1332.'}, {'Citation': 'Maurer M, Gimenez-Arnau A, Bernstein JA, et al. Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: a one-year extension study. Allergy 2022; 77:2175–2184.'}, {'Citation': 'Kuo BS, Li CH, Chen JB, et al. IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms. J Clin Invest 2022; 132:e157765.'}, {'Citation': 'Spekhorst LS, van der Rijst LP, de Graaf M, et al. Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients. Allergy 2022; 78:875–878.'}, {'Citation': 'Geba GP, Li D, Xu M, et al. Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol 2023; 151:756–766.'}, {'Citation': 'Rial MJ, Barroso B, Sastre J. Dupilumab for treatment of food allergy. J Allergy Clin Immunol Pract 2019; 7:673–674.'}, {'Citation': 'Braun C, Samaan K, Graham F, et al. Delayed-type hypersensitivity gastrointestinal symptoms induced by food oral immunotherapy and efficiently treated by dupilumab: a case report. Pediatr Allergy Immunol 2023; 34:e13935.'}, {'Citation': 'Zamarro Parra MS, Petryk Petryk Y, San Roman Sirvent S, et al. Dupilumab to induce tolerance to SLIT-Melocoton(R). Eur Ann Allergy Clin Immunol 2023.'}, {'Citation': 'Chinthrajah RS, Hernandez JD, Boyd SD, et al. Molecular and cellular mechanisms of food allergy and food tolerance. J Allergy Clin Immunol 2016; 137:984–997.'}, {'Citation': 'O’Grady SM, Kita H. ATP functions as a primary alarmin in allergen-induced type 2 immunity. Am J Physiol Cell Physiol 2023; 325:C1369–C1386.'}, {'Citation': 'Yang D, Han Z, Oppenheim JJ. Alarmins and immunity. Immunol Rev 2017; 280:41–56.'}, {'Citation': 'Ukleja-Sokolowska N, Zbikowska-Gotz M, Lis K, et al. Assessment of TSLP, IL 25 and IL 33 in patients with shrimp allergy. Allergy Asthma Clin Immunol 2021; 17:76.'}, {'Citation': 'Dwyer GK, D’Cruz LM, Turnquist HR. Emerging functions of IL-33 in homeostasis and immunity. Annu Rev Immunol 2022; 40:15–43.'}, {'Citation': 'Tordesillas L, Goswami R, Benede S, et al. Skin exposure promotes a Th2-dependent sensitization to peanut allergens. J Clin Invest 2014; 124:4965–4975.'}, {'Citation': 'Chinthrajah S, Cao S, Liu C, et al. Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy. JCI Insight 2019; 4:131347.'}, {'Citation': 'Humphreys NE, Xu D, Hepworth MR, et al. a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 2008; 180:2443–2449.'}, {'Citation': 'Brandt EB, Ruff BP, Filuta AL, et al. Thymic stromal lymphopoietin rather than IL-33 drives food allergy after epicutaneous sensitization to food allergen. J Allergy Clin Immunol 2023; 151:1660–1666. e4.'}, {'Citation': 'Cianferoni A, Spergel J. The importance of TSLP in allergic disease and its role as a potential therapeutic target. Expert Rev Clin Immunol 2014; 10:1463–1474.'}, {'Citation': 'Pavord ID, Hoyte FCL, Lindsley AW, et al. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR). Ann Allergy Asthma Immunol 2023; 131:587–597. e3.'}, {'Citation': 'Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med 2021; 384:1800–1809.'}, {'Citation': 'Corren J, Larson D, Altman MC, et al. Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial. J Allergy Clin Immunol 2023; 151:192–201.'}, {'Citation': 'Khodoun MV, Tomar S, Tocker JE, et al. Prevention of food allergy development and suppression of established food allergy by neutralization of thymic stromal lymphopoietin, IL-25, and IL-33. J Allergy Clin Immunol 2018; 141:171–179. e1.'}, {'Citation': 'Rizzi A, Lo Presti E, Chini R, et al. Emerging role of alarmins in food allergy: an update on pathophysiological insights, potential use as disease biomarkers, and therapeutic implications. J Clin Med 2023; 12:2699.'}, {'Citation': 'Stanbery AG, Shuchi S, Jakob von M, et al. TSLP, IL-33, and IL-25: not just for allergy and helminth infection. J Allergy Clin Immunol 2022; 150:1302–1313.'}, {'Citation': 'Han H, Thelen TD, Comeau MR, Ziegler SF. Thymic stromal lymphopoietin-mediated epicutaneous inflammation promotes acute diarrhea and anaphylaxis. J Clin Invest 2014; 124:5442–5452.'}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2024', 'Month': '4', 'Day': '24', 'Hour': '19', 'Minute': '5'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '28', 'Hour': '18', 'Minute': '44'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '28', 'Hour': '16', 'Minute': '3'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38547423', attributes={'IdType': 'pubmed'}), StringElement('10.1097/ACI.0000000000000981', attributes={'IdType': 'doi'}), StringElement('00130832-990000000-00117', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('CRSwNP', attributes={'MajorTopicYN': 'N'}), StringElement('asthma', attributes={'MajorTopicYN': 'N'}), StringElement('biological agents', attributes={'MajorTopicYN': 'N'}), StringElement('mepolizumab', attributes={'MajorTopicYN': 'N'}), StringElement('nasal polyposis', attributes={'MajorTopicYN': 'N'}), StringElement('omalizumab', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38541174', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '03', 'Day': '29'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '08'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '08'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('448', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.3390/medicina60030448', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1648-9144', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '60', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Mar', 'Day': '08'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Medicina (Kaunas, Lithuania)', 'ISOAbbreviation': 'Medicina (Kaunas)'}, 'ArticleTitle': 'The Effectiveness of Biological Agents on Chronic Rhinosinusitis with Nasal Polyposis in Patients with Comorbid Asthma: A Multicenter Real-Life Study from Türkiye.', 'Abstract': {'AbstractText': ['<i>Background and Objectives</i>: Real-life data on the efficacy of biologic agents (BAs) on asthma-comorbid CRSwNP are needed. Our primary goal is to investigate the effects of BAs on CRSwNP symptoms, as well as endoscopic and tomography scores. Our secondary goal is to show a reduction in the frequency of acute sinusitis exacerbations and the need for surgery. <i>Materials and Methods</i>: We conducted a multicenter, retrospective, real-life study. We screened the patients with asthma-comorbid CRSwNP treated with omalizumab or mepolizumab. A total of 69 patients (40 F/29 M; omalizumab n = 55, mepolizumab n = 14) were enrolled. We compared the visual analog scale (VAS), sinonasal outcome test-22 (SNOT-22), nasal congestion score (NCS), Lund-Mackay computed tomography score (LMS), and total endoscopic polyp scores (TPS) before and after BAs. We evaluated the endoscopic sinus surgery (ESS) and acute exacerbations of chronic rhinosinusitis (AECRS) frequencies separately, according to the BAs. <i>Results:</i> The overall median (min-max) age was 43 (21-69) years. The median (min-max) of biologic therapy duration was 35 (4-113) months for omalizumab and 13.5 (6-32) for mepolizumab. Significant improvements were seen in VAS, SNOT-22, and NCS with omalizumab and mepolizumab. A significant decrease was observed in TPS with omalizumab [95% CI: 0-4] (<i>p</i> < 0.001), but not with mepolizumab [95% CI: -0.5-2] (<i>p</i> = 0.335). The frequency of ESS and AECRS were significantly reduced with omalizumab [95% CI: 2-3] (<i>p</i> < 0.001) and [95% CI: 2-5] (<i>p</i> < 0.001); and mepolizumab [95% CI: 0-2] (<i>p</i> = 0.002) and [95% CI: 2-8.5] (<i>p</i> < 0.001), respectively. There was no significant difference in LMS with either of the BAs. <i>Conclusions:</i> Omalizumab and mepolizumab can provide a significant improvement in the sinonasal symptom scores. BAs are promising agents for CRSwNP patients with frequent exacerbations and multiple surgeries.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [], 'LastName': 'Demir', 'ForeName': 'Meryem', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [], 'LastName': 'Tunakan Dalgic', 'ForeName': 'Ceyda', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [], 'LastName': 'Mete Gokmen', 'ForeName': 'Emine Nihal', 'Initials': 'EN'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Radiology, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [StringElement('0000-0002-7520-760X', attributes={'Source': 'ORCID'})], 'LastName': 'Savas', 'ForeName': 'Recep', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Otorhinolaryngology, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [], 'LastName': 'Eroglu', 'ForeName': 'Suleyman', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Adana City Hospital, Adana 01230, Türkiye.'}], 'Identifier': [], 'LastName': 'Ozden', 'ForeName': 'Guzin', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, University of Health Sciences, Derince Training and Research Hospital, Kocaeli 41900, Türkiye.'}], 'Identifier': [], 'LastName': 'Orcen', 'ForeName': 'Cihan', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Erciyes University Faculty of Medicine, Kayseri 38039, Türkiye.'}], 'Identifier': [], 'LastName': 'Pacaci Cetin', 'ForeName': 'Gulden', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Erciyes University Faculty of Medicine, Kayseri 38039, Türkiye.'}], 'Identifier': [], 'LastName': 'Arslan', 'ForeName': 'Bahar', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Allergy and Immunology, Ataturk Training and Research Hospital, Katip Celebi University, Izmir 35360, Türkiye.'}], 'Identifier': [], 'LastName': 'Bilgir', 'ForeName': 'Ferda', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Ataturk City Hospital, Balikesir 10100, Türkiye.'}], 'Identifier': [], 'LastName': 'Bulut', 'ForeName': 'Gokten', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Mersin City Hospital, Mersin 33230, Türkiye.'}], 'Identifier': [], 'LastName': 'Akcam', 'ForeName': 'Nurullah Yekta', 'Initials': 'NY'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Biostatistics and Medical Informatics, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [], 'LastName': 'Ozgul', 'ForeName': 'Semiha', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Eskisehir City Hospital, Eskisehir 26080, Türkiye.'}], 'Identifier': [StringElement('0000-0002-0844-6352', attributes={'Source': 'ORCID'})], 'LastName': 'Cerci', 'ForeName': 'Pamir', 'Initials': 'P'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Cemil Tascioglu City Hospital, Istanbul 34384, Türkiye.'}], 'Identifier': [], 'LastName': 'Coskun', 'ForeName': 'Raif', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Otorhinolaryngology, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [], 'LastName': 'Gode', 'ForeName': 'Sercan', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Erciyes University Faculty of Medicine, Kayseri 38039, Türkiye.'}], 'Identifier': [], 'LastName': 'Yilmaz', 'ForeName': 'Insu', 'Initials': 'I'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [], 'LastName': 'Sin', 'ForeName': 'Aytul Zerrin', 'Initials': 'AZ'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Multicenter Study', attributes={'UI': 'D016448'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic'}), 'MedlineJournalInfo': {'Country': 'Switzerland', 'MedlineTA': 'Medicina (Kaunas)', 'NlmUniqueID': '9425208', 'ISSNLinking': '1010-660X'}, 'ChemicalList': [{'RegistryNumber': '2P471X1Z11', 'NameOfSubstance': StringElement('Omalizumab', attributes={'UI': 'D000069444'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Adult', attributes={'UI': 'D000328', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Aged', attributes={'UI': 'D000368', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Middle Aged', attributes={'UI': 'D008875', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('complications', attributes={'UI': 'Q000150', 'MajorTopicYN': 'N'}), StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Asthma', attributes={'UI': 'D001249', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Chronic Disease', attributes={'UI': 'D002908', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('complications', attributes={'UI': 'Q000150', 'MajorTopicYN': 'N'}), StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'}), StringElement('surgery', attributes={'UI': 'Q000601', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Nasal Polyps', attributes={'UI': 'D009298', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Omalizumab', attributes={'UI': 'D000069444', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Retrospective Studies', attributes={'UI': 'D012189', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Rhinosinusitis', attributes={'UI': 'D000096825', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('complications', attributes={'UI': 'Q000150', 'MajorTopicYN': 'N'}), StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Sinusitis', attributes={'UI': 'D012852', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Turkey', attributes={'UI': 'D014421', 'MajorTopicYN': 'N', 'Type': 'Geographic'})}, {'QualifierName': [], 'DescriptorName': StringElement('Male', attributes={'UI': 'D008297', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Female', attributes={'UI': 'D005260', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Young Adult', attributes={'UI': 'D055815', 'MajorTopicYN': 'N'})}], 'CoiStatement': 'The authors declare no conflicts of interest.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Curated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Fokkens W.J., Lund V.J., Hopkins C., Hellings P.W., Kern R., Reitsma S., Toppila-Salmi S., Bernal-Sprekelsen M., Mullol J., Alobid I., et al.  European Position Paper on Rhinosinusitis and Nasal Polyps 2020.  [(accessed on 1 January 2021)];Rhinology. 2020 58:1–464. doi: 10.4193/Rhin20.401. Available online:  https://www.rhinologyjournal.com.', 'ArticleIdList': [StringElement('10.4193/Rhin20.401', attributes={'IdType': 'doi'}), StringElement('32077450', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Dennis S.K., Lam K., Luong A. A Review of Classification Schemes for Chronic Rhinosinusitis with Nasal Polyposis Endotypes. Laryngoscope Investig. Otolaryngol. 2016;1:130–134.. doi: 10.1002/lio2.32.', 'ArticleIdList': [StringElement('10.1002/lio2.32', attributes={'IdType': 'doi'}), StringElement('PMC5113313', attributes={'IdType': 'pmc'}), StringElement('27917403', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kato A., Peters A.T., Stevens W.W., Schleimer R.P., Tan B.K., Kern R.C. Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches. Allergy Eur. J. Allergy Clin. Immunol. 2022;77:812–826. doi: 10.1111/all.15074.', 'ArticleIdList': [StringElement('10.1111/all.15074', attributes={'IdType': 'doi'}), StringElement('PMC9148187', attributes={'IdType': 'pmc'}), StringElement('34473358', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Orlandi R.R., Kingdom T.T., Smith T.L., Bleier B., DeConde A., Luong A.U., Poetker D.M., Soler Z., Welch K.C., Wise S.K., et al. International consensus statement on allergy and rhinology: Rhinosinusitis 2021. Int. Forum Allergy Rhinol. 2021;11:213–739. doi: 10.1002/alr.22741.', 'ArticleIdList': [StringElement('10.1002/alr.22741', attributes={'IdType': 'doi'}), StringElement('33236525', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bachert C., Bhattacharyya N., Desrosiers M., Khan A.H. Burden of disease in chronic rhinosinusitis with nasal polyps. J. Asthma Allergy. 2021;14:127–134. doi: 10.2147/JAA.S290424.', 'ArticleIdList': [StringElement('10.2147/JAA.S290424', attributes={'IdType': 'doi'}), StringElement('PMC7886239', attributes={'IdType': 'pmc'}), StringElement('33603409', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bachert C., Han J.K., Wagenmann M., Hosemann W., Lee S.E., Backer V., Mullol J., Gevaert P., Klimek L., Prokopakis E., et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J. Allergy Clin. Immunol. 2021;147:29–36. doi: 10.1016/j.jaci.2020.11.013.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2020.11.013', attributes={'IdType': 'doi'}), StringElement('33227318', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Weldring T., Smith S.M. Article Commentary: Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs) Health Serv. Insights. 2013;6:11093. doi: 10.4137/HSI.S11093.', 'ArticleIdList': [StringElement('10.4137/HSI.S11093', attributes={'IdType': 'doi'}), StringElement('PMC4089835', attributes={'IdType': 'pmc'}), StringElement('25114561', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mullol J., Azar A., Buchheit K.M., Hopkins C., Bernstein J.A. Chronic Rhinosinusitis with Nasal Polyps: Quality of Life in the Biologics Era. J. Allergy Clin. Immunol. Pract. 2022;10:1434–1453.e9. doi: 10.1016/j.jaip.2022.03.002.', 'ArticleIdList': [StringElement('10.1016/j.jaip.2022.03.002', attributes={'IdType': 'doi'}), StringElement('35306180', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Alobid I., Bernal-Sprekelsen M., Mullol J. Chronic rhinosinusitis and nasal polyps: The role of generic and specific questionnaires on assessing its impact on patient’s quality of life. Allergy Eur. J. Allergy Clin. Immunol. 2008;63:1267–1279. doi: 10.1111/j.1398-9995.2008.01828.x.', 'ArticleIdList': [StringElement('10.1111/j.1398-9995.2008.01828.x', attributes={'IdType': 'doi'}), StringElement('18782106', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Reddel H.K., Bacharier L.B., Bateman E.D., Brightling C.E., Brusselle G.G., Buhl R., Cruz A.A., Duijts L., Drazen J.M., FitzGerald J.M., et al. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Am. J. Respir. Crit. Care Med. 2022;205:17–35. doi: 10.1164/rccm.202109-2205PP.', 'ArticleIdList': [StringElement('10.1164/rccm.202109-2205PP', attributes={'IdType': 'doi'}), StringElement('PMC8865583', attributes={'IdType': 'pmc'}), StringElement('34658302', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Agache I., Song Y., Alonso-Coello P., Vogel Y., Rocha C., Solà I., Santero M., Akdis C.A., Akdis M., Canonica G.W., et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. Allergy Eur. J. Allergy Clin. Immunol. 2021;76:2337–2353. doi: 10.1111/all.14809.', 'ArticleIdList': [StringElement('10.1111/all.14809', attributes={'IdType': 'doi'}), StringElement('33683704', attributes={'IdType': 'pubmed'})]}, {'Citation': 'DeConde A.S., Soler Z.M. Chronic rhinosinusitis: Epidemiology and burden of disease. Am. J. Rhinol. Allergy. 2016;30:134–139. doi: 10.2500/ajra.2016.30.4297.', 'ArticleIdList': [StringElement('10.2500/ajra.2016.30.4297', attributes={'IdType': 'doi'}), StringElement('26980394', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Canonica G.W., Malvezzi L., Blasi F., Paggiaro P., Mantero M., Senna G., Heffler E., Bonavia M., Caiaffa P., Calabrese C., et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry. Respir. Med. 2020;166:105947. doi: 10.1016/j.rmed.2020.105947.', 'ArticleIdList': [StringElement('10.1016/j.rmed.2020.105947', attributes={'IdType': 'doi'}), StringElement('32250875', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Laidlaw T.M., Mullol J., Woessner K.M., Amin N., Mannent L.P. Chronic Rhinosinusitis with Nasal Polyps and Asthma. J. Allergy Clin. Immunol. Pract. 2021;9:1133–1141. doi: 10.1016/j.jaip.2020.09.063.', 'ArticleIdList': [StringElement('10.1016/j.jaip.2020.09.063', attributes={'IdType': 'doi'}), StringElement('33065369', attributes={'IdType': 'pubmed'})]}, {'Citation': 'DeConde A.S., Mace J.C., Levy J.M., Rudmik L., Alt J.A., Smith T.L. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127:550–555. doi: 10.1002/lary.26391.', 'ArticleIdList': [StringElement('10.1002/lary.26391', attributes={'IdType': 'doi'}), StringElement('PMC5321782', attributes={'IdType': 'pmc'}), StringElement('27859303', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bassiouni A., Wormald P. Role of frontal sinus surgery in nasal polyp recurrence. Laryngoscope. 2013;123:36–41. doi: 10.1002/lary.23610.', 'ArticleIdList': [StringElement('10.1002/lary.23610', attributes={'IdType': 'doi'}), StringElement('23070897', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Wynn R., Har-El G. Recurrence Rates after Endoscopic Sinus Surgery for Massive Sinus Polyposis. Laryngoscope. 2004;114:811–813. doi: 10.1097/00005537-200405000-00004.', 'ArticleIdList': [StringElement('10.1097/00005537-200405000-00004', attributes={'IdType': 'doi'}), StringElement('15126735', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ren L., Zhang N., Zhang L., Bachert C. Biologics for the treatment of chronic rhinosinusitis with nasal polyps—State of the art. World Allergy Organ. J. 2019;12:100050. doi: 10.1016/j.waojou.2019.100050.', 'ArticleIdList': [StringElement('10.1016/j.waojou.2019.100050', attributes={'IdType': 'doi'}), StringElement('PMC6700446', attributes={'IdType': 'pmc'}), StringElement('31452831', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Morse J.C., Miller C., Senior B. Management of chronic rhinosinusitis with nasal polyposis in the era of biologics. J. Asthma Allergy. 2021;14:873–882. doi: 10.2147/JAA.S258438.', 'ArticleIdList': [StringElement('10.2147/JAA.S258438', attributes={'IdType': 'doi'}), StringElement('PMC8285230', attributes={'IdType': 'pmc'}), StringElement('34285514', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cergan R., Berghi O.N., Dumitru M., Vrinceanu D., Manole F., Serboiu C.S. Biologics for Chronic Rhinosinusitis—A Modern Option for Therapy. Life. 2023;13:2165. doi: 10.3390/life13112165.', 'ArticleIdList': [StringElement('10.3390/life13112165', attributes={'IdType': 'doi'}), StringElement('PMC10672088', attributes={'IdType': 'pmc'}), StringElement('38004305', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gregurić T., Trkulja V., Baudoin T., Grgić M., Šmigovec I., Kalogera L. Differences in the sino-nasal outcome test 22 and visual analog scale symptom scores in chronic rhinosinusitis with and without nasal polyps. Am. J. Rhinol. Allergy. 2016;30:107–112. doi: 10.2500/ajra.2016.30.4274.', 'ArticleIdList': [StringElement('10.2500/ajra.2016.30.4274', attributes={'IdType': 'doi'}), StringElement('26980391', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gevaert P., Omachi T.A., Corren J., Mullol J., Han J., Lee S.E., Kaufman D., Ligueros-Saylan M., Howard M., Zhu R., et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J. Allergy Clin. Immunol. 2020;146:595–605. doi: 10.1016/j.jaci.2020.05.032.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2020.05.032', attributes={'IdType': 'doi'}), StringElement('32524991', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cakir Cetin A., Kumus O., Keskinoglu P., Sutay S., Ecevit M.C. Turkish validation of the Sino-Nasal Outcome Test-22. Clin. Otolaryngol. 2019;44:557–564. doi: 10.1111/coa.13332.', 'ArticleIdList': [StringElement('10.1111/coa.13332', attributes={'IdType': 'doi'}), StringElement('30891883', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gevaert P., Calus L., Van Zele T., Blomme K., De Ruyck N., Bauters W., Hellings P., Brusselle G., De Bacquer D., van Cauwenberge P., et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J. Allergy Clin. Immunol. 2013;131:110–116.e1. doi: 10.1016/j.jaci.2012.07.047.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2012.07.047', attributes={'IdType': 'doi'}), StringElement('23021878', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lund V.J., Mackay I.S. Staging in Rhinosinusitis.  [(accessed on 1 January 2021)];Rhinology. 1993 31:183–184. Available online:  https://www.researchgate.net/publication/15059640.', 'ArticleIdList': [StringElement('8140385', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Nonparametric Statistical Tests. Biostatistics for Biomedical Research.  [(accessed on 1 January 2021)].  Available online:  https://hbiostat.org/bbr/nonpar.'}, {'Citation': 'Gisondi P., Bellinato F., Girolomoni G. Skin adverse reactions to Sars-CoV-2 vaccination: A relevant responsibility issue for dermatologists. J. Eur. Acad. Dermatol. Venereol. 2022;36:165–166. doi: 10.1111/jdv.17854.', 'ArticleIdList': [StringElement('10.1111/jdv.17854', attributes={'IdType': 'doi'}), StringElement('35037307', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mümmler C., Dünzelmann K., Kneidinger N., Barnikel M., Munker D., Gröger M., Canis M., Behr J., Koch A., Haubner F., et al. Real-life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP. Clin. Transl. Allergy. 2021;11:e12049. doi: 10.1002/clt2.12049.', 'ArticleIdList': [StringElement('10.1002/clt2.12049', attributes={'IdType': 'doi'}), StringElement('PMC8322752', attributes={'IdType': 'pmc'}), StringElement('34331521', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bachert C., Han J.K., Desrosiers M., Hellings P.W., Amin N., Lee S.E., Mullol J., Greos L.S., Bosso J.V., Laidlaw T.M., et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638–1650. doi: 10.1016/S0140-6736(19)31881-1.', 'ArticleIdList': [StringElement('10.1016/S0140-6736(19)31881-1', attributes={'IdType': 'doi'}), StringElement('31543428', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bachert C., Han J.K., Desrosiers M.Y., Gevaert P., Heffler E., Hopkins C., Tversky J.R., Barker P., Cohen D., Emson C., et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2022;149:1309–1317.e12. doi: 10.1016/j.jaci.2021.08.030.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2021.08.030', attributes={'IdType': 'doi'}), StringElement('34599979', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Han J.K., Bachert C., Fokkens W., Desrosiers M., Wagenmann M., Lee S.E., Smith S.G., Martin N., Mayer B., Yancey S.W., et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 2021;9:1141–1153. doi: 10.1016/S2213-2600(21)00097-7.', 'ArticleIdList': [StringElement('10.1016/S2213-2600(21)00097-7', attributes={'IdType': 'doi'}), StringElement('33872587', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Schalek P., Hart L., Fuksa J., Guha A. Quality of life in CRSwNP: Evaluation of ACCESS and Lund–Mackay computed tomography scores versus the QoL questionnaire. Eur. Arch. Oto-Rhino-Laryngol. 2022;279:5721–5725. doi: 10.1007/s00405-022-07494-5.', 'ArticleIdList': [StringElement('10.1007/s00405-022-07494-5', attributes={'IdType': 'doi'}), StringElement('35717639', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Luong A.U., Chua A., Alim B.M., Olsson P., Javer A. Allergic Fungal Rhinosinusitis: The Role and Expectations of Biologics. J. Allergy Clin. Immunol. Pract. 2022;10:3156–3162. doi: 10.1016/j.jaip.2022.08.021.', 'ArticleIdList': [StringElement('10.1016/j.jaip.2022.08.021', attributes={'IdType': 'doi'}), StringElement('36028212', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Karp J., Dhillon I., Panchmatia R., Javer A. Subcutaneous Mepolizumab Injection: An Adjunctive Treatment for Recalcitrant Allergic Fungal Rhinosinusitis Patients with Asthma. Am. J. Rhinol. Allergy. 2021;35:256–263. doi: 10.1177/1945892420951486.', 'ArticleIdList': [StringElement('10.1177/1945892420951486', attributes={'IdType': 'doi'}), StringElement('32819148', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bulkhi A.A., Mirza A.A., Aburiziza A.J., Marglani O.A. Dupilumab: An emerging therapy in allergic fungal rhinosinusitis. World Allergy Organ. J. 2022;15:100638. doi: 10.1016/j.waojou.2022.100638.', 'ArticleIdList': [StringElement('10.1016/j.waojou.2022.100638', attributes={'IdType': 'doi'}), StringElement('PMC9023893', attributes={'IdType': 'pmc'}), StringElement('35497650', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gan E.C., Habib A.-R.R., Rajwani A., Javer A.R. Omalizumab therapy for refractory allergic fungal rhinosinusitis patients with moderate or severe asthma. Am. J. Otolaryngol. 2015;36:672–677. doi: 10.1016/j.amjoto.2015.05.008.', 'ArticleIdList': [StringElement('10.1016/j.amjoto.2015.05.008', attributes={'IdType': 'doi'}), StringElement('26117492', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pitlick M.M., Pongdee T. Combining Biologics Targeting Eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in Allergic and Inflammatory Diseases. World Allergy Organ. J. 2022;15:100707. doi: 10.1016/j.waojou.2022.100707.', 'ArticleIdList': [StringElement('10.1016/j.waojou.2022.100707', attributes={'IdType': 'doi'}), StringElement('PMC9574495', attributes={'IdType': 'pmc'}), StringElement('36267353', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Klain A., Indolfi C., Dinardo G., Licari A., Cardinale F., Caffarelli C., Manti S., Ricci G., Pingitore G., Tosca M., et al. United airway disease. Acta Biomed. 2021;92:e2021526. doi: 10.23750/abm.v92is7.12399.', 'ArticleIdList': [StringElement('10.23750/abm.v92is7.12399', attributes={'IdType': 'doi'}), StringElement('PMC9431894', attributes={'IdType': 'pmc'}), StringElement('34842594', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Berghi O.N., Vrinceanu D., Cergan R., Dumitru M., Costache A. Solanum melongena allergy (A comprehensive review) Exp. Ther. Med. 2021;22:1061. doi: 10.3892/etm.2021.10495.', 'ArticleIdList': [StringElement('10.3892/etm.2021.10495', attributes={'IdType': 'doi'}), StringElement('PMC8353643', attributes={'IdType': 'pmc'}), StringElement('34434275', attributes={'IdType': 'pubmed'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2024', 'Month': '2', 'Day': '9'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '1'}, attributes={'PubStatus': 'revised'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '5'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '29', 'Hour': '6', 'Minute': '46'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '28', 'Hour': '6', 'Minute': '46'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '28', 'Hour': '1', 'Minute': '11'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '8'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38541174', attributes={'IdType': 'pubmed'}), StringElement('PMC10972277', attributes={'IdType': 'pmc'}), StringElement('10.3390/medicina60030448', attributes={'IdType': 'doi'}), StringElement('medicina60030448', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('COPD', attributes={'MajorTopicYN': 'N'}), StringElement('benralizumab', attributes={'MajorTopicYN': 'N'}), StringElement('biological therapy', attributes={'MajorTopicYN': 'N'}), StringElement('endotypes', attributes={'MajorTopicYN': 'N'}), StringElement('phenotype', attributes={'MajorTopicYN': 'N'}), StringElement('severe eosinophilic asthma', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38541113', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '03', 'Day': '29'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '02'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '02', 'Day': '25'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('387', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.3390/medicina60030387', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1648-9144', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '60', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Feb', 'Day': '25'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Medicina (Kaunas, Lithuania)', 'ISOAbbreviation': 'Medicina (Kaunas)'}, 'ArticleTitle': 'Severe Asthma or Chronic Obstructive Pulmonary Disease with Eosinophilic Inflammation? From Uncertainty to Remission under Anti IL-5R Therapy.', 'Abstract': {'AbstractText': [\"<i>Background and Objectives</i>: Severe adult-onset eosinophilic asthma and COPD with eosinophilic inflammation are two entities with a similar clinical course and are sometimes difficult to differentiate in clinical practice, especially in patients with a history of smoking. Anti-IL-5 or -IL-5R biological therapy has been shown to be highly effective in severe eosinophilic asthma but has not demonstrated significant benefit in patients with COPD with the eosinophilic phenotype. Our aim was to illustrate this issue in the form of a case report. <i>Materials and Methods</i>: We present the case of a 67-year-old patient who is a former smoker with late-onset severe uncontrolled asthma (ACT score < 15) who experienced frequent exacerbations requiring treatment with systemic corticosteroids. The patient's lung function gradually worsened to a nadir FEV1 = 18%, despite a high dose of ICS in combination with a LABA and intermittent courses of OCS, with negative allergic skin-tests, but with high blood eosinophils level. Biological treatment with an anti-IL5R monoclonal antibody (benralizumab) was initiated, despite the difficulty in the differential diagnosis between asthma and COPD with eosinophilic inflammation. <i>Results</i>: The patient's evolution was favorable; clinical remission was effectively achieved with significant improvement in lung function (FEV1 > 100%), but with persistence of residual mild fixed airway obstructive dysfunction (FEV1/FVC < 0.7). The therapeutic response has been maintained to date. <i>Conclusions</i>: Benralizumab was shown to be very effective in a patient with late-onset severe eosinophilic asthma presenting features of chronic obstructive disease-habitual exposure to tobacco and inhaled noxious substances, and persistent airflow limitation on spirometry.\"]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Department, Infectious Diseases and Pulmonology Hospital \"Victor Babes\" Timisoara, 300310 Timisoara, Romania.'}], 'Identifier': [], 'LastName': 'Oprescu', 'ForeName': 'Bianca', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Department, Infectious Diseases and Pulmonology Hospital \"Victor Babes\" Timisoara, 300310 Timisoara, Romania.'}], 'Identifier': [], 'LastName': 'Raduna', 'ForeName': 'Oana', 'Initials': 'O'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Department, Infectious Diseases and Pulmonology Hospital \"Victor Babes\" Timisoara, 300310 Timisoara, Romania.'}, {'Identifier': [], 'Affiliation': 'Center for Research and Innovation in Precision Medicine of Respiratory Diseases, Department of Pulmonology, \"Victor Babes\" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.'}], 'Identifier': [StringElement('0000-0001-8897-8342', attributes={'Source': 'ORCID'})], 'LastName': 'Mihaicuta', 'ForeName': 'Stefan', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Department, Infectious Diseases and Pulmonology Hospital \"Victor Babes\" Timisoara, 300310 Timisoara, Romania.'}, {'Identifier': [], 'Affiliation': 'Center for Research and Innovation in Precision Medicine of Respiratory Diseases, Department of Pulmonology, \"Victor Babes\" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.'}], 'Identifier': [StringElement('0000-0002-7469-6755', attributes={'Source': 'ORCID'})], 'LastName': 'Frent', 'ForeName': 'Stefan', 'Initials': 'S'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Case Reports', attributes={'UI': 'D002363'})]}, attributes={'PubModel': 'Electronic'}), 'MedlineJournalInfo': {'Country': 'Switzerland', 'MedlineTA': 'Medicina (Kaunas)', 'NlmUniqueID': '9425208', 'ISSNLinking': '1010-660X'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Asthmatic Agents', attributes={'UI': 'D018927'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Aged', attributes={'UI': 'D000368', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'}), StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Asthmatic Agents', attributes={'UI': 'D018927', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('complications', attributes={'UI': 'Q000150', 'MajorTopicYN': 'N'}), StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Asthma', attributes={'UI': 'D001249', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Chronic Disease', attributes={'UI': 'D002908', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('complications', attributes={'UI': 'Q000150', 'MajorTopicYN': 'N'}), StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Eosinophilia', attributes={'UI': 'D004802', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Eosinophils', attributes={'UI': 'D004804', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Inflammation', attributes={'UI': 'D007249', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('complications', attributes={'UI': 'Q000150', 'MajorTopicYN': 'N'}), StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Pulmonary Disease, Chronic Obstructive', attributes={'UI': 'D029424', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Uncertainty', attributes={'UI': 'D035501', 'MajorTopicYN': 'N'})}], 'CoiStatement': 'The authors declare no conflicts of interest.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Curated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Carr T.F., Zeki A.A., Kraft M. Eosinophilic and Noneosinophilic Asthma. Am. J. Respir. Crit. Care Med. 2018;197:22–37. doi: 10.1164/rccm.201611-2232PP.', 'ArticleIdList': [StringElement('10.1164/rccm.201611-2232PP', attributes={'IdType': 'doi'}), StringElement('PMC5765385', attributes={'IdType': 'pmc'}), StringElement('28910134', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Dharmage S.C., Perret J.L., Custovic A. Epidemiology of Asthma in Children and Adults. Front. Pediatr. 2019;7:246. doi: 10.3389/fped.2019.00246.', 'ArticleIdList': [StringElement('10.3389/fped.2019.00246', attributes={'IdType': 'doi'}), StringElement('PMC6591438', attributes={'IdType': 'pmc'}), StringElement('31275909', attributes={'IdType': 'pubmed'})]}, {'Citation': 'To T., Stanojevic S., Moores G., Gershon A.S., Bateman E.D., Cruz A.A., Boulet L.-P. Global asthma prevalence in adults: Findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204. doi: 10.1186/s12889-021-11859-6. Erratum in BMC Public Health 2021, 21, 1809.', 'ArticleIdList': [StringElement('10.1186/s12889-021-11859-6', attributes={'IdType': 'doi'}), StringElement('PMC3353191', attributes={'IdType': 'pmc'}), StringElement('22429515', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Larsson K., Ställberg B., Lisspers K., Telg G., Johansson G., Thuresson M., Janson C. Prevalence and management of severe asthma in primary care: An observational cohort study in Sweden (PACEHR) Respir. Res. 2018;19:12. doi: 10.1186/s12931-018-0719-x.', 'ArticleIdList': [StringElement('10.1186/s12931-018-0719-x', attributes={'IdType': 'doi'}), StringElement('PMC5774144', attributes={'IdType': 'pmc'}), StringElement('29347939', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tsurumaki H., Matsuyama T., Ezawa K., Koga Y., Yatomi M., Aoki-Saito H., Chikamatsu K., Hisada T. Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis. Medicina. 2019;55:336. doi: 10.3390/medicina55070336.', 'ArticleIdList': [StringElement('10.3390/medicina55070336', attributes={'IdType': 'doi'}), StringElement('PMC6681373', attributes={'IdType': 'pmc'}), StringElement('31277327', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chung K.F., Wenzel S.E., Brozek J.L., Bush A., Castro M., Sterk P.J., Adcock I.M., Bateman E.D., Bel E.H., Bleecker E.R., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 2014;43:343–373. doi: 10.1183/09031936.00202013.', 'ArticleIdList': [StringElement('10.1183/09031936.00202013', attributes={'IdType': 'doi'}), StringElement('24337046', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ricciardolo FL M., Guida G., Bertolini F., Di Stefano A., Carriero V. Phenotype overlap in the natural history of asthma. Eur. Respir. Rev. 2023;32:220201. doi: 10.1183/16000617.0201-2022.', 'ArticleIdList': [StringElement('10.1183/16000617.0201-2022', attributes={'IdType': 'doi'}), StringElement('PMC10189644', attributes={'IdType': 'pmc'}), StringElement('37197769', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Oishi K., Matsunaga K., Shirai T., Hirai K., Gon Y. Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease. J. Clin. Med. 2020;9:2670. doi: 10.3390/jcm9082670.', 'ArticleIdList': [StringElement('10.3390/jcm9082670', attributes={'IdType': 'doi'}), StringElement('PMC7464674', attributes={'IdType': 'pmc'}), StringElement('32824775', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Papi A., Brightling C., Pedersen S.E., Reddel H.K. Asthma. Lancet. 2018;391:783–800. doi: 10.1016/S0140-6736(17)33311-1.', 'ArticleIdList': [StringElement('10.1016/S0140-6736(17)33311-1', attributes={'IdType': 'doi'}), StringElement('29273246', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Laviolette M., Gossage D.L., Gauvreau G., Leigh R., Olivenstein R., Katial R., Busse W.W., Wenzel S., Wu Y., Datta V., et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J. Allergy Clin. Immunol. 2013;132:1086–1096.e5. doi: 10.1016/j.jaci.2013.05.020.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2013.05.020', attributes={'IdType': 'doi'}), StringElement('PMC4172321', attributes={'IdType': 'pmc'}), StringElement('23866823', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kopp M.V. Omalizumab: Anti-IgE Therapy in Allergy. Curr. Allergy Asthma Rep. 2011;11:101–106. doi: 10.1007/s11882-010-0173-4.', 'ArticleIdList': [StringElement('10.1007/s11882-010-0173-4', attributes={'IdType': 'doi'}), StringElement('21243454', attributes={'IdType': 'pubmed'})]}, {'Citation': 'D’Ippolito D., Pisano M. Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis. Pharm. Ther. 2018;43:532–535.', 'ArticleIdList': [StringElement('PMC6110636', attributes={'IdType': 'pmc'}), StringElement('30186024', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Marone G., Spadaro G., Braile M., Poto R., Criscuolo G., Pahima H., Loffredo S., Levi-Schaffer F., Varricchi G. Tezepelumab: A novel biological therapy for the treatment of severe uncontrolled asthma. Expert Opin. Investig. Drugs. 2019;28:931–940. doi: 10.1080/13543784.2019.1672657.', 'ArticleIdList': [StringElement('10.1080/13543784.2019.1672657', attributes={'IdType': 'doi'}), StringElement('31549891', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pelaia C., Calabrese C., Vatrella A., Busceti M.T., Garofalo E., Lombardo N., Terracciano R., Pelaia G. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. BioMed Res. Int. 2018;2018:4839230. doi: 10.1155/2018/4839230.', 'ArticleIdList': [StringElement('10.1155/2018/4839230', attributes={'IdType': 'doi'}), StringElement('PMC5971345', attributes={'IdType': 'pmc'}), StringElement('29862274', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients (METREX). Identifier: NCT02105948.  [(accessed on 30 January 2024)];2017  Available online:  https://clinicaltrials.gov/study/NCT02105948.'}, {'Citation': 'Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD) (METREO). Identifier: NCT02105961.  [(accessed on 30 January 2024)];2017  Available online:  https://clinicaltrials.gov/study/NCT02105961.'}, {'Citation': 'Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (GALATHEA). Identifier: NCT02138916.  [(accessed on 30 January 2024)];2019  Available online:  https://clinicaltrials.gov/study/NCT02138916.'}, {'Citation': 'FitzGerald J.M., Bleecker E.R., Nair P., Korn S., Ohta K., Lommatzsch M., Ferguson G.T., Busse W.W., Barker P., Sproule S., et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141. doi: 10.1016/S0140-6736(16)31322-8.', 'ArticleIdList': [StringElement('10.1016/S0140-6736(16)31322-8', attributes={'IdType': 'doi'}), StringElement('27609406', attributes={'IdType': 'pubmed'})]}, {'Citation': 'A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA (BORA). Identifier: NCT02258542.  [(accessed on 30 January 2024)];2019  Available online:  https://clinicaltrials.gov/study/NCT02258542.'}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2024', 'Month': '1', 'Day': '31'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '2', 'Day': '18'}, attributes={'PubStatus': 'revised'}), DictElement({'Year': '2024', 'Month': '2', 'Day': '23'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '29', 'Hour': '6', 'Minute': '45'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '28', 'Hour': '6', 'Minute': '45'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '28', 'Hour': '1', 'Minute': '11'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '2', 'Day': '25'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38541113', attributes={'IdType': 'pubmed'}), StringElement('PMC10972318', attributes={'IdType': 'pmc'}), StringElement('10.3390/medicina60030387', attributes={'IdType': 'doi'}), StringElement('medicina60030387', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('anaphylaxis', attributes={'MajorTopicYN': 'N'}), StringElement('children', attributes={'MajorTopicYN': 'N'}), StringElement('drug', attributes={'MajorTopicYN': 'N'}), StringElement('drug-induced anaphylaxis', attributes={'MajorTopicYN': 'N'}), StringElement('hypersensitivity reaction', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': [], 'GeneralNote': [], 'PMID': StringElement('38540140', attributes={'Version': '1'}), 'DateRevised': {'Year': '2024', 'Month': '03', 'Day': '30'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '02', 'Day': '27'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('527', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.3390/biomedicines12030527', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2227-9059', attributes={'IssnType': 'Print'}), 'JournalIssue': DictElement({'Volume': '12', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Feb', 'Day': '27'}}, attributes={'CitedMedium': 'Print'}), 'Title': 'Biomedicines', 'ISOAbbreviation': 'Biomedicines'}, 'ArticleTitle': 'Drug-Induced Anaphylaxis in Children.', 'Abstract': {'AbstractText': ['Drug-induced anaphylaxis in children is less common than in adults and primarily involves beta-lactams and nonsteroidal anti-inflammatory drugs. Epidemiological studies show variable prevalence, influenced by age, gender, and atopic diseases. The pathophysiology includes IgE-mediated reactions and non-IgE mechanisms, like cytokine release reactions. We address drug-induced anaphylaxis in children, focusing on antibiotics, nonsteroidal anti-inflammatory drugs, neuromuscular blocking agents, and monoclonal antibodies. Diagnosis combines clinical criteria with in vitro, in vivo, and drug provocation tests. The immediate management of acute anaphylaxis primarily involves the use of adrenaline, coupled with long-term strategies, such as allergen avoidance and patient education. Desensitization protocols are crucial for children allergic to essential medications, particularly antibiotics and chemotherapy agents.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'UOC Pediatria, Azienda Ospedaliera San Camillo Forlanini, 00152 Roma, Italy.'}], 'Identifier': [], 'LastName': 'Bianchi', 'ForeName': 'Annamaria', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Translational Research in Pediatric Specialties Area, Division of Allergy, Bambino Gesù Children's Hospital, IRCCS, 00152 Roma, Italy.\"}], 'Identifier': [StringElement('0000-0003-0029-6254', attributes={'Source': 'ORCID'})], 'LastName': 'Valluzzi', 'ForeName': 'Rocco', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'UOC di Pediatria, Dipartimento Materno-Infantile, Università di Messina, 98100 Messina, Italy.'}], 'Identifier': [], 'LastName': 'Crisafulli', 'ForeName': 'Giuseppe', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'UOC di Pediatria e Neonatologia, Ospedale di Imola (BO), 40026 Imola, Italy.'}], 'Identifier': [StringElement('0000-0002-3955-1809', attributes={'Source': 'ORCID'})], 'LastName': 'Bottau', 'ForeName': 'Paolo', 'Initials': 'P'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'SC di Pediatria Fondazione IRCSS Policlinico San Matteo, 27100 Pavia, Italy.'}], 'Identifier': [], 'LastName': 'Caimmi', 'ForeName': 'Silvia', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'UOC Pediatria, Azienda Ospedaliero-Universitaria \"Ospedali Riuniti\", 60123 Ancona, Italy.'}], 'Identifier': [], 'LastName': 'Franceschini', 'ForeName': 'Fabrizio', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'UOC Pediatria, Azienda Ospedaliero-Universitaria \"Ospedali Riuniti\", 60123 Ancona, Italy.'}], 'Identifier': [], 'LastName': 'Liotti', 'ForeName': 'Lucia', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Allergy Unit, Meyer Children's Hospital IRCCS, 50132 Florence, Italy.\"}], 'Identifier': [], 'LastName': 'Mori', 'ForeName': 'Francesca', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"UOC di Pediatria Ospedale di Bolzano, Azienda Sanitaria dell'Alto Adige, 39100 Bolzano, Italy.\"}], 'Identifier': [], 'LastName': 'Riscassi', 'ForeName': 'Sara', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'SC Pediatria, Ospedale Latisana-Palmanova, Dipartimento Materno-Infantile Azienda Sanitaria, Universitaria Friuli Centrale, 33100 Udine, Italy.'}], 'Identifier': [StringElement('0000-0001-9443-5483', attributes={'Source': 'ORCID'})], 'LastName': 'Saretta', 'ForeName': 'Francesca', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinica Pediatrica, Dipartimento Medicina e Chirurgia, University of Parma, 43126 Parma, Italy.'}], 'Identifier': [], 'LastName': 'Scavone', 'ForeName': 'Sara', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinica Pediatrica, Dipartimento Medicina e Chirurgia, University of Parma, 43126 Parma, Italy.'}], 'Identifier': [StringElement('0000-0001-7710-6995', attributes={'Source': 'ORCID'})], 'LastName': 'Caffarelli', 'ForeName': 'Carlo', 'Initials': 'C'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Electronic'}), 'MedlineJournalInfo': {'Country': 'Switzerland', 'MedlineTA': 'Biomedicines', 'NlmUniqueID': '101691304', 'ISSNLinking': '2227-9059'}, 'CoiStatement': 'The authors declare no conflicts of interest.'}, attributes={'Status': 'PubMed-not-MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Muraro A., Worm M., Alviani C., Cardona V., DunnGalvin A., Garvey L.H., Riggioni C., de Silva D., Angier E., Arasi S., et al. EAACI guidelines: Anaphylaxis (2021 update) Allergy. 2022;77:357–377. doi: 10.1111/all.15032.', 'ArticleIdList': [StringElement('10.1111/all.15032', attributes={'IdType': 'doi'}), StringElement('34343358', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cardinale F., Amato A., Mastrototaro M.F., Caffarelli C., Crisafulli G., Franceschini F., Liotti L., Caimmi S., Bottau P., Saretta F., et al. Drug-induced anaphylaxis in children. Acta Biomed. 2019;90((Suppl. 3)):30–35.', 'ArticleIdList': [StringElement('PMC6502178', attributes={'IdType': 'pmc'}), StringElement('30830059', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Olabarri M., Vazquez P., Gonzalez-Posada A., Sanz N., Gonzalez-Peris S., Diez N., Vinuesa A., Martinez-Indart L., Benito J., Mintegi S. Risk Factors for Severe Anaphylaxis in Children. J. Pediatr. 2020;225:193–197. doi: 10.1016/j.jpeds.2020.06.021.', 'ArticleIdList': [StringElement('10.1016/j.jpeds.2020.06.021', attributes={'IdType': 'doi'}), StringElement('32544480', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Regateiro F.S., Marques M.L., Rebelo Gomes E. Drug-Induced Anaphylaxis: An Update on Epidemiology and Risk Factors. Int. Arch. Allergy Immunol. 2020;181:481–487. doi: 10.1159/000507445.', 'ArticleIdList': [StringElement('10.1159/000507445', attributes={'IdType': 'doi'}), StringElement('32396909', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Atanaskovic-Markovic M., Gomes E., Rodrigues Cernadas J., Du Toit G., Kidon M., Kuyucu S., Mori F., Ponvert C., Terreehorst I., Caubet J.C. Diagnosis and management of drug-induced anaphylaxis in children: An EAACI position paper. Pediatr. Allergy Immunol. 2019;30:269–276. doi: 10.1111/pai.13034.', 'ArticleIdList': [StringElement('10.1111/pai.13034', attributes={'IdType': 'doi'}), StringElement('30734362', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Muraro A., Lemanske R.F., Jr., Castells M., Torres M.J., Khan D., Simon H.U., Bindslev-Jensen C., Burks W., Poulsen L.K., Sampson H.A., et al. Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy. 2017;72:1006–1021. doi: 10.1111/all.13132.', 'ArticleIdList': [StringElement('10.1111/all.13132', attributes={'IdType': 'doi'}), StringElement('28122115', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pichler W.J. Delayed drug hypersensitivity reactions. Ann. Intern. Med. 2003;139:683–693. doi: 10.7326/0003-4819-139-8-200310210-00012.', 'ArticleIdList': [StringElement('10.7326/0003-4819-139-8-200310210-00012', attributes={'IdType': 'doi'}), StringElement('14568857', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Labella M., Garcia-Neuer M., Castells M. Application of precision medicine to the treatment of anaphylaxis. Curr. Opin. Allergy Clin. Immunol. 2018;18:190–197. doi: 10.1097/ACI.0000000000000435.', 'ArticleIdList': [StringElement('10.1097/ACI.0000000000000435', attributes={'IdType': 'doi'}), StringElement('29601357', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kumar M., Duraisamy K., Chow B.K. Unlocking the Non-IgE-Mediated Pseudo-Allergic Reaction Puzzle with Mas-Related G-Protein Coupled Receptor Member X2 (MRGPRX2) Cells. 2021;10:1033. doi: 10.3390/cells10051033.', 'ArticleIdList': [StringElement('10.3390/cells10051033', attributes={'IdType': 'doi'}), StringElement('PMC8146469', attributes={'IdType': 'pmc'}), StringElement('33925682', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kuehn H.S., Gilfillan A.M. G protein-coupled receptors and the modification of FcepsilonRI-mediated mast cell activation. Immunol. Lett. 2007;113:59–69. doi: 10.1016/j.imlet.2007.08.007.', 'ArticleIdList': [StringElement('10.1016/j.imlet.2007.08.007', attributes={'IdType': 'doi'}), StringElement('PMC2094129', attributes={'IdType': 'pmc'}), StringElement('17919738', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Caimmi S., Crisafulli G., Franceschini F., Liotti L., Bianchi A., Bottau P., Mori F., Triggiano P., Paglialunga C., Saretta F., et al. Hypersensitivity to Intravenous Iron Preparations. Children. 2022;9:1473. doi: 10.3390/children9101473.', 'ArticleIdList': [StringElement('10.3390/children9101473', attributes={'IdType': 'doi'}), StringElement('PMC9600424', attributes={'IdType': 'pmc'}), StringElement('36291409', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mori F., Saretta F., Bianchi A., Crisafulli G., Caimmi S., Liotti L., Bottau P., Franceschini F., Paglialunga C., Ricci G., et al. Hypersensitivity Reactions to monoclonal Antibodies in Children. Medicina. 2020;56:232. doi: 10.3390/medicina56050232.', 'ArticleIdList': [StringElement('10.3390/medicina56050232', attributes={'IdType': 'doi'}), StringElement('PMC7279169', attributes={'IdType': 'pmc'}), StringElement('32408641', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Shimabukuro-Vornhage A., Gödel P., Subklewe M., Stemmler H.J., Schlößer H.A., Schlaak M., Kochanek M., Böll B., von Bergwelt-Baildon M.S. Cytokine release syndrome. J. Immunother. Cancer. 2018;6:56. doi: 10.1186/s40425-018-0343-9.', 'ArticleIdList': [StringElement('10.1186/s40425-018-0343-9', attributes={'IdType': 'doi'}), StringElement('PMC6003181', attributes={'IdType': 'pmc'}), StringElement('29907163', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Doña I., Jurado-Escobar R., Perkins J.R., Ayuso P., Plaza-Serón M.C., Pérez-Sánchez N., Campo P., Bogas-Herrera G., Bartra J., Torres M.J., et al. Eicosanoid mediator profiles in different phenotypes of nonsteroidal anti-inflammatory drug-induced urticaria. Allergy. 2019;74:1135–1144. doi: 10.1111/all.13725.', 'ArticleIdList': [StringElement('10.1111/all.13725', attributes={'IdType': 'doi'}), StringElement('30667070', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Sampson H.A., Muñoz-Furlong A., Campbell R.L., Adkinson N.F., Jr., Bock S.A., Branum A., Brown S.G., Camargo C.A., Jr., Cydulka R., Galli S.J., et al. Second symposium on the definition and management of anaphylaxis: Summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J. Allergy Clin. Immunol. 2006;117:391–397. doi: 10.1016/j.jaci.2005.12.1303.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2005.12.1303', attributes={'IdType': 'doi'}), StringElement('16461139', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cardona V., Ansotegui I.J., Ebisawa M., El-Gamal Y., Fernandez Rivas M., Fineman S., Geller M., Gonzalez-Estrada A., Greenberger P.A., Sanchez Borges M., et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ. J. 2020;13:100472. doi: 10.1016/j.waojou.2020.100472.', 'ArticleIdList': [StringElement('10.1016/j.waojou.2020.100472', attributes={'IdType': 'doi'}), StringElement('PMC7607509', attributes={'IdType': 'pmc'}), StringElement('33204386', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Castells M. Diagnosis and management of anaphylaxis in precision medicine. J. Allergy Clin. Immunol. 2017;140:321–333. doi: 10.1016/j.jaci.2017.06.012.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2017.06.012', attributes={'IdType': 'doi'}), StringElement('28780940', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ring J., Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977;1:466–469. doi: 10.1016/S0140-6736(77)91953-5.', 'ArticleIdList': [StringElement('10.1016/S0140-6736(77)91953-5', attributes={'IdType': 'doi'}), StringElement('65572', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Brown S.G. Clinical features and severity grading of anaphylaxis. J. Allergy Clin. Immunol. 2004;114:371–376. doi: 10.1016/j.jaci.2004.04.029.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2004.04.029', attributes={'IdType': 'doi'}), StringElement('15316518', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Isabwe G.A.C., Garcia Neuer M., de Las Vecillas Sanchez L., Lynch D.M., Marquis K., Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes. J. Allergy Clin. Immunol. 2018;142:159–170. doi: 10.1016/j.jaci.2018.02.018.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2018.02.018', attributes={'IdType': 'doi'}), StringElement('29518427', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Xing Y., Zhang H., Sun S., Ma X., Pleasants R.A., Tang H., Zheng H., Zhai S., Wang T. Clinical features and treatment of pediatric patients with drug-induced anaphylaxis: A study based on pharmacovigilance data. Eur. J. Pediatr. 2018;177:145–154. doi: 10.1007/s00431-017-3048-z.', 'ArticleIdList': [StringElement('10.1007/s00431-017-3048-z', attributes={'IdType': 'doi'}), StringElement('PMC5748398', attributes={'IdType': 'pmc'}), StringElement('29168013', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hsin Y.C., Hsin Y.C., Huang J.L., Yeh K.W. Clinical features of adult and pediatric anaphylaxis in Taiwan. Asian Pac. J. Allergy Immunol. 2011;29:307–312.', 'ArticleIdList': [StringElement('22299309', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Jares E.J., Baena-Cagnani C.E., Sánchez-Borges M., Ensina L.F., Arias-Cruz A., Gómez M., Cuello M.N., Morfin-Maciel B.M., De Falco A., Barayazarra S., et al. Drug-induced anaphylaxis in Latin American countries. J. Allergy Clin. Immunol. Pract. 2015;3:780–788. doi: 10.1016/j.jaip.2015.05.012.', 'ArticleIdList': [StringElement('10.1016/j.jaip.2015.05.012', attributes={'IdType': 'doi'}), StringElement('26143020', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hanschmann T., Francuzik W., Dölle-Bierke S., Hofmeier K.S., Grabenhenrich L., Ruëff F., Renaudin J.M., Pföhler C., Treudler R., Bilò M.B., et al. Different phenotypes of drug-induced anaphylaxis-Data from the European Anaphylaxis Registry. Allergy. 2023;78:1615–1627. doi: 10.1111/all.15612.', 'ArticleIdList': [StringElement('10.1111/all.15612', attributes={'IdType': 'doi'}), StringElement('36479710', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gold M.S., MacDonald N.E., McMurtry C.M., Balakrishnan M.R., Heininger U., Menning L., Benes O., Pless R., Zuber P.L.F. Immunization stress-related response—Redefining immunization anxiety-related reaction as an adverse event following immunization. Vaccine. 2020;38:3015–3020. doi: 10.1016/j.vaccine.2020.02.046.', 'ArticleIdList': [StringElement('10.1016/j.vaccine.2020.02.046', attributes={'IdType': 'doi'}), StringElement('32131975', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Skowronski D.M., Strauss B., De Serres G., MacDonald D., Marion S.A., Naus M., Patrick D.M., Kendall P. Oculo-respiratory syndrome: A new influenza vaccine- associated adverse event? Clin. Infect. Dis. 2003;36:705–713. doi: 10.1086/367667.', 'ArticleIdList': [StringElement('10.1086/367667', attributes={'IdType': 'doi'}), StringElement('12627354', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gomes E.R., Brockow K., Kuyucu S., Saretta F., Mori F., Blanca-Lopez N., Ott H., Atanaskovic-Markovic M., Kidon M., Caubet J.C., et al. ENDA/EAACI Drug Allergy Interest Group. Drug hypersensitivity in children: Report from the pediatric task force of the EAACI Drug Allergy Interest Group. Allergy. 2016;71:149–161. doi: 10.1111/all.12774.', 'ArticleIdList': [StringElement('10.1111/all.12774', attributes={'IdType': 'doi'}), StringElement('26416157', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Erkoçoğlu M., Kaya A., Civelek E., Ozcan C., Cakır B., Akan A., Toyran M., Ginis T., Kocabas C.N. Prevalence of confirmed immediate type drug hypersensitivity reactions among school children. Pediatr. Allergy Immunol. 2013;24:160–167. doi: 10.1111/pai.12047.', 'ArticleIdList': [StringElement('10.1111/pai.12047', attributes={'IdType': 'doi'}), StringElement('23373964', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Brockow K., Romano A., Blanca M., Ring J., Pichler W., Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002;57:45–51. doi: 10.1046/j.0105-4538.2001.00001.x-i8.', 'ArticleIdList': [StringElement('10.1046/j.0105-4538.2001.00001.x-i8', attributes={'IdType': 'doi'}), StringElement('11991289', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Saretta F., Tomei L., Mori F., Mayorga C. In vitro diagnostic testing for drug allergy in children. Pediatr. Allergy Immunol. 2023;34:e13955. doi: 10.1111/pai.13955.', 'ArticleIdList': [StringElement('10.1111/pai.13955', attributes={'IdType': 'doi'}), StringElement('37102390', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Romano A., Atanaskovic-Markovic M., Barbaud A., Bircher A.J., Brockow K., Caubet J.C., Celik G., Cernadas J., Chiriac A.M., Demoly P., et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams—An EAACI position paper. Allergy. 2020;75:1300–1315. doi: 10.1111/all.14122.', 'ArticleIdList': [StringElement('10.1111/all.14122', attributes={'IdType': 'doi'}), StringElement('31749148', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hoffmann H.J., Santos A.F., Mayorga C., Nopp A., Eberlein B., Ferrer M., Rouzaire P., Ebo D.G., Sabato V., Sanz M.L., et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy. 2015;70:1393–1405. doi: 10.1111/all.12698.', 'ArticleIdList': [StringElement('10.1111/all.12698', attributes={'IdType': 'doi'}), StringElement('26198455', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mayorga C., Celik G., Rouzaire P., Whitaker P., Bonadonna P., Rodrigues-Cernadas J., Vultaggio A., Brockow K., Caubet J.C., Makowska J., et al. In vitro tests for Drug Allergy Task Force of EAACI Drug Interest Group. In vitro tests for Drug Allergy Task Force of EAACI Drug Interest Group. In vitro tests for drug hypersensitivity reactions: An ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2016;71:1103–1134. doi: 10.1111/all.12886.', 'ArticleIdList': [StringElement('10.1111/all.12886', attributes={'IdType': 'doi'}), StringElement('26991315', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Barbaud A., Romano A. Skin Testing Approaches for Immediate and Delayed Hypersensitivity Reactions. Immunol. Allergy Clin. N. Am. 2022;42:307–322. doi: 10.1016/j.iac.2022.01.003.', 'ArticleIdList': [StringElement('10.1016/j.iac.2022.01.003', attributes={'IdType': 'doi'}), StringElement('35469620', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Brockow K., Garvey L.H., Aberer W., Atanaskovic-Markovic M., Barbaud A., Bilo M.B., Bircher A., Blanca M., Bonadonna B., Campi P., et al. Skin test concentrations for systemically administered drugs—An ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68:702–712. doi: 10.1111/all.12142.', 'ArticleIdList': [StringElement('10.1111/all.12142', attributes={'IdType': 'doi'}), StringElement('23617635', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bruusgaard-Mouritsen M.A., Jensen B.M., Poulsen L.K., Duus Johansen J., Garvey L.H. In vitro tests for Drug Allergy Task Force of EAACI Drug Interest Group. Optimizing investigation of suspected allergy to polyethylene glycols. J. Allergy Clin. Immunol. 2022;149:168–175. doi: 10.1016/j.jaci.2021.05.020.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2021.05.020', attributes={'IdType': 'doi'}), StringElement('34052265', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Torres M.J., Romano A., Celik G., Demoly P., Khan D.A., Macy E., Park M., Blumenthal K., Aberer W., Castells M., et al. Approach to the diagnosis of drug hypersensitivity reactions: Similarities and differences between Europe and North America. Clin. Transl. Allergy. 2017;7:7. doi: 10.1186/s13601-017-0144-0.', 'ArticleIdList': [StringElement('10.1186/s13601-017-0144-0', attributes={'IdType': 'doi'}), StringElement('PMC5347172', attributes={'IdType': 'pmc'}), StringElement('28293415', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mayorga C., Ebo D.G., Lang D.M., Pichler W.J., Sabato V., Park M.A., Makowska J., Atanaskovic-Markovic M., Bonadonna P., Jares E. Controversies in drug allergy: In vitro testing. J. Allergy Clin. Immunol. 2019;143:56–65. doi: 10.1016/j.jaci.2018.09.022.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2018.09.022', attributes={'IdType': 'doi'}), StringElement('30573343', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Leysen J., Bridts C.H., De Clerck L.S., Vercauteren M., Lambert J., Weyler J.J., Stevens W.J., Ebo D.G. Allergy to rocuronium: From clinical suspicion to correct diagnosis. Allergy. 2011;66:1014–1019. doi: 10.1111/j.1398-9995.2011.02569.x.', 'ArticleIdList': [StringElement('10.1111/j.1398-9995.2011.02569.x', attributes={'IdType': 'doi'}), StringElement('21375539', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Trautmann A., Brockow K., Stoevesandt J. Metamizole-induced reactions as a paradigm of drug hypersensitivity: Non-allergic reactions, anaphylaxis, and delayed-type allergy. Clin. Exp. Allergy. 2020;50:1103–1106. doi: 10.1111/cea.13689.', 'ArticleIdList': [StringElement('10.1111/cea.13689', attributes={'IdType': 'doi'}), StringElement('32564452', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bavbek S., Pagani M., Alvarez-Cuesta E., Castells M., Dursun A.B., Hamadi S., Madrigal-Burgaleta R., Sanchez-Sanchez S., Vultaggio A. Hypersensitivity reactions to biologicals: An EAACI position paper. Allergy. 2022;77:39–54. doi: 10.1111/all.14984.', 'ArticleIdList': [StringElement('10.1111/all.14984', attributes={'IdType': 'doi'}), StringElement('34157134', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tejedor Alonso M., Moro Moro M., Múgica García M.V. Epidemiology of anaphylaxis. Clin. Exp. Allergy. 2015;45:1027–1039. doi: 10.1111/cea.12418.', 'ArticleIdList': [StringElement('10.1111/cea.12418', attributes={'IdType': 'doi'}), StringElement('25495512', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Yu J.E., Lin R.Y. The Epidemiology of Anaphylaxis. Clin. Rev. Allergy Immunol. 2018;54:366–374. doi: 10.1007/s12016-015-8503-x.', 'ArticleIdList': [StringElement('10.1007/s12016-015-8503-x', attributes={'IdType': 'doi'}), StringElement('26357949', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mullins R.J., Wainstein B.K., Barnes E.H., Liew W.K., Campbell D.E. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin. Exp. Allergy. 2016;46:1099–1110. doi: 10.1111/cea.12748.', 'ArticleIdList': [StringElement('10.1111/cea.12748', attributes={'IdType': 'doi'}), StringElement('27144664', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Jerschow E., Lin R.Y., Scaperotti M.M., McGinn A.P. Fatal anaphylaxis in the United States, 1999–2010: Temporal patterns and demographic associations. J. Allergy Clin. Immunol. 2014;134:1318–1328. doi: 10.1016/j.jaci.2014.08.018.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2014.08.018', attributes={'IdType': 'doi'}), StringElement('PMC4260987', attributes={'IdType': 'pmc'}), StringElement('25280385', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pouessel G., Tanno L.K., Claverie C., Lejeune S., Labreuche J., Dorkenoo A., Renaudin J.M., Eb M., Leteurtre S., Deschildre A. Fatal anaphylaxis in children in France: Analysis of national data. Pediatr. Allergy Immunol. 2018;29:101–104. doi: 10.1111/pai.12828.', 'ArticleIdList': [StringElement('10.1111/pai.12828', attributes={'IdType': 'doi'}), StringElement('29047172', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pouessel G., Claverie C., Labreuche J., Dorkenoo A., Renaudin J.M., Eb M., Lejeune S., Deschildre A., Leteurtre S. Fatal anaphylaxis in France: Analysis of national anaphylaxis data, 1979–2011. J. Allergy Clin. Immunol. 2017;140:610–612. doi: 10.1016/j.jaci.2017.02.014.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2017.02.014', attributes={'IdType': 'doi'}), StringElement('28283420', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tejedor-Alonso M.A., Martínez-Fernandez P., Vallejo-de-Torres G., Navarro-Escayola E., Moro-Moro M., Alberti-Masgrau N. Clinical and demographic characteristics of fatal anaphylaxis in Spain (1998–2011): A comparison between a series from the hospital system and a national forensic series. Clin. Exp. Allergy. 2019;49:82–91. doi: 10.1111/cea.13272.', 'ArticleIdList': [StringElement('10.1111/cea.13272', attributes={'IdType': 'doi'}), StringElement('30204277', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pouessel G., Alonzo S., Divaret-Chauveau A., Dumond P., Bradatan E., Liabeuf V., Beaumont P., Tscheiller S., Diesnis R., Renaudin J.M., et al. Allergy-Vigilance® Network. Fatal and near-fatal anaphylaxis: The Allergy-Vigilance® Network data (2002–2020) Allergy. 2023;78:1628–1638. doi: 10.1111/all.15645.', 'ArticleIdList': [StringElement('10.1111/all.15645', attributes={'IdType': 'doi'}), StringElement('36645170', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Wang Y., Allen K.J., Suaini N.H.A., McWilliam V., Peters R.L., Koplin J.J. The global incidence and prevalence of anaphylaxis in children in the general population: A systematic review. Allergy. 2019;74:1063–1080. doi: 10.1111/all.13732.', 'ArticleIdList': [StringElement('10.1111/all.13732', attributes={'IdType': 'doi'}), StringElement('30688375', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ramsey N.B., Guffey D., Anagnostou K., Coleman N.E., Davis C.M. Epidemiology of Anaphylaxis in Critically Ill Children in the United States and Canada. J. Allergy Clin. Immunol. Pract. 2019;7:2241–2249. doi: 10.1016/j.jaip.2019.04.025.', 'ArticleIdList': [StringElement('10.1016/j.jaip.2019.04.025', attributes={'IdType': 'doi'}), StringElement('PMC8411990', attributes={'IdType': 'pmc'}), StringElement('31051271', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Grabenhenrich L.B., Dölle S., Moneret-Vautrin A., Köhli A., Lange L., Spindler T., Ruëff F., Nemat K., Maris I., Roumpedaki E., et al. Anaphylaxis in children and adolescents: The European Anaphylaxis Registry. J. Allergy Clin. Immunol. 2016;137:1128–1137. doi: 10.1016/j.jaci.2015.11.015.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2015.11.015', attributes={'IdType': 'doi'}), StringElement('26806049', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Orhan F., Canitez Y., Bakirtas A., Yilmaz O., Boz A.B., Can D., Kuyucu S., Harmanci K., Tahan F., Reisli I., et al. Anaphylaxis in Turkish children: A multi-centre, retrospective, case study. Clin. Exp. Allergy. 2011;41:1767–1776. doi: 10.1111/j.1365-2222.2011.03859.x.', 'ArticleIdList': [StringElement('10.1111/j.1365-2222.2011.03859.x', attributes={'IdType': 'doi'}), StringElement('22092675', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Thomson H., Seith R., Craig S. Downstream consequences of diagnostic error in pediatric anaphylaxis. BMC Pediatr. 2018;18:40. doi: 10.1186/s12887-018-1024-z.', 'ArticleIdList': [StringElement('10.1186/s12887-018-1024-z', attributes={'IdType': 'doi'}), StringElement('PMC5803891', attributes={'IdType': 'pmc'}), StringElement('29415679', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Sousa-Pinto B., Fonseca J.A., Gomes E.R. Frequency of self-reported drug allergy: A systematic review and meta-analysis with meta-regression. Ann. Allergy Asthma Immunol. 2017;119:362–373. doi: 10.1016/j.anai.2017.07.009.', 'ArticleIdList': [StringElement('10.1016/j.anai.2017.07.009', attributes={'IdType': 'doi'}), StringElement('28779998', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cavkaytar O., Karaatmaca B., Cetinkaya P.G., Esenboga S., Arik Yilmaz E., Sahiner U.M., Sekerel B.E., Soyer O. Characteristics of drug-induced anaphylaxis in children and adolescents. Allergy Asthma Proc. 2017;38:56–63. doi: 10.2500/aap.2017.38.4064.', 'ArticleIdList': [StringElement('10.2500/aap.2017.38.4064', attributes={'IdType': 'doi'}), StringElement('28814352', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Topal E., Bakirtas A., Yilmaz O., Ertoy Karagol I.H., Arga M., Demirsoy M.S. Anaphylaxis in infancy compared with older children. Allergy Asthma Proc. 2013;34:233–238. doi: 10.2500/aap.2013.34.3658.', 'ArticleIdList': [StringElement('10.2500/aap.2013.34.3658', attributes={'IdType': 'doi'}), StringElement('23676572', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Muraro A., Roberts G., Clark A., Eigenmann P.A., Halken S., Lack G., Moneret-Vautrin A., Niggemann B., Rancé F., EAACI Task Force on Anaphylaxis in Children The management of anaphylaxis in childhood: Position paper of the European academy of allergology and clinical immunology. Allergy. 2007;62:857–871. doi: 10.1111/j.1398-9995.2007.01421.x.', 'ArticleIdList': [StringElement('10.1111/j.1398-9995.2007.01421.x', attributes={'IdType': 'doi'}), StringElement('17590200', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gonzalez-Perez A., Aponte Z., Vidaurre C.F., Rodriguez L.A. Anaphylaxis epidemiology in patients with and patients without asthma: A United Kingdom database review. J. Allergy Clin. Immunol. 2010;25:1098–1104. doi: 10.1016/j.jaci.2010.02.009.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2010.02.009', attributes={'IdType': 'doi'}), StringElement('20392483', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gabrielli S., Clarke A.E., Eisman H., Morris J., Joseph L., La Vieille S., Small P., Lim R., Enarson P., Zelcer M., et al. Disparities in rate, triggers, and management in pediatric and adult cases of suspected drug-induced anaphylaxis in Canada. Immun. Inflamm. Dis. 2018;6:3–12. doi: 10.1002/iid3.201.', 'ArticleIdList': [StringElement('10.1002/iid3.201', attributes={'IdType': 'doi'}), StringElement('PMC5818453', attributes={'IdType': 'pmc'}), StringElement('29094518', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Matito A., Morgado J.M., Sánchez-López P., Álvarez-Twose I., Sánchez-Muñoz L., Orfao A., Escribano L. Management of Anesthesia in Adult and Pediatric Mastocytosis: A Study of the Spanish Network on Mastocytosis (REMA) Based on 726 Anesthetic Procedures. Int. Arch. Allergy Immunol. 2015;167:47–56. doi: 10.1159/000436969.', 'ArticleIdList': [StringElement('10.1159/000436969', attributes={'IdType': 'doi'}), StringElement('26160029', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mori F., Crisafulli G., Bianchi A., Bottau P., Caimmi S., Franceschini F., Liotti L., Paglialunga C., Saretta F., Caffarelli C. Drugs and Vaccines Hypersensitivity in Children with Mastocytosis. J. Clin. Med. 2022;11:3153. doi: 10.3390/jcm11113153.', 'ArticleIdList': [StringElement('10.3390/jcm11113153', attributes={'IdType': 'doi'}), StringElement('PMC9181546', attributes={'IdType': 'pmc'}), StringElement('35683540', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cernadas J., Vasconcelos M.J., Carneiro-Leão L. Carneiro-Leão, L. Desensitization in children allergic to drugs: Indications, protocols, and limits. Pediatr. Allergy Immunol. 2023;34:e13965. doi: 10.1111/pai.13965.', 'ArticleIdList': [StringElement('10.1111/pai.13965', attributes={'IdType': 'doi'}), StringElement('37366205', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Burrows J.A., Nissen L.M., Kirkpatrick C.M., Bell S.C. Beta-lactam allergy in adults with cystic fibrosis. J. Cyst. Fibros. 2007;6:297–303. doi: 10.1016/j.jcf.2006.11.001.', 'ArticleIdList': [StringElement('10.1016/j.jcf.2006.11.001', attributes={'IdType': 'doi'}), StringElement('17182289', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Parmar J.S., Nasser S. Antibiotic allergy in cystic fibrosis. Thorax. 2005;60:517–520. doi: 10.1136/thx.2004.027953.', 'ArticleIdList': [StringElement('10.1136/thx.2004.027953', attributes={'IdType': 'doi'}), StringElement('PMC1747437', attributes={'IdType': 'pmc'}), StringElement('15923254', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Dilley M.A., Lee J.P., Platt C.D., Broyles A.D. Rituximab desensitization in pediatric patients: Results of a case series. Pediat. Allergy Immunol. Pulmonol. 2016;29:9–14. doi: 10.1089/ped.2015.0615.', 'ArticleIdList': [StringElement('10.1089/ped.2015.0615', attributes={'IdType': 'doi'}), StringElement('PMC4926203', attributes={'IdType': 'pmc'}), StringElement('27458538', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Aydogan M., Yologlu N., Gacar G., Uyan Z.S., Eser I., Karaoz E. Successful rapid rituximab desensitization in an adolescent patient with nephrotic syndrome: Increase in number of T-reg cells after desensitization. J. Allergy Clin. Immunol. 2013;132:478–480. doi: 10.1016/j.jaci.2013.02.004.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2013.02.004', attributes={'IdType': 'doi'}), StringElement('23582516', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Caimmi S.M., Caimmi D., Riscassi S., Marseglia G.L. A new pediatric protocol for rapid desensitization to monoclonal antibodies. Int. Arch. Allergy Immunol. 2014;165:214–218. doi: 10.1159/000369299.', 'ArticleIdList': [StringElement('10.1159/000369299', attributes={'IdType': 'doi'}), StringElement('25531534', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Puchner T.C., Kugathasan S., Kelly K.J., Binion D.G. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn’s disease patients with prior anaphylactic reaction. Inflamm. Bowel Dis. 2001;7:34–37. doi: 10.1097/00054725-200102000-00005.', 'ArticleIdList': [StringElement('10.1097/00054725-200102000-00005', attributes={'IdType': 'doi'}), StringElement('11233658', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Justet A., Neukirch C., Arrault X., Borie R., Dombret M.C., Crestani B. Successful rapid tocilizumab desensitization in a patient with Still disease. J. Allergy Clin. Immunol. Pract. 2014;2:631–632. doi: 10.1016/j.jaip.2014.04.015.', 'ArticleIdList': [StringElement('10.1016/j.jaip.2014.04.015', attributes={'IdType': 'doi'}), StringElement('25213064', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Castells M.C., Tennant N.M., Sloane D.E., Hsu F.I., Barrett N.A., Hong D.I., Laidlaw T.M., Legere H.J., Nallamshetty S.N., Palis R.I., et al. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. J. Allergy Clin. Immunol. 2008;122:574–580. doi: 10.1016/j.jaci.2008.02.044.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2008.02.044', attributes={'IdType': 'doi'}), StringElement('18502492', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Del Carmen Sancho M., Breslow R., Sloane D., Castells M. Desensitization for hypersensitivity reactions to medications. Chem. Immunol. Allergy. 2012;97:217–233.', 'ArticleIdList': [StringElement('22613865', attributes={'IdType': 'pubmed'})]}, {'Citation': \"Su Y., Wen J., Zhang H., Zou Z., Cai Y., Zhang C. Clinical Characteristics of Anaphylaxis in Children Aged 0–16 Years in Xi'an, China. Int. Arch. Allergy Immunol. 2023;184:220–227. doi: 10.1159/000527497.\", 'ArticleIdList': [StringElement('10.1159/000527497', attributes={'IdType': 'doi'}), StringElement('PMC10015755', attributes={'IdType': 'pmc'}), StringElement('36516810', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Blanca-Lopez N., Atanaskovic-Markovic M., Gomes E.R., Kidon M., Kuyucu S., Mori F., Soyer O., Caubet J.C. An EAACI Task Force report on allergy to beta-lactams in children: Clinical entities and diagnostic procedures. Pediatr. Allergy Immunol. 2021;32:1426–1436. doi: 10.1111/pai.13529.', 'ArticleIdList': [StringElement('10.1111/pai.13529', attributes={'IdType': 'doi'}), StringElement('33931922', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Süleyman A., Yücel E., Tamay Z.Ü., Güler N. Evaluation of Suspected Macrolide Allergies in Children. Turk. Arch. Pediatr. 2022;57:81–86. doi: 10.5152/TurkArchPediatr.2022.21223.', 'ArticleIdList': [StringElement('10.5152/TurkArchPediatr.2022.21223', attributes={'IdType': 'doi'}), StringElement('PMC8867500', attributes={'IdType': 'pmc'}), StringElement('35110083', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cavkaytar O., Arga M. NSAID Hypersensitivity in the Pediatric Population:Classification and Diagnostic Strategies. J. Asthma Allergy. 2022;15:1383–1399. doi: 10.2147/JAA.S267005.', 'ArticleIdList': [StringElement('10.2147/JAA.S267005', attributes={'IdType': 'doi'}), StringElement('PMC9527698', attributes={'IdType': 'pmc'}), StringElement('36199560', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kidon M., Blanca-Lopez N., Gomes E., Terreehorst I., Tanno L., Ponvert C., Chin C.W., Caubet J.C., Soyer O., Mori F., et al. EAACI/ENDA Position Paper: Diagnosis and management of hypersensitivity reactions to non- steroidal anti-inflammatory drugs (NSAIDs) in children and adolescents. Pediatr. Allergy Immunol. 2018;29:469–480. doi: 10.1111/pai.12915.', 'ArticleIdList': [StringElement('10.1111/pai.12915', attributes={'IdType': 'doi'}), StringElement('29693290', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kowalski M.L., Asero R., Bavbek S., Blanca M., Blanca-Lopez N., Bochenek G., Brockow K., Campo P., Celik G., Cernadas J., et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68:1219–1232. doi: 10.1111/all.12260.', 'ArticleIdList': [StringElement('10.1111/all.12260', attributes={'IdType': 'doi'}), StringElement('24117484', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Broyles A.D., Banerji A., Barmettler S., Biggs C.M., Blumenthal K., Brennan P.J., Breslow R.G., Brockow K., Buchheit K.M., Cahill K.N., et al. Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. J. Allergy Clin. Immunol. Pract. 2020;8:S16–S116. doi: 10.1016/j.jaip.2020.08.006.', 'ArticleIdList': [StringElement('10.1016/j.jaip.2020.08.006', attributes={'IdType': 'doi'}), StringElement('33039007', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Khan D.A., Banerji A., Phillips E.J., Solensky R., White A.A., Bernstein J.A., Chu D.K., Ellis A.K., Golden D.B.K., Greenhawt M.J., et al. Drug allergy: A 2022 practice parameter update. J. Allergy Clin. Immunol. 2022;150:1333–1393. doi: 10.1016/j.jaci.2022.08.028.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2022.08.028', attributes={'IdType': 'doi'}), StringElement('36122788', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cavkaytar O., Arik Yilmaz E., Karaatmaca B., Buyuktiryaki B., Sackesen C., Sekerel B.E., Soyer O. Different Phenotypes of Non-Steroidal Anti-Inflammatory Drug Hypersensitivity during Childhood. Int. Arch. Allergy Immunol. 2015;167:211–221. doi: 10.1159/000438992.', 'ArticleIdList': [StringElement('10.1159/000438992', attributes={'IdType': 'doi'}), StringElement('26315297', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cousin M., Chiriac A., Molinari N., Demoly P., Caimmi D. Phenotypical characterization of children with hypersensitivity reactions to NSAIDs. Pediatr. Allergy Immunol. 2016;27:743–748. doi: 10.1111/pai.12596.', 'ArticleIdList': [StringElement('10.1111/pai.12596', attributes={'IdType': 'doi'}), StringElement('27171669', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Yilmaz Topal O., Kulhas Celik I., Turgay Yagmur I., Toyran M., Civelek E., Karaatmaca B., Kocabas C.N., Dibek Misirlioglu E. Results of NSAID provocation tests and difficulties in the classification of children with nonsteroidal anti-inflammatory drug hypersensitivity. Ann. Allergy Asthma Immunol. 2020;125:202–207. doi: 10.1016/j.anai.2020.04.003.', 'ArticleIdList': [StringElement('10.1016/j.anai.2020.04.003', attributes={'IdType': 'doi'}), StringElement('32294526', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Caffarelli C., Franceschini F., Caimmi D., Mori F., Diaferio L., Di Mauro D., Mastrorilli C., Arasi S., Barni S., Bottau P., et al. SIAIP position paper: Provocation challenge to antibiotics and non-steroidal anti-inflammatory drugs in children. Ital. J. Pediatr. 2018;44:147. doi: 10.1186/s13052-018-0589-3.', 'ArticleIdList': [StringElement('10.1186/s13052-018-0589-3', attributes={'IdType': 'doi'}), StringElement('PMC6286516', attributes={'IdType': 'pmc'}), StringElement('30526636', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Heath J.L., Heath R.D., Tamboli C., Johnson L., Wilson A.S., Chervinskiy S., Bell M.C., Kennedy J.L. Mesalamine desensitization in a patient with treatment refractory ulcerative colitis and aspirin and nonsteroidal anti-inflammatory drug hypersensitivity. Ann. Allergy Asthma Immunol. 2017;118:518–520. doi: 10.1016/j.anai.2017.01.026.', 'ArticleIdList': [StringElement('10.1016/j.anai.2017.01.026', attributes={'IdType': 'doi'}), StringElement('28284977', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Romano A., Gaeta F., Caruso C., Fiocchi A., Valluzzi R.L. Evaluation and Updated Classification of Acute Hypersensitivity Reactions to Nonsteroidal Anti- Inflammatory Drugs (NSAIDs): NSAID-Exacerbated or -Induced Food Allergy. J. Allergy Clin. Immunol. Pract. 2023;11:1843–1853. doi: 10.1016/j.jaip.2023.03.036.', 'ArticleIdList': [StringElement('10.1016/j.jaip.2023.03.036', attributes={'IdType': 'doi'}), StringElement('36997117', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Karaatmaca B., Sahiner U.M., Sekerel B.E., Soyer O. Perioperative hypersensitivity reactions during childhood and outcomes of subsequent anesthesia. Paediatr. Anaesth. 2021;31:436–443. doi: 10.1111/pan.14126.', 'ArticleIdList': [StringElement('10.1111/pan.14126', attributes={'IdType': 'doi'}), StringElement('33423333', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Dewachter P., Mouton-Faivre C. Allergic risk during paediatric anaesthesia. Ann. Fr. Anesth. Reanim. 2010;29:215–226. doi: 10.1016/j.annfar.2009.11.014.', 'ArticleIdList': [StringElement('10.1016/j.annfar.2009.11.014', attributes={'IdType': 'doi'}), StringElement('20153947', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Karila C., Brunet-Langot D., Labbez F., Jacqmarcq O., Ponvert C., Paupe J., Scheinmann P., de Blic J. Anaphylaxis during anesthesia: Results of a 12-year survey at a French pediatric center. Allergy. 2005;60:828–834. doi: 10.1111/j.1398-9995.2005.00787.x.', 'ArticleIdList': [StringElement('10.1111/j.1398-9995.2005.00787.x', attributes={'IdType': 'doi'}), StringElement('15876315', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Harper N.J.N., Cook T.M., Garcez T., Farmer L., Floss K., Marinho S., Torevell H., Warner A., Ferguson K., Hitchman J., et al. Anaesthesia, surgery, and life-threatening allergic reactions: Epidemiology and clinical features of perioperative anaphylaxis in the 6th National Audit Project (NAP6) Br. J. Anaesth. 2018;121:159–171. doi: 10.1016/j.bja.2018.04.014.', 'ArticleIdList': [StringElement('10.1016/j.bja.2018.04.014', attributes={'IdType': 'doi'}), StringElement('29935567', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Reitter M., Petitpain N., Latarche C., Cottin J., Massy N., Demoly P. Fatal anaphylaxis with neuromuscular blocking agents: A risk factor and management analysis. Allergy. 2014;69:954–959. doi: 10.1111/all.12426.', 'ArticleIdList': [StringElement('10.1111/all.12426', attributes={'IdType': 'doi'}), StringElement('24813248', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Spoerl D., Nigolian H., Czarnetzki C., Harr T. Reclassifying anaphylaxis to neuromuscular blocking agents based on the presumed patho-mechanism: IgE-mediated, pharmacological adverse reaction or “Innate Hypersensitivity”? Int. J. Mol. Sci. 2017;18:1223. doi: 10.3390/ijms18061223.', 'ArticleIdList': [StringElement('10.3390/ijms18061223', attributes={'IdType': 'doi'}), StringElement('PMC5486046', attributes={'IdType': 'pmc'}), StringElement('28590439', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Stepanovic B., Sommerfield D., Lucas M., von Ungern-Sternberg B.S. An update on allergy and anaphylaxis in pediatric anesthesia. Paediatr. Anaesth. 2019;29:892–900. doi: 10.1111/pan.13703.', 'ArticleIdList': [StringElement('10.1111/pan.13703', attributes={'IdType': 'doi'}), StringElement('31379063', attributes={'IdType': 'pubmed'})]}, {'Citation': 'de Las Vecillas L., Caimmi D., Isabwe G.A.C., Madrigal-Burgaleta R., Soyer O., Tanno L., Vultaggio A., Giovannini M., Mori F. Hypersensitivity reactions to biologics in children. Expert Opin. Biol. Ther. 2023;23:61–72. doi: 10.1080/14712598.2022.2142039.', 'ArticleIdList': [StringElement('10.1080/14712598.2022.2142039', attributes={'IdType': 'doi'}), StringElement('36314361', attributes={'IdType': 'pubmed'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2023', 'Month': '12', 'Day': '29'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '2', 'Day': '18'}, attributes={'PubStatus': 'revised'}), DictElement({'Year': '2024', 'Month': '2', 'Day': '22'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '28', 'Hour': '6', 'Minute': '46'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '28', 'Hour': '6', 'Minute': '45'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '28', 'Hour': '1', 'Minute': '6'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '2', 'Day': '27'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38540140', attributes={'IdType': 'pubmed'}), StringElement('PMC10967707', attributes={'IdType': 'pmc'}), StringElement('10.3390/biomedicines12030527', attributes={'IdType': 'doi'}), StringElement('biomedicines12030527', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Antioxidative metabolism', attributes={'MajorTopicYN': 'N'}), StringElement('Heavy metals toxicity', attributes={'MajorTopicYN': 'N'}), StringElement('Metallothioneins (MTs)', attributes={'MajorTopicYN': 'N'}), StringElement('Remediation', attributes={'MajorTopicYN': 'N'}), StringElement('Scanning electron microscope (SEM)', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38539080', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '03', 'Day': '29'}, 'DateRevised': {'Year': '2024', 'Month': '03', 'Day': '30'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '27'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('221', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1186/s12870-024-04757-7', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1471-2229', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '24', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Mar', 'Day': '27'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'BMC plant biology', 'ISOAbbreviation': 'BMC Plant Biol'}, 'ArticleTitle': 'Inoculation of heavy metal resistant bacteria alleviated heavy metal-induced oxidative stress biomarkers in spinach (Spinacia oleracea L.).', 'Pagination': {'StartPage': '221', 'MedlinePgn': '221'}, 'Abstract': {'AbstractText': ['Most vegetable crops are severely affected by the uptake of heavy metals from the soil. Heavy metals in vegetable bodies generate reactive oxygen species (ROS) that unbalance the antioxidant defense system. This study was initiated to determine the physiological and biochemical characteristics of spinach plants grown on soil contaminated with heavy metals and responding to Bacillus cereus and Bacillus aerius were isolated from soil contaminated with heavy metals. Heavy metal contamination led to a significant reduction in seed germination, seedling biomass, protein, and total nitrogen content of spinach plants grown in contaminated soils compared to control soils. In contrast, a significant increase in the content of metallothioneins and antioxidant enzymes was observed. Plants inoculated with B. cereus and B. aerius significantly reduced the oxidative stress induced by heavy metals by improving seed germination (%), seedling growth, nitrogen, and protein content. The content of metallothioneins and the activities of antioxidant enzymes were reduced in spinach plants grown from seeds inoculated with bacterial strains. In addition, plants inoculated with, B. cereus and B. aerius showed greater stomata opening than plants grown on soil contaminated with heavy metals, whose stomata were almost closed. These results suggested that both bacterial strains enhanced plant growth by reducing oxidative stress caused by metals.'], 'CopyrightInformation': '© 2024. The Author(s).'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Biotechnology and Genetic Engineering, Kohat University of Science & Technology (KUST), Kohat, 26000, Pakistan. dr.jamil@kust.edu.pk.'}], 'Identifier': [], 'LastName': 'Jamil', 'ForeName': 'Muhammad', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Biotechnology and Genetic Engineering, Kohat University of Science & Technology (KUST), Kohat, 26000, Pakistan.'}], 'Identifier': [], 'LastName': 'Malook', 'ForeName': 'Ijaz', 'Initials': 'I'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Biology, University of Haripur, Haripur, 22620, Pakistan.'}], 'Identifier': [], 'LastName': 'Rehman', 'ForeName': 'Shafiq Ur', 'Initials': 'SU'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Botany, University of Science and Technology, Bannu, 28100, Pakistan.'}], 'Identifier': [], 'LastName': 'Aslam', 'ForeName': 'Muhammad Mudasar', 'Initials': 'MM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Biotechnology and Genetic Engineering, Kohat University of Science & Technology (KUST), Kohat, 26000, Pakistan.'}], 'Identifier': [], 'LastName': 'Fayyaz', 'ForeName': 'Muhammad', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Institute of Crop Science, College of Agriculture and Biotechnology, Zhejiang University, Hangzhou, 310027, China.'}], 'Identifier': [], 'LastName': 'Shah', 'ForeName': 'Gulmeena', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Crop and Animal Production, Sason Vocational School, Batman University, Batman, 72060, Turkey.'}], 'Identifier': [], 'LastName': 'Kaplan', 'ForeName': 'Alevcan', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Botany, Islamia College Peshawar, Peshawar, 25120, Pakistan. nomiflora@uop.edu.pk.'}, {'Identifier': [], 'Affiliation': 'University Public School, University of Peshawar, Peshawar, 25120, Pakistan. nomiflora@uop.edu.pk.'}], 'Identifier': [], 'LastName': 'Khan', 'ForeName': 'Muhammad Nauman', 'Initials': 'MN'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Plant Sciences, Quaid-I-Azam University, Islamabad, 45320, Pakistan. baberali@bs.qau.edu.pk.'}], 'Identifier': [], 'LastName': 'Ali', 'ForeName': 'Baber', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Institute of Plant Nutrition and Soil Science, Christian-Albrechts-Universität Zu Kiel, 24118, Kiel, Germany. roy@plantnutrition.uni-kiel.de.'}, {'Identifier': [], 'Affiliation': 'Department of Agroforestry & Environmental Science, Sylhet Agricultural University, Sylhet, 3100, Bangladesh. roy@plantnutrition.uni-kiel.de.'}], 'Identifier': [], 'LastName': 'Roy', 'ForeName': 'Rana', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Horticulture, Agricultural Faculty, Ataturk University, Erzurum, 25240, Türkiye.'}, {'Identifier': [], 'Affiliation': 'HGF Agro, Ata Teknokent, TR-25240, Erzurum, Türkiye.'}], 'Identifier': [], 'LastName': 'Ercisli', 'ForeName': 'Sezai', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.'}, {'Identifier': [], 'Affiliation': 'Faculty of Medicine, Yousef Abdul Latif Jameel Scientific Chair of Prophetic Medicine Application, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.'}], 'Identifier': [], 'LastName': 'Harakeh', 'ForeName': 'Steve', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Stem Cell Research Unit, King Fahd Medical Research Center, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.'}, {'Identifier': [], 'Affiliation': 'Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.'}], 'Identifier': [], 'LastName': 'Moulay', 'ForeName': 'Mohammed', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Institute of Industrial Biotechnology, Government College University, Lahore, 54000, Pakistan.'}], 'Identifier': [], 'LastName': 'Javed', 'ForeName': 'Muhammad Ammar', 'Initials': 'MA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Botany and Microbiology, Faculty of Science, Assiut University, Assiut, 71516, Egypt.'}], 'Identifier': [], 'LastName': 'Abeed', 'ForeName': 'Amany H A', 'Initials': 'AHA'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic'}), 'MedlineJournalInfo': {'Country': 'England', 'MedlineTA': 'BMC Plant Biol', 'NlmUniqueID': '100967807', 'ISSNLinking': '1471-2229'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Antioxidants', attributes={'UI': 'D000975'})}, {'RegistryNumber': 'FVF865388R', 'NameOfSubstance': StringElement('desloratadine', attributes={'UI': 'C121345'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Metals, Heavy', attributes={'UI': 'D019216'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Soil', attributes={'UI': 'D012987'})}, {'RegistryNumber': 'N762921K75', 'NameOfSubstance': StringElement('Nitrogen', attributes={'UI': 'D009584'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Soil Pollutants', attributes={'UI': 'D012989'})}, {'RegistryNumber': '7AJO3BO7QN', 'NameOfSubstance': StringElement('Loratadine', attributes={'UI': 'D017336'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Spinacia oleracea', attributes={'UI': 'D018724', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Antioxidants', attributes={'UI': 'D000975', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('toxicity', attributes={'UI': 'Q000633', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Metals, Heavy', attributes={'UI': 'D019216', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Oxidative Stress', attributes={'UI': 'D018384', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Bacteria', attributes={'UI': 'D001419', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('chemistry', attributes={'UI': 'Q000737', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Soil', attributes={'UI': 'D012987', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Plants', attributes={'UI': 'D010944', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Nitrogen', attributes={'UI': 'D009584', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('toxicity', attributes={'UI': 'Q000633', 'MajorTopicYN': 'N'}), StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Soil Pollutants', attributes={'UI': 'D012989', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('analogs & derivatives', attributes={'UI': 'Q000031', 'MajorTopicYN': 'Y'})], 'DescriptorName': StringElement('Loratadine', attributes={'UI': 'D017336', 'MajorTopicYN': 'N'})}], 'CoiStatement': 'The authors declare no competing interests.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Chen L, Luo S, Li X, Wan Y, Chen J, Liu C. Interaction of Cd-hyperaccumulator Solanum nigrum L. and functional endophyte Pseudomonas sp. Lk9 on soil heavy metals uptake. Soil Biol Biochem. 2014;68:300–308. doi: 10.1016/j.soilbio.2013.10.021.', 'ArticleIdList': [StringElement('10.1016/j.soilbio.2013.10.021', attributes={'IdType': 'doi'})]}, {'Citation': 'Shanker AK, Cervantes C, Loza-Tavera H, Avudainayagam S. Chromium toxicity in plants. Environ Int. 2005;31(5):739–753. doi: 10.1016/j.envint.2005.02.003.', 'ArticleIdList': [StringElement('10.1016/j.envint.2005.02.003', attributes={'IdType': 'doi'}), StringElement('15878200', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Millaleo R, Reyes-Díaz M, Ivanov A, Mora M, Alberdi M. Manganese as essential and toxic element for plants: transport, accumulation and resistance mechanisms. J Soil Sci Plant Nutr. 2010;10(4):470–481. doi: 10.4067/S0718-95162010000200008.', 'ArticleIdList': [StringElement('10.4067/S0718-95162010000200008', attributes={'IdType': 'doi'})]}, {'Citation': 'Shahid M, Khalid S, Abbas G, Shahid N, Nadeem M, Sabir M, Aslam M, Dumat C: Heavy metal stress and crop productivity. Crop production and global environmental issues 2015:1–25.'}, {'Citation': 'Abeed AH, Saleem MH, Asghar MA, Mumtaz S, Ameer A, Ali B, Alwahibi MS, Elshikh MS, Ercisli S, Elsharkawy MM: Ameliorative Effects of Exogenous Potassium Nitrate on Antioxidant Defense System and Mineral Nutrient Uptake in Radish (Raphanus sativus L.) under Salinity Stress. ACS Omega 2023.', 'ArticleIdList': [StringElement('PMC10308581', attributes={'IdType': 'pmc'}), StringElement('37396242', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ahmed T, Masood HA, Noman M, Al-Huqail AA, Alghanem SM, Khan MM, Muhammad S, Manzoor N, Rizwan M, Qi X: Biogenic silicon nanoparticles mitigate cadmium (Cd) toxicity in rapeseed (Brassica napus L.) by modulating the cellular oxidative stress metabolism and reducing Cd translocation. Journal of Hazardous Materials 2023;459:132070.', 'ArticleIdList': [StringElement('37478591', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Jalil S, Nazir MM, Al-Huqail AA, Ali B, Al-Qthanin RN, Asad MA, Eweda MA, Zulfiqar F, Onursal N, Masood HA. Silicon nanoparticles alleviate cadmium toxicity in rice (Oryza sativa L.) by modulating the nutritional profile and triggering stress-responsive genetic mechanisms. Ecotoxicol Environ Safe. 2023;268:115699. doi: 10.1016/j.ecoenv.2023.115699.', 'ArticleIdList': [StringElement('10.1016/j.ecoenv.2023.115699', attributes={'IdType': 'doi'}), StringElement('37979353', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Carrasco-Gil S, Estebaranz-Yubero M, Medel-Cuesta D, Millán R, Hernández LE. Influence of nitrate fertilization on Hg uptake and oxidative stress parameters in alfalfa plants cultivated in a Hg-polluted soil. Environ Exp Bot. 2012;75:16–24. doi: 10.1016/j.envexpbot.2011.08.013.', 'ArticleIdList': [StringElement('10.1016/j.envexpbot.2011.08.013', attributes={'IdType': 'doi'})]}, {'Citation': 'Hafeez A, Ali B, Javed MA, Saleem A, Fatima M, Fathi A, Afridi MS, Aydin V, Oral MA, Soudy FA. Plant breeding for harmony between sustainable agriculture, the environment, and global food security: an era of genomics-assisted breeding. Planta. 2023;258(5):97. doi: 10.1007/s00425-023-04252-7.', 'ArticleIdList': [StringElement('10.1007/s00425-023-04252-7', attributes={'IdType': 'doi'}), StringElement('37823963', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Rasheed A, Al-Huqail AA, Ali B, Alghanem SMS, Shah AA, Azeem F, Rizwan M, Al-Qthanin RN, Soudy FA: Molecular characterization of genes involved in tolerance of cadmium in Triticum aestivum (L.) under Cd stress. J Hazard Mater 2023:132955.', 'ArticleIdList': [StringElement('37976857', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Haque MM, Niloy NM, Khirul MA, Alam MF, Tareq SM: Appraisal of probabilistic human health risks of heavy metals in vegetables from industrial, non-industrial and arsenic contaminated areas of Bangladesh. Heliyon 2021;7(2).', 'ArticleIdList': [StringElement('PMC7921508', attributes={'IdType': 'pmc'}), StringElement('33718641', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pramanik K, Banerjee S, Mukherjee D, Saha KK, Maiti TK, Mandal NC: Beneficial role of plant growth-promoting rhizobacteria in bioremediation of heavy metal (loid)-contaminated agricultural fields. Microbes: The Foundation Stone of the Biosphere 2021:441–495.'}, {'Citation': 'Naghman R, Bhatti MT, Najabat Z, Hyder S, Rizvi ZF, Gondal AS, Zafar Z, Malik S, Iqbal R, Hafeez A. Organic amendments: a natural way to suppress phytopathogens: a sustainable approach to go green. Turk J Agricult Forest. 2023;47(5):602–622. doi: 10.55730/1300-011X.3113.', 'ArticleIdList': [StringElement('10.55730/1300-011X.3113', attributes={'IdType': 'doi'})]}, {'Citation': 'Mehmood N, Saeed M, Zafarullah S, Hyder S, Rizvi ZF, Gondal AS, Jamil N, Iqbal R, Ali B, Ercisli S. Multifaceted impacts of plant-beneficial pseudomonas spp. in managing various plant diseases and crop yield improvement. ACS omega. 2023;8(25):22296–22315. doi: 10.1021/acsomega.3c00870.', 'ArticleIdList': [StringElement('10.1021/acsomega.3c00870', attributes={'IdType': 'doi'}), StringElement('PMC10308577', attributes={'IdType': 'pmc'}), StringElement('37396244', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hurst CJ: Microbes: the foundation stone of the biosphere: Springer; 2021.'}, {'Citation': 'Khanna K, Jamwal VL, Kohli SK, Gandhi SG, Ohri P, Bhardwaj R, Wijaya L, Alyemeni MN, Ahmad P. Role of plant growth promoting Bacteria (PGPRs) as biocontrol agents of Meloidogyne incognita through improved plant defense of Lycopersicon esculentum. Plant Soil. 2019;436:325–345. doi: 10.1007/s11104-019-03932-2.', 'ArticleIdList': [StringElement('10.1007/s11104-019-03932-2', attributes={'IdType': 'doi'})]}, {'Citation': 'Adesemoye A, Torbert H, Kloepper J. Plant growth-promoting rhizobacteria allow reduced application rates of chemical fertilizers. Microb Ecol. 2009;58:921–929. doi: 10.1007/s00248-009-9531-y.', 'ArticleIdList': [StringElement('10.1007/s00248-009-9531-y', attributes={'IdType': 'doi'}), StringElement('19466478', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bashan Y, De-Bashan LE. How the plant growth-promoting bacterium Azospirillum promotes plant growth—a critical assessment. Adv Agron. 2010;108:77–136. doi: 10.1016/S0065-2113(10)08002-8.', 'ArticleIdList': [StringElement('10.1016/S0065-2113(10)08002-8', attributes={'IdType': 'doi'})]}, {'Citation': 'Berendsen RL, Pieterse CM, Bakker PA. The rhizosphere microbiome and plant health. Trends Plant Sci. 2012;17(8):478–486. doi: 10.1016/j.tplants.2012.04.001.', 'ArticleIdList': [StringElement('10.1016/j.tplants.2012.04.001', attributes={'IdType': 'doi'}), StringElement('22564542', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ali B, Hafeez A, Afridi MS, Javed MA, Sumaira, Suleman F, Nadeem M, Ali S, Alwahibi MS, Elshikh MS: Bacterial-Mediated Salinity Stress Tolerance in Maize (Zea mays L.): A Fortunate Way toward Sustainable Agriculture. ACS omega 2023.', 'ArticleIdList': [StringElement('PMC10275368', attributes={'IdType': 'pmc'}), StringElement('37332827', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hameed MA, Farooqi ZUR, Hussain MM, Ayub MA: PGPR-assisted bioremediation and plant growth: A sustainable approach for crop production using polluted soils. Plant growth regulators: Signalling under stress conditions 2021:403–420.'}, {'Citation': 'MACÊDO LdS, Morril W: Origem e comportamento dos metais fitotóxicos: revisão da literatura. Tecnol Ciência Agropecuária 2008;2(2):29–38.'}, {'Citation': 'Rizvi A, Zaidi A, Ameen F, Ahmed B, AlKahtani MD, Khan MS. Heavy metal induced stress on wheat: phytotoxicity and microbiological management. RSC Adv. 2020;10(63):38379–38403. doi: 10.1039/D0RA05610C.', 'ArticleIdList': [StringElement('10.1039/D0RA05610C', attributes={'IdType': 'doi'}), StringElement('PMC9121104', attributes={'IdType': 'pmc'}), StringElement('35693041', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Wang Q, Liang X, Dong Y, Xu L, Zhang X, Hou J, Fan Z. Effects of exogenous nitric oxide on cadmium toxicity, element contents and antioxidative system in perennial ryegrass. Plant Growth Regul. 2013;69:11–20. doi: 10.1007/s10725-012-9742-y.', 'ArticleIdList': [StringElement('10.1007/s10725-012-9742-y', attributes={'IdType': 'doi'})]}, {'Citation': 'Karaca A. Effect of organic wastes on the extractability of cadmium, copper, nickel, and zinc in soil. Geoderma. 2004;122(2–4):297–303. doi: 10.1016/j.geoderma.2004.01.016.', 'ArticleIdList': [StringElement('10.1016/j.geoderma.2004.01.016', attributes={'IdType': 'doi'})]}, {'Citation': 'Guo G, Lei M, Wang Y, Song B, Yang J. Accumulation of As, Cd, and Pb in sixteen wheat cultivars grown in contaminated soils and associated health risk assessment. Int J Environ Res Public Health. 2018;15(11):2601. doi: 10.3390/ijerph15112601.', 'ArticleIdList': [StringElement('10.3390/ijerph15112601', attributes={'IdType': 'doi'}), StringElement('PMC6266899', attributes={'IdType': 'pmc'}), StringElement('30469364', attributes={'IdType': 'pubmed'})]}, {'Citation': \"Rastgoo L, Alemzadeh A, Tale AM, Tazangi SE, Eslamzadeh T. Effects of copper, nickel and zinc on biochemical parameters and metal accumulation in Gouan',Aeluropus littoralis'. Plant Knowledge J. 2014;3(1):42–49.\"}, {'Citation': 'Pourrut B, Jean S, Silvestre J, Pinelli E. Lead-induced DNA damage in Vicia faba root cells: potential involvement of oxidative stress. Mut Res Genet Toxicol Environ Mutagenesis. 2011;726(2):123–128. doi: 10.1016/j.mrgentox.2011.09.001.', 'ArticleIdList': [StringElement('10.1016/j.mrgentox.2011.09.001', attributes={'IdType': 'doi'}), StringElement('21920457', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Jiang W, Liu D. Pb-induced cellular defense system in the root meristematic cells of Allium sativum L. BMC Plant Biol. 2010;10:1–8. doi: 10.1186/1471-2229-10-40.', 'ArticleIdList': [StringElement('10.1186/1471-2229-10-40', attributes={'IdType': 'doi'}), StringElement('PMC2848760', attributes={'IdType': 'pmc'}), StringElement('20196842', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Rascio N, Navari-Izzo F. Heavy metal hyperaccumulating plants: how and why do they do it? And what makes them so interesting? Plant Sci. 2011;180(2):169–181. doi: 10.1016/j.plantsci.2010.08.016.', 'ArticleIdList': [StringElement('10.1016/j.plantsci.2010.08.016', attributes={'IdType': 'doi'}), StringElement('21421358', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Maestri E, Marmiroli M, Visioli G, Marmiroli N. Metal tolerance and hyperaccumulation: costs and trade-offs between traits and environment. Environ Exp Bot. 2010;68(1):1–13. doi: 10.1016/j.envexpbot.2009.10.011.', 'ArticleIdList': [StringElement('10.1016/j.envexpbot.2009.10.011', attributes={'IdType': 'doi'})]}, {'Citation': 'Rea PA. Phytochelatin synthase: of a protease a peptide polymerase made. Physiol Plant. 2012;145(1):154–164. doi: 10.1111/j.1399-3054.2012.01571.x.', 'ArticleIdList': [StringElement('10.1111/j.1399-3054.2012.01571.x', attributes={'IdType': 'doi'}), StringElement('22224506', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Seth CS, Remans T, Keunen E, Jozefczak M, Gielen H, Opdenakker K, Weyens N, Vangronsveld J, Cuypers A. Phytoextraction of toxic metals: a central role for glutathione. Plant Cell Environ. 2012;35(2):334–346. doi: 10.1111/j.1365-3040.2011.02338.x.', 'ArticleIdList': [StringElement('10.1111/j.1365-3040.2011.02338.x', attributes={'IdType': 'doi'}), StringElement('21486307', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lomonte B, Angulo Y, Moreno E. Synthetic peptides derived from the C-terminal region of Lys49 phospholipase A2 homologues from viperidae snake venoms: biomimetic activities and potential applications. Curr Pharm Des. 2010;16(28):3224–3230. doi: 10.2174/138161210793292456.', 'ArticleIdList': [StringElement('10.2174/138161210793292456', attributes={'IdType': 'doi'}), StringElement('20687875', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hayat R, Ali S, Amara U, Khalid R, Ahmed I. Soil beneficial bacteria and their role in plant growth promotion: a review. Ann Microbiol. 2010;60:579–598. doi: 10.1007/s13213-010-0117-1.', 'ArticleIdList': [StringElement('10.1007/s13213-010-0117-1', attributes={'IdType': 'doi'})]}, {'Citation': 'Alia N, Sardar K, Said M, Salma K, Sadia A, Sadaf S, Toqeer A, Miklas S. Toxicity and bioaccumulation of heavy metals in spinach (Spinacia oleracea) grown in a controlled environment. Int J Environ Res Public Health. 2015;12(7):7400–7416. doi: 10.3390/ijerph120707400.', 'ArticleIdList': [StringElement('10.3390/ijerph120707400', attributes={'IdType': 'doi'}), StringElement('PMC4515664', attributes={'IdType': 'pmc'}), StringElement('26133131', attributes={'IdType': 'pubmed'})]}, {'Citation': 'De J, Ramaiah N, Vardanyan L. Detoxification of toxic heavy metals by marine bacteria highly resistant to mercury. Mar Biotechnol. 2008;10:471–477. doi: 10.1007/s10126-008-9083-z.', 'ArticleIdList': [StringElement('10.1007/s10126-008-9083-z', attributes={'IdType': 'doi'}), StringElement('18288535', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Shahraki A, Mohammadi-Sichani M, Ranjbar M. Identification of lead-resistant rhizobacteria of Carthamus tinctorius and their effects on lead absorption of Sunflower. J Appl Microbiol. 2022;132(4):3073–3080. doi: 10.1111/jam.15410.', 'ArticleIdList': [StringElement('10.1111/jam.15410', attributes={'IdType': 'doi'}), StringElement('34897903', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bilal S, Shahzad R, Imran M, Jan R, Kim KM, Lee I-J. Synergistic association of endophytic fungi enhances Glycine max L. resilience to combined abiotic stresses: Heavy metals, high temperature and drought stress. Indust CropsProd. 2020;143:111931. doi: 10.1016/j.indcrop.2019.111931.', 'ArticleIdList': [StringElement('10.1016/j.indcrop.2019.111931', attributes={'IdType': 'doi'})]}, {'Citation': 'Gao T, Liu Y, Yang D, Liu X, Zuo M, He Y, Wang H, Bao J, Shen Y, Tai X. Inoculation of exogenous complex bacteria to enhance resistance in alfalfa and combined remediation of heavy metal-contaminated soil. Curr Microbiol. 2023;80(6):213. doi: 10.1007/s00284-023-03299-9.', 'ArticleIdList': [StringElement('10.1007/s00284-023-03299-9', attributes={'IdType': 'doi'}), StringElement('37191724', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Orłowska E, Przybyłowicz W, Orlowski D, Mongwaketsi NP, Turnau K, Mesjasz-Przybyłowicz J. Mycorrhizal colonization affects the elemental distribution in roots of Ni-hyperaccumulator Berkheya coddii Roessler. Environ Pollut. 2013;175:100–109. doi: 10.1016/j.envpol.2012.12.028.', 'ArticleIdList': [StringElement('10.1016/j.envpol.2012.12.028', attributes={'IdType': 'doi'}), StringElement('23369753', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Choudhury R, Srivastava S: Zinc resistance mechanisms in bacteria. Current Science 2001:768–775.'}, {'Citation': 'Valls M, De Lorenzo V. Exploiting the genetic and biochemical capacities of bacteria for the remediation of heavy metal pollution. FEMS Microbiol Rev. 2002;26(4):327–338. doi: 10.1016/S0168-6445(02)00114-6.', 'ArticleIdList': [StringElement('10.1016/S0168-6445(02)00114-6', attributes={'IdType': 'doi'}), StringElement('12413663', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Malook I, Rehman SU, Khan MD, El-Hendawy SE, Al-Suhaibani NA, Aslam MM, Jamil M. Heavy metals induced lipid peroxidation in spinach mediated with microbes. Pak J Bot. 2017;49(6):2301–2308.'}, {'Citation': 'Mahmood A, Mahmoud AH, El-Abedein AIZ, Ashraf A, Almunqedhi BM. A comparative study of metals concentration in agricultural soil and vegetables irrigated by wastewater and tube well water. J King Saud Univ Sci. 2020;32(3):1861–1864. doi: 10.1016/j.jksus.2020.01.031.', 'ArticleIdList': [StringElement('10.1016/j.jksus.2020.01.031', attributes={'IdType': 'doi'})]}, {'Citation': 'Bashir S, Ali U, Shaaban M, Gulshan AB, Iqbal J, Khan S, Husain A, Ahmed N, Mehmood S, Kamran M. Role of sepiolite for cadmium (Cd) polluted soil restoration and spinach growth in wastewater irrigated agricultural soil. J Environ Manage. 2020;258:110020. doi: 10.1016/j.jenvman.2019.110020.', 'ArticleIdList': [StringElement('10.1016/j.jenvman.2019.110020', attributes={'IdType': 'doi'}), StringElement('31929061', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Noor AE. un Nisa Z, Sultana S, Al-Ghanim KA, Al-Misned F, Riaz MN, Ahmed Z, Mahboob S: Heavy metals toxicity in spinach (Spinacia oleracea) irrigated with sanitary wastewater in rural areas. J King Saud Univ Sci. 2023;35(1):102382. doi: 10.1016/j.jksus.2022.102382.', 'ArticleIdList': [StringElement('10.1016/j.jksus.2022.102382', attributes={'IdType': 'doi'})]}, {'Citation': 'Malook I, Atlas A. Rehman Su, Wang W, Jamil M: Smoke alleviates adverse effects induced by stress on rice. Toxicol Environ Chem. 2014;96(5):755–767. doi: 10.1080/02772248.2014.912776.', 'ArticleIdList': [StringElement('10.1080/02772248.2014.912776', attributes={'IdType': 'doi'})]}, {'Citation': 'Jamil M, Malook I, Rehman SU, Khan MD, Fayyaz M, Aslam MM, Rha ES. Multivariate geo-statistical perspective: Evaluation of agricultural soil contaminated by industrial estate’s effluents. Environ Geochem Health. 2022;44(1):57–68. doi: 10.1007/s10653-021-01007-9.', 'ArticleIdList': [StringElement('10.1007/s10653-021-01007-9', attributes={'IdType': 'doi'}), StringElement('34131852', attributes={'IdType': 'pubmed'})]}, {'Citation': 'EPA U: Method 3050B: Acid Digestion of Sediments. Sludges, and Soils 1996.'}, {'Citation': 'Khattak MR, Shah G, Naeem R, Fayyaz M, Rehman M, Anees M, Rha ES, Jamil M: Assessment of heavy metal tolerance and reduction potential of bacillus sp. isolated from the soils contaminated with industrial effluents. Fresenius Environ Bull 2021;30(4 A):4391–4401.'}, {'Citation': 'Nelson Da, Sommers LE: Total carbon, organic carbon, and organic matter. Methods of soil analysis: Part 2 chemical and microbiological properties 1983, 9:539–579.'}, {'Citation': 'Achakzai K, Khalid S, Bibi A. Determination of heavy metals in agricultural soil adjacent to functional brick kilns: a case study of Rawalpindi. Sci Technol Dev. 2017;34(3):122–129. doi: 10.3923/std.2015.122.129.', 'ArticleIdList': [StringElement('10.3923/std.2015.122.129', attributes={'IdType': 'doi'})]}, {'Citation': 'AOAC A: Official Methods of analysis. th ed. Association of Official Analytical Chemists, Washington, DC, EUA 1970, 997.'}, {'Citation': 'Pellett PL, Young VR: Nutritional evaluation of protein foods; report of a working group sponsored by the International Union of Nutritional Sciences and the United Nations University World Hunger Programme; 1980.'}, {'Citation': 'Cataldo RJ, Hidalgo LM, Neaman A, Gaete OH. Use of molecular biomarkers in Eisenia foetida to assess copper toxicity in agricultural soils affected by mining activities. J Soil Sci Plant Nutr. 2011;11(3):57–70.'}, {'Citation': 'Tsugama D, Liu S, Takano T. A rapid chemical method for lysing Arabidopsis cells for protein analysis. Plant Methods. 2011;7:1–7. doi: 10.1186/1746-4811-7-22.', 'ArticleIdList': [StringElement('10.1186/1746-4811-7-22', attributes={'IdType': 'doi'}), StringElement('PMC3150330', attributes={'IdType': 'pmc'}), StringElement('21762478', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680–685. doi: 10.1038/227680a0.', 'ArticleIdList': [StringElement('10.1038/227680a0', attributes={'IdType': 'doi'}), StringElement('5432063', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Muhammad J, Ijaz M, Salma P, Tayybah N, Arshad A, Sami UJ, Shafiq UR. Smoke priming, a potent protective agent against salinity: Effect on proline accumulation, elemental uptake, pigmental attributes and protein banding patterns of rice (Oryza Sativa) J Stress Physiol Biochem. 2013;9(1):169–183.'}, {'Citation': 'Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72(1–2):248–254. doi: 10.1016/0003-2697(76)90527-3.', 'ArticleIdList': [StringElement('10.1016/0003-2697(76)90527-3', attributes={'IdType': 'doi'}), StringElement('942051', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Zhang W, Zhang F, Raziuddin R, Gong H, Yang Z, Lu L, Ye Q, Zhou W. Effects of 5-aminolevulinic acid on oilseed rape seedling growth under herbicide toxicity stress. J Plant Growth Regul. 2008;27:159–169. doi: 10.1007/s00344-008-9042-y.', 'ArticleIdList': [StringElement('10.1007/s00344-008-9042-y', attributes={'IdType': 'doi'})]}, {'Citation': 'Ullah S, Khan MI, Khan MN, Ali U, Ali B, Iqbal R, Z Gaafar A-R, AlMunqedhi BM, Razak SA, Kaplan A: Efficacy of Naphthyl Acetic Acid Foliar Spray in Moderating Drought Effects on the Morphological and Physiological Traits of Maize Plants (Zea mays L.). ACS omega 2023.', 'ArticleIdList': [StringElement('PMC10268277', attributes={'IdType': 'pmc'}), StringElement('37323381', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Aebi H: [13] Catalase in vitro. In: Methods in enzymology. vol. 105: Elsevier; 1984: 121–126.', 'ArticleIdList': [StringElement('6727660', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hemeda H, Klein B. Effects of naturally occurring antioxidants on peroxidase activity of vegetable extracts. J Food Sci. 1990;55(1):184–185. doi: 10.1111/j.1365-2621.1990.tb06048.x.', 'ArticleIdList': [StringElement('10.1111/j.1365-2621.1990.tb06048.x', attributes={'IdType': 'doi'})]}, {'Citation': 'Shah NA, Ullah S, Nafees M, Khan MN: Exogenous Effect of Sugar Beet Extract On Physio-biochemical Traits of Hordeum vulagre L. Under Induced Salinity Stress. Gesunde Pflanzen 2023:1–13.'}, {'Citation': 'Ali S, Ullah S, Khan MN, Khan WM, Razak SA, Wahab S, Hafeez A, Khan Bangash SA, Poczai P. The effects of osmosis and thermo-priming on salinity stress tolerance in Vigna radiata L. Sustainability. 2022;14(19):12924. doi: 10.3390/su141912924.', 'ArticleIdList': [StringElement('10.3390/su141912924', attributes={'IdType': 'doi'})]}, {'Citation': 'Nakano Y, Asada K. Hydrogen peroxide is scavenged by ascorbate-specific peroxidase in spinach chloroplasts. Plant Cell Physiol. 1981;22(5):867–880.'}, {'Citation': 'Faryal S, Ullah R, Khan MN, Ali B, Hafeez A, Jaremko M, Qureshi KA. Thiourea-capped nanoapatites amplify osmotic stress tolerance in Zea mays L. by conserving photosynthetic pigments, osmolytes biosynthesis and antioxidant biosystems. Molecules. 2022;27(18):5744. doi: 10.3390/molecules27185744.', 'ArticleIdList': [StringElement('10.3390/molecules27185744', attributes={'IdType': 'doi'}), StringElement('PMC9505401', attributes={'IdType': 'pmc'}), StringElement('36144480', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Rehman K, Fatima F, Waheed I, Akash MSH. Prevalence of exposure of heavy metals and their impact on health consequences. J Cell Biochem. 2018;119(1):157–184. doi: 10.1002/jcb.26234.', 'ArticleIdList': [StringElement('10.1002/jcb.26234', attributes={'IdType': 'doi'}), StringElement('28643849', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Alshegaihi RM, Mfarrej MFB, Saleem MH, Parveen A, Ahmad KS, Ali B, Abeed AH, Alshehri D, Alghamdi SA, Alghanem SM. Effective citric acid and EDTA treatments in cadmium stress tolerance in pepper (Capsicum annuum L.) seedlings by regulating specific gene expression. South Afr J Botany. 2023;159:367–380. doi: 10.1016/j.sajb.2023.06.024.', 'ArticleIdList': [StringElement('10.1016/j.sajb.2023.06.024', attributes={'IdType': 'doi'})]}, {'Citation': 'Alhaithloul HAS, Ali B, Alghanem SMS, Zulfiqar F, Al-Robai SA, Ercisli S, Yong JWH, Moosa A, Irfan E, Ali Q. Effect of green-synthesized copper oxide nanoparticles on growth, physiology, nutrient uptake, and cadmium accumulation in Triticum aestivum (L) Ecotoxicol Environment Safe. 2023;268:115701. doi: 10.1016/j.ecoenv.2023.115701.', 'ArticleIdList': [StringElement('10.1016/j.ecoenv.2023.115701', attributes={'IdType': 'doi'}), StringElement('37979354', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Madhaiyan M, Kim B-Y, Poonguzhali S, Kwon S-W, Song M-H, Ryu J-H, Go S-J, Koo B-S, Sa T-M. Methylobacterium oryzae sp. nov., an aerobic, pink-pigmented, facultatively methylotrophic, 1-aminocyclopropane-1-carboxylate deaminase-producing bacterium isolated from rice. Int J Syst Evol Microbiol. 2007;57(2):326–331. doi: 10.1099/ijs.0.64603-0.', 'ArticleIdList': [StringElement('10.1099/ijs.0.64603-0', attributes={'IdType': 'doi'}), StringElement('17267973', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chen L, Luo S, Xiao X, Guo H, Chen J, Wan Y, Li B, Xu T, Xi Q, Rao C. Application of plant growth-promoting endophytes (PGPE) isolated from Solanum nigrum L. for phytoextraction of Cd-polluted soils. Appl Soil Ecol. 2010;46(3):383–389. doi: 10.1016/j.apsoil.2010.10.003.', 'ArticleIdList': [StringElement('10.1016/j.apsoil.2010.10.003', attributes={'IdType': 'doi'})]}, {'Citation': 'Sessitsch A, Kuffner M, Kidd P, Vangronsveld J, Wenzel WW, Fallmann K, Puschenreiter M. The role of plant-associated bacteria in the mobilization and phytoextraction of trace elements in contaminated soils. Soil Biol Biochem. 2013;60:182–194. doi: 10.1016/j.soilbio.2013.01.012.', 'ArticleIdList': [StringElement('10.1016/j.soilbio.2013.01.012', attributes={'IdType': 'doi'}), StringElement('PMC3618436', attributes={'IdType': 'pmc'}), StringElement('23645938', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ahemad M, Kibret M. Mechanisms and applications of plant growth promoting rhizobacteria: current perspective. J King Saud Univ Sci. 2014;26(1):1–20. doi: 10.1016/j.jksus.2013.05.001.', 'ArticleIdList': [StringElement('10.1016/j.jksus.2013.05.001', attributes={'IdType': 'doi'})]}, {'Citation': 'Ma Y, Oliveira RS, Freitas H, Zhang C. Biochemical and molecular mechanisms of plant-microbe-metal interactions: relevance for phytoremediation. Front Plant Sci. 2016;7:918. doi: 10.3389/fpls.2016.00918.', 'ArticleIdList': [StringElement('10.3389/fpls.2016.00918', attributes={'IdType': 'doi'}), StringElement('PMC4917562', attributes={'IdType': 'pmc'}), StringElement('27446148', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Shi G, Cai Q. Cadmium tolerance and accumulation in eight potential energy crops. Biotechnol Adv. 2009;27(5):555–561. doi: 10.1016/j.biotechadv.2009.04.006.', 'ArticleIdList': [StringElement('10.1016/j.biotechadv.2009.04.006', attributes={'IdType': 'doi'}), StringElement('19393309', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ahn YO, Kim SH, Lee J, Kim H, Lee H-S, Kwak S-S. Three Brassica rapa metallothionein genes are differentially regulated under various stress conditions. Mol Biol Rep. 2012;39:2059–2067. doi: 10.1007/s11033-011-0953-5.', 'ArticleIdList': [StringElement('10.1007/s11033-011-0953-5', attributes={'IdType': 'doi'}), StringElement('21643753', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Abedin MJ, Cresser MS, Meharg AA, Feldmann J, Cotter-Howells J. Arsenic accumulation and metabolism in rice (Oryza sativa L.) Environ SciTechnol. 2002;36(5):962–968. doi: 10.1021/es0101678.', 'ArticleIdList': [StringElement('10.1021/es0101678', attributes={'IdType': 'doi'}), StringElement('11918027', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Sheetal K, Singh S, Anand A, Prasad S. Heavy metal accumulation and effects on growth, biomass and physiological processes in mustard. Indian J Plant Physiol. 2016;21:219–223. doi: 10.1007/s40502-016-0221-8.', 'ArticleIdList': [StringElement('10.1007/s40502-016-0221-8', attributes={'IdType': 'doi'})]}, {'Citation': 'Aidid SB, Okamoto H. Responses of elongation growth rate, turgor pressure and cell wall extensibility of stem cells of Impatiens balsamina to lead, cadmium and zinc. Biometals. 1993;6:245–249. doi: 10.1007/BF00187763.', 'ArticleIdList': [StringElement('10.1007/BF00187763', attributes={'IdType': 'doi'})]}, {'Citation': 'Eun SO, Shik Youn H, Lee Y. Lead disturbs microtubule organization in the root meristem of Zea mays. Physiol Plant. 2000;110(3):357–365. doi: 10.1111/j.1399-3054.2000.1100310.x.', 'ArticleIdList': [StringElement('10.1111/j.1399-3054.2000.1100310.x', attributes={'IdType': 'doi'})]}, {'Citation': 'Khan AR, Ullah I, Khan AL, Park G-S, Waqas M, Hong S-J, Jung BK, Kwak Y, Lee I-J, Shin J-H. Improvement in phytoremediation potential of Solanum nigrum under cadmium contamination through endophytic-assisted Serratia sp RSC-14 inoculation. Environ Sci Pollut Res. 2015;22:14032–14042. doi: 10.1007/s11356-015-4647-8.', 'ArticleIdList': [StringElement('10.1007/s11356-015-4647-8', attributes={'IdType': 'doi'}), StringElement('25956518', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Goyal N, Jain S, Banerjee U. Comparative studies on the microbial adsorption of heavy metals. Adv Environ Res. 2003;7(2):311–319. doi: 10.1016/S1093-0191(02)00004-7.', 'ArticleIdList': [StringElement('10.1016/S1093-0191(02)00004-7', attributes={'IdType': 'doi'})]}, {'Citation': 'Glick BR, Cheng Z, Czarny J, Duan J: Promotion of plant growth by ACC deaminase-producing soil bacteria. New perspectives and approaches in plant growth-promoting Rhizobacteria research 2007:329–339.'}, {'Citation': 'Wang S, Wang PG, Qi Q. Influence of substrate conformation on the deglycosylation of ribonuclease B by recombinant yeast peptide: N-glycanase. Acta Biochim Biophys Sin. 2007;39(1):8–14. doi: 10.1111/j.1745-7270.2007.00244.x.', 'ArticleIdList': [StringElement('10.1111/j.1745-7270.2007.00244.x', attributes={'IdType': 'doi'}), StringElement('17213953', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ying X, Fang Z. Experimental research on heavy metal wastewater treatment with dipropyl dithiophosphate. J Hazard Mater. 2006;137(3):1636–1642. doi: 10.1016/j.jhazmat.2006.04.055.', 'ArticleIdList': [StringElement('10.1016/j.jhazmat.2006.04.055', attributes={'IdType': 'doi'}), StringElement('16846685', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Len N, Lindberg J, Ogle B. Digestibility and nitrogen retention of diets containing different levels of fibre in local (Mong Cai), F1 (Mong Cai× Yorkshire) and exotic (Landrace× Yorkshire) growing pigs in Vietnam. J Anim Physiol Anim Nutr. 2007;91(7–8):297–303. doi: 10.1111/j.1439-0396.2006.00653.x.', 'ArticleIdList': [StringElement('10.1111/j.1439-0396.2006.00653.x', attributes={'IdType': 'doi'}), StringElement('17615000', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Souza Rd. Ambrosini A, Passaglia LM: Plant growth-promoting bacteria as inoculants in agricultural soils. Genet Mol Biol. 2015;38:401–419. doi: 10.1590/S1415-475738420150053.', 'ArticleIdList': [StringElement('10.1590/S1415-475738420150053', attributes={'IdType': 'doi'}), StringElement('PMC4763327', attributes={'IdType': 'pmc'}), StringElement('26537605', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mahmood S, Hussain A, Saeed Z, Athar M. Germination and seedling growth of corn (Zea mays L.) under varying levels of copper and zinc. Int J EnvironSci Technol. 2005;2:269–274.'}, {'Citation': 'Castiglione S, Franchin C, Fossati T, Lingua G, Torrigiani P, Biondi S. High zinc concentrations reduce rooting capacity and alter metallothionein gene expression in white poplar (Populus alba L. cv. Villafranca) Chemosphere. 2007;67(6):1117–1126. doi: 10.1016/j.chemosphere.2006.11.039.', 'ArticleIdList': [StringElement('10.1016/j.chemosphere.2006.11.039', attributes={'IdType': 'doi'}), StringElement('17223164', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Abdelmigid H, Hassan AM, El-Rab S. Expression of metallothionein as a biomarker in response to various stress factors in different organisms. Int J Adv Res. 2014;2(10):683–695.'}, {'Citation': 'Hussein H-AA, Alshammari SO, Abd El-Sadek ME, Kenawy SK, Badawy AA: The promotive effect of putrescine on growth, biochemical constituents, and yield of wheat (Triticum aestivum L.) plants under water stress. Agriculture 2023;13(3):587.'}, {'Citation': 'Abeed AH. AL-Huqail AA, Albalawi S, Alghamdi SA, Ali B, Alghanem SM, Al-Haithloul HAS, Amro A, Tammam SA, El-Mahdy M: Calcium nanoparticles mitigate severe salt stress in Solanum lycopersicon by instigating the antioxidant defense system and renovating the protein profile. South Afr J Botany. 2023;161:36–52. doi: 10.1016/j.sajb.2023.08.005.', 'ArticleIdList': [StringElement('10.1016/j.sajb.2023.08.005', attributes={'IdType': 'doi'})]}, {'Citation': 'Alwutayd KM, Alghanem SMS, Alwutayd R, Alghamdi SA, Alabdallah NM, Al-Qthanin RN, Sarfraz W, Khalid N, Naeem N, Ali B. Mitigating chromium toxicity in rice (Oryza sativa L) via ABA and 6-BAP: Unveiling synergistic benefits on morphophysiological traits and ASA-GSH cycle. Sci Total Environ. 2024;908:168208. doi: 10.1016/j.scitotenv.2023.168208.', 'ArticleIdList': [StringElement('10.1016/j.scitotenv.2023.168208', attributes={'IdType': 'doi'}), StringElement('37914115', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Abdelfattah NA, Yousef MA, Badawy AA, Salem SS: Influence of biosynthesized magnesium oxide nanoparticles on growth and physiological aspects of cowpea (Vigna unguiculata L.) plant, cowpea beetle, and cytotoxicity. Biotechnol J 2023:2300301.', 'ArticleIdList': [StringElement('37615241', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kim P, Leckman JF, Mayes LC, Feldman R, Wang X, Swain JE. The plasticity of human maternal brain: longitudinal changes in brain anatomy during the early postpartum period. Behav Neurosci. 2010;124(5):695. doi: 10.1037/a0020884.', 'ArticleIdList': [StringElement('10.1037/a0020884', attributes={'IdType': 'doi'}), StringElement('PMC4318549', attributes={'IdType': 'pmc'}), StringElement('20939669', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Opdenakker K, Remans T, Keunen E, Vangronsveld J, Cuypers A. Exposure of Arabidopsis thaliana to Cd or Cu excess leads to oxidative stress mediated alterations in MAPKinase transcript levels. Environ Exp Bot. 2012;83:53–61. doi: 10.1016/j.envexpbot.2012.04.003.', 'ArticleIdList': [StringElement('10.1016/j.envexpbot.2012.04.003', attributes={'IdType': 'doi'})]}, {'Citation': 'Meier S, Azcón R, Cartes P, Borie F, Cornejo P. Alleviation of Cu toxicity in Oenothera picensis by copper-adapted arbuscular mycorrhizal fungi and treated agrowaste residue. Appl Soil Ecol. 2011;48(2):117–124. doi: 10.1016/j.apsoil.2011.04.005.', 'ArticleIdList': [StringElement('10.1016/j.apsoil.2011.04.005', attributes={'IdType': 'doi'})]}, {'Citation': 'Ishikawa T, Sakai K, Yoshimura K, Takeda T, Shigeoka S. cDNAs encoding spinach stromal and thylakoid-bound ascorbate peroxidase, differing in the presence or absence of their 3′-coding regions. FEBS Lett. 1996;384(3):289–293. doi: 10.1016/0014-5793(96)00332-8.', 'ArticleIdList': [StringElement('10.1016/0014-5793(96)00332-8', attributes={'IdType': 'doi'}), StringElement('8617374', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ishikawa T, Li Z-S, Lu Y-P, Rea PA. The GS-X pump in plant, yeast, and animal cells: structure, function, and gene expression. Biosci Rep. 1997;17(2):189–207. doi: 10.1023/A:1027385513483.', 'ArticleIdList': [StringElement('10.1023/A:1027385513483', attributes={'IdType': 'doi'}), StringElement('9217966', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Shumaila, Ullah S, Shah W, Hafeez A, Ali B, Khan S, Ercisli S, Al-Ghamdi AA, Elshikh MS: Biochar and Seed Priming Technique with Gallic Acid: An Approach toward Improving Morpho-Anatomical and Physiological Features of Solanum melongena L. under Induced NaCl and Boron Stresses. ACS Omega 2023;8(31):28207–28232.', 'ArticleIdList': [StringElement('PMC10763624', attributes={'IdType': 'pmc'}), StringElement('38173954', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Comstock JP. Hydraulic and chemical signalling in the control of stomatal conductance and transpiration. J Exp Bot. 2002;53(367):195–200. doi: 10.1093/jexbot/53.367.195.', 'ArticleIdList': [StringElement('10.1093/jexbot/53.367.195', attributes={'IdType': 'doi'}), StringElement('11807122', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Rafia A, Saba H, Shabana A: Phytotoxicit y of Pb: I. Effect of Pb on germination, growth, morphology and histomorphology of Phaseolu s mungo and Lens culinaris. Pak J Biol Sci 2006;9(5):979–984.'}, {'Citation': 'Ghelich S, Zarinkamar F. SEM studies of leaf surface structure changes due to lead toxicity in Hypericum perforatum L. Glob J Biodivers Sci Manage. 2013;3(2):256–263.'}, {'Citation': 'Singh S, Sinha S: Scanning electron microscopic studies and growth response of the plants of Helianthus annuus L. grown on tannery sludge amended soil. Environ Int 2004; 30(3):389–395.', 'ArticleIdList': [StringElement('14987871', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ameen F, Mumtaz S, Ali B, Hussain I, Hafeez A, Gul A, Elsharkawy MM, Hashim TA, Yasin G, Khan MN: The impact of Cu-polluted and organic soil on the fibrous plant; insights into plant growth promotion, antioxidant defences system, and oxidative stress. Funct Plant Biol 2023.', 'ArticleIdList': [StringElement('37231613', attributes={'IdType': 'pubmed'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2023', 'Month': '10', 'Day': '26'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '1', 'Day': '21'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '29', 'Hour': '6', 'Minute': '46'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '28', 'Hour': '6', 'Minute': '45'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '28', 'Hour': '0', 'Minute': '43'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '27'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38539080', attributes={'IdType': 'pubmed'}), StringElement('PMC10976752', attributes={'IdType': 'pmc'}), StringElement('10.1186/s12870-024-04757-7', attributes={'IdType': 'doi'}), StringElement('10.1186/s12870-024-04757-7', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [[DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Buisson', 'ForeName': 'Sarah', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Cheung', 'ForeName': 'S Y Amy', 'Initials': 'SYA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Chounta', 'ForeName': 'Vasiliki', 'Initials': 'V'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Deprez', 'ForeName': 'Isabelle', 'Initials': 'I'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Desmond', 'ForeName': 'Alicia Catherine', 'Initials': 'AC'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Han', 'ForeName': 'Kelong', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Hanley', 'ForeName': 'Sherika', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Lin', 'ForeName': 'Yu-Wei', 'Initials': 'YW'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Patel', 'ForeName': 'Faeezah', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Paul', 'ForeName': 'Mary E', 'Initials': 'ME'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Roberts', 'ForeName': 'Gilly', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Whitson', 'ForeName': 'Kyle', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Zabih', 'ForeName': 'Sara', 'Initials': 'S'}, attributes={'ValidYN': 'Y'})]], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38538160', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '03', 'Day': '29'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '16'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.1016/S2352-3018(23)00300-4', attributes={'EIdType': 'doi', 'ValidYN': 'Y'}), StringElement('S2352-3018(23)00300-4', attributes={'EIdType': 'pii', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2352-3018', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '11', 'Issue': '4', 'PubDate': {'Year': '2024', 'Month': 'Apr'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The lancet. HIV', 'ISOAbbreviation': 'Lancet HIV'}, 'ArticleTitle': 'Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.', 'Pagination': {'StartPage': 'e211', 'EndPage': 'e221', 'MedlinePgn': 'e211-e221'}, 'Abstract': {'AbstractText': [StringElement('Combined intramuscular long-acting cabotegravir and long-acting rilpivirine constitute the first long-acting combination antiretroviral therapy (ART) regimen approved for adults with HIV. The goal of the IMPAACT 2017 study (MOCHA [More Options for Children and Adolescents]) was to assess the safety and pharmacokinetics of these drugs in adolescents.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement(\"In this phase 1/2, multicentre, open-label, non-comparative, dose-finding study, virologically suppressed adolescents (aged 12-17 years; weight ≥35 kg; BMI ≤31·5 kg/m<sup>2</sup>) with HIV-1 on daily oral ART were enrolled at 15 centres in four countries (Botswana, South Africa, Thailand, and the USA). After 4-6 weeks of oral cabotegravir (cohort 1C) or rilpivirine (cohort 1R), participants received intramuscular long-acting cabotegravir or long-acting rilpivirine every 4 weeks or 8 weeks per the adult dosing regimens, while continuing pre-study ART. The primary outcomes were assessments of safety measures, including all adverse events, until week 4 for oral cabotegravir and until week 16 for long-acting cabotegravir and long-acting rilpivirine, and pharmacokinetic measures, including the area under the plasma concentration versus time curve during the dosing interval (AUC<sub>0-tau</sub>) and drug concentrations, at week 2 for oral dosing of cabotegravir and at week 16 for intramuscular dosing of cabotegravir and rilpivirine. Enrolment into cohort 1C or cohort 1R was based on the participant's pre-study ART, meaning that masking was not done. For pharmacokinetic analyses, blood samples were drawn at weeks 2-4 after oral dosing and weeks 4-16 after intramuscular dosing. Safety outcome measures were summarised using frequencies, percentages, and exact 95% CIs; pharmacokinetic parameters were summarised using descriptive statistics. This trial is registered at ClinicalTrials.gov, NCT03497676, and is closed to enrolment.\", attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('Between March 19, 2019, and Nov 25, 2021, 55 participants were enrolled: 30 in cohort 1C and 25 in cohort 1R. At week 16, 28 (97%, 95% CI 82-100) of the 29 dose-evaluable participants in cohort 1C and 21 (91%; 72-99) of the 23 dose-evaluable participants in cohort 1R had reported at least one adverse event, with the most common being injection-site pain (nine [31%] in cohort 1C; nine [39%] in cohort 1R; none were severe). One (4%, 95% CI 0-22) participant in cohort 1R had an adverse event of grade 3 or higher, leading to treatment discontinuation, which was defined as acute rilpivirine-related allergic reaction (self-limiting generalised urticaria) after the first oral dose. No deaths or life-threatening events occurred. In cohort 1C, the week 2 median cabotegravir AUC<sub>0-tau</sub> was 148·5 (range 37·2-433·1) μg·h/mL. The week 16 median concentrations for the every-4-weeks and every-8-weeks dosing was 3·11 μg/mL (range 1·22-6·19) and 1·15 μg/mL (<0·025-5·29) for cabotegravir and 52·9 ng/mL (31·9-148·0) and 39·1 ng/mL (27·2-81·3) for rilpivirine, respectively. These concentrations were similar to those in adults.', attributes={'Label': 'FINDINGS', 'NlmCategory': 'RESULTS'}), StringElement('Study data support using long-acting cabotegravir or long-acting rilpivirine, given every 4 weeks or 8 weeks, per the adult dosing regimens, in virologically suppressed adolescents aged 12 years and older and weighing at least 35 kg.', attributes={'Label': 'INTERPRETATION', 'NlmCategory': 'CONCLUSIONS'}), StringElement('The National Institutes of Health and ViiV Healthcare.', attributes={'Label': 'FUNDING', 'NlmCategory': 'BACKGROUND'})], 'CopyrightInformation': 'Copyright © 2024 Elsevier Ltd. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"St Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: aditya.gaur@stjude.org.\"}], 'Identifier': [], 'LastName': 'Gaur', 'ForeName': 'Aditya H', 'Initials': 'AH'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'University of California San Diego, La Jolla, CA, USA.'}], 'Identifier': [], 'LastName': 'Capparelli', 'ForeName': 'Edmund V', 'Initials': 'EV'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'FHI 360, Durham, NC, USA.'}], 'Identifier': [], 'LastName': 'Calabrese', 'ForeName': 'Katherine', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}], 'Identifier': [], 'LastName': 'Baltrusaitis', 'ForeName': 'Kristin', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}], 'Identifier': [], 'LastName': 'Marzinke', 'ForeName': 'Mark A', 'Initials': 'MA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'ViiV Healthcare, Madrid, Spain.'}], 'Identifier': [], 'LastName': 'McCoig', 'ForeName': 'Cynthia', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Janssen Research and Development, Beerse, Belgium.'}], 'Identifier': [], 'LastName': 'Van Solingen-Ristea', 'ForeName': 'Rodica M', 'Initials': 'RM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Baragwanath Academic Hospital, Johannesburg, South Africa.'}], 'Identifier': [], 'LastName': 'Mathiba', 'ForeName': 'Sisinyana Ruth', 'Initials': 'SR'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.'}], 'Identifier': [], 'LastName': 'Adeyeye', 'ForeName': 'Adeola', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Bethesda, MD, USA.'}], 'Identifier': [], 'LastName': 'Moye', 'ForeName': 'John H', 'Initials': 'JH'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Frontier Science Foundation, Amherst, NY, USA.'}], 'Identifier': [], 'LastName': 'Heckman', 'ForeName': 'Barbara', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"University of Pennsylvania Perelman School of Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.\"}], 'Identifier': [], 'LastName': 'Lowenthal', 'ForeName': 'Elizabeth D', 'Initials': 'ED'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Frontier Science Foundation, Boston, MA, USA.'}], 'Identifier': [], 'LastName': 'Ward', 'ForeName': 'Shawn', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Frontier Science Foundation, Boston, MA, USA.'}], 'Identifier': [], 'LastName': 'Milligan', 'ForeName': 'Ryan', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Frontier Science Foundation, Boston, MA, USA.'}], 'Identifier': [], 'LastName': 'Samson', 'ForeName': 'Pearl', 'Initials': 'P'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'University of California San Diego, La Jolla, CA, USA.'}], 'Identifier': [], 'LastName': 'Best', 'ForeName': 'Brookie M', 'Initials': 'BM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'ViiV Healthcare, ResearchTriangle Park, NC, USA.'}], 'Identifier': [], 'LastName': 'Harrington', 'ForeName': 'Conn M', 'Initials': 'CM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'ViiV Healthcare, ResearchTriangle Park, NC, USA.'}], 'Identifier': [], 'LastName': 'Ford', 'ForeName': 'Susan L', 'Initials': 'SL'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'GlaxoSmithKline, Mississauga, ON, Canada.'}], 'Identifier': [], 'LastName': 'Huang', 'ForeName': 'Jenny', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Janssen Research and Development, Beerse, Belgium.'}], 'Identifier': [], 'LastName': 'Crauwels', 'ForeName': 'Herta', 'Initials': 'H'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Janssen Research and Development, Beerse, Belgium.'}], 'Identifier': [], 'LastName': 'Vandermeulen', 'ForeName': 'Kati', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}], 'Identifier': [], 'LastName': 'Agwu', 'ForeName': 'Allison L', 'Initials': 'AL'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'University of Colorado School of Medicine, Aurora, CO, USA.'}], 'Identifier': [], 'LastName': 'Smith-Anderson', 'ForeName': 'Christiana', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Emory University School of Medicine-Children's Healthcare of Atlanta, Atlanta, GA, USA.\"}], 'Identifier': [], 'LastName': 'Camacho-Gonzalez', 'ForeName': 'Andres', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand.'}], 'Identifier': [], 'LastName': 'Ounchanum', 'ForeName': 'Pradthana', 'Initials': 'P'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Frontier Science Foundation, Amherst, NY, USA.'}], 'Identifier': [], 'LastName': 'Kneebone', 'ForeName': 'Jared L', 'Initials': 'JL'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.'}], 'Identifier': [], 'LastName': 'Townley', 'ForeName': 'Ellen', 'Initials': 'E'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; University of Alabama, Birmingham, AL, USA.'}], 'Identifier': [], 'LastName': 'Bolton Moore', 'ForeName': 'Carolyn', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'CollectiveName': 'IMPAACT 2017 Collaborators'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'CollectiveName': 'IMPAACT 2017 Team'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'DataBankList': ListElement([{'DataBankName': 'ClinicalTrials.gov', 'AccessionNumberList': ['NCT03497676']}], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': 'UM1 AI068616', 'Acronym': 'AI', 'Agency': 'NIAID NIH HHS', 'Country': 'United States'}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Multicenter Study', attributes={'UI': 'D016448'}), StringElement('Clinical Trial, Phase II', attributes={'UI': 'D017427'}), StringElement('Clinical Trial, Phase I', attributes={'UI': 'D017426'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'Netherlands', 'MedlineTA': 'Lancet HIV', 'NlmUniqueID': '101645355', 'ISSNLinking': '2352-3018'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-HIV Agents', attributes={'UI': 'D019380'})}, {'RegistryNumber': 'HMH0132Z1Q', 'NameOfSubstance': StringElement('cabotegravir', attributes={'UI': 'C584914'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Diketopiperazines', attributes={'UI': 'D054659'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Pyridones', attributes={'UI': 'D011728'})}, {'RegistryNumber': 'FI96A8X663', 'NameOfSubstance': StringElement('Rilpivirine', attributes={'UI': 'D000068696'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Adolescent', attributes={'UI': 'D000293', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Child', attributes={'UI': 'D002648', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Anti-HIV Agents', attributes={'UI': 'D019380', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Diketopiperazines', attributes={'UI': 'D054659', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('HIV Infections', attributes={'UI': 'D015658', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Pyridones', attributes={'UI': 'D011728', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'}), StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Rilpivirine', attributes={'UI': 'D000068696', 'MajorTopicYN': 'N'})}], 'CoiStatement': \"Declaration of interests BMB, KB, PS, AHG, MAM, KC, and PO received IMPAACT Network grant funding from the National Institutes of Health (NIH) to support work on this protocol. AHG and PO's institutions have Clinical Trials Agreements (CTAs) with ViiV Healthcare to support the IMPAACT 2017 study. AHG's institution has a CTA with Janssen to support COVID-19 research and AHG is part of the ViiV Healthcare Pediatric Advisory Board. BMB, KB, MAM, SW, and RM's institution receives funding from ViiV Healthcare. MAM is a consultant for Bio-rad and receives royalties from Elsevier; their institution receives funding from Gilead for industry-sponsored research and funding from the NIH for HIV prevention and microbicide-related research. BMB's institution receives grant funding from Janssen for the study. HC, RMVS-R, and KV are employees of Janssen and have stock and stock options with Johnson & Johnson. ALA received grants or contracts from Gilead, Merck, and ViiV; and is content development faculty for the Simply Speaking HIV Prevention Series, an expert witness, an unpaid Advocates for Youth Board Chair, and an unpaid HIVMA Vice Chair. AC-G is a ViiV Healthcare consultant. CM and CMH are employees at ViiV Healthcare. SLF and JH are employees at GSK. SLF and CM own GSK stock or stock options. EVC is a Data Safety and Management Board member for a paediatric antibacterial study with Melinta Pharmaceuticals. All other authors declare no competing interests.\"}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Curated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2023', 'Month': '5', 'Day': '18'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2023', 'Month': '10', 'Day': '6'}, attributes={'PubStatus': 'revised'}), DictElement({'Year': '2023', 'Month': '11', 'Day': '13'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '29', 'Hour': '6', 'Minute': '46'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '28', 'Hour': '0', 'Minute': '45'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '27', 'Hour': '21', 'Minute': '54'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38538160', attributes={'IdType': 'pubmed'}), StringElement('10.1016/S2352-3018(23)00300-4', attributes={'IdType': 'doi'}), StringElement('S2352-3018(23)00300-4', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38538153', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '24'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '26'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '27'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1097/ACI.0000000000000978', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1473-6322', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '24', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Jun', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Current opinion in allergy and clinical immunology', 'ISOAbbreviation': 'Curr Opin Allergy Clin Immunol'}, 'ArticleTitle': 'Role of biologics in severe food allergy.', 'Pagination': {'StartPage': '138', 'EndPage': '143', 'MedlinePgn': '138-143'}, 'Abstract': {'AbstractText': [StringElement('This review examine the dynamic landscape of food allergy treatment within the context of emerging biologics. Our purpose is to comprehensively evaluate the potential benefits, challenges, and transformative impact associated with the utilization of biologics in comparison to conventional therapeutic modalities.', attributes={'Label': 'PURPOSE OF REVIEW', 'NlmCategory': 'OBJECTIVE'}), StringElement('This document synthesizes recent scientific investigations to various biologics, such as omalizumab, ligelizumab, dupilumab, and tezepelumab, providing a nuanced understanding of their roles in oral immunotherapy, rapid desensitization, and overall food allergy management. Recent studies and clinical trials highlight the impact of anti-IgE treatment on food allergies, revealing critical findings such as dose-related efficacy, facilitation of rapid desensitization in peanut allergies, and the sustained positive outcomes observed in individuals with multifood allergies.', attributes={'Label': 'RECENT FINDINGS', 'NlmCategory': 'RESULTS'}), StringElement('The use of biologics presents a groundbreaking approach in the treatment of food allergies. The multifaceted action of these agents, along with their potential to overcome the challenges associated with traditional therapies, marks a significant advancement. Despite the persisting challenges of economic constraints and the need for further safety studies, biologics offer a promising avenue for improving the quality of life for individuals with food allergies. Ongoing research and collaborative efforts are imperative to fully realize the transformative potential inherent in these emerging therapeutic frontiers.', attributes={'Label': 'SUMMARY', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': 'Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Women, Children, and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples.'}], 'Identifier': [], 'LastName': 'Dinardo', 'ForeName': 'Giulio', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Pediatric Allergology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.\"}], 'Identifier': [], 'LastName': 'Cafarotti', 'ForeName': 'Arianna', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Pediatric Allergology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.\"}], 'Identifier': [], 'LastName': 'Fierro', 'ForeName': 'Vincenzo', 'Initials': 'V'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Pediatric Allergology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.\"}], 'Identifier': [], 'LastName': 'Artesani', 'ForeName': 'Maria Cristina', 'Initials': 'MC'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Women, Children, and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples.'}], 'Identifier': [], 'LastName': 'Indolfi', 'ForeName': 'Cristiana', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Women, Children, and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples.'}], 'Identifier': [], 'LastName': 'Miraglia Del Giudice', 'ForeName': 'Michele', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Pediatric Allergology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.\"}], 'Identifier': [], 'LastName': 'Fiocchi', 'ForeName': 'Alessandro', 'Initials': 'A'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Print-Electronic'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'Curr Opin Allergy Clin Immunol', 'NlmUniqueID': '100936359', 'ISSNLinking': '1473-6322'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Allergens', attributes={'UI': 'D000485'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Allergic Agents', attributes={'UI': 'D018926'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Biological Products', attributes={'UI': 'D001688'})}, {'RegistryNumber': '37341-29-0', 'NameOfSubstance': StringElement('Immunoglobulin E', attributes={'UI': 'D007073'})}, {'RegistryNumber': '2P471X1Z11', 'NameOfSubstance': StringElement('Omalizumab', attributes={'UI': 'D000069444'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('immunology', attributes={'UI': 'Q000276', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Allergens', attributes={'UI': 'D000485', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Allergic Agents', attributes={'UI': 'D018926', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Biological Products', attributes={'UI': 'D001688', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('methods', attributes={'UI': 'Q000379', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Desensitization, Immunologic', attributes={'UI': 'D003888', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'}), StringElement('immunology', attributes={'UI': 'Q000276', 'MajorTopicYN': 'N'}), StringElement('therapy', attributes={'UI': 'Q000628', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Food Hypersensitivity', attributes={'UI': 'D005512', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('immunology', attributes={'UI': 'Q000276', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Immunoglobulin E', attributes={'UI': 'D007073', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Omalizumab', attributes={'UI': 'D000069444', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Quality of Life', attributes={'UI': 'D011788', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Curated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Gupta RS, Warren CM, Smith BM, et al. Prevalence and severity of food allergies among US adults. JAMA Netw Open 2019; 2:e185630.'}, {'Citation': 'Grabenhenrich L, Trendelenburg V, Bellach J, et al. Frequency of food allergy in school-aged children in eight European countries—the EuroPrevall-iFAAM birth cohort. Allergy 2020; 75:2294–2308.'}, {'Citation': 'Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J 2020; 13:100472.'}, {'Citation': 'Simons FER, Ardusso LR, Bilò MB, et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J 2014; 7:9.'}, {'Citation': 'Westwell-Roper C, To S, Andjelic G, et al. Food-allergy-specific anxiety and distress in parents of children with food allergy: a systematic review. Pediatr Allergy Immunol 2022; 33:e13695.'}, {'Citation': 'Arasi S, Nurmatov U, Dunn-Galvin A, et al. WAO consensus on DEfinition of Food Allergy SEverity (DEFASE). World Allergy Organ J 2023; 16:100753.'}, {'Citation': \"Alvaro-Lozano M, Akdis CA, Akdis M, et al. EAACI allergen immunotherapy user's guide. Pediatr Allergy Immunol 2020; 31: (Suppl 25): 1–101.\"}, {'Citation': 'Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy 2017; 72:1133–1147.'}, {'Citation': 'Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy 2018; 73:799–815.'}, {'Citation': 'Arasi S, Ebisawa M, Eigenmann P, et al. Editorial comment on “Oral immunotherapy as a curative treatment for food-allergic preschool children: current evidence and potential underlying mechanisms”. Pediatr Allergy Immunol 2024; 35:e14071.'}, {'Citation': 'Dinardo G, Fierro V, Del Giudice MM, et al. Food-labeling issues for severe food-allergic consumers. Curr Opin Allergy Clin Immunol 2023; 23:233–238.'}, {'Citation': 'Chinthrajah RS, Cao S, Dunham T, et al. Oral immunotherapy for peanut allergy: the pro argument. World Allergy Organ J 2020; 13:100455.'}, {'Citation': 'O’B Hourihane J, Beyer K, Abbas A, et al. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. Lancet Child Adolesc Heal 2020; 4:728–739.'}, {'Citation': 'Bird JA, Spergel JM, Jones SM, et al. Efficacy and Safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract 2018; 6:476–485. e3.'}, {'Citation': 'Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral immunotherapy in children aged 1–3\\u200ayears with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Lancet 2022; 399:359–371.'}, {'Citation': 'Vickery BP, Berglund JP, Burk CM, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol 2017; 139:173–181. e8.'}, {'Citation': 'Pouessel G, Lezmi G. Oral immunotherapy for food allergy: translation from studies to clinical practice? World Allergy Organ J 2023; 16:100747.'}, {'Citation': 'Chinthrajah RS, Purington N, Andorf S, et al. Development of a tool predicting severity of allergic reaction during peanut challenge. Ann Allergy Asthma Immunol 2018; 121:69–76. e2.'}, {'Citation': 'Fleischer DM, Greenhawt M, Sussman G, et al. Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES Randomized Clinical Trial. JAMA 2019; 321:946–955.'}, {'Citation': 'Chu DK, Freitag T, Marrin A, et al. Peanut oral immunotherapy with or without H1 and H2 antihistamine premedication for peanut allergy (PISCES): a placebo-controlled randomized clinical trial. J allergy Clin Immunol Pract 2022; 10:2386–2394.'}, {'Citation': 'Ciaccio C, Goldsobel AB, Anagnostou A, et al. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials. Ann Allergy Asthma Immunol 2022; 129:758–768. e4.'}, {'Citation': 'Sindher SB, Fiocchi A, Zuberbier T, et al. The role of biologics in the treatment of food allergy. J Allergy Clin Immunol Pract 2023; 12:562–568.'}, {'Citation': 'Bousquet J, Humbert M, Gibson PG, et al. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract 2021; 9:2702–2714.'}, {'Citation': 'Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy 2020; 75:1023–1042.'}, {'Citation': 'Indolfi C, Dinardo G, Klain A, et al. Time effect of dupilumab to treat severe uncontrolled asthma in adolescents: a pilot study. Allergol Immunopathol (Madr) 2023; 51:12–18.'}, {'Citation': 'Dinardo G, Indolfi C, Klain A, et al. Treatment of severe asthma: fast action of dupilumab in the pediatric setting. Minerva Pediatr 2023; 75:312–313.'}, {'Citation': 'Agache I, Song Y, Alonso-Coello P, et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines. Allergy 2021; 76:2337–2353.'}, {'Citation': 'Sindher SB, Barshow S, Tirumalasetty J, et al. The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders. J Allergy Clin Immunol 2023; 151:595–606.'}, {'Citation': 'Zuberbier T, Wood RA, Bindslev-Jensen C, et al. Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis. J allergy Clin Immunol Pract 2023; 11:1134–1146.'}, {'Citation': 'Fiocchi A, Artesani MC, Riccardi C, et al. Impact of omalizumab on food allergy in patients treated for asthma: a real-life study. J allergy Clin Immunol Pract 2019; 7:1901–1909. e5.'}, {'Citation': 'Azzano P, Paquin M, Langlois A, et al. Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients. J Allergy Clin Immunol 2021; 147:233–243.'}, {'Citation': 'MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol 2017; 139:873–881. e8.'}, {'Citation': 'Brandström J, Vetander M, Sundqvist AC, et al. Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents. Clin Exp Allergy 2019; 49:1328–1341.'}, {'Citation': \"Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. J Allergy Clin Immunol 2016; 137:1103–1110. e11.\"}, {'Citation': 'Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2019; 394:1437–1449.'}, {'Citation': 'Bégin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol 2014; 10:7.'}, {'Citation': 'Andorf S, Purington N, Block WM, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol 2018; 3:85–94.'}, {'Citation': 'Andorf S, Purington N, Kumar D, et al. A phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals. EClinicalMedicine 2019; 7:27–38.'}, {'Citation': 'Langlois A, Lavergne MH, Leroux H, et al. Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multifood oral immunotherapy. Allergy Asthma Clin Immunol 2020; 16:25.'}, {'Citation': 'Sindher S, Kumar D, Purington N, et al. A phase 2 study of multi oral immunotherapy in multi food allergic patients to test immune markers after minimum maintenance dose using xolair. J Allergy Clin Immunol 2020; 145:AB135.'}, {'Citation': 'Arasi S, Mennini M, Cafarotti A, et al. Omalizumab as monotherapy for food allergy. Curr Opin Allergy Clin Immunol 2021; 21:286–291.'}, {'Citation': 'Dinardo G, Cafarotti A, Galletta F, et al. Omalizumab in severe asthma and food allergies with IgE levels >1500\\u200akU/L: two-year evaluation. Pediatr Allergy Immunol 2023; 34:e14057.'}, {'Citation': 'Sampson HA, Leung DYM, Burks AW, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011; 127:1309–1310. e1.'}, {'Citation': 'Wood RA, Chinthrajah RS, Rudman Spergel AK, et al. Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH). J Allergy Clin Immunol Glob 2022; 1:225–232.'}, {'Citation': 'Groetch M, Mudd K, Woch M, et al. Retail food equivalents for post-oral immunotherapy dosing in the omalizumab as monotherapy and as adjunct therapy to multi-allergen Oral Immunotherapy in Food-Allergic Children and Adults (OUtMATCH) Clinical Trial. J Allergy Clin Immunol Pract 2023; 11:572–580. e2.'}, {'Citation': 'Wood RA, Chinthrajah RS, Eggel A, et al. The rationale for development of ligelizumab in food allergy. World Allergy Organ J 2022; 15:100690.'}, {'Citation': 'Spekhorst LS, van der Rijst LP, de Graaf M, et al. Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients. Allergy 2023; 78:875–878.'}, {'Citation': 'Chinthrajah S, Cao S, Liu C, et al. Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy. JCI insight 2019; 4:131347.'}, {'Citation': 'Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med 2021; 385:1656–1668.'}, {'Citation': 'Corren J, Ambrose CS, Sałapa K, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy. J allergy Clin Immunol Pract 2021; 9:4334–4342. e6.'}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2024', 'Month': '4', 'Day': '24', 'Hour': '19', 'Minute': '6'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '28', 'Hour': '0', 'Minute': '45'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '27', 'Hour': '21', 'Minute': '52'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38538153', attributes={'IdType': 'pubmed'}), StringElement('10.1097/ACI.0000000000000978', attributes={'IdType': 'doi'}), StringElement('00130832-990000000-00113', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('chlorhexidine gluconate (CHG)', attributes={'MajorTopicYN': 'N'}), StringElement('off‐label use', attributes={'MajorTopicYN': 'N'}), StringElement('povidone‐iodine (PI)', attributes={'MajorTopicYN': 'N'}), StringElement('randomized controlled trial (RCT)', attributes={'MajorTopicYN': 'N'}), StringElement('vaginal antisepsis', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38536409', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '03', 'Day': '29'}, 'DateRevised': {'Year': '2024', 'Month': '03', 'Day': '29'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.1002/aorn.14111', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1878-0369', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '119', 'Issue': '4', 'PubDate': {'Year': '2024', 'Month': 'Apr'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'AORN journal', 'ISOAbbreviation': 'AORN J'}, 'ArticleTitle': 'A Randomized Controlled Trial of Povidone-Iodine Versus Chlorhexidine Gluconate With Isopropyl Alcohol for Preoperative Vaginal Antisepsis.', 'Pagination': {'StartPage': '261', 'EndPage': '274', 'MedlinePgn': '261-274'}, 'Abstract': {'AbstractText': ['Many surgeons request use of 10% povidone-iodine (PI) for vaginal antisepsis; however, when PI is contraindicated, some surgeons request use of chlorhexidine gluconate (CHG) instead. The purpose of this randomized controlled trial was to determine any significant differences in self-reported symptoms associated with vaginal antisepsis with either 10% PI scrub or 4% CHG with 4% isopropyl alcohol. The control group comprised 62 participants who underwent vaginal antisepsis with the PI product, and the intervention group comprised 58 participants who underwent vaginal antisepsis with the CHG product. Participants completed surveys immediately before surgery, immediately after surgery, and 48 to 72 hours after surgery. No significant differences were found in the reported vaginal symptoms between the two groups for any survey. One participant in the intervention group reported symptoms consistent with an allergic reaction. Additional studies are needed on the use of CHG for vaginal antisepsis.'], 'CopyrightInformation': '© AORN, Inc, 2024.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Dunn', 'ForeName': 'Debra', 'Initials': 'D'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Yannotti', 'ForeName': 'Kara', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Centrella-Nigro', 'ForeName': 'Andrea', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Correa', 'ForeName': 'Stacy', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': \"O'Dea\", 'ForeName': 'Denise', 'Initials': 'D'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Wiley', 'ForeName': 'Sandra', 'Initials': 'S'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Randomized Controlled Trial', attributes={'UI': 'D016449'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'AORN J', 'NlmUniqueID': '0372403', 'ISSNLinking': '0001-2092'}, 'ChemicalList': [{'RegistryNumber': 'MOR84MUD8E', 'NameOfSubstance': StringElement('chlorhexidine gluconate', attributes={'UI': 'C010882'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Infective Agents, Local', attributes={'UI': 'D000891'})}, {'RegistryNumber': '85H0HZU99M', 'NameOfSubstance': StringElement('Povidone-Iodine', attributes={'UI': 'D011206'})}, {'RegistryNumber': 'ND2M416302', 'NameOfSubstance': StringElement('2-Propanol', attributes={'UI': 'D019840'})}, {'RegistryNumber': 'R4KO0DY52L', 'NameOfSubstance': StringElement('Chlorhexidine', attributes={'UI': 'D002710'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Female', attributes={'UI': 'D005260', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Infective Agents, Local', attributes={'UI': 'D000891', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Povidone-Iodine', attributes={'UI': 'D011206', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('2-Propanol', attributes={'UI': 'D019840', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('prevention & control', attributes={'UI': 'Q000517', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Surgical Wound Infection', attributes={'UI': 'D013530', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Preoperative Care', attributes={'UI': 'D011300', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'}), StringElement('analogs & derivatives', attributes={'UI': 'Q000031', 'MajorTopicYN': 'Y'})], 'DescriptorName': StringElement('Chlorhexidine', attributes={'UI': 'D002710', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Antisepsis', attributes={'UI': 'D000985', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Echols K, Graves M, LeBlanc KG, Marzolf S, Yount A. Role of antiseptics in the prevention of surgical site infections. Dermatol Surg. 2015;41(6):667‐676. https://doi.org/10.1097/dss.0000000000000375'}, {'Citation': \"King CA. Infection prevention and control. In: Rothrock JC, ed. Alexander's Care of the Patient in Surgery. 17th ed. St Louis, MO: Elsevier, Inc; 2023:53‐102.\"}, {'Citation': 'Reichman DE, Greenberg JA. Reducing surgical site infections: a review. Rev Obstet Gynecol. 2009;2(4):212‐221.'}, {'Citation': 'Skeith AE, Morgan DEM, Schmidt PC. Vaginal preparation with povidone‐iodine or chlorhexidine before hysterectomy: a propensity score matched analysis. Am J Obstet Gynecol. 2021;225(5):560.e1‐560.e9. https://doi.org/10.1016/j.ajog.2021.08.035'}, {'Citation': 'Patterson P. Quandary: what to do for vaginal prep. OR Manager. 2011;27(8):19‐23. Accessed November 16, 2023. https://www.ormanager.com/quandary‐what‐to‐do‐for‐vaginal‐prep/'}, {'Citation': 'Tumolo J. Surgical scrub recalled. Pharmacy Learning Network. February 23, 2023. Accessed November 22, 2023. https://www.hmpgloballearningnetwork.com/site/pln/news/surgical‐scrub‐recalled'}, {'Citation': 'Guideline for preoperative patient skin antisepsis. In: Guidelines for Perioperative Practice. Denver, CO: AORN, Inc; 2024:611‐664.'}, {'Citation': 'Cardinal Health ‐ chlorhexidine gluconate 4% liquid. DailyMed. Updated July 24, 2019. Accessed November 22, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b9c46b7‐6515‐1b9a‐e054‐00144ff88e88'}, {'Citation': \"Bigliardi PL, Eggars M, Cataldo M, Kapil R, Shet M, Pugsley MK. Iodine and iodine‐containing compounds. In: McDonnell G, Hansen JM, eds. Block's Disinfection, Sterilization, and Preservation. 6th ed. Philadelphia, PA: Wolters Kluwer; 2021:306‐331.\"}, {'Citation': 'Tran AQ, Topilow N, Rong A, et\\xa0al. Comparison of skin antiseptic agents and the role of 0.01% hypochlorous acid. Aesthet Surg J. 2021;41(10):1170‐1175. https://doi.org/10.1093/asj/sjaa322'}, {'Citation': 'Supradeeptha C, Shandilya SM, Naresh A, Satyaprasad J. Aqueous based povidone‐iodine related chemical burn under the tourniquet (a case report) and literature review. J Orthop. 2013;10(3):152‐154. https://doi.org/10.1016/j.jor.2013.07.007'}, {'Citation': 'Larson E. Guideline for use of topical antimicrobial agents. Am J Infect Control. 1988;16(6):253‐266. https://doi.org/10.1016/s0196‐6553(88)80005‐1'}, {'Citation': 'Le Pabic F, Sainte‐Laudy J, Blanchard N, Moneret‐Vautrin DA. First case of anaphylaxis to iodinated povidone. Allergy. 2003;58(8):826‐827. https://doi.org/10.1034/j.1398‐9995.2003.00254.x'}, {'Citation': 'Castelain F, Girardin P, Moumane L, Aubin F, Pelletier F. Anaphylactic reaction to povidone in a skin antiseptic. Contact Dermatitis. 2016;74(1):55‐56. https://doi.org/10.1111/cod.12473'}, {'Citation': 'Tanner J. Patient skin preparation. In: Hughes SJ, Mardell A, eds. Oxford Handbook of Perioperative Practice. New York, NY: Oxford University Press; 2009:259‐269.'}, {'Citation': 'Hill LVH, Embil JA. Vaginitis: current microbiologic and clinical concepts. CMAJ. 1986;134(4):321‐331. Accessed December 13, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1490817/pdf/cmaj00112‐0035.pdf'}, {'Citation': 'Duffy CR, Garcia‐So J, Arjemian B, Gyamfi‐Bannerman C, Han YW. A randomized trial of the bactericidal effects of chlorhexidine vs povidone‐iodine vaginal preparation. Am J Obstet Gynecol MFM. 2020;2(3):100114. https://doi.org/10.1016/j.ajogmf.2020.100114'}, {'Citation': 'Lakhi NA, Tricorico G, Osipova Y, Moretti ML. Vaginal cleansing with chlorhexidine gluconate or povidone‐iodine prior to cesarean delivery: a randomized comparator‐controlled trial. Am J Obstet Gynecol MFM. 2019;1(1):2‐9. https://doi.org/10.1016/j.ajogmf.2019.03.004'}, {'Citation': 'Vorherr H, Vorherr UF, Mehta P, Ulrich JA, Messer RH. Vaginal absorption of povidone‐iodine. JAMA. 1980;244(23):2628‐2629. https://doi.org/10.1001/jama.1980.03310230030018'}, {'Citation': 'Thong CL, Lambros M, Stewart MG, Kam PCA. An unexpected cause of an acute hypersensitivity reaction during recovery from anaesthesia. Anaesth Intensive Care. 2005;33(4):521‐524. https://doi.org/10.1177/0310057x0503300417'}, {'Citation': 'Calogiuri GF, Di Leo E, Trautmann A, Nettis E, Ferrannini A, Vacca A. Chlorhexidine hypersensitivity: a critical and updated review. J Allergy Ther. 2013;4(4):1000141. https://doi.org/10.4172/2155‐6121.1000141'}, {'Citation': \"Menon VP. Chlorhexidine. In: McDonnell G, Hansen JM, eds. Block's Disinfection, Sterilization, and Preservation. 6th ed. Philadelphia, PA: Wolters Kluwer; 2021:477‐506.\"}, {'Citation': 'Lowbury EJL, Lilly HA. Use of 4% chlorhexidine detergent solution (Hibiscrub) and other methods of disinfection. Br Med J. 1973;1(5352):510‐515. Accessed December 13, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1588678/pdf/brmedj01545‐0022.pdf'}, {'Citation': 'Goldenberg RL, McClure EM, Saleem S, Rouse D, Vermund S. Use of vaginally administered chlorhexidine during labor to improve pregnancy outcomes. Obstet Gynecol. 2006;107(5):1139‐1146. https://doi.org/10.1097/01.aog.0000215000.65665.dd'}, {'Citation': 'Shubair M, Stanek R, White S, Larsen B. Effects of chlorhexidine gluconate douche on normal vaginal flora. Gynecol Obstet Invest. 1992;34(4):229‐233. https://doi.org/10.1159/000292767'}, {'Citation': 'Vorherr H, Vorherr UF, Mehta P, Ulrich JA, Messer RH. Antimicrobial effect of chlorhexidine and povidone‐iodine on vaginal bacteria. J Infect. 1984;8(3):195‐199. https://doi.org/10.1016/s0163‐4453(84)93811‐8'}, {'Citation': 'Hibiclens ‐ chlorhexidine gluconate solution. DailyMed. Updated December 21, 2021. Accessed November 16, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4275eb53‐1a7e‐4a91‐aac1‐1085f40fac88'}, {'Citation': 'Betasept ‐ antiseptic surgical scrub solution. DailyMed. Updated June 11, 2023. Accessed November 16, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e64e7bf‐e88f‐4056‐c9e1‐b49a277daa6c'}, {'Citation': 'Committee on Practice Bulletins–Gynecology. ACOG Practice Bulletin No. 195. Prevention of infection after gynecologic procedures. Obstet Gynecol. 2018;131(6):e172‐e189. https://doi.org/10.1097/aog.0000000000002670'}, {'Citation': 'Understanding unapproved use of approved drugs “off label.” US Food and Drug Administration. Reviewed February 5, 2018. Accessed November 16, 2023. https://www.fda.gov/patients/learn‐about‐expanded‐access‐and‐other‐treatment‐options/understanding‐unapproved‐use‐approved‐drugs‐label'}, {'Citation': 'Calderwood MS, Anderson DJ, Bratzler DW, et\\xa0al. Strategies to prevent surgical site infections in acute‐care hospitals: 2022 update. Infect Control Hosp Epidemiol. 2023;44(5):695‐720. https://doi.org/10.1017/ice.2023.67'}, {'Citation': 'Stone R, Carey E, Fader AN, et\\xa0al. Enhanced recovery and surgical optimization protocol for minimally invasive gynecologic surgery: an AAGL white paper. J Minim Invasive Gynecol. 2021;28(2):179‐203. https://doi.org/10.1016/j.jmig.2020.08.006'}, {'Citation': 'Amstey MS, Jones AP. Preparation of the vagina for surgery. A comparison of povidone‐iodine and saline solution. JAMA. 1981;245(8):839‐841. https://doi.org/10.1001/jama.1981.03310330029019'}, {'Citation': 'Lewis LA, Lathi RB, Crochet P, Nezhat C. Preoperative vaginal preparation with baby shampoo compared with povidone‐iodine before gynecologic procedures. J Minim Invasiv Gynecol. 2007;14(6):736‐739. https://doi.org/10.1016/j.jmig.2007.05.010'}, {'Citation': 'Al‐Niaimi A, Rice LW, Shitanshu U, et\\xa0al. Safety and tolerability of chlorhexidine gluconate (2%) as a vaginal operative preparation in patients undergoing gynecologic surgery. Am J Infect Control. 2016;44(9):996‐998. https://doi.org/10.1016/j.ajic.2016.02.036'}, {'Citation': 'Wilson CM, Gray G, Read JS, et\\xa0al. Tolerance and safety of different concentrations of chlorhexidine for peripartum vaginal and infant washes: HIVNET 025. J Acquir Immune Defic Syndr. 2004;35(2):138‐143. https://doi.org/10.1097/00126334‐200402010‐00006'}, {'Citation': 'Rastogi S, Glaser L, Friedman J, Carter IV, Milad MP. Tolerance of chlorhexidine gluconate vaginal cleansing solution: a randomized controlled trial. J Gynecol Surg. 2020;36(1):13‐19. https://doi.org/10.1089/gyn.2019.0066'}, {'Citation': 'Rockefeller NF, Petersen TR, Komesu YM, et\\xa0al. Chlorhexidine gluconate vs povidone‐iodine vaginal antisepsis for urogynecologic surgery: a randomized controlled noninferiority trial. Am J Obstet Gynecol. 2022;227(1):66.e1‐66.e9. https://doi.org/10.1016/j.ajog.2021.12.260'}, {'Citation': 'Patnam R, Askew AL, Alby K, et\\xa0al. A randomized clinical trial comparing the efficacy and safety of 2% versus 4% chlorhexidine gluconate for surgical preparation of the vagina. Female Pelvic Med Reconstr Surg. 2022;28(7):400‐407. https://doi.org/10.1097/spv.0000000000001194'}, {'Citation': 'Research randomizer. Social Psychology Network. Accessed December 13, 2023. https://www.randomizer.org/'}, {'Citation': 'Milad M. Tolerance of chlorhexidine gluconate versus povidone iodine vaginal cleansing solution: a randomized control trial. National Library of Medicine. May 9, 2018. Accessed November 16, 2023. https://clinicaltrials.gov/ProvidedDocs/59/NCT03305159/Prot_SAP_000.pdf'}, {'Citation': 'The PRO‐CTCAE Measurement System. National Cancer Institute: Division of Cancer Control & Population Sciences. Accessed November 22, 2023. https://healthcaredelivery.cancer.gov/pro‐ctcae/measurement.html'}, {'Citation': 'Burman LG, Christensen P, Christensen K, et\\xa0al; Swedish Chlorhexidine Study Group. Prevention of excess neonatal morbidity associated with group B streptococci by vaginal chlorhexidine disinfection during labour. Lancet. 1992;340(8811):65‐69. https://doi.org/10.1016/0140‐6736(92)90393‐h'}, {'Citation': 'Rouse DJ, Hauth JC, Andrews WW, Mills BB, Maher JE. Chlorhexidine vaginal irrigation for the prevention of peripartal infection: a placebo‐controlled randomized clinical trial. Am J Obstet Gynecol. 1997;176(3):617‐622. https://doi.org/10.1016/s0002‐9378(97)70557‐x'}, {'Citation': 'Gaillard P, Mwanyumba F, Verhofstede C, et\\xa0al. Vaginal lavage with chlorhexidine during labour to reduce mother‐to‐child HIV transmission: clinical trial in Mombasa, Kenya. AIDS. 2001;15(3):389‐396. https://doi.org/10.1097/00002030‐200102160‐00012'}, {'Citation': 'Biggar RJ, Miotti PG, Taha TE, et\\xa0al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet. 1996;347(9016):1647‐1650. https://doi.org/10.1016/s0140‐6736(96)91486‐5'}, {'Citation': 'Culligan PJ, Kubik K, Murphy M, Blackwell L, Snyder J. A randomized trial that compared povidone iodine and chlorhexidine as antiseptics for vaginal hysterectomy. Am J Obstet Gynecol. 2005;192(2):422‐425. https://doi.org/10.1016/j.ajog.2004.08.010'}, {'Citation': 'Dang D, Dearholt SL, Bissett L, Ascenzi J, Whalen M. Johns Hopkins Evidence‐Based Practice for Nurses and Healthcare Professionals: Model and Guidelines. 4th ed. Indianapolis, IN: Sigma Theta Tau International; 2022.'}], 'ReferenceList': [], 'Title': 'REFERENCES'}], 'History': [DictElement({'Year': '2023', 'Month': '3', 'Day': '25'}, attributes={'PubStatus': 'revised'}), DictElement({'Year': '2022', 'Month': '5', 'Day': '2'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2023', 'Month': '5', 'Day': '4'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '29', 'Hour': '6', 'Minute': '47'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '27', 'Hour': '18', 'Minute': '44'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '27', 'Hour': '12', 'Minute': '4'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38536409', attributes={'IdType': 'pubmed'}), StringElement('10.1002/aorn.14111', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Dose equivalence', attributes={'MajorTopicYN': 'N'}), StringElement('Dose response', attributes={'MajorTopicYN': 'N'}), StringElement('Duration of action', attributes={'MajorTopicYN': 'N'}), StringElement('Inhaled corticosteroid', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [DictElement({'AbstractText': ['Patients with asthma often rely on inhaled corticosteroids to manage their symptoms by controlling lung inflammation. Inhaled corticosteroids can be used at low, medium, or high doses; however, the effectiveness, safety, and how long the effects last for a particular inhaled corticosteroid molecule are not considered when choosing them. This study investigated the safety and efficacy of different inhaled corticosteroid molecules. Leveraging published data on the mode of anti-inflammatory action and the rates these molecules are absorbed and eliminated from the body, we estimated their effectiveness and safety profiles, including duration of action in the lungs and systemic exposure levels. Some inhaled corticosteroid molecules such as fluticasone furoate, fluticasone propionate, and ciclesonide were found to exhibit high anti-inflammatory effectiveness in the lungs with minimal systemic exposure, contrasting the perceived similarities among currently used drug molecules. Anti-inflammatory duration of the unwanted systemic effect in the rest of the body was unique for each inhaled corticosteroid molecule. Notably, even the lowest doses of most inhaled corticosteroids were found to be effective in the lungs when taken as prescribed, supporting previous observations that clinical benefits are mostly realized at lower doses. Furthermore, estimated post dose durations of effectiveness for different inhaled corticosteroid molecules varied widely among different molecules, with some lasting a few hours and others lasting more than 80\\xa0h, suggesting significant differences in their duration of action. Overall, these findings demonstrate the potential advantage of using longer-acting inhaled corticosteroids, particularly for patients with asthma who may face challenges in adhering to prescribed regimens.'], 'CopyrightInformation': '© 2024. The Author(s).'}, attributes={'Type': 'plain-language-summary', 'Language': 'eng'})], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38532238', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '26'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '28'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '27'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1007/s12325-024-02823-y', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1865-8652', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '41', 'Issue': '5', 'PubDate': {'Year': '2024', 'Month': 'May'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Advances in therapy', 'ISOAbbreviation': 'Adv Ther'}, 'ArticleTitle': 'Pharmacological Basis of Differences in Dose Response, Dose Equivalence, and Duration of Action of Inhaled Corticosteroids.', 'Pagination': {'StartPage': '1995', 'EndPage': '2009', 'MedlinePgn': '1995-2009'}, 'Abstract': {'AbstractText': [StringElement('Asthma treatment guidelines classify inhaled corticosteroid (ICS) regimens as low, medium, or high dose. However, efficacy and safety are not independently assessed accordingly. Moreover, differences in ICS duration of action are not considered when a dose regimen is selected. We investigated the efficacy and safety implications of these limitations for available ICS molecules.', attributes={'Label': 'INTRODUCTION', 'NlmCategory': 'BACKGROUND'}), StringElement('Published pharmacodynamic and pharmacokinetic parameters were used, alongside physiological and pharmacological principles, to estimate the efficacy and safety of available ICS molecules. Extent and duration of glucocorticoid receptor (GR) occupancy in the lung (efficacy) and cortisol suppression (systemic exposure and safety) were estimated.', attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('Some ICS regimens (e.g., fluticasone furoate, fluticasone propionate, and ciclesonide) rank high for efficacy but low for systemic exposure, contrary to how ICS dose equivalence is currently viewed. Differences in dose-response relationships for efficacy and systemic exposure were unique for each ICS regimen and reflected in their therapeutic indices. Notably, even low doses of most ICSs can generate high GR occupancy (≥\\u200990%) across the entire dose interval at steady state, which may explain previously reported difficulties in obtaining dose responses within the clinical dose range and observations that most clinical benefit typically occurs at low doses. The estimated post dose duration of lung GR occupancy for ICS molecules was categorized as 4-6\\xa0h (short), 14-16\\xa0h (medium), 25-40\\xa0h (long), or >\\u200980\\xa0h (ultra-long), suggesting potentially large differences in anti-inflammatory duration of action.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('In a real-world clinical setting where there may be poor adherence to prescribed therapy, our findings suggest a significant therapeutic advantage for longer-acting ICS molecules in patients with asthma.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': '© 2024. The Author(s).'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinical Pharmacology and Experimental Medicine, GSK Research and Development, Brentford, UK.'}], 'Identifier': [StringElement('0000-0003-0684-5621', attributes={'Source': 'ORCID'})], 'LastName': 'Daley-Yates', 'ForeName': 'Peter T', 'Initials': 'PT'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'GSK, Singapore, 139234, Singapore. bhumika.x.aggarwal@gsk.com.'}], 'Identifier': [StringElement('0000-0002-8370-9319', attributes={'Source': 'ORCID'})], 'LastName': 'Aggarwal', 'ForeName': 'Bhumika', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'GSK, Abbotsford, VIC, Australia.'}, {'Identifier': [], 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.'}], 'Identifier': [StringElement('0000-0002-2111-1370', attributes={'Source': 'ORCID'})], 'LastName': 'Plank', 'ForeName': 'Maximilian', 'Initials': 'M'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'}), StringElement(\"Research Support, Non-U.S. Gov't\", attributes={'UI': 'D013485'})]}, attributes={'PubModel': 'Print-Electronic'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'Adv Ther', 'NlmUniqueID': '8611864', 'ISSNLinking': '0741-238X'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Adrenal Cortex Hormones', attributes={'UI': 'D000305'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Asthmatic Agents', attributes={'UI': 'D018927'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Receptors, Glucocorticoid', attributes={'UI': 'D011965'})}, {'RegistryNumber': 'CUT2W21N7U', 'NameOfSubstance': StringElement('Fluticasone', attributes={'UI': 'D000068298'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Administration, Inhalation', attributes={'UI': 'D000280', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Asthma', attributes={'UI': 'D001249', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Dose-Response Relationship, Drug', attributes={'UI': 'D004305', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('administration & dosage', attributes={'UI': 'Q000008', 'MajorTopicYN': 'N'}), StringElement('pharmacokinetics', attributes={'UI': 'Q000493', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Adrenal Cortex Hormones', attributes={'UI': 'D000305', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('administration & dosage', attributes={'UI': 'Q000008', 'MajorTopicYN': 'N'}), StringElement('pharmacokinetics', attributes={'UI': 'Q000493', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Asthmatic Agents', attributes={'UI': 'D018927', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug effects', attributes={'UI': 'Q000187', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Receptors, Glucocorticoid', attributes={'UI': 'D011965', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Treatment Outcome', attributes={'UI': 'D016896', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('administration & dosage', attributes={'UI': 'Q000008', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Fluticasone', attributes={'UI': 'D000068298', 'MajorTopicYN': 'N'})}], 'CoiStatement': 'Peter T. Daley-Yates was an employee and a shareholder of GSK at the time of the study. Bhumika Aggarwal and Maximilian Plank are employees and shareholders of GSK.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Global Initiative for Asthma. Global strategy for asthma management and prevention 2014. https://ginasthma.org/. Accessed 20 Oct 2023.'}, {'Citation': 'British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2003;58 Suppl 1(Suppl 1):i1–94.', 'ArticleIdList': [StringElement('PMC1766014', attributes={'IdType': 'pmc'}), StringElement('12653493', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372–380. doi: 10.1111/bcp.12637.', 'ArticleIdList': [StringElement('10.1111/bcp.12637', attributes={'IdType': 'doi'}), StringElement('PMC4574823', attributes={'IdType': 'pmc'}), StringElement('25808113', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Daley-Yates PT. Pharmacological basis of inhaled corticosteroid (ICS) dose equivalence and duration of action. Thorax. 2019;74:A215–A216.', 'ArticleIdList': [StringElement('PMC11052795', attributes={'IdType': 'pmc'}), StringElement('38532238', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Daley-Yates PT, Brealey N, Thomas S, et al. Therapeutic index of inhaled corticosteroids in asthma: a dose-response comparison on airway hyperresponsiveness and adrenal axis suppression. Br J Clin Pharmacol. 2021;87(2):483–493. doi: 10.1111/bcp.14406.', 'ArticleIdList': [StringElement('10.1111/bcp.14406', attributes={'IdType': 'doi'}), StringElement('PMC9328361', attributes={'IdType': 'pmc'}), StringElement('32484940', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Daley-Yates PT, Aggarwal B, Lulic Z, Fulmali S, Cruz AA, Singh D. Pharmacology versus convenience: a benefit/risk analysis of regular maintenance versus infrequent or as-needed inhaled corticosteroid use in mild asthma. Adv Ther. 2022;39(1):706–726. doi: 10.1007/s12325-021-01976-4.', 'ArticleIdList': [StringElement('10.1007/s12325-021-01976-4', attributes={'IdType': 'doi'}), StringElement('PMC8799535', attributes={'IdType': 'pmc'}), StringElement('34873657', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Masoli M, Holt S, Weatherall M, Beasley R. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J. 2004;23(4):552–558. doi: 10.1183/09031936.04.00076604.', 'ArticleIdList': [StringElement('10.1183/09031936.04.00076604', attributes={'IdType': 'doi'}), StringElement('15083753', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ. 2001;323(7307):253–256. doi: 10.1136/bmj.323.7307.253.', 'ArticleIdList': [StringElement('10.1136/bmj.323.7307.253', attributes={'IdType': 'doi'}), StringElement('PMC35344', attributes={'IdType': 'pmc'}), StringElement('11485952', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Beasley R, Harper J, Bird G, Maijers I, Weatherall M, Pavord ID. Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology. Am J Respir Crit Care Med. 2019;199(12):1471–1477. doi: 10.1164/rccm.201810-1868CI.', 'ArticleIdList': [StringElement('10.1164/rccm.201810-1868CI', attributes={'IdType': 'doi'}), StringElement('30645143', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chanez P, Karlstrom R, Godard P. High or standard initial dose of budesonide to control mild-to-moderate asthma? Eur Respir J. 2001;17(5):856–862. doi: 10.1183/09031936.01.17508560.', 'ArticleIdList': [StringElement('10.1183/09031936.01.17508560', attributes={'IdType': 'doi'}), StringElement('11488316', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Masoli M, Weatherall M, Holt S, Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax. 2004;59(1):16–20.', 'ArticleIdList': [StringElement('PMC1758851', attributes={'IdType': 'pmc'}), StringElement('14694240', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Esmailpour N, Högger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J. 1997;10(7):1496–1499. doi: 10.1183/09031936.97.10071496.', 'ArticleIdList': [StringElement('10.1183/09031936.97.10071496', attributes={'IdType': 'doi'}), StringElement('9230236', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hochhaus G, Rohdewald P, Mollmann H, Greschuchna D. Identification of glucocorticoid receptors in normal and neoplastic adult human lung. Res Exp Med (Berl) 1983;182(1):71–78. doi: 10.1007/BF01852289.', 'ArticleIdList': [StringElement('10.1007/BF01852289', attributes={'IdType': 'doi'}), StringElement('6856988', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Rousseau GG, Baxter JD. Glucocorticoid receptors. Monogr Endocrinol. 1979;12:49–77. doi: 10.1007/978-3-642-81265-1_3.', 'ArticleIdList': [StringElement('10.1007/978-3-642-81265-1_3', attributes={'IdType': 'doi'}), StringElement('386089', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lotvall J, Inman M, O’Byrne P. Measurement of airway hyperresponsiveness: new considerations. Thorax. 1998;53(5):419–424. doi: 10.1136/thx.53.5.419.', 'ArticleIdList': [StringElement('10.1136/thx.53.5.419', attributes={'IdType': 'doi'}), StringElement('PMC1745221', attributes={'IdType': 'pmc'}), StringElement('9708238', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Singh D, Garcia G, Maneechotesuwan K, et al. New versus old: the impact of changing patterns of inhaled corticosteroid prescribing and dosing regimens in asthma management. Adv Ther. 2022;39(5):1895–1914. doi: 10.1007/s12325-022-02092-7.', 'ArticleIdList': [StringElement('10.1007/s12325-022-02092-7', attributes={'IdType': 'doi'}), StringElement('PMC9056489', attributes={'IdType': 'pmc'}), StringElement('35284999', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lawrence M, Wolfe J, Webb DR, et al. Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. Am J Respir Crit Care Med. 1997;156:744–751. doi: 10.1164/ajrccm.156.3.9608058.', 'ArticleIdList': [StringElement('10.1164/ajrccm.156.3.9608058', attributes={'IdType': 'doi'}), StringElement('9309988', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gustafsson P, Tsanakas J, Gold M, Primhak R, Radford M, Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200\\xa0micrograms/day with inhaled beclomethasone dipropionate 400\\xa0micrograms/day in mild and moderate asthma. Arch Dis Child. 1993;69(2):206–211. doi: 10.1136/adc.69.2.206.', 'ArticleIdList': [StringElement('10.1136/adc.69.2.206', attributes={'IdType': 'doi'}), StringElement('PMC1029458', attributes={'IdType': 'pmc'}), StringElement('8215522', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Leblanc P, Mink S, Keistinen T, Saarelainen PA, Ringdal N, Payne SL. A comparison of fluticasone propionate 200\\xa0μg/day with beclomethasone dipropionate 400\\xa0μg/day in adult asthma. Allergy. 1994;49(5):380–385. doi: 10.1111/j.1398-9995.1994.tb02286.x.', 'ArticleIdList': [StringElement('10.1111/j.1398-9995.1994.tb02286.x', attributes={'IdType': 'doi'}), StringElement('8092438', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bardsley G, Daley-Yates PT, Baines A, et al. Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial. Respir Res. 2018;19(1):133. doi: 10.1186/s12931-018-0836-6.', 'ArticleIdList': [StringElement('10.1186/s12931-018-0836-6', attributes={'IdType': 'doi'}), StringElement('PMC6044077', attributes={'IdType': 'pmc'}), StringElement('30001712', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3. Philadelphia: Lea & Febiger; 1995.'}, {'Citation': 'Faassen F, Kelder J, Lenders J, Onderwater R, Vromans H. Physicochemical properties and transport of steroids across Caco-2 cells. Pharm Res. 2003;20(2):177–186. doi: 10.1023/A:1022210801734.', 'ArticleIdList': [StringElement('10.1023/A:1022210801734', attributes={'IdType': 'doi'}), StringElement('12636155', attributes={'IdType': 'pubmed'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2023', 'Month': '11', 'Day': '21'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '2', 'Day': '13'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '27', 'Hour': '9', 'Minute': '48'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '27', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '27', 'Hour': '0', 'Minute': '36'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '27'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38532238', attributes={'IdType': 'pubmed'}), StringElement('10.1007/s12325-024-02823-y', attributes={'IdType': 'doi'}), StringElement('10.1007/s12325-024-02823-y', attributes={'IdType': 'pii'}), StringElement('PMC11052795', attributes={'IdType': 'pmc'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38531640', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '22'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '22'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '18'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1124/jpet.123.002060', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1521-0103', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '389', 'Issue': '2', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '18'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The Journal of pharmacology and experimental therapeutics', 'ISOAbbreviation': 'J Pharmacol Exp Ther'}, 'ArticleTitle': 'Initial Characterization of a Transgenic Mouse with Overexpression of the Human H<sub>1</sub>-Histamine Receptor on the Heart.', 'Pagination': {'StartPage': '174', 'EndPage': '185', 'MedlinePgn': '174-185'}, 'Abstract': {'AbstractText': ['There is a debate on whether H<sub>1</sub>-histamine receptors can alter contractility in the mammalian heart. We studied here a new transgenic mouse model where we increased genetically the cardiac level of the H<sub>1</sub>-histamine receptor. We wanted to know if histamine could augment or decrease contractile parameters in mice with cardiac-specific overexpression of human H<sub>1</sub>-histamine receptors (H<sub>1</sub>-TG) and compared these findings with those in littermate wild-type mice (WT). In H<sub>1</sub>-TG mice, we studied the presence of H<sub>1</sub>-histamine receptors by autoradiography of the atrium and ventricle using [<sup>3</sup>H]mepyramine. The messenger RNA for human H<sub>1</sub>-histamine receptors was present in the heart from H<sub>1</sub>-TG and absent from WT. Using in situ hybridization, we noted mRNA for the human H<sub>1</sub>-histamine receptor in cardiac cells from H<sub>1</sub>-TG. We noted that histamine (1 nM-10 <i>µ</i>M) in paced (1 Hz) left atrial preparations from H<sub>1</sub>-TG, exerted at each concentration of histamine initially reduced force of contraction and then raised contractile force. Likewise, in spontaneously beating left atrial preparations from H<sub>1</sub>-TG, we noted that histamine led to a transient reduction in the spontaneous beating rate followed by an augmentation in the beating rate. The negative inotropic and chronotropic and the positive inotropic effects on histamine in isolated atrial muscle strips from H<sub>1</sub>-TG were attenuated by the H<sub>1</sub>-histamine receptor antagonist mepyramine. Histamine failed to exert an increased force or reduce the heartbeat in atrial preparations from WT. We concluded that stimulation of H<sub>1</sub>-histamine-receptors can decrease and then augment contractile force in the mammalian heart and stimulation of H<sub>1</sub>-histamine receptors exerts a negative chronotropic effect. SIGNIFICANCE STATEMENT: We made novel transgenic mice with cardiomyocyte-specific high expressional levels of the human H<sub>1</sub>-histamine receptor to contribute to the clarification of the controversy on whether H<sub>1</sub>-histamine receptors increase or decrease contractility and beating rate in the mammalian heart. From our data, we conclude that stimulation of H<sub>1</sub>-histamine receptors first decrease and then raise contractile force in the mammalian heart but exert solely negative chronotropic effects.'], 'CopyrightInformation': 'Copyright © 2024 by The American Society for Pharmacology and Experimental Therapeutics.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Rayo Abella', 'ForeName': 'Lina Maria', 'Initials': 'LM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Jacob', 'ForeName': 'Hannes', 'Initials': 'H'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Keller', 'ForeName': 'Max', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Schindler', 'ForeName': 'Lisa', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Pockes', 'ForeName': 'Steffen', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Pitzl', 'ForeName': 'Sebastian', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Klimas', 'ForeName': 'Jan', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [StringElement('0000-0001-7055-9561', attributes={'Source': 'ORCID'})], 'LastName': 'Hadova', 'ForeName': 'Katarína', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Schneider', 'ForeName': 'Sarah', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Buchwalow', 'ForeName': 'Igor B', 'Initials': 'IB'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Jin', 'ForeName': 'CongYu', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Panula', 'ForeName': 'Pertti', 'Initials': 'P'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Kirchhefer', 'ForeName': 'Uwe', 'Initials': 'U'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.) joachim.neumann@medizin.uni-halle.de.\"}], 'Identifier': [StringElement('0000-0001-5018-3851', attributes={'Source': 'ORCID'})], 'LastName': 'Neumann', 'ForeName': 'Joachim', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [StringElement('0000-0001-6986-485X', attributes={'Source': 'ORCID'})], 'LastName': 'Gergs', 'ForeName': 'Ulrich', 'Initials': 'U'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'J Pharmacol Exp Ther', 'NlmUniqueID': '0376362', 'ISSNLinking': '0022-3565'}, 'ChemicalList': [{'RegistryNumber': '820484N8I3', 'NameOfSubstance': StringElement('Histamine', attributes={'UI': 'D006632'})}, {'RegistryNumber': 'HPE317O9TL', 'NameOfSubstance': StringElement('Pyrilamine', attributes={'UI': 'D011738'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Receptors, Histamine', attributes={'UI': 'D011968'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Receptors, Histamine H1', attributes={'UI': 'D011969'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Mice', attributes={'UI': 'D051379', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Animals', attributes={'UI': 'D000818', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Mice, Transgenic', attributes={'UI': 'D008822', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Histamine', attributes={'UI': 'D006632', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Pyrilamine', attributes={'UI': 'D011738', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Myocardial Contraction', attributes={'UI': 'D009200', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Heart', attributes={'UI': 'D006321', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Receptors, Histamine', attributes={'UI': 'D011968', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Heart Atria', attributes={'UI': 'D006325', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Heart Rate', attributes={'UI': 'D006339', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('genetics', attributes={'UI': 'Q000235', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Receptors, Histamine H1', attributes={'UI': 'D011969', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Mammals', attributes={'UI': 'D008322', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2023', 'Month': '12', 'Day': '7'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '2', 'Day': '20'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '22', 'Hour': '6', 'Minute': '45'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '27', 'Hour': '0', 'Minute': '44'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '26', 'Hour': '21', 'Minute': '32'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38531640', attributes={'IdType': 'pubmed'}), StringElement('10.1124/jpet.123.002060', attributes={'IdType': 'doi'}), StringElement('jpet.123.002060', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38528089', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '03', 'Day': '27'}, 'DateRevised': {'Year': '2024', 'Month': '03', 'Day': '28'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '25'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('7076', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1038/s41598-024-57776-7', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2045-2322', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '14', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Mar', 'Day': '25'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Scientific reports', 'ISOAbbreviation': 'Sci Rep'}, 'ArticleTitle': 'Ketotifen directly modifies the fibrotic response of human skin fibroblasts.', 'Pagination': {'StartPage': '7076', 'MedlinePgn': '7076'}, 'Abstract': {'AbstractText': ['Fibrosis is a destructive, end-stage disease process. In the skin, it is associated with systemic sclerosis and scarring with considerable health burden. Ketotifen is a clinical antihistamine and mast cell stabilizer. Studies have demonstrated mast cell-dependent anti-fibrotic effects of ketotifen but direct effects on fibroblasts have not been determined. Human dermal fibroblasts were treated with pro-fibrotic transforming growth factor-β1 (TGFβ) followed by ketotifen or control treatments to determine direct effects on fibrotic fibroblasts. Ketotifen impaired TGFβ-induced α-smooth muscle actin gene and protein responses and decreased cytoskeletal- and contractility-associated gene responses associated with fibrosis. Ketotifen reduced Yes-associated protein phosphorylation, transcriptional coactivator with PDZ binding motif transcript and protein levels, and phosphorylation of protein kinase B. In a fibroblast-populated collagen gel contraction assay, ketotifen reduced the contractile activity of TGFβ-activated fibroblasts. In a murine model of bleomycin-induced skin fibrosis, collagen density and dermal thickness were significantly decreased in ketotifen-treated mice supporting in vitro findings. These results support a novel, direct anti-fibrotic activity of ketotifen, reducing pro-fibrotic phenotypic changes in fibroblasts and reducing collagen fibres in fibrotic mouse skin. Together, these findings suggest novel therapeutic potential and a novel mechanism of action for ketotifen in the context of fibrosis.'], 'CopyrightInformation': '© 2024. The Author(s).'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pathology, Dalhousie University, 5850 College Street, Room 7-C, PO BOX 15000, Halifax, NS, B3H 4R2, Canada.'}], 'Identifier': [], 'LastName': 'Leong', 'ForeName': 'Edwin', 'Initials': 'E'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Microbiology and Immunology, Dalhousie University, Halifax, Canada.'}], 'Identifier': [], 'LastName': 'Al-Bitar', 'ForeName': 'Haya', 'Initials': 'H'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pathology, Dalhousie University, 5850 College Street, Room 7-C, PO BOX 15000, Halifax, NS, B3H 4R2, Canada. jean.marshall@dal.ca.'}, {'Identifier': [], 'Affiliation': 'Department of Microbiology and Immunology, Dalhousie University, Halifax, Canada. jean.marshall@dal.ca.'}, {'Identifier': [], 'Affiliation': 'Beatrice Hunter Cancer Research Institute, Halifax, Canada. jean.marshall@dal.ca.'}], 'Identifier': [], 'LastName': 'Marshall', 'ForeName': 'Jean S', 'Initials': 'JS'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Microbiology and Immunology, Dalhousie University, Halifax, Canada. michael.bezuhly@iwk.nshealth.ca.'}, {'Identifier': [], 'Affiliation': 'Beatrice Hunter Cancer Research Institute, Halifax, Canada. michael.bezuhly@iwk.nshealth.ca.'}, {'Identifier': [], 'Affiliation': 'Division of Plastic Surgery, Izaak Walton Killam Health Centre, 5850/5980 University Avenue, PO Box 9700, Halifax, NS, B3K 6R8, Canada. michael.bezuhly@iwk.nshealth.ca.'}, {'Identifier': [], 'Affiliation': 'Department of Surgery, Dalhousie University, Halifax, Canada. michael.bezuhly@iwk.nshealth.ca.'}], 'Identifier': [], 'LastName': 'Bezuhly', 'ForeName': 'Michael', 'Initials': 'M'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': 'THC135230', 'Agency': 'CIHR', 'Country': 'Canada'}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic'}), 'MedlineJournalInfo': {'Country': 'England', 'MedlineTA': 'Sci Rep', 'NlmUniqueID': '101563288', 'ISSNLinking': '2045-2322'}, 'ChemicalList': [{'RegistryNumber': 'X49220T18G', 'NameOfSubstance': StringElement('Ketotifen', attributes={'UI': 'D007665'})}, {'RegistryNumber': '9007-34-5', 'NameOfSubstance': StringElement('Collagen', attributes={'UI': 'D003094'})}, {'RegistryNumber': '11056-06-7', 'NameOfSubstance': StringElement('Bleomycin', attributes={'UI': 'D001761'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Transforming Growth Factor beta1', attributes={'UI': 'D053773'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Transforming Growth Factor beta', attributes={'UI': 'D016212'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Mice', attributes={'UI': 'D051379', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Animals', attributes={'UI': 'D000818', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'}), StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'}), StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Ketotifen', attributes={'UI': 'D007665', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Fibrosis', attributes={'UI': 'D005355', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Skin', attributes={'UI': 'D012867', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Scleroderma, Systemic', attributes={'UI': 'D012595', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Collagen', attributes={'UI': 'D003094', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Fibroblasts', attributes={'UI': 'D005347', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Bleomycin', attributes={'UI': 'D001761', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Transforming Growth Factor beta1', attributes={'UI': 'D053773', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Cells, Cultured', attributes={'UI': 'D002478', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Transforming Growth Factor beta', attributes={'UI': 'D016212', 'MajorTopicYN': 'N'})}], 'CoiStatement': 'The authors declare no competing interests.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Wynn TA. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008;214:199–210. doi: 10.1002/path.2277.', 'ArticleIdList': [StringElement('10.1002/path.2277', attributes={'IdType': 'doi'}), StringElement('PMC2693329', attributes={'IdType': 'pmc'}), StringElement('18161745', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Wynn TA, Ramalingam TR. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat. Med. 2012;18:1028–1040. doi: 10.1038/nm.2807.', 'ArticleIdList': [StringElement('10.1038/nm.2807', attributes={'IdType': 'doi'}), StringElement('PMC3405917', attributes={'IdType': 'pmc'}), StringElement('22772564', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Muhl L, et al. Single-cell analysis uncovers fibroblast heterogeneity and criteria for fibroblast and mural cell identification and discrimination. Nat. Commun. 2020;111:1–18.', 'ArticleIdList': [StringElement('PMC7414220', attributes={'IdType': 'pmc'}), StringElement('32769974', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lynch MD, Watt FM. Fibroblast heterogeneity: Implications for human disease. J. Clin. Invest. 2018;128:26–35. doi: 10.1172/JCI93555.', 'ArticleIdList': [StringElement('10.1172/JCI93555', attributes={'IdType': 'doi'}), StringElement('PMC5749540', attributes={'IdType': 'pmc'}), StringElement('29293096', attributes={'IdType': 'pubmed'})]}, {'Citation': 'D’Urso M, Kurniawan NA. Mechanical and physical regulation of fibroblast-myofibroblast transition: From cellular mechanoresponse to tissue pathology. Front. Bioeng. Biotechnol. 2020;8:1–15.', 'ArticleIdList': [StringElement('PMC7793682', attributes={'IdType': 'pmc'}), StringElement('33425874', attributes={'IdType': 'pubmed'})]}, {'Citation': 'McAnulty RJ. Fibroblasts and myofibroblasts: Their source, function and role in disease. Int. J. Biochem. Cell Biol. 2007;39:666–671. doi: 10.1016/j.biocel.2006.11.005.', 'ArticleIdList': [StringElement('10.1016/j.biocel.2006.11.005', attributes={'IdType': 'doi'}), StringElement('17196874', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Distler JHW, et al. Shared and distinct mechanisms of fibrosis. Nat. Rev. Rheumatol. 2019;15:705–730. doi: 10.1038/s41584-019-0322-7.', 'ArticleIdList': [StringElement('10.1038/s41584-019-0322-7', attributes={'IdType': 'doi'}), StringElement('31712723', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Duscher D, et al. Mechanotransduction and fibrosis. J. Biomech. 2014;47:1997–2005. doi: 10.1016/j.jbiomech.2014.03.031.', 'ArticleIdList': [StringElement('10.1016/j.jbiomech.2014.03.031', attributes={'IdType': 'doi'}), StringElement('PMC4425300', attributes={'IdType': 'pmc'}), StringElement('24709567', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Barnes LA, et al. Mechanical forces in cutaneous wound healing: Emerging therapies to minimize scar formation. Adv. Wound Care. 2018;7:47–56. doi: 10.1089/wound.2016.0709.', 'ArticleIdList': [StringElement('10.1089/wound.2016.0709', attributes={'IdType': 'doi'}), StringElement('PMC5792236', attributes={'IdType': 'pmc'}), StringElement('29392093', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Varani J, et al. Decreased collagen production in chronologically aged skin: Roles of age-dependent alteration in fibroblast function and defective mechanical stimulation. Am. J. Pathol. 2006;168:1861–1868. doi: 10.2353/ajpath.2006.051302.', 'ArticleIdList': [StringElement('10.2353/ajpath.2006.051302', attributes={'IdType': 'doi'}), StringElement('PMC1606623', attributes={'IdType': 'pmc'}), StringElement('16723701', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kuehlmann B, Bonham CA, Zucal I, Prantl L, Gurtner GC. Mechanotransduction in wound healing and fibrosis. J. Clin. Med. 2020;9:1–19. doi: 10.3390/jcm9051423.', 'ArticleIdList': [StringElement('10.3390/jcm9051423', attributes={'IdType': 'doi'}), StringElement('PMC7290354', attributes={'IdType': 'pmc'}), StringElement('32403382', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Leong E, Bezuhly M, Marshall JS. Distinct metalloproteinase expression and functions in systemic sclerosis and fibrosis: What we know and the potential for intervention. Front. Physiol. 2021;12:1–9. doi: 10.3389/fphys.2021.727451.', 'ArticleIdList': [StringElement('10.3389/fphys.2021.727451', attributes={'IdType': 'doi'}), StringElement('PMC8432940', attributes={'IdType': 'pmc'}), StringElement('34512395', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Liu R, Hossain MM, Chen X, Jin JP. Mechanoregulation of SM22α/Transgelin. Biochemistry. 2017;56:5526–5538. doi: 10.1021/acs.biochem.7b00794.', 'ArticleIdList': [StringElement('10.1021/acs.biochem.7b00794', attributes={'IdType': 'doi'}), StringElement('28898058', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Choo YY, et al. Calponin 1 contributes to myofibroblast differentiation of human pleural mesothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2022;322:L348–L364. doi: 10.1152/ajplung.00289.2021.', 'ArticleIdList': [StringElement('10.1152/ajplung.00289.2021', attributes={'IdType': 'doi'}), StringElement('PMC8858681', attributes={'IdType': 'pmc'}), StringElement('35018804', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Daimon E, Shibukawa Y, Wada Y. Calponin 3 regulates stress fiber formation in dermal fibroblasts during wound healing. Arch. Dermatol. Res. 2013;305:571–584. doi: 10.1007/s00403-013-1343-8.', 'ArticleIdList': [StringElement('10.1007/s00403-013-1343-8', attributes={'IdType': 'doi'}), StringElement('23545751', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Alenghat FJ, Ingber DE. Mechanotransduction: All signals point to cytoskeleton, matrix, and integrins. Sci. STKE. 2002;119:1–4.', 'ArticleIdList': [StringElement('11842240', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Wang N, Tytell JD, Ingber DE. Mechanotransduction at a distance: Mechanically coupling the extracellular matrix with the nucleus. Nat. Rev. Mol. Cell Biol. 2009;101:75–82. doi: 10.1038/nrm2594.', 'ArticleIdList': [StringElement('10.1038/nrm2594', attributes={'IdType': 'doi'}), StringElement('19197334', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Halder G, Dupont S, Piccolo S. Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat. Rev. Mol. Cell Biol. 2012;139:591–600. doi: 10.1038/nrm3416.', 'ArticleIdList': [StringElement('10.1038/nrm3416', attributes={'IdType': 'doi'}), StringElement('22895435', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Liu F, et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2015;308:L344–L357. doi: 10.1152/ajplung.00300.2014.', 'ArticleIdList': [StringElement('10.1152/ajplung.00300.2014', attributes={'IdType': 'doi'}), StringElement('PMC4329470', attributes={'IdType': 'pmc'}), StringElement('25502501', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cai X, Wang KC, Meng Z. Mechanoregulation of YAP and TAZ in cellular homeostasis and disease progression. Front. Cell Dev. Biol. 2021;9:1–12. doi: 10.3389/fcell.2021.673599.', 'ArticleIdList': [StringElement('10.3389/fcell.2021.673599', attributes={'IdType': 'doi'}), StringElement('PMC8182050', attributes={'IdType': 'pmc'}), StringElement('34109179', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163:811–828. doi: 10.1016/j.cell.2015.10.044.', 'ArticleIdList': [StringElement('10.1016/j.cell.2015.10.044', attributes={'IdType': 'doi'}), StringElement('PMC4638384', attributes={'IdType': 'pmc'}), StringElement('26544935', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Link PA, et al. Combined control of the fibroblast contractile program by YAP and TAZ. Am. J. Physiol. Lung Cell. Mol. Physiol. 2022;322:L23–L32. doi: 10.1152/ajplung.00210.2021.', 'ArticleIdList': [StringElement('10.1152/ajplung.00210.2021', attributes={'IdType': 'doi'}), StringElement('PMC8721907', attributes={'IdType': 'pmc'}), StringElement('34755530', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gallant-Behm CL, Hildebrand KA, Hart DA. The mast cell stabilizer ketotifen prevents development of excessive skin wound contraction and fibrosis in red Duroc pigs. Wound Repair Regen. 2008;16:226–233. doi: 10.1111/j.1524-475X.2008.00363.x.', 'ArticleIdList': [StringElement('10.1111/j.1524-475X.2008.00363.x', attributes={'IdType': 'doi'}), StringElement('18318808', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tibbo ME, et al. Anti-fibrotic effects of the antihistamine ketotifen in a rabbit model of arthrofibrosis. Bone Jt. Res. 2020;9:302–310. doi: 10.1302/2046-3758.96.BJR-2019-0272.R2.', 'ArticleIdList': [StringElement('10.1302/2046-3758.96.BJR-2019-0272.R2', attributes={'IdType': 'doi'}), StringElement('PMC7376284', attributes={'IdType': 'pmc'}), StringElement('32728431', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Monument MJ, et al. The mast cell stabilizer ketotifen reduces joint capsule fibrosis in a rabbit model of post-traumatic joint contractures. Inflamm. Res. 2012;61:285–292. doi: 10.1007/s00011-011-0409-3.', 'ArticleIdList': [StringElement('10.1007/s00011-011-0409-3', attributes={'IdType': 'doi'}), StringElement('PMC3710138', attributes={'IdType': 'pmc'}), StringElement('22173279', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mia MM, Singh MK. New insights into Hippo/YAP signaling in fibrotic diseases. Cells. 2022;11:1–22. doi: 10.3390/cells11132065.', 'ArticleIdList': [StringElement('10.3390/cells11132065', attributes={'IdType': 'doi'}), StringElement('PMC9265296', attributes={'IdType': 'pmc'}), StringElement('35805148', attributes={'IdType': 'pubmed'})]}, {'Citation': 'He X, et al. Myofibroblast YAP/TAZ activation is a key step in organ fibrogenesis. JCI Insight. 2022;7:1–17. doi: 10.1172/jci.insight.146243.', 'ArticleIdList': [StringElement('10.1172/jci.insight.146243', attributes={'IdType': 'doi'}), StringElement('PMC8876427', attributes={'IdType': 'pmc'}), StringElement('35191398', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Borreguero-Muñoz N, et al. The Hippo pathway integrates PI3K–Akt signals with mechanical and polarity cues to control tissue growth. PLoS Biol. 2019;17:1–31. doi: 10.1371/journal.pbio.3000509.', 'ArticleIdList': [StringElement('10.1371/journal.pbio.3000509', attributes={'IdType': 'doi'}), StringElement('PMC6814241', attributes={'IdType': 'pmc'}), StringElement('31613895', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Eyres M, et al. Spatially resolved deconvolution of the fibrotic niche in lung fibrosis. Cell Rep. 2022;40:1–22. doi: 10.1016/j.celrep.2022.111230.', 'ArticleIdList': [StringElement('10.1016/j.celrep.2022.111230', attributes={'IdType': 'doi'}), StringElement('PMC10073410', attributes={'IdType': 'pmc'}), StringElement('35977489', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cerri S, et al. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment. Respir. Med. 2019;159:1–6. doi: 10.1016/j.rmed.2019.105803.', 'ArticleIdList': [StringElement('10.1016/j.rmed.2019.105803', attributes={'IdType': 'doi'}), StringElement('31670147', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Cameli P, et al. Long-term follow-up of patients with idiopathic pulmonary fibrosis treated with pirfenidone or nintedanib: A real-life comparison study. Front. Mol. Biosci. 2020;7:1–8. doi: 10.3389/fmolb.2020.581828.', 'ArticleIdList': [StringElement('10.3389/fmolb.2020.581828', attributes={'IdType': 'doi'}), StringElement('PMC7498677', attributes={'IdType': 'pmc'}), StringElement('33102528', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Conte E, et al. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur. J. Pharm. Sci. 2014;58:13–19. doi: 10.1016/j.ejps.2014.02.014.', 'ArticleIdList': [StringElement('10.1016/j.ejps.2014.02.014', attributes={'IdType': 'doi'}), StringElement('24613900', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Wollin L, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. J. 2015;45:1434–1445. doi: 10.1183/09031936.00174914.', 'ArticleIdList': [StringElement('10.1183/09031936.00174914', attributes={'IdType': 'doi'}), StringElement('PMC4416110', attributes={'IdType': 'pmc'}), StringElement('25745043', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Abelson MB, Chapin MJ, Kapik BM, Shams NBK. Efficacy of Ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model. Arch. Ophthalmol. 2003;121:626–630. doi: 10.1001/archopht.121.5.626.', 'ArticleIdList': [StringElement('10.1001/archopht.121.5.626', attributes={'IdType': 'doi'}), StringElement('12742839', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Sokol KC, Amar NK, Starkey J, Grant JA. Ketotifen in the management of chronic urticaria: Resurrection of an old drug. Ann. Allergy Asthma Immunol. 2013;111:433–436. doi: 10.1016/j.anai.2013.10.003.', 'ArticleIdList': [StringElement('10.1016/j.anai.2013.10.003', attributes={'IdType': 'doi'}), StringElement('PMC4309375', attributes={'IdType': 'pmc'}), StringElement('24267353', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-β signaling in fibrosis. Growth Factors. 2011;29:196–202. doi: 10.3109/08977194.2011.595714.', 'ArticleIdList': [StringElement('10.3109/08977194.2011.595714', attributes={'IdType': 'doi'}), StringElement('PMC4408550', attributes={'IdType': 'pmc'}), StringElement('21740331', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Vallée A, Lecarpentier Y. TGF-β in fibrosis by acting as a conductor for contractile properties of myofibroblasts. Cell Biosci. 2019;91:1–15.', 'ArticleIdList': [StringElement('PMC6902440', attributes={'IdType': 'pmc'}), StringElement('31827764', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hinz B, Dugina V, Ballestrem C, Wehrle-Haller B, Chaponnier C. α-smooth muscle actin is crucial for focal adhesion maturation in myofibroblasts. Mol. Biol. Cell. 2003;14:2508–2519. doi: 10.1091/mbc.e02-11-0729.', 'ArticleIdList': [StringElement('10.1091/mbc.e02-11-0729', attributes={'IdType': 'doi'}), StringElement('PMC194898', attributes={'IdType': 'pmc'}), StringElement('12808047', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol. Biol. Cell. 2001;12:2730–2741. doi: 10.1091/mbc.12.9.2730.', 'ArticleIdList': [StringElement('10.1091/mbc.12.9.2730', attributes={'IdType': 'doi'}), StringElement('PMC59708', attributes={'IdType': 'pmc'}), StringElement('11553712', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Shinde AV, Humeres C, Frangogiannis NG. The role of α-smooth muscle actin in fibroblast-mediated matrix contraction and remodeling. Biochim. Biophys. Acta Mol. Basis Dis. 2017;1863:298–309. doi: 10.1016/j.bbadis.2016.11.006.', 'ArticleIdList': [StringElement('10.1016/j.bbadis.2016.11.006', attributes={'IdType': 'doi'}), StringElement('PMC5163362', attributes={'IdType': 'pmc'}), StringElement('27825850', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hinz B, et al. Recent developments in myofibroblast biology: Paradigms for connective tissue remodeling. Am. J. Pathol. 2012;180:1340–1355. doi: 10.1016/j.ajpath.2012.02.004.', 'ArticleIdList': [StringElement('10.1016/j.ajpath.2012.02.004', attributes={'IdType': 'doi'}), StringElement('PMC3640252', attributes={'IdType': 'pmc'}), StringElement('22387320', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hinz B, Gabbiani G. Mechanisms of force generation and transmission by myofibroblasts. Curr. Opin. Biotechnol. 2003;14:538–546. doi: 10.1016/j.copbio.2003.08.006.', 'ArticleIdList': [StringElement('10.1016/j.copbio.2003.08.006', attributes={'IdType': 'doi'}), StringElement('14580586', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tai Y, et al. Myofibroblasts: Function, formation, and scope of molecular therapies for skin fibrosis. Biomolecules. 2021;11:1–27. doi: 10.3390/biom11081095.', 'ArticleIdList': [StringElement('10.3390/biom11081095', attributes={'IdType': 'doi'}), StringElement('PMC8391320', attributes={'IdType': 'pmc'}), StringElement('34439762', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Sandbo N, Dulin N. The actin cytoskeleton in myofibroblast differentiation: Ultrastructure defining form and driving function. Transl. Res. 2011;158:181–196. doi: 10.1016/j.trsl.2011.05.004.', 'ArticleIdList': [StringElement('10.1016/j.trsl.2011.05.004', attributes={'IdType': 'doi'}), StringElement('PMC3324184', attributes={'IdType': 'pmc'}), StringElement('21925115', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Guo X, Chen Xia Guo S-Y, Chen S-Y. Transforming growth factor-β and smooth muscle differentiation. World. J. Biol. Chem. 2012;3:41–52. doi: 10.4331/wjbc.v3.i3.41.', 'ArticleIdList': [StringElement('10.4331/wjbc.v3.i3.41', attributes={'IdType': 'doi'}), StringElement('PMC3312200', attributes={'IdType': 'pmc'}), StringElement('22451850', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Qiu P, Feng XH, Li L. Interaction of Smad3 and SRF-associated complex mediates TGF-β1 signals to regulate SM22 transcription during myofibroblast differentiation. J. Mol. Cell. Cardiol. 2003;35:1407–1420. doi: 10.1016/j.yjmcc.2003.09.002.', 'ArticleIdList': [StringElement('10.1016/j.yjmcc.2003.09.002', attributes={'IdType': 'doi'}), StringElement('14654367', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Liu R, Jin JP. Calponin isoforms CNN1, CNN2 and CNN3: Regulators for actin cytoskeleton functions in smooth muscle and non-muscle cells. Gene. 2016;585:143–153. doi: 10.1016/j.gene.2016.02.040.', 'ArticleIdList': [StringElement('10.1016/j.gene.2016.02.040', attributes={'IdType': 'doi'}), StringElement('PMC5325697', attributes={'IdType': 'pmc'}), StringElement('26970176', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Elsafadi M, et al. Transgelin is a TGFβ-inducible gene that regulates osteoblastic and adipogenic differentiation of human skeletal stem cells through actin cytoskeleston organization. Cell Death Dis. 2016;7:e2321–e2321. doi: 10.1038/cddis.2016.196.', 'ArticleIdList': [StringElement('10.1038/cddis.2016.196', attributes={'IdType': 'doi'}), StringElement('PMC5108308', attributes={'IdType': 'pmc'}), StringElement('27490926', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Zeidan A, et al. Ablation of SM22α decreases contractility and actin contents of mouse vascular smooth muscle. FEBS Lett. 2004;562:141–146. doi: 10.1016/S0014-5793(04)00220-0.', 'ArticleIdList': [StringElement('10.1016/S0014-5793(04)00220-0', attributes={'IdType': 'doi'}), StringElement('15044015', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Feng HZ, Wang H, Takahashi K, Jin JP. Double deletion of calponin 1 and calponin 2 in mice decreases systemic blood pressure with blunted length-tension response of aortic smooth muscle. J. Mol. Cell. Cardiol. 2019;129:49–57. doi: 10.1016/j.yjmcc.2019.01.026.', 'ArticleIdList': [StringElement('10.1016/j.yjmcc.2019.01.026', attributes={'IdType': 'doi'}), StringElement('PMC6486848', attributes={'IdType': 'pmc'}), StringElement('30707993', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gokey JJ, Patel SD, Kropski JA. The role of hippo/YAP signaling in alveolar repair and pulmonary fibrosis. Front. Med. 2021;8:1–7. doi: 10.3389/fmed.2021.752316.', 'ArticleIdList': [StringElement('10.3389/fmed.2021.752316', attributes={'IdType': 'doi'}), StringElement('PMC8520933', attributes={'IdType': 'pmc'}), StringElement('34671628', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mia MM, et al. Loss of Yap/Taz in cardiac fibroblasts attenuates adverse remodelling and improves cardiac function. Cardiovasc. Res. 2022;118:1785–1804. doi: 10.1093/cvr/cvab205.', 'ArticleIdList': [StringElement('10.1093/cvr/cvab205', attributes={'IdType': 'doi'}), StringElement('34132780', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Garoffolo G, et al. Reduction of cardiac fibrosis by interference with YAP-dependent transactivation. Circ. Res. 2022;131:239–257. doi: 10.1161/CIRCRESAHA.121.319373.', 'ArticleIdList': [StringElement('10.1161/CIRCRESAHA.121.319373', attributes={'IdType': 'doi'}), StringElement('35770662', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Noguchi S, et al. TAZ contributes to pulmonary fibrosis by activating profibrotic functions of lung fibroblasts. Sci. Rep. 2017;7:1–11. doi: 10.1038/srep42595.', 'ArticleIdList': [StringElement('10.1038/srep42595', attributes={'IdType': 'doi'}), StringElement('PMC5307361', attributes={'IdType': 'pmc'}), StringElement('28195168', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Miranda MZ, et al. TGF-β1 regulates the expression and transcriptional activity of TAZ protein via a Smad3-independent, myocardin-related transcription factor-mediated mechanism. J. Biol. Chem. 2017;292:14902–14920. doi: 10.1074/jbc.M117.780502.', 'ArticleIdList': [StringElement('10.1074/jbc.M117.780502', attributes={'IdType': 'doi'}), StringElement('PMC5592669', attributes={'IdType': 'pmc'}), StringElement('28739802', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Szeto SG, et al. YAP/TAZ are mechanoregulators of TGF-b-smad signaling and renal fibrogenesis. J. Am. Soc. Nephrol. 2016;27:3117–3128. doi: 10.1681/ASN.2015050499.', 'ArticleIdList': [StringElement('10.1681/ASN.2015050499', attributes={'IdType': 'doi'}), StringElement('PMC5042658', attributes={'IdType': 'pmc'}), StringElement('26961347', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Zhao B, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747–2761. doi: 10.1101/gad.1602907.', 'ArticleIdList': [StringElement('10.1101/gad.1602907', attributes={'IdType': 'doi'}), StringElement('PMC2045129', attributes={'IdType': 'pmc'}), StringElement('17974916', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Moon S, et al. Phosphorylation by NLK inhibits YAP -14-3-3-interactions and induces its nuclear localization. EMBO Rep. 2017;18:61–71. doi: 10.15252/embr.201642683.', 'ArticleIdList': [StringElement('10.15252/embr.201642683', attributes={'IdType': 'doi'}), StringElement('PMC5210122', attributes={'IdType': 'pmc'}), StringElement('27979972', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Wang X, et al. Hepatocyte TAZ/WWTR1 promotes inflammation and fibrosis in Nonalcoholic steatohepatitis. Cell Metab. 2016;24:848–862. doi: 10.1016/j.cmet.2016.09.016.', 'ArticleIdList': [StringElement('10.1016/j.cmet.2016.09.016', attributes={'IdType': 'doi'}), StringElement('PMC5226184', attributes={'IdType': 'pmc'}), StringElement('28068223', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Morrison J, et al. Transcriptional profiling confirms the therapeutic effects of mast cell stabilization in a dengue disease model. J. Virol. 2017;91:617–634. doi: 10.1128/JVI.00617-17.', 'ArticleIdList': [StringElement('10.1128/JVI.00617-17', attributes={'IdType': 'doi'}), StringElement('PMC5571258', attributes={'IdType': 'pmc'}), StringElement('28659489', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Toyama T, et al. Therapeutic targeting of TAZ and YAP by dimethyl fumarate in systemic sclerosis fibrosis. J. Invest. Dermatol. 2018;138:78–88. doi: 10.1016/j.jid.2017.08.024.', 'ArticleIdList': [StringElement('10.1016/j.jid.2017.08.024', attributes={'IdType': 'doi'}), StringElement('PMC5742036', attributes={'IdType': 'pmc'}), StringElement('28870693', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Gui Y, et al. Yap/Taz mediates mTORC2-stimulated fibroblast activation and kidney fibrosis. J. Biol. Chem. 2018;293:16364–16375. doi: 10.1074/jbc.RA118.004073.', 'ArticleIdList': [StringElement('10.1074/jbc.RA118.004073', attributes={'IdType': 'doi'}), StringElement('PMC6200934', attributes={'IdType': 'pmc'}), StringElement('30154246', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hsu HS, et al. Involvement of ER stress, PI3K/AKT activation, and lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis. Sci. Rep. 2017;7:1–11. doi: 10.1038/s41598-017-14612-5.', 'ArticleIdList': [StringElement('10.1038/s41598-017-14612-5', attributes={'IdType': 'doi'}), StringElement('PMC5660192', attributes={'IdType': 'pmc'}), StringElement('29079731', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Qin W, Cao L, Massey IY. Role of PI3K/Akt signaling pathway in cardiac fibrosis. Mol. Cell. Biochem. 2021;476:4045–4059. doi: 10.1007/s11010-021-04219-w.', 'ArticleIdList': [StringElement('10.1007/s11010-021-04219-w', attributes={'IdType': 'doi'}), StringElement('34244974', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Zhang XL, Xing RG, Chen L, Liu CR, Miao ZG. PI3K/Akt signaling is involved in the pathogenesis of bleomycin-induced pulmonary fibrosis via regulation of epithelial-mesenchymal transition. Mol. Med. Rep. 2016;14:5699–5706. doi: 10.3892/mmr.2016.5960.', 'ArticleIdList': [StringElement('10.3892/mmr.2016.5960', attributes={'IdType': 'doi'}), StringElement('27878273', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lu Y, et al. Phosphatidylinositol-3-kinase/Akt regulates bleomycin-induced fibroblast proliferation and collagen production. Am. J. Respir. Cell Mol. Biol. 2010;42:432–441. doi: 10.1165/rcmb.2009-0002OC.', 'ArticleIdList': [StringElement('10.1165/rcmb.2009-0002OC', attributes={'IdType': 'doi'}), StringElement('PMC2848736', attributes={'IdType': 'pmc'}), StringElement('19520917', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bujor AM, et al. Akt blockade downregulates collagen and upregulates MMP1 in human dermal fibroblasts. J. Invest. Dermatol. 2008;128:1906–1914. doi: 10.1038/jid.2008.39.', 'ArticleIdList': [StringElement('10.1038/jid.2008.39', attributes={'IdType': 'doi'}), StringElement('18323784', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Morin F, et al. Niclosamide prevents systemic sclerosis in a reactive oxygen species-induced mouse model. J. Immunol. 2016;197:3018–3028. doi: 10.4049/jimmunol.1502482.', 'ArticleIdList': [StringElement('10.4049/jimmunol.1502482', attributes={'IdType': 'doi'}), StringElement('27613696', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hildebrand KA, Zhang M, Befus AD, Salo PT, Hart DA. A myofibroblast–mast cell–neuropeptide axis of fibrosis in post-traumatic joint contractures: An in vitro analysis of mechanistic components. J. Orthop. Res. 2014;32:1290–1296. doi: 10.1002/jor.22676.', 'ArticleIdList': [StringElement('10.1002/jor.22676', attributes={'IdType': 'doi'}), StringElement('24985721', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Monument MJ, et al. The mast cell stabilizer ketotifen fumarate lessens contracture severity and myofibroblast hyperplasia: A study of a rabbit model of posttraumatic joint contractures. J. Bone Jt. Surg. 2010;92:1468–1477. doi: 10.2106/JBJS.I.00684.', 'ArticleIdList': [StringElement('10.2106/JBJS.I.00684', attributes={'IdType': 'doi'}), StringElement('PMC3033391', attributes={'IdType': 'pmc'}), StringElement('20516323', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Narayanan AS, Page RC, Swanson J. Collagen synthesis by human fibroblasts Regulation by transforming growth factor-fl in the presence of other inflammatory mediators. Biochem. J. 1989;260:463–469. doi: 10.1042/bj2600463.', 'ArticleIdList': [StringElement('10.1042/bj2600463', attributes={'IdType': 'doi'}), StringElement('PMC1138691', attributes={'IdType': 'pmc'}), StringElement('2504143', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Fisher GJ, Varani J, Voorhees JJ. Looking older: Fibroblast collapse and therapeutic implications. Arch. Dermatol. 2008;144:666–672. doi: 10.1001/archderm.144.5.666.', 'ArticleIdList': [StringElement('10.1001/archderm.144.5.666', attributes={'IdType': 'doi'}), StringElement('PMC2887041', attributes={'IdType': 'pmc'}), StringElement('18490597', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Walker M, Harley R, Leroy EC. Ketotifen prevents skin fibrosis in the tight skin mouse. J. Rheumatol. 1990;17:57–59.', 'ArticleIdList': [StringElement('2313674', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Abdalla M, Goc A, Segar L, Somanath PR. Akt1 mediates α-smooth muscle actin expression and myofibroblast differentiation via myocardin and serum response factor. J. Biol. Chem. 2013;288:33483–33493. doi: 10.1074/jbc.M113.504290.', 'ArticleIdList': [StringElement('10.1074/jbc.M113.504290', attributes={'IdType': 'doi'}), StringElement('PMC3829193', attributes={'IdType': 'pmc'}), StringElement('24106278', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Paterno J, et al. Akt-mediated mechanotransduction in murine fibroblasts during hypertrophic scar formation. Wound Repair Regen. 2011;19:49–58. doi: 10.1111/j.1524-475X.2010.00643.x.', 'ArticleIdList': [StringElement('10.1111/j.1524-475X.2010.00643.x', attributes={'IdType': 'doi'}), StringElement('21134033', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Li G, Li YY, Sun JE, Lin WH, Zhou RX. ILK–PI3K/AKT pathway participates in cutaneous wound contraction by regulating fibroblast migration and differentiation to myofibroblast. Lab. Investig. 2016;96:741–751. doi: 10.1038/labinvest.2016.48.', 'ArticleIdList': [StringElement('10.1038/labinvest.2016.48', attributes={'IdType': 'doi'}), StringElement('27111285', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hua H, et al. Targeting Akt in cancer for precision therapy. J. Hematol. Oncol. 2021;14:1–25. doi: 10.1186/s13045-021-01137-8.', 'ArticleIdList': [StringElement('10.1186/s13045-021-01137-8', attributes={'IdType': 'doi'}), StringElement('PMC8379749', attributes={'IdType': 'pmc'}), StringElement('34419139', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Martorana F, et al. AKT inhibitors: New weapons in the fight against breast cancer? Front. Pharmacol. 2021;12:1–13. doi: 10.3389/fphar.2021.662232.', 'ArticleIdList': [StringElement('10.3389/fphar.2021.662232', attributes={'IdType': 'doi'}), StringElement('PMC8118639', attributes={'IdType': 'pmc'}), StringElement('33995085', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hirai H, et al. MK-2206, an allosteric akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 2010;9:1956–1967. doi: 10.1158/1535-7163.MCT-09-1012.', 'ArticleIdList': [StringElement('10.1158/1535-7163.MCT-09-1012', attributes={'IdType': 'doi'}), StringElement('20571069', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene. 2005;24:7391–7393. doi: 10.1038/sj.onc.1209100.', 'ArticleIdList': [StringElement('10.1038/sj.onc.1209100', attributes={'IdType': 'doi'}), StringElement('16288285', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Vasudevan KM, Garraway LA. AKT signaling in physiology and disease. Curr. Top. Microbiol. Immunol. 2010;2:105–133.', 'ArticleIdList': [StringElement('20549472', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chen Y, Yu Q, Xu CB. A convenient method for quantifying collagen fibers in atherosclerotic lesions by imagej software. Int. J. Clin. Exp. Med. 2017;10:14904–14910.'}, {'Citation': 'Murphy A, et al. Angiotensin II type i receptor blockade is associated with decreased cutaneous scar formation in a rat model. Plast. Reconstr. Surg. 2019;144:803E–813E. doi: 10.1097/PRS.0000000000006173.', 'ArticleIdList': [StringElement('10.1097/PRS.0000000000006173', attributes={'IdType': 'doi'}), StringElement('31385893', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ehrlich HP, Moyer KE. Cell-populated collagen lattice contraction model for the investigation of fibroblast collagen interactions. Methods Mol. Biol. 2013;1037:45–58. doi: 10.1007/978-1-62703-505-7_3.', 'ArticleIdList': [StringElement('10.1007/978-1-62703-505-7_3', attributes={'IdType': 'doi'}), StringElement('24029929', attributes={'IdType': 'pubmed'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2023', 'Month': '10', 'Day': '26'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '21'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '27', 'Hour': '6', 'Minute': '43'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '26', 'Hour': '6', 'Minute': '45'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '26', 'Hour': '0', 'Minute': '20'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '25'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38528089', attributes={'IdType': 'pubmed'}), StringElement('PMC10963735', attributes={'IdType': 'pmc'}), StringElement('10.1038/s41598-024-57776-7', attributes={'IdType': 'doi'}), StringElement('10.1038/s41598-024-57776-7', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38527052', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '03', 'Day': '27'}, 'DateRevised': {'Year': '2024', 'Month': '03', 'Day': '27'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '25'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('e0301024', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1371/journal.pone.0301024', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1932-6203', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '19', 'Issue': '3', 'PubDate': {'Year': '2024'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'PloS one', 'ISOAbbreviation': 'PLoS One'}, 'ArticleTitle': 'Codeine and promethazine: Exploratory study on \"lean\" or \"sizzurp\"\\xa0using national survey data and an online forum.', 'Pagination': {'StartPage': 'e0301024', 'MedlinePgn': 'e0301024'}, 'Abstract': {'AbstractText': [StringElement('The concoction known as \"lean\" containing codeine and promethazine, holds a prominent cultural presence and is often referenced in mass media platforms (e.g., music and social media). Surprisingly, there\\'s a scarcity of national data characterizing the use of lean. Therefore, the current study investigated the use of lean using national survey data and online forum participant input, and focused on identifying concurrent substance use, exploring co-administration with other substances (e.g., alcohol, cannabis), and determining lean-related experiences.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement('We analyzed data from the National Survey on Drug Use and Health (NSDUH) spanning 2007-2019, identifying persons who used lean (weighted N = 42,275). Additionally, we conducted a Reddit-based study to gather insights about lean consumtion (N = 192).', attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('The NSDUH data indicated that lean use was most prevalent among teenagers and young adults (ages 13-21), accounting for 66% of the sample. This trend was more pronounced in male respondents (75%) compared to females. Additionally, the use was predominantly observed among Black/African American (29%), Hispanic (28%), and White (33%) populations, with these groups also reporting higher levels of concurrent alcohol and cannabis use. Similarly, findings from Reddit showed that individuals who used lean were predominantly male (67%) and exhibited elevated concurrent rates of alcohol (83%) and cannabis (46%) use in the past 30 days. Moreover, approximately 66% of respondents met criteria for severe lean use disorder, and 37% acknowledged driving under its influence.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('The NSDUH data found that mostly young adult males reported consuming lean in the past twelve months, though the racial/ethnic breakdown of persons who used lean was diverse. The Reddit data found that most individuals in the sample met the criteria for a substance use disorder pertaining to their lean consumption. These findings underscore the clinical significance and necessity for further controlled research on lean.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': 'Copyright: © 2024 Ware et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Social Work, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.'}], 'Identifier': [StringElement('0000-0002-3269-5324', attributes={'Source': 'ORCID'})], 'LastName': 'Ware', 'ForeName': 'Orrin D', 'Initials': 'OD'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Medicine, Johns Hopkins University, Baltimore, MD, United States of America.'}], 'Identifier': [StringElement('0000-0003-2182-1644', attributes={'Source': 'ORCID'})], 'LastName': 'Garcia-Romeu', 'ForeName': 'Albert', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Medicine, Johns Hopkins University, Baltimore, MD, United States of America.'}], 'Identifier': [], 'LastName': 'Zamarripa', 'ForeName': 'C Austin', 'Initials': 'CA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.'}], 'Identifier': [], 'LastName': 'Hughes', 'ForeName': 'Tamera', 'Initials': 'T'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Medicine, Johns Hopkins University, Baltimore, MD, United States of America.'}], 'Identifier': [], 'LastName': 'Wager', 'ForeName': 'Leeza', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Medicine, Johns Hopkins University, Baltimore, MD, United States of America.'}], 'Identifier': [], 'LastName': 'Spindle', 'ForeName': 'Tory', 'Initials': 'T'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic-eCollection'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'PLoS One', 'NlmUniqueID': '101285081', 'ISSNLinking': '1932-6203'}, 'ChemicalList': [{'RegistryNumber': 'UX6OWY2V7J', 'NameOfSubstance': StringElement('Codeine', attributes={'UI': 'D003061'})}, {'RegistryNumber': 'FF28EJQ494', 'NameOfSubstance': StringElement('Promethazine', attributes={'UI': 'D011398'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Adolescent', attributes={'UI': 'D000293', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Female', attributes={'UI': 'D005260', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Young Adult', attributes={'UI': 'D055815', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Male', attributes={'UI': 'D008297', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('United States', attributes={'UI': 'D014481', 'MajorTopicYN': 'N', 'Type': 'Geographic'})}, {'QualifierName': [], 'DescriptorName': StringElement('Codeine', attributes={'UI': 'D003061', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Promethazine', attributes={'UI': 'D011398', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Health Surveys', attributes={'UI': 'D006306', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Hispanic or Latino', attributes={'UI': 'D006630', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('epidemiology', attributes={'UI': 'Q000453', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Substance-Related Disorders', attributes={'UI': 'D019966', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Cannabis', attributes={'UI': 'D002188', 'MajorTopicYN': 'Y'})}], 'CoiStatement': 'The authors have declared that no competing interests exist.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Miuli A, Stigliano G, Lalli A, Coladonato M, D’Angelo L, Esposito F, et al.. \"Purple Drank\" (Codeine and Promethazine Cough Syrup): A Systematic Review of a Social Phenomenon with Medical Implications. J Psychoactive Drugs. 2020;52(5):453–62. doi: 10.1080/02791072.2020.1797250', 'ArticleIdList': [StringElement('10.1080/02791072.2020.1797250', attributes={'IdType': 'doi'}), StringElement('32748711', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Schifano F, Chiappini S, Miuli A, Mosca A, Santovito MC, Corkery JM, et al.. Focus on Over-the-Counter Drugs’ Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants. Front Psychiatry. 2021;12:657397. doi: 10.3389/fpsyt.2021.657397', 'ArticleIdList': [StringElement('10.3389/fpsyt.2021.657397', attributes={'IdType': 'doi'}), StringElement('PMC8138162', attributes={'IdType': 'pmc'}), StringElement('34025478', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Garcin L, Le Roch M, Agbessi CA, Lobut JB, Lecoeur A, Benoist G. [Purple drank: A dangerous cocktail]. Arch Pediatr. 2016;23(11):1165–8.', 'ArticleIdList': [StringElement('27670723', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hart M, Agnich LE, Stogner J, Miller BL. ’Me and my drank:’ Exploring the relationship between musical preferences and purple drank experimentation. American Journal of Criminal Justice. 2013;39:172–86.'}, {'Citation': 'Palamar JJ. Use of \"Lean\" Among Electronic Dance Music Party Attendees. Am J Addict. 2019;28(5):347–52. doi: 10.1111/ajad.12897', 'ArticleIdList': [StringElement('10.1111/ajad.12897', attributes={'IdType': 'doi'}), StringElement('PMC6706295', attributes={'IdType': 'pmc'}), StringElement('31041819', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tettey N-S, Siddiqui K, Llamoca H, Nagamine S, Ahn S. Purple drank, sizurp, and lean: Hip-Hop music and codeine use, A call to action for public health educators. International Journal of Psychological Studies. 2020;12(1).'}, {'Citation': 'Cherian R, Westbrook M, Ramo D, Sarkar U. Representations of Codeine Misuse on Instagram: Content Analysis. JMIR Public Health Surveill. 2018;4(1):e22.', 'ArticleIdList': [StringElement('PMC5883072', attributes={'IdType': 'pmc'}), StringElement('29559422', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Peters RJ, Kelder SH, Markham CM, Yacoubian GS, Peters LA, Ellis A. Beliefs and social norms about codeine and promethazine hydrochloride cough syrup (CPHCS) onset and perceived addiction among urban Houstonian adolescents: an addiction trend in the city of lean. J Drug Educ. 2003;33(4):415–25. doi: 10.2190/NXJ6-U60J-XTY0-09MP', 'ArticleIdList': [StringElement('10.2190/NXJ6-U60J-XTY0-09MP', attributes={'IdType': 'doi'}), StringElement('15237866', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Peters R, Yacoubian GS, Rhodes W, Forsythe KJ, Bowers KS, Eulian VM, et al.. Beliefs and social norms about codeine and promethazine hydrochloride cough syrup (CPHCS) use and addiction among multi-ethnic college students. J Psychoactive Drugs. 2007;39(3):277–82. doi: 10.1080/02791072.2007.10400614', 'ArticleIdList': [StringElement('10.1080/02791072.2007.10400614', attributes={'IdType': 'doi'}), StringElement('18159781', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Peteet B, Roundtree C, Dixon S, Mosley C, Miller-Roenigk B, White J, et al.. ’Codeine crazy:’ a content analysis of prescription drug references in popular music. Journal of Youth Studies. 2021;24(8):1100–16.'}, {'Citation': 'Ware OD. Lean/Sizzurp Ingredients, Use, and Coping With Mental Health Symptoms. Subst Abuse. 2023;17:11782218231195226.', 'ArticleIdList': [StringElement('PMC10517614', attributes={'IdType': 'pmc'}), StringElement('37746632', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Billboard. Lil Nas X 2022. Available from: https://www.billboard.com/artist/lil-nas-x/.'}, {'Citation': 'Billboard. Roddy Ricch 2022. Available from: https://www.billboard.com/artist/roddy-ricch/.'}, {'Citation': 'Billboard. Internet Money 2022. Available from: https://www.billboard.com/artist/internet-money/.'}, {'Citation': 'Billboard. Gunna 2023. Available from: https://www.billboard.com/artist/gunna/.'}, {'Citation': 'Schiff PL. Opium and its Alkaloids. American Journal of Pharmaceutical Education. 2022;66:186–94.'}, {'Citation': 'Ino H, Nakazawa E. Over-the-Counter Drug Misuse and Dependence: Public Health Ethics’ Foray into Fight against the Codeine Crisis. Pharmacy (Basel). 2022;10(6). doi: 10.3390/pharmacy10060155', 'ArticleIdList': [StringElement('10.3390/pharmacy10060155', attributes={'IdType': 'doi'}), StringElement('PMC9703961', attributes={'IdType': 'pmc'}), StringElement('36412831', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Zuraw BL, Christiansen SC. Histamine, bradykinin, and their antagonists. In: Brunton L L KBC, editor. Goodman and Gilman’s: The Pharmacological Basis of Therapeutics. 14th Edition ed: McGraw Hill; 2023.'}, {'Citation': 'Southard BT, Khalili YA. StatPearls: Promethazine\\n2023. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31335081.'}, {'Citation': 'United States Food and Drug Administration. FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use: Includes updates to help reduce unnecessary prescribing\\n2023. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use.'}, {'Citation': 'Agnich LE, Stogner JM, Miller BL, Marcum CD. Purple drank prevalence and characteristics of misusers of codeine cough syrup mixtures. Addict Behav. 2013;38(9):2445–9. doi: 10.1016/j.addbeh.2013.03.020', 'ArticleIdList': [StringElement('10.1016/j.addbeh.2013.03.020', attributes={'IdType': 'doi'}), StringElement('23688907', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Crummy EA, O’Neal TJ, Baskin BM, Ferguson SM. One Is Not Enough: Understanding and Modeling Polysubstance Use. Front Neurosci. 2020;14:569. doi: 10.3389/fnins.2020.00569', 'ArticleIdList': [StringElement('10.3389/fnins.2020.00569', attributes={'IdType': 'doi'}), StringElement('PMC7309369', attributes={'IdType': 'pmc'}), StringElement('32612502', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Compton WM, Valentino RJ, DuPont RL. Polysubstance use in the U.S. opioid crisis. Mol Psychiatry. 2021;26(1):41–50. doi: 10.1038/s41380-020-00949-3', 'ArticleIdList': [StringElement('10.1038/s41380-020-00949-3', attributes={'IdType': 'doi'}), StringElement('PMC7815508', attributes={'IdType': 'pmc'}), StringElement('33188253', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ellis JD, Rabinowitz JA, Ware OD, Wells J, Dunn KE, Huhn AS. Patterns of polysubstance use and clinical comorbidity among persons seeking substance use treatment: An observational study. J Subst Use Addict Treat. 2023;146:208932. doi: 10.1016/j.josat.2022.208932', 'ArticleIdList': [StringElement('10.1016/j.josat.2022.208932', attributes={'IdType': 'doi'}), StringElement('PMC10035066', attributes={'IdType': 'pmc'}), StringElement('36880895', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Palmer A, Scott N, Dietze P, Higgs P. Motivations for crystal methamphetamine-opioid co-injection/co-use amongst community-recruited people who inject drugs: a qualitative study. Harm Reduct J. 2020;17(1):14. doi: 10.1186/s12954-020-00360-9', 'ArticleIdList': [StringElement('10.1186/s12954-020-00360-9', attributes={'IdType': 'doi'}), StringElement('PMC7047412', attributes={'IdType': 'pmc'}), StringElement('32106854', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ware OD, Manuel JI, Huhn AS. Adults With Opioid and Methamphetamine Co-use Have Lower Odds of Completing Short-Term Residential Treatment Than Other Opioid Co-use Groups: A Retrospective Health Services Study. Front Psychiatry. 2021;12:784229. doi: 10.3389/fpsyt.2021.784229', 'ArticleIdList': [StringElement('10.3389/fpsyt.2021.784229', attributes={'IdType': 'doi'}), StringElement('PMC8692265', attributes={'IdType': 'pmc'}), StringElement('34955930', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Boileau-Falardeau M, Contreras G, Gariépy G, Laprise C. Patterns and motivations of polysubstance use: a rapid review of the qualitative evidence. Health Promot Chronic Dis Prev Can. 2022;42(2):47–59.', 'ArticleIdList': [StringElement('0', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report; 2022.'}, {'Citation': 'American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed., text rev.) 2022. Available from: https://dsm.psychiatryonline.org/doi/book/10.1176/appi.books.9780890425787.', 'ArticleIdList': [StringElement('10.1176/appi.books.9780890425787', attributes={'IdType': 'doi'})]}, {'Citation': 'Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health (NSDUH): 2002–2019. [Available from: https://www.datafiles.samhsa.gov/dataset/nsduh-2002-2019-ds0001-nsduh-2002-2019-ds0001]'}, {'Citation': 'Qualtrics. Qualtrics. Provo, UT 2023.'}, {'Citation': 'Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158(16):1789–95. doi: 10.1001/archinte.158.16.1789', 'ArticleIdList': [StringElement('10.1001/archinte.158.16.1789', attributes={'IdType': 'doi'}), StringElement('9738608', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Adamson SJ, Kay-Lambkin FJ, Baker AL, Lewin TJ, Thornton L, Kelly BJ, et al.. An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Drug Alcohol Depend. 2010;110(1–2):137–43. doi: 10.1016/j.drugalcdep.2010.02.017', 'ArticleIdList': [StringElement('10.1016/j.drugalcdep.2010.02.017', attributes={'IdType': 'doi'}), StringElement('20347232', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Substance Abuse and Mental Health Services Administration. Treating substance use disorder in older adults: Updated 2020: Substance Abuse and Mental Health Services Administration; 2020.', 'ArticleIdList': [StringElement('34106564', attributes={'IdType': 'pubmed'})]}, {'Citation': 'IBM Corp. IBM SPSS Statistics: Version 28.0. Armonk, NY2021.'}, {'Citation': 'R Core Team. R: A language and environment for statistical computing Vienne, Austria 2022 [Available from: https://www.R-project.org/.'}, {'Citation': 'Wickham H. ggplot2: Elegant graphics for data analysis. New York: Springer-Verlag; 2016.'}, {'Citation': 'Ligges U, Maechler M. scatterplot3d - An R Package for Visualizing Multivariate Data. Journal of Statistical Software. 2003;8(11):1–20.'}, {'Citation': 'Chiappini S, Schifano F. What about \"Pharming\"? Issues Regarding the Misuse of Prescription and Over-the-Counter Drugs. Brain Sci. 2020;10(10).', 'ArticleIdList': [StringElement('PMC7602178', attributes={'IdType': 'pmc'}), StringElement('33066476', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chiappini S, Schifano F, Corkery JM, Guirguis A. Beyond the ’purple drank’: Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports. J Psychopharmacol. 2021;35(6):681–92. doi: 10.1177/0269881120959615', 'ArticleIdList': [StringElement('10.1177/0269881120959615', attributes={'IdType': 'doi'}), StringElement('PMC8278560', attributes={'IdType': 'pmc'}), StringElement('33427017', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Rosenberger W, Teske J, Klintschar M, Dziadosz M. Detection of pharmaceuticals in \"dirty sprite\" using gas chromatography and mass spectrometry. Drug Test Anal. 2022;14(3):539–44. doi: 10.1002/dta.3116', 'ArticleIdList': [StringElement('10.1002/dta.3116', attributes={'IdType': 'doi'}), StringElement('34142460', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Elwood WN. Sticky business: patterns of procurement and misuse of prescription cough syrup in Houston. J Psychoactive Drugs. 2001;33(2):121–33. doi: 10.1080/02791072.2001.10400477', 'ArticleIdList': [StringElement('10.1080/02791072.2001.10400477', attributes={'IdType': 'doi'}), StringElement('11476259', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ahmed H. Recognising post-traumatic stress disorder in cough syrup misuse. Lancet Psychiatry. 2020;7(9):737–8. doi: 10.1016/S2215-0366(20)30345-X', 'ArticleIdList': [StringElement('10.1016/S2215-0366(20)30345-X', attributes={'IdType': 'doi'}), StringElement('32828158', attributes={'IdType': 'pubmed'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2023', 'Month': '11', 'Day': '18'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '6'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '27', 'Hour': '6', 'Minute': '43'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '25', 'Hour': '18', 'Minute': '42'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '25', 'Hour': '13', 'Minute': '35'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '25'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38527052', attributes={'IdType': 'pubmed'}), StringElement('PMC10962845', attributes={'IdType': 'pmc'}), StringElement('10.1371/journal.pone.0301024', attributes={'IdType': 'doi'}), StringElement('PONE-D-23-38380', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38526588', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '03', 'Day': '26'}, 'DateRevised': {'Year': '2024', 'Month': '03', 'Day': '27'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.38212/2224-6614.3495', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2224-6614', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '32', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Mar', 'Day': '15'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Journal of food and drug analysis', 'ISOAbbreviation': 'J Food Drug Anal'}, 'ArticleTitle': 'An acute herb-drug interaction of Magnoliae Officinalis Cortex with methotrexate via inhibiting multidrug resistance-associated protein 2.', 'Pagination': {'StartPage': '103', 'EndPage': '111', 'MedlinePgn': '103-111'}, 'Abstract': {'AbstractText': ['Magnoliae Officinalis Cortex (MOC), an herbal drug, contains polyphenolic lignans mainly magnolol (MN) and honokiol (HK). Methotrexate (MTX), a critical drug for cancers and autoimmune deseases, is a substrate of multidrug resistance-associated protein 2 (MRP2) and breast cancer resistance protein (BCRP). This study investigated the effect of coadministration of MOC on the pharmacokinetics of MTX and relevant mechanisms. Sprague-Dawley rats were orally administered MTX alone and with single dose (2.0 and 4.0 g/kg) and repeated seven doses of MOC (2.0 g/kg thrice daily for 2 days, the 7th dose given at 0.5 h before MTX). The serum concentrations of MTX were determined by a fluorescence polarization immunoassay. The results showed that a single dose of MOC at 2.0 g/kg significantly increased the AUC<sub>0-t</sub> and MRT of MTX by 352% and 308%, and a single dose at 4.0 g/kg significantly enhanced the AUC<sub>0-t</sub> and MRT by 362% and 291%, respectively. Likewise, repeated seven doses of MOC at 2.0 g/kg significantly increased the AUC<sub>0-t</sub> and MRT of MTX by 461% and 334%, respectively. Mechanism studies indicated that the function of MRP2 was significantly inhibited by MN, HK and the serum metabolites of MOC (MOCM), whereas BCRP was not inhibited by MOCM. In conclusion, coadministration of MOC markedly enhanced the systemic exposure and mean residence time of MTX through inhibiting the MRP2-mediated excretion of MTX.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan 406040, ROC.'}, {'Identifier': [], 'Affiliation': 'Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan 404327, ROC.'}], 'Identifier': [], 'LastName': 'Yu', 'ForeName': 'Chung-Ping', 'Initials': 'CP'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan 406040, ROC.'}], 'Identifier': [], 'LastName': 'Li', 'ForeName': 'Pei-Ying', 'Initials': 'PY'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan 406040, ROC.'}], 'Identifier': [], 'LastName': 'Chen', 'ForeName': 'Szu-Yu', 'Initials': 'SY'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan 406040, ROC.'}], 'Identifier': [], 'LastName': 'Lin', 'ForeName': 'Shiuan-Pey', 'Initials': 'SP'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Institute of Chinese Pharmaceutical Sciences, China Medical University, Taichung, Taiwan 404333, ROC.'}], 'Identifier': [], 'LastName': 'Chen', 'ForeName': 'Ying-Chen', 'Initials': 'YC'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan 406040, ROC.'}, {'Identifier': [], 'Affiliation': 'Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan 404327, ROC.'}], 'Identifier': [], 'LastName': 'Ho', 'ForeName': 'Lu-Ching', 'Initials': 'LC'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan 406040, ROC.'}, {'Identifier': [], 'Affiliation': 'Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan 404327, ROC.'}], 'Identifier': [], 'LastName': 'Hsieh', 'ForeName': 'Yow-Wen', 'Initials': 'YW'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan 406040, ROC.'}, {'Identifier': [], 'Affiliation': 'Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan 404327, ROC.'}], 'Identifier': [], 'LastName': 'Hou', 'ForeName': 'Yu-Chi', 'Initials': 'YC'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'China (Republic : 1949- )', 'MedlineTA': 'J Food Drug Anal', 'NlmUniqueID': '101630927'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Multidrug Resistance-Associated Protein 2', attributes={'UI': 'D000089762'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('ATP Binding Cassette Transporter, Subfamily G, Member 2', attributes={'UI': 'D000070997'})}, {'RegistryNumber': 'YL5FZ2Y5U1', 'NameOfSubstance': StringElement('Methotrexate', attributes={'UI': 'D008727'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Neoplasm Proteins', attributes={'UI': 'D009363'})}, {'RegistryNumber': '11513CCO0N', 'NameOfSubstance': StringElement('honokiol', attributes={'UI': 'C005499'})}, {'RegistryNumber': '001E35HGVF', 'NameOfSubstance': StringElement('magnolol', attributes={'UI': 'C005498'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Allyl Compounds', attributes={'UI': 'D000498'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Biphenyl Compounds', attributes={'UI': 'D001713'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Phenols', attributes={'UI': 'D010636'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Lignans', attributes={'UI': 'D017705'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Rats', attributes={'UI': 'D051381', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Animals', attributes={'UI': 'D000818', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Rats, Sprague-Dawley', attributes={'UI': 'D017207', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Multidrug Resistance-Associated Protein 2', attributes={'UI': 'D000089762', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('genetics', attributes={'UI': 'Q000235', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('ATP Binding Cassette Transporter, Subfamily G, Member 2', attributes={'UI': 'D000070997', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Herb-Drug Interactions', attributes={'UI': 'D041743', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('pharmacology', attributes={'UI': 'Q000494', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Methotrexate', attributes={'UI': 'D008727', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Neoplasm Proteins', attributes={'UI': 'D009363', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Allyl Compounds', attributes={'UI': 'D000498', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Biphenyl Compounds', attributes={'UI': 'D001713', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Phenols', attributes={'UI': 'D010636', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Lignans', attributes={'UI': 'D017705', 'MajorTopicYN': 'Y'})}], 'CoiStatement': '<b>Conflicts of interest:</b> The authors declare that there are no conflicts of interest.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Lee YJ, Lee YM, Lee CK, Jung JK, Han SB, Hong JT. Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther. 2011;130:157–76.', 'ArticleIdList': [StringElement('21277893', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Yan R, Yu S, Liu H, Xue Z, Yang B. An HPLC-DAD method for simultaneous quantitative determination of four active hydrophilic compounds in Magnoliae officinalis cortex. J Chromatogr Sci. 2015;53:598–602.', 'ArticleIdList': [StringElement('25085894', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Jiang Y, Vaysse J, Gilard V, Balayssac S, Dejean S, Malet-Martino M, et al. Quality assessment of commercial Magnoliae officinalis Cortex by (1)H-NMR-based metabolomics and HPLC methods. Phytochem Anal. 2012;23:387–95.', 'ArticleIdList': [StringElement('22025447', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Walker JM, Maitra A, Walker J, Ehrnhoefer-Ressler MM, Inui T, Somoza V. Identification of Magnolia officinalis L. bark extract as the most potent anti-inflammatory of four plant extracts. Am J Chin Med. 2013;41:531–44.', 'ArticleIdList': [StringElement('23711140', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chan SS-K, Zhao M, Lao L, Fong HH, Che C-T. Magnolol and honokiol account for the anti-spasmodic effect of Magnolia officinalis in isolated Guinea pig ileum. Planta Med. 2008;74:381–4.', 'ArticleIdList': [StringElement('18484527', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Chen CR, Zhou XZ, Luo YJ, Huang ZL, Urade Y, Qu WM. Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, induces sleep via the benzodiazepine site of GABA(A) receptor in mice. Neuropharmacology. 2012;63:1191–9.', 'ArticleIdList': [StringElement('22771461', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Xu Q, Yi LT, Pan Y, Wang X, Li YC, Li JM, et al. Antide-pressant-like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:715–25.', 'ArticleIdList': [StringElement('18093712', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mottaghi S, Abbaszadeh H. Natural lignans honokiol and magnolol as potential anticarcinogenic and anticancer agents. A comprehensive mechanistic review. Nutr Cancer. 2022;74:761–78.', 'ArticleIdList': [StringElement('34047218', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Poivre M, Duez P. Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E. Wilson (Houpo) and its constituents. J Zhejiang Univ - Sci B. 2017;18:194.', 'ArticleIdList': [StringElement('PMC5365644', attributes={'IdType': 'pmc'}), StringElement('28271656', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bui D, Li L, Yin T, Wang X, Gao S, You M, et al. Pharmacokinetic and metabolic profiling of key active components of dietary supplement Magnolia officinalis extract for prevention against oral carcinoma. J Agric Food Chem. 2020;68:6576–87.', 'ArticleIdList': [StringElement('PMC7604171', attributes={'IdType': 'pmc'}), StringElement('32348135', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lin SP, Tsai SY, Lee Chao PD, Chen YC, Hou YC. Pharmacokinetics, bioavailability, and tissue distribution of magnolol following single and repeated dosing of magnolol to rats. Planta Med. 2011;77:1800–5.', 'ArticleIdList': [StringElement('21638244', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Wang JJ, Miao XL, Chen JY, Chen Y. The pharmacokinetics and tissue distribution of honokiol and its metabolites in rats. Eur J Drug Metab Pharmacokinet. 2016;41:587–94.', 'ArticleIdList': [StringElement('25956504', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Keppler D. Uptake and efflux transporters for conjugates in human hepatocytes. Methods Enzymol. 2005;400:531–42.', 'ArticleIdList': [StringElement('16399368', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Liu YH, Di YM, Zhou ZW, Mo SL, Zhou SF. Multidrug resistance-associated proteins and implications in drug development. Clin Exp Pharmacol Physiol. 2009;37:115–20.', 'ArticleIdList': [StringElement('19566819', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Järvinen E, Deng F, Kiander W, Sinokki A, Kidron H, Sjöstedt N. The role of uptake and efflux transporters in the disposition of glucuronide and sulfate conjugates. Front Pharmacol. 2022;12:802539.', 'ArticleIdList': [StringElement('PMC8793843', attributes={'IdType': 'pmc'}), StringElement('35095509', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Yu CP, Li PY, Chen SY, Lin SP, Hou YC. Magnolol and honokiol inhibited the function and expression of BCRP with mechanism exploration. Molecules. 2021;26:7390.', 'ArticleIdList': [StringElement('PMC8659015', attributes={'IdType': 'pmc'}), StringElement('34885972', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol. 2006;25:231–59.', 'ArticleIdList': [StringElement('16815813', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Vlaming ML, Pala Z, van Esch A, Wagenaar E, van Tellingen O, de Waart DR, et al. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin Cancer Res. 2008;14:8152–60.', 'ArticleIdList': [StringElement('19088030', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Vlaming ML, van Esch A, van de Steeg E, Pala Z, Wagenaar E, van Tellingen O, et al. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate. Drug Metab Dispos. 2011;39:1338–44.', 'ArticleIdList': [StringElement('21566011', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Liu X. Transporter-mediated drug-drug interactions and their significance. Adv Exp Med Biol. 2019;1141:241–91.', 'ArticleIdList': [StringElement('31571167', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Abolmaali SS, Tamaddon AM, Dinarvand R. A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. Cancer Chemother Pharmacol. 2013;71:1115–30.', 'ArticleIdList': [StringElement('23292116', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978;41:36–51.', 'ArticleIdList': [StringElement('342086', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: past, present and future. Clin Exp Dermatol. 2013;38:573–88.', 'ArticleIdList': [StringElement('23837932', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Montaudie H, Sbidian E, Paul C, Maza A, Gallini A, Aractingi S, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol. 2011;25(Suppl 2):12–8.', 'ArticleIdList': [StringElement('21388454', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bourre-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37:1416–21.', 'ArticleIdList': [StringElement('20436072', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Keysser G. Methotrexate toxicity. Myths and facts. Z Rheumatol. 2011;70:108–13.', 'ArticleIdList': [StringElement('21267730', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tsukada T, Nakano T, Miyata T, Sasaki S. Life-threatening gastrointestinal mucosal necrosis during methotrexate treatment for rheumatoid arthritis. Case Rep Gastroenterol. 2013;7:470–5.', 'ArticleIdList': [StringElement('PMC3843920', attributes={'IdType': 'pmc'}), StringElement('24348319', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lagas JS, van der Kruijssen CM, van de Wetering K, Beijnen JH, Schinkel AH. Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009;37:129–36.', 'ArticleIdList': [StringElement('18845662', attributes={'IdType': 'pubmed'})]}, {'Citation': 'El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Therapeut. 2007;320:229–35.', 'ArticleIdList': [StringElement('17005917', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hamed KM, Dighriri IM, Baomar AF, Alharthy BT, Alenazi FE, Alali GH, et al. Overview of methotrexate toxicity: a comprehensive literature review. Cureus. 2022:14.', 'ArticleIdList': [StringElement('PMC9595261', attributes={'IdType': 'pmc'}), StringElement('36312688', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Yu CP, Hsieh YC, Shia CS, Hsu PW, Chen JY, Hou YC, et al. Increased systemic exposure of methotrexate by a polyphenol-rich herb via modulation on efflux transporters multidrug resistance-associated protein 2 and breast cancer resistance protein. J Pharm Sci. 2016;105:343–9.', 'ArticleIdList': [StringElement('26852865', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Taiwan Herbal Pharmacopeia. 4th Edition Committee Taiwan herbal Pharmacopeia. 4th ed. Department of Chinese Medicine and Pharmacy, Ministry of Health and Welfare; 2022. English version.'}, {'Citation': 'Food and Drug Administration. Guidance for Industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Vol. 7. Center for Drug Evaluation and Research CDER; 2005. p. 0.001.'}, {'Citation': 'Xiao L, Yi T, Chen M, Lam CWK, Zhou H. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: activation of MRP3 with concurrent inhibition of MRP2 and BCRP. Eur J Pharmaceut Sci. 2016;93:456–67.', 'ArticleIdList': [StringElement('27586020', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63.', 'ArticleIdList': [StringElement('6606682', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hsu PW, Shia CS, Wu CT, Chang NW, Chao PL, Hou YC. Noni increased the systemic exposure of methotrexate in rats through inhibition on multi-drug resistance protein 2 and breast cancer resistance protein (BCRP) J Funct Foods. 2013;5:1414–20.'}, {'Citation': 'Wang RQ, Ge X, Chen X, Hu S, Yang L, Li D, et al. Ballpoint tip-protected oil-in-salt liquid-phase microextraction with high performance liquid chromatography for the determination of magnolol and honokiol from cortex Magnoliae officinalis. Instrum Sci Technol. 2020;48:254–68.'}, {'Citation': 'Tsai TH, Chen CF. Identification and determination of honokiol and magnolol from Magnolia officinalis by high-performance liquid chromatography with phtodiode-array UV detection. J Chromatogr A. 1992;598:143–6.'}, {'Citation': 'Zheng L, Zhu L, Zhao M, Shi J, Li Y, Yu J, et al. In vivo exposure of kaempferol is driven by phase II metabolic enzymes and efflux transporters. AAPS J. 2016;18:1289–99.', 'ArticleIdList': [StringElement('PMC7702721', attributes={'IdType': 'pmc'}), StringElement('27393480', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Brand W, Oosterhuis B, Krajcsi P, Barron D, Dionisi F, Van Bladeren PJ, et al. Interaction of hesperetin glucuronide conjugates with human BCRP, MRP2 and MRP3 as detected in membrane vesicles of overexpressing baculovirus-infected Sf9 cells. Biopharm Drug Dispos. 2011;32:530–5.', 'ArticleIdList': [StringElement('22083890', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Wang L, Sun R, Zhang Q, Luo Q, Zeng S, Li X, et al. An update on polyphenol disposition via coupled metabolic pathways. Expert Opin Drug Met. 2019;15:151–65.', 'ArticleIdList': [StringElement('30583703', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Coates LC, Merola JF, Grieb SM, Mease PJ, Duffin KC. Methotrexate in psoriasis and psoriatic arthritis. J Rheumatol Suppl. 2020;96:31–5.', 'ArticleIdList': [StringElement('32482765', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J, et al. Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med. 2020;172:369–80.', 'ArticleIdList': [StringElement('PMC7229518', attributes={'IdType': 'pmc'}), StringElement('32066146', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lucas CJ, Dimmitt SB, Martin JH. Optimising low-dose methotrexate for rheumatoid arthritis—a review. Br J Clin Pharmacol. 2019;85:2228–34.', 'ArticleIdList': [StringElement('PMC6783593', attributes={'IdType': 'pmc'}), StringElement('31276602', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Song Z, Hu Y, Liu S, Wang G, Zhai S, Zhang X, et al. Medication therapy of high-dose methotrexate: an evidence-based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Br J Clin Pharmacol. 2022;88:2456–72.', 'ArticleIdList': [StringElement('34729817', attributes={'IdType': 'pubmed'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2023', 'Month': '9', 'Day': '18'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '1', 'Day': '8'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '26', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '25', 'Hour': '12', 'Minute': '45'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '25', 'Hour': '12', 'Minute': '4'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '15'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38526588', attributes={'IdType': 'pubmed'}), StringElement('PMC10962649', attributes={'IdType': 'pmc'}), StringElement('10.38212/2224-6614.3495', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38525509', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '03', 'Day': '26'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '02'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.5152/j.aott.2024.21066', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2589-1294', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '58', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Jan'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Acta orthopaedica et traumatologica turcica', 'ISOAbbreviation': 'Acta Orthop Traumatol Turc'}, 'ArticleTitle': 'Distal femur morphology and the suitability of standard guides for knee arthroplasty in the Turkish population.', 'Pagination': {'StartPage': '39', 'EndPage': '44', 'MedlinePgn': '39-44'}, 'Abstract': {'AbstractText': [StringElement('The aim of this study was to evaluate the posterior condylar angle (PCA) and condylar twist angle (CTA) of the distal femur in the Turkish population and its concordance with the current standard prosthesis guides used in total knee arthroplasty (TKA).', attributes={'Label': 'OBJECTIVE'}), StringElement('Two hundred and forty knees of 120 Turkish subjects (60 male and 60 female) were included in this study. PCA, CTA, femoral mediolateral lengths (fML), medial femoral anteroposterior lengths (fMAP), lateral femoral anteroposterior lengths (fLAP), distances between the trochlear groove and fMAP (DBTG-fMAP), distances between the trochlear groove and fLAP (DBTG-fLAP), medial posterior condylar cartilage thickness (MPCCT) and lateral posterior condylar cartilage thicknesses (LPCCT) were measured on magnetic resonance imaging (MRI).', attributes={'Label': 'METHODS'}), StringElement('The median CTA was 7° (range: 0°-13.0°) and the median PCA was 4° (range 0°-11.0°) (P < .0001). The median fML was 79.5 mm (range: 65.7-98.9). The median length of the fMAP was 58.2 mm (range: 46.8-69.0) and the median length of fLAP was 58.2 mm (range: 48.4-73.0). The DBTG-fMAP was 15.2 mm (range: 5.2-23.2), and DBTG-fLAP length was 21.9mm (range: 16.4-29.4). The median MPCCT and LPCCT were 2.4 mm (range: 1.6-3.6) and 2.3 mm (range: 1.2-2.8), respectively. The intraclass correlation coefficient for quantifying interobserver and intraobserver reliability showed excellent agreement regarding the PCA and CTA.', attributes={'Label': 'RESULTS'}), StringElement('This study has shown us that PCA and CTA may be higher in the Turkish population. Although it is not known whether these results have any clinical utility, it may be useful for surgeons to keep this in mind to prevent femoral component malposition.', attributes={'Label': 'CONCLUSION'}), StringElement('Level IV, Diagnostic Study.', attributes={'Label': 'LEVEL OF EVIDENCE'})]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Orthopaedics and Traumatology, Bezmialem Vakıf University, Istanbul, Turkey.'}], 'Identifier': [], 'LastName': 'İncesoy', 'ForeName': 'Mustafa Alper', 'Initials': 'MA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Orthopaedics and Traumatology, Universitätsklinikum Tübingen, Tübingen, Germany.'}], 'Identifier': [], 'LastName': 'Güngören', 'ForeName': 'Nurdan', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Orthopaedics and Traumatology, Rotkreuzklinik Wertheim, Wertheim, Germany.'}], 'Identifier': [], 'LastName': 'Aliyev', 'ForeName': 'Orkhan', 'Initials': 'O'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Orthopaedics and Traumatology, Bezmialem Vakıf University, Istanbul, Turkey.'}], 'Identifier': [], 'LastName': 'Elmalı', 'ForeName': 'Nurzat', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Orthopaedics and Traumatology, Bezmialem Vakıf University, Istanbul, Turkey.'}], 'Identifier': [], 'LastName': 'Tuncay', 'ForeName': 'İbrahim', 'Initials': 'İ'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Orthopaedics and Traumatology, Bezmialem Vakıf University, Istanbul, Turkey.'}], 'Identifier': [], 'LastName': 'Yıldız', 'ForeName': 'Fatih', 'Initials': 'F'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'Turkey', 'MedlineTA': 'Acta Orthop Traumatol Turc', 'NlmUniqueID': '9424806', 'ISSNLinking': '1017-995X'}, 'ChemicalList': [{'RegistryNumber': 'SV0CSG527L', 'NameOfSubstance': StringElement('Fluorometholone', attributes={'UI': 'D005469'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Male', attributes={'UI': 'D008297', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Female', attributes={'UI': 'D005260', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('methods', attributes={'UI': 'Q000379', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Arthroplasty, Replacement, Knee', attributes={'UI': 'D019645', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('diagnostic imaging', attributes={'UI': 'Q000000981', 'MajorTopicYN': 'N'}), StringElement('surgery', attributes={'UI': 'Q000601', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Knee Joint', attributes={'UI': 'D007719', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Reproducibility of Results', attributes={'UI': 'D015203', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Fluorometholone', attributes={'UI': 'D005469', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('diagnostic imaging', attributes={'UI': 'Q000000981', 'MajorTopicYN': 'N'}), StringElement('surgery', attributes={'UI': 'Q000601', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Femur', attributes={'UI': 'D005269', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('surgery', attributes={'UI': 'Q000601', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Osteoarthritis, Knee', attributes={'UI': 'D020370', 'MajorTopicYN': 'Y'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2024', 'Month': '3', 'Day': '26', 'Hour': '6', 'Minute': '45'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '25', 'Hour': '6', 'Minute': '43'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '25', 'Hour': '4', 'Minute': '44'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38525509', attributes={'IdType': 'pubmed'}), StringElement('10.5152/j.aott.2024.21066', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('HCE-T cell-based models', attributes={'MajorTopicYN': 'N'}), StringElement('Ketotifen hydrogen fumarate', attributes={'MajorTopicYN': 'N'}), StringElement('Mucoadhesivity', attributes={'MajorTopicYN': 'N'}), StringElement('Ocular itch test', attributes={'MajorTopicYN': 'N'}), StringElement('Polysaccharide polymers', attributes={'MajorTopicYN': 'N'}), StringElement('Rheological synergism', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38522490', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '15'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '15'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '23'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1016/j.ijpharm.2024.124033', attributes={'EIdType': 'doi', 'ValidYN': 'Y'}), StringElement('S0378-5173(24)00267-9', attributes={'EIdType': 'pii', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1873-3476', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '655', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '25'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'International journal of pharmaceutics', 'ISOAbbreviation': 'Int J Pharm'}, 'ArticleTitle': 'Synergism of polysaccharide polymers in antihistamine eye drops: Influence on physicochemical properties and in vivo efficacy.', 'Pagination': {'StartPage': '124033', 'MedlinePgn': '124033'}, 'Abstract': {'AbstractText': ['The incorporation of polymers into drug delivery vehicles has been shown to be a useful approach to prolong the residence time of drugs in the precorneal tear film and to improve penetration into biological membranes. The main objective of this research was to formulate novel viscous eye drops with ketotifen as the active ingredient, containing the polysaccharides: chitosan (MCH), hydroxypropyl guar gum (HPG) and hyaluronic acid (SH) alone and in combination as functional polymers. DSC and FT-IR techniques showed the compatibility between ketotifen and polymers. Physicochemical and rheological analysis at ambient and simulated physiological conditions, as well as the evaluation of mucoadhesive properties showed that vehicles containing combinations of polymers have suitable physicochemical and functional properties with demonstrated synergism between combined polymers (MCH and HPG i.e. SH and HPG). The drug permeability was successfully estimated in vitro using HCE-T cell-based models. MTT cytotoxicity assay demonstrates that the tested formulations were non-toxic and well tolerated. In vivo preclinical study on mice revealed that both vehicles containing mixed polymers enhanced and prolonged the antipruritic/analgesic-like effect of ophthalmic ketotifen. Based on these results, both combinations of polysaccharide polymers, especially SH-HPG, could be considered as potential new carriers for ketotifen for ophthalmic use.'], 'CopyrightInformation': 'Copyright © 2024 Elsevier B.V. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Technology and Cosmetology, University of Banja Luka, Faculty of Medicine, Save Mrkalja 14, 78000 Banja Luka, Bosnia and Herzegovina. Electronic address: andjelka.racic@med.unibl.org.'}], 'Identifier': [], 'LastName': 'Račić', 'ForeName': 'Anđelka', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'R&D, PLIVA Croatia Ltd., TEVA Group Member, Prilaz baruna Filipovića 29, 10000 Zagreb, Croatia. Electronic address: bisera.jurisicdukovski@pliva.com.'}], 'Identifier': [], 'LastName': 'Jurišić Dukovski', 'ForeName': 'Bisera', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Technology, University of Zagreb, Faculty of Pharmacy and Biochemistry, Ante Kovačića 1, 10000 Zagreb, Croatia. Electronic address: jasmina.lovric@pharma.unizg.hr.'}], 'Identifier': [], 'LastName': 'Lovrić', 'ForeName': 'Jasmina', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Chemistry, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia. Electronic address: vladimir.dobricic@pharmacy.bg.ac.rs.'}], 'Identifier': [], 'LastName': 'Dobričić', 'ForeName': 'Vladimir', 'Initials': 'V'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, University College Cork, Cork, Ireland. Electronic address: svucen@ucc.ie.'}], 'Identifier': [], 'LastName': 'Vučen', 'ForeName': 'Sonja', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmacology, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia. Electronic address: ana.micov@pharmacy.bg.ac.rs.'}], 'Identifier': [], 'LastName': 'Micov', 'ForeName': 'Ana', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmacology, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia. Electronic address: radica.stepanovic@pharmacy.bg.ac.rs.'}], 'Identifier': [], 'LastName': 'Stepanović-Petrović', 'ForeName': 'Radica', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmacology, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia. Electronic address: maja.tomic@pharmacy.bg.ac.rs.'}], 'Identifier': [], 'LastName': 'Tomić', 'ForeName': 'Maja', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmacology, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia. Electronic address: uros.pecikoza@pharmacy.bg.ac.rs.'}], 'Identifier': [], 'LastName': 'Pecikoza', 'ForeName': 'Uroš', 'Initials': 'U'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Chemical Engineering, University of Novi Sad, Faculty of Technology Novi Sad, Bulevar cara Lazara 1, 21000 Novi Sad, Serbia. Electronic address: ilicj@uns.ac.rs.'}], 'Identifier': [], 'LastName': 'Bajac', 'ForeName': 'Jelena', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Technology and Cosmetology, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia. Electronic address: danina.krajisnik@pharmacy.bg.ac.rs.'}], 'Identifier': [], 'LastName': 'Krajišnik', 'ForeName': 'Danina', 'Initials': 'D'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'}), 'MedlineJournalInfo': {'Country': 'Netherlands', 'MedlineTA': 'Int J Pharm', 'NlmUniqueID': '7804127', 'ISSNLinking': '0378-5173'}, 'ChemicalList': [{'RegistryNumber': 'X49220T18G', 'NameOfSubstance': StringElement('Ketotifen', attributes={'UI': 'D007665'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Ophthalmic Solutions', attributes={'UI': 'D009883'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Polymers', attributes={'UI': 'D011108'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Polysaccharides', attributes={'UI': 'D011134'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Histamine Antagonists', attributes={'UI': 'D006633'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Animals', attributes={'UI': 'D000818', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Mice', attributes={'UI': 'D051379', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Ketotifen', attributes={'UI': 'D007665', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('chemistry', attributes={'UI': 'Q000737', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Ophthalmic Solutions', attributes={'UI': 'D009883', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Polymers', attributes={'UI': 'D011108', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Spectroscopy, Fourier Transform Infrared', attributes={'UI': 'D017550', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('chemistry', attributes={'UI': 'Q000737', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Polysaccharides', attributes={'UI': 'D011134', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Histamine Antagonists', attributes={'UI': 'D006633', 'MajorTopicYN': 'N'})}], 'CoiStatement': 'Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2023', 'Month': '12', 'Day': '12'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '19'}, attributes={'PubStatus': 'revised'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '20'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '15', 'Hour': '6', 'Minute': '43'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '25', 'Hour': '0', 'Minute': '42'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '24', 'Hour': '20', 'Minute': '24'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38522490', attributes={'IdType': 'pubmed'}), StringElement('10.1016/j.ijpharm.2024.124033', attributes={'IdType': 'doi'}), StringElement('S0378-5173(24)00267-9', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('children poisoning', attributes={'MajorTopicYN': 'N'}), StringElement('dimetindene', attributes={'MajorTopicYN': 'N'}), StringElement('sedating antihistamines', attributes={'MajorTopicYN': 'N'}), StringElement('toxic dose', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38520199', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '17'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '17'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '23'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1111/bcpt.14005', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1742-7843', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '134', 'Issue': '5', 'PubDate': {'Year': '2024', 'Month': 'May'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Basic & clinical pharmacology & toxicology', 'ISOAbbreviation': 'Basic Clin Pharmacol Toxicol'}, 'ArticleTitle': 'Dimetindene-Is the minimum toxic dose for children too strict?', 'Pagination': {'StartPage': '750', 'EndPage': '755', 'MedlinePgn': '750-755'}, 'Abstract': {'AbstractText': ['Dimetindene is a sedating antihistamine indicated for the symptomatic treatment of allergic conditions. Dimetindene is marketed among others under the trade name Fenistil (oral solution). Toxicity data are limited, and there is no consensus on the dose at which children require hospitalization. Objective is to determine the potentially toxic dose in children. Data in children with age up to 15\\u2009years were obtained from hospital discharge reports. Of 139 paediatric hospital discharge reports, 23 cases (16.5%) were excluded because of uncertain ingestion. In 116 children (46 boys and 70 girls, mean age 2\\xa0years and 9\\xa0months\\u2009±\\u20091\\xa0year and 1\\xa0month), the majority of children developed no symptoms (87 children, 75%, mean age 3\\xa0years±1\\xa0year) and the remaining 29 children (25%, mean age 2\\xa0years and 11\\u2009months\\u2009±\\u20091\\xa0year and 3\\xa0months) developed only mild and spontaneously resolving symptoms of poisoning after a dose of 0.82\\u2009±\\u20090.32\\u2009mg/kg b.w. (range 0.26-1.82\\u2009mg/kg). In 98% of all cases, hospitalized children were observed for a maximum 24\\u2009h, and their condition did not require specific treatment. In conclusion, the prognosis for accidental dimetindene poisoning in children appears to be good and the minimum toxic dose has been determined to be 0.5\\xa0mg/kg b.w.'], 'CopyrightInformation': '© 2024 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Toxicological Information Center, Department of Occupational Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.'}, {'Identifier': [], 'Affiliation': 'Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.'}], 'Identifier': [StringElement('0000-0001-7647-4120', attributes={'Source': 'ORCID'})], 'LastName': 'Čečrle', 'ForeName': 'Michal', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Toxicological Information Center, Department of Occupational Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.'}], 'Identifier': [], 'LastName': 'Pelclová', 'ForeName': 'Daniela', 'Initials': 'D'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'J. Heyrovsky Institute of Physical Chemistry of the Czech Academy of Sciences, Prague, Czech Republic.'}], 'Identifier': [], 'LastName': 'Tomáš', 'ForeName': 'Navrátil', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Toxicological Information Center, Department of Occupational Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.'}], 'Identifier': [], 'LastName': 'Zacharov', 'ForeName': 'Sergej', 'Initials': 'S'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': '207041-3', 'Agency': 'COOPERATIO Pharmacology', 'Country': ''}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'}), 'MedlineJournalInfo': {'Country': 'England', 'MedlineTA': 'Basic Clin Pharmacol Toxicol', 'NlmUniqueID': '101208422', 'ISSNLinking': '1742-7835'}, 'ChemicalList': [{'RegistryNumber': '661FH77Z3P', 'NameOfSubstance': StringElement('Dimethindene', attributes={'UI': 'D004115'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Histamine H1 Antagonists', attributes={'UI': 'D006634'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Male', attributes={'UI': 'D008297', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Female', attributes={'UI': 'D005260', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Child', attributes={'UI': 'D002648', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Child, Preschool', attributes={'UI': 'D002675', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Dimethindene', attributes={'UI': 'D004115', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Histamine H1 Antagonists', attributes={'UI': 'D006634', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Hospitalization', attributes={'UI': 'D006760', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapy', attributes={'UI': 'Q000628', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Poisoning', attributes={'UI': 'D011041', 'MajorTopicYN': 'Y'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Tiligada E, Ennis M. Histamine pharmacology: from Sir Henry Dale to the 21st century. Br J Pharmacol. 2020;177(3):469‐489. doi:10.1111/bph.14524'}, {'Citation': 'De Bruyne P, Christiaens T, Boussery K, Mehuys E, Van Winckel M. Are antihistamines effective in children? A review of the evidence. Arch Dis Child. 2017;102(1):56‐60. doi:10.1136/archdischild‐2015‐310416'}, {'Citation': 'Summary of product characteristics. Fenistil 1mg/ml por gtt sol 1x20ml (available online: https://prehledy.sukl.cz/prehled_leciv.html#/detail-reg/0173500) [cit. 2023‐6‐12]'}, {'Citation': 'Zakharov S, Tomas N, Pelclova D. Medication errors‐‐an enduring problem for children and elderly patients. Ups J Med Sci. 2012;117(3):309‐317. doi:10.3109/03009734.2012.659771'}, {'Citation': 'Zakharov S, Navratil T, Pelclova D. Analysis of medication errors of health care providers on the basis of data from the Czech Toxicological Information Centre over an 11‐year period (2000‐2010). Basic Clin Pharmacol Toxicol. 2012;110(5):427‐432. doi:10.1111/j.1742‐7843.2011.00830.x'}, {'Citation': 'Urban M, Leššo R, Pelclová D. Unintentional pharmaceutical‐related medication errors caused by laypersons reported to the Toxicological Information Centre in the Czech Republic. Basic Clin Pharmacol Toxicol. 2016;119(1):115‐119. doi:10.1111/bcpt.12578'}, {'Citation': 'TOXINZ. Dimethindene Maleate. 2022. https://www.toxinz.com/Spec/2191188/235311'}, {'Citation': 'Flynn JT, Kaelber DC, Baker‐Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3):e20171904. doi:10.1542/peds.2017‐1904'}, {'Citation': 'Fleming S, Thompson M, Stevens R, et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. Lancet. 2011;377(9770):1011‐1018. doi:10.1016/S0140‐6736(10)62226‐X'}, {'Citation': 'Tveden‐Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT 2023 policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol. 2023;133(4):391‐396. doi:10.1111/bcpt.13944'}, {'Citation': 'Lübke G. Dimetindenmaleat. In: Mühlendahl KE, Oberdisse U, Bunjes R, Brockstedt M, eds. Vergiftungen im Kindesalter. 4th ed. Thieme; 2003. ISBN 3‐13‐129814‐6'}, {'Citation': 'Chu FK. Review of the epidemiology and characteristics of intentional cyproheptadine overdose in Hong Kong. Clin Toxicol. 49(7):681‐683.'}, {'Citation': 'Teng A, Bartle A, Sadeh A, Mindell J. Infant and toddler sleep in Australia and New Zealand. J Paediatr Child Health. 2012;48(3):268‐273. doi:10.1111/j.1440‐1754.2011.02251.x'}, {'Citation': 'Plackova S, Caganova B, Faltanova P, Kresanek J. Pediatric dimetindene exposure. Abstract, 34. International Congress of EAPCCT. Clin Toxicol. 2014;52(4):418.'}, {'Citation': 'Fenistil gto por. State Institute for drug control, Slovakia https://www.sukl.sk/hlavna-stranka-1/english-version/special-pages/medical-product-detail?page_id=842&lie_id=26252 [cit. 2023‐08‐25]'}], 'ReferenceList': [], 'Title': 'REFERENCES'}], 'History': [DictElement({'Year': '2024', 'Month': '2', 'Day': '27'}, attributes={'PubStatus': 'revised'}), DictElement({'Year': '2023', 'Month': '11', 'Day': '30'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '2'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '4', 'Day': '17', 'Hour': '6', 'Minute': '42'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '23', 'Hour': '20', 'Minute': '43'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '23', 'Hour': '4', 'Minute': '32'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38520199', attributes={'IdType': 'pubmed'}), StringElement('10.1111/bcpt.14005', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('antazoline', attributes={'MajorTopicYN': 'N'}), StringElement('dansyl chloride', attributes={'MajorTopicYN': 'N'}), StringElement('second derivative', attributes={'MajorTopicYN': 'N'}), StringElement('synchronous fluorescence', attributes={'MajorTopicYN': 'N'}), StringElement('tetryzoline', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38516711', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '03', 'Day': '25'}, 'DateRevised': {'Year': '2024', 'Month': '03', 'Day': '25'}, 'Article': DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.1002/bio.4728', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1522-7243', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '39', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Mar'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Luminescence : the journal of biological and chemical luminescence', 'ISOAbbreviation': 'Luminescence'}, 'ArticleTitle': 'A novel green spectrofluorimetric method for simultaneous determination of antazoline and tetryzoline in their ophthalmic formulation.', 'Pagination': {'StartPage': 'e4728', 'MedlinePgn': 'e4728'}, 'Abstract': {'AbstractText': ['A novel spectrofluorimetric method has been developed for determination of antazoline (ANT) and tetryzoline (TET) in their pharmaceutical formulation. A combined application of synchronous spectrofluorimetry and second derivative mathematical treatment was developed. The proposed method depends on reacting the cited drugs with dansyl chloride (DNS-Cl) being a suitable derivatizing agent generating highly fluorescent derivatives measured at emission wavelengths of 703.0 and 642.0\\xa0nm after excitation wavelengths of 350.0 and 320.0\\xa0nm for ANT and TET, respectively. The joint use of synchronous spectrofluorimetry with second derivative mathematical treatment is for the first time to be developed and optimized in aid of using fluorescence data manager software generating second derivative peak amplitudes at 556.5\\xa0nm for ANT and 516.7\\xa0nm for TET. Linear responses have been represented over a wide range of concentration (0.5-12.0\\xa0μg/mL for ANT and 0.5-10.0\\xa0μg/mL for TET). Additionally, statistical comparison of the developed method with the official ones has been carried out where no significant difference was found. Additionally, greenness profile assessment was accomplished by means of four metric tools. Indeed, the method developed is found to be precise, sensitive, and discriminating to assess the cited drugs for regular analysis.'], 'CopyrightInformation': '© 2024 John Wiley & Sons Ltd.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Future University in Egypt, Cairo, 11835, Egypt.'}], 'Identifier': [StringElement('0000-0003-1947-9843', attributes={'Source': 'ORCID'})], 'LastName': 'Hussein', 'ForeName': 'Ola G', 'Initials': 'OG'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Future University in Egypt, Cairo, 11835, Egypt.'}], 'Identifier': [], 'LastName': 'Ahmed', 'ForeName': 'Dina A', 'Initials': 'DA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}], 'Identifier': [], 'LastName': 'Abdelkawy', 'ForeName': 'Mohamed', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}], 'Identifier': [], 'LastName': 'Rezk', 'ForeName': 'Mamdouh R', 'Initials': 'MR'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}], 'Identifier': [StringElement('0000-0002-3075-6197', attributes={'Source': 'ORCID'})], 'LastName': 'Rostom', 'ForeName': 'Yasmin', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'}), 'MedlineJournalInfo': {'Country': 'England', 'MedlineTA': 'Luminescence', 'NlmUniqueID': '100889025', 'ISSNLinking': '1522-7235'}, 'ChemicalList': [{'RegistryNumber': 'S9U025Y077', 'NameOfSubstance': StringElement('tetrahydrozoline', attributes={'UI': 'C005810'})}, {'RegistryNumber': 'DHA8014SS1', 'NameOfSubstance': StringElement('Antazoline', attributes={'UI': 'D000865'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Imidazoles', attributes={'UI': 'D007093'})}], 'MeshHeadingList': [{'QualifierName': [StringElement('analysis', attributes={'UI': 'Q000032', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Antazoline', attributes={'UI': 'D000865', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('methods', attributes={'UI': 'Q000379', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Spectrometry, Fluorescence', attributes={'UI': 'D013050', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Imidazoles', attributes={'UI': 'D007093', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'Y.‐Q. Li, X.‐Y. Li, A. A. F. Shindi, Z.‐X. Zou, Q. Liu, L.‐R. Lin, N. Li, Rev. Fluoresc. 2012, 2010, 95.'}, {'Citation': 'G.‐Z. Chen, X.‐Z. Huang, J.‐G. Xu, Z. Zheng, Z.‐B. Wang, Science, Beijing 1990, 112.'}, {'Citation': 'J. R. Lakowicz, Opics in Fluorescence Spectroscopy: Principles, Springer Science & Business Media, New York 1992.'}, {'Citation': 'M. R. Elghobashy, M. R. Rezk, Anal. Bioanal. Electrochem. 2014, 6, 461.'}, {'Citation': 'M. R. Elghobashy, A. M. Mahmoud, M. R. Rezk, M. K. Abd El‐Rahman, J. Electrochem. Soc. 2014, 162, H1.'}, {'Citation': 'M. Wadie, H. M. Marzouk, M. R. Rezk, E. M. Abdel‐Moety, M. A. Tantawy, Anal. Chim. Acta 2022, 1200, 339599.'}, {'Citation': 'M. A. Tantawy, S. A. Weshahy, M. Wadie, M. R. Rezk, Biomed. Chromatogr. 2020, 34, e4850.'}, {'Citation': 'M. A. Tantawy, S. A. Weshahy, M. Wadie, M. R. Rezk, Microchem. J. 2020, 157, 104905.'}, {'Citation': 'E. M. Abdel‐Moety, N. A. Elragehy, N. Y. Hassan, M. R. Rezk, J. Chromatogr. Sci. 2010, 48, 624.'}, {'Citation': 'M. R. Rezk, E. M. Abdel‐Moety, M. Wadie, M. A. Tantawy, J.Sep. Sci. 2021, 44, 530.'}, {'Citation': 'M. A. Tantawy, S. A. Weshahy, M. Wadie, M. R. Rezk, Anal. Methods. 2020, 12, 3368.'}, {'Citation': 'M. Wadie, E. M. Abdel‐Moety, M. R. Rezk, M. A. Tantawy, Microchem. J. 2021, 165, 106095.'}, {'Citation': 'M. R. Rezk, H. H. Monir, H. M. Marzouk, Spectrochim. Acta A Mol. Biomol. Spectrosc. 2019, 213, 159.'}, {'Citation': 'M. R. Rezk, M. A. Tantawy, M. Wadie, S. A. Weshahy, Spectrochim. Acta A Mol. Biomol. Spectrosc. 2020, 227, 117547.'}, {'Citation': 'H. A. El Fiky, M. F. Abd El Ghany, A. M. Badawey, N. Fares, D. A. Ahmed, Future J. Pharm.Sci. 2024, 10, 1.'}, {'Citation': 'D. Patra, A. Mishra, TrAC, Trends Anal. Chem. 2002, 21, 787.'}, {'Citation': 'G. Weber, Biochem. J. 1952, 51, 145.'}, {'Citation': 'R. Wang, Y. Chu, X. Li, B. Wan, T. Yu, L. Wang, L. Hao, M. Guo, Biomed. Chromatogr. 2013, 27, 1595.'}, {'Citation': 'I. S. C. S. E. Martindale, The Extra Pharmacopoeia, 35th ed., Pharmaceutical Press, London, UK 2007.'}, {'Citation': 'U.S.P.U.S. Pharmacopeia, I. Convention, Rockville, MD, 2000. USP 24 NF 19.'}, {'Citation': 'L. M. Abdel‐Halim, M. K. Abd‐El Rahman, N. K. Ramadan, H. F. E. Sanabary, M. Y. Salem, Spectrochim. Acta A Mol. Biomol. Spectrosc. 2016, 159, 98.'}, {'Citation': 'W. A. Shadoul, E. A. G. Kariem, K. E. E. Ibrahim, M. Ebied, Asian J. Pharm. Sci. Res. 2011, 1, 29.'}, {'Citation': 'M. Gumustas, U. Alshana, N. Ertas, N. G. Goger, S. A. Ozkan, B. Uslu, J. Pharm. Biomed. Anal. 2016, 124, 390.'}, {'Citation': 'A. Bekele, A. Hymete, A. A. Bekhit, Thai J. Pharm. Sci. 2013, 3, 37.'}, {'Citation': 'O. G. Hussein, M. Abdelkawy, M. R. Rezk, D. A. Ahmed, Y. Rostom, Results Chem. 2023, 5, 100920.'}, {'Citation': 'O. G. Hussein, Y. Rostom, M. Abdelkawy, M. R. Rezk, D. A. Ahmed, J.Chromatogr. Sci. 2023, bmad042.'}, {'Citation': 'N. Seiler, Methods Biochem. Anal. 1970, 18, 259.'}, {'Citation': 'A. Gałuszka, Z. M. Migaszewski, P. Konieczka, J. Namieśnik, TrAC, Trends Anal. Chem. 2012, 37, 61.'}, {'Citation': 'L. H. Keith, L. U. Gron, J. L. Young, Chem. Rev. 2007, 107, 2695.'}, {'Citation': 'J. Płotka‐Wasylka, Talanta 2018, 181, 204.'}, {'Citation': 'F. Pena‐Pereira, W. Wojnowski, M. Tobiszewski, Anal. Chem. 2020, 92, 10076.'}, {'Citation': 'G. Chen, X. Huang, J. Xu, Z. Zheng, Z. Wang, The Methods of Fluorescence Analysis, Vol. 112, Science Press, Beijing, RP China 1990.'}, {'Citation': 'N. El‐Enany, F. Belal, M. Rizk, J. Fluoresc. 2008, 18, 349.'}, {'Citation': 'F. A. L. El‐Sayed, T. A. Mohamed, A. E. Taha, Chem. Ind. Chem. Eng.Q. 2010, 16, 31.'}, {'Citation': 'C. Cruces‐Blanco, A. Segura Carretero, S. Fernández Peinado, Microchim. Acta 2000, 134, 107.'}, {'Citation': 'S. T. Ulu, Luminescence 2012, 27, 426.'}, {'Citation': 'A. Karasakal, S. T. Ulu, J.Anal. Chem. 2015, 70, 708.'}, {'Citation': 'M. A. Omar, H. M. Ahmed, M. A. Hammad, S. M. Derayea, Spectrochim. Acta A Mol. Biomol. Spectrosc. 2015, 135, 472.'}, {'Citation': 'M. M. Ayad, M. Abd El‐Hay, Anal. 1984, 109, 1431.'}, {'Citation': 'J. Pütter, J. Drug Metab. Pharmacokinet. 1979, 4, 143.'}, {'Citation': 'Z. Aydoğmuş, F. Sarı, S. T. Ulu, J. Fluoresc. 2012, 22, 549.'}, {'Citation': \"N. Seiler, M. Wiechmann, Fresenius' Zeitschrift für analytische Chemie 1966, 220, 109.\"}, {'Citation': 'A. Boulton, Anal. 1968, 16(1968), 327.'}, {'Citation': 'L. P. Penzes, G. W. Oertel, J. Chromatogr. A. 1970, 51, 325.'}, {'Citation': 'W. Gray, B. Hartley, Biochem. J. 1963, 89, 379.'}, {'Citation': 'W. Gray, Methods in Enzymology, 1967, 11, 139.'}, {'Citation': 'M. Frei‐Häusler, R. Frei, O. Hutzinger, J. Chromatogr. A. 1973, 79, 209.'}, {'Citation': 'A. Niederwieser, G. Pataki, Progress in Thin‐Layer Chromatography and Related Methods, Ann Arbor, United States 1970.'}, {'Citation': 'ICH, Q2 (R1): Validation of analytical procedures: text and methodology, International Conference on Harmonization, Geneva, 2005, pp. 1–13.'}, {'Citation': 'B. Myors, K. R. Murphy, A. Wolach, Statistical Power Analysis: A Simple and General Model for Traditional and Modern Hypothesis Tests, Routledge, New York 2010.'}], 'ReferenceList': [], 'Title': 'REFERENCES'}], 'History': [DictElement({'Year': '2024', 'Month': '1', 'Day': '31'}, attributes={'PubStatus': 'revised'}), DictElement({'Year': '2023', 'Month': '12', 'Day': '1'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '2', 'Day': '27'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '25', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '22', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '22', 'Hour': '4', 'Minute': '18'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38516711', attributes={'IdType': 'pubmed'}), StringElement('10.1002/bio.4728', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38511703', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '03', 'Day': '22'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '11'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '21'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1097/01.NAJ.0001010556.28403.79', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1538-7488', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '124', 'Issue': '4', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The American journal of nursing', 'ISOAbbreviation': 'Am J Nurs'}, 'ArticleTitle': 'Stronger Warnings for Promethazine Hydrochloride Injection.', 'Pagination': {'StartPage': '22', 'MedlinePgn': '22'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .'}], 'Identifier': [], 'LastName': 'Aschenbrenner', 'ForeName': 'Diane S', 'Initials': 'DS'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'Am J Nurs', 'NlmUniqueID': '0372646', 'ISSNLinking': '0002-936X'}, 'ChemicalList': [{'RegistryNumber': 'FF28EJQ494', 'NameOfSubstance': StringElement('Promethazine', attributes={'UI': 'D011398'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Promethazine', attributes={'UI': 'D011398', 'MajorTopicYN': 'Y'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2024', 'Month': '3', 'Day': '22', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '21', 'Hour': '12', 'Minute': '46'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '21', 'Hour': '8', 'Minute': '3'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38511703', attributes={'IdType': 'pubmed'}), StringElement('10.1097/01.NAJ.0001010556.28403.79', attributes={'IdType': 'doi'}), StringElement('00000446-202404000-00020', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Chronic spontaneous urticaria', attributes={'MajorTopicYN': 'N'}), StringElement('angioedema', attributes={'MajorTopicYN': 'N'}), StringElement('comedication', attributes={'MajorTopicYN': 'N'}), StringElement('comorbidity', attributes={'MajorTopicYN': 'N'}), StringElement('real-life', attributes={'MajorTopicYN': 'N'}), StringElement('systemic therapy', attributes={'MajorTopicYN': 'N'}), StringElement('wheals', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38508226', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '03', 'Day': '22'}, 'DateRevised': {'Year': '2024', 'Month': '03', 'Day': '22'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '20'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1080/09546634.2024.2329784', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1471-1753', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '35', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Dec'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The Journal of dermatological treatment', 'ISOAbbreviation': 'J Dermatolog Treat'}, 'ArticleTitle': 'UCOMB-real life data: treatment strategies for chronic urticaria patients with comorbidities.', 'Pagination': {'StartPage': '2329784', 'MedlinePgn': '2329784'}, 'Abstract': {'AbstractText': [StringElement('There is a lack of real-life safety data on treatment options for chronic urticaria in the presence of comedication and comorbidities.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'UNASSIGNED'}), StringElement('We present a single-center UCARE pilot study of 212 outpatients with chronic urticaria. Patients were divided into three groups according to different CU therapies according to international guidelines.', attributes={'Label': 'METHODS', 'NlmCategory': 'UNASSIGNED'}), StringElement('Of 212 patients, 108 (mean age 48.9\\u2009years, 71.3% female) had 59 comorbidities, including cardiovascular, autoimmune and malignant diseases. Patients were followed for a mean of 24.6\\u2009months (SD ± 21.3). Urticaria therapies were divided into three groups: A: 105 (97.2%) with omalizumab and 2nd generation antihistamines), B: 16 patients (14.8%): dual therapy with antihistamines and cyclosporine in 10 (9.3%), montelukast in five (4. 6%), dapsone in four (3.7%), hydroxychloroquine in one patient (0.9%), C: 12 (11.1%) patients received a third drug for 4.9\\u2009months (SD ± 3.2) and one quadruple therapy (2.1\\u2009months). 10 out of 12 (83.3%) patients received montelukast, two (16.7%) cyclosporine, two (16.7%) dapsone and one (8.3%) hydroxychloroquine as a third drug for chronic urticaria.', attributes={'Label': 'RESULTS', 'NlmCategory': 'UNASSIGNED'}), StringElement('Combining treatment modalities for chronic urticaria and comorbidities are available and feasible with a good safety profile.', attributes={'Label': 'CONCLUSIONS', 'NlmCategory': 'UNASSIGNED'})]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.'}], 'Identifier': [], 'LastName': 'Staubach', 'ForeName': 'Petra', 'Initials': 'P'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.'}], 'Identifier': [], 'LastName': 'Bilo', 'ForeName': 'Benedikt', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology IFA, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'Identifier': [], 'Affiliation': 'Fraunhofer Insitute for Translational Medicine and Pharmacology, ITMP Berlin, Immunology and Allergology IA, Berlin, Germany.'}], 'Identifier': [], 'LastName': 'Fluhr', 'ForeName': 'Joachim W', 'Initials': 'JW'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology IFA, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'Identifier': [], 'Affiliation': 'Fraunhofer Insitute for Translational Medicine and Pharmacology, ITMP Berlin, Immunology and Allergology IA, Berlin, Germany.'}], 'Identifier': [], 'LastName': 'Krause', 'ForeName': 'Karoline', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}], 'Identifier': [], 'LastName': 'Kulthanan', 'ForeName': 'Kanokvalai', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, Acıbadem University School of Medicine, Istanbul, Turkey.'}], 'Identifier': [], 'LastName': 'Salman', 'ForeName': 'Andac', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Medicine, Campbelltown Hospital and Western Sydney University Sydney, Campbelltown, Australia.'}], 'Identifier': [], 'LastName': 'Katelaris', 'ForeName': 'Connie', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Rheumatology, Allergy and Immunology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.'}], 'Identifier': [], 'LastName': 'Bernstein', 'ForeName': 'Jonathan A', 'Initials': 'JA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology IFA, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'Identifier': [], 'Affiliation': 'Fraunhofer Insitute for Translational Medicine and Pharmacology, ITMP Berlin, Immunology and Allergology IA, Berlin, Germany.'}], 'Identifier': [], 'LastName': 'Maurer', 'ForeName': 'Marcus', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.'}], 'Identifier': [StringElement('0000-0001-7044-2216', attributes={'Source': 'ORCID'})], 'LastName': 'Mann', 'ForeName': 'Caroline', 'Initials': 'C'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'}), 'MedlineJournalInfo': {'Country': 'England', 'MedlineTA': 'J Dermatolog Treat', 'NlmUniqueID': '8918133', 'ISSNLinking': '0954-6634'}, 'ChemicalList': [{'RegistryNumber': 'MHM278SD3E', 'NameOfSubstance': StringElement('montelukast', attributes={'UI': 'C093875'})}, {'RegistryNumber': '4QWG6N8QKH', 'NameOfSubstance': StringElement('Hydroxychloroquine', attributes={'UI': 'D006886'})}, {'RegistryNumber': '2P471X1Z11', 'NameOfSubstance': StringElement('Omalizumab', attributes={'UI': 'D000069444'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Histamine H1 Antagonists', attributes={'UI': 'D006634'})}, {'RegistryNumber': '83HN0GTJ6D', 'NameOfSubstance': StringElement('Cyclosporine', attributes={'UI': 'D016572'})}, {'RegistryNumber': '8W5C518302', 'NameOfSubstance': StringElement('Dapsone', attributes={'UI': 'D003622'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Allergic Agents', attributes={'UI': 'D018926'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Acetates', attributes={'UI': 'D000085'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Cyclopropanes', attributes={'UI': 'D003521'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Quinolines', attributes={'UI': 'D011804'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Sulfides', attributes={'UI': 'D013440'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Female', attributes={'UI': 'D005260', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Middle Aged', attributes={'UI': 'D008875', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Male', attributes={'UI': 'D008297', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Hydroxychloroquine', attributes={'UI': 'D006886', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Pilot Projects', attributes={'UI': 'D010865', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Chronic Disease', attributes={'UI': 'D002908', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Chronic Urticaria', attributes={'UI': 'D000080223', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Urticaria', attributes={'UI': 'D014581', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Omalizumab', attributes={'UI': 'D000069444', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Histamine H1 Antagonists', attributes={'UI': 'D006634', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Cyclosporine', attributes={'UI': 'D016572', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Dapsone', attributes={'UI': 'D003622', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Allergic Agents', attributes={'UI': 'D018926', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Acetates', attributes={'UI': 'D000085', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Cyclopropanes', attributes={'UI': 'D003521', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Quinolines', attributes={'UI': 'D011804', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Sulfides', attributes={'UI': 'D013440', 'MajorTopicYN': 'Y'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2024', 'Month': '3', 'Day': '22', 'Hour': '6', 'Minute': '44'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '21', 'Hour': '0', 'Minute': '43'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '20', 'Hour': '20', 'Minute': '23'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38508226', attributes={'IdType': 'pubmed'}), StringElement('10.1080/09546634.2024.2329784', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Dupilumab', attributes={'MajorTopicYN': 'N'}), StringElement('Etokimab', attributes={'MajorTopicYN': 'N'}), StringElement('Food allergy', attributes={'MajorTopicYN': 'N'}), StringElement('Mepolizumab', attributes={'MajorTopicYN': 'N'}), StringElement('Monoclonal antibodies', attributes={'MajorTopicYN': 'N'}), StringElement('Omalizumab', attributes={'MajorTopicYN': 'N'}), StringElement('Oral immunotherapy', attributes={'MajorTopicYN': 'N'}), StringElement('TNX-901', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [DictElement({'AbstractText': ['A pesar de los avances prometedores en la inmunoterapia oral para alergias alimentarias, su implementación médica enfrenta limitaciones. Se investigan opciones no específicas basadas en la inhibición de la vía inflamatoria tipo 2, incluyendo anticuerpos monoclonales. El TNX-901 y omalizumab han demostrado aumentar los umbrales de reacción, reduciendo eventos adversos en pacientes con alergia al cacahuate. El dupilumab, que bloquea el receptor alfa de IL-4, muestra resultados positivos en alergias alimentarias, así como en la esofagitis eosinofílica. Anticuerpos contra alarminas y anti-IL-5, como etokimab y mepolizumab, han demostrado eficacia en estudios preclínicos y ensayos clínicos. Aunque se necesitan más estudios para establecer su uso clínico práctico y determinar la idoneidad para distintos tipos de alergias alimentarias, estos anticuerpos monoclonales presentan un horizonte prometedor para el tratamiento de dichas condiciones.']}, attributes={'Type': 'Publisher', 'Language': 'spa'})], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38506875', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '03', 'Day': '21'}, 'DateRevised': {'Year': '2024', 'Month': '03', 'Day': '21'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2023', 'Month': '12', 'Day': '31'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.29262/ram.v70i4.1340', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['spa'], 'Journal': {'ISSN': StringElement('2448-9190', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '70', 'Issue': '4', 'PubDate': {'Year': '2023', 'Month': 'Dec', 'Day': '31'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)', 'ISOAbbreviation': 'Rev Alerg Mex'}, 'ArticleTitle': '[Application of biologicals in patients with food allergies].', 'Pagination': {'StartPage': '297', 'EndPage': '299', 'MedlinePgn': '297-299'}, 'Abstract': {'AbstractText': ['Despite promising advancements in oral immunotherapy for food allergies, medical implementation faces limitations. Non-specific treatment options based on inhibiting the type 2 inflammatory pathway, including monoclonal antibodies, are under investigation. TNX-901 and omalizumab have demonstrated increased reaction thresholds, reducing adverse events in peanut-allergic patients. Dupilumab, blocking the IL-4 receptor, shows positive results in both food allergies and eosinophilic esophagitis. Antibodies against alarmins and anti-IL-5, such as etokimab and mepolizumab, have proven efficacy in preclinical studies and clinical trials. While further studies are needed to establish their practical clinical use and determine suitability for different types of food allergies, these monoclonal antibodies present a promising horizon for the treatment of such conditions.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Inmunóloga, adscrita a la Clínica Indisa, Santiago de Chile.todoasma@gmail.com.'}], 'Identifier': [StringElement('0009-0003-8058-8587', attributes={'Source': 'ORCID'})], 'LastName': 'Agar Muñoz', 'ForeName': 'Ana María', 'Initials': 'AM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Médico Asistente, Alergólogo e Inmunólogo Clínico, Clínica Internacional Lima-Peru; Director Médico en Emedic Salud, Lima, Perú.'}], 'Identifier': [StringElement('0000-0003-3517-305', attributes={'Source': 'ORCID'})], 'LastName': 'Galván Calle', 'ForeName': 'César Alberto', 'Initials': 'CA'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('English Abstract', attributes={'UI': 'D004740'}), StringElement('Journal Article', attributes={'UI': 'D016428'})], 'VernacularTitle': 'Aplicación de biológicos en pacientes con alergia alimentaria.'}, attributes={'PubModel': 'Electronic'}), 'MedlineJournalInfo': {'Country': 'Mexico', 'MedlineTA': 'Rev Alerg Mex', 'NlmUniqueID': '9438824', 'ISSNLinking': '0002-5151'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Biological Products', attributes={'UI': 'D001688'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Antibodies, Monoclonal', attributes={'UI': 'D000911'})}, {'RegistryNumber': '2P471X1Z11', 'NameOfSubstance': StringElement('Omalizumab', attributes={'UI': 'D000069444'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Biological Products', attributes={'UI': 'D001688', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Antibodies, Monoclonal', attributes={'UI': 'D000911', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('complications', attributes={'UI': 'Q000150', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Food Hypersensitivity', attributes={'UI': 'D005512', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Immunotherapy', attributes={'UI': 'D007167', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Omalizumab', attributes={'UI': 'D000069444', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2023', 'Month': '8', 'Day': '1'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2023', 'Month': '10', 'Day': '29'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '21', 'Hour': '12', 'Minute': '46'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '20', 'Hour': '12', 'Minute': '43'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '20', 'Hour': '11', 'Minute': '43'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38506875', attributes={'IdType': 'pubmed'}), StringElement('10.29262/ram.v70i4.1340', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Allergens', attributes={'MajorTopicYN': 'N'}), StringElement('Anaphylaxis', attributes={'MajorTopicYN': 'N'}), StringElement('Epinephrine', attributes={'MajorTopicYN': 'N'}), StringElement('Food allergy', attributes={'MajorTopicYN': 'N'}), StringElement('Omalizumab', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [DictElement({'AbstractText': ['La alergia alimentaria es un trastorno crónico frecuente que afecta a lactantes, niños, adolescentes y adultos. La prevalencia de alergia alimentaria se ha incrementado en las últimas décadas en todo el mundo, sin limitarse a los países occidentales. Puesto que no existe ningún tratamiento, éste se centra en evitar los alergenos, además de la educación de pacientes y cuidadores en el tratamiento de urgencia de las reacciones agudas, por ejemplo: aplicación de epinefrina. Los estudios sugieren que las reacciones accidentales ocurren en alrededor del 45% de los niños con alergia alimentaria cada año, aunque la mayor parte de las reacciones son de gravedad leve o moderada. Los ingresos hospitalarios por anafilaxia alimentaria varían de 4 a 20 por cada 100,000 habitantes; las muertes son raras, con una incidencia estimada de 0.03 a 0.3 por cada millón de personas con alergia alimentaria. La muerte por anafilaxia alimentaria es rara y parece haberse mantenido estable, posiblemente por el aumento en el etiquetado de alérgenos alimentarios, los servicios de diagnóstico, las tasas de prescripción de epinefrina intramuscular y la concienciación acerca de alergias alimentarias. Omalizumab es un fármaco aprobado para varias alteraciones (urticaria crónica o asma difícil) y puede ayudar a reducir los síntomas asociados con la alergia alimentaria. La importancia relativa de las tecnologías alternativas, las estrategias de gestión y las políticas para la alergia alimentaria varía de una región a otra, debido a las diferencias en la epidemiología, educación, bienestar socioeconómico y preferencias culturales de la población.']}, attributes={'Type': 'Publisher', 'Language': 'spa'})], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38506857', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '03', 'Day': '21'}, 'DateRevised': {'Year': '2024', 'Month': '03', 'Day': '21'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2023', 'Month': '12', 'Day': '31'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.29262/ram.v70i4.1308', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['spa'], 'Journal': {'ISSN': StringElement('2448-9190', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '70', 'Issue': '4', 'PubDate': {'Year': '2023', 'Month': 'Dec', 'Day': '31'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)', 'ISOAbbreviation': 'Rev Alerg Mex'}, 'ArticleTitle': '[Introduction to food allergy].', 'Pagination': {'StartPage': '208', 'EndPage': '210', 'MedlinePgn': '208-210'}, 'Abstract': {'AbstractText': ['Food allergy is a common chronic disorder that affects infants, children, adolescents, and adults. The prevalence of food allergy has increased in recent decades throughout the world, not limited to Western countries. Since there is no treatment, this focuses on avoiding allergens, in addition to educating patients and caregivers in the emergency treatment of acute reactions, for example: application of epinephrine. Studies suggest that accidental reactions occur in about 45% of children with food allergies each year, although most reactions are mild or moderate in severity. Hospital admissions for food anaphylaxis vary from 4 to 20 per 100,000 inhabitants; Deaths are rare, with an estimated incidence of 0.03 to 0.3 per million people with food allergy. Death from food anaphylaxis is rare and appears to have remained stable, possibly due to increases in food allergen labeling, diagnostic services, rates of intramuscular epinephrine prescription, and awareness of food allergies. Omalizumab is a drug approved for several disorders (chronic hives or difficult asthma) and may help reduce symptoms associated with food allergy. The relative importance of alternative technologies, management strategies and policies for food allergy varies from one region to another, due to differences in the epidemiology, education, socioeconomic well-being, and cultural preferences of the population.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Director Médico Ejecutivo, Expresidente de la Organización Mundial de Alergia (WAO). Jefe del Departamento de Alergia e Inmunología, Hospital Quironsalud, Bizkaia, Bilbao, España.todoasma@gmail.com.'}], 'Identifier': [StringElement('00000-0002-6942-1511', attributes={'Source': 'ORCID'})], 'LastName': 'Ansotegui Zubeldia', 'ForeName': 'Ignacio Javier', 'Initials': 'IJ'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Director responsable de la S.C. de Pediatría, Hospital Materno Infantil Macedonio Melloni, Milán, Italia. Director del Departamento Materno Infantil, Hospital Fatebenefratelli-Ophthalmic de Milán, Italia. Profesor adjunto de la Escuela de Es-pecialización en Pediatría III, Universidad de Milán y Consejero de la Sociedad Italiana de Pediatría, Sección Lombarda. Pediatric Hospital Bambino Gesú IRCCS Allergy division, Roma, Italia.'}], 'Identifier': [StringElement('0000-0002-2549-0523', attributes={'Source': 'ORCID'})], 'LastName': 'Fiocchi', 'ForeName': 'Alessandro', 'Initials': 'A'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('English Abstract', attributes={'UI': 'D004740'}), StringElement('Journal Article', attributes={'UI': 'D016428'})], 'VernacularTitle': 'Introducción en alergia alimentaria.'}, attributes={'PubModel': 'Electronic'}), 'MedlineJournalInfo': {'Country': 'Mexico', 'MedlineTA': 'Rev Alerg Mex', 'NlmUniqueID': '9438824', 'ISSNLinking': '0002-5151'}, 'ChemicalList': [{'RegistryNumber': 'YKH834O4BH', 'NameOfSubstance': StringElement('Epinephrine', attributes={'UI': 'D004837'})}, {'RegistryNumber': '2P471X1Z11', 'NameOfSubstance': StringElement('Omalizumab', attributes={'UI': 'D000069444'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Adolescent', attributes={'UI': 'D000293', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Adult', attributes={'UI': 'D000328', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Child', attributes={'UI': 'D002648', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Infant', attributes={'UI': 'D007223', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('diagnosis', attributes={'UI': 'Q000175', 'MajorTopicYN': 'N'}), StringElement('epidemiology', attributes={'UI': 'Q000453', 'MajorTopicYN': 'N'}), StringElement('etiology', attributes={'UI': 'Q000209', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anaphylaxis', attributes={'UI': 'D000707', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('diagnosis', attributes={'UI': 'Q000175', 'MajorTopicYN': 'N'}), StringElement('therapy', attributes={'UI': 'Q000628', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Food Hypersensitivity', attributes={'UI': 'D005512', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Asthma', attributes={'UI': 'D001249', 'MajorTopicYN': 'Y'})}, {'QualifierName': [StringElement('therapeutic use', attributes={'UI': 'Q000627', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Epinephrine', attributes={'UI': 'D004837', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Omalizumab', attributes={'UI': 'D000069444', 'MajorTopicYN': 'N'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2023', 'Month': '8', 'Day': '1'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2023', 'Month': '10', 'Day': '29'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '21', 'Hour': '12', 'Minute': '43'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '20', 'Hour': '12', 'Minute': '45'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '20', 'Hour': '11', 'Minute': '43'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38506857', attributes={'IdType': 'pubmed'}), StringElement('10.29262/ram.v70i4.1308', attributes={'IdType': 'doi'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('Allergic rhinitis', attributes={'MajorTopicYN': 'N'}), StringElement('Antibiotics', attributes={'MajorTopicYN': 'N'}), StringElement('Asthma', attributes={'MajorTopicYN': 'N'}), StringElement('Atopic dermatitis', attributes={'MajorTopicYN': 'N'}), StringElement('Prenatal exposure', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38504329', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '03', 'Day': '21'}, 'DateRevised': {'Year': '2024', 'Month': '03', 'Day': '22'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '20'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('189', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1186/s40001-024-01793-9', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2047-783X', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '29', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Mar', 'Day': '20'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'European journal of medical research', 'ISOAbbreviation': 'Eur J Med Res'}, 'ArticleTitle': 'Antibiotic exposure during pregnancy increases risk for childhood atopic diseases: a nationwide cohort study.', 'Pagination': {'StartPage': '189', 'MedlinePgn': '189'}, 'Abstract': {'AbstractText': [StringElement('The prevalence of atopic diseases has increased in recent decades. A possible link between antibiotic use during pregnancy and childhood atopic disease has been proposed. The aim of this study is to explore the association of antibiotic exposure during pregnancy with childhood atopic diseases from a nationwide, population-based perspective.', attributes={'Label': 'PURPOSE', 'NlmCategory': 'OBJECTIVE'}), StringElement(\"This was a nationwide population-based cohort study. Taiwan's National Health Insurance Research Database was the main source of data. The pairing of mothers and children was achieved by linking the NHIRD with the Taiwan Maternal and Child Health Database. This study enrolled the first-time pregnancies from 2004 to 2010. Infants of multiple delivery, preterm delivery, and death before 5\\xa0years old were excluded. All participants were followed up at least for 5\\xa0years. Antenatal antibiotics prescribed to mothers during the pregnancy period were reviewed. Children with more than\\xa0two outpatient visits, or one admission, with a main\\xa0diagnosis of asthma, allergic rhinitis, or atopic dermatitis were regarded as having an atopic disease.\", attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('A total of 900,584 children were enrolled in this study. The adjusted hazard ratios of antibiotic exposure during pregnancy to childhood atopic diseases were 1.12 for atopic dermatitis, 1.06 for asthma, and 1.08 for allergic rhinitis, all of which reached statistical significance. The trimester effect was not significant. There was a trend showing the higher the number of times a child was prenatally exposed to antibiotics, the higher the hazard ratio was for childhood atopic diseases.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('Prenatal antibiotic exposure might increase the risk of childhood atopic diseases in a dose-dependent manner.', attributes={'Label': 'CONCLUSIONS', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': '© 2024. The Author(s).'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pediatrics, Show Chwan Memorial Hospital, Changhua, Taiwan.'}], 'Identifier': [], 'LastName': 'Tai', 'ForeName': 'Sheng-Kang', 'Initials': 'SK'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Children's Medical Center, Taichung Veterans General Hospital, Taichung, Taiwan.\"}, {'Identifier': [], 'Affiliation': 'Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.'}, {'Identifier': [], 'Affiliation': 'School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.'}], 'Identifier': [], 'LastName': 'Lin', 'ForeName': 'Yi-Hsuan', 'Initials': 'YH'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Medical Research, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sec. 4, Taichung, 40705, Taiwan.'}], 'Identifier': [], 'LastName': 'Lin', 'ForeName': 'Ching-Heng', 'Initials': 'CH'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Children's Medical Center, Taichung Veterans General Hospital, Taichung, Taiwan. mingclin@gmail.com.\"}, {'Identifier': [], 'Affiliation': 'Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan. mingclin@gmail.com.'}, {'Identifier': [], 'Affiliation': 'School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. mingclin@gmail.com.'}, {'Identifier': [], 'Affiliation': 'Department of Food and Nutrition, Providence University, Taichung, Taiwan. mingclin@gmail.com.'}, {'Identifier': [], 'Affiliation': 'School of Medicine, Chung Shan Medical University, Taichung, Taiwan. mingclin@gmail.com.'}], 'Identifier': [], 'LastName': 'Lin', 'ForeName': 'Ming-Chih', 'Initials': 'MC'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': 'TCVGH-1116503C', 'Agency': 'Taichung Veterans General Hospital Reserach Fund', 'Country': ''}, {'GrantID': 'TCVGH-1107309D', 'Agency': 'Taichung Veterans General Hospital Reserach Fund', 'Country': ''}, {'GrantID': 'FCU1118025', 'Agency': 'Taichung Veterans General Hospital Reserach Fund', 'Country': ''}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic'}), 'MedlineJournalInfo': {'Country': 'England', 'MedlineTA': 'Eur J Med Res', 'NlmUniqueID': '9517857', 'ISSNLinking': '0949-2321'}, 'ChemicalList': [{'RegistryNumber': '0', 'NameOfSubstance': StringElement('Anti-Bacterial Agents', attributes={'UI': 'D000900'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Child', attributes={'UI': 'D002648', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Infant', attributes={'UI': 'D007223', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Infant, Newborn', attributes={'UI': 'D007231', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Humans', attributes={'UI': 'D006801', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Female', attributes={'UI': 'D005260', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Pregnancy', attributes={'UI': 'D011247', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Child, Preschool', attributes={'UI': 'D002675', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('chemically induced', attributes={'UI': 'Q000139', 'MajorTopicYN': 'N'}), StringElement('epidemiology', attributes={'UI': 'Q000453', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Dermatitis, Atopic', attributes={'UI': 'D003876', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Cohort Studies', attributes={'UI': 'D015331', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('adverse effects', attributes={'UI': 'Q000009', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Anti-Bacterial Agents', attributes={'UI': 'D000900', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('chemically induced', attributes={'UI': 'Q000139', 'MajorTopicYN': 'N'}), StringElement('epidemiology', attributes={'UI': 'Q000453', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Asthma', attributes={'UI': 'D001249', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Rhinitis, Allergic', attributes={'UI': 'D065631', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Mothers', attributes={'UI': 'D009035', 'MajorTopicYN': 'N'})}], 'CoiStatement': 'The authors have no relevant financial or non-financial interests to disclose.'}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [{'Reference': [{'Citation': 'DeBolt CA, Johnson S, Harishankar K, Monro J, Kaplowitz E, Bianco A, Stone J. Antenatal corticosteroids decrease the risk of composite neonatal respiratory morbidity in planned early term Cesarean deliveries. Am J Perinatol. 2022;39:915–920. doi: 10.1055/a-1674-6198.', 'ArticleIdList': [StringElement('10.1055/a-1674-6198', attributes={'IdType': 'doi'}), StringElement('34670323', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Ledger WJ, Blaser MJ. Are we using too many antibiotics during pregnancy? BJOG Int J Obstetr Gynaecol. 2013;120:1450–1452. doi: 10.1111/1471-0528.12371.', 'ArticleIdList': [StringElement('10.1111/1471-0528.12371', attributes={'IdType': 'doi'}), StringElement('PMC4492536', attributes={'IdType': 'pmc'}), StringElement('24118809', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Petersen I, Gilbert R, Evans S, Ridolfi A, Nazareth I. Oral antibiotic prescribing during pregnancy in primary care: UK population-based study. J Antimicrob Chemother. 2010;65:2238–2246. doi: 10.1093/jac/dkq307.', 'ArticleIdList': [StringElement('10.1093/jac/dkq307', attributes={'IdType': 'doi'}), StringElement('20716554', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, Williams H, Group IPTS. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733–743. doi: 10.1016/S0140-6736(06)69283-0.', 'ArticleIdList': [StringElement('10.1016/S0140-6736(06)69283-0', attributes={'IdType': 'doi'}), StringElement('16935684', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Dhami S, Sheikh A. Estimating the prevalence of aero-allergy and/or food allergy in infants, children and young people with moderate-to-severe atopic eczema/dermatitis in primary care: multi-centre, cross-sectional study. J R Soc Med. 2015;108:229–236. doi: 10.1177/0141076814562982.', 'ArticleIdList': [StringElement('10.1177/0141076814562982', attributes={'IdType': 'doi'}), StringElement('PMC4480555', attributes={'IdType': 'pmc'}), StringElement('25567768', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Peters RL, Koplin JJ, Gurrin LC, Dharmage SC, Wake M, Ponsonby AL, Tang MLK, Lowe AJ, Matheson M, Dwyer T, Allen KJ, HealthNuts S. The prevalence of food allergy and other allergic diseases in early childhood in a population-based study: HealthNuts age 4-year follow-up. J Allergy Clin Immunol. 2017;140(145–153):e148. doi: 10.1016/j.jaci.2017.02.019.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2017.02.019', attributes={'IdType': 'doi'}), StringElement('28514997', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, FitzGerald JM. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24. doi: 10.1186/1471-2466-9-24.', 'ArticleIdList': [StringElement('10.1186/1471-2466-9-24', attributes={'IdType': 'doi'}), StringElement('PMC2698859', attributes={'IdType': 'pmc'}), StringElement('19454036', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Milliken S, Allen RM, Lamont RF. The role of antimicrobial treatment during pregnancy on the neonatal gut microbiome and the development of atopy, asthma, allergy and obesity in childhood. Expert Opin Drug Saf. 2019;18:173–185. doi: 10.1080/14740338.2019.1579795.', 'ArticleIdList': [StringElement('10.1080/14740338.2019.1579795', attributes={'IdType': 'doi'}), StringElement('30739516', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Tapiainen T, Koivusaari P, Brinkac L, Lorenzi HA, Salo J, Renko M, Pruikkonen H, Pokka T, Li W, Nelson K, Pirttila AM, Tejesvi MV. Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants. Sci Rep. 2019;9:10635. doi: 10.1038/s41598-019-46964-5.', 'ArticleIdList': [StringElement('10.1038/s41598-019-46964-5', attributes={'IdType': 'doi'}), StringElement('PMC6650395', attributes={'IdType': 'pmc'}), StringElement('31337807', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Zhang M, Differding MK, Benjamin-Neelon SE, Ostbye T, Hoyo C, Mueller NT. Association of prenatal antibiotics with measures of infant adiposity and the gut microbiome. Ann Clin Microbiol Antimicrob. 2019;18:18. doi: 10.1186/s12941-019-0318-9.', 'ArticleIdList': [StringElement('10.1186/s12941-019-0318-9', attributes={'IdType': 'doi'}), StringElement('PMC6587281', attributes={'IdType': 'pmc'}), StringElement('31226994', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Miller JE, Wu C, Pedersen LH, de Klerk N, Olsen J, Burgner DP. Maternal antibiotic exposure during pregnancy and hospitalization with infection in offspring: a population-based cohort study. Int J Epidemiol. 2018;47:561–571. doi: 10.1093/ije/dyx272.', 'ArticleIdList': [StringElement('10.1093/ije/dyx272', attributes={'IdType': 'doi'}), StringElement('29415232', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Pelzer E, Gomez-Arango LF, Barrett HL, Nitert MD. Review: maternal health and the placental microbiome. Placenta. 2017;54:30–37. doi: 10.1016/j.placenta.2016.12.003.', 'ArticleIdList': [StringElement('10.1016/j.placenta.2016.12.003', attributes={'IdType': 'doi'}), StringElement('28034467', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Metsala J, Lundqvist A, Virta LJ, Kaila M, Gissler M, Virtanen SM. Prenatal and post-natal exposure to antibiotics and risk of asthma in childhood. Clin Exp Allergy. 2015;45:137–145. doi: 10.1111/cea.12356.', 'ArticleIdList': [StringElement('10.1111/cea.12356', attributes={'IdType': 'doi'}), StringElement('24943808', attributes={'IdType': 'pubmed'})]}, {'Citation': \"Ho Chan WS. Taiwan's healthcare report 2010. EPMA J. 2010;1:563–585. doi: 10.1007/s13167-010-0056-8.\", 'ArticleIdList': [StringElement('10.1007/s13167-010-0056-8', attributes={'IdType': 'doi'}), StringElement('PMC3405348', attributes={'IdType': 'pmc'}), StringElement('23199110', attributes={'IdType': 'pubmed'})]}, {'Citation': \"Lin MC, Lai MS. Pediatricians' role in caring for preschool children in Taiwan under the national health insurance program. J Formos Med Assoc. 2009;108:849–855. doi: 10.1016/S0929-6646(09)60416-2.\", 'ArticleIdList': [StringElement('10.1016/S0929-6646(09)60416-2', attributes={'IdType': 'doi'}), StringElement('19933028', attributes={'IdType': 'pubmed'})]}, {'Citation': \"Hsieh CY, Su CC, Shao SC, Sung SF, Lin SJ, Kao Yang YH, Lai EC. Taiwan's National Health Insurance Research Database: past and future. Clin Epidemiol. 2019;11:349–358. doi: 10.2147/CLEP.S196293.\", 'ArticleIdList': [StringElement('10.2147/CLEP.S196293', attributes={'IdType': 'doi'}), StringElement('PMC6509937', attributes={'IdType': 'pmc'}), StringElement('31118821', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Wu TP, Liang FW, Huang YL, Chen LH, Lu TH. Maternal mortality in Taiwan: a nationwide data linkage study. PLoS ONE. 2015;10:e0132547. doi: 10.1371/journal.pone.0132547.', 'ArticleIdList': [StringElement('10.1371/journal.pone.0132547', attributes={'IdType': 'doi'}), StringElement('PMC4523206', attributes={'IdType': 'pmc'}), StringElement('26237411', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Uldbjerg CS, Miller JE, Burgner D, Pedersen LH, Bech BH. Antibiotic exposure during pregnancy and childhood asthma: a national birth cohort study investigating timing of exposure and mode of delivery. Arch Dis Child. 2021;106:888–894. doi: 10.1136/archdischild-2020-319659.', 'ArticleIdList': [StringElement('10.1136/archdischild-2020-319659', attributes={'IdType': 'doi'}), StringElement('33563603', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Lapin B, Piorkowski J, Ownby D, Freels S, Chavez N, Hernandez E, Wagner-Cassanova C, Pelzel D, Vergara C, Persky V. Relationship between prenatal antibiotic use and asthma in at-risk children. Ann Allergy Asthma Immunol. 2015;114:203–207. doi: 10.1016/j.anai.2014.11.014.', 'ArticleIdList': [StringElement('10.1016/j.anai.2014.11.014', attributes={'IdType': 'doi'}), StringElement('PMC4352392', attributes={'IdType': 'pmc'}), StringElement('25532738', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Mulder B, Pouwels K, Schuiling-Veninga C, Bos H, De Vries T, Jick S, Hak E. Antibiotic use during pregnancy and asthma in preschool children: the influence of confounding. Clin Exp Allergy. 2016;46:1214–1226. doi: 10.1111/cea.12756.', 'ArticleIdList': [StringElement('10.1111/cea.12756', attributes={'IdType': 'doi'}), StringElement('27159872', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Zhao D, Su H, Cheng J, Wang X, Xie M, Li K, Wen L, Yang H. Prenatal antibiotic use and risk of childhood wheeze/asthma: a meta-analysis. Pediatr Allergy Immunol. 2015;26:756–764. doi: 10.1111/pai.12436.', 'ArticleIdList': [StringElement('10.1111/pai.12436', attributes={'IdType': 'doi'}), StringElement('26126682', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Bai L, Zhao D, Cheng Q, Zhang Y, Wang S, Zhang H, Xie M, He R, Su H. Trimester-specific association between antibiotics exposure during pregnancy and childhood asthma or wheeze: the role of confounding. Ann Epidemiol. 2019;30:1–8. doi: 10.1016/j.annepidem.2018.10.003.', 'ArticleIdList': [StringElement('10.1016/j.annepidem.2018.10.003', attributes={'IdType': 'doi'}), StringElement('30448356', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Dom S, Droste JH, Sariachvili MA, Hagendorens MM, Oostveen E, Bridts CH, Stevens WJ, Wieringa MH, Weyler JJ. Pre- and post-natal exposure to antibiotics and the development of eczema, recurrent wheezing and atopic sensitization in children up to the age of 4 years. Clin Exp Allergy. 2010;40:1378–1387. doi: 10.1111/j.1365-2222.2010.03538.x.', 'ArticleIdList': [StringElement('10.1111/j.1365-2222.2010.03538.x', attributes={'IdType': 'doi'}), StringElement('20545699', attributes={'IdType': 'pubmed'})]}, {'Citation': 'McKeever TM, Lewis SA, Smith C, Hubbard R. The importance of prenatal exposures on the development of allergic disease: a birth cohort study using the West Midlands General Practice Database. Am J Respir Crit Care Med. 2002;166:827–832. doi: 10.1164/rccm.200202-158OC.', 'ArticleIdList': [StringElement('10.1164/rccm.200202-158OC', attributes={'IdType': 'doi'}), StringElement('12231492', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Kuo CH, Kuo HF, Huang CH, Yang SN, Lee MS, Hung CH. Early life exposure to antibiotics and the risk of childhood allergic diseases: an update from the perspective of the hygiene hypothesis. J Microbiol Immunol Infect Wei mian yu gan ran za zhi. 2013;46:320–329. doi: 10.1016/j.jmii.2013.04.005.', 'ArticleIdList': [StringElement('10.1016/j.jmii.2013.04.005', attributes={'IdType': 'doi'}), StringElement('23751771', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Russell SL, Gold MJ, Willing BP, Thorson L, McNagny KM, Finlay BB. Perinatal antibiotic treatment affects murine microbiota, immune responses and allergic asthma. Gut Microbes. 2013;4:158–164. doi: 10.4161/gmic.23567.', 'ArticleIdList': [StringElement('10.4161/gmic.23567', attributes={'IdType': 'doi'}), StringElement('PMC3595077', attributes={'IdType': 'pmc'}), StringElement('23333861', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Abrahamsson TR, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand L, Jenmalm MC. Low diversity of the gut microbiota in infants with atopic eczema. J Allergy Clin Immunol. 2012;129:434–440 e431-432. doi: 10.1016/j.jaci.2011.10.025.', 'ArticleIdList': [StringElement('10.1016/j.jaci.2011.10.025', attributes={'IdType': 'doi'}), StringElement('22153774', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Penders J, Stobberingh EE, van den Brandt PA, Thijs C. The role of the intestinal microbiota in the development of atopic disorders. Allergy. 2007;62:1223–1236. doi: 10.1111/j.1398-9995.2007.01462.x.', 'ArticleIdList': [StringElement('10.1111/j.1398-9995.2007.01462.x', attributes={'IdType': 'doi'}), StringElement('17711557', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Al Alam D, Danopoulos S, Grubbs B, Ali N, MacAogain M, Chotirmall SH, Warburton D, Gaggar A, Ambalavanan N, Lal CV. Human fetal lungs harbor a microbiome signature. Am J Respir Crit Care Med. 2020;201:1002–1006. doi: 10.1164/rccm.201911-2127LE.', 'ArticleIdList': [StringElement('10.1164/rccm.201911-2127LE', attributes={'IdType': 'doi'}), StringElement('PMC7159424', attributes={'IdType': 'pmc'}), StringElement('31898918', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Francino MP. Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances. Front Microbiol. 2015;6:1543. doi: 10.3389/fmicb.2015.01543.', 'ArticleIdList': [StringElement('10.3389/fmicb.2015.01543', attributes={'IdType': 'doi'}), StringElement('PMC4709861', attributes={'IdType': 'pmc'}), StringElement('26793178', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Turi KN, Gebretsadik T, Ding T, Abreo A, Stone C, Hartert TV, Wu P. Dose, timing, and spectrum of prenatal antibiotic exposure and risk of childhood asthma. Clin Infect Dis. 2021;72:455–462. doi: 10.1093/cid/ciaa085.', 'ArticleIdList': [StringElement('10.1093/cid/ciaa085', attributes={'IdType': 'doi'}), StringElement('PMC7850553', attributes={'IdType': 'pmc'}), StringElement('31994697', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Oyama N, Sudo N, Sogawa H, Kubo C. Antibiotic use during infancy promotes a shift in the TH1/TH2 balance toward TH2-dominant immunity in mice. J Allergy Clin Immunol. 2001;107:153–159. doi: 10.1067/mai.2001.111142.', 'ArticleIdList': [StringElement('10.1067/mai.2001.111142', attributes={'IdType': 'doi'}), StringElement('11150005', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Sudo N, Yu XN, Aiba Y, Oyama N, Sonoda J, Koga Y, Kubo C. An oral introduction of intestinal bacteria prevents the development of a long-term Th2-skewed immunological memory induced by neonatal antibiotic treatment in mice. Clin Exp Allergy. 2002;32:1112–1116. doi: 10.1046/j.1365-2222.2002.01430.x.', 'ArticleIdList': [StringElement('10.1046/j.1365-2222.2002.01430.x', attributes={'IdType': 'doi'}), StringElement('12100062', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Loewen K, Monchka B, Mahmud SM, t JongAzad GMB. Prenatal antibiotic exposure and childhood asthma: a population-based study. Eur Respir J. 2018;52:1702070. doi: 10.1183/13993003.02070-2017.', 'ArticleIdList': [StringElement('10.1183/13993003.02070-2017', attributes={'IdType': 'doi'}), StringElement('29678946', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Higgins D, Karmaus W, Jiang Y, Banerjee P, Sulaiman IM, Arshad HS. Infant wheezing and prenatal antibiotic exposure and mode of delivery: a prospective birth cohort study. J Asthma. 2021;58:770–781. doi: 10.1080/02770903.2020.1734023.', 'ArticleIdList': [StringElement('10.1080/02770903.2020.1734023', attributes={'IdType': 'doi'}), StringElement('PMC7592169', attributes={'IdType': 'pmc'}), StringElement('32141344', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Liu L, Pan Y, Zhu Y, Song Y, Su X, Yang L, Li M. Association between rhinovirus wheezing illness and the development of childhood asthma: a meta-analysis. BMJ Open. 2017;7:e013034. doi: 10.1136/bmjopen-2016-013034.', 'ArticleIdList': [StringElement('10.1136/bmjopen-2016-013034', attributes={'IdType': 'doi'}), StringElement('PMC5387933', attributes={'IdType': 'pmc'}), StringElement('28373249', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Calvani M, Alessandri C, Sopo SM, Panetta V, Tripodi S, Torre A, Pingitore G, Frediani T, Volterrani A, Lazio Association of Pediatric Allergology Study G Infectious and uterus related complications during pregnancy and development of atopic and nonatopic asthma in children. Allergy. 2004;59:99–106. doi: 10.1046/j.1398-9995.2003.00338.x.', 'ArticleIdList': [StringElement('10.1046/j.1398-9995.2003.00338.x', attributes={'IdType': 'doi'}), StringElement('14674941', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Stokholm J, Sevelsted A, Bonnelykke K, Bisgaard H. Maternal propensity for infections and risk of childhood asthma: a registry-based cohort study. Lancet Respir Med. 2014;2:631–637. doi: 10.1016/S2213-2600(14)70152-3.', 'ArticleIdList': [StringElement('10.1016/S2213-2600(14)70152-3', attributes={'IdType': 'doi'}), StringElement('25066330', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Yang C-T, Lin C-H, Lin M-C. Gestational hypertension and risk of atopic diseases in offspring, a national-wide cohort study. Front Pediatr. 2023 doi: 10.3389/fped.2023.1283782.', 'ArticleIdList': [StringElement('10.3389/fped.2023.1283782', attributes={'IdType': 'doi'}), StringElement('PMC10701899', attributes={'IdType': 'pmc'}), StringElement('38078331', attributes={'IdType': 'pubmed'})]}, {'Citation': 'Hsu MC, Lin CH, Lin MC. Maternal gestational diabetes mellitus and risk of allergic diseases in offspring. Pediatr Neonatol. 2023 doi: 10.1016/j.pedneo.2023.06.012.', 'ArticleIdList': [StringElement('10.1016/j.pedneo.2023.06.012', attributes={'IdType': 'doi'}), StringElement('38052685', attributes={'IdType': 'pubmed'})]}], 'ReferenceList': []}], 'History': [DictElement({'Year': '2022', 'Month': '12', 'Day': '8'}, attributes={'PubStatus': 'received'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '13'}, attributes={'PubStatus': 'accepted'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '21', 'Hour': '12', 'Minute': '44'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '20', 'Hour': '6', 'Minute': '45'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '20', 'Hour': '0', 'Minute': '53'}, attributes={'PubStatus': 'entrez'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '20'}, attributes={'PubStatus': 'pmc-release'})], 'PublicationStatus': 'epublish', 'ArticleIdList': [StringElement('38504329', attributes={'IdType': 'pubmed'}), StringElement('PMC10953187', attributes={'IdType': 'pmc'}), StringElement('10.1186/s40001-024-01793-9', attributes={'IdType': 'doi'}), StringElement('10.1186/s40001-024-01793-9', attributes={'IdType': 'pii'})]}}, {'MedlineCitation': DictElement({'SpaceFlightMission': [], 'InvestigatorList': [], 'KeywordList': [ListElement([StringElement('adipocyte interaction', attributes={'MajorTopicYN': 'N'}), StringElement('adipose tissue', attributes={'MajorTopicYN': 'N'}), StringElement('immune microenvironment', attributes={'MajorTopicYN': 'N'}), StringElement('nanomodulator', attributes={'MajorTopicYN': 'N'}), StringElement('obesity', attributes={'MajorTopicYN': 'N'})], attributes={'Owner': 'NOTNLM'})], 'OtherAbstract': [], 'OtherID': [], 'CitationSubset': ['IM'], 'GeneralNote': [], 'PMID': StringElement('38498418', attributes={'Version': '1'}), 'DateCompleted': {'Year': '2024', 'Month': '04', 'Day': '03'}, 'DateRevised': {'Year': '2024', 'Month': '04', 'Day': '03'}, 'Article': DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '18'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1021/acsnano.3c06001', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1936-086X', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '18', 'Issue': '13', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '02'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'ACS nano', 'ISOAbbreviation': 'ACS Nano'}, 'ArticleTitle': 'Nanomodulator-Mediated Restructuring of Adipose Tissue Immune Microenvironments for Antiobesity Treatment.', 'Pagination': {'StartPage': '9311', 'EndPage': '9330', 'MedlinePgn': '9311-9330'}, 'Abstract': {'AbstractText': ['In obesity, the interactions between proinflammatory macrophages and adipocytes in white adipose tissues are known to play a crucial role in disease progression by providing inflammatory microenvironments. Here, we report that the functional nanoparticle-mediated modulation of crosstalk between adipocytes and macrophages can remodel adipocyte immune microenvironments. As a functional nanomodulator, we designed antivascular cell adhesion molecule (VCAM)-1 antibody-conjugated and amlexanox-loaded polydopamine nanoparticles (VAPN). Amlexanox was used as a model drug to increase energy expenditure. Compared to nanoparticles lacking antibody modification or amlexanox, VAPN showed significantly greater binding to VCAM-1-expressing adipocytes and lowered the interaction of adipocytes with macrophages. In high fat diet-fed mice, repeated subcutaneous administration of VAPN increased the populations of beige adipocytes and ameliorated inflammation in white adipose tissues. Moreover, the localized application of VAPN <i>in vivo</i> exerted a systemic metabolic effect and reduced metabolic disorders, including insulin tolerance and liver steatosis. These findings suggested that VAPN had potential to modulate the immune microenvironments of adipose tissues for the immunologic treatment of obesity. Although we used amlexanox as a model drug and anti-VCAM-1 antibody in VAPN, the concept of immune nanomodulators can be widely applied to the immunological treatment of obesity.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.'}], 'Identifier': [], 'LastName': 'Li', 'ForeName': 'Qiaoyun', 'Initials': 'Q'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.'}], 'Identifier': [], 'LastName': 'Byun', 'ForeName': 'Junho', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.'}], 'Identifier': [], 'LastName': 'Choi', 'ForeName': 'Jaehyun', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.'}], 'Identifier': [], 'LastName': 'Park', 'ForeName': 'Jinwon', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.'}], 'Identifier': [], 'LastName': 'Lee', 'ForeName': 'Jaiwoo', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.'}], 'Identifier': [StringElement('0000-0002-0969-3339', attributes={'Source': 'ORCID'})], 'LastName': 'Oh', 'ForeName': 'Yu-Kyoung', 'Initials': 'YK'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'}), 'MedlineJournalInfo': {'Country': 'United States', 'MedlineTA': 'ACS Nano', 'NlmUniqueID': '101313589', 'ISSNLinking': '1936-0851'}, 'ChemicalList': [{'RegistryNumber': 'BRL1C2459K', 'NameOfSubstance': StringElement('amlexanox', attributes={'UI': 'C045742'})}, {'RegistryNumber': '0', 'NameOfSubstance': StringElement('Aminopyridines', attributes={'UI': 'D000631'})}], 'MeshHeadingList': [{'QualifierName': [], 'DescriptorName': StringElement('Mice', attributes={'UI': 'D051379', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Animals', attributes={'UI': 'D000818', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Adipose Tissue', attributes={'UI': 'D000273', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Adipose Tissue, White', attributes={'UI': 'D052436', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('drug therapy', attributes={'UI': 'Q000188', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Obesity', attributes={'UI': 'D009765', 'MajorTopicYN': 'N'})}, {'QualifierName': [StringElement('metabolism', attributes={'UI': 'Q000378', 'MajorTopicYN': 'N'})], 'DescriptorName': StringElement('Adipocytes, Beige', attributes={'UI': 'D000069797', 'MajorTopicYN': 'Y'})}, {'QualifierName': [], 'DescriptorName': StringElement('Mice, Inbred C57BL', attributes={'UI': 'D008810', 'MajorTopicYN': 'N'})}, {'QualifierName': [], 'DescriptorName': StringElement('Aminopyridines', attributes={'UI': 'D000631', 'MajorTopicYN': 'Y'})}]}, attributes={'Status': 'MEDLINE', 'Owner': 'NLM', 'IndexingMethod': 'Automated'}), 'PubmedData': {'ReferenceList': [], 'History': [DictElement({'Year': '2024', 'Month': '4', 'Day': '3', 'Hour': '6', 'Minute': '43'}, attributes={'PubStatus': 'medline'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '19', 'Hour': '0', 'Minute': '42'}, attributes={'PubStatus': 'pubmed'}), DictElement({'Year': '2024', 'Month': '3', 'Day': '18', 'Hour': '13', 'Minute': '33'}, attributes={'PubStatus': 'entrez'})], 'PublicationStatus': 'ppublish', 'ArticleIdList': [StringElement('38498418', attributes={'IdType': 'pubmed'}), StringElement('10.1021/acsnano.3c06001', attributes={'IdType': 'doi'})]}}]\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.5578/tt.202401795', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2980-3187', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '72', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Mar'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Tuberkuloz ve toraks', 'ISOAbbreviation': 'Tuberk Toraks'}, 'ArticleTitle': 'Results of omalizumab treatment in chronic eosinophilic pneumonia: Real-life data.', 'Pagination': {'StartPage': '71', 'EndPage': '81', 'MedlinePgn': '71-81'}, 'Abstract': {'AbstractText': [StringElement('Recurrences occur when corticosteroid therapy is discontinued or reduced during the treatment of chronic eosinophilic pneumonia (CEP). The probability of recurrence is once in 50% of patients and twice or more in 25%. In such instances, new treatment options are deemed necessary. This study aims to assess the efficacy of omalizumab treatment as a steroid-sparing drug in patients with CEP.', attributes={'Label': 'INTRODUCTION', 'NlmCategory': 'UNASSIGNED'}), StringElement('The clinical features of patients treated with omalizumab for recurrent CEP were evaluated retrospectively before and after treatment. All data from patients and diagnoses were reviewed. The effects of treatment on recurrence rate, oral corticosteroid (OCS) use and lung functions, peripheral eosinophil values, and symptom scores were evaluated. Radiological regression was also evaluated.', attributes={'Label': 'MATERIALS AND METHODS', 'NlmCategory': 'UNASSIGNED'}), StringElement('In the final analysis, we included ten patients with a median follow-up of 22 months after initiation of omalizumab. During this follow-up period, the results were associated with a significant reduction in the number of asthma attacks per year, the number of CEP relapses, the rate of hospitalization, the amount of corticosteroids consumed daily, and the total corticosteroid dose. In addition, improvement was observed in the symptom scores and lung functions of the patients. Systemic steroids were completely discontinued in two patients receiving omalizumab treatment. In other patients, the mean steroid dose was reduced by 77.2 percent in the first year of omalizumab treatment and 82 percent in the second year, respectively. Nevertheless, there was no elevation in peripheral eosinophil count, and radiological regression was observed.', attributes={'Label': 'RESULT', 'NlmCategory': 'UNASSIGNED'}), StringElement('Omalizumab can be an effective treatment for CEP and can be used as a steroid-sparing agent.', attributes={'Label': 'CONCLUSIONS', 'NlmCategory': 'UNASSIGNED'})]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinic of Immunology and Allergy, Health Sciences University Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye.'}], 'Identifier': [], 'LastName': 'Başa Akdoğan', 'ForeName': 'Buket', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinic of Immunology and Allergy, Health Sciences University Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye.'}], 'Identifier': [], 'LastName': 'Aksu', 'ForeName': 'Kurtuluş', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinic of Immunology and Allergy, Health Sciences University Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye.'}], 'Identifier': [], 'LastName': 'Koca Kalkan', 'ForeName': 'İlkay', 'Initials': 'İ'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinic of Immunology and Allergy, Health Sciences University Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye.'}], 'Identifier': [], 'LastName': 'Köycü Buhari', 'ForeName': 'Gözde', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinic of Immunology and Allergy, Health Sciences University Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye.'}], 'Identifier': [], 'LastName': 'Özdedeoğlu', 'ForeName': 'Özlem', 'Initials': 'Ö'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinic of Immunology and Allergy, Health Sciences University Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye.'}], 'Identifier': [], 'LastName': 'Ateş', 'ForeName': 'Hale', 'Initials': 'H'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinic of Immunology and Allergy, Health Sciences University Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye.'}], 'Identifier': [], 'LastName': 'Öner Erkekol', 'ForeName': 'Ferda', 'Initials': 'F'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})], 'VernacularTitle': 'Kronik eozinofilik pnömonide omalizumab tedavisinin sonuçları: Gerçek yaşam verileri.'}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.1177/03000605241246740', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1473-2300', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '52', 'Issue': '4', 'PubDate': {'Year': '2024', 'Month': 'Apr'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The Journal of international medical research', 'ISOAbbreviation': 'J Int Med Res'}, 'ArticleTitle': 'Tezepelumab: patient selection and place in therapy in severe asthma.', 'Pagination': {'StartPage': '3000605241246740', 'MedlinePgn': '3000605241246740'}, 'Abstract': {'AbstractText': ['Asthma is a disease characterised by heterogeneous and multifaceted airway inflammation. Despite the availability of effective treatments, a substantial percentage of patients with the type 2 (T2)-high, but mainly the T2-low, phenotype complain of persistent symptoms, airflow limitation, and poor response to treatments. Currently available biologicals target T2 cytokines, but no monoclonal antibodies or other specific therapeutic options are available for non-T2 asthma. However, targeted therapy against alarmins is radically changing this perspective. The development of alarmin-targeted therapies, of which tezepelumab (TZP) is the first example, may offer broad action on inflammatory pathways as well as an enhanced therapeutic effect on epithelial dysfunction. In this regard, TZP demonstrated positive results not only in patients with severe T2 asthma but also those with non-allergic, non-eosinophilic disease. Therefore, it is necessary to identify clinical features of patients who can benefit from an upstream targeted therapy such as anti-thymic stromal lymphopoietin. The aims of this narrative review are to understand the role of alarmins in asthma pathogenesis and epithelial dysfunction, examine the rationale underlying the indication of TZP treatment in severe asthma, summarise the results of clinical studies, and recognise the specific characteristics of patients potentially eligible for TZP treatment.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}, {'Identifier': [], 'Affiliation': 'Pulmonology and Otolaryngology Multidisciplinary Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [StringElement('0000-0003-3950-5789', attributes={'Source': 'ORCID'})], 'LastName': 'Menzella', 'ForeName': 'Francesco', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology and Otolaryngology Multidisciplinary Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}, {'Identifier': [], 'Affiliation': 'Otolaryngology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [StringElement('0000-0003-1024-2997', attributes={'Source': 'ORCID'})], 'LastName': 'Munari', 'ForeName': 'Sara', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}, {'Identifier': [], 'Affiliation': 'Pulmonology and Otolaryngology Multidisciplinary Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [], 'LastName': 'Corsi', 'ForeName': 'Lorenzo', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}, {'Identifier': [], 'Affiliation': 'Pulmonology and Otolaryngology Multidisciplinary Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [], 'LastName': 'Tonin', 'ForeName': 'Silvia', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology and Otolaryngology Multidisciplinary Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}, {'Identifier': [], 'Affiliation': 'Otolaryngology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [], 'LastName': 'Cestaro', 'ForeName': 'Walter', 'Initials': 'W'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [StringElement('0000-0001-7560-9361', attributes={'Source': 'ORCID'})], 'LastName': 'Ballarin', 'ForeName': 'Andrea', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [], 'LastName': 'Floriani', 'ForeName': 'Ariel', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy.'}], 'Identifier': [], 'LastName': 'Dartora', 'ForeName': 'Cristina', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Asthma Center and Allergy Unit, University of Verona & AOUI Verona, Policlinico GB Rossi, Verona, Italy.'}], 'Identifier': [], 'LastName': 'Senna', 'ForeName': 'Gianenrico', 'Initials': 'G'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '19'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('659', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.3390/medicina60040659', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1648-9144', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '60', 'Issue': '4', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '19'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Medicina (Kaunas, Lithuania)', 'ISOAbbreviation': 'Medicina (Kaunas)'}, 'ArticleTitle': 'Comparing the Risk of Infusion-Related Reactions and Tolerability in Patients Given Cetirizine or Diphenhydramine Prior to Ocrelizumab Infusion (PRECEPT).', 'Abstract': {'AbstractText': ['<i>Background:</i> Ocrelizumab is an effective medication for multiple sclerosis. However, infusion-related reactions (IRRs) are a concern for patients and may lead to discontinuation of ocrelizumab. To minimize IRRs, pre-medications are administered. However, from our experience, these medications, especially diphenhydramine, can cause marked drowsiness. The primary objective of this study was to evaluate whether cetirizine is non-inferior to diphenhydramine in limiting the proportion and severity of reactions from ocrelizumab infusions. <i>Methods:</i> Twenty participants were serially randomized in a 1:1 ratio to receive 10 mg of cetirizine or 25 mg of diphenhydramine orally prior to their first three ocrelizumab infusions. <i>Results:</i> The rate of IRRs in this study was similar across both treatment groups with no increase in the risk of severity, and no grade 3 IRRs. Further, patients receiving cetirizine experienced a reduction in fatigue. While there was not a significant difference in global satisfaction, this score increased over time in the cetirizine arm while it remained unchanged in the diphenhydramine arm. <i>Conclusions:</i> Overall, our results suggest that cetirizine does not increase the risk of infusion-related reactions compared to diphenhydramine.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Providence Brain and Spine Institute, Portland, OR 97225, USA.'}], 'Identifier': [], 'LastName': 'Smoot', 'ForeName': 'Kyle', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Providence Brain and Spine Institute, Portland, OR 97225, USA.'}], 'Identifier': [], 'LastName': 'Marginean', 'ForeName': 'Horia', 'Initials': 'H'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Providence Brain and Spine Institute, Portland, OR 97225, USA.'}], 'Identifier': [], 'LastName': 'Gervasi-Follmar', 'ForeName': 'Tiffany', 'Initials': 'T'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Providence Brain and Spine Institute, Portland, OR 97225, USA.'}], 'Identifier': [], 'LastName': 'Chen', 'ForeName': 'Chiayi', 'Initials': 'C'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': 'NA', 'Agency': 'Genentech', 'Country': ''}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Randomized Controlled Trial', attributes={'UI': 'D016449'}), StringElement('Comparative Study', attributes={'UI': 'D003160'})]}, attributes={'PubModel': 'Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '22'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('4565', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.3390/ijms25084565', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1422-0067', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '25', 'Issue': '8', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '22'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'International journal of molecular sciences', 'ISOAbbreviation': 'Int J Mol Sci'}, 'ArticleTitle': 'Dual Drug Repurposing: The Example of Saracatinib.', 'Abstract': {'AbstractText': [\"Saracatinib (AZD0530) is a dual Src/Abl inhibitor initially developed by AstraZeneca for cancer treatment; however, data from 2006 to 2024 reveal that this drug has been tested not only for cancer treatment, but also for the treatment of other diseases. Despite the promising pre-clinical results and the tolerability shown in phase I trials, where a maximum tolerated dose of 175 mg was defined, phase II clinical data demonstrated a low therapeutic action against several cancers and an elevated rate of adverse effects. Recently, pre-clinical research aimed at reducing the toxic effects and enhancing the therapeutic performance of saracatinib using nanoparticles and different pharmacological combinations has shown promising results. Concomitantly, saracatinib was repurposed to treat Alzheimer's disease, targeting Fyn. It showed great clinical results and required a lower daily dose than that defined for cancer treatment, 125 mg and 175 mg, respectively. In addition to Alzheimer's disease, this Src inhibitor has also been studied in relation to other health conditions such as pulmonary and liver fibrosis and even for analgesic and anti-allergic functions. Although saracatinib is still not approved by the Food and Drug Administration (FDA), the large number of alternative uses for saracatinib and the elevated number of pre-clinical and clinical trials performed suggest the huge potential of this drug for the treatment of different kinds of diseases.\"]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.'}, {'Identifier': [], 'Affiliation': 'CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.'}], 'Identifier': [StringElement('0009-0007-5324-8826', attributes={'Source': 'ORCID'})], 'LastName': 'Ramos', 'ForeName': 'Raquel', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.'}, {'Identifier': [], 'Affiliation': 'CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.'}, {'Identifier': [], 'Affiliation': 'Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.'}], 'Identifier': [StringElement('0000-0002-1283-1042', attributes={'Source': 'ORCID'})], 'LastName': 'Vale', 'ForeName': 'Nuno', 'Initials': 'N'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '26'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1208/s12248-024-00913-x', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1550-7416', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '26', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '26'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The AAPS journal', 'ISOAbbreviation': 'AAPS J'}, 'ArticleTitle': 'Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability.', 'Pagination': {'StartPage': '56', 'MedlinePgn': '56'}, 'Abstract': {'AbstractText': ['Advair Diskus is an essential treatment for asthma and chronic obstructive pulmonary disease. It is a dry powder inhaler with a combination of fluticasone propionate (FP) and salmeterol xinafoate (SX). However, the pharmacokinetics (PK) batch-to-batch variability of the reference-listed drug (RLD) hindered its generic product development. This work developed the PK models for inhaled FP and SX that could represent potential batch variability. Two batches each of the reference and the test product (R<sub>1</sub>, R<sub>2</sub>, T<sub>1</sub>, T<sub>2</sub>) of Advair Diskus (100\\xa0μg FP/50\\xa0μg SX inhalation) were administered to 60 healthy subjects in a 4-period, 4-sequence crossover study. The failure of the bioequivalence (BE) between R<sub>1</sub> and R<sub>2</sub> confirmed the high between-batch variability of the RLD. Non-linear mixed effect modeling was used to estimate the population mean PK parameters for each batch. For FP, a 2-compartment model with a sequential dual zero-order absorption best described the PK profile. For SX, a 2-compartment model with a first-order absorption model best fit the data. Both models were able to capture the plasma concentration, the maximum concentration, and the total exposure (AUC<sub>inf</sub>) adequately for each batch, which could be used to simulate the BE study in the future. In vitro properties were also measured for each batch, and the batch with a higher fraction of the fine particle (diameter\\u2009<\\u20091\\xa0µm,\\u2009<\\u20092\\xa0µm) had a higher AUC<sub>inf</sub>. This positive correlation for both FP and SX could potentially assist the batch selection for the PK BE study.'], 'CopyrightInformation': '© 2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Center for Translational Medicine, School of Pharmacy, University of Maryland, 20 North Pine Street, Baltimore, Maryland, 21201, USA.'}], 'Identifier': [], 'LastName': 'Li', 'ForeName': 'Shuhui', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Feng', 'ForeName': 'Kairui', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Lee', 'ForeName': 'Jieon', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Gong', 'ForeName': 'Yuqing', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Wu', 'ForeName': 'Fang', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Newman', 'ForeName': 'Bryan', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Yoon', 'ForeName': 'Miyoung', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Fang', 'ForeName': 'Lanyan', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA.'}], 'Identifier': [], 'LastName': 'Zhao', 'ForeName': 'Liang', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Center for Translational Medicine, School of Pharmacy, University of Maryland, 20 North Pine Street, Baltimore, Maryland, 21201, USA. jgobburu@rx.umaryland.edu.'}], 'Identifier': [], 'LastName': 'Gobburu', 'ForeName': 'Jogarao V S', 'Initials': 'JVS'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Randomized Controlled Trial', attributes={'UI': 'D016449'}), StringElement(\"Research Support, Non-U.S. Gov't\", attributes={'UI': 'D013485'})]}, attributes={'PubModel': 'Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '26'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1038/s41598-024-59190-5', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2045-2322', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '14', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '26'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Scientific reports', 'ISOAbbreviation': 'Sci Rep'}, 'ArticleTitle': 'The new preservative-free ophthalmic formulation of bilastine 0.6% preserves the ocular surface epithelial integrity in a comparative in vitro study.', 'Pagination': {'StartPage': '9598', 'MedlinePgn': '9598'}, 'Abstract': {'AbstractText': ['Allergic conjunctivitis (AC) is the most common form of allergic eye disease and an increasingly prevalent condition. Topical eye drop treatments are the usual approach for managing AC, although their impact on the ocular surface is not frequently investigated. The aim of this study was to perform a comparative physicochemical characterization, and in vitro biological evaluations in primary conjunctival and corneal epithelial cells of the new multidose preservative-free bilastine 0.6% and main commercially available eye drops. MTT assay was used to measure cell viability; oxidative stress was analyzed with a ROS-sensitive probe; and apoptosis was evaluated monitoring caspase 3/7 activation. Differences in pH value, osmolarity, viscosity and phosphate levels were identified. Among all formulations, bilastine exhibited pH, osmolarity and viscosity values closer to tear film (7.4, 300\\xa0mOsm/l and ~\\xa01.5-10\\xa0mPa·s, respectively), and was the only phosphates-free solution. Single-dose ketotifen did not induce ROS production, and single-dose azelastine and bilastine only induced a mild increase. Bilastine and single-dose ketotifen and azelastine showed high survival rates attributable to the absence of preservative in its formulation, not inducing caspase-3/7-mediated apoptosis after 24\\xa0h. Our findings support the use of the new bilastine 0.6% for treating patients with AC to preserve and maintain the integrity of the ocular surface.'], 'CopyrightInformation': '© 2024. The Author(s).'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Research, Development and Innovation Department (R&D+I Department), Faes Farma, Av. Autonomía 10, 48940, Leioa, Bizkaia, Spain.'}, {'Identifier': [], 'Affiliation': 'Department of Cell Biology and Histology, School of Medicine and Nursing, University of the Basque Country, Leioa, Spain.'}], 'Identifier': [], 'LastName': 'Arana', 'ForeName': 'Eider', 'Initials': 'E'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Research, Development and Innovation Department (R&D+I Department), Faes Farma, Av. Autonomía 10, 48940, Leioa, Bizkaia, Spain.'}], 'Identifier': [], 'LastName': 'Gonzalo', 'ForeName': 'Ana', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Cell Biology and Histology, School of Medicine and Nursing, University of the Basque Country, Leioa, Spain.'}, {'Identifier': [], 'Affiliation': 'Biobizkaia Health Research Institute, Barakaldo, Spain.'}], 'Identifier': [], 'LastName': 'Andollo', 'ForeName': 'Noelia', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Biotechnology Area, GAIKER Technology Centre, Basque Research and Technology Alliance, Zamudio, Spain.'}], 'Identifier': [], 'LastName': 'Goñi-de-Cerio', 'ForeName': 'Felipe', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Biotechnology Area, GAIKER Technology Centre, Basque Research and Technology Alliance, Zamudio, Spain.'}], 'Identifier': [], 'LastName': 'Gómez-Fernández', 'ForeName': 'Paloma', 'Initials': 'P'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Innoprot SL, Bizkaia Technology Park, Derio, Bizkaia, Spain.'}], 'Identifier': [], 'LastName': 'Salado', 'ForeName': 'Clarisa', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Research, Development and Innovation Department (R&D+I Department), Faes Farma, Av. Autonomía 10, 48940, Leioa, Bizkaia, Spain.'}], 'Identifier': [], 'LastName': 'Hernández', 'ForeName': 'Gonzalo', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Research, Development and Innovation Department (R&D+I Department), Faes Farma, Av. Autonomía 10, 48940, Leioa, Bizkaia, Spain. tsuarez@faes.es.'}], 'Identifier': [], 'LastName': 'Suárez-Cortés', 'ForeName': 'Tatiana', 'Initials': 'T'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': 'BIKAINTEK Program (48-AF-W2-2018-00008)', 'Agency': 'Basque Government, Spain', 'Country': ''}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement(\"Research Support, Non-U.S. Gov't\", attributes={'UI': 'D013485'}), StringElement('Comparative Study', attributes={'UI': 'D003160'})]}, attributes={'PubModel': 'Electronic'})\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [StringElement('e13742', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1111/crj.13742', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1752-699X', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '18', 'Issue': '4', 'PubDate': {'Year': '2024', 'Month': 'Apr'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The clinical respiratory journal', 'ISOAbbreviation': 'Clin Respir J'}, 'ArticleTitle': 'Studying of anti-inflammatory and antioxidant effects of tectorigenin in ovalbumin-induced asthma mice models.', 'Pagination': {'StartPage': 'e13742', 'MedlinePgn': 'e13742'}, 'Abstract': {'AbstractText': [StringElement('Allergic asthma is an important respiratory system problem characterized by airway inflammation, breathlessness, and bronchoconstriction. Allergic asthma and its outcomes are triggered by type 2 allergic immune responses. Tectorigenin is a methoxy-isoflavone with anti-inflammatory effects. In this study, we investigated the effects of tectorigenin on the pathophysiology of allergic asthma in an animal model.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement('Asthmatic mice were treated with tectorigenin. Then airway hyperresponsiveness (AHR), eosinophil percentage, levels of interleukin (IL)-33, IL-25, IL-13, IL-5, IL-4, total and ovalbumin (OVA)-specific immunoglobulin (Ig)E, and lung histopathology were evaluated.', attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('Tectorigenin significantly (P 〈 0.05) reduced eosinophil infiltration (41\\u2009±\\u20097%) in the broncho-alveolar lavage fluid (BALF), serum IL-5 level (41\\u2009±\\u20095, pg/mL), and bronchial and vascular inflammation (scores of 1.3\\u2009±\\u20090.2 and 1.1\\u2009±\\u20090.3, respectively) but had no significant effects on AHR, serum levels of IL-33, -25, -13, and -4 (403\\u2009±\\u200924, 56\\u2009±\\u20097, 154\\u2009±\\u200911, and 89\\u2009±\\u20096 pg/mL, respectively), total and OVA-specific IgE (2684\\u2009±\\u2009265 and 264\\u2009±\\u200919\\u2009ng/mL, respectively), goblet cell hyperplasia, and mucus production.', attributes={'Label': 'RESULT', 'NlmCategory': 'RESULTS'}), StringElement('Tectorigenin could control inflammation and the secretion of inflammatory mediators of asthma, so it can be regarded as a potential antiasthma treatment with the ability to control eosinophilia-related problems.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': '© 2024 The Authors. The Clinical Respiratory Journal published by John Wiley & Sons Ltd.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Department of Integrated Traditional Medicine and Western Medicine, Xi'an Children's Hospital, Xi'an, China.\"}], 'Identifier': [], 'LastName': 'Guo', 'ForeName': 'Jingning', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Department of Integrated Traditional Medicine and Western Medicine, Xi'an Children's Hospital, Xi'an, China.\"}], 'Identifier': [], 'LastName': 'Shi', 'ForeName': 'Yanping', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Department of Integrated Traditional Medicine and Western Medicine, Xi'an Children's Hospital, Xi'an, China.\"}], 'Identifier': [], 'LastName': 'Wang', 'ForeName': 'Yujun', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.'}], 'Identifier': [], 'LastName': 'Athari', 'ForeName': 'Seyyed Shamsadin', 'Initials': 'SS'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Department of Integrated Traditional Medicine and Western Medicine, Xi'an Children's Hospital, Xi'an, China.\"}], 'Identifier': [StringElement('0000-0002-5658-5525', attributes={'Source': 'ORCID'})], 'LastName': 'Chen', 'ForeName': 'Tao', 'Initials': 'T'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '25'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1097/ACI.0000000000000985', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1473-6322', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '24', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Jun', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Current opinion in allergy and clinical immunology', 'ISOAbbreviation': 'Curr Opin Allergy Clin Immunol'}, 'ArticleTitle': 'Omalizumab is the Columbus egg for food allergies.', 'Pagination': {'StartPage': '144', 'EndPage': '146', 'MedlinePgn': '144-146'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pediatric Hospital Bambino Gesù IRCCS, Rome, Italy.'}], 'Identifier': [], 'LastName': 'Fiocchi', 'ForeName': 'Alessandro', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'NHO Sagamihara National Hospital, Tokyo, Japan.'}], 'Identifier': [], 'LastName': 'Ebisawa', 'ForeName': 'Motohiro', 'Initials': 'M'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Editorial', attributes={'UI': 'D016421'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '23'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('175', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1186/s12931-024-02814-1', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1465-993X', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '25', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '23'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Respiratory research', 'ISOAbbreviation': 'Respir Res'}, 'ArticleTitle': 'PI3Kγδ inhibition suppresses key disease features in a rat model of asthma.', 'Pagination': {'StartPage': '175', 'MedlinePgn': '175'}, 'Abstract': {'AbstractText': [StringElement('Two isoforms of Phosphoinositide 3-kinase (PI3K), p110γ and p110δ, are predominantly expressed in leukocytes and represent attractive therapeutic targets for the treatment of allergic asthma. The study aim was to assess the impact of administration of an inhaled PI3Kγδ inhibitor (AZD8154) in a rat model of asthma.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement('Firstly, we checked that the tool compound, AZD8154, inhibited rat PI3K γ & δ kinases using rat cell-based assays. Subsequently, a time-course study was conducted in a rat model of asthma to assess PI3K activity in the lung and how it is temporally associated with other key transcription pathways and asthma like features of the model. Finally, the impact on lung dosed AZD8154 on target engagement, pathway specificity, airway inflammation and lung function changes was assessed.', attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('Data showed that AZD8154 could inhibit rat PI3K γ & δ isoforms and, in a rat model of allergic asthma the PI3K pathway was activated in the lung. Intratracheal administration of AZD8154 caused a dose related suppression PI3K pathway activation (reduction in pAkt) and unlike after budesonide treatment, STAT and NF-κB pathways were not affected by AZD8154. The suppression of the PI3K pathway led to a marked inhibition of airway inflammation and reduction in changes in lung function.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('These data show that a dual PI3Kγδ inhibitor suppress key features of disease in a rat model of asthma to a similar degree as budesonide and indicate that dual PI3Kγδ inhibition may be an effective treatment for people suffering from allergic asthma.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': '© 2024. The Author(s).'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}, {'Identifier': [], 'Affiliation': 'Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK.'}], 'Identifier': [], 'LastName': 'Pinkerton', 'ForeName': 'James W', 'Initials': 'JW'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}], 'Identifier': [], 'LastName': 'Preite', 'ForeName': 'Silvia', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}], 'Identifier': [], 'LastName': 'Piras', 'ForeName': 'Antonio', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}, {'Identifier': [], 'Affiliation': 'Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK.'}], 'Identifier': [], 'LastName': 'Zervas', 'ForeName': 'Dimitrios', 'Initials': 'D'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}, {'Identifier': [], 'Affiliation': 'Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK.'}], 'Identifier': [], 'LastName': 'Markou', 'ForeName': 'Thomais', 'Initials': 'T'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}, {'Identifier': [], 'Affiliation': 'Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK.'}], 'Identifier': [], 'LastName': 'Freeman', 'ForeName': 'Mark S', 'Initials': 'MS'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}], 'Identifier': [], 'LastName': 'Hofving', 'ForeName': 'Tobias', 'Initials': 'T'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}], 'Identifier': [], 'LastName': 'Ivarsson', 'ForeName': 'Emil', 'Initials': 'E'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}, {'Identifier': [], 'Affiliation': 'Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK.'}], 'Identifier': [], 'LastName': 'Bonvini', 'ForeName': 'Sara J', 'Initials': 'SJ'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}], 'Identifier': [], 'LastName': 'Brailsford', 'ForeName': 'Wayne', 'Initials': 'W'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}], 'Identifier': [], 'LastName': 'Yrlid', 'ForeName': 'Linda', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.'}, {'Identifier': [], 'Affiliation': 'Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK.'}], 'Identifier': [], 'LastName': 'Belvisi', 'ForeName': 'Maria G', 'Initials': 'MG'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Early Respiratory & Immunology, Biopharmaceuticals R&D AstraZeneca, Gothenburg, Sweden. mark.birrell@astrazeneca.com.'}, {'Identifier': [], 'Affiliation': 'Respiratory Pharmacology group, Airway Disease section, NHLI, Imperial College, London, UK. mark.birrell@astrazeneca.com.'}], 'Identifier': [], 'LastName': 'Birrell', 'ForeName': 'Mark A', 'Initials': 'MA'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic'})\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [], 'Language': ['rus'], 'Journal': {'ISSN': StringElement('1728-2985', attributes={'IssnType': 'Print'}), 'JournalIssue': DictElement({'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Mar'}}, attributes={'CitedMedium': 'Print'}), 'Title': 'Urologiia (Moscow, Russia : 1999)', 'ISOAbbreviation': 'Urologiia'}, 'ArticleTitle': '[Antibacterial prophylaxis with fosfomycin at the time of the urethral catheter removal after radical prostatectomy (prospective randomized trial)].', 'Pagination': {'StartPage': '35', 'EndPage': '40', 'MedlinePgn': '35-40'}, 'Abstract': {'AbstractText': [StringElement('To evaluate the effect of antibacterial prophylaxis using oral fosfomycin during the removal of a urethral catheter after radical prostatectomy on the development of urinary tract infection, severity of leukocyturia and bacteriuria, as well as the severity of lower urinary tract symptoms.', attributes={'Label': 'AIM', 'NlmCategory': 'OBJECTIVE'}), StringElement('A single-center, non-blind, prospective, randomized controlled trial was carried out. The main group included 40 patients, and the control group included 37 patients. In the group 1, patients received two doses of oral fosfomycin, 3 g, namely in the evening on the day of catheter removal (the first dose) and 48 hours after catheter removal (the second dose). In the group 2, patients did not receive any antibacterial prophylaxis after urethral catheter removal. The endpoints of the study were confirmed episodes of urinary tract infection within 1 month after removal of the urethral catheter, leukocyturia and bacteriuria in urinalysis/urine culture) and severity of the lower urinary tract symptoms assessed by IPSS questionnaire.', attributes={'Label': 'MATERIALS AND METHODS', 'NlmCategory': 'METHODS'}), StringElement('In the group 2, urinary tract infection was noted in 17.1%, while in the group 2 only in 2.6% of patients (p=0.032). Leukocyturia and bacteriuria were significantly less common in the group receiving antibacterial prophylaxis with fosfomycin (18.4% vs. 48.6%, respectively; p=0.006). Positive urine culture was observed in 7.9% vs. 25.7%, respectively (p=0.035). Four weeks after removal of the urethral catheter, the average IPSS score was significantly higher in the group 2 (13.2 vs. 9.5 points; p=0.002). There were no cases of allergic reaction and pseudomembranous colitis associated with C. difficile in both groups. Diarrhea cured with sorbents was noted in 2 patients (5.2%) in fosfomycin group.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('Antibacterial prophylaxis using two oral doses of fosfomycin 3 g on the day of urethral catheter removal and 48 hours after catheter removal after radical prostatectomy appears to be an effective scheme that reduces the incidence of urinary tract infection and the severity of lower urinary tract symptoms, and is characterized by a minimal risk of adverse events. It is necessary to carried out further research and develop clear recommendations for antibacterial prevention in urological interventions requiring prolonged urethral catheterization.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'CONCLUSIONS'})]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Russian Medical Academy of Continuous Professional Education, Department of Urology and Surgical Andrology, Moscow, Russia.'}, {'Identifier': [], 'Affiliation': 'S.P. Botkins State Clinical Hospital, Moscow, Russia.'}], 'Identifier': [], 'LastName': 'Veliev E', 'ForeName': 'I', 'Initials': 'I'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Russian Medical Academy of Continuous Professional Education, Department of Urology and Surgical Andrology, Moscow, Russia.'}, {'Identifier': [], 'Affiliation': 'S.P. Botkins State Clinical Hospital, Moscow, Russia.'}], 'Identifier': [], 'LastName': 'Sokolov E', 'ForeName': 'A', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Russian Medical Academy of Continuous Professional Education, Department of Urology and Surgical Andrology, Moscow, Russia.'}, {'Identifier': [], 'Affiliation': 'S.P. Botkins State Clinical Hospital, Moscow, Russia.'}], 'Identifier': [], 'LastName': 'Metelev A', 'ForeName': 'Yu', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Russian Medical Academy of Continuous Professional Education, Department of Urology and Surgical Andrology, Moscow, Russia.'}, {'Identifier': [], 'Affiliation': 'S.P. Botkins State Clinical Hospital, Moscow, Russia.'}], 'Identifier': [], 'LastName': 'Aliev E', 'ForeName': 'N', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Russian Medical Academy of Continuous Professional Education, Department of Urology and Surgical Andrology, Moscow, Russia.'}, {'Identifier': [], 'Affiliation': 'S.P. Botkins State Clinical Hospital, Moscow, Russia.'}], 'Identifier': [], 'LastName': 'Polyakova A', 'ForeName': 'S', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Russian Medical Academy of Continuous Professional Education, Department of Urology and Surgical Andrology, Moscow, Russia.'}, {'Identifier': [], 'Affiliation': 'S.P. Botkins State Clinical Hospital, Moscow, Russia.'}], 'Identifier': [], 'LastName': 'Ivkin E', 'ForeName': 'V', 'Initials': 'V'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Randomized Controlled Trial', attributes={'UI': 'D016449'}), StringElement('English Abstract', attributes={'UI': 'D004740'})]}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '04'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('1360296', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.3389/fimmu.2024.1360296', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1664-3224', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '15', 'PubDate': {'Year': '2024'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Frontiers in immunology', 'ISOAbbreviation': 'Front Immunol'}, 'ArticleTitle': 'MASTer cell: chief immune modulator and inductor of antimicrobial immune response.', 'Pagination': {'StartPage': '1360296', 'MedlinePgn': '1360296'}, 'Abstract': {'AbstractText': ['Mast cells have long been recognized for their involvement in allergic pathology through the immunoglobulin E (IgE)-mediated degranulation mechanism. However, there is growing evidence of other \"non-canonical\" degranulation mechanisms activated by certain pathogen recognition receptors. Mast cells release several mediators, including histamine, cytokines, chemokines, prostaglandins, and leukotrienes, to initiate and enhance inflammation. The chemical nature of activating stimuli influences receptors, triggering mechanisms for the secretion of formed and new synthesized mediators. Mast cells have more than 30 known surface receptors that activate different pathways for direct and indirect activation by microbes. Different bacterial strains stimulate mast cells through various ligands, initiating the innate immune response, which aids in clearing the bacterial burden. Mast cell interactions with adaptative immune cells also play a crucial role in infections. Recent publications revealed another \"non-canonical\" degranulation mechanism present in tryptase and chymase mast cells in humans and connective tissue mast cells in mice, occurring through the activation of the Mas-related G protein-coupled receptor (MRGPRX2/b2). This receptor represents a new therapeutic target alongside antibiotic therapy. There is an urgent need to reconsider and redefine the biological role of these MASTer cells of innate immunity, extending beyond their involvement in allergic pathology.'], 'CopyrightInformation': 'Copyright © 2024 Suárez Vázquez, López López and Salinas Carmona.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Immunology, School of Medicine and Dr. Jose Eleuterio Gonzalez University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Mexico.'}], 'Identifier': [], 'LastName': 'Suárez Vázquez', 'ForeName': 'Tomás Alejandro', 'Initials': 'TA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Immunology, School of Medicine and Dr. Jose Eleuterio Gonzalez University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Mexico.'}], 'Identifier': [], 'LastName': 'López López', 'ForeName': 'Nallely', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Immunology, School of Medicine and Dr. Jose Eleuterio Gonzalez University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Mexico.'}], 'Identifier': [], 'LastName': 'Salinas Carmona', 'ForeName': 'Mario César', 'Initials': 'MC'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Electronic-eCollection'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '12'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1016/j.ijpharm.2024.124116', attributes={'EIdType': 'doi', 'ValidYN': 'Y'}), StringElement('S0378-5173(24)00350-8', attributes={'EIdType': 'pii', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1873-3476', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '656', 'PubDate': {'Year': '2024', 'Month': 'May', 'Day': '10'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'International journal of pharmaceutics', 'ISOAbbreviation': 'Int J Pharm'}, 'ArticleTitle': 'Nanoscale colocalized thermal and chemical mapping of pharmaceutical powder aerosols.', 'Pagination': {'StartPage': '124116', 'MedlinePgn': '124116'}, 'Abstract': {'AbstractText': ['Inhalation of pharmaceutical aerosol formulations is widely used to treat respiratory diseases. Spatially resolved thermal characterization offers promise for better understanding drug release rates from particles; however, this has been an analytical challenge due to the small particle size (from a few micrometers down to nanometers) and the complex composition of the formulations. Here, we employ nano-thermal analysis (nanoTA) to probe the nanothermal domain of a pharmaceutical aerosol formulation containing a mixture of fluticasone propionate (FP), salmeterol xinafoate (SX), and excipient lactose, which is widely used to treat asthma and chronic obstructive pulmonary disease (COPD). Furthermore, atomic force microscopy-infrared spectroscopy (AFM-IR) and AFM force measurements are performed to provide nanochemical and nanomechanical information to complement the nanothermal data. The colocalized thermal and chemical mapping clearly reveals the surface heterogeneity of the drugs in the aerosol particles and demonstrates the contribution of the surface chemical composition to the variation in the thermal properties of the particles. We present a powerful analytical approach for in-depth characterization of thermal/chemical/morphological properties of dry powder inhaler particles at micro- and nanometer scales. This approach can be used to facilitate the comparison between generics and reference inhalation products and further the development of high-performance pharmaceutical formulations.'], 'CopyrightInformation': 'Copyright © 2024 Elsevier B.V. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Chemical & Biological Engineering, Monash University, Clayton, VIC 3800, Australia; Future Industries Institute, University of South Australia, Mawson Lakes, SA 5095, Australia.'}], 'Identifier': [], 'LastName': 'Zhang', 'ForeName': 'Jing', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Advanced Drug Delivery Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia; Department of Mechanical and Materials Engineering, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.'}], 'Identifier': [], 'LastName': 'Khanal', 'ForeName': 'Dipesh', 'Initials': 'D'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Advanced Drug Delivery Group, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia. Electronic address: kim.chan@sydney.edu.au.'}], 'Identifier': [], 'LastName': 'Chan', 'ForeName': 'Hak-Kim', 'Initials': 'HK'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Chemical & Biological Engineering, Monash University, Clayton, VIC 3800, Australia; Department of Mechanical and Materials Engineering, University of Alabama at Birmingham, Birmingham, AL, 35294, USA; Division of Pulmonology, Allergy, and Critical Care Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address: mmbanasz@uab.edu.'}], 'Identifier': [], 'LastName': 'Banaszak Holl', 'ForeName': 'Mark M', 'Initials': 'MM'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'})\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1512-0112', attributes={'IssnType': 'Print'}), 'JournalIssue': DictElement({'Issue': '347', 'PubDate': {'Year': '2024', 'Month': 'Feb'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Georgian medical news', 'ISOAbbreviation': 'Georgian Med News'}, 'ArticleTitle': 'HISTOLOGICAL AND BIOCHEMICAL STUDY OF THE EFFECT OF FEXOFENADINE ON SALIVARY GLAND IN RATS.', 'Pagination': {'StartPage': '38', 'EndPage': '40', 'MedlinePgn': '38-40'}, 'Abstract': {'AbstractText': ['Fexofenadine is a newly introduced oral non-sedating agent used for allergic diseases. We sought to investigate the effects of the use of fexofenadine on the salivary gland of adult male albino rats. 30 adult male albino rats were classified randomly into 3 groups, as follows: Group A (control group) which consisted of 10 healthy rats. Group B (treated group) which consisted of 10 rats received FEX 5mg/kg/day, and Group C (treated group) which consisted of 10 rats received FEX 10mg/kg/day. Blood samples were obtained to assess serum levels of Thioredoxin reductase (TRX) and malondialdehyde (MDA). Salivary glands were removed and prepared for histological examination. This study showed that significantly (p<0.05) higher TRX and MDA levels were observed in group B and group C, compared to group A. The histological examination for salivary tissues revealed degenerative changes in serous cells of acini were present with deep pyknotic nuclei. Vacuolar cytoplasmic degeneration is also seen in other certain cells. Blood congestion was present in the intralobular blood vessels, particularly around the striated ducts. The glandular secretion duct contained mucus and serous secretion and the wall of the duct was surrounded by many WBCs with macrophage. Fexofenadine hydrochloride use induces remarkable histopathological changes with dose-dependent response and remarkably linked to elevation of oxidative stress markers.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': '1College of Medicine, Tikrit University, Iraq.'}], 'Identifier': [], 'LastName': 'Mahmood', 'ForeName': 'E', 'Initials': 'E'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': '1College of Medicine, Tikrit University, Iraq.'}], 'Identifier': [], 'LastName': 'Sarhat', 'ForeName': 'E', 'Initials': 'E'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': '1College of Medicine, Tikrit University, Iraq.'}], 'Identifier': [], 'LastName': 'Tawfeq', 'ForeName': 'M', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': '2College of Veterinary Medicine, Tikrit University, Iraq.'}], 'Identifier': [], 'LastName': 'Wadee', 'ForeName': 'S', 'Initials': 'S'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [StringElement('e37852', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1097/MD.0000000000037852', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1536-5964', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '103', 'Issue': '15', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '12'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Medicine', 'ISOAbbreviation': 'Medicine (Baltimore)'}, 'ArticleTitle': 'Serotonin syndrome treated with cyproheptadine using NPi from a digital pupillometer as a therapeutic indicator: A case report.', 'Pagination': {'StartPage': 'e37852', 'MedlinePgn': 'e37852'}, 'Abstract': {'AbstractText': [StringElement('Serotonin syndrome is a potentially life-threatening condition resulting from the use of antidepressants, their interactions with other serotonergic medications, or poisoning. It presents with a triad of psychiatric, dysautonomic, and neurological symptoms and is sometimes fatal. While cyproheptadine is a specific treatment option, the optimal duration of its administration remains unclear. The purpose of this report is to quantitatively assess the endpoints of serotonin syndrome treatment. Based on the hypothesis that neurological pupil index (NPi) on a digital pupil recorder would correlate with the severity of the serotonin syndrome, we administered cyproheptadine using NPi as an indicator.', attributes={'Label': 'RATIONALE', 'NlmCategory': 'BACKGROUND'}), StringElement('A patient with a history of depression was brought to our hospital after he overdosed on 251 tablets of serotonin and noradrenaline reuptake inhibitors.', attributes={'Label': 'PATIENT CONCERNS', 'NlmCategory': 'METHODS'}), StringElement('On day 3, the patient was diagnosed with serotonin syndrome.', attributes={'Label': 'DIAGNOSES', 'NlmCategory': 'METHODS'}), StringElement('Cyproheptadine syrup was administered at 4\\u2009mg every 4 hours. The NPi of the automated pupillometer was simultaneously measured. On day 5, the NPi exceeded 3.0 cyproheptadine was discontinued.', attributes={'Label': 'INTERVENTIONS', 'NlmCategory': 'METHODS'}), StringElement('The patient was discharged on day 7.', attributes={'Label': 'OUTCOMES', 'NlmCategory': 'RESULTS'}), StringElement('The lack of considerable improvement during the treatment period suggests that the patient may have improved on his own. In this case, the relationship between NPi and the severity of serotonin syndrome could not be determined.', attributes={'Label': 'LESSONS', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': 'Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Emergency Medicine, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.'}], 'Identifier': [StringElement('0000-0002-4465-5688', attributes={'Source': 'ORCID'})], 'LastName': 'Sugaya', 'ForeName': 'Kazuki', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Emergency Medicine, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.'}], 'Identifier': [], 'LastName': 'Misawa', 'ForeName': 'Tomotaka', 'Initials': 'T'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Regional Emergency Medicine, Fukushima Medical University, Fukushima City, Fukushima, Japan.'}], 'Identifier': [], 'LastName': 'Onodera', 'ForeName': 'Makoto', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Emergency Medicine, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.'}], 'Identifier': [], 'LastName': 'Iseki', 'ForeName': 'Ken', 'Initials': 'K'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Case Reports', attributes={'UI': 'D002363'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.1111/hel.13073', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1523-5378', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '29', 'Issue': '2', 'PubDate': {'Year': '2024', 'Season': 'Mar-Apr'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Helicobacter', 'ISOAbbreviation': 'Helicobacter'}, 'ArticleTitle': 'Application of cefuroxime in the eradication therapy of Helicobacter pylori infection: A review article.', 'Pagination': {'StartPage': 'e13073', 'MedlinePgn': 'e13073'}, 'Abstract': {'AbstractText': [StringElement('Helicobacter pylori infection and its associated diseases represent a significant global health concern. Patients who cannot use amoxicillin pose a therapeutic challenge and necessitate alternative medications. Preliminary research indicates that cefuroxime demonstrates promising potential for eradicating H. pylori infection, and there is a lack of comprehensive review articles on the use of cefuroxime.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement('This study conducts a thorough systematic literature review and synthesis. A comprehensive systematic search was conducted in PubMed, Web of Science, EMBASE, China National Knowledge Infrastructure, China Biology Medicine disc, and Wanfang Data up to January 13, 2024. The search strategy utilized the following keywords: (Cefuroxime) AND (Helicobacter pylori OR Helicobacter nemestrinae OR Campylobacter pylori OR Campylobacter pylori subsp. pylori OR Campylobacter pyloridis OR H. pylori OR Hp) for both English and Chinese language publications. Sixteen studies from five different countries or regions were included in final literature review.', attributes={'Label': 'MATERIALS AND METHODS', 'NlmCategory': 'METHODS'}), StringElement('Analysis results indicate that H. pylori is sensitive to cefuroxime, with resistance rates similar to amoxicillin being relatively low. Regimens containing cefuroxime have shown favorable eradication rates, which were comparable to those of the regimens containing amoxicillin. Regarding safety, the incidence of adverse reactions in cefuroxime-containing eradication regimens was comparable to that of amoxicillin-containing regimens or other bismuth quadruple regimens, with no significant increase in allergic reactions in penicillin-allergic patients. Regarding compliance, studies consistently report high compliance rates for regimens containing cefuroxime.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('Cefuroxime can serve as an alternative to amoxicillin for the patients allergic to penicillin with satisfactory efficacies, safety, and compliance.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': '© 2024 John Wiley & Sons Ltd.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Gastroenterology, Peking University Third Hospital, Beijing, China.'}], 'Identifier': [StringElement('0000-0001-7844-1357', attributes={'Source': 'ORCID'})], 'LastName': 'Mi', 'ForeName': 'Changmin', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Gastroenterology, Peking University Third Hospital, Beijing, China.'}], 'Identifier': [], 'LastName': 'Suo', 'ForeName': 'Baojun', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Gastroenterology, Peking University Third Hospital, Beijing, China.'}], 'Identifier': [], 'LastName': 'Tian', 'ForeName': 'Xueli', 'Initials': 'X'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Gastroenterology, Peking University Third Hospital, Beijing, China.'}], 'Identifier': [], 'LastName': 'Wang', 'ForeName': 'Yuxin', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Gastroenterology, Peking University Third Hospital, Beijing, China.'}], 'Identifier': [], 'LastName': 'Ma', 'ForeName': 'Lingling', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Gastroenterology, Peking University Third Hospital, Beijing, China.'}], 'Identifier': [StringElement('0000-0003-0976-419X', attributes={'Source': 'ORCID'})], 'LastName': 'Song', 'ForeName': 'Zhiqiang', 'Initials': 'Z'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': '82170562', 'Agency': 'The National Natural Science Foundation of China', 'Country': ''}, {'GrantID': '7232199', 'Agency': 'Beijing Natural Science Foundation', 'Country': ''}, {'GrantID': '2022-2-4093', 'Agency': \"Capital's Funds for Health Improvement and Research\", 'Country': ''}, {'GrantID': 'BYSYFY2021003', 'Agency': 'Youth Incubation Fund of Peking University Third Hospital', 'Country': ''}, {'GrantID': 'BYSYZD2023008', 'Agency': 'Key Clinical Projects of Peking University Third Hospital', 'Country': ''}, {'GrantID': 'BZ0371', 'Agency': 'Key Laboratory for Helicobacter pylori Infection and Upper Gastrointestinal Diseases in Beijing', 'Country': ''}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Systematic Review', attributes={'UI': 'D000078182'}), StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '27'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('1298021', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.3389/fphar.2024.1298021', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1663-9812', attributes={'IssnType': 'Print'}), 'JournalIssue': DictElement({'Volume': '15', 'PubDate': {'Year': '2024'}}, attributes={'CitedMedium': 'Print'}), 'Title': 'Frontiers in pharmacology', 'ISOAbbreviation': 'Front Pharmacol'}, 'ArticleTitle': 'Detection of iodixanol-induced allergic reaction signals in Chinese inpatients: a multi-center retrospective database study using prescription sequence symmetry analysis.', 'Pagination': {'StartPage': '1298021', 'MedlinePgn': '1298021'}, 'Abstract': {'AbstractText': [StringElement('This study aimed to explore the signal detection method for allergic reactions induced by inpatient iodixanol injection.', attributes={'Label': 'OBJECTIVE', 'NlmCategory': 'UNASSIGNED'}), StringElement('A database of 3,719,217 hospitalized patients from 20 large Chinese general hospitals was processed and analyzed using the prescription sequence symmetry analysis (PSSA) method.', attributes={'Label': 'METHODS', 'NlmCategory': 'UNASSIGNED'}), StringElement('126,680 inpatients who used iodixanol and were concurrently treated with anti-allergic drugs were analyzed. In the medical records of these patients, only 32 had documented iodixanol allergies. Statistical analysis identified 22 drugs in 4 categories-calcium preparations, adrenergic/dopaminergic agents, glucocorticoids, and antihistamines-as marker drugs. With time intervals of 3, 7, and 28\\xa0days, the adjusted sequence ratios (aSRs) for all anti-allergics and the 4 categories were greater than 1. The 7-day aSRs were 2.12 (95% CI: 2.08-2.15), 1.70 (95% CI: 1.68-1.73), 3.85 (95% confidence interval [CI]: 3.75-2.30), 2.30 (95% CI: 2.26-2.35), and 1.95 (95% CI: 1.89-2.02), respectively. The proportions of adverse drug events indicated by each signal were as follows: all anti-allergics (2.92%-3%), calcium gluconate (0.19%-0.52%), adrenergic/dopaminergic agents (2.20%-3.37%), glucocorticoids (3.13%-3.76%), and antihistamines (1.05%-1.32%).', attributes={'Label': 'RESULTS', 'NlmCategory': 'UNASSIGNED'}), StringElement('This first multi-center Chinese inpatient database study detected iodixanol-induced allergy signals, revealing that reactions may be much higher than those in collected spontaneous reports. Iodixanol risk exposure was closer to actual pharmaceutical care findings. PSSA application with ≤7-day intervals appears better suited for monitoring late allergic reaction signals with these drugs.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'UNASSIGNED'})], 'CopyrightInformation': 'Copyright © 2024 Zhang, Yang, Yang, Sun, Chen and Xu.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmacy, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.'}], 'Identifier': [], 'LastName': 'Zhang', 'ForeName': 'Dandan', 'Initials': 'D'}, attributes={'ValidYN': 'Y', 'EqualContrib': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Electric Engineering and Automation, East China University of Science and Technology, Shanghai, China.'}], 'Identifier': [], 'LastName': 'Yang', 'ForeName': 'Xinchen', 'Initials': 'X'}, attributes={'ValidYN': 'Y', 'EqualContrib': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Medical Department, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.\"}], 'Identifier': [], 'LastName': 'Yang', 'ForeName': 'Zhangwei', 'Initials': 'Z'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Medical Department, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.\"}], 'Identifier': [], 'LastName': 'Sun', 'ForeName': 'Wei', 'Initials': 'W'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Medical Department, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.\"}], 'Identifier': [], 'LastName': 'Chen', 'ForeName': 'Shunjie', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Health Statistics Teaching and Research Section, Tongji University, Shanghai, China.'}], 'Identifier': [], 'LastName': 'Xu', 'ForeName': 'Lingxiao', 'Initials': 'L'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic-eCollection'})\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [], 'Language': ['chi'], 'Journal': {'ISSN': StringElement('1671-167X', attributes={'IssnType': 'Print'}), 'JournalIssue': DictElement({'Volume': '56', 'Issue': '2', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '18'}}, attributes={'CitedMedium': 'Print'}), 'Title': 'Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences', 'ISOAbbreviation': 'Beijing Da Xue Xue Bao Yi Xue Ban'}, 'ArticleTitle': '[Comparison of the early analgesic efficacy of three different drugs after anterior cruciate ligament reconstruction].', 'Pagination': {'StartPage': '293', 'EndPage': '298', 'MedlinePgn': '293-298'}, 'Abstract': {'AbstractText': [StringElement('The pain-relieving effect and safety of compound aminopyrine phenacetin tablets, tramcontin (tramadol hydrochloride sustained-release tablets) and dolantin in the early stage of autologous tendon reconstruction of the anterior cruciate ligament (ACL) of the knee joint were compared.', attributes={'Label': 'OBJECTIVE', 'NlmCategory': 'OBJECTIVE'}), StringElement('Retrospective analysis of postoperative pain and drug analgesia in 45 patients performed by the same group from November 2018 to February 2019. The random area group design was divided into two groups according to whether ACL rupture was combined with meniscal injury, group A was 24 patients with ACL reconstruction of knee joint and group B was 21 patients with ACL fracture combined with meniscus injury. The two groups were divided into three subgroups respectively according to the actual treatment of postoperative analgesic drugs received by the patients, including 4 cases of compound aminopyrine phenacetin tablets, 11 cases of oral tramcontin, 9 cases of intramuscular dolantin combined with phenergan in group A; 3 cases of compound aminopyrine phenacetin tablets, 10 cases of oral tramcontin, and 8 cases of intramuscular dolantin combined with phenergan in group B. When the early postoperative patients complain about pain and actively ask for analgesia. When the patients complained about pain after the operation and actively asked for analgesia, they were randomly given painkillers, tramcontin or dolantin combined with phenergan to relieve pain. Pain visual analogue scale (VAS) was used to evaluate pain relief and observe the occurrence of adverse reactions.', attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('There were no significant dif-ferences in gender, age, body mass index, and time of hospital stay between the two groups of patients (<i>P</i> > 0.05). In the patients who used tramcontin and dolantin combined with phenergan to relieve pain judging by VAS score before and 1 h after taking the drug, it was found that the pain situation of the patient was significantly relieved, and the difference before and after taking the drug had statistical significance (<i>P</i> < 0.05). Pairwise comparisons of the three drugs applied in the two groups showed significantly greater pain relief in the dolantin combined with phenergan group than in the remaining two drugs. There was no significant difference (<i>P</i> > 0.05). Dolantin was prone to nausea and vomiting, but the application of phenergan was also used to reduce side effects. In terms of adverse reactions, only 1 case of nausea occurred in the tramcontin group for simple ACL reconstruction, and none of the patients in the other groups showed serious complications and allergic reactions.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('Whether in cruciate ligament reconstruction alone or combined with meniscus molding or suture, compound aminopyrine phenacetin tablets, tramcontin, dolantin combined with phenergan can effectively relieve pain. Among the three drugs, dolantin caused the largest pain relief. At the same time, the combination of phenergan effectively reduced the adverse reactions, such as vomiting and nausea, and increased the drug safety.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'CONCLUSIONS'})]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine in Hebei Province, Cangzhou 061001, Hebei, China.'}, {'Identifier': [], 'Affiliation': 'Hebei Key Laboratory of Integrated Traditional and Western Medicine in Osteoarthrosis Research (Pre-paring), Cangzhou 061001, Hebei, China.'}], 'Identifier': [], 'LastName': 'Wang', 'ForeName': 'Jiangjing', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Sports Medicine, Peking University Third Hospital, Beijing 100191, China.'}], 'Identifier': [], 'LastName': 'Wei', 'ForeName': 'Shunyi', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Sports Medicine, Peking University Third Hospital, Beijing 100191, China.'}], 'Identifier': [], 'LastName': 'Ao', 'ForeName': 'Yingfang', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Sports Medicine, Peking University Third Hospital, Beijing 100191, China.'}], 'Identifier': [], 'LastName': 'Yang', 'ForeName': 'Yuping', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Comparative Study', attributes={'UI': 'D003160'}), StringElement('English Abstract', attributes={'UI': 'D004740'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.58347/tml.2024.1699b', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1523-2859', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '66', 'Issue': '1699', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The Medical letter on drugs and therapeutics', 'ISOAbbreviation': 'Med Lett Drugs Ther'}, 'ArticleTitle': 'Omalizumab (Xolair) for food allergy.', 'Pagination': {'StartPage': '54', 'EndPage': '56', 'MedlinePgn': '54-56'}, 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '04'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1080/16078454.2024.2337307', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1607-8454', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '29', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Dec'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Hematology (Amsterdam, Netherlands)', 'ISOAbbreviation': 'Hematology'}, 'ArticleTitle': 'Honokiol induces apoptosis and autophagy in dexamethasone-resistant T-acute lymphoblastic leukemia CEM-C1 cells.', 'Pagination': {'StartPage': '2337307', 'MedlinePgn': '2337307'}, 'Abstract': {'AbstractText': ['<b>Objective:</b> To study whether and, if so, how honokiol overcome dexamethasone resistance in DEX-resistant CEM-C1 cells. <b>Methods:</b> We investigated the effect of honokiol (0-20 µM) on cell proliferation, cell cycle, cell apoptosis and autophagy in DEX-resistant CEM-C1 cells and DEX-sensitive CEM-C7 cells. We also determined the role of c-Myc protein and mRNA in the occurrence of T-ALL associated dexamethasone resistance western blot and reverse transcription-qPCR (RT-qPCR) analysis. <b>Results:</b> Cell Counting Kit (CCK)-8 assay shows that DEX-resistant CEM-C1 cell lines were highly resistant to dexamethasone with IC50 of 364.1\\u2009±\\u200929.5 µM for 48 h treatment. However, upon treatment with dexamethasone in combination with 1.5 µM of honokiol for 48 h, the IC50 of CEM-C1 cells significantly decreased to 126.2\\u2009±\\u200912.3 µM, and the reversal fold was 2.88. Conversely, the IC50 of CEM-C7 cells was not changed combination of dexamethasone and honokiol as compared to that of CEM-C7 cells treated with dexamethasone alone. It has been shown that honokiol induced T-ALL cell growth inhibition by apoptosis and autophagy via downregulating cell cycle-regulated proteins (Cyclin E, CDK4, and Cyclin D1) and anti-apoptotic proteins BCL-2 and upregulating pro-apoptotic proteins Bax and led to PARP cleavage. Honokiol may overcome dexamethasone resistance in DEX-resistant CEM-C1 cell lines via the suppression of c-Myc mRNA expression. <b>Conclusion:</b> The combination of honokiol and DEX were better than DEX alone in DEX-resistant CEM-C1 cell lines. Honokiol may regulate T-ALL-related dexamethasone resistance by affecting c-Myc.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Pediatric Department, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Hubei, People's Republic of China.\"}], 'Identifier': [], 'LastName': 'Liu', 'ForeName': 'Yang', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Pediatric Department, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Hubei, People's Republic of China.\"}], 'Identifier': [], 'LastName': 'Zhang', 'ForeName': 'Suqian', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Pediatric Department, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Hubei, People's Republic of China.\"}], 'Identifier': [StringElement('0000-0002-9422-2741', attributes={'Source': 'ORCID'})], 'LastName': 'Tan', 'ForeName': 'Yajuan', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2023', 'Month': '10', 'Day': '30'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1016/j.jaip.2023.10.035', attributes={'EIdType': 'doi', 'ValidYN': 'Y'}), StringElement('S2213-2198(23)01189-3', attributes={'EIdType': 'pii', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2213-2201', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '12', 'Issue': '2', 'PubDate': {'Year': '2024', 'Month': 'Feb'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The journal of allergy and clinical immunology. In practice', 'ISOAbbreviation': 'J Allergy Clin Immunol Pract'}, 'ArticleTitle': 'Safety of Direct Drug Provocation for the Evaluation of Penicillin Allergy in Low-Risk Adults.', 'Pagination': {'StartPage': '451', 'EndPage': '457.e2', 'MedlinePgn': '451-457.e2'}, 'Abstract': {'AbstractText': [StringElement('About 10% of patients have a penicillin allergy label, but less than 5% of them are actually allergic. Unnecessary penicillin avoidance is associated with serious medical consequences. Given the growing number of these labels, it is imperative that our diagnostic strategy for penicillin allergy be as efficient as possible. The validity of traditionally used skin tests (STs) has been questioned, whereas drug provocation testing (DPT), the criterion standard, without previous ST appears very safe in most cases.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement('To evaluate the safety of direct DPT without consideration for ST results and the validity of ST in the diagnosis of penicillin allergy.', attributes={'Label': 'OBJECTIVE', 'NlmCategory': 'OBJECTIVE'}), StringElement('In this prospective cohort study without a control group, we recruited patients consulting an allergist for penicillin allergy. Patients underwent ST followed by DPT regardless of ST results. Patients with anaphylaxis to penicillin within the past 5 years or a severe delayed reaction were excluded, as were those with significant cardiorespiratory comorbidity.', attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('None of the 1002 recruited patients had a serious reaction to DPT. Ten (1.0%) had a mild immediate reaction, of whom only 1 (0.1%) was considered likely IgE-mediated. The positive and negative predictive values of ST for an immediate reaction were 3.6% and 99.1%, respectively.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('In a low-risk adult population reporting penicillin allergy, ST has very poor positive predictive value. Direct DPT without ST is safe and appears to be an ideal diagnostic strategy to remove penicillin allergy labels that could be implemented in first-line practice.', attributes={'Label': 'CONCLUSIONS', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': 'Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Brillant-Marquis', 'ForeName': 'Frédéric', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Proulx', 'ForeName': 'Émilie', 'Initials': 'É'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Ratnarajah', 'ForeName': 'Kayadri', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Lavoie', 'ForeName': 'Aubert', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Gauthier', 'ForeName': 'Amélie', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Gagnon', 'ForeName': 'Rémi', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Boursiquot', 'ForeName': 'Jean-Nicolas', 'Initials': 'JN'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Verreault', 'ForeName': 'Nina', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Marois', 'ForeName': 'Louis', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Bédard', 'ForeName': 'Marc-Antoine', 'Initials': 'MA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Boivin', 'ForeName': 'Martine', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Bédard', 'ForeName': 'Pierre-Michel', 'Initials': 'PM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Institut National de Santé Publique du Québec, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'Ouakki', 'ForeName': 'Manale', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Institut National de Santé Publique du Québec, Québec City, Québec, Canada.'}], 'Identifier': [], 'LastName': 'De Serres', 'ForeName': 'Gaston', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Clinical Immunology, Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Québec City, Québec, Canada. Electronic address: jean-philippe.drolet.med@ssss.gouv.qc.ca.'}], 'Identifier': [], 'LastName': 'Drolet', 'ForeName': 'Jean-Philippe', 'Initials': 'JP'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '27'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1016/j.saa.2024.124204', attributes={'EIdType': 'doi', 'ValidYN': 'Y'}), StringElement('S1386-1425(24)00370-6', attributes={'EIdType': 'pii', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1873-3557', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '314', 'PubDate': {'Year': '2024', 'Month': 'Jun', 'Day': '05'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy', 'ISOAbbreviation': 'Spectrochim Acta A Mol Biomol Spectrosc'}, 'ArticleTitle': 'Carbon dots-adorned silver nanoparticles as a straightforward sustainable colorimetric sensor for the rapid detection of ketotifen in eye drops and aqueous humor.', 'Pagination': {'StartPage': '124204', 'MedlinePgn': '124204'}, 'Abstract': {'AbstractText': [\"The rapid and accurate detection of drug molecules in pharmaceutical formulations and biological samples is of paramount importance. In this research article, we present a novel colorimetric sensor based on carbon dots decorated silver nanoparticles (CDs/AgNPs) for the rapid detection of ketotifen (KTF), a widely used antihistamine drug. The CDs were synthesized via a facile one-step microwave-assisted method and subsequently conjugated onto AgNPs through a simple adsorption process, forming a stable CDs/AgNPs composite. The resulting composite exhibited unique optical properties, including a strong absorption peak at 410\\xa0nm with remarkable intensity reduction and color changes upon the addition of KTF. The developed colorimetric sensor exhibited a wide linear range of 3.0-40.0\\xa0µg\\xa0mL<sup>-1</sup> (R<sup>2</sup>\\xa0=\\xa00.9996), with a %RSD of 2.41, and a low limit of detection (LOD) of 0.981\\xa0µg\\xa0mL<sup>-1</sup>. Furthermore, the sensor's practical applicability was evaluated by successfully detecting KTF in eye drops and artificial aqueous humor, demonstrating a remarkable percentage recovery exceeding 96.0\\xa0%. Finally, a comprehensive evaluation of the greenness and blueness of the method was performed using analytical eco-scale, GAPI, AGREEprep, and BAGI tools. The results of these assessments indicate its exceptional sustainability. Overall, the proposed method holds significant potential for applications in pharmaceutical quality control and therapeutic monitoring, contributing to improved patient care and drug safety in the field of ophthalmology.\"], 'CopyrightInformation': 'Copyright © 2024 Elsevier B.V. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.'}], 'Identifier': [], 'LastName': 'Saad', 'ForeName': 'Aya Magdy', 'Initials': 'AM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt. Electronic address: asmaakamal91@mans.edu.eg.'}], 'Identifier': [], 'LastName': 'El-Deen', 'ForeName': 'Asmaa Kamal', 'Initials': 'AK'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt; Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura National University, Gamasa 7731168, Egypt.'}], 'Identifier': [], 'LastName': 'Nasr', 'ForeName': 'Jenny Jeehan Mohamed', 'Initials': 'JJM'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '01'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1097/ACI.0000000000000987', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1473-6322', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '24', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Jun', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Current opinion in allergy and clinical immunology', 'ISOAbbreviation': 'Curr Opin Allergy Clin Immunol'}, 'ArticleTitle': 'Biological treatments in childhood asthma.', 'Pagination': {'StartPage': '114', 'EndPage': '121', 'MedlinePgn': '114-121'}, 'Abstract': {'AbstractText': [StringElement('The aim is to update the information currently available for the use of biologics in severe asthma in children, in order to facilitate their prescription as far as possible.', attributes={'Label': 'PURPOSE OF REVIEW', 'NlmCategory': 'OBJECTIVE'}), StringElement('The appearance of biologics for the treatment of severe asthma has meant a revolutionary change in the therapeutic approach to this disease. Currently, five biologics have been approved for severe asthma in children and/or adolescents by the regulatory agencies: omalizumab, mepolizumab, benralizumab, dupilumab and tezepelumab. But despite their positive results in terms of efficacy, there are still relevant points of debate that should induce caution when selecting the most appropriate biologic in a child with severe asthma. Indeed, safety is essential and, for several of the existing treatments, the availability of medium-term to long-term data in this regard is scarce.', attributes={'Label': 'RECENT FINDINGS', 'NlmCategory': 'RESULTS'}), StringElement('The use of biologics can facilitate the therapeutic paradigm shift from pleiotropic treatments to personalized medicine. However, the choice of the most appropriate biologics remains a pending issue. On the other hand, to the extent that several of the biologics have been available for a relatively short time, the most robust evidence in terms of efficacy and safety in children is that of omalizumab.', attributes={'Label': 'SUMMARY', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': 'Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Health Research Institute La Fe, Valencia.'}], 'Identifier': [], 'LastName': 'Nieto-García', 'ForeName': 'Antonio', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Allergy Service, Hospital de la Plana, Villarreal, Castellón.'}], 'Identifier': [], 'LastName': 'Nieto-Cid', 'ForeName': 'María', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pediatric Pulmonology & Allergy Unit, Hospital la Fe, Valencia, Spain.'}], 'Identifier': [], 'LastName': 'Mazón-Ramos', 'ForeName': 'Ángel', 'Initials': 'Á'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Print-Electronic'})\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.36849/JDD.7919', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1545-9616', attributes={'IssnType': 'Print'}), 'JournalIssue': DictElement({'Volume': '23', 'Issue': '4', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Journal of drugs in dermatology : JDD', 'ISOAbbreviation': 'J Drugs Dermatol'}, 'ArticleTitle': 'Clinical Impacts of Omalizumab on the Psychiatric Comorbidities of Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis.', 'Pagination': {'StartPage': 'e116', 'EndPage': 'e117', 'MedlinePgn': 'e116-e117'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Tan', 'ForeName': 'Marcus G', 'Initials': 'MG'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Bailey', 'ForeName': 'Adrian M J', 'Initials': 'AMJ'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Dorus', 'ForeName': 'Brian', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Kirchhof', 'ForeName': 'Mark G', 'Initials': 'MG'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Meta-Analysis', attributes={'UI': 'D017418'}), StringElement('Systematic Review', attributes={'UI': 'D000078182'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '01', 'Day': '22'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('24', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.11604/pamj.2024.47.24.41038', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1937-8688', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '47', 'PubDate': {'Year': '2024'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The Pan African medical journal', 'ISOAbbreviation': 'Pan Afr Med J'}, 'ArticleTitle': 'An overview of a preliminary multicenter retrospective study on food and drug allergies in Moroccan pediatric population.', 'Pagination': {'StartPage': '24', 'MedlinePgn': '24'}, 'Abstract': {'AbstractText': [StringElement('this study aimed to investigate the prevalence and management of food allergies (FA) and drug allergies (DA) in Morocco. Sparse and conflicting epidemiological data exist on the exact prevalence of allergies in the country. The rise in allergies can be attributed to various factors.', attributes={'Label': 'INTRODUCTION', 'NlmCategory': 'UNASSIGNED'}), StringElement('the study analyzed data from patients with suspected FA and DA who sought medical attention. Statistical tests were used to analyze the data, percentages were computed for qualitative variables, and for quantitative variables, medians or means accompanied by standard deviations (SD) were calculated. The Chi-square test was employed to assess categorical variables. A p-value < 0.05 was considered statistically significant.', attributes={'Label': 'METHODS', 'NlmCategory': 'UNASSIGNED'}), StringElement(\"Cow's milk was the most reported food allergen (58.2%), followed by egg and nuts (23.4% and 12.1%, respectively). The most affected age group was children under 5 years. Antibiotics were the leading cause of reported drug allergies (44.8%), particularly Beta-lactams. Immediate reactions were commonly associated with antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs). Symptoms of FA included acute urticaria, vomiting, anaphylactic shock, and facial edema. Urticaria was the most frequent symptom of DA. Antihistamines and corticosteroids were the main treatments used for both FA and DA.\", attributes={'Label': 'RESULTS', 'NlmCategory': 'UNASSIGNED'}), StringElement('the prevalence of FA and DA in Morocco remains uncertain due to limited data. There is a need for centralized data collection and awareness among clinicians and the general population regarding allergies. The study highlights the importance of proper diagnosis and management of allergies to ensure patient safety. The findings emphasize the necessity of establishing a mandatory center for allergy care in Morocco to improve the understanding and management of allergic conditions.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'UNASSIGNED'})], 'CopyrightInformation': 'Copyright: Zakaria Zidane et al.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Biology and Health, Research Center of Biotechnologies and Health, University Hassan II of Casablanca, Faculty of Sciences Ben M´sik, Avenue Cdt Driss El Harti, B.P 7955, Sidi Othmane, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Zidane', 'ForeName': 'Zakaria', 'Initials': 'Z'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Biology and Health, Research Center of Biotechnologies and Health, University Hassan II of Casablanca, Faculty of Sciences Ben M´sik, Avenue Cdt Driss El Harti, B.P 7955, Sidi Othmane, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Chahine', 'ForeName': 'Chaimaa', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Biology and Health, Research Center of Biotechnologies and Health, University Hassan II of Casablanca, Faculty of Sciences Ben M´sik, Avenue Cdt Driss El Harti, B.P 7955, Sidi Othmane, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Mohtadi', 'ForeName': 'Karima', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Biology and Health, Research Center of Biotechnologies and Health, University Hassan II of Casablanca, Faculty of Sciences Ben M´sik, Avenue Cdt Driss El Harti, B.P 7955, Sidi Othmane, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Chakroun', 'ForeName': 'Azeddine', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Biology and Health, Research Center of Biotechnologies and Health, University Hassan II of Casablanca, Faculty of Sciences Ben M´sik, Avenue Cdt Driss El Harti, B.P 7955, Sidi Othmane, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Saïle', 'ForeName': 'Rachid', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Clinical Immunology, Inflammation and Allergies, University Hassan II of Casablanca, Faculty of Medicine, 19 Rue Tarik Ibnou Ziad, BP 9154, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Bousfiha', 'ForeName': 'Ahmed Aziz', 'Initials': 'AA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pediatric Service, University Hospital Mohammed VI, Oujda, Morocco.'}], 'Identifier': [], 'LastName': 'Rkain', 'ForeName': 'Maria', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Liberal Sector Allergologists, Casablanca, Rabat and Oujda, Morocco.'}], 'Identifier': [], 'LastName': 'Chaer', 'ForeName': 'Sanae Elimlahi', 'Initials': 'SE'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Liberal Sector Allergologists, Casablanca, Rabat and Oujda, Morocco.'}], 'Identifier': [], 'LastName': 'Gueddari', 'ForeName': 'Youness El', 'Initials': 'YE'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pediatric Service, University Hospital Hassan II, Fès, Morocco.'}], 'Identifier': [], 'LastName': 'Hbibi', 'ForeName': 'Mohammed', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Liberal Sector Allergologists, Casablanca, Rabat and Oujda, Morocco.'}], 'Identifier': [], 'LastName': 'Daoudi', 'ForeName': 'Laila Tazi', 'Initials': 'LT'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Clinical Immunology, Inflammation and Allergies, University Hassan II of Casablanca, Faculty of Medicine, 19 Rue Tarik Ibnou Ziad, BP 9154, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Benhsaien', 'ForeName': 'Ibtihal', 'Initials': 'I'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Medical Biotechnology, University of Mohammed V de Rabat, Faculty of Medicine of Rabat, Impasse Souissi, Rabat 10100, Morocco.'}], 'Identifier': [], 'LastName': 'Elhafidi', 'ForeName': 'Naima', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Laboratory of Biology and Health, Research Center of Biotechnologies and Health, University Hassan II of Casablanca, Faculty of Sciences Ben M´sik, Avenue Cdt Driss El Harti, B.P 7955, Sidi Othmane, Casablanca, Morocco.'}], 'Identifier': [], 'LastName': 'Alj', 'ForeName': 'Hanane Salih', 'Initials': 'HS'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Electronic-eCollection'})\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.1684/ejd.2024.4600', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1952-4013', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '34', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Feb', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'European journal of dermatology : EJD', 'ISOAbbreviation': 'Eur J Dermatol'}, 'ArticleTitle': 'Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review.', 'Pagination': {'StartPage': '3', 'EndPage': '12', 'MedlinePgn': '3-12'}, 'Abstract': {'AbstractText': [\"Chronic spontaneous urticaria (CSU) is a relatively common dermatological disorder characterized by sudden and unpredictable onset of pruritic wheals and/or angioedema, for more than six weeks. It is a mast cell-mediated histaminergic disorder, considerably worsening patients' quality of life. Current treatment options include anti-histamines, omalizumab and cyclosporine, in a step-wise algorithmic approach, aimed at complete symptom control. Patients do not respond uniformly to these therapeutic options due to phenotypic and endotypic heterogeneity, and often remain uncontrolled/poorly controlled. Recent research is focused on identifying certain biomarkers to predict therapeutic response and facilitate patient-targeted personalized treatment, for maximum benefit. The current article summarizes various biomarkers explored to date, and also elaborates their role in predicting therapeutic response to anti-histamines, omalizumab and cyclosporine, in CSU patients. High disease activity, elevated CRP/ESR and elevated D-dimer are the most important predictors of non/poor-response to antihistamines. Low and very low baseline IgE, elevated CRP/ESR, ASST+, BAT/BHRA+, basopenia, eosinopenia, and elevated D-dimer are predictors of poor and good response to omalizumab and cyclosporine, respectively. Additionally, normal or slightly elevated baseline IgE and FceR1 overexpression are predictors of a faster response with omalizumab. However, none of these predictors have so far been completely validated and are not yet recommended for routine use. Thus, large-scale prospective studies are needed to confirm these predictive biomarkers and identify new ones to achieve the goal of personalized medicine for CSU.\"]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, Hospital del Mar. IMIM, Universitat Pompeu Fabra, Barcelona, Spain.'}], 'Identifier': [], 'LastName': 'Gimenez-Arnau', 'ForeName': 'Ana Maria', 'Initials': 'AM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, Acıbadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Turkey.'}], 'Identifier': [], 'LastName': 'Salman', 'ForeName': 'Andaç', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, College of Medicine and Sagore Dutta Hospital, Kolkata, India.'}], 'Identifier': [], 'LastName': 'Podder', 'ForeName': 'Indrashis', 'Initials': 'I'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Review', attributes={'UI': 'D016454'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '26'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1016/j.ajem.2024.03.027', attributes={'EIdType': 'doi', 'ValidYN': 'Y'}), StringElement('S0735-6757(24)00139-6', attributes={'EIdType': 'pii', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1532-8171', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '79', 'PubDate': {'Year': '2024', 'Month': 'May'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The American journal of emergency medicine', 'ISOAbbreviation': 'Am J Emerg Med'}, 'ArticleTitle': 'Precipitated opioid withdrawal in a patient started on olanzapine/samidorphan.', 'Pagination': {'StartPage': '230.e1', 'EndPage': '230.e2', 'MedlinePgn': '230.e1-230.e2'}, 'Abstract': {'AbstractText': [StringElement('Olanzapine/Samidorphan (Lybalvi®) is a novel oral agent for the treatment of schizophrenia and bipolar I disorder. It was designed to reduce weight gain associated with olanzapine. Samidorphan is an analog of naltrexone, initially intended to treat substance use disorders by antagonizing mu, delta, and kappa opioid receptors.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement('We present the case of a 36-year-old who took their first dose of olanzapine/samidorphan shortly before calling for emergency services. The patient took diphenhydramine and an epinephrine autoinjector for what they thought was an allergic reaction but continued to have symptoms. EMS reported involuntary muscle movements thought to be due to dystonia from olanzapine. In the ED, they experienced generalized muscle spasms lasting for several seconds and diaphoresis. Initially, the staff treated for a presumed dystonic reaction to olanzapine and administered diphenhydramine 25\\xa0mg IV, diazepam 2\\xa0mg IV, midazolam 5\\xa0mg IV, and benztropine 1\\xa0mg IV without improvement. It was later determined that the patient took 16\\xa0mg of buprenorphine SL daily. With this information, precipitated opioid withdrawal was felt to be the likely cause of symptoms. The patient received 16\\xa0mg of buprenorphine for an initial Clinical Opiate Withdrawal Scale (COWS) score of 11 with repeat COWS of 6. Why should an emergency physician be aware of this? Initiating olanzapine/samidorphan in the setting of chronic opioid therapy may result in precipitated opioid withdrawal. Additional SL buprenorphine may be a reasonable treatment modality.', attributes={'Label': 'CASE REPORT', 'NlmCategory': 'METHODS'})], 'CopyrightInformation': 'Copyright © 2024 Elsevier Inc. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Virginia Poison Center, Division of Clinical Toxicology, United States of America; Department of Emergency Medicine, Virginia Commonwealth University Health System, Richmond, VA, United States of America.'}], 'Identifier': [], 'LastName': 'Chambers', 'ForeName': 'Andrew', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Emergency Medicine, Virginia Commonwealth University Health System, Richmond, VA, United States of America. Electronic address: Jessica.patton@vcuhealth.org.'}], 'Identifier': [], 'LastName': 'Patton', 'ForeName': 'Jessica', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Virginia Poison Center, Division of Clinical Toxicology, United States of America; Department of Emergency Medicine, Virginia Commonwealth University Health System, Richmond, VA, United States of America.'}], 'Identifier': [], 'LastName': 'Wills', 'ForeName': 'Brandon K', 'Initials': 'BK'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Case Reports', attributes={'UI': 'D002363'})]}, attributes={'PubModel': 'Print-Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '30'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('146', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1186/s12931-024-02780-8', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1465-993X', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '25', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Mar', 'Day': '30'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Respiratory research', 'ISOAbbreviation': 'Respir Res'}, 'ArticleTitle': 'A novel quinoline with airway relaxant effects and anti-inflammatory properties.', 'Pagination': {'StartPage': '146', 'MedlinePgn': '146'}, 'Abstract': {'AbstractText': [StringElement('In chronic pulmonary diseases characterized by inflammation and airway obstruction, such as asthma and COPD, there are unmet needs for improved treatment. Quinolines is a group of small heterocyclic compounds that have a broad range of pharmacological properties. Here, we investigated the airway relaxant and anti-inflammatory properties of a novel quinoline (RCD405).', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement('The airway relaxant effect of RCD405 was examined in isolated airways from humans, dogs, rats and mice. Murine models of ovalbumin (OVA)-induced allergic asthma and LPS-induced airway inflammation were used to study the effects in vivo. RCD405 (10\\xa0mg/kg) or, for comparisons in selected studies, budesonide (3\\xa0mg/kg), were administered intratracheally 1\\xa0h prior to each challenge. Airway responsiveness was determined using methacholine provocation. Immune cell recruitment to bronchi was measured using flow cytometry and histological analyses were applied to investigate cell influx and goblet cell hyperplasia of the airways. Furthermore, production of cytokines and chemokines was measured using a multiplex immunoassay. The expression levels of asthma-related genes in murine lung tissue were determined by PCR. The involvement of NF-κB and metabolic activity was measured in the human monocytic cell line THP-1.', attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('RCD405 demonstrated a relaxant effect on carbachol precontracted airways in all four species investigated (potency ranking: human\\u2009=\\u2009rat\\u2009>\\u2009dog\\u2009=\\u2009mouse). The OVA-specific IgE and airway hyperresponsiveness (AHR) were significantly reduced by intratracheal treatment with RCD405, while no significant changes were observed for budesonide. In addition, administration of RCD405 to mice significantly decreased the expression of proinflammatory cytokines and chemokines as well as recruitment of immune cells to the lungs in both OVA- and LPS-induced airway inflammation, with a similar effect as for budesonide (in the OVA-model). However, the effect on gene expression of Il-4, IL-5 and Il-13 was more pronounced for RCD405 as compared to budesonide. Finally, in vitro, RCD405 reduced the LPS-induced NF-κB activation and by itself reduced cellular metabolism.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('RCD405 has airway relaxant effects, and it reduces AHR as well as airway inflammation in the models used, suggesting that it could be a clinically relevant compound to treat inflammatory airway diseases. Possible targets of this compound are complexes of mitochondrial oxidative phosphorylation, resulting in decreased metabolic activity of targeted cells as well as through pathways associated to NF-κB. However, further studies are needed to elucidate the mode of action.', attributes={'Label': 'CONCLUSIONS', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': '© 2024. The Author(s).'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Clinical Sciences Lund, Respiratory Medicine, Allergology, & Palliative Medicine, Lund University and Skåne University Hospital, Lund, Sweden.'}], 'Identifier': [], 'LastName': 'Bergwik', 'ForeName': 'Jesper', 'Initials': 'J'}, attributes={'ValidYN': 'Y', 'EqualContrib': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Experimental Asthma and Allergy Research Unit, Institute of Environmental Medicine (IMM), Karolinska Institutet, Biomedicum, Solnavägen 9, 171 65, Stockholm, Sweden.'}], 'Identifier': [], 'LastName': 'Liu', 'ForeName': 'Jielu', 'Initials': 'J'}, attributes={'ValidYN': 'Y', 'EqualContrib': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Clinical Sciences Lund, Respiratory Medicine, Allergology, & Palliative Medicine, Lund University and Skåne University Hospital, Lund, Sweden.'}], 'Identifier': [], 'LastName': 'Padra', 'ForeName': 'Médea', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Clinical Sciences Lund, Respiratory Medicine, Allergology, & Palliative Medicine, Lund University and Skåne University Hospital, Lund, Sweden.'}], 'Identifier': [], 'LastName': 'Bhongir', 'ForeName': 'Ravi K V', 'Initials': 'RKV'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Clinical Sciences Lund, Respiratory Medicine, Allergology, & Palliative Medicine, Lund University and Skåne University Hospital, Lund, Sweden.'}], 'Identifier': [], 'LastName': 'Tanner', 'ForeName': 'Lloyd', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Experimental Asthma and Allergy Research Unit, Institute of Environmental Medicine (IMM), Karolinska Institutet, Biomedicum, Solnavägen 9, 171 65, Stockholm, Sweden.'}], 'Identifier': [], 'LastName': 'Xiang', 'ForeName': 'Yujiao', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Arcede Pharma AB, Medicon Village, Lund, Sweden.'}], 'Identifier': [], 'LastName': 'Lundblad', 'ForeName': 'Mia', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Clinical Sciences Lund, Respiratory Medicine, Allergology, & Palliative Medicine, Lund University and Skåne University Hospital, Lund, Sweden.'}], 'Identifier': [], 'LastName': 'Egesten', 'ForeName': 'Arne', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Experimental Asthma and Allergy Research Unit, Institute of Environmental Medicine (IMM), Karolinska Institutet, Biomedicum, Solnavägen 9, 171 65, Stockholm, Sweden. Mikael.Adner@ki.se.'}], 'Identifier': [], 'LastName': 'Adner', 'ForeName': 'Mikael', 'Initials': 'M'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': '2020-011166', 'Agency': 'Vetenskapsrådet', 'Country': ''}, {'GrantID': '2019-01630', 'Agency': 'Vetenskapsrådet', 'Country': ''}, {'GrantID': '46402', 'Agency': 'The Swedish Government Funds for Clinical Research The Swedish Government Funds for Clinical Research', 'Country': ''}, {'GrantID': '20190160', 'Agency': 'Hjärt-Lungfonden', 'Country': ''}, {'GrantID': '20210297', 'Agency': 'Hjärt-Lungfonden', 'Country': ''}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '28'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1097/ACI.0000000000000981', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1473-6322', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '24', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Jun', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Current opinion in allergy and clinical immunology', 'ISOAbbreviation': 'Curr Opin Allergy Clin Immunol'}, 'ArticleTitle': 'New biologics for food allergy.', 'Pagination': {'StartPage': '147', 'EndPage': '152', 'MedlinePgn': '147-152'}, 'Abstract': {'AbstractText': [StringElement('This review aims to explore role of emerging biologics, including ligelizumab, UB-221, dupilumab, and antialarmins, in food allergy management. With a focus on recent developments, we evaluate their promise in mitigating adverse events during oral immunotherapy (OIT), reducing allergic reactions, and addressing the limitations of current therapeutic options.', attributes={'Label': 'PURPOSE OF REVIEW', 'NlmCategory': 'OBJECTIVE'}), StringElement('Antiimmunoglobulin E mAbs, exemplified by omalizumab, demonstrate efficacy in desensitization and safety improvement during multiallergen OIT. Next-generation antibodies like ligelizumab and UB-221 exhibit enhanced potency and unique mechanisms, holding promise for food allergy treatment. Dupilumab, targeting IL-4 receptor alpha, presents potential benefits in decreasing allergen-specific IgE and modifying the atopic march. Exploration of antialarmins, specifically anti-IL-33 (etokimab) and anti-TSLP (tezepelumab), reveals encouraging results, with etokimab showing early success in peanut allergy trials.', attributes={'Label': 'RECENT FINDINGS', 'NlmCategory': 'RESULTS'}), StringElement('Biologics hold promising potential for food allergy treatment. Tailoring therapeutic approaches based on shared decision-making becomes pivotal. While omalizumab remains a significant option, next-generation anti-IgE antibodies and agents targeting alarmins exhibit unique strengths. Dupilumab, despite limited success as monotherapy, shows promise as an adjunct for OIT. Careful consideration of treatment goals, patient preferences, and the evolving landscape of biologics will shape future clinical practice, offering allergists an expanded toolbox for personalized food allergy management.', attributes={'Label': 'SUMMARY', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': 'Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pathology, Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA.'}], 'Identifier': [], 'LastName': 'Schuetz', 'ForeName': 'Jackson P', 'Initials': 'JP'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Anderson', 'ForeName': 'Brent', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Sindher', 'ForeName': 'Sayantani B', 'Initials': 'SB'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Print-Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '08'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('448', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.3390/medicina60030448', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1648-9144', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '60', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Mar', 'Day': '08'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Medicina (Kaunas, Lithuania)', 'ISOAbbreviation': 'Medicina (Kaunas)'}, 'ArticleTitle': 'The Effectiveness of Biological Agents on Chronic Rhinosinusitis with Nasal Polyposis in Patients with Comorbid Asthma: A Multicenter Real-Life Study from Türkiye.', 'Abstract': {'AbstractText': ['<i>Background and Objectives</i>: Real-life data on the efficacy of biologic agents (BAs) on asthma-comorbid CRSwNP are needed. Our primary goal is to investigate the effects of BAs on CRSwNP symptoms, as well as endoscopic and tomography scores. Our secondary goal is to show a reduction in the frequency of acute sinusitis exacerbations and the need for surgery. <i>Materials and Methods</i>: We conducted a multicenter, retrospective, real-life study. We screened the patients with asthma-comorbid CRSwNP treated with omalizumab or mepolizumab. A total of 69 patients (40 F/29 M; omalizumab n = 55, mepolizumab n = 14) were enrolled. We compared the visual analog scale (VAS), sinonasal outcome test-22 (SNOT-22), nasal congestion score (NCS), Lund-Mackay computed tomography score (LMS), and total endoscopic polyp scores (TPS) before and after BAs. We evaluated the endoscopic sinus surgery (ESS) and acute exacerbations of chronic rhinosinusitis (AECRS) frequencies separately, according to the BAs. <i>Results:</i> The overall median (min-max) age was 43 (21-69) years. The median (min-max) of biologic therapy duration was 35 (4-113) months for omalizumab and 13.5 (6-32) for mepolizumab. Significant improvements were seen in VAS, SNOT-22, and NCS with omalizumab and mepolizumab. A significant decrease was observed in TPS with omalizumab [95% CI: 0-4] (<i>p</i> < 0.001), but not with mepolizumab [95% CI: -0.5-2] (<i>p</i> = 0.335). The frequency of ESS and AECRS were significantly reduced with omalizumab [95% CI: 2-3] (<i>p</i> < 0.001) and [95% CI: 2-5] (<i>p</i> < 0.001); and mepolizumab [95% CI: 0-2] (<i>p</i> = 0.002) and [95% CI: 2-8.5] (<i>p</i> < 0.001), respectively. There was no significant difference in LMS with either of the BAs. <i>Conclusions:</i> Omalizumab and mepolizumab can provide a significant improvement in the sinonasal symptom scores. BAs are promising agents for CRSwNP patients with frequent exacerbations and multiple surgeries.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [], 'LastName': 'Demir', 'ForeName': 'Meryem', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [], 'LastName': 'Tunakan Dalgic', 'ForeName': 'Ceyda', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [], 'LastName': 'Mete Gokmen', 'ForeName': 'Emine Nihal', 'Initials': 'EN'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Radiology, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [StringElement('0000-0002-7520-760X', attributes={'Source': 'ORCID'})], 'LastName': 'Savas', 'ForeName': 'Recep', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Otorhinolaryngology, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [], 'LastName': 'Eroglu', 'ForeName': 'Suleyman', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Adana City Hospital, Adana 01230, Türkiye.'}], 'Identifier': [], 'LastName': 'Ozden', 'ForeName': 'Guzin', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, University of Health Sciences, Derince Training and Research Hospital, Kocaeli 41900, Türkiye.'}], 'Identifier': [], 'LastName': 'Orcen', 'ForeName': 'Cihan', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Erciyes University Faculty of Medicine, Kayseri 38039, Türkiye.'}], 'Identifier': [], 'LastName': 'Pacaci Cetin', 'ForeName': 'Gulden', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Erciyes University Faculty of Medicine, Kayseri 38039, Türkiye.'}], 'Identifier': [], 'LastName': 'Arslan', 'ForeName': 'Bahar', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Allergy and Immunology, Ataturk Training and Research Hospital, Katip Celebi University, Izmir 35360, Türkiye.'}], 'Identifier': [], 'LastName': 'Bilgir', 'ForeName': 'Ferda', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Ataturk City Hospital, Balikesir 10100, Türkiye.'}], 'Identifier': [], 'LastName': 'Bulut', 'ForeName': 'Gokten', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Mersin City Hospital, Mersin 33230, Türkiye.'}], 'Identifier': [], 'LastName': 'Akcam', 'ForeName': 'Nurullah Yekta', 'Initials': 'NY'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Biostatistics and Medical Informatics, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [], 'LastName': 'Ozgul', 'ForeName': 'Semiha', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Eskisehir City Hospital, Eskisehir 26080, Türkiye.'}], 'Identifier': [StringElement('0000-0002-0844-6352', attributes={'Source': 'ORCID'})], 'LastName': 'Cerci', 'ForeName': 'Pamir', 'Initials': 'P'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Cemil Tascioglu City Hospital, Istanbul 34384, Türkiye.'}], 'Identifier': [], 'LastName': 'Coskun', 'ForeName': 'Raif', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Otorhinolaryngology, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [], 'LastName': 'Gode', 'ForeName': 'Sercan', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Erciyes University Faculty of Medicine, Kayseri 38039, Türkiye.'}], 'Identifier': [], 'LastName': 'Yilmaz', 'ForeName': 'Insu', 'Initials': 'I'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Ege University Faculty of Medicine, Izmir 35100, Türkiye.'}], 'Identifier': [], 'LastName': 'Sin', 'ForeName': 'Aytul Zerrin', 'Initials': 'AZ'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Multicenter Study', attributes={'UI': 'D016448'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '02', 'Day': '25'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('387', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.3390/medicina60030387', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1648-9144', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '60', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Feb', 'Day': '25'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Medicina (Kaunas, Lithuania)', 'ISOAbbreviation': 'Medicina (Kaunas)'}, 'ArticleTitle': 'Severe Asthma or Chronic Obstructive Pulmonary Disease with Eosinophilic Inflammation? From Uncertainty to Remission under Anti IL-5R Therapy.', 'Abstract': {'AbstractText': [\"<i>Background and Objectives</i>: Severe adult-onset eosinophilic asthma and COPD with eosinophilic inflammation are two entities with a similar clinical course and are sometimes difficult to differentiate in clinical practice, especially in patients with a history of smoking. Anti-IL-5 or -IL-5R biological therapy has been shown to be highly effective in severe eosinophilic asthma but has not demonstrated significant benefit in patients with COPD with the eosinophilic phenotype. Our aim was to illustrate this issue in the form of a case report. <i>Materials and Methods</i>: We present the case of a 67-year-old patient who is a former smoker with late-onset severe uncontrolled asthma (ACT score < 15) who experienced frequent exacerbations requiring treatment with systemic corticosteroids. The patient's lung function gradually worsened to a nadir FEV1 = 18%, despite a high dose of ICS in combination with a LABA and intermittent courses of OCS, with negative allergic skin-tests, but with high blood eosinophils level. Biological treatment with an anti-IL5R monoclonal antibody (benralizumab) was initiated, despite the difficulty in the differential diagnosis between asthma and COPD with eosinophilic inflammation. <i>Results</i>: The patient's evolution was favorable; clinical remission was effectively achieved with significant improvement in lung function (FEV1 > 100%), but with persistence of residual mild fixed airway obstructive dysfunction (FEV1/FVC < 0.7). The therapeutic response has been maintained to date. <i>Conclusions</i>: Benralizumab was shown to be very effective in a patient with late-onset severe eosinophilic asthma presenting features of chronic obstructive disease-habitual exposure to tobacco and inhaled noxious substances, and persistent airflow limitation on spirometry.\"]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Department, Infectious Diseases and Pulmonology Hospital \"Victor Babes\" Timisoara, 300310 Timisoara, Romania.'}], 'Identifier': [], 'LastName': 'Oprescu', 'ForeName': 'Bianca', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Department, Infectious Diseases and Pulmonology Hospital \"Victor Babes\" Timisoara, 300310 Timisoara, Romania.'}], 'Identifier': [], 'LastName': 'Raduna', 'ForeName': 'Oana', 'Initials': 'O'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Department, Infectious Diseases and Pulmonology Hospital \"Victor Babes\" Timisoara, 300310 Timisoara, Romania.'}, {'Identifier': [], 'Affiliation': 'Center for Research and Innovation in Precision Medicine of Respiratory Diseases, Department of Pulmonology, \"Victor Babes\" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.'}], 'Identifier': [StringElement('0000-0001-8897-8342', attributes={'Source': 'ORCID'})], 'LastName': 'Mihaicuta', 'ForeName': 'Stefan', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Pulmonology Department, Infectious Diseases and Pulmonology Hospital \"Victor Babes\" Timisoara, 300310 Timisoara, Romania.'}, {'Identifier': [], 'Affiliation': 'Center for Research and Innovation in Precision Medicine of Respiratory Diseases, Department of Pulmonology, \"Victor Babes\" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.'}], 'Identifier': [StringElement('0000-0002-7469-6755', attributes={'Source': 'ORCID'})], 'LastName': 'Frent', 'ForeName': 'Stefan', 'Initials': 'S'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Case Reports', attributes={'UI': 'D002363'})]}, attributes={'PubModel': 'Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '02', 'Day': '27'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('527', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.3390/biomedicines12030527', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2227-9059', attributes={'IssnType': 'Print'}), 'JournalIssue': DictElement({'Volume': '12', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Feb', 'Day': '27'}}, attributes={'CitedMedium': 'Print'}), 'Title': 'Biomedicines', 'ISOAbbreviation': 'Biomedicines'}, 'ArticleTitle': 'Drug-Induced Anaphylaxis in Children.', 'Abstract': {'AbstractText': ['Drug-induced anaphylaxis in children is less common than in adults and primarily involves beta-lactams and nonsteroidal anti-inflammatory drugs. Epidemiological studies show variable prevalence, influenced by age, gender, and atopic diseases. The pathophysiology includes IgE-mediated reactions and non-IgE mechanisms, like cytokine release reactions. We address drug-induced anaphylaxis in children, focusing on antibiotics, nonsteroidal anti-inflammatory drugs, neuromuscular blocking agents, and monoclonal antibodies. Diagnosis combines clinical criteria with in vitro, in vivo, and drug provocation tests. The immediate management of acute anaphylaxis primarily involves the use of adrenaline, coupled with long-term strategies, such as allergen avoidance and patient education. Desensitization protocols are crucial for children allergic to essential medications, particularly antibiotics and chemotherapy agents.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'UOC Pediatria, Azienda Ospedaliera San Camillo Forlanini, 00152 Roma, Italy.'}], 'Identifier': [], 'LastName': 'Bianchi', 'ForeName': 'Annamaria', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Translational Research in Pediatric Specialties Area, Division of Allergy, Bambino Gesù Children's Hospital, IRCCS, 00152 Roma, Italy.\"}], 'Identifier': [StringElement('0000-0003-0029-6254', attributes={'Source': 'ORCID'})], 'LastName': 'Valluzzi', 'ForeName': 'Rocco', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'UOC di Pediatria, Dipartimento Materno-Infantile, Università di Messina, 98100 Messina, Italy.'}], 'Identifier': [], 'LastName': 'Crisafulli', 'ForeName': 'Giuseppe', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'UOC di Pediatria e Neonatologia, Ospedale di Imola (BO), 40026 Imola, Italy.'}], 'Identifier': [StringElement('0000-0002-3955-1809', attributes={'Source': 'ORCID'})], 'LastName': 'Bottau', 'ForeName': 'Paolo', 'Initials': 'P'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'SC di Pediatria Fondazione IRCSS Policlinico San Matteo, 27100 Pavia, Italy.'}], 'Identifier': [], 'LastName': 'Caimmi', 'ForeName': 'Silvia', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'UOC Pediatria, Azienda Ospedaliero-Universitaria \"Ospedali Riuniti\", 60123 Ancona, Italy.'}], 'Identifier': [], 'LastName': 'Franceschini', 'ForeName': 'Fabrizio', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'UOC Pediatria, Azienda Ospedaliero-Universitaria \"Ospedali Riuniti\", 60123 Ancona, Italy.'}], 'Identifier': [], 'LastName': 'Liotti', 'ForeName': 'Lucia', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Allergy Unit, Meyer Children's Hospital IRCCS, 50132 Florence, Italy.\"}], 'Identifier': [], 'LastName': 'Mori', 'ForeName': 'Francesca', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"UOC di Pediatria Ospedale di Bolzano, Azienda Sanitaria dell'Alto Adige, 39100 Bolzano, Italy.\"}], 'Identifier': [], 'LastName': 'Riscassi', 'ForeName': 'Sara', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'SC Pediatria, Ospedale Latisana-Palmanova, Dipartimento Materno-Infantile Azienda Sanitaria, Universitaria Friuli Centrale, 33100 Udine, Italy.'}], 'Identifier': [StringElement('0000-0001-9443-5483', attributes={'Source': 'ORCID'})], 'LastName': 'Saretta', 'ForeName': 'Francesca', 'Initials': 'F'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinica Pediatrica, Dipartimento Medicina e Chirurgia, University of Parma, 43126 Parma, Italy.'}], 'Identifier': [], 'LastName': 'Scavone', 'ForeName': 'Sara', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinica Pediatrica, Dipartimento Medicina e Chirurgia, University of Parma, 43126 Parma, Italy.'}], 'Identifier': [StringElement('0000-0001-7710-6995', attributes={'Source': 'ORCID'})], 'LastName': 'Caffarelli', 'ForeName': 'Carlo', 'Initials': 'C'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '27'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('221', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1186/s12870-024-04757-7', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1471-2229', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '24', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Mar', 'Day': '27'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'BMC plant biology', 'ISOAbbreviation': 'BMC Plant Biol'}, 'ArticleTitle': 'Inoculation of heavy metal resistant bacteria alleviated heavy metal-induced oxidative stress biomarkers in spinach (Spinacia oleracea L.).', 'Pagination': {'StartPage': '221', 'MedlinePgn': '221'}, 'Abstract': {'AbstractText': ['Most vegetable crops are severely affected by the uptake of heavy metals from the soil. Heavy metals in vegetable bodies generate reactive oxygen species (ROS) that unbalance the antioxidant defense system. This study was initiated to determine the physiological and biochemical characteristics of spinach plants grown on soil contaminated with heavy metals and responding to Bacillus cereus and Bacillus aerius were isolated from soil contaminated with heavy metals. Heavy metal contamination led to a significant reduction in seed germination, seedling biomass, protein, and total nitrogen content of spinach plants grown in contaminated soils compared to control soils. In contrast, a significant increase in the content of metallothioneins and antioxidant enzymes was observed. Plants inoculated with B. cereus and B. aerius significantly reduced the oxidative stress induced by heavy metals by improving seed germination (%), seedling growth, nitrogen, and protein content. The content of metallothioneins and the activities of antioxidant enzymes were reduced in spinach plants grown from seeds inoculated with bacterial strains. In addition, plants inoculated with, B. cereus and B. aerius showed greater stomata opening than plants grown on soil contaminated with heavy metals, whose stomata were almost closed. These results suggested that both bacterial strains enhanced plant growth by reducing oxidative stress caused by metals.'], 'CopyrightInformation': '© 2024. The Author(s).'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Biotechnology and Genetic Engineering, Kohat University of Science & Technology (KUST), Kohat, 26000, Pakistan. dr.jamil@kust.edu.pk.'}], 'Identifier': [], 'LastName': 'Jamil', 'ForeName': 'Muhammad', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Biotechnology and Genetic Engineering, Kohat University of Science & Technology (KUST), Kohat, 26000, Pakistan.'}], 'Identifier': [], 'LastName': 'Malook', 'ForeName': 'Ijaz', 'Initials': 'I'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Biology, University of Haripur, Haripur, 22620, Pakistan.'}], 'Identifier': [], 'LastName': 'Rehman', 'ForeName': 'Shafiq Ur', 'Initials': 'SU'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Botany, University of Science and Technology, Bannu, 28100, Pakistan.'}], 'Identifier': [], 'LastName': 'Aslam', 'ForeName': 'Muhammad Mudasar', 'Initials': 'MM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Biotechnology and Genetic Engineering, Kohat University of Science & Technology (KUST), Kohat, 26000, Pakistan.'}], 'Identifier': [], 'LastName': 'Fayyaz', 'ForeName': 'Muhammad', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Institute of Crop Science, College of Agriculture and Biotechnology, Zhejiang University, Hangzhou, 310027, China.'}], 'Identifier': [], 'LastName': 'Shah', 'ForeName': 'Gulmeena', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Crop and Animal Production, Sason Vocational School, Batman University, Batman, 72060, Turkey.'}], 'Identifier': [], 'LastName': 'Kaplan', 'ForeName': 'Alevcan', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Botany, Islamia College Peshawar, Peshawar, 25120, Pakistan. nomiflora@uop.edu.pk.'}, {'Identifier': [], 'Affiliation': 'University Public School, University of Peshawar, Peshawar, 25120, Pakistan. nomiflora@uop.edu.pk.'}], 'Identifier': [], 'LastName': 'Khan', 'ForeName': 'Muhammad Nauman', 'Initials': 'MN'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Plant Sciences, Quaid-I-Azam University, Islamabad, 45320, Pakistan. baberali@bs.qau.edu.pk.'}], 'Identifier': [], 'LastName': 'Ali', 'ForeName': 'Baber', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Institute of Plant Nutrition and Soil Science, Christian-Albrechts-Universität Zu Kiel, 24118, Kiel, Germany. roy@plantnutrition.uni-kiel.de.'}, {'Identifier': [], 'Affiliation': 'Department of Agroforestry & Environmental Science, Sylhet Agricultural University, Sylhet, 3100, Bangladesh. roy@plantnutrition.uni-kiel.de.'}], 'Identifier': [], 'LastName': 'Roy', 'ForeName': 'Rana', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Horticulture, Agricultural Faculty, Ataturk University, Erzurum, 25240, Türkiye.'}, {'Identifier': [], 'Affiliation': 'HGF Agro, Ata Teknokent, TR-25240, Erzurum, Türkiye.'}], 'Identifier': [], 'LastName': 'Ercisli', 'ForeName': 'Sezai', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.'}, {'Identifier': [], 'Affiliation': 'Faculty of Medicine, Yousef Abdul Latif Jameel Scientific Chair of Prophetic Medicine Application, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.'}], 'Identifier': [], 'LastName': 'Harakeh', 'ForeName': 'Steve', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Stem Cell Research Unit, King Fahd Medical Research Center, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.'}, {'Identifier': [], 'Affiliation': 'Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.'}], 'Identifier': [], 'LastName': 'Moulay', 'ForeName': 'Mohammed', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Institute of Industrial Biotechnology, Government College University, Lahore, 54000, Pakistan.'}], 'Identifier': [], 'LastName': 'Javed', 'ForeName': 'Muhammad Ammar', 'Initials': 'MA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Botany and Microbiology, Faculty of Science, Assiut University, Assiut, 71516, Egypt.'}], 'Identifier': [], 'LastName': 'Abeed', 'ForeName': 'Amany H A', 'Initials': 'AHA'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic'})\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.1016/S2352-3018(23)00300-4', attributes={'EIdType': 'doi', 'ValidYN': 'Y'}), StringElement('S2352-3018(23)00300-4', attributes={'EIdType': 'pii', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2352-3018', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '11', 'Issue': '4', 'PubDate': {'Year': '2024', 'Month': 'Apr'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The lancet. HIV', 'ISOAbbreviation': 'Lancet HIV'}, 'ArticleTitle': 'Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.', 'Pagination': {'StartPage': 'e211', 'EndPage': 'e221', 'MedlinePgn': 'e211-e221'}, 'Abstract': {'AbstractText': [StringElement('Combined intramuscular long-acting cabotegravir and long-acting rilpivirine constitute the first long-acting combination antiretroviral therapy (ART) regimen approved for adults with HIV. The goal of the IMPAACT 2017 study (MOCHA [More Options for Children and Adolescents]) was to assess the safety and pharmacokinetics of these drugs in adolescents.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement(\"In this phase 1/2, multicentre, open-label, non-comparative, dose-finding study, virologically suppressed adolescents (aged 12-17 years; weight ≥35 kg; BMI ≤31·5 kg/m<sup>2</sup>) with HIV-1 on daily oral ART were enrolled at 15 centres in four countries (Botswana, South Africa, Thailand, and the USA). After 4-6 weeks of oral cabotegravir (cohort 1C) or rilpivirine (cohort 1R), participants received intramuscular long-acting cabotegravir or long-acting rilpivirine every 4 weeks or 8 weeks per the adult dosing regimens, while continuing pre-study ART. The primary outcomes were assessments of safety measures, including all adverse events, until week 4 for oral cabotegravir and until week 16 for long-acting cabotegravir and long-acting rilpivirine, and pharmacokinetic measures, including the area under the plasma concentration versus time curve during the dosing interval (AUC<sub>0-tau</sub>) and drug concentrations, at week 2 for oral dosing of cabotegravir and at week 16 for intramuscular dosing of cabotegravir and rilpivirine. Enrolment into cohort 1C or cohort 1R was based on the participant's pre-study ART, meaning that masking was not done. For pharmacokinetic analyses, blood samples were drawn at weeks 2-4 after oral dosing and weeks 4-16 after intramuscular dosing. Safety outcome measures were summarised using frequencies, percentages, and exact 95% CIs; pharmacokinetic parameters were summarised using descriptive statistics. This trial is registered at ClinicalTrials.gov, NCT03497676, and is closed to enrolment.\", attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('Between March 19, 2019, and Nov 25, 2021, 55 participants were enrolled: 30 in cohort 1C and 25 in cohort 1R. At week 16, 28 (97%, 95% CI 82-100) of the 29 dose-evaluable participants in cohort 1C and 21 (91%; 72-99) of the 23 dose-evaluable participants in cohort 1R had reported at least one adverse event, with the most common being injection-site pain (nine [31%] in cohort 1C; nine [39%] in cohort 1R; none were severe). One (4%, 95% CI 0-22) participant in cohort 1R had an adverse event of grade 3 or higher, leading to treatment discontinuation, which was defined as acute rilpivirine-related allergic reaction (self-limiting generalised urticaria) after the first oral dose. No deaths or life-threatening events occurred. In cohort 1C, the week 2 median cabotegravir AUC<sub>0-tau</sub> was 148·5 (range 37·2-433·1) μg·h/mL. The week 16 median concentrations for the every-4-weeks and every-8-weeks dosing was 3·11 μg/mL (range 1·22-6·19) and 1·15 μg/mL (<0·025-5·29) for cabotegravir and 52·9 ng/mL (31·9-148·0) and 39·1 ng/mL (27·2-81·3) for rilpivirine, respectively. These concentrations were similar to those in adults.', attributes={'Label': 'FINDINGS', 'NlmCategory': 'RESULTS'}), StringElement('Study data support using long-acting cabotegravir or long-acting rilpivirine, given every 4 weeks or 8 weeks, per the adult dosing regimens, in virologically suppressed adolescents aged 12 years and older and weighing at least 35 kg.', attributes={'Label': 'INTERPRETATION', 'NlmCategory': 'CONCLUSIONS'}), StringElement('The National Institutes of Health and ViiV Healthcare.', attributes={'Label': 'FUNDING', 'NlmCategory': 'BACKGROUND'})], 'CopyrightInformation': 'Copyright © 2024 Elsevier Ltd. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"St Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: aditya.gaur@stjude.org.\"}], 'Identifier': [], 'LastName': 'Gaur', 'ForeName': 'Aditya H', 'Initials': 'AH'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'University of California San Diego, La Jolla, CA, USA.'}], 'Identifier': [], 'LastName': 'Capparelli', 'ForeName': 'Edmund V', 'Initials': 'EV'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'FHI 360, Durham, NC, USA.'}], 'Identifier': [], 'LastName': 'Calabrese', 'ForeName': 'Katherine', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}], 'Identifier': [], 'LastName': 'Baltrusaitis', 'ForeName': 'Kristin', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}], 'Identifier': [], 'LastName': 'Marzinke', 'ForeName': 'Mark A', 'Initials': 'MA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'ViiV Healthcare, Madrid, Spain.'}], 'Identifier': [], 'LastName': 'McCoig', 'ForeName': 'Cynthia', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Janssen Research and Development, Beerse, Belgium.'}], 'Identifier': [], 'LastName': 'Van Solingen-Ristea', 'ForeName': 'Rodica M', 'Initials': 'RM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Baragwanath Academic Hospital, Johannesburg, South Africa.'}], 'Identifier': [], 'LastName': 'Mathiba', 'ForeName': 'Sisinyana Ruth', 'Initials': 'SR'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.'}], 'Identifier': [], 'LastName': 'Adeyeye', 'ForeName': 'Adeola', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Bethesda, MD, USA.'}], 'Identifier': [], 'LastName': 'Moye', 'ForeName': 'John H', 'Initials': 'JH'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Frontier Science Foundation, Amherst, NY, USA.'}], 'Identifier': [], 'LastName': 'Heckman', 'ForeName': 'Barbara', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"University of Pennsylvania Perelman School of Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.\"}], 'Identifier': [], 'LastName': 'Lowenthal', 'ForeName': 'Elizabeth D', 'Initials': 'ED'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Frontier Science Foundation, Boston, MA, USA.'}], 'Identifier': [], 'LastName': 'Ward', 'ForeName': 'Shawn', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Frontier Science Foundation, Boston, MA, USA.'}], 'Identifier': [], 'LastName': 'Milligan', 'ForeName': 'Ryan', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Frontier Science Foundation, Boston, MA, USA.'}], 'Identifier': [], 'LastName': 'Samson', 'ForeName': 'Pearl', 'Initials': 'P'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'University of California San Diego, La Jolla, CA, USA.'}], 'Identifier': [], 'LastName': 'Best', 'ForeName': 'Brookie M', 'Initials': 'BM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'ViiV Healthcare, ResearchTriangle Park, NC, USA.'}], 'Identifier': [], 'LastName': 'Harrington', 'ForeName': 'Conn M', 'Initials': 'CM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'ViiV Healthcare, ResearchTriangle Park, NC, USA.'}], 'Identifier': [], 'LastName': 'Ford', 'ForeName': 'Susan L', 'Initials': 'SL'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'GlaxoSmithKline, Mississauga, ON, Canada.'}], 'Identifier': [], 'LastName': 'Huang', 'ForeName': 'Jenny', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Janssen Research and Development, Beerse, Belgium.'}], 'Identifier': [], 'LastName': 'Crauwels', 'ForeName': 'Herta', 'Initials': 'H'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Janssen Research and Development, Beerse, Belgium.'}], 'Identifier': [], 'LastName': 'Vandermeulen', 'ForeName': 'Kati', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}], 'Identifier': [], 'LastName': 'Agwu', 'ForeName': 'Allison L', 'Initials': 'AL'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'University of Colorado School of Medicine, Aurora, CO, USA.'}], 'Identifier': [], 'LastName': 'Smith-Anderson', 'ForeName': 'Christiana', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Emory University School of Medicine-Children's Healthcare of Atlanta, Atlanta, GA, USA.\"}], 'Identifier': [], 'LastName': 'Camacho-Gonzalez', 'ForeName': 'Andres', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand.'}], 'Identifier': [], 'LastName': 'Ounchanum', 'ForeName': 'Pradthana', 'Initials': 'P'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Frontier Science Foundation, Amherst, NY, USA.'}], 'Identifier': [], 'LastName': 'Kneebone', 'ForeName': 'Jared L', 'Initials': 'JL'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.'}], 'Identifier': [], 'LastName': 'Townley', 'ForeName': 'Ellen', 'Initials': 'E'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; University of Alabama, Birmingham, AL, USA.'}], 'Identifier': [], 'LastName': 'Bolton Moore', 'ForeName': 'Carolyn', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'CollectiveName': 'IMPAACT 2017 Collaborators'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'CollectiveName': 'IMPAACT 2017 Team'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'DataBankList': ListElement([{'DataBankName': 'ClinicalTrials.gov', 'AccessionNumberList': ['NCT03497676']}], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': 'UM1 AI068616', 'Acronym': 'AI', 'Agency': 'NIAID NIH HHS', 'Country': 'United States'}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Multicenter Study', attributes={'UI': 'D016448'}), StringElement('Clinical Trial, Phase II', attributes={'UI': 'D017427'}), StringElement('Clinical Trial, Phase I', attributes={'UI': 'D017426'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '27'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1097/ACI.0000000000000978', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1473-6322', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '24', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Jun', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Current opinion in allergy and clinical immunology', 'ISOAbbreviation': 'Curr Opin Allergy Clin Immunol'}, 'ArticleTitle': 'Role of biologics in severe food allergy.', 'Pagination': {'StartPage': '138', 'EndPage': '143', 'MedlinePgn': '138-143'}, 'Abstract': {'AbstractText': [StringElement('This review examine the dynamic landscape of food allergy treatment within the context of emerging biologics. Our purpose is to comprehensively evaluate the potential benefits, challenges, and transformative impact associated with the utilization of biologics in comparison to conventional therapeutic modalities.', attributes={'Label': 'PURPOSE OF REVIEW', 'NlmCategory': 'OBJECTIVE'}), StringElement('This document synthesizes recent scientific investigations to various biologics, such as omalizumab, ligelizumab, dupilumab, and tezepelumab, providing a nuanced understanding of their roles in oral immunotherapy, rapid desensitization, and overall food allergy management. Recent studies and clinical trials highlight the impact of anti-IgE treatment on food allergies, revealing critical findings such as dose-related efficacy, facilitation of rapid desensitization in peanut allergies, and the sustained positive outcomes observed in individuals with multifood allergies.', attributes={'Label': 'RECENT FINDINGS', 'NlmCategory': 'RESULTS'}), StringElement('The use of biologics presents a groundbreaking approach in the treatment of food allergies. The multifaceted action of these agents, along with their potential to overcome the challenges associated with traditional therapies, marks a significant advancement. Despite the persisting challenges of economic constraints and the need for further safety studies, biologics offer a promising avenue for improving the quality of life for individuals with food allergies. Ongoing research and collaborative efforts are imperative to fully realize the transformative potential inherent in these emerging therapeutic frontiers.', attributes={'Label': 'SUMMARY', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': 'Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Women, Children, and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples.'}], 'Identifier': [], 'LastName': 'Dinardo', 'ForeName': 'Giulio', 'Initials': 'G'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Pediatric Allergology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.\"}], 'Identifier': [], 'LastName': 'Cafarotti', 'ForeName': 'Arianna', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Pediatric Allergology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.\"}], 'Identifier': [], 'LastName': 'Fierro', 'ForeName': 'Vincenzo', 'Initials': 'V'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Pediatric Allergology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.\"}], 'Identifier': [], 'LastName': 'Artesani', 'ForeName': 'Maria Cristina', 'Initials': 'MC'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Women, Children, and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples.'}], 'Identifier': [], 'LastName': 'Indolfi', 'ForeName': 'Cristiana', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Women, Children, and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples.'}], 'Identifier': [], 'LastName': 'Miraglia Del Giudice', 'ForeName': 'Michele', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Pediatric Allergology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.\"}], 'Identifier': [], 'LastName': 'Fiocchi', 'ForeName': 'Alessandro', 'Initials': 'A'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'})]}, attributes={'PubModel': 'Print-Electronic'})\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.1002/aorn.14111', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1878-0369', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '119', 'Issue': '4', 'PubDate': {'Year': '2024', 'Month': 'Apr'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'AORN journal', 'ISOAbbreviation': 'AORN J'}, 'ArticleTitle': 'A Randomized Controlled Trial of Povidone-Iodine Versus Chlorhexidine Gluconate With Isopropyl Alcohol for Preoperative Vaginal Antisepsis.', 'Pagination': {'StartPage': '261', 'EndPage': '274', 'MedlinePgn': '261-274'}, 'Abstract': {'AbstractText': ['Many surgeons request use of 10% povidone-iodine (PI) for vaginal antisepsis; however, when PI is contraindicated, some surgeons request use of chlorhexidine gluconate (CHG) instead. The purpose of this randomized controlled trial was to determine any significant differences in self-reported symptoms associated with vaginal antisepsis with either 10% PI scrub or 4% CHG with 4% isopropyl alcohol. The control group comprised 62 participants who underwent vaginal antisepsis with the PI product, and the intervention group comprised 58 participants who underwent vaginal antisepsis with the CHG product. Participants completed surveys immediately before surgery, immediately after surgery, and 48 to 72 hours after surgery. No significant differences were found in the reported vaginal symptoms between the two groups for any survey. One participant in the intervention group reported symptoms consistent with an allergic reaction. Additional studies are needed on the use of CHG for vaginal antisepsis.'], 'CopyrightInformation': '© AORN, Inc, 2024.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Dunn', 'ForeName': 'Debra', 'Initials': 'D'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Yannotti', 'ForeName': 'Kara', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Centrella-Nigro', 'ForeName': 'Andrea', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Correa', 'ForeName': 'Stacy', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': \"O'Dea\", 'ForeName': 'Denise', 'Initials': 'D'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [], 'Identifier': [], 'LastName': 'Wiley', 'ForeName': 'Sandra', 'Initials': 'S'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Randomized Controlled Trial', attributes={'UI': 'D016449'}), StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '27'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1007/s12325-024-02823-y', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1865-8652', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '41', 'Issue': '5', 'PubDate': {'Year': '2024', 'Month': 'May'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Advances in therapy', 'ISOAbbreviation': 'Adv Ther'}, 'ArticleTitle': 'Pharmacological Basis of Differences in Dose Response, Dose Equivalence, and Duration of Action of Inhaled Corticosteroids.', 'Pagination': {'StartPage': '1995', 'EndPage': '2009', 'MedlinePgn': '1995-2009'}, 'Abstract': {'AbstractText': [StringElement('Asthma treatment guidelines classify inhaled corticosteroid (ICS) regimens as low, medium, or high dose. However, efficacy and safety are not independently assessed accordingly. Moreover, differences in ICS duration of action are not considered when a dose regimen is selected. We investigated the efficacy and safety implications of these limitations for available ICS molecules.', attributes={'Label': 'INTRODUCTION', 'NlmCategory': 'BACKGROUND'}), StringElement('Published pharmacodynamic and pharmacokinetic parameters were used, alongside physiological and pharmacological principles, to estimate the efficacy and safety of available ICS molecules. Extent and duration of glucocorticoid receptor (GR) occupancy in the lung (efficacy) and cortisol suppression (systemic exposure and safety) were estimated.', attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('Some ICS regimens (e.g., fluticasone furoate, fluticasone propionate, and ciclesonide) rank high for efficacy but low for systemic exposure, contrary to how ICS dose equivalence is currently viewed. Differences in dose-response relationships for efficacy and systemic exposure were unique for each ICS regimen and reflected in their therapeutic indices. Notably, even low doses of most ICSs can generate high GR occupancy (≥\\u200990%) across the entire dose interval at steady state, which may explain previously reported difficulties in obtaining dose responses within the clinical dose range and observations that most clinical benefit typically occurs at low doses. The estimated post dose duration of lung GR occupancy for ICS molecules was categorized as 4-6\\xa0h (short), 14-16\\xa0h (medium), 25-40\\xa0h (long), or >\\u200980\\xa0h (ultra-long), suggesting potentially large differences in anti-inflammatory duration of action.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('In a real-world clinical setting where there may be poor adherence to prescribed therapy, our findings suggest a significant therapeutic advantage for longer-acting ICS molecules in patients with asthma.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': '© 2024. The Author(s).'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Clinical Pharmacology and Experimental Medicine, GSK Research and Development, Brentford, UK.'}], 'Identifier': [StringElement('0000-0003-0684-5621', attributes={'Source': 'ORCID'})], 'LastName': 'Daley-Yates', 'ForeName': 'Peter T', 'Initials': 'PT'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'GSK, Singapore, 139234, Singapore. bhumika.x.aggarwal@gsk.com.'}], 'Identifier': [StringElement('0000-0002-8370-9319', attributes={'Source': 'ORCID'})], 'LastName': 'Aggarwal', 'ForeName': 'Bhumika', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'GSK, Abbotsford, VIC, Australia.'}, {'Identifier': [], 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.'}], 'Identifier': [StringElement('0000-0002-2111-1370', attributes={'Source': 'ORCID'})], 'LastName': 'Plank', 'ForeName': 'Maximilian', 'Initials': 'M'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'}), StringElement('Review', attributes={'UI': 'D016454'}), StringElement(\"Research Support, Non-U.S. Gov't\", attributes={'UI': 'D013485'})]}, attributes={'PubModel': 'Print-Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '04', 'Day': '18'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1124/jpet.123.002060', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1521-0103', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '389', 'Issue': '2', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '18'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The Journal of pharmacology and experimental therapeutics', 'ISOAbbreviation': 'J Pharmacol Exp Ther'}, 'ArticleTitle': 'Initial Characterization of a Transgenic Mouse with Overexpression of the Human H<sub>1</sub>-Histamine Receptor on the Heart.', 'Pagination': {'StartPage': '174', 'EndPage': '185', 'MedlinePgn': '174-185'}, 'Abstract': {'AbstractText': ['There is a debate on whether H<sub>1</sub>-histamine receptors can alter contractility in the mammalian heart. We studied here a new transgenic mouse model where we increased genetically the cardiac level of the H<sub>1</sub>-histamine receptor. We wanted to know if histamine could augment or decrease contractile parameters in mice with cardiac-specific overexpression of human H<sub>1</sub>-histamine receptors (H<sub>1</sub>-TG) and compared these findings with those in littermate wild-type mice (WT). In H<sub>1</sub>-TG mice, we studied the presence of H<sub>1</sub>-histamine receptors by autoradiography of the atrium and ventricle using [<sup>3</sup>H]mepyramine. The messenger RNA for human H<sub>1</sub>-histamine receptors was present in the heart from H<sub>1</sub>-TG and absent from WT. Using in situ hybridization, we noted mRNA for the human H<sub>1</sub>-histamine receptor in cardiac cells from H<sub>1</sub>-TG. We noted that histamine (1 nM-10 <i>µ</i>M) in paced (1 Hz) left atrial preparations from H<sub>1</sub>-TG, exerted at each concentration of histamine initially reduced force of contraction and then raised contractile force. Likewise, in spontaneously beating left atrial preparations from H<sub>1</sub>-TG, we noted that histamine led to a transient reduction in the spontaneous beating rate followed by an augmentation in the beating rate. The negative inotropic and chronotropic and the positive inotropic effects on histamine in isolated atrial muscle strips from H<sub>1</sub>-TG were attenuated by the H<sub>1</sub>-histamine receptor antagonist mepyramine. Histamine failed to exert an increased force or reduce the heartbeat in atrial preparations from WT. We concluded that stimulation of H<sub>1</sub>-histamine-receptors can decrease and then augment contractile force in the mammalian heart and stimulation of H<sub>1</sub>-histamine receptors exerts a negative chronotropic effect. SIGNIFICANCE STATEMENT: We made novel transgenic mice with cardiomyocyte-specific high expressional levels of the human H<sub>1</sub>-histamine receptor to contribute to the clarification of the controversy on whether H<sub>1</sub>-histamine receptors increase or decrease contractility and beating rate in the mammalian heart. From our data, we conclude that stimulation of H<sub>1</sub>-histamine receptors first decrease and then raise contractile force in the mammalian heart but exert solely negative chronotropic effects.'], 'CopyrightInformation': 'Copyright © 2024 by The American Society for Pharmacology and Experimental Therapeutics.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Rayo Abella', 'ForeName': 'Lina Maria', 'Initials': 'LM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Jacob', 'ForeName': 'Hannes', 'Initials': 'H'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Keller', 'ForeName': 'Max', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Schindler', 'ForeName': 'Lisa', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Pockes', 'ForeName': 'Steffen', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Pitzl', 'ForeName': 'Sebastian', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Klimas', 'ForeName': 'Jan', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [StringElement('0000-0001-7055-9561', attributes={'Source': 'ORCID'})], 'LastName': 'Hadova', 'ForeName': 'Katarína', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Schneider', 'ForeName': 'Sarah', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Buchwalow', 'ForeName': 'Igor B', 'Initials': 'IB'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Jin', 'ForeName': 'CongYu', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Panula', 'ForeName': 'Pertti', 'Initials': 'P'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [], 'LastName': 'Kirchhefer', 'ForeName': 'Uwe', 'Initials': 'U'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.) joachim.neumann@medizin.uni-halle.de.\"}], 'Identifier': [StringElement('0000-0001-5018-3851', attributes={'Source': 'ORCID'})], 'LastName': 'Neumann', 'ForeName': 'Joachim', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (L.M.R.A., H.J., S.S., J.N., U.G.); Institute of Pharmacy, University of Regensburg, Regensburg, Germany (M.K., L.S., S.Po., S.Pi.); Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic (J.K., K.H.); Institute for Hematopathology, Hamburg, Germany and Scientific and Educational Resource Center for Molecular Morphology, Peoples' FriendshipUniversity of Russia, Moscow, Russia (I.B.B.); Department of Anatomy, University of Helsinki, Helsinki, Finland (C.J., P.P.); Institute of Pharmacology and Toxicology, Westfälische Wilhelms-University of Münster, Münster, Germany (U.K.).\"}], 'Identifier': [StringElement('0000-0001-6986-485X', attributes={'Source': 'ORCID'})], 'LastName': 'Gergs', 'ForeName': 'Ulrich', 'Initials': 'U'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '25'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('7076', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1038/s41598-024-57776-7', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2045-2322', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '14', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Mar', 'Day': '25'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Scientific reports', 'ISOAbbreviation': 'Sci Rep'}, 'ArticleTitle': 'Ketotifen directly modifies the fibrotic response of human skin fibroblasts.', 'Pagination': {'StartPage': '7076', 'MedlinePgn': '7076'}, 'Abstract': {'AbstractText': ['Fibrosis is a destructive, end-stage disease process. In the skin, it is associated with systemic sclerosis and scarring with considerable health burden. Ketotifen is a clinical antihistamine and mast cell stabilizer. Studies have demonstrated mast cell-dependent anti-fibrotic effects of ketotifen but direct effects on fibroblasts have not been determined. Human dermal fibroblasts were treated with pro-fibrotic transforming growth factor-β1 (TGFβ) followed by ketotifen or control treatments to determine direct effects on fibrotic fibroblasts. Ketotifen impaired TGFβ-induced α-smooth muscle actin gene and protein responses and decreased cytoskeletal- and contractility-associated gene responses associated with fibrosis. Ketotifen reduced Yes-associated protein phosphorylation, transcriptional coactivator with PDZ binding motif transcript and protein levels, and phosphorylation of protein kinase B. In a fibroblast-populated collagen gel contraction assay, ketotifen reduced the contractile activity of TGFβ-activated fibroblasts. In a murine model of bleomycin-induced skin fibrosis, collagen density and dermal thickness were significantly decreased in ketotifen-treated mice supporting in vitro findings. These results support a novel, direct anti-fibrotic activity of ketotifen, reducing pro-fibrotic phenotypic changes in fibroblasts and reducing collagen fibres in fibrotic mouse skin. Together, these findings suggest novel therapeutic potential and a novel mechanism of action for ketotifen in the context of fibrosis.'], 'CopyrightInformation': '© 2024. The Author(s).'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pathology, Dalhousie University, 5850 College Street, Room 7-C, PO BOX 15000, Halifax, NS, B3H 4R2, Canada.'}], 'Identifier': [], 'LastName': 'Leong', 'ForeName': 'Edwin', 'Initials': 'E'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Microbiology and Immunology, Dalhousie University, Halifax, Canada.'}], 'Identifier': [], 'LastName': 'Al-Bitar', 'ForeName': 'Haya', 'Initials': 'H'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pathology, Dalhousie University, 5850 College Street, Room 7-C, PO BOX 15000, Halifax, NS, B3H 4R2, Canada. jean.marshall@dal.ca.'}, {'Identifier': [], 'Affiliation': 'Department of Microbiology and Immunology, Dalhousie University, Halifax, Canada. jean.marshall@dal.ca.'}, {'Identifier': [], 'Affiliation': 'Beatrice Hunter Cancer Research Institute, Halifax, Canada. jean.marshall@dal.ca.'}], 'Identifier': [], 'LastName': 'Marshall', 'ForeName': 'Jean S', 'Initials': 'JS'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Microbiology and Immunology, Dalhousie University, Halifax, Canada. michael.bezuhly@iwk.nshealth.ca.'}, {'Identifier': [], 'Affiliation': 'Beatrice Hunter Cancer Research Institute, Halifax, Canada. michael.bezuhly@iwk.nshealth.ca.'}, {'Identifier': [], 'Affiliation': 'Division of Plastic Surgery, Izaak Walton Killam Health Centre, 5850/5980 University Avenue, PO Box 9700, Halifax, NS, B3K 6R8, Canada. michael.bezuhly@iwk.nshealth.ca.'}, {'Identifier': [], 'Affiliation': 'Department of Surgery, Dalhousie University, Halifax, Canada. michael.bezuhly@iwk.nshealth.ca.'}], 'Identifier': [], 'LastName': 'Bezuhly', 'ForeName': 'Michael', 'Initials': 'M'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': 'THC135230', 'Agency': 'CIHR', 'Country': 'Canada'}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '25'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('e0301024', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1371/journal.pone.0301024', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1932-6203', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '19', 'Issue': '3', 'PubDate': {'Year': '2024'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'PloS one', 'ISOAbbreviation': 'PLoS One'}, 'ArticleTitle': 'Codeine and promethazine: Exploratory study on \"lean\" or \"sizzurp\"\\xa0using national survey data and an online forum.', 'Pagination': {'StartPage': 'e0301024', 'MedlinePgn': 'e0301024'}, 'Abstract': {'AbstractText': [StringElement('The concoction known as \"lean\" containing codeine and promethazine, holds a prominent cultural presence and is often referenced in mass media platforms (e.g., music and social media). Surprisingly, there\\'s a scarcity of national data characterizing the use of lean. Therefore, the current study investigated the use of lean using national survey data and online forum participant input, and focused on identifying concurrent substance use, exploring co-administration with other substances (e.g., alcohol, cannabis), and determining lean-related experiences.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'BACKGROUND'}), StringElement('We analyzed data from the National Survey on Drug Use and Health (NSDUH) spanning 2007-2019, identifying persons who used lean (weighted N = 42,275). Additionally, we conducted a Reddit-based study to gather insights about lean consumtion (N = 192).', attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('The NSDUH data indicated that lean use was most prevalent among teenagers and young adults (ages 13-21), accounting for 66% of the sample. This trend was more pronounced in male respondents (75%) compared to females. Additionally, the use was predominantly observed among Black/African American (29%), Hispanic (28%), and White (33%) populations, with these groups also reporting higher levels of concurrent alcohol and cannabis use. Similarly, findings from Reddit showed that individuals who used lean were predominantly male (67%) and exhibited elevated concurrent rates of alcohol (83%) and cannabis (46%) use in the past 30 days. Moreover, approximately 66% of respondents met criteria for severe lean use disorder, and 37% acknowledged driving under its influence.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('The NSDUH data found that mostly young adult males reported consuming lean in the past twelve months, though the racial/ethnic breakdown of persons who used lean was diverse. The Reddit data found that most individuals in the sample met the criteria for a substance use disorder pertaining to their lean consumption. These findings underscore the clinical significance and necessity for further controlled research on lean.', attributes={'Label': 'CONCLUSION', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': 'Copyright: © 2024 Ware et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Social Work, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.'}], 'Identifier': [StringElement('0000-0002-3269-5324', attributes={'Source': 'ORCID'})], 'LastName': 'Ware', 'ForeName': 'Orrin D', 'Initials': 'OD'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Medicine, Johns Hopkins University, Baltimore, MD, United States of America.'}], 'Identifier': [StringElement('0000-0003-2182-1644', attributes={'Source': 'ORCID'})], 'LastName': 'Garcia-Romeu', 'ForeName': 'Albert', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Medicine, Johns Hopkins University, Baltimore, MD, United States of America.'}], 'Identifier': [], 'LastName': 'Zamarripa', 'ForeName': 'C Austin', 'Initials': 'CA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.'}], 'Identifier': [], 'LastName': 'Hughes', 'ForeName': 'Tamera', 'Initials': 'T'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Medicine, Johns Hopkins University, Baltimore, MD, United States of America.'}], 'Identifier': [], 'LastName': 'Wager', 'ForeName': 'Leeza', 'Initials': 'L'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Medicine, Johns Hopkins University, Baltimore, MD, United States of America.'}], 'Identifier': [], 'LastName': 'Spindle', 'ForeName': 'Tory', 'Initials': 'T'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic-eCollection'})\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.38212/2224-6614.3495', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2224-6614', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '32', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Mar', 'Day': '15'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Journal of food and drug analysis', 'ISOAbbreviation': 'J Food Drug Anal'}, 'ArticleTitle': 'An acute herb-drug interaction of Magnoliae Officinalis Cortex with methotrexate via inhibiting multidrug resistance-associated protein 2.', 'Pagination': {'StartPage': '103', 'EndPage': '111', 'MedlinePgn': '103-111'}, 'Abstract': {'AbstractText': ['Magnoliae Officinalis Cortex (MOC), an herbal drug, contains polyphenolic lignans mainly magnolol (MN) and honokiol (HK). Methotrexate (MTX), a critical drug for cancers and autoimmune deseases, is a substrate of multidrug resistance-associated protein 2 (MRP2) and breast cancer resistance protein (BCRP). This study investigated the effect of coadministration of MOC on the pharmacokinetics of MTX and relevant mechanisms. Sprague-Dawley rats were orally administered MTX alone and with single dose (2.0 and 4.0 g/kg) and repeated seven doses of MOC (2.0 g/kg thrice daily for 2 days, the 7th dose given at 0.5 h before MTX). The serum concentrations of MTX were determined by a fluorescence polarization immunoassay. The results showed that a single dose of MOC at 2.0 g/kg significantly increased the AUC<sub>0-t</sub> and MRT of MTX by 352% and 308%, and a single dose at 4.0 g/kg significantly enhanced the AUC<sub>0-t</sub> and MRT by 362% and 291%, respectively. Likewise, repeated seven doses of MOC at 2.0 g/kg significantly increased the AUC<sub>0-t</sub> and MRT of MTX by 461% and 334%, respectively. Mechanism studies indicated that the function of MRP2 was significantly inhibited by MN, HK and the serum metabolites of MOC (MOCM), whereas BCRP was not inhibited by MOCM. In conclusion, coadministration of MOC markedly enhanced the systemic exposure and mean residence time of MTX through inhibiting the MRP2-mediated excretion of MTX.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan 406040, ROC.'}, {'Identifier': [], 'Affiliation': 'Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan 404327, ROC.'}], 'Identifier': [], 'LastName': 'Yu', 'ForeName': 'Chung-Ping', 'Initials': 'CP'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan 406040, ROC.'}], 'Identifier': [], 'LastName': 'Li', 'ForeName': 'Pei-Ying', 'Initials': 'PY'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan 406040, ROC.'}], 'Identifier': [], 'LastName': 'Chen', 'ForeName': 'Szu-Yu', 'Initials': 'SY'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan 406040, ROC.'}], 'Identifier': [], 'LastName': 'Lin', 'ForeName': 'Shiuan-Pey', 'Initials': 'SP'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Institute of Chinese Pharmaceutical Sciences, China Medical University, Taichung, Taiwan 404333, ROC.'}], 'Identifier': [], 'LastName': 'Chen', 'ForeName': 'Ying-Chen', 'Initials': 'YC'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan 406040, ROC.'}, {'Identifier': [], 'Affiliation': 'Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan 404327, ROC.'}], 'Identifier': [], 'LastName': 'Ho', 'ForeName': 'Lu-Ching', 'Initials': 'LC'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan 406040, ROC.'}, {'Identifier': [], 'Affiliation': 'Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan 404327, ROC.'}], 'Identifier': [], 'LastName': 'Hsieh', 'ForeName': 'Yow-Wen', 'Initials': 'YW'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan 406040, ROC.'}, {'Identifier': [], 'Affiliation': 'Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan 404327, ROC.'}], 'Identifier': [], 'LastName': 'Hou', 'ForeName': 'Yu-Chi', 'Initials': 'YC'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.5152/j.aott.2024.21066', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2589-1294', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '58', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Jan'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Acta orthopaedica et traumatologica turcica', 'ISOAbbreviation': 'Acta Orthop Traumatol Turc'}, 'ArticleTitle': 'Distal femur morphology and the suitability of standard guides for knee arthroplasty in the Turkish population.', 'Pagination': {'StartPage': '39', 'EndPage': '44', 'MedlinePgn': '39-44'}, 'Abstract': {'AbstractText': [StringElement('The aim of this study was to evaluate the posterior condylar angle (PCA) and condylar twist angle (CTA) of the distal femur in the Turkish population and its concordance with the current standard prosthesis guides used in total knee arthroplasty (TKA).', attributes={'Label': 'OBJECTIVE'}), StringElement('Two hundred and forty knees of 120 Turkish subjects (60 male and 60 female) were included in this study. PCA, CTA, femoral mediolateral lengths (fML), medial femoral anteroposterior lengths (fMAP), lateral femoral anteroposterior lengths (fLAP), distances between the trochlear groove and fMAP (DBTG-fMAP), distances between the trochlear groove and fLAP (DBTG-fLAP), medial posterior condylar cartilage thickness (MPCCT) and lateral posterior condylar cartilage thicknesses (LPCCT) were measured on magnetic resonance imaging (MRI).', attributes={'Label': 'METHODS'}), StringElement('The median CTA was 7° (range: 0°-13.0°) and the median PCA was 4° (range 0°-11.0°) (P < .0001). The median fML was 79.5 mm (range: 65.7-98.9). The median length of the fMAP was 58.2 mm (range: 46.8-69.0) and the median length of fLAP was 58.2 mm (range: 48.4-73.0). The DBTG-fMAP was 15.2 mm (range: 5.2-23.2), and DBTG-fLAP length was 21.9mm (range: 16.4-29.4). The median MPCCT and LPCCT were 2.4 mm (range: 1.6-3.6) and 2.3 mm (range: 1.2-2.8), respectively. The intraclass correlation coefficient for quantifying interobserver and intraobserver reliability showed excellent agreement regarding the PCA and CTA.', attributes={'Label': 'RESULTS'}), StringElement('This study has shown us that PCA and CTA may be higher in the Turkish population. Although it is not known whether these results have any clinical utility, it may be useful for surgeons to keep this in mind to prevent femoral component malposition.', attributes={'Label': 'CONCLUSION'}), StringElement('Level IV, Diagnostic Study.', attributes={'Label': 'LEVEL OF EVIDENCE'})]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Orthopaedics and Traumatology, Bezmialem Vakıf University, Istanbul, Turkey.'}], 'Identifier': [], 'LastName': 'İncesoy', 'ForeName': 'Mustafa Alper', 'Initials': 'MA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Orthopaedics and Traumatology, Universitätsklinikum Tübingen, Tübingen, Germany.'}], 'Identifier': [], 'LastName': 'Güngören', 'ForeName': 'Nurdan', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Orthopaedics and Traumatology, Rotkreuzklinik Wertheim, Wertheim, Germany.'}], 'Identifier': [], 'LastName': 'Aliyev', 'ForeName': 'Orkhan', 'Initials': 'O'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Orthopaedics and Traumatology, Bezmialem Vakıf University, Istanbul, Turkey.'}], 'Identifier': [], 'LastName': 'Elmalı', 'ForeName': 'Nurzat', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Orthopaedics and Traumatology, Bezmialem Vakıf University, Istanbul, Turkey.'}], 'Identifier': [], 'LastName': 'Tuncay', 'ForeName': 'İbrahim', 'Initials': 'İ'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Orthopaedics and Traumatology, Bezmialem Vakıf University, Istanbul, Turkey.'}], 'Identifier': [], 'LastName': 'Yıldız', 'ForeName': 'Fatih', 'Initials': 'F'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '23'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1016/j.ijpharm.2024.124033', attributes={'EIdType': 'doi', 'ValidYN': 'Y'}), StringElement('S0378-5173(24)00267-9', attributes={'EIdType': 'pii', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1873-3476', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '655', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '25'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'International journal of pharmaceutics', 'ISOAbbreviation': 'Int J Pharm'}, 'ArticleTitle': 'Synergism of polysaccharide polymers in antihistamine eye drops: Influence on physicochemical properties and in vivo efficacy.', 'Pagination': {'StartPage': '124033', 'MedlinePgn': '124033'}, 'Abstract': {'AbstractText': ['The incorporation of polymers into drug delivery vehicles has been shown to be a useful approach to prolong the residence time of drugs in the precorneal tear film and to improve penetration into biological membranes. The main objective of this research was to formulate novel viscous eye drops with ketotifen as the active ingredient, containing the polysaccharides: chitosan (MCH), hydroxypropyl guar gum (HPG) and hyaluronic acid (SH) alone and in combination as functional polymers. DSC and FT-IR techniques showed the compatibility between ketotifen and polymers. Physicochemical and rheological analysis at ambient and simulated physiological conditions, as well as the evaluation of mucoadhesive properties showed that vehicles containing combinations of polymers have suitable physicochemical and functional properties with demonstrated synergism between combined polymers (MCH and HPG i.e. SH and HPG). The drug permeability was successfully estimated in vitro using HCE-T cell-based models. MTT cytotoxicity assay demonstrates that the tested formulations were non-toxic and well tolerated. In vivo preclinical study on mice revealed that both vehicles containing mixed polymers enhanced and prolonged the antipruritic/analgesic-like effect of ophthalmic ketotifen. Based on these results, both combinations of polysaccharide polymers, especially SH-HPG, could be considered as potential new carriers for ketotifen for ophthalmic use.'], 'CopyrightInformation': 'Copyright © 2024 Elsevier B.V. All rights reserved.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Technology and Cosmetology, University of Banja Luka, Faculty of Medicine, Save Mrkalja 14, 78000 Banja Luka, Bosnia and Herzegovina. Electronic address: andjelka.racic@med.unibl.org.'}], 'Identifier': [], 'LastName': 'Račić', 'ForeName': 'Anđelka', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'R&D, PLIVA Croatia Ltd., TEVA Group Member, Prilaz baruna Filipovića 29, 10000 Zagreb, Croatia. Electronic address: bisera.jurisicdukovski@pliva.com.'}], 'Identifier': [], 'LastName': 'Jurišić Dukovski', 'ForeName': 'Bisera', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Technology, University of Zagreb, Faculty of Pharmacy and Biochemistry, Ante Kovačića 1, 10000 Zagreb, Croatia. Electronic address: jasmina.lovric@pharma.unizg.hr.'}], 'Identifier': [], 'LastName': 'Lovrić', 'ForeName': 'Jasmina', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Chemistry, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia. Electronic address: vladimir.dobricic@pharmacy.bg.ac.rs.'}], 'Identifier': [], 'LastName': 'Dobričić', 'ForeName': 'Vladimir', 'Initials': 'V'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'School of Pharmacy, University College Cork, Cork, Ireland. Electronic address: svucen@ucc.ie.'}], 'Identifier': [], 'LastName': 'Vučen', 'ForeName': 'Sonja', 'Initials': 'S'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmacology, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia. Electronic address: ana.micov@pharmacy.bg.ac.rs.'}], 'Identifier': [], 'LastName': 'Micov', 'ForeName': 'Ana', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmacology, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia. Electronic address: radica.stepanovic@pharmacy.bg.ac.rs.'}], 'Identifier': [], 'LastName': 'Stepanović-Petrović', 'ForeName': 'Radica', 'Initials': 'R'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmacology, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia. Electronic address: maja.tomic@pharmacy.bg.ac.rs.'}], 'Identifier': [], 'LastName': 'Tomić', 'ForeName': 'Maja', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmacology, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia. Electronic address: uros.pecikoza@pharmacy.bg.ac.rs.'}], 'Identifier': [], 'LastName': 'Pecikoza', 'ForeName': 'Uroš', 'Initials': 'U'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Chemical Engineering, University of Novi Sad, Faculty of Technology Novi Sad, Bulevar cara Lazara 1, 21000 Novi Sad, Serbia. Electronic address: ilicj@uns.ac.rs.'}], 'Identifier': [], 'LastName': 'Bajac', 'ForeName': 'Jelena', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Technology and Cosmetology, University of Belgrade-Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia. Electronic address: danina.krajisnik@pharmacy.bg.ac.rs.'}], 'Identifier': [], 'LastName': 'Krajišnik', 'ForeName': 'Danina', 'Initials': 'D'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '23'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1111/bcpt.14005', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1742-7843', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '134', 'Issue': '5', 'PubDate': {'Year': '2024', 'Month': 'May'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Basic & clinical pharmacology & toxicology', 'ISOAbbreviation': 'Basic Clin Pharmacol Toxicol'}, 'ArticleTitle': 'Dimetindene-Is the minimum toxic dose for children too strict?', 'Pagination': {'StartPage': '750', 'EndPage': '755', 'MedlinePgn': '750-755'}, 'Abstract': {'AbstractText': ['Dimetindene is a sedating antihistamine indicated for the symptomatic treatment of allergic conditions. Dimetindene is marketed among others under the trade name Fenistil (oral solution). Toxicity data are limited, and there is no consensus on the dose at which children require hospitalization. Objective is to determine the potentially toxic dose in children. Data in children with age up to 15\\u2009years were obtained from hospital discharge reports. Of 139 paediatric hospital discharge reports, 23 cases (16.5%) were excluded because of uncertain ingestion. In 116 children (46 boys and 70 girls, mean age 2\\xa0years and 9\\xa0months\\u2009±\\u20091\\xa0year and 1\\xa0month), the majority of children developed no symptoms (87 children, 75%, mean age 3\\xa0years±1\\xa0year) and the remaining 29 children (25%, mean age 2\\xa0years and 11\\u2009months\\u2009±\\u20091\\xa0year and 3\\xa0months) developed only mild and spontaneously resolving symptoms of poisoning after a dose of 0.82\\u2009±\\u20090.32\\u2009mg/kg b.w. (range 0.26-1.82\\u2009mg/kg). In 98% of all cases, hospitalized children were observed for a maximum 24\\u2009h, and their condition did not require specific treatment. In conclusion, the prognosis for accidental dimetindene poisoning in children appears to be good and the minimum toxic dose has been determined to be 0.5\\xa0mg/kg b.w.'], 'CopyrightInformation': '© 2024 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Toxicological Information Center, Department of Occupational Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.'}, {'Identifier': [], 'Affiliation': 'Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.'}], 'Identifier': [StringElement('0000-0001-7647-4120', attributes={'Source': 'ORCID'})], 'LastName': 'Čečrle', 'ForeName': 'Michal', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Toxicological Information Center, Department of Occupational Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.'}], 'Identifier': [], 'LastName': 'Pelclová', 'ForeName': 'Daniela', 'Initials': 'D'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'J. Heyrovsky Institute of Physical Chemistry of the Czech Academy of Sciences, Prague, Czech Republic.'}], 'Identifier': [], 'LastName': 'Tomáš', 'ForeName': 'Navrátil', 'Initials': 'N'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Toxicological Information Center, Department of Occupational Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.'}], 'Identifier': [], 'LastName': 'Zacharov', 'ForeName': 'Sergej', 'Initials': 'S'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': '207041-3', 'Agency': 'COOPERATIO Pharmacology', 'Country': ''}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'})\n",
            "DictElement({'ArticleDate': [], 'ELocationID': [StringElement('10.1002/bio.4728', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1522-7243', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '39', 'Issue': '3', 'PubDate': {'Year': '2024', 'Month': 'Mar'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Luminescence : the journal of biological and chemical luminescence', 'ISOAbbreviation': 'Luminescence'}, 'ArticleTitle': 'A novel green spectrofluorimetric method for simultaneous determination of antazoline and tetryzoline in their ophthalmic formulation.', 'Pagination': {'StartPage': 'e4728', 'MedlinePgn': 'e4728'}, 'Abstract': {'AbstractText': ['A novel spectrofluorimetric method has been developed for determination of antazoline (ANT) and tetryzoline (TET) in their pharmaceutical formulation. A combined application of synchronous spectrofluorimetry and second derivative mathematical treatment was developed. The proposed method depends on reacting the cited drugs with dansyl chloride (DNS-Cl) being a suitable derivatizing agent generating highly fluorescent derivatives measured at emission wavelengths of 703.0 and 642.0\\xa0nm after excitation wavelengths of 350.0 and 320.0\\xa0nm for ANT and TET, respectively. The joint use of synchronous spectrofluorimetry with second derivative mathematical treatment is for the first time to be developed and optimized in aid of using fluorescence data manager software generating second derivative peak amplitudes at 556.5\\xa0nm for ANT and 516.7\\xa0nm for TET. Linear responses have been represented over a wide range of concentration (0.5-12.0\\xa0μg/mL for ANT and 0.5-10.0\\xa0μg/mL for TET). Additionally, statistical comparison of the developed method with the official ones has been carried out where no significant difference was found. Additionally, greenness profile assessment was accomplished by means of four metric tools. Indeed, the method developed is found to be precise, sensitive, and discriminating to assess the cited drugs for regular analysis.'], 'CopyrightInformation': '© 2024 John Wiley & Sons Ltd.'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Future University in Egypt, Cairo, 11835, Egypt.'}], 'Identifier': [StringElement('0000-0003-1947-9843', attributes={'Source': 'ORCID'})], 'LastName': 'Hussein', 'ForeName': 'Ola G', 'Initials': 'OG'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Future University in Egypt, Cairo, 11835, Egypt.'}], 'Identifier': [], 'LastName': 'Ahmed', 'ForeName': 'Dina A', 'Initials': 'DA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}], 'Identifier': [], 'LastName': 'Abdelkawy', 'ForeName': 'Mohamed', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}], 'Identifier': [], 'LastName': 'Rezk', 'ForeName': 'Mamdouh R', 'Initials': 'MR'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}], 'Identifier': [StringElement('0000-0002-3075-6197', attributes={'Source': 'ORCID'})], 'LastName': 'Rostom', 'ForeName': 'Yasmin', 'Initials': 'Y'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '21'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1097/01.NAJ.0001010556.28403.79', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1538-7488', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '124', 'Issue': '4', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '01'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The American journal of nursing', 'ISOAbbreviation': 'Am J Nurs'}, 'ArticleTitle': 'Stronger Warnings for Promethazine Hydrochloride Injection.', 'Pagination': {'StartPage': '22', 'MedlinePgn': '22'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .'}], 'Identifier': [], 'LastName': 'Aschenbrenner', 'ForeName': 'Diane S', 'Initials': 'DS'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '20'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1080/09546634.2024.2329784', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1471-1753', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '35', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Dec'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'The Journal of dermatological treatment', 'ISOAbbreviation': 'J Dermatolog Treat'}, 'ArticleTitle': 'UCOMB-real life data: treatment strategies for chronic urticaria patients with comorbidities.', 'Pagination': {'StartPage': '2329784', 'MedlinePgn': '2329784'}, 'Abstract': {'AbstractText': [StringElement('There is a lack of real-life safety data on treatment options for chronic urticaria in the presence of comedication and comorbidities.', attributes={'Label': 'BACKGROUND', 'NlmCategory': 'UNASSIGNED'}), StringElement('We present a single-center UCARE pilot study of 212 outpatients with chronic urticaria. Patients were divided into three groups according to different CU therapies according to international guidelines.', attributes={'Label': 'METHODS', 'NlmCategory': 'UNASSIGNED'}), StringElement('Of 212 patients, 108 (mean age 48.9\\u2009years, 71.3% female) had 59 comorbidities, including cardiovascular, autoimmune and malignant diseases. Patients were followed for a mean of 24.6\\u2009months (SD ± 21.3). Urticaria therapies were divided into three groups: A: 105 (97.2%) with omalizumab and 2nd generation antihistamines), B: 16 patients (14.8%): dual therapy with antihistamines and cyclosporine in 10 (9.3%), montelukast in five (4. 6%), dapsone in four (3.7%), hydroxychloroquine in one patient (0.9%), C: 12 (11.1%) patients received a third drug for 4.9\\u2009months (SD ± 3.2) and one quadruple therapy (2.1\\u2009months). 10 out of 12 (83.3%) patients received montelukast, two (16.7%) cyclosporine, two (16.7%) dapsone and one (8.3%) hydroxychloroquine as a third drug for chronic urticaria.', attributes={'Label': 'RESULTS', 'NlmCategory': 'UNASSIGNED'}), StringElement('Combining treatment modalities for chronic urticaria and comorbidities are available and feasible with a good safety profile.', attributes={'Label': 'CONCLUSIONS', 'NlmCategory': 'UNASSIGNED'})]}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.'}], 'Identifier': [], 'LastName': 'Staubach', 'ForeName': 'Petra', 'Initials': 'P'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.'}], 'Identifier': [], 'LastName': 'Bilo', 'ForeName': 'Benedikt', 'Initials': 'B'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology IFA, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'Identifier': [], 'Affiliation': 'Fraunhofer Insitute for Translational Medicine and Pharmacology, ITMP Berlin, Immunology and Allergology IA, Berlin, Germany.'}], 'Identifier': [], 'LastName': 'Fluhr', 'ForeName': 'Joachim W', 'Initials': 'JW'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology IFA, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'Identifier': [], 'Affiliation': 'Fraunhofer Insitute for Translational Medicine and Pharmacology, ITMP Berlin, Immunology and Allergology IA, Berlin, Germany.'}], 'Identifier': [], 'LastName': 'Krause', 'ForeName': 'Karoline', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}], 'Identifier': [], 'LastName': 'Kulthanan', 'ForeName': 'Kanokvalai', 'Initials': 'K'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, Acıbadem University School of Medicine, Istanbul, Turkey.'}], 'Identifier': [], 'LastName': 'Salman', 'ForeName': 'Andac', 'Initials': 'A'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Medicine, Campbelltown Hospital and Western Sydney University Sydney, Campbelltown, Australia.'}], 'Identifier': [], 'LastName': 'Katelaris', 'ForeName': 'Connie', 'Initials': 'C'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Division of Rheumatology, Allergy and Immunology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.'}], 'Identifier': [], 'LastName': 'Bernstein', 'ForeName': 'Jonathan A', 'Initials': 'JA'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology IFA, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'Identifier': [], 'Affiliation': 'Fraunhofer Insitute for Translational Medicine and Pharmacology, ITMP Berlin, Immunology and Allergology IA, Berlin, Germany.'}], 'Identifier': [], 'LastName': 'Maurer', 'ForeName': 'Marcus', 'Initials': 'M'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.'}], 'Identifier': [StringElement('0000-0001-7044-2216', attributes={'Source': 'ORCID'})], 'LastName': 'Mann', 'ForeName': 'Caroline', 'Initials': 'C'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2023', 'Month': '12', 'Day': '31'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.29262/ram.v70i4.1340', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['spa'], 'Journal': {'ISSN': StringElement('2448-9190', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '70', 'Issue': '4', 'PubDate': {'Year': '2023', 'Month': 'Dec', 'Day': '31'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)', 'ISOAbbreviation': 'Rev Alerg Mex'}, 'ArticleTitle': '[Application of biologicals in patients with food allergies].', 'Pagination': {'StartPage': '297', 'EndPage': '299', 'MedlinePgn': '297-299'}, 'Abstract': {'AbstractText': ['Despite promising advancements in oral immunotherapy for food allergies, medical implementation faces limitations. Non-specific treatment options based on inhibiting the type 2 inflammatory pathway, including monoclonal antibodies, are under investigation. TNX-901 and omalizumab have demonstrated increased reaction thresholds, reducing adverse events in peanut-allergic patients. Dupilumab, blocking the IL-4 receptor, shows positive results in both food allergies and eosinophilic esophagitis. Antibodies against alarmins and anti-IL-5, such as etokimab and mepolizumab, have proven efficacy in preclinical studies and clinical trials. While further studies are needed to establish their practical clinical use and determine suitability for different types of food allergies, these monoclonal antibodies present a promising horizon for the treatment of such conditions.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Inmunóloga, adscrita a la Clínica Indisa, Santiago de Chile.todoasma@gmail.com.'}], 'Identifier': [StringElement('0009-0003-8058-8587', attributes={'Source': 'ORCID'})], 'LastName': 'Agar Muñoz', 'ForeName': 'Ana María', 'Initials': 'AM'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Médico Asistente, Alergólogo e Inmunólogo Clínico, Clínica Internacional Lima-Peru; Director Médico en Emedic Salud, Lima, Perú.'}], 'Identifier': [StringElement('0000-0003-3517-305', attributes={'Source': 'ORCID'})], 'LastName': 'Galván Calle', 'ForeName': 'César Alberto', 'Initials': 'CA'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('English Abstract', attributes={'UI': 'D004740'}), StringElement('Journal Article', attributes={'UI': 'D016428'})], 'VernacularTitle': 'Aplicación de biológicos en pacientes con alergia alimentaria.'}, attributes={'PubModel': 'Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2023', 'Month': '12', 'Day': '31'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.29262/ram.v70i4.1308', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['spa'], 'Journal': {'ISSN': StringElement('2448-9190', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '70', 'Issue': '4', 'PubDate': {'Year': '2023', 'Month': 'Dec', 'Day': '31'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)', 'ISOAbbreviation': 'Rev Alerg Mex'}, 'ArticleTitle': '[Introduction to food allergy].', 'Pagination': {'StartPage': '208', 'EndPage': '210', 'MedlinePgn': '208-210'}, 'Abstract': {'AbstractText': ['Food allergy is a common chronic disorder that affects infants, children, adolescents, and adults. The prevalence of food allergy has increased in recent decades throughout the world, not limited to Western countries. Since there is no treatment, this focuses on avoiding allergens, in addition to educating patients and caregivers in the emergency treatment of acute reactions, for example: application of epinephrine. Studies suggest that accidental reactions occur in about 45% of children with food allergies each year, although most reactions are mild or moderate in severity. Hospital admissions for food anaphylaxis vary from 4 to 20 per 100,000 inhabitants; Deaths are rare, with an estimated incidence of 0.03 to 0.3 per million people with food allergy. Death from food anaphylaxis is rare and appears to have remained stable, possibly due to increases in food allergen labeling, diagnostic services, rates of intramuscular epinephrine prescription, and awareness of food allergies. Omalizumab is a drug approved for several disorders (chronic hives or difficult asthma) and may help reduce symptoms associated with food allergy. The relative importance of alternative technologies, management strategies and policies for food allergy varies from one region to another, due to differences in the epidemiology, education, socioeconomic well-being, and cultural preferences of the population.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Director Médico Ejecutivo, Expresidente de la Organización Mundial de Alergia (WAO). Jefe del Departamento de Alergia e Inmunología, Hospital Quironsalud, Bizkaia, Bilbao, España.todoasma@gmail.com.'}], 'Identifier': [StringElement('00000-0002-6942-1511', attributes={'Source': 'ORCID'})], 'LastName': 'Ansotegui Zubeldia', 'ForeName': 'Ignacio Javier', 'Initials': 'IJ'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Director responsable de la S.C. de Pediatría, Hospital Materno Infantil Macedonio Melloni, Milán, Italia. Director del Departamento Materno Infantil, Hospital Fatebenefratelli-Ophthalmic de Milán, Italia. Profesor adjunto de la Escuela de Es-pecialización en Pediatría III, Universidad de Milán y Consejero de la Sociedad Italiana de Pediatría, Sección Lombarda. Pediatric Hospital Bambino Gesú IRCCS Allergy division, Roma, Italia.'}], 'Identifier': [StringElement('0000-0002-2549-0523', attributes={'Source': 'ORCID'})], 'LastName': 'Fiocchi', 'ForeName': 'Alessandro', 'Initials': 'A'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('English Abstract', attributes={'UI': 'D004740'}), StringElement('Journal Article', attributes={'UI': 'D016428'})], 'VernacularTitle': 'Introducción en alergia alimentaria.'}, attributes={'PubModel': 'Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '20'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('189', attributes={'EIdType': 'pii', 'ValidYN': 'Y'}), StringElement('10.1186/s40001-024-01793-9', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('2047-783X', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '29', 'Issue': '1', 'PubDate': {'Year': '2024', 'Month': 'Mar', 'Day': '20'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'European journal of medical research', 'ISOAbbreviation': 'Eur J Med Res'}, 'ArticleTitle': 'Antibiotic exposure during pregnancy increases risk for childhood atopic diseases: a nationwide cohort study.', 'Pagination': {'StartPage': '189', 'MedlinePgn': '189'}, 'Abstract': {'AbstractText': [StringElement('The prevalence of atopic diseases has increased in recent decades. A possible link between antibiotic use during pregnancy and childhood atopic disease has been proposed. The aim of this study is to explore the association of antibiotic exposure during pregnancy with childhood atopic diseases from a nationwide, population-based perspective.', attributes={'Label': 'PURPOSE', 'NlmCategory': 'OBJECTIVE'}), StringElement(\"This was a nationwide population-based cohort study. Taiwan's National Health Insurance Research Database was the main source of data. The pairing of mothers and children was achieved by linking the NHIRD with the Taiwan Maternal and Child Health Database. This study enrolled the first-time pregnancies from 2004 to 2010. Infants of multiple delivery, preterm delivery, and death before 5\\xa0years old were excluded. All participants were followed up at least for 5\\xa0years. Antenatal antibiotics prescribed to mothers during the pregnancy period were reviewed. Children with more than\\xa0two outpatient visits, or one admission, with a main\\xa0diagnosis of asthma, allergic rhinitis, or atopic dermatitis were regarded as having an atopic disease.\", attributes={'Label': 'METHODS', 'NlmCategory': 'METHODS'}), StringElement('A total of 900,584 children were enrolled in this study. The adjusted hazard ratios of antibiotic exposure during pregnancy to childhood atopic diseases were 1.12 for atopic dermatitis, 1.06 for asthma, and 1.08 for allergic rhinitis, all of which reached statistical significance. The trimester effect was not significant. There was a trend showing the higher the number of times a child was prenatally exposed to antibiotics, the higher the hazard ratio was for childhood atopic diseases.', attributes={'Label': 'RESULTS', 'NlmCategory': 'RESULTS'}), StringElement('Prenatal antibiotic exposure might increase the risk of childhood atopic diseases in a dose-dependent manner.', attributes={'Label': 'CONCLUSIONS', 'NlmCategory': 'CONCLUSIONS'})], 'CopyrightInformation': '© 2024. The Author(s).'}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Pediatrics, Show Chwan Memorial Hospital, Changhua, Taiwan.'}], 'Identifier': [], 'LastName': 'Tai', 'ForeName': 'Sheng-Kang', 'Initials': 'SK'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Children's Medical Center, Taichung Veterans General Hospital, Taichung, Taiwan.\"}, {'Identifier': [], 'Affiliation': 'Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.'}, {'Identifier': [], 'Affiliation': 'School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.'}], 'Identifier': [], 'LastName': 'Lin', 'ForeName': 'Yi-Hsuan', 'Initials': 'YH'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'Department of Medical Research, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sec. 4, Taichung, 40705, Taiwan.'}], 'Identifier': [], 'LastName': 'Lin', 'ForeName': 'Ching-Heng', 'Initials': 'CH'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': \"Children's Medical Center, Taichung Veterans General Hospital, Taichung, Taiwan. mingclin@gmail.com.\"}, {'Identifier': [], 'Affiliation': 'Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan. mingclin@gmail.com.'}, {'Identifier': [], 'Affiliation': 'School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. mingclin@gmail.com.'}, {'Identifier': [], 'Affiliation': 'Department of Food and Nutrition, Providence University, Taichung, Taiwan. mingclin@gmail.com.'}, {'Identifier': [], 'Affiliation': 'School of Medicine, Chung Shan Medical University, Taichung, Taiwan. mingclin@gmail.com.'}], 'Identifier': [], 'LastName': 'Lin', 'ForeName': 'Ming-Chih', 'Initials': 'MC'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'GrantList': ListElement([{'GrantID': 'TCVGH-1116503C', 'Agency': 'Taichung Veterans General Hospital Reserach Fund', 'Country': ''}, {'GrantID': 'TCVGH-1107309D', 'Agency': 'Taichung Veterans General Hospital Reserach Fund', 'Country': ''}, {'GrantID': 'FCU1118025', 'Agency': 'Taichung Veterans General Hospital Reserach Fund', 'Country': ''}], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Electronic'})\n",
            "DictElement({'ArticleDate': [DictElement({'Year': '2024', 'Month': '03', 'Day': '18'}, attributes={'DateType': 'Electronic'})], 'ELocationID': [StringElement('10.1021/acsnano.3c06001', attributes={'EIdType': 'doi', 'ValidYN': 'Y'})], 'Language': ['eng'], 'Journal': {'ISSN': StringElement('1936-086X', attributes={'IssnType': 'Electronic'}), 'JournalIssue': DictElement({'Volume': '18', 'Issue': '13', 'PubDate': {'Year': '2024', 'Month': 'Apr', 'Day': '02'}}, attributes={'CitedMedium': 'Internet'}), 'Title': 'ACS nano', 'ISOAbbreviation': 'ACS Nano'}, 'ArticleTitle': 'Nanomodulator-Mediated Restructuring of Adipose Tissue Immune Microenvironments for Antiobesity Treatment.', 'Pagination': {'StartPage': '9311', 'EndPage': '9330', 'MedlinePgn': '9311-9330'}, 'Abstract': {'AbstractText': ['In obesity, the interactions between proinflammatory macrophages and adipocytes in white adipose tissues are known to play a crucial role in disease progression by providing inflammatory microenvironments. Here, we report that the functional nanoparticle-mediated modulation of crosstalk between adipocytes and macrophages can remodel adipocyte immune microenvironments. As a functional nanomodulator, we designed antivascular cell adhesion molecule (VCAM)-1 antibody-conjugated and amlexanox-loaded polydopamine nanoparticles (VAPN). Amlexanox was used as a model drug to increase energy expenditure. Compared to nanoparticles lacking antibody modification or amlexanox, VAPN showed significantly greater binding to VCAM-1-expressing adipocytes and lowered the interaction of adipocytes with macrophages. In high fat diet-fed mice, repeated subcutaneous administration of VAPN increased the populations of beige adipocytes and ameliorated inflammation in white adipose tissues. Moreover, the localized application of VAPN <i>in vivo</i> exerted a systemic metabolic effect and reduced metabolic disorders, including insulin tolerance and liver steatosis. These findings suggested that VAPN had potential to modulate the immune microenvironments of adipose tissues for the immunologic treatment of obesity. Although we used amlexanox as a model drug and anti-VCAM-1 antibody in VAPN, the concept of immune nanomodulators can be widely applied to the immunological treatment of obesity.']}, 'AuthorList': ListElement([DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.'}], 'Identifier': [], 'LastName': 'Li', 'ForeName': 'Qiaoyun', 'Initials': 'Q'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.'}], 'Identifier': [], 'LastName': 'Byun', 'ForeName': 'Junho', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.'}], 'Identifier': [], 'LastName': 'Choi', 'ForeName': 'Jaehyun', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.'}], 'Identifier': [], 'LastName': 'Park', 'ForeName': 'Jinwon', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.'}], 'Identifier': [], 'LastName': 'Lee', 'ForeName': 'Jaiwoo', 'Initials': 'J'}, attributes={'ValidYN': 'Y'}), DictElement({'AffiliationInfo': [{'Identifier': [], 'Affiliation': 'College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.'}], 'Identifier': [StringElement('0000-0002-0969-3339', attributes={'Source': 'ORCID'})], 'LastName': 'Oh', 'ForeName': 'Yu-Kyoung', 'Initials': 'YK'}, attributes={'ValidYN': 'Y'})], attributes={'CompleteYN': 'Y'}), 'PublicationTypeList': [StringElement('Journal Article', attributes={'UI': 'D016428'})]}, attributes={'PubModel': 'Print-Electronic'})\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "for article in xml_data['PubmedArticle']:\n",
        "    abstract_text = \"\"\n",
        "    try:\n",
        "        abstract_text = article['MedlineCitation']['Article']['Abstract']['AbstractText']\n",
        "        if isinstance(abstract_text, list):\n",
        "            for text in abstract_text:\n",
        "                print(text)\n",
        "        else:\n",
        "            print(abstract_text)\n",
        "    except KeyError:\n",
        "        print(\"Abstract not found for this article.\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Rz9U4mPaqMJc",
        "outputId": "99c45b6b-38a0-4b85-ae01-9921b428dc38"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Recurrences occur when corticosteroid therapy is discontinued or reduced during the treatment of chronic eosinophilic pneumonia (CEP). The probability of recurrence is once in 50% of patients and twice or more in 25%. In such instances, new treatment options are deemed necessary. This study aims to assess the efficacy of omalizumab treatment as a steroid-sparing drug in patients with CEP.\n",
            "The clinical features of patients treated with omalizumab for recurrent CEP were evaluated retrospectively before and after treatment. All data from patients and diagnoses were reviewed. The effects of treatment on recurrence rate, oral corticosteroid (OCS) use and lung functions, peripheral eosinophil values, and symptom scores were evaluated. Radiological regression was also evaluated.\n",
            "In the final analysis, we included ten patients with a median follow-up of 22 months after initiation of omalizumab. During this follow-up period, the results were associated with a significant reduction in the number of asthma attacks per year, the number of CEP relapses, the rate of hospitalization, the amount of corticosteroids consumed daily, and the total corticosteroid dose. In addition, improvement was observed in the symptom scores and lung functions of the patients. Systemic steroids were completely discontinued in two patients receiving omalizumab treatment. In other patients, the mean steroid dose was reduced by 77.2 percent in the first year of omalizumab treatment and 82 percent in the second year, respectively. Nevertheless, there was no elevation in peripheral eosinophil count, and radiological regression was observed.\n",
            "Omalizumab can be an effective treatment for CEP and can be used as a steroid-sparing agent.\n",
            "Asthma is a disease characterised by heterogeneous and multifaceted airway inflammation. Despite the availability of effective treatments, a substantial percentage of patients with the type 2 (T2)-high, but mainly the T2-low, phenotype complain of persistent symptoms, airflow limitation, and poor response to treatments. Currently available biologicals target T2 cytokines, but no monoclonal antibodies or other specific therapeutic options are available for non-T2 asthma. However, targeted therapy against alarmins is radically changing this perspective. The development of alarmin-targeted therapies, of which tezepelumab (TZP) is the first example, may offer broad action on inflammatory pathways as well as an enhanced therapeutic effect on epithelial dysfunction. In this regard, TZP demonstrated positive results not only in patients with severe T2 asthma but also those with non-allergic, non-eosinophilic disease. Therefore, it is necessary to identify clinical features of patients who can benefit from an upstream targeted therapy such as anti-thymic stromal lymphopoietin. The aims of this narrative review are to understand the role of alarmins in asthma pathogenesis and epithelial dysfunction, examine the rationale underlying the indication of TZP treatment in severe asthma, summarise the results of clinical studies, and recognise the specific characteristics of patients potentially eligible for TZP treatment.\n",
            "<i>Background:</i> Ocrelizumab is an effective medication for multiple sclerosis. However, infusion-related reactions (IRRs) are a concern for patients and may lead to discontinuation of ocrelizumab. To minimize IRRs, pre-medications are administered. However, from our experience, these medications, especially diphenhydramine, can cause marked drowsiness. The primary objective of this study was to evaluate whether cetirizine is non-inferior to diphenhydramine in limiting the proportion and severity of reactions from ocrelizumab infusions. <i>Methods:</i> Twenty participants were serially randomized in a 1:1 ratio to receive 10 mg of cetirizine or 25 mg of diphenhydramine orally prior to their first three ocrelizumab infusions. <i>Results:</i> The rate of IRRs in this study was similar across both treatment groups with no increase in the risk of severity, and no grade 3 IRRs. Further, patients receiving cetirizine experienced a reduction in fatigue. While there was not a significant difference in global satisfaction, this score increased over time in the cetirizine arm while it remained unchanged in the diphenhydramine arm. <i>Conclusions:</i> Overall, our results suggest that cetirizine does not increase the risk of infusion-related reactions compared to diphenhydramine.\n",
            "Saracatinib (AZD0530) is a dual Src/Abl inhibitor initially developed by AstraZeneca for cancer treatment; however, data from 2006 to 2024 reveal that this drug has been tested not only for cancer treatment, but also for the treatment of other diseases. Despite the promising pre-clinical results and the tolerability shown in phase I trials, where a maximum tolerated dose of 175 mg was defined, phase II clinical data demonstrated a low therapeutic action against several cancers and an elevated rate of adverse effects. Recently, pre-clinical research aimed at reducing the toxic effects and enhancing the therapeutic performance of saracatinib using nanoparticles and different pharmacological combinations has shown promising results. Concomitantly, saracatinib was repurposed to treat Alzheimer's disease, targeting Fyn. It showed great clinical results and required a lower daily dose than that defined for cancer treatment, 125 mg and 175 mg, respectively. In addition to Alzheimer's disease, this Src inhibitor has also been studied in relation to other health conditions such as pulmonary and liver fibrosis and even for analgesic and anti-allergic functions. Although saracatinib is still not approved by the Food and Drug Administration (FDA), the large number of alternative uses for saracatinib and the elevated number of pre-clinical and clinical trials performed suggest the huge potential of this drug for the treatment of different kinds of diseases.\n",
            "Advair Diskus is an essential treatment for asthma and chronic obstructive pulmonary disease. It is a dry powder inhaler with a combination of fluticasone propionate (FP) and salmeterol xinafoate (SX). However, the pharmacokinetics (PK) batch-to-batch variability of the reference-listed drug (RLD) hindered its generic product development. This work developed the PK models for inhaled FP and SX that could represent potential batch variability. Two batches each of the reference and the test product (R<sub>1</sub>, R<sub>2</sub>, T<sub>1</sub>, T<sub>2</sub>) of Advair Diskus (100 μg FP/50 μg SX inhalation) were administered to 60 healthy subjects in a 4-period, 4-sequence crossover study. The failure of the bioequivalence (BE) between R<sub>1</sub> and R<sub>2</sub> confirmed the high between-batch variability of the RLD. Non-linear mixed effect modeling was used to estimate the population mean PK parameters for each batch. For FP, a 2-compartment model with a sequential dual zero-order absorption best described the PK profile. For SX, a 2-compartment model with a first-order absorption model best fit the data. Both models were able to capture the plasma concentration, the maximum concentration, and the total exposure (AUC<sub>inf</sub>) adequately for each batch, which could be used to simulate the BE study in the future. In vitro properties were also measured for each batch, and the batch with a higher fraction of the fine particle (diameter < 1 µm, < 2 µm) had a higher AUC<sub>inf</sub>. This positive correlation for both FP and SX could potentially assist the batch selection for the PK BE study.\n",
            "Allergic conjunctivitis (AC) is the most common form of allergic eye disease and an increasingly prevalent condition. Topical eye drop treatments are the usual approach for managing AC, although their impact on the ocular surface is not frequently investigated. The aim of this study was to perform a comparative physicochemical characterization, and in vitro biological evaluations in primary conjunctival and corneal epithelial cells of the new multidose preservative-free bilastine 0.6% and main commercially available eye drops. MTT assay was used to measure cell viability; oxidative stress was analyzed with a ROS-sensitive probe; and apoptosis was evaluated monitoring caspase 3/7 activation. Differences in pH value, osmolarity, viscosity and phosphate levels were identified. Among all formulations, bilastine exhibited pH, osmolarity and viscosity values closer to tear film (7.4, 300 mOsm/l and ~ 1.5-10 mPa·s, respectively), and was the only phosphates-free solution. Single-dose ketotifen did not induce ROS production, and single-dose azelastine and bilastine only induced a mild increase. Bilastine and single-dose ketotifen and azelastine showed high survival rates attributable to the absence of preservative in its formulation, not inducing caspase-3/7-mediated apoptosis after 24 h. Our findings support the use of the new bilastine 0.6% for treating patients with AC to preserve and maintain the integrity of the ocular surface.\n",
            "Allergic asthma is an important respiratory system problem characterized by airway inflammation, breathlessness, and bronchoconstriction. Allergic asthma and its outcomes are triggered by type 2 allergic immune responses. Tectorigenin is a methoxy-isoflavone with anti-inflammatory effects. In this study, we investigated the effects of tectorigenin on the pathophysiology of allergic asthma in an animal model.\n",
            "Asthmatic mice were treated with tectorigenin. Then airway hyperresponsiveness (AHR), eosinophil percentage, levels of interleukin (IL)-33, IL-25, IL-13, IL-5, IL-4, total and ovalbumin (OVA)-specific immunoglobulin (Ig)E, and lung histopathology were evaluated.\n",
            "Tectorigenin significantly (P 〈 0.05) reduced eosinophil infiltration (41 ± 7%) in the broncho-alveolar lavage fluid (BALF), serum IL-5 level (41 ± 5, pg/mL), and bronchial and vascular inflammation (scores of 1.3 ± 0.2 and 1.1 ± 0.3, respectively) but had no significant effects on AHR, serum levels of IL-33, -25, -13, and -4 (403 ± 24, 56 ± 7, 154 ± 11, and 89 ± 6 pg/mL, respectively), total and OVA-specific IgE (2684 ± 265 and 264 ± 19 ng/mL, respectively), goblet cell hyperplasia, and mucus production.\n",
            "Tectorigenin could control inflammation and the secretion of inflammatory mediators of asthma, so it can be regarded as a potential antiasthma treatment with the ability to control eosinophilia-related problems.\n",
            "Abstract not found for this article.\n",
            "Two isoforms of Phosphoinositide 3-kinase (PI3K), p110γ and p110δ, are predominantly expressed in leukocytes and represent attractive therapeutic targets for the treatment of allergic asthma. The study aim was to assess the impact of administration of an inhaled PI3Kγδ inhibitor (AZD8154) in a rat model of asthma.\n",
            "Firstly, we checked that the tool compound, AZD8154, inhibited rat PI3K γ & δ kinases using rat cell-based assays. Subsequently, a time-course study was conducted in a rat model of asthma to assess PI3K activity in the lung and how it is temporally associated with other key transcription pathways and asthma like features of the model. Finally, the impact on lung dosed AZD8154 on target engagement, pathway specificity, airway inflammation and lung function changes was assessed.\n",
            "Data showed that AZD8154 could inhibit rat PI3K γ & δ isoforms and, in a rat model of allergic asthma the PI3K pathway was activated in the lung. Intratracheal administration of AZD8154 caused a dose related suppression PI3K pathway activation (reduction in pAkt) and unlike after budesonide treatment, STAT and NF-κB pathways were not affected by AZD8154. The suppression of the PI3K pathway led to a marked inhibition of airway inflammation and reduction in changes in lung function.\n",
            "These data show that a dual PI3Kγδ inhibitor suppress key features of disease in a rat model of asthma to a similar degree as budesonide and indicate that dual PI3Kγδ inhibition may be an effective treatment for people suffering from allergic asthma.\n",
            "To evaluate the effect of antibacterial prophylaxis using oral fosfomycin during the removal of a urethral catheter after radical prostatectomy on the development of urinary tract infection, severity of leukocyturia and bacteriuria, as well as the severity of lower urinary tract symptoms.\n",
            "A single-center, non-blind, prospective, randomized controlled trial was carried out. The main group included 40 patients, and the control group included 37 patients. In the group 1, patients received two doses of oral fosfomycin, 3 g, namely in the evening on the day of catheter removal (the first dose) and 48 hours after catheter removal (the second dose). In the group 2, patients did not receive any antibacterial prophylaxis after urethral catheter removal. The endpoints of the study were confirmed episodes of urinary tract infection within 1 month after removal of the urethral catheter, leukocyturia and bacteriuria in urinalysis/urine culture) and severity of the lower urinary tract symptoms assessed by IPSS questionnaire.\n",
            "In the group 2, urinary tract infection was noted in 17.1%, while in the group 2 only in 2.6% of patients (p=0.032). Leukocyturia and bacteriuria were significantly less common in the group receiving antibacterial prophylaxis with fosfomycin (18.4% vs. 48.6%, respectively; p=0.006). Positive urine culture was observed in 7.9% vs. 25.7%, respectively (p=0.035). Four weeks after removal of the urethral catheter, the average IPSS score was significantly higher in the group 2 (13.2 vs. 9.5 points; p=0.002). There were no cases of allergic reaction and pseudomembranous colitis associated with C. difficile in both groups. Diarrhea cured with sorbents was noted in 2 patients (5.2%) in fosfomycin group.\n",
            "Antibacterial prophylaxis using two oral doses of fosfomycin 3 g on the day of urethral catheter removal and 48 hours after catheter removal after radical prostatectomy appears to be an effective scheme that reduces the incidence of urinary tract infection and the severity of lower urinary tract symptoms, and is characterized by a minimal risk of adverse events. It is necessary to carried out further research and develop clear recommendations for antibacterial prevention in urological interventions requiring prolonged urethral catheterization.\n",
            "Mast cells have long been recognized for their involvement in allergic pathology through the immunoglobulin E (IgE)-mediated degranulation mechanism. However, there is growing evidence of other \"non-canonical\" degranulation mechanisms activated by certain pathogen recognition receptors. Mast cells release several mediators, including histamine, cytokines, chemokines, prostaglandins, and leukotrienes, to initiate and enhance inflammation. The chemical nature of activating stimuli influences receptors, triggering mechanisms for the secretion of formed and new synthesized mediators. Mast cells have more than 30 known surface receptors that activate different pathways for direct and indirect activation by microbes. Different bacterial strains stimulate mast cells through various ligands, initiating the innate immune response, which aids in clearing the bacterial burden. Mast cell interactions with adaptative immune cells also play a crucial role in infections. Recent publications revealed another \"non-canonical\" degranulation mechanism present in tryptase and chymase mast cells in humans and connective tissue mast cells in mice, occurring through the activation of the Mas-related G protein-coupled receptor (MRGPRX2/b2). This receptor represents a new therapeutic target alongside antibiotic therapy. There is an urgent need to reconsider and redefine the biological role of these MASTer cells of innate immunity, extending beyond their involvement in allergic pathology.\n",
            "Inhalation of pharmaceutical aerosol formulations is widely used to treat respiratory diseases. Spatially resolved thermal characterization offers promise for better understanding drug release rates from particles; however, this has been an analytical challenge due to the small particle size (from a few micrometers down to nanometers) and the complex composition of the formulations. Here, we employ nano-thermal analysis (nanoTA) to probe the nanothermal domain of a pharmaceutical aerosol formulation containing a mixture of fluticasone propionate (FP), salmeterol xinafoate (SX), and excipient lactose, which is widely used to treat asthma and chronic obstructive pulmonary disease (COPD). Furthermore, atomic force microscopy-infrared spectroscopy (AFM-IR) and AFM force measurements are performed to provide nanochemical and nanomechanical information to complement the nanothermal data. The colocalized thermal and chemical mapping clearly reveals the surface heterogeneity of the drugs in the aerosol particles and demonstrates the contribution of the surface chemical composition to the variation in the thermal properties of the particles. We present a powerful analytical approach for in-depth characterization of thermal/chemical/morphological properties of dry powder inhaler particles at micro- and nanometer scales. This approach can be used to facilitate the comparison between generics and reference inhalation products and further the development of high-performance pharmaceutical formulations.\n",
            "Fexofenadine is a newly introduced oral non-sedating agent used for allergic diseases. We sought to investigate the effects of the use of fexofenadine on the salivary gland of adult male albino rats. 30 adult male albino rats were classified randomly into 3 groups, as follows: Group A (control group) which consisted of 10 healthy rats. Group B (treated group) which consisted of 10 rats received FEX 5mg/kg/day, and Group C (treated group) which consisted of 10 rats received FEX 10mg/kg/day. Blood samples were obtained to assess serum levels of Thioredoxin reductase (TRX) and malondialdehyde (MDA). Salivary glands were removed and prepared for histological examination. This study showed that significantly (p<0.05) higher TRX and MDA levels were observed in group B and group C, compared to group A. The histological examination for salivary tissues revealed degenerative changes in serous cells of acini were present with deep pyknotic nuclei. Vacuolar cytoplasmic degeneration is also seen in other certain cells. Blood congestion was present in the intralobular blood vessels, particularly around the striated ducts. The glandular secretion duct contained mucus and serous secretion and the wall of the duct was surrounded by many WBCs with macrophage. Fexofenadine hydrochloride use induces remarkable histopathological changes with dose-dependent response and remarkably linked to elevation of oxidative stress markers.\n",
            "Serotonin syndrome is a potentially life-threatening condition resulting from the use of antidepressants, their interactions with other serotonergic medications, or poisoning. It presents with a triad of psychiatric, dysautonomic, and neurological symptoms and is sometimes fatal. While cyproheptadine is a specific treatment option, the optimal duration of its administration remains unclear. The purpose of this report is to quantitatively assess the endpoints of serotonin syndrome treatment. Based on the hypothesis that neurological pupil index (NPi) on a digital pupil recorder would correlate with the severity of the serotonin syndrome, we administered cyproheptadine using NPi as an indicator.\n",
            "A patient with a history of depression was brought to our hospital after he overdosed on 251 tablets of serotonin and noradrenaline reuptake inhibitors.\n",
            "On day 3, the patient was diagnosed with serotonin syndrome.\n",
            "Cyproheptadine syrup was administered at 4 mg every 4 hours. The NPi of the automated pupillometer was simultaneously measured. On day 5, the NPi exceeded 3.0 cyproheptadine was discontinued.\n",
            "The patient was discharged on day 7.\n",
            "The lack of considerable improvement during the treatment period suggests that the patient may have improved on his own. In this case, the relationship between NPi and the severity of serotonin syndrome could not be determined.\n",
            "Helicobacter pylori infection and its associated diseases represent a significant global health concern. Patients who cannot use amoxicillin pose a therapeutic challenge and necessitate alternative medications. Preliminary research indicates that cefuroxime demonstrates promising potential for eradicating H. pylori infection, and there is a lack of comprehensive review articles on the use of cefuroxime.\n",
            "This study conducts a thorough systematic literature review and synthesis. A comprehensive systematic search was conducted in PubMed, Web of Science, EMBASE, China National Knowledge Infrastructure, China Biology Medicine disc, and Wanfang Data up to January 13, 2024. The search strategy utilized the following keywords: (Cefuroxime) AND (Helicobacter pylori OR Helicobacter nemestrinae OR Campylobacter pylori OR Campylobacter pylori subsp. pylori OR Campylobacter pyloridis OR H. pylori OR Hp) for both English and Chinese language publications. Sixteen studies from five different countries or regions were included in final literature review.\n",
            "Analysis results indicate that H. pylori is sensitive to cefuroxime, with resistance rates similar to amoxicillin being relatively low. Regimens containing cefuroxime have shown favorable eradication rates, which were comparable to those of the regimens containing amoxicillin. Regarding safety, the incidence of adverse reactions in cefuroxime-containing eradication regimens was comparable to that of amoxicillin-containing regimens or other bismuth quadruple regimens, with no significant increase in allergic reactions in penicillin-allergic patients. Regarding compliance, studies consistently report high compliance rates for regimens containing cefuroxime.\n",
            "Cefuroxime can serve as an alternative to amoxicillin for the patients allergic to penicillin with satisfactory efficacies, safety, and compliance.\n",
            "This study aimed to explore the signal detection method for allergic reactions induced by inpatient iodixanol injection.\n",
            "A database of 3,719,217 hospitalized patients from 20 large Chinese general hospitals was processed and analyzed using the prescription sequence symmetry analysis (PSSA) method.\n",
            "126,680 inpatients who used iodixanol and were concurrently treated with anti-allergic drugs were analyzed. In the medical records of these patients, only 32 had documented iodixanol allergies. Statistical analysis identified 22 drugs in 4 categories-calcium preparations, adrenergic/dopaminergic agents, glucocorticoids, and antihistamines-as marker drugs. With time intervals of 3, 7, and 28 days, the adjusted sequence ratios (aSRs) for all anti-allergics and the 4 categories were greater than 1. The 7-day aSRs were 2.12 (95% CI: 2.08-2.15), 1.70 (95% CI: 1.68-1.73), 3.85 (95% confidence interval [CI]: 3.75-2.30), 2.30 (95% CI: 2.26-2.35), and 1.95 (95% CI: 1.89-2.02), respectively. The proportions of adverse drug events indicated by each signal were as follows: all anti-allergics (2.92%-3%), calcium gluconate (0.19%-0.52%), adrenergic/dopaminergic agents (2.20%-3.37%), glucocorticoids (3.13%-3.76%), and antihistamines (1.05%-1.32%).\n",
            "This first multi-center Chinese inpatient database study detected iodixanol-induced allergy signals, revealing that reactions may be much higher than those in collected spontaneous reports. Iodixanol risk exposure was closer to actual pharmaceutical care findings. PSSA application with ≤7-day intervals appears better suited for monitoring late allergic reaction signals with these drugs.\n",
            "The pain-relieving effect and safety of compound aminopyrine phenacetin tablets, tramcontin (tramadol hydrochloride sustained-release tablets) and dolantin in the early stage of autologous tendon reconstruction of the anterior cruciate ligament (ACL) of the knee joint were compared.\n",
            "Retrospective analysis of postoperative pain and drug analgesia in 45 patients performed by the same group from November 2018 to February 2019. The random area group design was divided into two groups according to whether ACL rupture was combined with meniscal injury, group A was 24 patients with ACL reconstruction of knee joint and group B was 21 patients with ACL fracture combined with meniscus injury. The two groups were divided into three subgroups respectively according to the actual treatment of postoperative analgesic drugs received by the patients, including 4 cases of compound aminopyrine phenacetin tablets, 11 cases of oral tramcontin, 9 cases of intramuscular dolantin combined with phenergan in group A; 3 cases of compound aminopyrine phenacetin tablets, 10 cases of oral tramcontin, and 8 cases of intramuscular dolantin combined with phenergan in group B. When the early postoperative patients complain about pain and actively ask for analgesia. When the patients complained about pain after the operation and actively asked for analgesia, they were randomly given painkillers, tramcontin or dolantin combined with phenergan to relieve pain. Pain visual analogue scale (VAS) was used to evaluate pain relief and observe the occurrence of adverse reactions.\n",
            "There were no significant dif-ferences in gender, age, body mass index, and time of hospital stay between the two groups of patients (<i>P</i> > 0.05). In the patients who used tramcontin and dolantin combined with phenergan to relieve pain judging by VAS score before and 1 h after taking the drug, it was found that the pain situation of the patient was significantly relieved, and the difference before and after taking the drug had statistical significance (<i>P</i> < 0.05). Pairwise comparisons of the three drugs applied in the two groups showed significantly greater pain relief in the dolantin combined with phenergan group than in the remaining two drugs. There was no significant difference (<i>P</i> > 0.05). Dolantin was prone to nausea and vomiting, but the application of phenergan was also used to reduce side effects. In terms of adverse reactions, only 1 case of nausea occurred in the tramcontin group for simple ACL reconstruction, and none of the patients in the other groups showed serious complications and allergic reactions.\n",
            "Whether in cruciate ligament reconstruction alone or combined with meniscus molding or suture, compound aminopyrine phenacetin tablets, tramcontin, dolantin combined with phenergan can effectively relieve pain. Among the three drugs, dolantin caused the largest pain relief. At the same time, the combination of phenergan effectively reduced the adverse reactions, such as vomiting and nausea, and increased the drug safety.\n",
            "Abstract not found for this article.\n",
            "<b>Objective:</b> To study whether and, if so, how honokiol overcome dexamethasone resistance in DEX-resistant CEM-C1 cells. <b>Methods:</b> We investigated the effect of honokiol (0-20 µM) on cell proliferation, cell cycle, cell apoptosis and autophagy in DEX-resistant CEM-C1 cells and DEX-sensitive CEM-C7 cells. We also determined the role of c-Myc protein and mRNA in the occurrence of T-ALL associated dexamethasone resistance western blot and reverse transcription-qPCR (RT-qPCR) analysis. <b>Results:</b> Cell Counting Kit (CCK)-8 assay shows that DEX-resistant CEM-C1 cell lines were highly resistant to dexamethasone with IC50 of 364.1 ± 29.5 µM for 48 h treatment. However, upon treatment with dexamethasone in combination with 1.5 µM of honokiol for 48 h, the IC50 of CEM-C1 cells significantly decreased to 126.2 ± 12.3 µM, and the reversal fold was 2.88. Conversely, the IC50 of CEM-C7 cells was not changed combination of dexamethasone and honokiol as compared to that of CEM-C7 cells treated with dexamethasone alone. It has been shown that honokiol induced T-ALL cell growth inhibition by apoptosis and autophagy via downregulating cell cycle-regulated proteins (Cyclin E, CDK4, and Cyclin D1) and anti-apoptotic proteins BCL-2 and upregulating pro-apoptotic proteins Bax and led to PARP cleavage. Honokiol may overcome dexamethasone resistance in DEX-resistant CEM-C1 cell lines via the suppression of c-Myc mRNA expression. <b>Conclusion:</b> The combination of honokiol and DEX were better than DEX alone in DEX-resistant CEM-C1 cell lines. Honokiol may regulate T-ALL-related dexamethasone resistance by affecting c-Myc.\n",
            "About 10% of patients have a penicillin allergy label, but less than 5% of them are actually allergic. Unnecessary penicillin avoidance is associated with serious medical consequences. Given the growing number of these labels, it is imperative that our diagnostic strategy for penicillin allergy be as efficient as possible. The validity of traditionally used skin tests (STs) has been questioned, whereas drug provocation testing (DPT), the criterion standard, without previous ST appears very safe in most cases.\n",
            "To evaluate the safety of direct DPT without consideration for ST results and the validity of ST in the diagnosis of penicillin allergy.\n",
            "In this prospective cohort study without a control group, we recruited patients consulting an allergist for penicillin allergy. Patients underwent ST followed by DPT regardless of ST results. Patients with anaphylaxis to penicillin within the past 5 years or a severe delayed reaction were excluded, as were those with significant cardiorespiratory comorbidity.\n",
            "None of the 1002 recruited patients had a serious reaction to DPT. Ten (1.0%) had a mild immediate reaction, of whom only 1 (0.1%) was considered likely IgE-mediated. The positive and negative predictive values of ST for an immediate reaction were 3.6% and 99.1%, respectively.\n",
            "In a low-risk adult population reporting penicillin allergy, ST has very poor positive predictive value. Direct DPT without ST is safe and appears to be an ideal diagnostic strategy to remove penicillin allergy labels that could be implemented in first-line practice.\n",
            "The rapid and accurate detection of drug molecules in pharmaceutical formulations and biological samples is of paramount importance. In this research article, we present a novel colorimetric sensor based on carbon dots decorated silver nanoparticles (CDs/AgNPs) for the rapid detection of ketotifen (KTF), a widely used antihistamine drug. The CDs were synthesized via a facile one-step microwave-assisted method and subsequently conjugated onto AgNPs through a simple adsorption process, forming a stable CDs/AgNPs composite. The resulting composite exhibited unique optical properties, including a strong absorption peak at 410 nm with remarkable intensity reduction and color changes upon the addition of KTF. The developed colorimetric sensor exhibited a wide linear range of 3.0-40.0 µg mL<sup>-1</sup> (R<sup>2</sup> = 0.9996), with a %RSD of 2.41, and a low limit of detection (LOD) of 0.981 µg mL<sup>-1</sup>. Furthermore, the sensor's practical applicability was evaluated by successfully detecting KTF in eye drops and artificial aqueous humor, demonstrating a remarkable percentage recovery exceeding 96.0 %. Finally, a comprehensive evaluation of the greenness and blueness of the method was performed using analytical eco-scale, GAPI, AGREEprep, and BAGI tools. The results of these assessments indicate its exceptional sustainability. Overall, the proposed method holds significant potential for applications in pharmaceutical quality control and therapeutic monitoring, contributing to improved patient care and drug safety in the field of ophthalmology.\n",
            "The aim is to update the information currently available for the use of biologics in severe asthma in children, in order to facilitate their prescription as far as possible.\n",
            "The appearance of biologics for the treatment of severe asthma has meant a revolutionary change in the therapeutic approach to this disease. Currently, five biologics have been approved for severe asthma in children and/or adolescents by the regulatory agencies: omalizumab, mepolizumab, benralizumab, dupilumab and tezepelumab. But despite their positive results in terms of efficacy, there are still relevant points of debate that should induce caution when selecting the most appropriate biologic in a child with severe asthma. Indeed, safety is essential and, for several of the existing treatments, the availability of medium-term to long-term data in this regard is scarce.\n",
            "The use of biologics can facilitate the therapeutic paradigm shift from pleiotropic treatments to personalized medicine. However, the choice of the most appropriate biologics remains a pending issue. On the other hand, to the extent that several of the biologics have been available for a relatively short time, the most robust evidence in terms of efficacy and safety in children is that of omalizumab.\n",
            "Abstract not found for this article.\n",
            "this study aimed to investigate the prevalence and management of food allergies (FA) and drug allergies (DA) in Morocco. Sparse and conflicting epidemiological data exist on the exact prevalence of allergies in the country. The rise in allergies can be attributed to various factors.\n",
            "the study analyzed data from patients with suspected FA and DA who sought medical attention. Statistical tests were used to analyze the data, percentages were computed for qualitative variables, and for quantitative variables, medians or means accompanied by standard deviations (SD) were calculated. The Chi-square test was employed to assess categorical variables. A p-value < 0.05 was considered statistically significant.\n",
            "Cow's milk was the most reported food allergen (58.2%), followed by egg and nuts (23.4% and 12.1%, respectively). The most affected age group was children under 5 years. Antibiotics were the leading cause of reported drug allergies (44.8%), particularly Beta-lactams. Immediate reactions were commonly associated with antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs). Symptoms of FA included acute urticaria, vomiting, anaphylactic shock, and facial edema. Urticaria was the most frequent symptom of DA. Antihistamines and corticosteroids were the main treatments used for both FA and DA.\n",
            "the prevalence of FA and DA in Morocco remains uncertain due to limited data. There is a need for centralized data collection and awareness among clinicians and the general population regarding allergies. The study highlights the importance of proper diagnosis and management of allergies to ensure patient safety. The findings emphasize the necessity of establishing a mandatory center for allergy care in Morocco to improve the understanding and management of allergic conditions.\n",
            "Chronic spontaneous urticaria (CSU) is a relatively common dermatological disorder characterized by sudden and unpredictable onset of pruritic wheals and/or angioedema, for more than six weeks. It is a mast cell-mediated histaminergic disorder, considerably worsening patients' quality of life. Current treatment options include anti-histamines, omalizumab and cyclosporine, in a step-wise algorithmic approach, aimed at complete symptom control. Patients do not respond uniformly to these therapeutic options due to phenotypic and endotypic heterogeneity, and often remain uncontrolled/poorly controlled. Recent research is focused on identifying certain biomarkers to predict therapeutic response and facilitate patient-targeted personalized treatment, for maximum benefit. The current article summarizes various biomarkers explored to date, and also elaborates their role in predicting therapeutic response to anti-histamines, omalizumab and cyclosporine, in CSU patients. High disease activity, elevated CRP/ESR and elevated D-dimer are the most important predictors of non/poor-response to antihistamines. Low and very low baseline IgE, elevated CRP/ESR, ASST+, BAT/BHRA+, basopenia, eosinopenia, and elevated D-dimer are predictors of poor and good response to omalizumab and cyclosporine, respectively. Additionally, normal or slightly elevated baseline IgE and FceR1 overexpression are predictors of a faster response with omalizumab. However, none of these predictors have so far been completely validated and are not yet recommended for routine use. Thus, large-scale prospective studies are needed to confirm these predictive biomarkers and identify new ones to achieve the goal of personalized medicine for CSU.\n",
            "Olanzapine/Samidorphan (Lybalvi®) is a novel oral agent for the treatment of schizophrenia and bipolar I disorder. It was designed to reduce weight gain associated with olanzapine. Samidorphan is an analog of naltrexone, initially intended to treat substance use disorders by antagonizing mu, delta, and kappa opioid receptors.\n",
            "We present the case of a 36-year-old who took their first dose of olanzapine/samidorphan shortly before calling for emergency services. The patient took diphenhydramine and an epinephrine autoinjector for what they thought was an allergic reaction but continued to have symptoms. EMS reported involuntary muscle movements thought to be due to dystonia from olanzapine. In the ED, they experienced generalized muscle spasms lasting for several seconds and diaphoresis. Initially, the staff treated for a presumed dystonic reaction to olanzapine and administered diphenhydramine 25 mg IV, diazepam 2 mg IV, midazolam 5 mg IV, and benztropine 1 mg IV without improvement. It was later determined that the patient took 16 mg of buprenorphine SL daily. With this information, precipitated opioid withdrawal was felt to be the likely cause of symptoms. The patient received 16 mg of buprenorphine for an initial Clinical Opiate Withdrawal Scale (COWS) score of 11 with repeat COWS of 6. Why should an emergency physician be aware of this? Initiating olanzapine/samidorphan in the setting of chronic opioid therapy may result in precipitated opioid withdrawal. Additional SL buprenorphine may be a reasonable treatment modality.\n",
            "In chronic pulmonary diseases characterized by inflammation and airway obstruction, such as asthma and COPD, there are unmet needs for improved treatment. Quinolines is a group of small heterocyclic compounds that have a broad range of pharmacological properties. Here, we investigated the airway relaxant and anti-inflammatory properties of a novel quinoline (RCD405).\n",
            "The airway relaxant effect of RCD405 was examined in isolated airways from humans, dogs, rats and mice. Murine models of ovalbumin (OVA)-induced allergic asthma and LPS-induced airway inflammation were used to study the effects in vivo. RCD405 (10 mg/kg) or, for comparisons in selected studies, budesonide (3 mg/kg), were administered intratracheally 1 h prior to each challenge. Airway responsiveness was determined using methacholine provocation. Immune cell recruitment to bronchi was measured using flow cytometry and histological analyses were applied to investigate cell influx and goblet cell hyperplasia of the airways. Furthermore, production of cytokines and chemokines was measured using a multiplex immunoassay. The expression levels of asthma-related genes in murine lung tissue were determined by PCR. The involvement of NF-κB and metabolic activity was measured in the human monocytic cell line THP-1.\n",
            "RCD405 demonstrated a relaxant effect on carbachol precontracted airways in all four species investigated (potency ranking: human = rat > dog = mouse). The OVA-specific IgE and airway hyperresponsiveness (AHR) were significantly reduced by intratracheal treatment with RCD405, while no significant changes were observed for budesonide. In addition, administration of RCD405 to mice significantly decreased the expression of proinflammatory cytokines and chemokines as well as recruitment of immune cells to the lungs in both OVA- and LPS-induced airway inflammation, with a similar effect as for budesonide (in the OVA-model). However, the effect on gene expression of Il-4, IL-5 and Il-13 was more pronounced for RCD405 as compared to budesonide. Finally, in vitro, RCD405 reduced the LPS-induced NF-κB activation and by itself reduced cellular metabolism.\n",
            "RCD405 has airway relaxant effects, and it reduces AHR as well as airway inflammation in the models used, suggesting that it could be a clinically relevant compound to treat inflammatory airway diseases. Possible targets of this compound are complexes of mitochondrial oxidative phosphorylation, resulting in decreased metabolic activity of targeted cells as well as through pathways associated to NF-κB. However, further studies are needed to elucidate the mode of action.\n",
            "This review aims to explore role of emerging biologics, including ligelizumab, UB-221, dupilumab, and antialarmins, in food allergy management. With a focus on recent developments, we evaluate their promise in mitigating adverse events during oral immunotherapy (OIT), reducing allergic reactions, and addressing the limitations of current therapeutic options.\n",
            "Antiimmunoglobulin E mAbs, exemplified by omalizumab, demonstrate efficacy in desensitization and safety improvement during multiallergen OIT. Next-generation antibodies like ligelizumab and UB-221 exhibit enhanced potency and unique mechanisms, holding promise for food allergy treatment. Dupilumab, targeting IL-4 receptor alpha, presents potential benefits in decreasing allergen-specific IgE and modifying the atopic march. Exploration of antialarmins, specifically anti-IL-33 (etokimab) and anti-TSLP (tezepelumab), reveals encouraging results, with etokimab showing early success in peanut allergy trials.\n",
            "Biologics hold promising potential for food allergy treatment. Tailoring therapeutic approaches based on shared decision-making becomes pivotal. While omalizumab remains a significant option, next-generation anti-IgE antibodies and agents targeting alarmins exhibit unique strengths. Dupilumab, despite limited success as monotherapy, shows promise as an adjunct for OIT. Careful consideration of treatment goals, patient preferences, and the evolving landscape of biologics will shape future clinical practice, offering allergists an expanded toolbox for personalized food allergy management.\n",
            "<i>Background and Objectives</i>: Real-life data on the efficacy of biologic agents (BAs) on asthma-comorbid CRSwNP are needed. Our primary goal is to investigate the effects of BAs on CRSwNP symptoms, as well as endoscopic and tomography scores. Our secondary goal is to show a reduction in the frequency of acute sinusitis exacerbations and the need for surgery. <i>Materials and Methods</i>: We conducted a multicenter, retrospective, real-life study. We screened the patients with asthma-comorbid CRSwNP treated with omalizumab or mepolizumab. A total of 69 patients (40 F/29 M; omalizumab n = 55, mepolizumab n = 14) were enrolled. We compared the visual analog scale (VAS), sinonasal outcome test-22 (SNOT-22), nasal congestion score (NCS), Lund-Mackay computed tomography score (LMS), and total endoscopic polyp scores (TPS) before and after BAs. We evaluated the endoscopic sinus surgery (ESS) and acute exacerbations of chronic rhinosinusitis (AECRS) frequencies separately, according to the BAs. <i>Results:</i> The overall median (min-max) age was 43 (21-69) years. The median (min-max) of biologic therapy duration was 35 (4-113) months for omalizumab and 13.5 (6-32) for mepolizumab. Significant improvements were seen in VAS, SNOT-22, and NCS with omalizumab and mepolizumab. A significant decrease was observed in TPS with omalizumab [95% CI: 0-4] (<i>p</i> < 0.001), but not with mepolizumab [95% CI: -0.5-2] (<i>p</i> = 0.335). The frequency of ESS and AECRS were significantly reduced with omalizumab [95% CI: 2-3] (<i>p</i> < 0.001) and [95% CI: 2-5] (<i>p</i> < 0.001); and mepolizumab [95% CI: 0-2] (<i>p</i> = 0.002) and [95% CI: 2-8.5] (<i>p</i> < 0.001), respectively. There was no significant difference in LMS with either of the BAs. <i>Conclusions:</i> Omalizumab and mepolizumab can provide a significant improvement in the sinonasal symptom scores. BAs are promising agents for CRSwNP patients with frequent exacerbations and multiple surgeries.\n",
            "<i>Background and Objectives</i>: Severe adult-onset eosinophilic asthma and COPD with eosinophilic inflammation are two entities with a similar clinical course and are sometimes difficult to differentiate in clinical practice, especially in patients with a history of smoking. Anti-IL-5 or -IL-5R biological therapy has been shown to be highly effective in severe eosinophilic asthma but has not demonstrated significant benefit in patients with COPD with the eosinophilic phenotype. Our aim was to illustrate this issue in the form of a case report. <i>Materials and Methods</i>: We present the case of a 67-year-old patient who is a former smoker with late-onset severe uncontrolled asthma (ACT score < 15) who experienced frequent exacerbations requiring treatment with systemic corticosteroids. The patient's lung function gradually worsened to a nadir FEV1 = 18%, despite a high dose of ICS in combination with a LABA and intermittent courses of OCS, with negative allergic skin-tests, but with high blood eosinophils level. Biological treatment with an anti-IL5R monoclonal antibody (benralizumab) was initiated, despite the difficulty in the differential diagnosis between asthma and COPD with eosinophilic inflammation. <i>Results</i>: The patient's evolution was favorable; clinical remission was effectively achieved with significant improvement in lung function (FEV1 > 100%), but with persistence of residual mild fixed airway obstructive dysfunction (FEV1/FVC < 0.7). The therapeutic response has been maintained to date. <i>Conclusions</i>: Benralizumab was shown to be very effective in a patient with late-onset severe eosinophilic asthma presenting features of chronic obstructive disease-habitual exposure to tobacco and inhaled noxious substances, and persistent airflow limitation on spirometry.\n",
            "Drug-induced anaphylaxis in children is less common than in adults and primarily involves beta-lactams and nonsteroidal anti-inflammatory drugs. Epidemiological studies show variable prevalence, influenced by age, gender, and atopic diseases. The pathophysiology includes IgE-mediated reactions and non-IgE mechanisms, like cytokine release reactions. We address drug-induced anaphylaxis in children, focusing on antibiotics, nonsteroidal anti-inflammatory drugs, neuromuscular blocking agents, and monoclonal antibodies. Diagnosis combines clinical criteria with in vitro, in vivo, and drug provocation tests. The immediate management of acute anaphylaxis primarily involves the use of adrenaline, coupled with long-term strategies, such as allergen avoidance and patient education. Desensitization protocols are crucial for children allergic to essential medications, particularly antibiotics and chemotherapy agents.\n",
            "Most vegetable crops are severely affected by the uptake of heavy metals from the soil. Heavy metals in vegetable bodies generate reactive oxygen species (ROS) that unbalance the antioxidant defense system. This study was initiated to determine the physiological and biochemical characteristics of spinach plants grown on soil contaminated with heavy metals and responding to Bacillus cereus and Bacillus aerius were isolated from soil contaminated with heavy metals. Heavy metal contamination led to a significant reduction in seed germination, seedling biomass, protein, and total nitrogen content of spinach plants grown in contaminated soils compared to control soils. In contrast, a significant increase in the content of metallothioneins and antioxidant enzymes was observed. Plants inoculated with B. cereus and B. aerius significantly reduced the oxidative stress induced by heavy metals by improving seed germination (%), seedling growth, nitrogen, and protein content. The content of metallothioneins and the activities of antioxidant enzymes were reduced in spinach plants grown from seeds inoculated with bacterial strains. In addition, plants inoculated with, B. cereus and B. aerius showed greater stomata opening than plants grown on soil contaminated with heavy metals, whose stomata were almost closed. These results suggested that both bacterial strains enhanced plant growth by reducing oxidative stress caused by metals.\n",
            "Combined intramuscular long-acting cabotegravir and long-acting rilpivirine constitute the first long-acting combination antiretroviral therapy (ART) regimen approved for adults with HIV. The goal of the IMPAACT 2017 study (MOCHA [More Options for Children and Adolescents]) was to assess the safety and pharmacokinetics of these drugs in adolescents.\n",
            "In this phase 1/2, multicentre, open-label, non-comparative, dose-finding study, virologically suppressed adolescents (aged 12-17 years; weight ≥35 kg; BMI ≤31·5 kg/m<sup>2</sup>) with HIV-1 on daily oral ART were enrolled at 15 centres in four countries (Botswana, South Africa, Thailand, and the USA). After 4-6 weeks of oral cabotegravir (cohort 1C) or rilpivirine (cohort 1R), participants received intramuscular long-acting cabotegravir or long-acting rilpivirine every 4 weeks or 8 weeks per the adult dosing regimens, while continuing pre-study ART. The primary outcomes were assessments of safety measures, including all adverse events, until week 4 for oral cabotegravir and until week 16 for long-acting cabotegravir and long-acting rilpivirine, and pharmacokinetic measures, including the area under the plasma concentration versus time curve during the dosing interval (AUC<sub>0-tau</sub>) and drug concentrations, at week 2 for oral dosing of cabotegravir and at week 16 for intramuscular dosing of cabotegravir and rilpivirine. Enrolment into cohort 1C or cohort 1R was based on the participant's pre-study ART, meaning that masking was not done. For pharmacokinetic analyses, blood samples were drawn at weeks 2-4 after oral dosing and weeks 4-16 after intramuscular dosing. Safety outcome measures were summarised using frequencies, percentages, and exact 95% CIs; pharmacokinetic parameters were summarised using descriptive statistics. This trial is registered at ClinicalTrials.gov, NCT03497676, and is closed to enrolment.\n",
            "Between March 19, 2019, and Nov 25, 2021, 55 participants were enrolled: 30 in cohort 1C and 25 in cohort 1R. At week 16, 28 (97%, 95% CI 82-100) of the 29 dose-evaluable participants in cohort 1C and 21 (91%; 72-99) of the 23 dose-evaluable participants in cohort 1R had reported at least one adverse event, with the most common being injection-site pain (nine [31%] in cohort 1C; nine [39%] in cohort 1R; none were severe). One (4%, 95% CI 0-22) participant in cohort 1R had an adverse event of grade 3 or higher, leading to treatment discontinuation, which was defined as acute rilpivirine-related allergic reaction (self-limiting generalised urticaria) after the first oral dose. No deaths or life-threatening events occurred. In cohort 1C, the week 2 median cabotegravir AUC<sub>0-tau</sub> was 148·5 (range 37·2-433·1) μg·h/mL. The week 16 median concentrations for the every-4-weeks and every-8-weeks dosing was 3·11 μg/mL (range 1·22-6·19) and 1·15 μg/mL (<0·025-5·29) for cabotegravir and 52·9 ng/mL (31·9-148·0) and 39·1 ng/mL (27·2-81·3) for rilpivirine, respectively. These concentrations were similar to those in adults.\n",
            "Study data support using long-acting cabotegravir or long-acting rilpivirine, given every 4 weeks or 8 weeks, per the adult dosing regimens, in virologically suppressed adolescents aged 12 years and older and weighing at least 35 kg.\n",
            "The National Institutes of Health and ViiV Healthcare.\n",
            "This review examine the dynamic landscape of food allergy treatment within the context of emerging biologics. Our purpose is to comprehensively evaluate the potential benefits, challenges, and transformative impact associated with the utilization of biologics in comparison to conventional therapeutic modalities.\n",
            "This document synthesizes recent scientific investigations to various biologics, such as omalizumab, ligelizumab, dupilumab, and tezepelumab, providing a nuanced understanding of their roles in oral immunotherapy, rapid desensitization, and overall food allergy management. Recent studies and clinical trials highlight the impact of anti-IgE treatment on food allergies, revealing critical findings such as dose-related efficacy, facilitation of rapid desensitization in peanut allergies, and the sustained positive outcomes observed in individuals with multifood allergies.\n",
            "The use of biologics presents a groundbreaking approach in the treatment of food allergies. The multifaceted action of these agents, along with their potential to overcome the challenges associated with traditional therapies, marks a significant advancement. Despite the persisting challenges of economic constraints and the need for further safety studies, biologics offer a promising avenue for improving the quality of life for individuals with food allergies. Ongoing research and collaborative efforts are imperative to fully realize the transformative potential inherent in these emerging therapeutic frontiers.\n",
            "Many surgeons request use of 10% povidone-iodine (PI) for vaginal antisepsis; however, when PI is contraindicated, some surgeons request use of chlorhexidine gluconate (CHG) instead. The purpose of this randomized controlled trial was to determine any significant differences in self-reported symptoms associated with vaginal antisepsis with either 10% PI scrub or 4% CHG with 4% isopropyl alcohol. The control group comprised 62 participants who underwent vaginal antisepsis with the PI product, and the intervention group comprised 58 participants who underwent vaginal antisepsis with the CHG product. Participants completed surveys immediately before surgery, immediately after surgery, and 48 to 72 hours after surgery. No significant differences were found in the reported vaginal symptoms between the two groups for any survey. One participant in the intervention group reported symptoms consistent with an allergic reaction. Additional studies are needed on the use of CHG for vaginal antisepsis.\n",
            "Asthma treatment guidelines classify inhaled corticosteroid (ICS) regimens as low, medium, or high dose. However, efficacy and safety are not independently assessed accordingly. Moreover, differences in ICS duration of action are not considered when a dose regimen is selected. We investigated the efficacy and safety implications of these limitations for available ICS molecules.\n",
            "Published pharmacodynamic and pharmacokinetic parameters were used, alongside physiological and pharmacological principles, to estimate the efficacy and safety of available ICS molecules. Extent and duration of glucocorticoid receptor (GR) occupancy in the lung (efficacy) and cortisol suppression (systemic exposure and safety) were estimated.\n",
            "Some ICS regimens (e.g., fluticasone furoate, fluticasone propionate, and ciclesonide) rank high for efficacy but low for systemic exposure, contrary to how ICS dose equivalence is currently viewed. Differences in dose-response relationships for efficacy and systemic exposure were unique for each ICS regimen and reflected in their therapeutic indices. Notably, even low doses of most ICSs can generate high GR occupancy (≥ 90%) across the entire dose interval at steady state, which may explain previously reported difficulties in obtaining dose responses within the clinical dose range and observations that most clinical benefit typically occurs at low doses. The estimated post dose duration of lung GR occupancy for ICS molecules was categorized as 4-6 h (short), 14-16 h (medium), 25-40 h (long), or > 80 h (ultra-long), suggesting potentially large differences in anti-inflammatory duration of action.\n",
            "In a real-world clinical setting where there may be poor adherence to prescribed therapy, our findings suggest a significant therapeutic advantage for longer-acting ICS molecules in patients with asthma.\n",
            "There is a debate on whether H<sub>1</sub>-histamine receptors can alter contractility in the mammalian heart. We studied here a new transgenic mouse model where we increased genetically the cardiac level of the H<sub>1</sub>-histamine receptor. We wanted to know if histamine could augment or decrease contractile parameters in mice with cardiac-specific overexpression of human H<sub>1</sub>-histamine receptors (H<sub>1</sub>-TG) and compared these findings with those in littermate wild-type mice (WT). In H<sub>1</sub>-TG mice, we studied the presence of H<sub>1</sub>-histamine receptors by autoradiography of the atrium and ventricle using [<sup>3</sup>H]mepyramine. The messenger RNA for human H<sub>1</sub>-histamine receptors was present in the heart from H<sub>1</sub>-TG and absent from WT. Using in situ hybridization, we noted mRNA for the human H<sub>1</sub>-histamine receptor in cardiac cells from H<sub>1</sub>-TG. We noted that histamine (1 nM-10 <i>µ</i>M) in paced (1 Hz) left atrial preparations from H<sub>1</sub>-TG, exerted at each concentration of histamine initially reduced force of contraction and then raised contractile force. Likewise, in spontaneously beating left atrial preparations from H<sub>1</sub>-TG, we noted that histamine led to a transient reduction in the spontaneous beating rate followed by an augmentation in the beating rate. The negative inotropic and chronotropic and the positive inotropic effects on histamine in isolated atrial muscle strips from H<sub>1</sub>-TG were attenuated by the H<sub>1</sub>-histamine receptor antagonist mepyramine. Histamine failed to exert an increased force or reduce the heartbeat in atrial preparations from WT. We concluded that stimulation of H<sub>1</sub>-histamine-receptors can decrease and then augment contractile force in the mammalian heart and stimulation of H<sub>1</sub>-histamine receptors exerts a negative chronotropic effect. SIGNIFICANCE STATEMENT: We made novel transgenic mice with cardiomyocyte-specific high expressional levels of the human H<sub>1</sub>-histamine receptor to contribute to the clarification of the controversy on whether H<sub>1</sub>-histamine receptors increase or decrease contractility and beating rate in the mammalian heart. From our data, we conclude that stimulation of H<sub>1</sub>-histamine receptors first decrease and then raise contractile force in the mammalian heart but exert solely negative chronotropic effects.\n",
            "Fibrosis is a destructive, end-stage disease process. In the skin, it is associated with systemic sclerosis and scarring with considerable health burden. Ketotifen is a clinical antihistamine and mast cell stabilizer. Studies have demonstrated mast cell-dependent anti-fibrotic effects of ketotifen but direct effects on fibroblasts have not been determined. Human dermal fibroblasts were treated with pro-fibrotic transforming growth factor-β1 (TGFβ) followed by ketotifen or control treatments to determine direct effects on fibrotic fibroblasts. Ketotifen impaired TGFβ-induced α-smooth muscle actin gene and protein responses and decreased cytoskeletal- and contractility-associated gene responses associated with fibrosis. Ketotifen reduced Yes-associated protein phosphorylation, transcriptional coactivator with PDZ binding motif transcript and protein levels, and phosphorylation of protein kinase B. In a fibroblast-populated collagen gel contraction assay, ketotifen reduced the contractile activity of TGFβ-activated fibroblasts. In a murine model of bleomycin-induced skin fibrosis, collagen density and dermal thickness were significantly decreased in ketotifen-treated mice supporting in vitro findings. These results support a novel, direct anti-fibrotic activity of ketotifen, reducing pro-fibrotic phenotypic changes in fibroblasts and reducing collagen fibres in fibrotic mouse skin. Together, these findings suggest novel therapeutic potential and a novel mechanism of action for ketotifen in the context of fibrosis.\n",
            "The concoction known as \"lean\" containing codeine and promethazine, holds a prominent cultural presence and is often referenced in mass media platforms (e.g., music and social media). Surprisingly, there's a scarcity of national data characterizing the use of lean. Therefore, the current study investigated the use of lean using national survey data and online forum participant input, and focused on identifying concurrent substance use, exploring co-administration with other substances (e.g., alcohol, cannabis), and determining lean-related experiences.\n",
            "We analyzed data from the National Survey on Drug Use and Health (NSDUH) spanning 2007-2019, identifying persons who used lean (weighted N = 42,275). Additionally, we conducted a Reddit-based study to gather insights about lean consumtion (N = 192).\n",
            "The NSDUH data indicated that lean use was most prevalent among teenagers and young adults (ages 13-21), accounting for 66% of the sample. This trend was more pronounced in male respondents (75%) compared to females. Additionally, the use was predominantly observed among Black/African American (29%), Hispanic (28%), and White (33%) populations, with these groups also reporting higher levels of concurrent alcohol and cannabis use. Similarly, findings from Reddit showed that individuals who used lean were predominantly male (67%) and exhibited elevated concurrent rates of alcohol (83%) and cannabis (46%) use in the past 30 days. Moreover, approximately 66% of respondents met criteria for severe lean use disorder, and 37% acknowledged driving under its influence.\n",
            "The NSDUH data found that mostly young adult males reported consuming lean in the past twelve months, though the racial/ethnic breakdown of persons who used lean was diverse. The Reddit data found that most individuals in the sample met the criteria for a substance use disorder pertaining to their lean consumption. These findings underscore the clinical significance and necessity for further controlled research on lean.\n",
            "Magnoliae Officinalis Cortex (MOC), an herbal drug, contains polyphenolic lignans mainly magnolol (MN) and honokiol (HK). Methotrexate (MTX), a critical drug for cancers and autoimmune deseases, is a substrate of multidrug resistance-associated protein 2 (MRP2) and breast cancer resistance protein (BCRP). This study investigated the effect of coadministration of MOC on the pharmacokinetics of MTX and relevant mechanisms. Sprague-Dawley rats were orally administered MTX alone and with single dose (2.0 and 4.0 g/kg) and repeated seven doses of MOC (2.0 g/kg thrice daily for 2 days, the 7th dose given at 0.5 h before MTX). The serum concentrations of MTX were determined by a fluorescence polarization immunoassay. The results showed that a single dose of MOC at 2.0 g/kg significantly increased the AUC<sub>0-t</sub> and MRT of MTX by 352% and 308%, and a single dose at 4.0 g/kg significantly enhanced the AUC<sub>0-t</sub> and MRT by 362% and 291%, respectively. Likewise, repeated seven doses of MOC at 2.0 g/kg significantly increased the AUC<sub>0-t</sub> and MRT of MTX by 461% and 334%, respectively. Mechanism studies indicated that the function of MRP2 was significantly inhibited by MN, HK and the serum metabolites of MOC (MOCM), whereas BCRP was not inhibited by MOCM. In conclusion, coadministration of MOC markedly enhanced the systemic exposure and mean residence time of MTX through inhibiting the MRP2-mediated excretion of MTX.\n",
            "The aim of this study was to evaluate the posterior condylar angle (PCA) and condylar twist angle (CTA) of the distal femur in the Turkish population and its concordance with the current standard prosthesis guides used in total knee arthroplasty (TKA).\n",
            "Two hundred and forty knees of 120 Turkish subjects (60 male and 60 female) were included in this study. PCA, CTA, femoral mediolateral lengths (fML), medial femoral anteroposterior lengths (fMAP), lateral femoral anteroposterior lengths (fLAP), distances between the trochlear groove and fMAP (DBTG-fMAP), distances between the trochlear groove and fLAP (DBTG-fLAP), medial posterior condylar cartilage thickness (MPCCT) and lateral posterior condylar cartilage thicknesses (LPCCT) were measured on magnetic resonance imaging (MRI).\n",
            "The median CTA was 7° (range: 0°-13.0°) and the median PCA was 4° (range 0°-11.0°) (P < .0001). The median fML was 79.5 mm (range: 65.7-98.9). The median length of the fMAP was 58.2 mm (range: 46.8-69.0) and the median length of fLAP was 58.2 mm (range: 48.4-73.0). The DBTG-fMAP was 15.2 mm (range: 5.2-23.2), and DBTG-fLAP length was 21.9mm (range: 16.4-29.4). The median MPCCT and LPCCT were 2.4 mm (range: 1.6-3.6) and 2.3 mm (range: 1.2-2.8), respectively. The intraclass correlation coefficient for quantifying interobserver and intraobserver reliability showed excellent agreement regarding the PCA and CTA.\n",
            "This study has shown us that PCA and CTA may be higher in the Turkish population. Although it is not known whether these results have any clinical utility, it may be useful for surgeons to keep this in mind to prevent femoral component malposition.\n",
            "Level IV, Diagnostic Study.\n",
            "The incorporation of polymers into drug delivery vehicles has been shown to be a useful approach to prolong the residence time of drugs in the precorneal tear film and to improve penetration into biological membranes. The main objective of this research was to formulate novel viscous eye drops with ketotifen as the active ingredient, containing the polysaccharides: chitosan (MCH), hydroxypropyl guar gum (HPG) and hyaluronic acid (SH) alone and in combination as functional polymers. DSC and FT-IR techniques showed the compatibility between ketotifen and polymers. Physicochemical and rheological analysis at ambient and simulated physiological conditions, as well as the evaluation of mucoadhesive properties showed that vehicles containing combinations of polymers have suitable physicochemical and functional properties with demonstrated synergism between combined polymers (MCH and HPG i.e. SH and HPG). The drug permeability was successfully estimated in vitro using HCE-T cell-based models. MTT cytotoxicity assay demonstrates that the tested formulations were non-toxic and well tolerated. In vivo preclinical study on mice revealed that both vehicles containing mixed polymers enhanced and prolonged the antipruritic/analgesic-like effect of ophthalmic ketotifen. Based on these results, both combinations of polysaccharide polymers, especially SH-HPG, could be considered as potential new carriers for ketotifen for ophthalmic use.\n",
            "Dimetindene is a sedating antihistamine indicated for the symptomatic treatment of allergic conditions. Dimetindene is marketed among others under the trade name Fenistil (oral solution). Toxicity data are limited, and there is no consensus on the dose at which children require hospitalization. Objective is to determine the potentially toxic dose in children. Data in children with age up to 15 years were obtained from hospital discharge reports. Of 139 paediatric hospital discharge reports, 23 cases (16.5%) were excluded because of uncertain ingestion. In 116 children (46 boys and 70 girls, mean age 2 years and 9 months ± 1 year and 1 month), the majority of children developed no symptoms (87 children, 75%, mean age 3 years±1 year) and the remaining 29 children (25%, mean age 2 years and 11 months ± 1 year and 3 months) developed only mild and spontaneously resolving symptoms of poisoning after a dose of 0.82 ± 0.32 mg/kg b.w. (range 0.26-1.82 mg/kg). In 98% of all cases, hospitalized children were observed for a maximum 24 h, and their condition did not require specific treatment. In conclusion, the prognosis for accidental dimetindene poisoning in children appears to be good and the minimum toxic dose has been determined to be 0.5 mg/kg b.w.\n",
            "A novel spectrofluorimetric method has been developed for determination of antazoline (ANT) and tetryzoline (TET) in their pharmaceutical formulation. A combined application of synchronous spectrofluorimetry and second derivative mathematical treatment was developed. The proposed method depends on reacting the cited drugs with dansyl chloride (DNS-Cl) being a suitable derivatizing agent generating highly fluorescent derivatives measured at emission wavelengths of 703.0 and 642.0 nm after excitation wavelengths of 350.0 and 320.0 nm for ANT and TET, respectively. The joint use of synchronous spectrofluorimetry with second derivative mathematical treatment is for the first time to be developed and optimized in aid of using fluorescence data manager software generating second derivative peak amplitudes at 556.5 nm for ANT and 516.7 nm for TET. Linear responses have been represented over a wide range of concentration (0.5-12.0 μg/mL for ANT and 0.5-10.0 μg/mL for TET). Additionally, statistical comparison of the developed method with the official ones has been carried out where no significant difference was found. Additionally, greenness profile assessment was accomplished by means of four metric tools. Indeed, the method developed is found to be precise, sensitive, and discriminating to assess the cited drugs for regular analysis.\n",
            "Abstract not found for this article.\n",
            "There is a lack of real-life safety data on treatment options for chronic urticaria in the presence of comedication and comorbidities.\n",
            "We present a single-center UCARE pilot study of 212 outpatients with chronic urticaria. Patients were divided into three groups according to different CU therapies according to international guidelines.\n",
            "Of 212 patients, 108 (mean age 48.9 years, 71.3% female) had 59 comorbidities, including cardiovascular, autoimmune and malignant diseases. Patients were followed for a mean of 24.6 months (SD ± 21.3). Urticaria therapies were divided into three groups: A: 105 (97.2%) with omalizumab and 2nd generation antihistamines), B: 16 patients (14.8%): dual therapy with antihistamines and cyclosporine in 10 (9.3%), montelukast in five (4. 6%), dapsone in four (3.7%), hydroxychloroquine in one patient (0.9%), C: 12 (11.1%) patients received a third drug for 4.9 months (SD ± 3.2) and one quadruple therapy (2.1 months). 10 out of 12 (83.3%) patients received montelukast, two (16.7%) cyclosporine, two (16.7%) dapsone and one (8.3%) hydroxychloroquine as a third drug for chronic urticaria.\n",
            "Combining treatment modalities for chronic urticaria and comorbidities are available and feasible with a good safety profile.\n",
            "Despite promising advancements in oral immunotherapy for food allergies, medical implementation faces limitations. Non-specific treatment options based on inhibiting the type 2 inflammatory pathway, including monoclonal antibodies, are under investigation. TNX-901 and omalizumab have demonstrated increased reaction thresholds, reducing adverse events in peanut-allergic patients. Dupilumab, blocking the IL-4 receptor, shows positive results in both food allergies and eosinophilic esophagitis. Antibodies against alarmins and anti-IL-5, such as etokimab and mepolizumab, have proven efficacy in preclinical studies and clinical trials. While further studies are needed to establish their practical clinical use and determine suitability for different types of food allergies, these monoclonal antibodies present a promising horizon for the treatment of such conditions.\n",
            "Food allergy is a common chronic disorder that affects infants, children, adolescents, and adults. The prevalence of food allergy has increased in recent decades throughout the world, not limited to Western countries. Since there is no treatment, this focuses on avoiding allergens, in addition to educating patients and caregivers in the emergency treatment of acute reactions, for example: application of epinephrine. Studies suggest that accidental reactions occur in about 45% of children with food allergies each year, although most reactions are mild or moderate in severity. Hospital admissions for food anaphylaxis vary from 4 to 20 per 100,000 inhabitants; Deaths are rare, with an estimated incidence of 0.03 to 0.3 per million people with food allergy. Death from food anaphylaxis is rare and appears to have remained stable, possibly due to increases in food allergen labeling, diagnostic services, rates of intramuscular epinephrine prescription, and awareness of food allergies. Omalizumab is a drug approved for several disorders (chronic hives or difficult asthma) and may help reduce symptoms associated with food allergy. The relative importance of alternative technologies, management strategies and policies for food allergy varies from one region to another, due to differences in the epidemiology, education, socioeconomic well-being, and cultural preferences of the population.\n",
            "The prevalence of atopic diseases has increased in recent decades. A possible link between antibiotic use during pregnancy and childhood atopic disease has been proposed. The aim of this study is to explore the association of antibiotic exposure during pregnancy with childhood atopic diseases from a nationwide, population-based perspective.\n",
            "This was a nationwide population-based cohort study. Taiwan's National Health Insurance Research Database was the main source of data. The pairing of mothers and children was achieved by linking the NHIRD with the Taiwan Maternal and Child Health Database. This study enrolled the first-time pregnancies from 2004 to 2010. Infants of multiple delivery, preterm delivery, and death before 5 years old were excluded. All participants were followed up at least for 5 years. Antenatal antibiotics prescribed to mothers during the pregnancy period were reviewed. Children with more than two outpatient visits, or one admission, with a main diagnosis of asthma, allergic rhinitis, or atopic dermatitis were regarded as having an atopic disease.\n",
            "A total of 900,584 children were enrolled in this study. The adjusted hazard ratios of antibiotic exposure during pregnancy to childhood atopic diseases were 1.12 for atopic dermatitis, 1.06 for asthma, and 1.08 for allergic rhinitis, all of which reached statistical significance. The trimester effect was not significant. There was a trend showing the higher the number of times a child was prenatally exposed to antibiotics, the higher the hazard ratio was for childhood atopic diseases.\n",
            "Prenatal antibiotic exposure might increase the risk of childhood atopic diseases in a dose-dependent manner.\n",
            "In obesity, the interactions between proinflammatory macrophages and adipocytes in white adipose tissues are known to play a crucial role in disease progression by providing inflammatory microenvironments. Here, we report that the functional nanoparticle-mediated modulation of crosstalk between adipocytes and macrophages can remodel adipocyte immune microenvironments. As a functional nanomodulator, we designed antivascular cell adhesion molecule (VCAM)-1 antibody-conjugated and amlexanox-loaded polydopamine nanoparticles (VAPN). Amlexanox was used as a model drug to increase energy expenditure. Compared to nanoparticles lacking antibody modification or amlexanox, VAPN showed significantly greater binding to VCAM-1-expressing adipocytes and lowered the interaction of adipocytes with macrophages. In high fat diet-fed mice, repeated subcutaneous administration of VAPN increased the populations of beige adipocytes and ameliorated inflammation in white adipose tissues. Moreover, the localized application of VAPN <i>in vivo</i> exerted a systemic metabolic effect and reduced metabolic disorders, including insulin tolerance and liver steatosis. These findings suggested that VAPN had potential to modulate the immune microenvironments of adipose tissues for the immunologic treatment of obesity. Although we used amlexanox as a model drug and anti-VCAM-1 antibody in VAPN, the concept of immune nanomodulators can be widely applied to the immunological treatment of obesity.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install -U spacy"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "NvDCNb3K-U4u",
        "outputId": "bde0933b-a100-4182-a907-9cbc02c3dc3f"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: spacy in /usr/local/lib/python3.10/dist-packages (3.7.4)\n",
            "Requirement already satisfied: spacy-legacy<3.1.0,>=3.0.11 in /usr/local/lib/python3.10/dist-packages (from spacy) (3.0.12)\n",
            "Requirement already satisfied: spacy-loggers<2.0.0,>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (1.0.5)\n",
            "Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (1.0.10)\n",
            "Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy) (2.0.8)\n",
            "Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy) (3.0.9)\n",
            "Requirement already satisfied: thinc<8.3.0,>=8.2.2 in /usr/local/lib/python3.10/dist-packages (from spacy) (8.2.3)\n",
            "Requirement already satisfied: wasabi<1.2.0,>=0.9.1 in /usr/local/lib/python3.10/dist-packages (from spacy) (1.1.2)\n",
            "Requirement already satisfied: srsly<3.0.0,>=2.4.3 in /usr/local/lib/python3.10/dist-packages (from spacy) (2.4.8)\n",
            "Requirement already satisfied: catalogue<2.1.0,>=2.0.6 in /usr/local/lib/python3.10/dist-packages (from spacy) (2.0.10)\n",
            "Requirement already satisfied: weasel<0.4.0,>=0.1.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (0.3.4)\n",
            "Requirement already satisfied: typer<0.10.0,>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (0.9.4)\n",
            "Requirement already satisfied: smart-open<7.0.0,>=5.2.1 in /usr/local/lib/python3.10/dist-packages (from spacy) (6.4.0)\n",
            "Requirement already satisfied: tqdm<5.0.0,>=4.38.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (4.66.2)\n",
            "Requirement already satisfied: requests<3.0.0,>=2.13.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (2.31.0)\n",
            "Requirement already satisfied: pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4 in /usr/local/lib/python3.10/dist-packages (from spacy) (2.7.0)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from spacy) (3.1.3)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.10/dist-packages (from spacy) (67.7.2)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (24.0)\n",
            "Requirement already satisfied: langcodes<4.0.0,>=3.2.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (3.3.0)\n",
            "Requirement already satisfied: numpy>=1.19.0 in /usr/local/lib/python3.10/dist-packages (from spacy) (1.25.2)\n",
            "Requirement already satisfied: annotated-types>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy) (0.6.0)\n",
            "Requirement already satisfied: pydantic-core==2.18.1 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy) (2.18.1)\n",
            "Requirement already satisfied: typing-extensions>=4.6.1 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy) (4.11.0)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy) (3.7)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy) (2024.2.2)\n",
            "Requirement already satisfied: blis<0.8.0,>=0.7.8 in /usr/local/lib/python3.10/dist-packages (from thinc<8.3.0,>=8.2.2->spacy) (0.7.11)\n",
            "Requirement already satisfied: confection<1.0.0,>=0.0.1 in /usr/local/lib/python3.10/dist-packages (from thinc<8.3.0,>=8.2.2->spacy) (0.1.4)\n",
            "Requirement already satisfied: click<9.0.0,>=7.1.1 in /usr/local/lib/python3.10/dist-packages (from typer<0.10.0,>=0.3.0->spacy) (8.1.7)\n",
            "Requirement already satisfied: cloudpathlib<0.17.0,>=0.7.0 in /usr/local/lib/python3.10/dist-packages (from weasel<0.4.0,>=0.1.0->spacy) (0.16.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->spacy) (2.1.5)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!python -m spacy download en_core_web_sm"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "e6uxQou5_F9H",
        "outputId": "d8b46b4d-e86e-42f6-9a57-31144690bda4"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting en-core-web-sm==3.7.1\n",
            "  Downloading https://github.com/explosion/spacy-models/releases/download/en_core_web_sm-3.7.1/en_core_web_sm-3.7.1-py3-none-any.whl (12.8 MB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m12.8/12.8 MB\u001b[0m \u001b[31m42.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: spacy<3.8.0,>=3.7.2 in /usr/local/lib/python3.10/dist-packages (from en-core-web-sm==3.7.1) (3.7.4)\n",
            "Requirement already satisfied: spacy-legacy<3.1.0,>=3.0.11 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (3.0.12)\n",
            "Requirement already satisfied: spacy-loggers<2.0.0,>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (1.0.5)\n",
            "Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (1.0.10)\n",
            "Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.0.8)\n",
            "Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (3.0.9)\n",
            "Requirement already satisfied: thinc<8.3.0,>=8.2.2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (8.2.3)\n",
            "Requirement already satisfied: wasabi<1.2.0,>=0.9.1 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (1.1.2)\n",
            "Requirement already satisfied: srsly<3.0.0,>=2.4.3 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.4.8)\n",
            "Requirement already satisfied: catalogue<2.1.0,>=2.0.6 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.0.10)\n",
            "Requirement already satisfied: weasel<0.4.0,>=0.1.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (0.3.4)\n",
            "Requirement already satisfied: typer<0.10.0,>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (0.9.4)\n",
            "Requirement already satisfied: smart-open<7.0.0,>=5.2.1 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (6.4.0)\n",
            "Requirement already satisfied: tqdm<5.0.0,>=4.38.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (4.66.2)\n",
            "Requirement already satisfied: requests<3.0.0,>=2.13.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.31.0)\n",
            "Requirement already satisfied: pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.7.0)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (3.1.3)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (67.7.2)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (24.0)\n",
            "Requirement already satisfied: langcodes<4.0.0,>=3.2.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (3.3.0)\n",
            "Requirement already satisfied: numpy>=1.19.0 in /usr/local/lib/python3.10/dist-packages (from spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (1.25.2)\n",
            "Requirement already satisfied: annotated-types>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (0.6.0)\n",
            "Requirement already satisfied: pydantic-core==2.18.1 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.18.1)\n",
            "Requirement already satisfied: typing-extensions>=4.6.1 in /usr/local/lib/python3.10/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (4.11.0)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (3.7)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.13.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2024.2.2)\n",
            "Requirement already satisfied: blis<0.8.0,>=0.7.8 in /usr/local/lib/python3.10/dist-packages (from thinc<8.3.0,>=8.2.2->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (0.7.11)\n",
            "Requirement already satisfied: confection<1.0.0,>=0.0.1 in /usr/local/lib/python3.10/dist-packages (from thinc<8.3.0,>=8.2.2->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (0.1.4)\n",
            "Requirement already satisfied: click<9.0.0,>=7.1.1 in /usr/local/lib/python3.10/dist-packages (from typer<0.10.0,>=0.3.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (8.1.7)\n",
            "Requirement already satisfied: cloudpathlib<0.17.0,>=0.7.0 in /usr/local/lib/python3.10/dist-packages (from weasel<0.4.0,>=0.1.0->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (0.16.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->spacy<3.8.0,>=3.7.2->en-core-web-sm==3.7.1) (2.1.5)\n",
            "\u001b[38;5;2m✔ Download and installation successful\u001b[0m\n",
            "You can now load the package via spacy.load('en_core_web_sm')\n",
            "\u001b[38;5;3m⚠ Restart to reload dependencies\u001b[0m\n",
            "If you are in a Jupyter or Colab notebook, you may need to restart Python in\n",
            "order to load all the package's dependencies. You can do this by selecting the\n",
            "'Restart kernel' or 'Restart runtime' option.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import spacy\n",
        "from spacy.lang.en.stop_words import STOP_WORDS\n",
        "from string import punctuation"
      ],
      "metadata": {
        "id": "r564YjRDAS7b"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "stopwords = STOP_WORDS\n",
        "stopwords"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "7F5p9eupAvDI",
        "outputId": "5da763e8-cd0e-4c9e-b91e-9090e4c7af20"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{\"'d\",\n",
              " \"'ll\",\n",
              " \"'m\",\n",
              " \"'re\",\n",
              " \"'s\",\n",
              " \"'ve\",\n",
              " 'a',\n",
              " 'about',\n",
              " 'above',\n",
              " 'across',\n",
              " 'after',\n",
              " 'afterwards',\n",
              " 'again',\n",
              " 'against',\n",
              " 'all',\n",
              " 'almost',\n",
              " 'alone',\n",
              " 'along',\n",
              " 'already',\n",
              " 'also',\n",
              " 'although',\n",
              " 'always',\n",
              " 'am',\n",
              " 'among',\n",
              " 'amongst',\n",
              " 'amount',\n",
              " 'an',\n",
              " 'and',\n",
              " 'another',\n",
              " 'any',\n",
              " 'anyhow',\n",
              " 'anyone',\n",
              " 'anything',\n",
              " 'anyway',\n",
              " 'anywhere',\n",
              " 'are',\n",
              " 'around',\n",
              " 'as',\n",
              " 'at',\n",
              " 'back',\n",
              " 'be',\n",
              " 'became',\n",
              " 'because',\n",
              " 'become',\n",
              " 'becomes',\n",
              " 'becoming',\n",
              " 'been',\n",
              " 'before',\n",
              " 'beforehand',\n",
              " 'behind',\n",
              " 'being',\n",
              " 'below',\n",
              " 'beside',\n",
              " 'besides',\n",
              " 'between',\n",
              " 'beyond',\n",
              " 'both',\n",
              " 'bottom',\n",
              " 'but',\n",
              " 'by',\n",
              " 'ca',\n",
              " 'call',\n",
              " 'can',\n",
              " 'cannot',\n",
              " 'could',\n",
              " 'did',\n",
              " 'do',\n",
              " 'does',\n",
              " 'doing',\n",
              " 'done',\n",
              " 'down',\n",
              " 'due',\n",
              " 'during',\n",
              " 'each',\n",
              " 'eight',\n",
              " 'either',\n",
              " 'eleven',\n",
              " 'else',\n",
              " 'elsewhere',\n",
              " 'empty',\n",
              " 'enough',\n",
              " 'even',\n",
              " 'ever',\n",
              " 'every',\n",
              " 'everyone',\n",
              " 'everything',\n",
              " 'everywhere',\n",
              " 'except',\n",
              " 'few',\n",
              " 'fifteen',\n",
              " 'fifty',\n",
              " 'first',\n",
              " 'five',\n",
              " 'for',\n",
              " 'former',\n",
              " 'formerly',\n",
              " 'forty',\n",
              " 'four',\n",
              " 'from',\n",
              " 'front',\n",
              " 'full',\n",
              " 'further',\n",
              " 'get',\n",
              " 'give',\n",
              " 'go',\n",
              " 'had',\n",
              " 'has',\n",
              " 'have',\n",
              " 'he',\n",
              " 'hence',\n",
              " 'her',\n",
              " 'here',\n",
              " 'hereafter',\n",
              " 'hereby',\n",
              " 'herein',\n",
              " 'hereupon',\n",
              " 'hers',\n",
              " 'herself',\n",
              " 'him',\n",
              " 'himself',\n",
              " 'his',\n",
              " 'how',\n",
              " 'however',\n",
              " 'hundred',\n",
              " 'i',\n",
              " 'if',\n",
              " 'in',\n",
              " 'indeed',\n",
              " 'into',\n",
              " 'is',\n",
              " 'it',\n",
              " 'its',\n",
              " 'itself',\n",
              " 'just',\n",
              " 'keep',\n",
              " 'last',\n",
              " 'latter',\n",
              " 'latterly',\n",
              " 'least',\n",
              " 'less',\n",
              " 'made',\n",
              " 'make',\n",
              " 'many',\n",
              " 'may',\n",
              " 'me',\n",
              " 'meanwhile',\n",
              " 'might',\n",
              " 'mine',\n",
              " 'more',\n",
              " 'moreover',\n",
              " 'most',\n",
              " 'mostly',\n",
              " 'move',\n",
              " 'much',\n",
              " 'must',\n",
              " 'my',\n",
              " 'myself',\n",
              " \"n't\",\n",
              " 'name',\n",
              " 'namely',\n",
              " 'neither',\n",
              " 'never',\n",
              " 'nevertheless',\n",
              " 'next',\n",
              " 'nine',\n",
              " 'no',\n",
              " 'nobody',\n",
              " 'none',\n",
              " 'noone',\n",
              " 'nor',\n",
              " 'not',\n",
              " 'nothing',\n",
              " 'now',\n",
              " 'nowhere',\n",
              " 'n‘t',\n",
              " 'n’t',\n",
              " 'of',\n",
              " 'off',\n",
              " 'often',\n",
              " 'on',\n",
              " 'once',\n",
              " 'one',\n",
              " 'only',\n",
              " 'onto',\n",
              " 'or',\n",
              " 'other',\n",
              " 'others',\n",
              " 'otherwise',\n",
              " 'our',\n",
              " 'ours',\n",
              " 'ourselves',\n",
              " 'out',\n",
              " 'over',\n",
              " 'own',\n",
              " 'part',\n",
              " 'per',\n",
              " 'perhaps',\n",
              " 'please',\n",
              " 'put',\n",
              " 'quite',\n",
              " 'rather',\n",
              " 're',\n",
              " 'really',\n",
              " 'regarding',\n",
              " 'same',\n",
              " 'say',\n",
              " 'see',\n",
              " 'seem',\n",
              " 'seemed',\n",
              " 'seeming',\n",
              " 'seems',\n",
              " 'serious',\n",
              " 'several',\n",
              " 'she',\n",
              " 'should',\n",
              " 'show',\n",
              " 'side',\n",
              " 'since',\n",
              " 'six',\n",
              " 'sixty',\n",
              " 'so',\n",
              " 'some',\n",
              " 'somehow',\n",
              " 'someone',\n",
              " 'something',\n",
              " 'sometime',\n",
              " 'sometimes',\n",
              " 'somewhere',\n",
              " 'still',\n",
              " 'such',\n",
              " 'take',\n",
              " 'ten',\n",
              " 'than',\n",
              " 'that',\n",
              " 'the',\n",
              " 'their',\n",
              " 'them',\n",
              " 'themselves',\n",
              " 'then',\n",
              " 'thence',\n",
              " 'there',\n",
              " 'thereafter',\n",
              " 'thereby',\n",
              " 'therefore',\n",
              " 'therein',\n",
              " 'thereupon',\n",
              " 'these',\n",
              " 'they',\n",
              " 'third',\n",
              " 'this',\n",
              " 'those',\n",
              " 'though',\n",
              " 'three',\n",
              " 'through',\n",
              " 'throughout',\n",
              " 'thru',\n",
              " 'thus',\n",
              " 'to',\n",
              " 'together',\n",
              " 'too',\n",
              " 'top',\n",
              " 'toward',\n",
              " 'towards',\n",
              " 'twelve',\n",
              " 'twenty',\n",
              " 'two',\n",
              " 'under',\n",
              " 'unless',\n",
              " 'until',\n",
              " 'up',\n",
              " 'upon',\n",
              " 'us',\n",
              " 'used',\n",
              " 'using',\n",
              " 'various',\n",
              " 'very',\n",
              " 'via',\n",
              " 'was',\n",
              " 'we',\n",
              " 'well',\n",
              " 'were',\n",
              " 'what',\n",
              " 'whatever',\n",
              " 'when',\n",
              " 'whence',\n",
              " 'whenever',\n",
              " 'where',\n",
              " 'whereafter',\n",
              " 'whereas',\n",
              " 'whereby',\n",
              " 'wherein',\n",
              " 'whereupon',\n",
              " 'wherever',\n",
              " 'whether',\n",
              " 'which',\n",
              " 'while',\n",
              " 'whither',\n",
              " 'who',\n",
              " 'whoever',\n",
              " 'whole',\n",
              " 'whom',\n",
              " 'whose',\n",
              " 'why',\n",
              " 'will',\n",
              " 'with',\n",
              " 'within',\n",
              " 'without',\n",
              " 'would',\n",
              " 'yet',\n",
              " 'you',\n",
              " 'your',\n",
              " 'yours',\n",
              " 'yourself',\n",
              " 'yourselves',\n",
              " '‘d',\n",
              " '‘ll',\n",
              " '‘m',\n",
              " '‘re',\n",
              " '‘s',\n",
              " '‘ve',\n",
              " '’d',\n",
              " '’ll',\n",
              " '’m',\n",
              " '’re',\n",
              " '’s',\n",
              " '’ve'}"
            ]
          },
          "metadata": {},
          "execution_count": 12
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "nlp=spacy.load('en_core_web_sm')"
      ],
      "metadata": {
        "id": "-cPH1Bs7Fr1S"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "doc=nlp(text)"
      ],
      "metadata": {
        "id": "x2jvnqr3Fucg"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "text=str(text)"
      ],
      "metadata": {
        "id": "FKJdAqztGH02"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "tokens=[token.text for token in doc]"
      ],
      "metadata": {
        "id": "yxuuLSk6E5Cx"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "text"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 123
        },
        "id": "hTROmgkHHs_w",
        "outputId": "86fa294e-a267-4b54-e528-77ac39c5ca9c"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'In obesity, the interactions between proinflammatory macrophages and adipocytes in white adipose tissues are known to play a crucial role in disease progression by providing inflammatory microenvironments. Here, we report that the functional nanoparticle-mediated modulation of crosstalk between adipocytes and macrophages can remodel adipocyte immune microenvironments. As a functional nanomodulator, we designed antivascular cell adhesion molecule (VCAM)-1 antibody-conjugated and amlexanox-loaded polydopamine nanoparticles (VAPN). Amlexanox was used as a model drug to increase energy expenditure. Compared to nanoparticles lacking antibody modification or amlexanox, VAPN showed significantly greater binding to VCAM-1-expressing adipocytes and lowered the interaction of adipocytes with macrophages. In high fat diet-fed mice, repeated subcutaneous administration of VAPN increased the populations of beige adipocytes and ameliorated inflammation in white adipose tissues. Moreover, the localized application of VAPN <i>in vivo</i> exerted a systemic metabolic effect and reduced metabolic disorders, including insulin tolerance and liver steatosis. These findings suggested that VAPN had potential to modulate the immune microenvironments of adipose tissues for the immunologic treatment of obesity. Although we used amlexanox as a model drug and anti-VCAM-1 antibody in VAPN, the concept of immune nanomodulators can be widely applied to the immunological treatment of obesity.'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 34
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "punctuation=punctuation +'\\n'\n",
        "punctuation"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 36
        },
        "id": "1ZjC6LhvJF6y",
        "outputId": "d5a1c794-4595-4768-de2a-1e5a58b654ab"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'!\"#$%&\\'()*+,-./:;<=>?@[\\\\]^_`{|}~\\n'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 21
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "word_frequencies={}\n",
        "for word in doc:\n",
        "  if word.text.lower() not in stopwords:\n",
        "    if word.text.lower() not in punctuation:\n",
        "      if word.text not in word_frequencies.keys():\n",
        "        word_frequencies[word.text]=1\n",
        "      else:\n",
        "        word_frequencies[word.text]+=1\n"
      ],
      "metadata": {
        "id": "bN8tE5wVJh6a"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "display(word_frequencies)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "rqQLGWwrL23Y",
        "outputId": "62ba68c5-b282-4bc7-81ef-60dbffc32c70"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "{'obesity': 3,\n",
              " 'interactions': 1,\n",
              " 'proinflammatory': 1,\n",
              " 'macrophages': 3,\n",
              " 'adipocytes': 5,\n",
              " 'white': 2,\n",
              " 'adipose': 3,\n",
              " 'tissues': 3,\n",
              " 'known': 1,\n",
              " 'play': 1,\n",
              " 'crucial': 1,\n",
              " 'role': 1,\n",
              " 'disease': 1,\n",
              " 'progression': 1,\n",
              " 'providing': 1,\n",
              " 'inflammatory': 1,\n",
              " 'microenvironments': 3,\n",
              " 'report': 1,\n",
              " 'functional': 2,\n",
              " 'nanoparticle': 1,\n",
              " 'mediated': 1,\n",
              " 'modulation': 1,\n",
              " 'crosstalk': 1,\n",
              " 'remodel': 1,\n",
              " 'adipocyte': 1,\n",
              " 'immune': 3,\n",
              " 'nanomodulator': 1,\n",
              " 'designed': 1,\n",
              " 'antivascular': 1,\n",
              " 'cell': 1,\n",
              " 'adhesion': 1,\n",
              " 'molecule': 1,\n",
              " 'VCAM)-1': 1,\n",
              " 'antibody': 3,\n",
              " 'conjugated': 1,\n",
              " 'amlexanox': 3,\n",
              " 'loaded': 1,\n",
              " 'polydopamine': 1,\n",
              " 'nanoparticles': 2,\n",
              " 'VAPN': 6,\n",
              " 'Amlexanox': 1,\n",
              " 'model': 2,\n",
              " 'drug': 2,\n",
              " 'increase': 1,\n",
              " 'energy': 1,\n",
              " 'expenditure': 1,\n",
              " 'Compared': 1,\n",
              " 'lacking': 1,\n",
              " 'modification': 1,\n",
              " 'showed': 1,\n",
              " 'significantly': 1,\n",
              " 'greater': 1,\n",
              " 'binding': 1,\n",
              " 'VCAM-1': 2,\n",
              " 'expressing': 1,\n",
              " 'lowered': 1,\n",
              " 'interaction': 1,\n",
              " 'high': 1,\n",
              " 'fat': 1,\n",
              " 'diet': 1,\n",
              " 'fed': 1,\n",
              " 'mice': 1,\n",
              " 'repeated': 1,\n",
              " 'subcutaneous': 1,\n",
              " 'administration': 1,\n",
              " 'increased': 1,\n",
              " 'populations': 1,\n",
              " 'beige': 1,\n",
              " 'ameliorated': 1,\n",
              " 'inflammation': 1,\n",
              " 'localized': 1,\n",
              " 'application': 1,\n",
              " 'vivo</i': 1,\n",
              " 'exerted': 1,\n",
              " 'systemic': 1,\n",
              " 'metabolic': 2,\n",
              " 'effect': 1,\n",
              " 'reduced': 1,\n",
              " 'disorders': 1,\n",
              " 'including': 1,\n",
              " 'insulin': 1,\n",
              " 'tolerance': 1,\n",
              " 'liver': 1,\n",
              " 'steatosis': 1,\n",
              " 'findings': 1,\n",
              " 'suggested': 1,\n",
              " 'potential': 1,\n",
              " 'modulate': 1,\n",
              " 'immunologic': 1,\n",
              " 'treatment': 2,\n",
              " 'anti': 1,\n",
              " 'concept': 1,\n",
              " 'nanomodulators': 1,\n",
              " 'widely': 1,\n",
              " 'applied': 1,\n",
              " 'immunological': 1}"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "max_frequency=max(word_frequencies.values()) # максимальная частота слов"
      ],
      "metadata": {
        "id": "3e5nKTdOJRIs"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "max_frequency"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "S2PejRdJMh8Z",
        "outputId": "2c7f0808-8207-4ec6-ff04-4ef1983e23eb"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "6"
            ]
          },
          "metadata": {},
          "execution_count": 26
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# нормализованная частота слов\n",
        "for word in word_frequencies.keys():\n",
        "  word_frequencies[word]=word_frequencies[word]/max_frequency"
      ],
      "metadata": {
        "id": "VsUFzYMFNM32"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "display(word_frequencies)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "aqE0MR8XOC7P",
        "outputId": "a032a381-65e7-4dd4-80a4-8098c27a4ca5"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "{'obesity': 0.5,\n",
              " 'interactions': 0.16666666666666666,\n",
              " 'proinflammatory': 0.16666666666666666,\n",
              " 'macrophages': 0.5,\n",
              " 'adipocytes': 0.8333333333333334,\n",
              " 'white': 0.3333333333333333,\n",
              " 'adipose': 0.5,\n",
              " 'tissues': 0.5,\n",
              " 'known': 0.16666666666666666,\n",
              " 'play': 0.16666666666666666,\n",
              " 'crucial': 0.16666666666666666,\n",
              " 'role': 0.16666666666666666,\n",
              " 'disease': 0.16666666666666666,\n",
              " 'progression': 0.16666666666666666,\n",
              " 'providing': 0.16666666666666666,\n",
              " 'inflammatory': 0.16666666666666666,\n",
              " 'microenvironments': 0.5,\n",
              " 'report': 0.16666666666666666,\n",
              " 'functional': 0.3333333333333333,\n",
              " 'nanoparticle': 0.16666666666666666,\n",
              " 'mediated': 0.16666666666666666,\n",
              " 'modulation': 0.16666666666666666,\n",
              " 'crosstalk': 0.16666666666666666,\n",
              " 'remodel': 0.16666666666666666,\n",
              " 'adipocyte': 0.16666666666666666,\n",
              " 'immune': 0.5,\n",
              " 'nanomodulator': 0.16666666666666666,\n",
              " 'designed': 0.16666666666666666,\n",
              " 'antivascular': 0.16666666666666666,\n",
              " 'cell': 0.16666666666666666,\n",
              " 'adhesion': 0.16666666666666666,\n",
              " 'molecule': 0.16666666666666666,\n",
              " 'VCAM)-1': 0.16666666666666666,\n",
              " 'antibody': 0.5,\n",
              " 'conjugated': 0.16666666666666666,\n",
              " 'amlexanox': 0.5,\n",
              " 'loaded': 0.16666666666666666,\n",
              " 'polydopamine': 0.16666666666666666,\n",
              " 'nanoparticles': 0.3333333333333333,\n",
              " 'VAPN': 1.0,\n",
              " 'Amlexanox': 0.16666666666666666,\n",
              " 'model': 0.3333333333333333,\n",
              " 'drug': 0.3333333333333333,\n",
              " 'increase': 0.16666666666666666,\n",
              " 'energy': 0.16666666666666666,\n",
              " 'expenditure': 0.16666666666666666,\n",
              " 'Compared': 0.16666666666666666,\n",
              " 'lacking': 0.16666666666666666,\n",
              " 'modification': 0.16666666666666666,\n",
              " 'showed': 0.16666666666666666,\n",
              " 'significantly': 0.16666666666666666,\n",
              " 'greater': 0.16666666666666666,\n",
              " 'binding': 0.16666666666666666,\n",
              " 'VCAM-1': 0.3333333333333333,\n",
              " 'expressing': 0.16666666666666666,\n",
              " 'lowered': 0.16666666666666666,\n",
              " 'interaction': 0.16666666666666666,\n",
              " 'high': 0.16666666666666666,\n",
              " 'fat': 0.16666666666666666,\n",
              " 'diet': 0.16666666666666666,\n",
              " 'fed': 0.16666666666666666,\n",
              " 'mice': 0.16666666666666666,\n",
              " 'repeated': 0.16666666666666666,\n",
              " 'subcutaneous': 0.16666666666666666,\n",
              " 'administration': 0.16666666666666666,\n",
              " 'increased': 0.16666666666666666,\n",
              " 'populations': 0.16666666666666666,\n",
              " 'beige': 0.16666666666666666,\n",
              " 'ameliorated': 0.16666666666666666,\n",
              " 'inflammation': 0.16666666666666666,\n",
              " 'localized': 0.16666666666666666,\n",
              " 'application': 0.16666666666666666,\n",
              " 'vivo</i': 0.16666666666666666,\n",
              " 'exerted': 0.16666666666666666,\n",
              " 'systemic': 0.16666666666666666,\n",
              " 'metabolic': 0.3333333333333333,\n",
              " 'effect': 0.16666666666666666,\n",
              " 'reduced': 0.16666666666666666,\n",
              " 'disorders': 0.16666666666666666,\n",
              " 'including': 0.16666666666666666,\n",
              " 'insulin': 0.16666666666666666,\n",
              " 'tolerance': 0.16666666666666666,\n",
              " 'liver': 0.16666666666666666,\n",
              " 'steatosis': 0.16666666666666666,\n",
              " 'findings': 0.16666666666666666,\n",
              " 'suggested': 0.16666666666666666,\n",
              " 'potential': 0.16666666666666666,\n",
              " 'modulate': 0.16666666666666666,\n",
              " 'immunologic': 0.16666666666666666,\n",
              " 'treatment': 0.3333333333333333,\n",
              " 'anti': 0.16666666666666666,\n",
              " 'concept': 0.16666666666666666,\n",
              " 'nanomodulators': 0.16666666666666666,\n",
              " 'widely': 0.16666666666666666,\n",
              " 'applied': 0.16666666666666666,\n",
              " 'immunological': 0.16666666666666666}"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# разбиение предложения на лексемы\n",
        "sentence_tokens=[sent for sent in doc.sents]\n",
        "display(sentence_tokens)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 243
        },
        "id": "AUC9KMIZOUoT",
        "outputId": "ed4ffdbf-9bf1-49e4-96ad-ad1e58d24262"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "[In obesity, the interactions between proinflammatory macrophages and adipocytes in white adipose tissues are known to play a crucial role in disease progression by providing inflammatory microenvironments.,\n",
              " Here, we report that the functional nanoparticle-mediated modulation of crosstalk between adipocytes and macrophages can remodel adipocyte immune microenvironments.,\n",
              " As a functional nanomodulator, we designed antivascular cell adhesion molecule (VCAM)-1 antibody-conjugated and amlexanox-loaded polydopamine nanoparticles (VAPN).,\n",
              " Amlexanox was used as a model drug to increase energy expenditure.,\n",
              " Compared to nanoparticles lacking antibody modification or amlexanox, VAPN showed significantly greater binding to VCAM-1-expressing adipocytes and lowered the interaction of adipocytes with macrophages.,\n",
              " In high fat diet-fed mice, repeated subcutaneous administration of VAPN increased the populations of beige adipocytes and ameliorated inflammation in white adipose tissues.,\n",
              " Moreover, the localized application of VAPN <i>in vivo</i> exerted a systemic metabolic effect and reduced metabolic disorders, including insulin tolerance and liver steatosis.,\n",
              " These findings suggested that VAPN had potential to modulate the immune microenvironments of adipose tissues for the immunologic treatment of obesity.,\n",
              " Although we used amlexanox as a model drug and anti-VCAM-1 antibody in VAPN, the concept of immune nanomodulators can be widely applied to the immunological treatment of obesity.]"
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "sentence_scores={}\n",
        "for sent in sentence_tokens:\n",
        "  for word in sent:\n",
        "    if word.text.lower() in word_frequencies.keys():\n",
        "      if sent not in sentence_scores.keys():\n",
        "        sentence_scores[sent]=word_frequencies[word.text.lower()]\n",
        "      else:\n",
        "        sentence_scores[sent]=+word_frequencies[word.text.lower()]"
      ],
      "metadata": {
        "id": "MitqqKEqTJ4o"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "sentence_scores"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "d_TAeYdCUhxo",
        "outputId": "9cf0ad14-93a5-4b84-ac6a-7e7ba1ebcbc5"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{In obesity, the interactions between proinflammatory macrophages and adipocytes in white adipose tissues are known to play a crucial role in disease progression by providing inflammatory microenvironments.: 3,\n",
              " Here, we report that the functional nanoparticle-mediated modulation of crosstalk between adipocytes and macrophages can remodel adipocyte immune microenvironments.: 3,\n",
              " As a functional nanomodulator, we designed antivascular cell adhesion molecule (VCAM)-1 antibody-conjugated and amlexanox-loaded polydopamine nanoparticles (VAPN).: 2,\n",
              " Amlexanox was used as a model drug to increase energy expenditure.: 1,\n",
              " Compared to nanoparticles lacking antibody modification or amlexanox, VAPN showed significantly greater binding to VCAM-1-expressing adipocytes and lowered the interaction of adipocytes with macrophages.: 3,\n",
              " In high fat diet-fed mice, repeated subcutaneous administration of VAPN increased the populations of beige adipocytes and ameliorated inflammation in white adipose tissues.: 3,\n",
              " Moreover, the localized application of VAPN <i>in vivo</i> exerted a systemic metabolic effect and reduced metabolic disorders, including insulin tolerance and liver steatosis.: 1,\n",
              " These findings suggested that VAPN had potential to modulate the immune microenvironments of adipose tissues for the immunologic treatment of obesity.: 3,\n",
              " Although we used amlexanox as a model drug and anti-VCAM-1 antibody in VAPN, the concept of immune nanomodulators can be widely applied to the immunological treatment of obesity.: 3}"
            ]
          },
          "metadata": {},
          "execution_count": 55
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# 30% c max оценкой\n",
        "from heapq import nlargest"
      ],
      "metadata": {
        "id": "ATXW7LnEVGwJ"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "select_length=int(len(sentence_tokens)*0.3)\n",
        "select_length"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "d1jkPetAVpTa",
        "outputId": "892d1950-4505-42af-e729-34606c08a564"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "2"
            ]
          },
          "metadata": {},
          "execution_count": 57
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "summary=nlargest(select_length,sentence_scores,key=sentence_scores.get)"
      ],
      "metadata": {
        "id": "dpUONpCdWhZ_"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "summary"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Jkwy73vVW71V",
        "outputId": "e8620484-21b1-4709-cd4f-c75cf97b9e83"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[In obesity, the interactions between proinflammatory macrophages and adipocytes in white adipose tissues are known to play a crucial role in disease progression by providing inflammatory microenvironments.,\n",
              " Compared to nanoparticles lacking antibody modification or amlexanox, VAPN showed significantly greater binding to VCAM-1-expressing adipocytes and lowered the interaction of adipocytes with macrophages.]"
            ]
          },
          "metadata": {},
          "execution_count": 44
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "display(str(text))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 123
        },
        "id": "8wrTYHuYYON2",
        "outputId": "7751d873-6f16-4068-f143-abd44db2eeab"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "'In obesity, the interactions between proinflammatory macrophages and adipocytes in white adipose tissues are known to play a crucial role in disease progression by providing inflammatory microenvironments. Here, we report that the functional nanoparticle-mediated modulation of crosstalk between adipocytes and macrophages can remodel adipocyte immune microenvironments. As a functional nanomodulator, we designed antivascular cell adhesion molecule (VCAM)-1 antibody-conjugated and amlexanox-loaded polydopamine nanoparticles (VAPN). Amlexanox was used as a model drug to increase energy expenditure. Compared to nanoparticles lacking antibody modification or amlexanox, VAPN showed significantly greater binding to VCAM-1-expressing adipocytes and lowered the interaction of adipocytes with macrophages. In high fat diet-fed mice, repeated subcutaneous administration of VAPN increased the populations of beige adipocytes and ameliorated inflammation in white adipose tissues. Moreover, the localized application of VAPN <i>in vivo</i> exerted a systemic metabolic effect and reduced metabolic disorders, including insulin tolerance and liver steatosis. These findings suggested that VAPN had potential to modulate the immune microenvironments of adipose tissues for the immunologic treatment of obesity. Although we used amlexanox as a model drug and anti-VCAM-1 antibody in VAPN, the concept of immune nanomodulators can be widely applied to the immunological treatment of obesity.'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "len(text)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "93U8EqWkYHVF",
        "outputId": "37e78767-be51-4b16-a876-a67974e315c1"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "1485"
            ]
          },
          "metadata": {},
          "execution_count": 52
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "len(summary)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "R_5dtJqSZUy2",
        "outputId": "65857e1c-2b2e-467f-f7f5-6af5339db743"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "409"
            ]
          },
          "metadata": {},
          "execution_count": 53
        }
      ]
    }
  ]
}